



# Acta Haematologica

International Journal of Hematology  
Journal International d'Hématologie  
Internationale Zeitschrift für Hämatologie

34

Official Organ of the European Division of the International Society of Hematology

---

Editor-in-Chief	H. LÖDDY, Basel	G. ROSENOW, New York, N.Y.	
Managing Editors	S. MOESCHLIN, Solothurn	A. VIDEBAEK, København	J. WALDENSTRÖM, Malmö
	A. ALDER, Aarau	J. GUANICH, Barcelona	W. P. MURPHY, Boston, Mass.
	G. BICKEL, Genève	A. HITTMANN, Innsbruck	N. G. NORDENSON, Stockholm
	B. M. VON BONSDORFF, Helsinki	P. INTROZZI, Pavia	A. PAVLOVSKY, Buenos Aires
	C. R. DAS GUPTA, Calcutta	F. KOLLER, Basel	F. REDMANN, Istanbul
	P. FARRERAS-VALENTI, Barcelona	J. H. LAWRENCE, Berkeley, Calif.	E. STORTI, Pavia
	A. FISCHU, Genova	P. LEVINE, Raritan, N.J.	E. UNDERITZ, Basel
	L. GROSS, Bronx, N.Y.	J. MALLARMÉ, Paris	
		L. M. MEYER, Brooklyn, N.Y.	

S Karger Basel München Paris London • New York • Sydney  
Arnold Böcklin Straße 25, CH-4001 Basel (Switzerland)

---

All rights, including that of translation into other languages, reserved  
Photomechanical reproduction (photocopy, microcopy) of this volume or parts thereof  
without special permission of the publishers is prohibited

© Copyright 1973 by S. Karger AG, Verlag für Medizin und Naturwissenschaften, Basel  
Printed in Switzerland by National-Zeitung AG, Basel

# Index

## No. 1

MÖRIS W., HENNEKEUSER, H. H., WESTERHAUSEN, M., STANG-VON, C. und LESCHE, R. (Freiburg i. Br.) Haarzell-Leukämie	1
NEUWIRTOVÁ, R., ŠETKOVÁ, O., HOUSKOVÁ, J., POCH, T., DORAZILOVÁ, V., and DONNER, L. (Prague) Phagocytic Activity of Leukaemic Blasts	17
NAVONE, R., PALESTRO, G., and RESEGOTTI, L. (Turin) Quantitative Studies of Macrophages in Blood Cultures in Hodgkin's Disease	25
MICHELMAYR, G., HUBER, C., BRAUNSTEINER, H., and HUBER, H. (Innsbruck) Insoluble PHA - A B-Cell Mitogen in Man?	30
NATH, I., CURTIS, J., MANGALIK, A., and TALWAR, G. P. (New Delhi) Lympho- cytes Devoid of T and B Cell Markers in Chronic Lymphatic Leukemia	37
DARBIT, T. and DIMI, E. (Vicenza) Dissociation between Factor VIII (Activity and Antigen) and Ristocetin Induced Platelet Aggregation in von Willebrand's Disease	44
SCHNEIDER, K., WIECZORKIEWICZ, A., RYTWINSKI, K. et BARTNIKOWA, W. (Gli- wice) Un cas myélome aiguë atypique une leucémie ARN	49
NORTH, M. L., DARBET, P. D., LEHMANN, H., and JUTZ, J. G. (Strasbourg) Haemoglobin Stanleyville II (a78 [E7] Asn→Lys) Found in France	56
RAHBAR, S., AZIZI, M., and NOWZARI, G. (Tehran) A Case of Homozygous Haemoglobin Lepore <sup>TH</sup> in Iran	60

## No. 2

MITROU, P. S., FISCHER, M. and HÖBNER, K. (Frankfurt/M.) Some Aspects of Erythropoietic Cell Proliferation in Erythroleukemia	65
GIOVANNINI, L. and BOCCHINI, V. (Perugia) Different Molecular Weight of the Plasmatic Erythropoietin Compared with the Renal and Splenic Erythropoietic Factors in the Rabbit	75
GÄRTIGENS, P. and BENNER, K. U. (Aölin) Desaggregation of Human Red Blood Cells by Various Surface-Active Agents as Related to Changes of Cell Shape and Hemolysis	82
JATHAR, V. S., INANDAR DESHMUKH, A. B., REGE, D. V., and SATOSKAR, R. S. (Bombay) Vitamin B <sub>12</sub> and Vegetarianism in India	90
TUDHOPE, G. R. and HOPKINS, J. (Dundee) Lipid Peroxidation in Human Erythro- cytes in Tocopherol Deficiency	98
PALVA, H. L. A., KOVATTO, O., and PALVA, I. P. (Budapest) Aplastic Anaemia after Exposure to a Weed Killer, 2 Methyl-4-Chlorophenoxyacetic Acid	105
FRALLE, H., SCHÄDER, R., and LÖFFLER, H. (Giessen) New Kind of Cytoplasmic Inclusions of Plasma Cells in Acid Malic Acid Deficiency	109



GIROLAMI, A., COSTA, P., BRUNETTI, A., and PRIMOTI, O. (Bolzano) Classical Factor X Deficiency Report of a Further Case	115
Varia	123
No. 3	
LALLA, M. (Helsinki) Proliferation of Blood Leucocytes in the Neonatal Period	129
MALOTIJEV, M., KOSTRZEWSKA, A., and KOWAL, E. (Bialystok) Intracellular Potential in Normal and Leukemic Lymphocytes	135
GEDDES, A. D., KIRCHEN, M. E., and MARSHALL, G. J. (Los Angeles, Calif.) Localization of Leukocyte Alkaline Phosphatase in Human Neutrophils	145
DANESHMAND, G. (Tehran) Erythrocyte Glucose-6-Phosphate Dehydrogenase in Tehran	152
ISAACS-SODEYE, W. A., SOFOWORA, E. A., WILLIAMS, A. O., MARQUIS V. O., ADEKUNLE, A. A., and ANDERSON, C. O. (Ile-Ife) Extract of <i>Fagara zanthoxyloides</i> Root in Sickle Cell Anaemia Toxicology and Preliminary Clinical Trials	158
KOTSIOPOULOS, P. N., SKIROS, P., and ANASTASIOU, C. (Athens) The <i>in vitro</i> Effect of Analgesics on the Electrophoretic Pattern of the Red Cell Membrane Proteins	165
ITYENGAR, B. (New Delhi) Influence of Hemolysis on the Marginal Zone Reticuloendothelial Cells of the Spleen	170
CARTEI, G. and DINI, E. (Vicenza) Coexistence of $\beta$ -Thalassaemia Trait and Gilbert's Syndrome in Three Families	175
HUHN, D. and ASCHER, S. (München) Mikrokaryoblastenschub bei chronischer Myelose	183
Book Review Buchbesprechung Livre nouveau	191
Varia	192
No. 4	
SCHICK, P., TREPFEL, F., LEHMANN-BROCKHAUS, E., and NIETMANN, H. (München) Autotransfusion of $^3\text{H}$ -Cytidine-Labelled Blood Lymphocytes in Patients with Hodgkin's Disease and Non-Hodgkin Patients I Limitations of the Method	193
SCHICK, P., TREPFEL, F., EDER, M., MATZNER, M., BENEDIK, S., THIEM, H., KABOTH, W., BIGEMANN, H., and FLIEDNER, T. M. (München) Autotransfusion of $^3\text{H}$ -Cytidine-Labelled Blood Lymphocytes in Patients with Hodgkin's Disease and Non-Hodgkin Patients II Exchangeable Lymphocyte Pools	206
HENG LIEM, H., TAVASSOLI, M., and MÜLLER-EBERHARD, U. (La Jolla, Calif.) Cellular and Subcellular Localization of Heme and Hemopexin in the Rabbit	219
MCCARTHY, K. F. and MACVITTIE, T. J. (Bethesda, Md.) Erythrocytic Committed Hematopoietic Stem Cells in the Peripheral Blood of Mice	226
THADANI, U., ABER, C. P., and TAYLOR, J. J. (Kingston upon Hull) Massive Splenomegaly, Pancytopenia and Haemolytic Anaemia in Sarcoidosis	230

# Index

ZITOUN, R., BERNADOU, A., JAMES, J. M., SORIA, J., and BOUSSER, J. (Paris) Acute Myelo-Monocytic Leukaemia A Terminal Complication of Paroxysmal Nocturnal Haemoglobinuria	241
POGLIANI, E., COFRANESCO, E., and PRAGA, C. (Milan) Anti Heparin Activity of a Macroglobulin from a Patient with Breast Adenocarcinoma	249
Book Review Buchbesprechung Livre nouveau	256

## No. 5

SCHMALZL, F., HUEHN, D., ASAMER, H., and BRAUNSTENER, H. (Innsbruck) Hairy Cell Leukemia ('Leukemic Reticuloendotheliosis') Reticulosarcoma, and Monocytic Leukemia Cytochemical and Ultrastructural Investigations	257
WASASTIENA, C., VUORINEN, E., LEHTINEN, M., IKKALA, E., and HUIJALA, E. (Helsinki) The Cytochemical $\beta$ -Glucuronidase Reaction in the Differential Diagnosis of Acute Leukaemias	277
HAHN, D., BAVIERA, B., and GANZONI, A. M. (Basel) Functional Heterogeneity of the Transport Iron Compartment I <i>In vivo</i> Radiouiron Clearance from High and Low Saturated Transferrin	285
DIALDETTI, M., NOTTI, I., FISHMAN, P., and BESSLER, H. (Petah Tiqva) Transfer of Iron Dextran Across the Placenta	292
HOLBOUYAN, L., STOLTZ, J. F., and GOGUEL, A. (Boulogne B. Marcourt) <i>In vitro</i> and <i>In vivo</i> Influence of Penicillin G on Platelet Aggregation	300
MULHARBY, T., ROTHSCHILD, H., and FREEMAN, J. (New Orleans, La.) An <i>In vitro</i> Method to Study the Participation of Various Components in Autoimmune Hemolytic Anemia	309
KAMUZORA, H., RINGELHANN, B., KONOTY AHU, F. I. D., LEHMANN, H., and LORRIN, P. A. (Cambridge) Further Investigations of the $\gamma$ -Chain in a Ghana ian Adult, Homozygous for Hereditary Persistence of Fetal Haemoglobin. Isolation of $\gamma$ CB-3 Peptides and $\alpha\gamma/\beta\gamma$ Ratio Determination in Human Hb F	315

## No. 6

HAHN, D. and GANZONI, A. M. (Basel) Functional Heterogeneity of the Transport Iron Compartment II <i>In vivo</i> Differences Between Transferrin Iron Binding Sites, and <i>In vitro</i> Interbinding Site Iron Exchange	321
MARKKANEN, T., PAJULA, R.-L., VIKKANEN, S., HIMANEN, P., and JÄRVINEN, M. (Turku) Binding of Folic Acid to Serum Proteins V Trinitated Folic Acid in the Liver	329
KALIAKMANIS, N., MELESIPOLOS, A., ECONOMIDOU, I., and VLASSOPOULOS, A. (Athens) Quantitative Determination of Immunoglobulins in Chronic Renal Failure	336
ARCAKY, A. and CAVDAR, A. O. (Ankara) Changes of Trace Minerals (Serum Iron, Zinc, Copper and Magnesium) in Thalassemia	341

GRIFONT V, KAMUTORA H, LEHMANN, H., and CHARLESWORTH D (Cambridge)	
A New Hb Variant Hb F Sard oua $\gamma^{71}$ (E 18) Isoleucine $\rightarrow$ Threon as Found in a Family with Hb G Philadelphia, $\beta$ -Chain Deficiency and a Lepore-Like Haemoglobin Indistinguishable from Hb A <sub>1</sub>	347
DYLANSEY, A, ALKAN, M L, HO, W, KAPLAN H, TIBERIN P, and RACHIMIZ WITZ, H (Beer Sheva) Chronic Eosinophilic Leukemia Complicated by Epidural Myeloblastoma	356
Book Reviews Buchbesprechungen Livres nouveaux	362
Varia	364
Indexes	
<i>Index rerum</i>	365
<i>Index autorum</i>	376

## Haarzell-Leukämie

W. MÖNITUS, H. H. HENNEKEUSER<sup>1</sup>, M. WESTERHAUSEN, C. STANG-VORS<sup>2</sup> und  
R. LESCH

Medizinische Universitätsklinik, Anatomisches Institut und Pathologisches Institut der  
Universitätsklinik Freiburg i. Br.

**Abstract** Chronical course, splenomegaly and pancytopenia are characteristic for hairy cell leukemia. The main feature are so-called hairy cells in peripheral blood. This cells were investigated by cytological, cytochemical, histological and electron microscopical methods. Special cytoplasmic inclusions seem to be specific for this cell type.

**Key Words**  
Cytochemistry  
Electron microscopy  
Hairy cell leukemia  
Leukemic reticuloendotheliosis  
Reticuloses

Die sogenannte Haarzell Leukämie (HZL) ist bisher im deutschen Schrifttum nur selten beschrieben worden [23]. Die meisten Publikationen stammen aus den USA und führen für dieses Krankheitsbild unterschiedliche Bezeichnungen (leucemic reticuloendotheliosis, neoplastic lymphoid reticulum cells in the blood, chronic reticulo-lymphocytic leukemia, hairy cell leukemia, reticulum cell leukemia). Die Besonderheit dieser Leukämie ist das Auftreten sogenannter Haarzellen oder 'hairy cells' im peripheren Blut [3, 5, 6, 10, 20, 28, 30, 32, 34, 38].

Die HZL wird erst seit der Beschreibung von BOUROSSE *et al.* [3] als einheitliches Krankheitsbild aufgefasst. In den meisten Untersuchungen wurde sie bisher unter der Bezeichnung «leucemic reticuloendotheliosis» beschrieben. Vor dem Jahr 1958 wurde sie jedoch nicht exakt gegen das leukämisch verlaufende Retikulom abgegrenzt (Bezeichnungen im amerikanischen Schrifttum: leucemic reticulum cell sarcoma [27, 39], histiocytic lymphoma [31], histiocytic leukemia [26]). Erstmalig verglich PLUMMER [30] 12 Fälle von HZL mit 100 Retikulomen, bei denen er jedoch niemals Haarzellen

<sup>1</sup> Mit Unterstützung durch Mittel der Schürzkommission beim Bundesministerium des Innern.

<sup>2</sup> Frau A. H. LEYB und Frau D. CARSAR danken wir für die hervorragende technische Hilfe.

im peripheren Blut fand. Er wies ausserdem auf den relativ kurzen Krankheitsverlauf der Retikulosarkome hin, der im Mittel 9 Monate beträgt. SCHWITZER und KASS [33] bestätigen dies. Auch elektronenmikroskopische Befunde unterstreichen den Unterschied zwischen dem leukämisch verlaufenden Retikulosarkom und der HZL [11, 33]. Es ist anzunehmen, dass die von GOSTLYN *et al.* [13] anhand von 49 Fällen beschriebene Retikulendotheliome nur mit Vorbehalten als HZL angesehen werden darf. Die Kasuistik weist hier auf 10 Fälle mit ausgedehnten spezifischen Hautinfiltraten hin, ein Befund, der bei HZL äusserst selten ist.

Das namensgebende Strukturmerkmal der HZL-Zellen besteht in der Ausprägung langer, «haarartiger» Zytoplasmafortsätze. Neben diesen typischen HZL-Zellen gehören Panzytopenie, Infiltration von Knochenmark, Milz, Leber und Lymphknoten, ausgeprägte Splenomegalie und ein chronischer Verlauf zum Bild der HZL. Sie ist eine Erkrankung des mittleren und höheren Lebensalters (60% sind älter als 50 Jahre) und wurde bisher bei Kindern nicht beobachtet. Männer erkranken wesentlich häufiger als Frauen (etwa 5:1). Insgesamt sind etwa 2% aller Leukämien HZL.

Seit 1958 sind zirka 170 Fälle von HZL beschrieben worden [1, 3, 5, 6, 8, 10, 19, 20, 28–30, 32, 34, 35, 38]. Gegenstand der vorliegenden Arbeit sind zytochemische und elektronenmikroskopische Untersuchungen an HZL-Zellen, sowie histologische Befunde an Knochenmark, Milz, Leber und Lymphknoten bei 4 Fällen von HZL, die wir in den Jahren 1972 und 1973 beobachteten.

### Kasuistik

*Fall 1* 54-jähriger Mann, 1967 Beinvenenthrombose, 1969 Thrombozytopenie, anschließend Marcoumarbehandlung. August 1970 Aufnahme in auswärtigem Krankenhaus wegen Anämie und Leukopenie. Ulcerationen im Bereich der Mundschleimhaut, Hämaturie. BSG 136/152. Antikoagulantientherapie abgesetzt. Therapie: Bluttransfusionen. In der Folgezeit weiterhin Abgeschlagenheit, Müdigkeit, Kopfschmerzen, Schwindel und Gewichtsabnahme von 9 kg in 2 Monaten. Wiederaufnahme wegen Panzytopenie, ausgeprägter Splenomegalie und starker Hämaturie. Sternalpunktion, Punctio sicca. Beckenkammibiopsie (Medizinische Universitätsklinik Freiburg). Infiltration von atypischen, teils lymphoiden, teils retikulären Zellen mit Verdrängung des normalen Markes und Faserbildung. Verlegung in die Medizinische Universitätsklinik Freiburg.

Aufnahmebefund (Februar 1972): Diffuse petechiale Blutungen. Kleine Retinalblutung. Leber nicht vergrößert, Milz 5 cm unter dem Rippenbogen. Keine Lymphknotenvergrößerung. Laborwerte: Tabelle I. Zytochemischer Befund: Tabelle II. Therapieversuch mit Vincristin und Decortin. Weiterhin Bluttransfusionen. Im Verlauf nekrotisierende Angina und schwerste, nicht zu beherrschende Bronchopneumonie. Exitus letalis. Obduktion verweigert.

*Fall 2* 58-jähriger Mann, 1969 Grippe. In der Folgezeit Klagen über Leistungsminder-

Tabelle I Laboratoriumsbefunde bei Fällen 1-4

	Fall 1	Fall 2	Fall 3	Fall 4
BSG, mm	136/150	94/110	95/129	40/100
Hb, g%	7,2	11,0	10,1	9,2
Erythrozyten, Mio	2,5	4,4	3,47	2,46
Leukozyten	2 600	6 500	5 600	2 800
HZ, %	83	80	70	84
Thrombozyten	80 000	40 000	51 000	87 000
Sternalpunktat	Punctio sicca	90% HZ	70% HZ	über 90% HZ
Paraproteine	0	0	0	0

Tabelle II Vergleichende zytochemische Befunde an Lymphozyten, Haarzellen und Monozyten

	Lymphozyt	Haarzelle	Monozyt
Peroxidase und Chloroacetatasetaze	0	0	0-+
PAS	+	+	+
Unspezifische Esterasen	+	+	+++
Saure Phosphatase	+	++	++
$\beta$ -Glucuronidase	+	0	+

lung Müdigkeit und Dyspnoe. Gelegentlich Hämoptoe. Aufnahme November 1971 in der Medizinischen Universitätsklinik Freiburg.

Befund: Leber handbreit unter dem Rippenbogen, Mfz 15 cm unter dem Rippenbogen. Keine Lymphknotenvergrößerung. Laborwerte: Tabelle I. Zytochemische Befunde: Tabelle II. Lymphangiographie o. B. Laparoskopie: Infiltration von Leber und Milz. Histologisch: Tumorzellinfiltrate bei lymphoepithelialer Systemerkrankung. Beckenhämorrhagie. Infiltration von atypischen retikulären Zellen, meist in lokaler Anordnung, deutliche Pervernichtung. Weitgehende Verdrängung des blutbildenden Marks. Therapie: Vincristin und Decortin später Velbe, Natulan und Endosan (bis August 1972), dann Endosan bis Juli 1973. Zweite Aufnahme September 1972 wegen Bronchopneumonie. Schnelle Rückbildung unter Antibiotika. Entlassung nach einem Monat. Juli 1973: erneute Aufnahme wegen heftigster linksseitiger Oberbauchschmerzen. Klinisch: Milzinfarkt. Versuch der Milzbestrahlung mit Telecobalt. Zunehmende Kachexie, hämorrhagische Diathese und Bronchopneumonie. Exitus letalis.

Obduktionsbefund: Hepatomegalie (340 g), Splenomegalie (2200 g) mit 7 cm grossem, reifallendem, antriebschem Infarkt. Femur- und Wirbelmark: Normales Fettmark und rotes blutbildendes Mark weitgehend durch landkarenartige, weißlich-graue Herde ersetzt. Blutungen in Mfz, Knochenmark und Lunge. Schleimhautblutung in Magen und Harnblase. Lymphknoten fast überall vergrößert. Lymphknoten des Lun-

genhilus Infiltrate atypischer Zellen Milz Ausgedehnte Tumorzellinfiltration teilweise durch Blutungen überlagert Leber Dichte rundkernige Infiltrationen der Portalfelder, nur spärliche Infiltration der Sinusoide Cholestase Todesursache Schwere areaktive Pneumonie und Zeichen einer massiven Rechtsherzbelastung

Fall 3 39-jähriger Mann, früher häufig Anginen und rheumatische Beschwerden 1971 und 1972 Gewichtsverlust von 10 kg Leistungsabfall Herbst 1972 mehrfach Hauthämatome nach Bagatelltraumen Januar 1973 starke Nachblutung nach Zahnextraktion Wegen Thrombopenie Aufnahme in die Medizinische Universitätsklinik Freiburg Februar 1973

Befund Deutliche Blässe keine Lymphknotenvergrößerung Leber 2 Quersfinger unter dem Rippenbogen, Milz 25 cm unter dem Rippenbogen Lymphografie Vergrößerung und teilweise Zerstörung mit Speicherdefekten der Lymphknoten paraaortal Laborwerte Tabelle I Zytochemische Befunde Tabelle II Beckenkammibiopsie Infiltration von atypischen Zellen und weitgehende Verdrängung des blutbildenden Markes Deutliche Faser Vermehrung Häufig Plasmazellen und Gewebmastzellen Therapie Vincristin und Decortin Hierunter Größenabnahme der Milz und Rückgang der Lymphknotenvergrößerung bei Lymphangiografiekontrolle Entlassung Erneute Aufnahme wegen Panzytopenie im Mai 1973 Befund Deutlicher Ikterus Übriger Befund unverändert Zytochemische Therapie mit Vincristin Mustargen und Natulan Rückgang der Milzvergrößerung um 6 cm Rückbildung des Ikterus Unverändert Panzytopenie In der Folgezeit hämorrhagische Diathese und Pneumonie Septische Temperaturen Exitus letalis

Obduktionsbefund Ausgeprägte Vergrößerung der Leber (2630 g) und der Milz (3940 g) Zahlreiche anämische Infarkte mit ausgedehnten Hämorrhagien der Milz Verbackene Lymphknotenpakete Mark von Sternum Wirbelkörper und Femur durch homogene weißlich gelbe Herde verdrängt Im Femurmark landkartenartige Nekrosen Blutungen in Milz Lymphknoten Peritoneum Nierenbecken, Endokard Haut und Magen schleimhaut In beiden Lungenoberlappen areaktive hämorrhagische Pneumonie Todesursache Akutes Rechtsherzversagen bei starker areaktiver Pneumonie Dichte Infiltrationen von atypischen Zellen in Milz Lymphknoten und Knochenmark, deutliche Faser Vermehrung des Knochenmarkes In der Leber diffuse Infiltration sowohl der Portalfelder als auch der Sinusoide, hier auch in doppeltreihigen Strängen angeordnet

Fall 4 59-jähriger Mann, nie ernstlich krank Leistungsminderung im letzten halben Jahr Anfang April 1973 Panzytopenie Wegen Verdachtes einer malignen Systemerkrankung Aufnahme in der Medizinischen Universitätsklinik Freiburg Juli 1973

Befund Blässe Milz 4 cm unter dem Rippenbogen, keine Lymphknotenvergrößerung Leber nicht vergrößert Laborwerte Tabelle I Zytochemische Befunde Tabelle II Beckenkammibiopsie Weitgehende Verdrängung des normalen blutbildenden Markes durch atypische Zellen deutliche Faservermehrung Therapie Vincristin Decortin Nach 3 Wochen Entlassung in unverändertem Zustand Erneute Aufnahme im August 1973 wegen Lungeninfarktes Deutliche Belastungs-dyspnoe EKG Zeichen einer akuten Cor pulmonale Röntgenthorax Mediastinalverbreiterung Verdacht auf Lymphome Therapieversuch mit Adriamycin Antibiotische Therapie keine Besserung, kein Nachweis von Pilzen im Sputum Unter Herzkreislaufversagen Exitus letalis

Obduktionsbefund 10 x 5 x 3 cm grosse hämorrhagische Nekrose zwischen Aortenbogen und Arteria pulmonalis links im vorderen Mediastinum In diesem Bereich grosser Parietalthrombus der Aorta descendens Große bröckelige Gefäßausgüsse in den Oberlappenästen der linken Pulmonalarterie Gesamter linker Lungenoberlappen hämorrha

gisch infarziert 5 cm langer Embolus im Oberlappenast der rechten Pulmonalarterie 3 cm grosser Lungeninfarkt im rechten Oberlappen Ausgedehnter Pilzbefall mit *Candida albicans* im Bereich des Med. astinum der Lungen des Kehlkopfes und des Antrum ventriculi Dichte Durchsetzung von Pilzfäden im Bereich der Parietalthrombose der Aorta descendens, in den Blutgefässen der Pulmonalarterien sowie in den hämorrhagischen Infarkten der Lunge Weiterhin ausgedehnte weißlich-gelbe Infiltrate in Wirbelsäule, Sternum und Beckenmark

### Mikroskopische Befunde

#### Lichtmikroskopie

Bei der HZL findet man im Blut und Knochenmark einen besonderen Zelltyp, der durch eine auffallend unregelmässige Begrenzung gekennzeichnet ist Nach *papanoptischer Färbung* lassen sich «haarformige» Zytoplasmaausläufer erkennen Die Zellen sind in der Regel grösser als Lymphozyten und besitzen ovale bis leicht eingebuchtete Kerne mit lockerem Chromatin Das blassere, graublaue Zytoplasma erscheint wabig und enthält manchmal vakuolenartige Strukturen Azurgranula sind nicht nachweisbar Dagegen kommen stäbchenförmige Gebilde vor, die einen kristallartigen Eindruck machen (Abb 1, 5)

#### Zytochemische Färbungen

Die Peroxydase Reaktion [36] fiel obligat negativ aus Die PAS-Färbung [14] brachte neben einer diffusen Tingierung immer feine Granulationen (Abb 1c) In einem Fall waren auch grössere Granula vorhanden, nie jedoch PAS-positive Schollen oder grobtropfige Einlagerungen Die unspezifische Esterase-Reaktion [22] zeigte die übliche Basizität, die  $\alpha$ -Glukuronidase [24] einen negativen Ausfall Die saure Phosphatase Reaktion [12] ist stets in wechselnder Stärke vorhanden (Abb 1c) Neben einer diffusen Anfärbung zeigte sie auch ein deutlich granuläres Muster Die Knochenmarkshistologie (Methode nach Bickhardt [4]) ergab einen gesteigerten Zellgehalt der Markräume mit weitgehender Verdrängung des Fettmarks Eine normale Erythropoese fand sich nur noch spärlich in Form kleiner Erythroblastennetze (Abb 2) Die Granulopoese fehlte nahezu vollständig Nur vereinzelt liessen sich im Balkennähe Promyelozyten mit Hilfe der für sie typischen Chloracetatesterase Reaktion [14] auffinden In den Markräumen lagen Haarzellen meist in lockerer Anordnung und zeigten teils lymphoide, teils retikulären Charakter Auch hier waren in ihrem Zytoplasma stäbchenförmige Gebilde nachweisbar (Abb 3) Zwischen ihnen kamen vereinzelt Plasmazellen und Mastzellen vor Mit Hilfe der Veräusserungsmethode [4]






Abb. 1 Haarzellen im peripheren Blut a Papanicolaou Färbung b Saure Phosphatase-Reaktion c PAS Färbung  $\times 1200$

konnte eine deutliche Faservermehrung dargestellt werden, die abhängig von der Dauer des Krankheitsverlaufes zunahm. Dabei schienen Erythroblasteninseln ausgespart zu sein (Abb. 5). Die Punktionszylinder der Leber zeigten bei regelmässigem Läppchenaufbau eine dichte Infiltration der Periportalfelder mit atypischen Zellen, die bohnenförmige bis ovale, chromatinreiche Kerne mit kleinen Nukleolen aufwiesen. Dazwischen lagen vereinzelt Lymphozyten und Plasmazellen. Die Gallengänge waren intakt, die Sinusoide mässig ausgeweitet. Hier wurden atypische Zellen beobachtet, die häufig in dichten, zweireihigen Kolonnen angeordnet waren (Abb. 4). Einzelnekrosen fanden sich im Parenchym selten. In der Milz waren vereinzelt noch Malpighische Körperchen nachweisbar. Die rote Pulpa war mässig gestaut und zeigte teils dichte, teils lockere Infiltrate atypischer Zellen. Die nur unwesentlich vergrösserten Lymphknoten wiesen keine Lymphfollikel mehr auf. Neben Retikulumzellen, Lymphozyten und Plasmazellen kamen atypische Zellen vor, die an verschiedenen Stellen die Lymphknotenkapsel durchbrachen und das angrenzende Fettgewebe infiltrierten.

### Elektronenmikroskopie

Im elektronenmikroskopischen Bild erscheinen die Haarzellen unregelmässig gestaltet und besitzen stets Pseudopodien unterschiedlicher Länge (Abb. 6). Der relativ grosse Kern zeigt oft eine deutliche Impression und ist von einer gleichmässigen perinukleären Zisterne umgeben, die vereinzelt Kernporen aufweist. Das Zytoplasma ist auffallend reich an Mikrofilamenten und Polyribosomen, die sich zu den sogenannten Ribosomen-Lamellen-Komplexen [19] zusammenlagern können (Abb. 7, 8). Nur selten treten Profile des granulären ER in Erscheinung. Stets sind Zentriole vorhanden, die durch zahlreiche Satelliten und mächtige Kondensationszentren gekennzeichnet sind (Abb. 9). Mitochondrien mit deutlichen Cristae liegen gruppenweise im Zytoplasma. Häufig kommen «multivesicular bodies» vor, ebenso grosse Vakuolen mit heteromorphem Inhalt (Abb. 9, 10). Das Plasmalemma der Zellen zeigt vereinzelt Miktopinozytosevesikulationen. Oft ist an der extrazellulären Seite filamentäres Material in kleinen Klumpen angelagert. Die Pseudopodien der Haarzellen berühren sich untereinander und nehmen auch Kontakt mit den Membranen der Erythrozyten auf.

---

Abb. 2 Knochenmark mit unterschiedlich dichter Infiltration von Haarzellen. Reste der normalen Blutzirkulation in der Mitte. Giemsa-Färbung. × 240




Abb. 3 Knochenmark stärker vergrößert. Die Haarzellen sind netzartig angeordnet. Stäbchenförmiger Einschluss im Zytoplasma einer Haarzelle oben rechts. Giemsa I Färbung  $\times 600$

## Diskussion

Der Beginn einer Erkrankung an HZL ist meistens nicht eindeutig zu bestimmen, da die klinischen Symptome uncharakteristisch sind. Die meisten Patienten klagten über Leistungsminderung, Müdigkeit, Neigung zu Infekten, sowie Druckgefühl und Schmerzen im linken Oberbauch. Letztere sind durch die Splenomegalie erklärbar, die in 75–100% der Fälle gefunden wird [3, 6, 10, 18, 20]. Auch unsere Patienten hatten eine ausgeprägte Milzvergrößerung. Im Verlauf der Erkrankung treten häufig Milzinfarkte auf, die bei zwei unserer Patienten erhebliche Beschwerden verursachten. Eine Lebervergrößerung wird nur in der Hälfte der Fälle [3, 6, 10], eine Vergrößerung der Lymphknoten nur selten beobachtet. Einmal konnte bei einer Lymphangiographie ein paraaortaler Lymphknotenbefall mit weitgehender Strukturzerstörung festgestellt werden, obwohl oberflächliche Lymphknoten nicht zu tasten waren. Dieser Befund deckt sich mit den pathologischen Veränderungen, die durch Lymphangiographie von BOIRON *et al* [2] in 3 von 4 Fällen, von LANDRIN *et al* [10] in 6 von 9 Fällen und von CATONSKY *et al* [6] in 2 von 6 Fällen beobachtet wurden. In 2 Fällen beschrieb PLENDL *et al* [30] eine meningeale Aussaat.

Die Panzytopenie – bisher in allen Fällen der HZL beobachtet – schwankt in ihrem Ausmaß und hat als wichtiges Symptom zu gelten. Erythropoese, Granulopoese und Thrombopoese können unterschiedlich betroffen sein, oft ist nur ein Zellstrang betroffen. Bei unseren Patienten lagen die Hb-Werte zwischen 7,2 und 11,0 g%, die Erythrozytenzahlen zwischen 2,5 und 4,4 Mio und die Thrombozytenzahlen zwischen 40 000 und 80 000. LANDRIN *et al* [10] beobachteten bei 66% der Patienten Thrombozytenzahlen unter 100 000. In 3 von 4 Fällen fanden sie eine vermehrte Sequestration in der Milz als Ausdruck eines Hyperspleniesyndroms. Wir stellten in 2 Fällen mit zunehmender Milzvergrößerung ein Absinken der Thrombozytenzahlen fest. Dabei muss jedoch beachtet werden, dass im Verlauf der HZL eine zunehmende Infiltration des Knochenmarkes erfolgt, die die Thrombopoese zurückdrängt. FISCHER [9] zeigte, dass bei ausgeprägter Splenomegalie keineswegs ein Hyperspleniesyndrom vorliegen muss. Die Leukozytenwerte lagen in unseren Fällen zwischen 2600 und 6500. Der Anteil der

Abb. 4 Reihenartige Anordnung der Härrzellen in den Lebersinusoiden. Giemsa-Färbung  $\times 400$ .

Abb. 5 Infiltration im Knochenmark, die im Bereich einer Erythroblastenkugel fehlt. Verfärbung nach Gomori  $\times 800$ .






Abb. 8 Haarzelle (Auschnitt) »R-bosomen-Lamellen-Komplex« im Querschnitt  $\times 56\,000$

Haarzellen machte hierbei zeitweise 70–84% aus. Diese ausgeprägte Granulozytopenie dürfte für die Infektanfälligkeit der Patienten verantwortlich sein. In der Literatur werden nur in Einzelfällen Leukozytosen von mehr als 15 000 angeführt [10, 20, 30, 38]. Nur in einem Fall ist eine erhebliche Leukozytose von 134 000 beschrieben worden [3].

Die Sternalspunktion ist vielfach unergiebig. BOURONCLE *et al.* [3] beschrieben ein Punctio »ceca« in 77% der Fälle. Der Grund dürfte in der vermehrten Faserbildung des Knochenmarkes zu suchen sein. Da bei der HZL die Anzahl der Haarzellen im peripheren Blut schwankt, kann bei geringem Auftreten das Krankheitsbild zunächst verkannt werden. Die charakteristische Struktur der Zellen ist jedoch in der panoptischen Färbung unverkennbar und zeigt sich besonders gut im Phasenkontrast [1, 34, 35]. In 2 Fällen konnten wir stabchenförmige Gebilde in den Zellen nachweisen, die auch FLANDRIN *et al.* [10] und KATAYAMA *et al.* [19] kürzlich beschrieben haben. Offensichtlich handelt es sich hierbei um dieselben Strukturen, die im elektronenmikroskopischen Bild als sogenannte Ribosomen-Lamellen-Komplexe in Erscheinung treten [18]. Wir beobachteten diese Gebilde sowohl im peripheren Blut wie auch im Knochenmark, wo sie bis jetzt noch nicht beschrieben worden sind.

Abb. 6 Elektronenmikroskopische Übersichtsaufnahme der Haarzellen  $\times 9000$

Abb. 7 Haarzelle mit sogenannten »R-bosomen-Lamellen-Komplexen«. Unten rechts: Haarzelle im Hellmikroskop  $\times 9000$




Abb. 9 Haarzelle (Auschnitt) Zentral und «multivesicular body»  $\times 14\,000$




Abb. 10 Haarzelle (Auschnitt) Vakuole mit heteromorphem Inhalt und «multivesicular body»  $\times 56\,000$

Zytochemisch ergeben sich bei der PAS Reaktion neben einem diffusen auch ein granularer bei der unspezifischen Esterase ein feingranularer Ausfall. Eine wichtige Rolle spielt die saure Phosphatase Reaktion, die in den Haarzellen stets positiv ist. YAM *et al.* [37] fanden ein für Haarzellen typisches Fehlen der Tartrathemmung der sauren Phosphatase. Dieser Befund

wurde von FLANDRIN *et al* [10] KATAYAMA *et al* [17] und CATOVSKY *et al* [6] bestätigt. YAM *et al* [38] konnten zeigen, dass es sich bei dieser sauren Phosphatase um das Isoenzym (Nr. 5) handelt, das bei normalen Lymphozyten und bei chronischen lymphatischen Leukämien allenfalls in ganz geringem Masse vorkommt [21]. KATAYAMA *et al* [17] beschrieben dies auch für einen Teil der Retikulumzellen in Hodgkin-Infiltraten.

Im Knochenmark geht mit dem deutlich gesteigerten Zellgehalt eine Verdrängung des Fettmarkes einher. Reste der normalen Granulo-, Thrombo- und Erythropoese können noch vorhanden sein, stets ist jedoch ein vermehrter Leveragehalt anzutreffen.

Unsere histologischen Befunde aus Leber, Milz und Lymphknoten stimmen mit den Beschreibungen der Literatur überein [6, 10, 18]. Die elektronenmikroskopischen Befunde an Haarzellen bestätigen die phasenkontrastmikroskopischen Beobachtungen von TRIBOWITZ *et al* [35], dass dieser Zelltyp eine ausgeprägte Eigenmotilität besitzt, die auch im peripheren Blut nicht aufgegeben wird. Lange, bereits im Lichtmikroskop sichtbare Pseudopodien und zahlreiche Mikrofilamente sind morphologische Strukturmerkmale dieser amöboiden Bewegungsfähigkeit. Die sogenannten Ribosomen-Lamellen Komplexe [6, 10, 16, 18] dürften jedoch in anderem Zusammenhang zu deuten sein. Ihr lichtmikroskopisches Äquivalent bilden wahrscheinlich die stäbchenartigen Zytoplasmaeinschlüsse der Haarzellen. Die Aufklärung ihrer Struktur und Genese ist Gegenstand weiterer Untersuchungen. Phagozytose konnte von uns elektronenmikroskopisch nicht nachgewiesen werden. Die lichtmikroskopisch sichtbare, granuläre Reaktion der sauren Phosphatase weist jedoch in diese Richtung. So können die Vakuolen heteromorphen Inhalts als Phagolysosomen oder autophagische Vakuolen angesehen werden. Auffallend ist das spärliche Auftreten des granularen ER. Bei den im Zytoplasma frei liegenden elektronendichten Granula von Ribosomenkaliber dürfte es sich zum Teil um  $\beta$  Glykogen handeln, eine Annahme, die durch die positive PAS Reaktion gestützt wird.

Die licht- und elektronenmikroskopischen Befunde der HZL lassen heute eine sichere Abgrenzung zu der chronischen lymphatischen Leukämie, den Lymphosarkomen sowie zu den leukämisch verlaufenden Retikulosarkomen zu. In der Mehrzahl der Fälle wird ein chronischer Verlauf beschrieben. Im Einzelfall muss jedoch immer mit Komplikationen durch die Panzytopenie (Hämorrhagien, Infektionen) gerechnet werden. Die Angaben über therapeutische Massnahmen sind in der Literatur nicht einheitlich. Nach CATOVSKY *et al* [6] und FLANDRIN *et al* [10] scheinen Zytostatika wenig erfolgversprechend zu sein. Auch wir konnten kein Ansprechen auf eine zytostatische



Therapie beobachten. Guten Erfolg sehen mehrere Autoren in der Splenektomie [10, 20], die CATOVSKY *et al* [6] sogar als das Mittel der Wahl bezeichneten. Sicher wird diese Therapie in Fällen mit einem Hyperspleniesyndrom das Krankheitsbild günstig beeinflussen.

### *Zusammenfassung*

Chronischer Verlauf Splenomegalie und Panzytopenie lassen die Haarzell Leukämie oft schwer von anderen lymphoretikulären Systemerkrankungen abgrenzen. Die Besonderheit dieser Leukämie ist das Auftreten von sogenannten Haarzellen im peripheren Blut. An diesem Zelltyp wurden zytologische, zytochemische, histologische und elektronenmikroskopische Untersuchungen durchgeführt. Hierbei konnten sowohl lichtmikroskopisch als auch elektronenmikroskopisch Strukturmerkmale nachgewiesen werden, die für diesen Zelltyp spezifisch sind.

### *References*

- 1 BERG, B. and BRANDT, L. Cytology, distribution and function of the neoplastic cells in leukaemic reticuloendotheliosis. *Scand J Haemat* 7: 428 (1970).
- 2 BOIRON, M., FLANDRIN, G., RIPAULT, J., LOTHOLLARY, P., TIEET, F., JAQUELAY, C. et BERNARD, J. Histolymphocyte médullaire et splénique d'apparence primitive. *Nouv Rev franç Hémat* 8: 179 (1968).
- 3 BOURONCLE, B. A., WISMAN, B. H., and DOAN, C. A. Leucemic reticuloendotheliosis. *Blood* 13: 609 (1958).
- 4 BURKHARDT, R. Farbatlas der klinischen Histopathologie von Knochenmark und Knochen (Springer, Berlin 1970).
- 5 BURNS, C. P., MACA, R. D., and HOAG, J. C. Biochemical, morphological and immunological observations of leucemic reticuloendotheliosis. *Cancer Res* 33: 1615 (1973).
- 6 CATOVSKY, D., PETTIT, J. E., GALTON, D. A. G., SPIERS, A. S. D., and HARRISON, C. V. Leucaemic reticuloendotheliosis (hairy cell leukaemia). A distinct clinicopathological entity. *Brit J Haemat* 26: 9 (1974).
- 7 CATOVSKY, D., PETTIT, J. E., GALETTI, J., OKON, A., and GALTON, D. A. G. The B lymphocyte nature of the hairy cell of leukaemic reticuloendotheliosis. *Brit J Haemat* 26: 29 (1974).
- 8 DELAMAIL, G. Lymphoid myelofibrosis. *Acta haemat* 45: 88 (1971).
- 9 FISCHER, J. Hypersplenismus. *Internist* 12: 176 (1971).
- 10 FLANDRIN, G., DANIEL, M. T., FOURCADE, M. et CHIFFOUL, N. Leucémie à tricholeucocyte (hairy cell leukemia). Etude clinique et cytologique de 55 observations. *Nouv Rev franç Hémat* 13: 609 (1973).
- 11 GHADIALLY, F. N. and SAINSIDER, L. F. Ultrastructure of hairy cell leukemia. *Cancer* 29: 444 (1972).
- 12 GOLDBERG, A. F. and BARKA, T. Acid phosphatase activity in human blood cells. *Nature, Lond* 195: 297 (1962).

- 13 GINSBURG, G. R.; HANSON, D. H., and GRAY, G. L. Leukaemic reticuloendotheliosis. *Canad med Ass J* 74 836 (1956)
- 14 GRAUMANN, W. Zur Standardisierung des Schiffschens Reagens. *Z. wiss. Mikr.* 67 225 (1953)
- 15 HENNERFELDER, H. H. Histochemischer Nachweis von Naphthol-AS-D-Chloracetat-Esterase an Methacrylat-Schnitten. *Klin. Wochschr.* 50 213 (1972)
- 16 HIRIYAMA, M. "Polyosome-lamellae complex" in the adenoma of the human adrenal cortex. *J. Ultrastruct. Res.* 27 205 (1969)
- 17 KATAYAMA, I., LI, C. Y., and YAM, L. T. Histochemical study of acid phosphatase isoenzyme in leucemic reticuloendotheliosis. *Cancer* 29 157 (1972)
- 18 KATAYAMA, I., LI, C. Y., and YAM, L. T. Ultrastructural characteristics of the "hairy cells" of leucemic reticuloendotheliosis. *Amer. J. Path.* 67 361 (1972)
- 19 KATAYAMA, I., NAGY, G. K., and BALOGH, K., jr. Light microscopic identification of the ribosome-lamellae complex in "hairy cells" of leucemic reticuloendotheliosis. *Cancer* 32 843 (1973)
- 20 LI, S. L., RONNER, F., ROSENTHAL, N., and ROSENTHAL, R. L. Reticulum cell leukaemia. *N. Y. J. Med.* 69 422 (1969)
- 21 LI, C. Y., YAM, L. T., and LAM, K. W. Studies of acid phosphatase isoenzyme in human leucocytes: demonstration of isoenzyme cell specificity. *J. Histochem. Cytochem.* 18 901 (1970)
- 22 LÖFFLER, H. Cytochemischer Nachweis von unspezifischer Esterase in Ausstrichen. *Klin. Wochschr.* 39 1220 (1961)
- 23 LÖFFLER, H. Zytochemische Klassifizierung der akuten Leukosen, in: *Staatler. Chemo- und Immuntherapie der Leukosen und malignen Lymphome* (Bohmann, Wien 1969)
- 24 LORBAUTIER, P., YAM, L. T., and MITTAL, W. J. Cytochemical demonstration of  $\beta$ -glucuronidase in blood and bone marrow cells. *J. Histochem. Cytochem.* 15 680 (1967)
- 25 LOWENBRAU, S., SUTHERLAND, J. C., FELDMAN, M. J., and STERICK, A. A. Transformation of reticular cell sarcoma to acute leukemia. *Cancer* 26 579 (1971)
- 26 LUBES, R. J. The pathological picture of malignant lymphoma, in: *ZARATONITS. Proc. Int. Conf. Leukemia Lymphoma* (Lea & Febiger, Philadelphia 1968)
- 27 MARIN-PADILLA, M., JAHNKE, H. D., and MORROW, W. C. Leukemic reticulum cell sarcoma (reticulum cell sarcoma terminating in acute leukemia). *Amer. J. Clin. Path.* 41 402 (1964)
- 28 MITTAL, W. J., MEDVETZ, I. B., WITTE, B., and DAMSKE, W. Neoplastic lymphoid reticulum cells in the peripheral blood: a histochemical study. *Blood* 17 206 (1961)
- 29 PADILLA, M., and SCHWARTZ, B. L. Leukemic reticuloendotheliosis: electron microscopy of circulating lymphoid cells. *Neur. Rev. franc. Hémat.* 11 547 (1971)
- 30 PRINCEWILL, I. W. Hairy cell leukemia. *Canad. med. Ass. J.* 102 1036 (1970)
- 31 RAFFAELLI, H. Tumors of the hematopoietic system, in: *Atlas of tumor pathology*, sect. 3 fasc. 8 (A.I.P. Washington 1966)
- 32 RUBIN, A. B., DEKLEA, S. D., CHOW, L. N., GLADE, P. R., and DAMSKE, W. Chronic reticulo-lymphocytic leukemia. Relationship of leukemia reticuloendo-

- theliosis' through functional characterisation of circulating mononuclear cells. *Amer J Med* 47: 149 (1969)
- 33 SCHNITZER B and KASS L. Leukemic phase of reticulum cell sarcoma (histiocytic lymphoma). *Cancer* 31: 547 (1973)
- 34 SCHRIER R and DONNELLY, J W. 'Hairy' cells in the blood in lymphoreticular neoplastic disease and flagellated cells of normal lymph nodes. *Blood* 27: 199 (1966)
- 35 TRIMOWITZ, S., MASTER, B., and FRASCA, J M. Leucemic reticuloendotheliosis. *Blood* 38: 288 (1971)
- 36 UNDRITZ, F.: Peroxidaserreaktionen und ihre praktische Bedeutung in Myeloiden Zyto und Histochemie in der Hämatologie (Springer Berlin 1963)
- 37 YAM L T, CASTOLDI G L, GARVEY, M B, and FINKE, H E. Functional cyto-genetic and cytochemical study of the leukemic reticulum cells. *Blood* 32: 90 (1968)
- 38 YAM L T, LI C Y, and LAM K W. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. *New Engl J Med* 284: 357 (1971)
- 39 ZIFFERIN, J L and ULMANN, J E. Reticulum cell sarcoma terminating in acute leukemia. *Blood* 15: 277 (1960)

## Phagocytic Activity of Leukaemic Blasts

R. NĚLUBÍTOVÁ, O. ŠEIKOVÁ, J. HOLSKOVÁ, T. POCH, V. DORAZILOVÁ  
and L. DOVNER

Department of Medicine Institute of Pathology Medical Faculty,  
Department of Haematology, Pediatric Faculty, Charles University, Prague

**Abstract** Phagocytic activity of leukaemic blasts in 20 adults and 16 children suffering from acute leukaemia was studied *in vitro* by the use of ferrooxidisaccharate. Most frequently phagocytosing blasts were encountered in myelomonocytic leukaemias. The morphological character of positive blasts resembled often that of monocytoid cells. In lymphoblastic and reticular leukaemias phagocytic ability of blasts was an exceptional finding.

### Key Words

Acute leukaemia  
Ferrooxidisaccharate phagocytosis  
Phagocytosis in leukaemia

Numerous papers appeared on phagocytosis in acute leukaemia, paying attention mainly to mature granulocytes [2, 4, 6, 7, 16, 17, 19-21, 23-25]. Phagocytic capability of leukaemic blasts was studied less intensively and on small groups of patients only and no uniform results were reported so far [2, 5, 8-9, 11-14, 17, 18, 22, 24]. As regard the blasts in healthy bone marrow it is believed that they are not capable of phagocytosis [9-10, 12-13].

In our paper phagocytic activity of leukaemic blasts has been followed up in order to explain two questions: are leukaemic blastic cells capable of phagocytosis and if this is the case, to what degree? Would the presence of phagocytosis contribute to the classification of acute leukaemia?

### Method and Material

For the study of phagocytosis ferrooxidisaccharate (Ferrocid Acqua, Austria) was used, a substance easily ingested by normal micro- and macrophages [14]. Under sterile conditions ferrooxidisaccharate was added in excess to the heparinized

blood so that the final concentration was 5 mg of iron on 100 ml of blood. The blood sample was incubated 1 h in 37°C. Supernatant plasma with buffy coat was centrifuged and from the sediment blood smears were made. They were stained according to Perl's method and counterstained with neutral red. At least 400 blasts were evaluated in 4 slides and the percentage of blasts with blue granules of iron was assessed. In order to estimate the intensity of phagocytosis cells were divided into 3 classes according to the content of iron ingested. Parallel evaluation of cellular morphology was performed on identical panoptically stained smears.

In addition neutrophils containing ingested iron were recorded. In blood samples of control persons under the same laboratory conditions 34-94 cells/100 phagocytes contain ingested ferritoxidsaccharate [15a].

Cytochemical examination of leukaemias included conventional methods for neutral lipids, peroxidase, non-specific esterases (normal and blocked by sodium fluoride), further PAS reaction and staining for nucleoli.

Samples for electron microscopy from 13 patients were fixed by glutaraldehyde and after osmification embedded into araldite. Sections were not contrasted and were examined in the microscope JEM 7.

Phagocytosis was studied in 36 patients: 20 adults and 16 children. Acute haemoblastosis was classified as myeloblastic in 12 cases, as myelomonocytic in 11 cases, lymphoblastic and reticular in 12 cases. The precise classification was not possible in 4 cases (table I).

## Results

In 20 cases out of 36, blasts did not show any phagocytosis or only very few cells contained several small grains of iron (table II). In 7 cases with weak phagocytosis less than 10% of blasts were positive and the intensity of phagocytosis was minor or medium (see also table I). In 9 cases phagocytosis was marked, more frequently encountered in adults. Adult leukaemias were markedly positive in 35% of cases, contrary to 12% in children group. Individual cases are presented in table I.

Phagocytosing blasts did not possess any special morphology (fig 1, 2). They were larger than inactive blasts with scarce plasma or presented monocytoid nucleus of more mature character than negative cells. Similarly, in electronic microscope blasts with round nucleus and small rim of plasma did not contain ferrisaccharate, while cells with monocytoid nucleus did. Grains of stainable iron in optical microscope were frequently of unequal size, often localized at the periphery of the cell in weakly phagocytosing blasts and also above the nucleus in more intensive phagocytosis. Some of larger grains of stainable iron were lighter and transparent. All this resembled more the monocytic type of phagocytosis of ferritoxidsaccharate than the neutrophilic type [15]. Corresponding

Table 1 Cytochemical classification of acute leukaemia and percentage of phagocytosing blasts and neutrophils in individual cases

Type of leukaemia	Case No	Sex	Age years	Percentage of positive blasts and intensity of phagocytosis	Percentage of positive neutrophils
Myeloblastic	1	m	13	0	9
	2	f	76	0	45
	3	f	36	0	83
	4	f	35	0	72
	5	f	58	0	88
	6	m	13	0	21
	7	m	57	1	20
	8	m	29	1	63
	9	m	53	2+	25
	10	f	43	2+	59
	11	f	73	3+	8
	12	f	46	24++	30
Myelomonocytic	1	m	13	5+	46
	2	m	9	8+	88
	3	m	59	15+++	100
	4 <sup>1</sup>	m	2	24+++	52
	5	m	56	40++	97
	6	m	77	52+++	100
	7	f	17	57++	94
	8	f	40	72+++	60
Lymphoblastic, reticular	1	f	8	0	0
	2	m	7	0	0
	3	m	52	0	2
	4	f	60	0	4
	5	f	18	0	37
	6	m	7	0	37
	7	f	2	0	38
	8	m	5	0	50
	9	m	6	0	75
	10	f	36	0	88
	11	f	11	0	35
	12	f	8	3++	100
Non-differentiated	1	m	8	0	95
	2	m	14	2++	24
	3	m	53	22+	44
	4	f	13	49+++	10

<sup>1</sup> Leukaemic cells possessed the character of relatively mature monocyctic cells. Clinical course and autopsy findings were consistent with the diagnosis of acute leukaemia.



Fig 1 Non differentiated leukaemia in a 13 year old girl 49% positive blasts

Fig 2 Myelomonocytic leukaemia in a 77 year old man 52% positive blasts

Table II Phagocytic activity of leukaemic blasts

Phagocytosis	Positive blasts, %	Adults	Children	Total
Negative	2	10	10	20
Weak	2.8	3	4	7
Marked	15.72	7	2	9

findings in electron microscope were phagocytic vacuoles of various sizes, some of them thickly, some thinly filled with ferritin/oxide/charate (fig 3)

In samples with a high percentage of phagocytosing cells the estimation of positive blasts was no problem for the observer only in rare cases intensive clumping of phagocytosing more sticky cells prevented to assess even higher percentage of positive blasts since the remaining isolated blasts in the smear often were negative (case No 3 with myelomonocytic leukaemia in table I). In cases with very low percentage of positive cells differentiation between monocytoid blasts and positive



*Fig. 3* Electron microscop photograph from the same patient as in figure 2. Ferron disaccharate ingested in cytoplasm of a monocyto-d blast. Adherent particles on cellular membrane and formation of phagocytotic vacuoles  $\times 760$ .

atypical monocytes or myelocytes was not always easy and could be a cause of erroneous result. In these cases thorough study of panoptically stained smears was especially important.

A correlation of the presence or absence of phagocytosing blasts with the cytochemical type of leukaemia is demonstrated in table I. Positive blasts were found in all cases of myelomonocytic leukaemias. In the majority of these leukaemias phagocytosis was marked. Contrary to that phagocytosis was an exception in lymphoblastic and reticular leukaemias.

In two thirds of leukaemic patients mature neutrophils demonstrated normal or busy phagocytosis especially in myelomonocytic leukaemias (table I). In two lymphoblastic leukaemias no cells at all were capable of phagocytosis. No relation between phagocytosis and the number of leukocytes or the absolute number of blasts was found.



In the majority of adult and in some children leukaemias phagocytosis was examined repeatedly and identical results were obtained with one exception. In the blood sample of patient No. 9 (table 1) with myeloblastic leukaemia during the relaps after 3 months 12% positive blasts were found.

### *Discussion*

For the study of phagocytosis in acute leukaemia various material was used as indian ink [14, 24], microbes [5, 9, 11], yeast [2, 7, 17], latex particles [8] or white cells attacked by antinuclear factors [13]. In our laboratory ferritoxisaccharate was chosen for two reasons mainly: it is easily ingested by the cell and the whole procedure does not require any elaborate equipment and can be performed in any haematological laboratory.

From our results it may be assumed that capability of phagocytosis, at least of inert particles as ferrisaccharate, is not an exception in blasts of acute leukaemia. The question remains, why some blasts have this ability and others have not. It might be a matter of mere chance, as Bessis [1] is convinced, that under certain conditions every cell is capable of phagocytosis. Or it might be primarily a matter of serum factors [7]. This seems to be less probable, since in majority of our cases with negative blasts, neutrophils did phagocytose. However, this alternative cannot be excluded on the basis of our results and needs further elucidation. Finally, phagocytosis might be the property of the leukaemic cell, given by its different cellular origin. The validity of the last alternative is supported by our results, showing relationship with the cytochemical type of leukaemia. Phagocytosing blasts were present especially in myelomonocytic leukaemias. Also the morphological character of positive blasts resembled often that of monocytes. The small number of cases examined do not permit us to claim that phagocytosis occurs in all cases of myelomonocytic leukaemia in general. However, similar observations may be found in the literature [3, 18, 24]. Phagocytic activity of monocytic blasts must be connected with some special function and metabolism of these leukaemic cells, as for example with their high content of lysozyme [3]. The exceptional finding of phagocytosis in lymphoblastic and reticular group is not surprising, as phagocytosis is not a property of the lymphoid cell. More or less diverse morphology of phagocytosing and non phagocytosing blasts in some cases of leukaemias is

suggestive for the presence of a mixed population of blasts, consisting either of cells of various maturity or cells of different cellular origin

The small number of patients investigated does not warrant us to suggest the examination of phagocytosis as a functional test completing cytochemical classification of leukaemias. An accessory question arises whether phagocytosis might be a way of transport of some pharmacologically important compounds into the leukaemic cell

### References

- 1 BERNARD J, BRESSI M, BIORZI G, *et al*. Définition du système réticuloendothélial en 1963. *Nouv Rev franç Hémat* 3: 779-804 (1963)
- 2 BRANDT L. Studies on the phagocytic activity of neutrophilic leucocytes. *Scand J Haemat*, suppl 2 (1967)
- 3 CATOVSEY B and GALTON D A G. Isozyme activity and nitro-blue tetrazolium reduction in leukaemic cells. *J clin Path* 26: 60-69 (1973)
- 4 CONSTANTOPOULOS A, LIXITTA V, CROSS W H, and NUNAN V A. Phagocytic activity of the leukaemic cell and its response to the phagocytosis stimulating tetrapeptide tuftsin. *Cancer Res* 33: 1230-1234 (1973)
- 5 FIEBIGER J and KOSTAROWI J. Über Phagozytose der Leukocyten bei verschiedenen hamatologischen Erkrankungen. *Folia haemat*, Lpz. 73: 301-306 (1945)
- 6 GOLDMAN J M and CATOVSEY D. The function of phagocytic leucocytes in leukaemia. *Brit J Haemat* 23: suppl (1972)
- 7 GOLDMAN J M and THO H H. Phagocytic function of leucocytes from patients with acute myeloid and chronic granulocytic leukaemia. *Brit J Haemat* 23: 299-308 (1973)
- 8 HANDLER F S, HANDLER J E, and CHURCHMAN A B. Phagocytic activity of leukaemic myeloblasts. *Blut* 6: 511-524 (1969)
- 9 HERZOG A J. The phagocytic activity of human leucocytes with special reference to their type and maturity. *Amer J Path* 14: 496-603 (1939)
- 10 HILTONSON J F and MURPHY M. Phagocytic activity in bone marrow cells. *Proc Soc exp Biol*, N Y 35: 27-29 (1936)
- 11 JACOBSTADT I. Über Phagozytosenversuche mit Myeloblasten, Myelocyten und eosinophilen Leukocyten. *Virchows Arch path Anat* 234: 12-20 (1921)
- 12 JENSEN M. Phagocytic activities of various types of leucocytes. *Acta med scand* 137: suppl 213 (1948)
- 13 MARMON A and DODDING F. The phagocytic response to the LF factor of leucocytes from chronic granulocytic and acute leukaemia. In: HAYDON. *Current research in leukaemia* pp 16-22 (University Press, Cambridge 1965)
- 14 MCCLIFF D and HARTIG J. Maturation of leukaemic blast cells. *Acta haemat Basel* 45: 344-349 (1971)
- 15 NICHOLSON L R and ZETKOVÁ O. Phagocytosis in freshly prepared human leucocytes. *Czechoslov J Haematol* 112: 45-47 (1973)

In the majority of adult and in some children leukemias phagocytosis was examined repeatedly and identical results were obtained with one exception. In the blood sample of patient No. 9 (table I) with myeloblastic leukemia during the relapse after 3 months 12% positive blasts were found.

### *Discussion*

For the study of phagocytosis in acute leukemia various material was used as indian ink [14-24] microbes [5, 9, 11] yeast [2, 7, 17] latex particles [8] or white cells attacked by antinuclear factors [13]. In our laboratory ferrisaccharate was chosen for two reasons mainly: it is easily ingested by the cell and the whole procedure does not require any elaborate equipment and can be performed in any haematological laboratory.

From our results it may be assumed that capability of phagocytosis at least of inert particles as ferrisaccharate is not an exception in blasts of acute leukemia. The question remains why some blasts have this ability and others have not. It might be a matter of mere chance as Bressis [1] is convinced that under certain conditions every cell is capable of phagocytosis. Or it might be primarily a matter of serum factors [7]. This seems to be less probable since in majority of our cases with negative blasts neutrophils did phagocytose. However, this alternative cannot be excluded on the basis of our results and needs further elucidation. Finally phagocytosis might be the property of the leukaemic cell given by its different cellular origin. The validity of the last alternative is supported by our results showing relationship with the cytochemical type of leukemia. Phagocytosing blasts were present especially in myelomonocytic leukemias. Also the morphological character of positive blasts resembled often that of monocytes. The small number of cases examined do not permit us to claim that phagocytosis occurs in all cases of myelomonocytic leukemia in general. However similar observations may be found in the literature [3, 18-24]. Phagocytic activity of monocytic blasts must be connected with some special function and metabolism of these leukaemic cells as for example with their high content of lysozyme [3]. The exceptional finding of phagocytosis in lymphoblastic and reticular group is not surprising as phagocytosis is not a property of the lymphoid cell. More or less diverse morphology of phagocytosing and non phagocytosing blasts in some cases of leukemias is

suggestive for the presence of a mixed population of blasts consisting either of cells of various maturity or cells of different cellular origin

The small number of patients investigated does not warrant us to suggest the examination of phagocytosis as a functional test completing cytochemical classification of leukaemias. An accessory question arises whether phagocytosis might be a way of transport of some pharmacologically important compounds into the leukaemic cell

### References

- 1 BERNARD, J, BEISS, M., BROZZI, G., *et al*. Définition du système réticuloendothélial en 1963. *Nouv Rev franç Hémat* 3: 779-804 (1963)
- 2 BRANDT, L. Studies on the phagocytic activity of neutrophilic leucocytes. *Scand J Haemat.*, suppl 2 (1967)
- 3 CATOVSKY, D. and GALTOM, D. A. G. Lysozyme activity and nitro-blue tetrazolium reduction in leukaemic cells. *J clin Path* 26: 60-69 (1973)
- 4 CONSTANTOPOULOS, A., LIETZTA, V., CROSBY, W. H., and NAJJAR, V. A. Phagocytic activity of the leukaemic cell and its response to the phagocytosis stimulating tetrapeptide tuftsin. *Cancer Res* 33: 1230-1234 (1973)
- 5 EHRH, J. und KOMAROW, J. Über Phagozytose der Leukocyten bei verschiedenen hämatologischen Erkrankungen. *Folia haemat., Lpz.* 73: 301-306 (1955)
- 6 GOLDMAN, J. M. and CATOVSKY, D. The function of phagocytic leukocytes in leukaemia. *Brit J Haemat* 23: suppl (1972)
- 7 GOLDMAN, J. M. and THIBO, K. H. Phagocytic function of leukocytes from patients with acute myeloid and chronic granulocytic leukaemia. *Brit J Haemat* 25: 279-309 (1973)
- 8 HANDLER, F. S., HANDLER, L. E., and CHRISTOPHER, A. B. Phagocytic activity of leukaemia myeloblasts. *Blut* 6: 511-524 (1969)
- 9 HENZON, A. J. The phagocytic activity of human leukocytes with special reference to their type and maturity. *Amer J Path* 14: 596-603 (1938)
- 10 HEDDERSON, I. J. and MENGER, M. Phagocytic activity in bone marrow cells. *Proc Soc exp Biol.* N. Y. 35: 27-29 (1936)
- 11 JACOBSTHAL, F. Über Phagozytoseversuche mit Myeloblasten, Myelocyten und eosinophilen Leukocyten. *Vierteljahrsschr path. Anat.* 234: 12-20 (1921)
- 12 JERSID, M. Phagocytic activities of various types of leukocytes. *Acta med scand* 131: suppl 213 (1949)
- 13 MARWANT, A. and DAMASCO, T. The phagocytic response to the LF factor of leukocytes from chronic granulocytic and acute leukaemias. in: *Hatthor Current research in leukaemia*, pp. 16-22 (University Press, Cambridge 1965)
- 14 MULLER, H. and HARTIG, J. Maturation of leukaemic Mast cells. *Acta haemat Basel* 45: 344-349 (1971)
- 15 NEUMAYROVÁ, R. and SETKOVÁ, O. Fagocytiva injekčních preparátů železa leukocyty. *Čas. lék. čes.* 112: 45-47 (1973)

- 15a NEUWIRTOVÁ R., SEJKOVÁ O., KLEINER P., and DONNER L. Phagocytosis in malignant lymphoma and its influence by cytostatics in Leukämien und maligne Lymphome pp 562-565 (Urban & Schwarzenberg Wien 1972)
- 16 PARUL M., FRY, G. et LAURRY J. Indice opsonique et valeur phagocytaire dans la leucémie aigue C R Soc Biol 68 244 (1910)
- 17 PINNA, E. and GALTON D. A. G. Studies of neutrophil function II Pathological aspects Brit J Haemat 12 633-645 (1966)
- 18 PLAVRATY, R. V. J. et HUMBER J. C. Culture de moelle osseuse sur lames tournantes Rev Hémat 11 343-356 (1956)
- 19 ROSSER F., VALMONT, I., KOZINN P. J., and CAROLINE L. Leukocyte function in patients with leukaemia Cancer 25 835-937 (1970)
- 20 SHARRA A. J., SHIRLEY, W., SILVARAJ R. J., et al. The phagocytic capabilities of leukocytes from myeloproliferative and other neoplastic disorders Cancer Res 25 1199-1206 (1965)
- 21 SILVER R. T., BRAL, G. A., SCHNEIDERMAN M. A., and MCCULLOUGH N. B. The role of the mature neutrophil in bacterial infection in acute leukemia Blood 12 814-821 (1957)
- 22 SIRUMIA M. M. and BOERNER I. Phagocytic activity of circulating cells in the various types of leukemia Amer J Path 11 335-349 (1937)
- 23 TORNATOR K. Phagocytic activity of cells of the inflammatory exudate in human leukemia Cancer Res 27 1756-1760 (1967)
- 24 WARTER J. et MANTZ J. M. L'épreuve de phagocytose de l'encre de Chine *in vitro*. Son intérêt dans le diagnostic des leucoses à monocytes Sem Hôp., Paris 43 514-519 (1967)
- 25 ZITTOU H. et BIERCH, P. A. L'adhésivité au verre et le pouvoir phagocytaire des polynucléaires dans les syndromes myeloprolifératifs et les anémies réfractaires, Path Biol 21 271-277 (1973)

## Quantitative Studies of Macrophages in Blood Cultures in Hodgkin's Disease

R. NAVONE, G. PALESTRO and L. RESEGOTTI

Institute of Morbid Anatomy University of Turin and Department of Medicine E, S. Giovanni Battista Regional Hospital, Turin

**Abstract** In Hodgkin's disease blood cultures showed a close relationship between the rate of blastic transformation of PHA stimulated lymphocytes and the number of macrophages appearing in unstimulated cultures. Despite individual variations in single cases the yield of macrophages agreed closely with the lymphocyte transformation rate. Results are discussed in connection with hypothesis on the origin of macrophages in culture.

### Key Words

Blood culture  
Hodgkin's disease  
Lymphocyte transformation  
Macrophages  
Phytohaemagglutinin

In chronic lymphocytic leukaemia (CLL) previous experiments [14] disclosed a direct relationship between the percentage of blastic transformation of lymphocytes stimulated *in vitro* with phytohaemagglutinin (PHA) and the amount of macrophages which appeared in cultures without PHA. Such relationship has been regarded as not casual, since, however, the low number of both blast cells and macrophages in cases of CLL with high white blood cell count could be referred to an excessive dilution of normal lymphocytes and monocytes by leukaemic cells [10], we have now investigated the same problem in Hodgkin's disease, a condition in which a frequent if not constant decrease of PHA blastic transformation of lymphocytes [1, 6, 9, 11, 16, 19] is associated with a normal or low white blood cell count.

### Materials and Methods

Leucocytes obtained from venous blood of 17 normal subjects and 40 patients with Hodgkin's disease in various stages, either treated or untreated, were cultured *in vitro*. The cultures were performed as described elsewhere [20] in TC 199 Well

come with antibiotics and 15% autologous serum after mechanical defibrination of the blood and separation of leucocytes with gelatin (Plasmagel Roger Bellon). The unpurified buffy coat was added to the medium so as to obtain a final cellular concentration of  $2 \times 10^6$  ml the whole culture volume being 15 ml. In all cases blood cultures were performed both with and without PHA Wellcome (0.02 ml/ml of medium). An 18 x 18 mm glass slide was put at the bottom of the culture tubes according to BENNETT and COHEN [2].

The percentage of blastic transformation of lymphocytes was assessed morphologically after 3 days, whereas the macrophages adherent to the slides were counted after 6 days of culture. Macrophage counts were carried out on eight different areas, of 1 mm<sup>2</sup> each, and the mean arithmetical value was calculated.

### Results

The results are summarized in table I. In healthy subjects the percentage of blast cells in PHA stimulated cultures was  $80.06 \pm 6.09\%$ , the

Table I Blast cells and macrophages in blood cultures from normal subjects and patients with Hodgkin's disease

Diagnosis	Number of cases	Blastic transformation of lymphocytes with PHA %	Number of macrophages mm <sup>2</sup> without PHA
Normal subjects	17	80.06 (65-90) SD 6.09	96.17 (42-210) SD 40.54
Hodgkin's disease			
All cases	40	46.95 (4-84) SD 23.82	37.02 (0-119) SD 34.40
Cases with PHA Blastic transformation under 30%	12	17.94 (4-30) SD 8.97	1.83 (0-6) SD 2.82
Cases ranging from 30 to 60%	11	41.36 (31-57) SD 7.91	23.54 (1-70) SD 20.90
Cases over 60%	17	70.35 (61-84) SD 6.62	70.49 (21-119) SD 32.63

number of macrophages in cultures without PHA was  $96.17 \pm 50.58 / \text{mm}^2$ . In Hodgkin's disease the blastic transformation of lymphocytes in PHA stimulated cultures was lower than in normal subjects i.e.  $46.55 \pm 23.82\%$  and the number of macrophages appearing in unstimulated cultures was also relatively low ( $37.02 \pm 38.40 / \text{mm}^2$ ). However, in individual results varied within a very large range as shown by the high standard deviations. Therefore we divided our patients in three groups according to the degree of PHA blastic transformation of lymphocytes (table 1). In cases with a low blastic transformation (under  $30\%$ , mean value  $17.58 \pm 8.57\%$ ) also the number of macrophages was very low ( $1.83 \pm 2.82 / \text{mm}^2$ ). In cases with a blastic transformation ranging from 30 to  $60\%$  (mean value  $41.36 \pm 7.96\%$ ) the number of macrophages was somewhat higher than in the previous group ( $23.54 \pm 20.90 / \text{mm}^2$ ). In cases with an high almost normal percentage of blast cells (over  $60\%$ , mean value  $70.35 \pm 6.62\%$ ) the number of macrophages in the cultures without PHA ( $70.59 \pm 32.13 / \text{mm}^2$ ) approached that observed in normal subjects.

### Discussion

In *in vitro* blood cultures from patients with Wiskott-Aldrich syndrome and Hodgkin's disease BLAISE *et al* [5] observed that the yield of macrophages obtained from patients was generally lower than in controls. In skin window preparations in Hodgkin's disease REBLICK *et al* [15] reported a reduction of the overall cellularity whilst using a similar technique GILSON *et al* [7] found a copious cellular migration (over  $90\%$  of the cells being macrophages) either in normal subjects and in Hodgkin's disease.

Our results show that a direct relationship exists between the percentage of PHA induced blastic transformation of lymphocytes and the number of macrophages appearing in unstimulated cultures in Hodgkin's disease. The cases with a low percentage of blast cells showed also a low number of macrophages whilst a high transformation of lymphocytes was constantly associated with a high yield of macrophages, as we already observed in CLL [14].

The evaluation of the present findings cannot be univocal as the interpretation of the mechanism of decreased PHA lymphocyte transformation in Hodgkin's disease has led to different hypotheses. (1) If it is assumed that a plasmatic factor is involved [11-17] it could be suggested that the



same factor also inhibits the development of macrophages in blood cultures (2) Others [3, 13] believe that a depletion of the PHA responsive circulating T-lymphocytes is responsible for the low blastic transformation in some cases of Hodgkin's disease. If it is also assumed that lymphocytes could transform into macrophages in blood cultures [4, 8], the lymphopenia often observed in advanced cases of Hodgkin's disease (which are those with a low PHA lymphocyte transformation) [9, 16, 19] could also account for the decreased yield of macrophages. (3) If the source of macrophages in culture were only the monocytes [12, 18] the number of these should be reduced in peripheral blood of patients with Hodgkin's disease with a low blastic transformation of lymphocytes. This observation, however, has not been reported. Therefore, it seems that hypothesis 1 and 2 are more likely to be correct.

### References

- 1 AISENBORN A C. Quantitative estimation of the reactivity of normal and Hodgkin's disease lymphocytes with thymidine  $2^{14}$ . *Nature Lond* 203: 1233-1235 (1965).
- 2 BENNETT, W. L., and COHEN Z. A. The isolation and selected properties of blood monocytes. *J exp Med* 123: 145-160 (1966).
- 3 BENNINGHOFF E L., GIMARDY, R. I., and PERLHUTZ D. D. Thoracic duct and blood lymphocytes in cancer. *Lancet* ii: 264-265 (1973).
- 4 BIRMAN L. Lymphocytes and macrophages *in vitro*. Their activities in relation to functions of small lymphocytes. *Lab Invest* 15: 1094-1099 (1966).
- 5 BLASEY, H. M., OPPENHEIM J. J., SIEGEL R. C., and WALDMAN T. A. Lymphocyte macrophage interaction in antigen induced *in vitro* lymphocyte transformation in patients with the Wiskott-Aldrich syndrome and other diseases with anergy. *Cell Immunol* 4: 228-242 (1972).
- 6 ELVIS M. W., COHENOT M., and ISRAELI M. C. G. The potential of lymphocytes from patients with leukaemia and reticuloses to transform under the influence of phytohaemagglutinin. *Acta haemat., Basel* 37: 100-109 (1967).
- 7 GILBERT M. I., HUTTON G., and BLACKBURN F. K. Skin window macrophages in malignant lymphoma. *Brit J Haemat* 25: 293-297 (1973).
- 8 GOLDBERGER J., ELVIS M. W., and ISRAELI M. C. G. The formation of macrophages from lymphocytes *in vitro*. *Exp Cell Res* 39: 476-482 (1975).
- 9 HAN T. and SOGAEL, J. F. Lymphocyte response to phytohemagglutinin in Hodgkin's disease. *Amer J Med* 48: 728-734 (1970).
- 10 HEINE K. M., STUBB, H., HOFER I., and WIEBER H. Lymphozytentransformationstest bei chronischer lymphatischer Leukose unter Berücksichtigung der absoluten Lymphozytenzahl im Blut. *Acta haemat., Basel* 41: 144-153 (1970).
- 11 HERSH F. M. and JAYNE W. S. Blastogenic responses of lymphocytes from patients with untreated and treated lymphomas. *Lymphology* 2: 150-160 (1979).

- 12 LAMVIK, J. H. The transformation of human mononuclear leukocytes *in vitro*. II. Precursors of large mononuclear cells on coverslips. *Acta haemat., Basel* 37: 32-41 (1967).
- 13 MATCHETT, K. M., HILAN, A. T., and KREMER, W. H. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating T lymphocytes. *J. clin. Invest.* 52: 1908-1917 (1973).
- 14 NAVONE, R., MAZZUCCO, G., and STRAMIGNONI, A. Quantitative studies of macrophages in blood cultures in chronic lymphocytic leukaemia. *Acta haemat., Basel* 49: 335-339 (1973).
- 15 REBLICK, J. W., MONTO, R. W., MONAGHAN, F. A., and REDDIE, J. M. Potentialities of the lymphocyte with an additional reference to its dysfunction in Hodgkin's disease. *Ann. N. Y. Acad. Sci.* 73: 8-39 (1959).
- 16 SCHULZEIN, P. G., PAPPAS, A., and LEWIS, T. Stimulation der Blutlymphocyten durch Phytohämagglutinin bei chronischer Lymphadenose, Lymphosarkomatose und Lymphogranulomatose. *Klin. Wochschr.* 46: 493-490 (1968).
- 17 SCHULZEIN, P. G., SCHNEIDER, W., and PAPPAS, A. Inhibition of transformation of normal lymphocytes by plasma factor from patients with Hodgkin's disease and cancer. *Lancet* ii: 1265 (1971).
- 18 SUTTON, J. S., and WEISS, L. Transformation of monocytes in tissue culture into macrophages, epithelioid cells and multinucleated giant cells. *J. Cell Biol.* 29: 303-332 (1966).
- 19 TELBOWITZ, S., MAYER, H., and DEL ROSARIO, A. Lymphocyte response to phytohemagglutinin in Hodgkin's disease, lymphatic leukemia and lymphosarcoma. *Cancer* 19: 2019-2023 (1966).
- 20 VOLANTE, G., RUSSOLANI, G., and STRAMIGNONI, A. Ricerche sui mononucleati del sangue umano in cultura. I. Dati morfologici con e senza trattamento con fitoemagglutina. *Pathologica* 59: 1-22 (1966).

## Insoluble PHA – A B-Cell Mitogen in Man?<sup>1</sup>

G MICHELMAYR, C HUBER, H BRAUNSTEINER and H HUBER

Medizinische Universitätsklinik (Chairman Prof Dr H BRAUNSTEINER) Innsbruck

**Abstract** Blood lymphocytes of normal individuals and of patients with chronic lymphocytic leukemia were evaluated for their histogenic response to insoluble PHA. In *in vitro* least preferential stimulation of normal B lymphocytes was observed whereas leukemic lymphocytes were almost insensitive. This result supports the hypothesis of a functionally defective B lymphocyte population in chronic lymphocytic leukemia.

Various cell surface markers have been used to characterize lymphocyte populations [1, 3, 15, 16, 19, 21], which differ in their response to some mitogens [4, 6]. In mice a variety of experimental evidence suggests that phytohemagglutinin (PHA) acts only on T-lymphocytes [12]. B lymphocytes are also sensitive to PHA but only if the mitogen is presented in an insoluble form [7]. We have examined the response of normal and leukemic human peripheral blood lymphocytes to insoluble (sepharose-bound) PHA in comparison to the soluble mitogen.

### *Materials and Methods*

Cyanogen bromide activated sepharose (Sephacrose 4B Pharmacia Uppsala) was used. The coupling procedure with PHA P (Difco Lab., Detroit) was carried out as described by GRAYSON *et al* [7]. The loaded beads were then kept at 4°C overnight and used for the experiments on the next day. For determining the amount of bound PHA the mitogen was labelled with iodine 125 (Farbwerke Hoechst Frankfurt specific activity 8.15 Ci <sup>125</sup>I/mg B) by the chloramine T method [11].

<sup>1</sup> Supported by the Fond zur Förderung der wissenschaftlichen Forschung No 1769.

Lymphocytes from 12 patients with chronic lymphocytic leukemia (CLL) were investigated. The total white blood cell count ranged from  $12 \cdot 10^9$  to  $324 \cdot 10^9/\mu\text{l}$  with 69-99% lymphocytes. Three patients were under treatment with corticosteroids and 9 were treated with chlorambucil and corticosteroids. As controls we used lymphocytes from 10 hospitalized persons who showed a normal blood picture and did not exhibit immunological abnormalities. The lymphocytes were cultured under standard conditions [9].

Lymphocyte suspensions without sepharose beads as well as cultures incubated with PHA free beads served as controls. In some experiments the culture supernatants were obtained and tested for mitogenic activity. These supernatants had no stimulatory effect. Replicate cultures were performed in 4 patients, the results differed up to 25%.

$^3\text{H}$  thymidine incorporation into DNA was evaluated after 12 h labelling and the stimulation index calculated as follows:

$$\frac{\text{counts/min in the presence of mitogen}}{\text{counts/min in the absence of mitogen}}$$

The method of WYBRAW *et al* [22] with some modifications was employed for obtaining lymphocyte suspensions enriched with B or T lymphocytes. After rosetting, the lymphocyte suspensions were loaded on a Ficoll Hypaque gradient (1 ml cell suspension to 1 ml flotation medium). The tubes were centrifuged at 400 g for 20 min and the pellet as well as the interface fraction were collected using a Pasteur pipette. After determining the percentage of rosette forming lymphocytes (at least 3 bound red cells to one lymphocyte) the SRBC were hemolyzed by a short hypotonic shock, the cells washed twice in Hanks solution, resuspended in TC 199 and cultured with insoluble or soluble PHA under culture conditions.

### Results

In 3 experiments with  $^{125}\text{I}$ -PHA it was shown that about 90% of the PHA was bound to the sepharose beads when using 10 mg PHA. Using larger amounts of PHA the percentage of bound PHA decreased (fig. 1). The optimal dose for soluble PHA determined in previous experiments was  $20 \mu\text{g}$  PHA/ml culture for normal as well as leukemic lymphocytes. The dose-response curve of insoluble PHA was similar in controls and patients: the optimal concentration in both groups was  $40 \mu\text{g}$  bound PHA/ml culture (fig. 2).

In the presence of soluble or insoluble PHA, the maximal PHA-response of normal lymphocytes occurred at 72 h. Under both conditions leukemic lymphocytes showed a delayed response, with low values at day 3 and higher values at days 5 and 7 (fig. 3). Therefore the experiments were performed with an incubation period of 5 days.




Fig. 1. Dosis dependence of bound PHA to sepharose beads (3 experiments). PHA was labelled with <sup>125</sup>I and various amounts incubated with sepharose beads.

Fig. 2. Stimulation of normal (○-○) and leukemic (●-●) lymphocytes by various amounts of sepharose-PHA




Fig. 3. Stimulation of normal (○-○) and leukemic (▲-▲) lymphocytes by sepharose-PHA after various incubation times.

Lymphocytes from 10 controls and 12 patients with CLL were tested. The blastogenic response, as measured by <sup>3</sup>H-thymidine incorporation, is shown in table I. In the controls, soluble PHA was more effective than the insoluble mitogen. The average stimulation index was approximately three times higher. In patients with CLL there were 2 groups. Three patients with a very low transformation in the presence of soluble PHA showed a better transformation by insoluble PHA. The

Table 1 Transformation of normal and leukemic lymphocytes by insoluble PHA in comparison to soluble PHA

	Soluble PHA		Insoluble PHA	
	counts/min	stimulation index	counts/min	stimulation index
<b>Controls</b>				
1	94,315	133	21,079	30
2	85,300	170	11,449	22
3	73,150	133	11,101	39
4	47,634	II	21,516	36
5	46,707	618	1,365	111
6	43,540	70	32,909	53
7	34,321	70	22,814	46
8	28,816	58	8,882	111
9	24,726	34	3,734	5
10	18,361	14	5,649	5
<b>CLL</b>				
1	66,912	467	23,377	164
2	51,130	84	13,930	21
3	49,022	235	9,236	43
4	29,221	41	12,721	18
5	25,858	50	15,829	30
6	18,791	38	9,245	19
7	17,091	13	16,382	12
8	16,194	24	4,097	6
9	9,460	22	2,889	7
10	3,943	19	7,768	33
11	2,468	9	6,870	24
12	111	1	213	2

other 9 patients showed a higher transformation by soluble PHA, in 6 of these the values were within the range of our controls.

In 5 controls and in 5 CLL patients experiments were performed to enrich B- and T-lymphocytes. The results of the response are seen in figure 4. In controls the percentage of rosette-forming lymphocytes was between 23 and 55%. After centrifugation there was an enrichment of rosette-forming cells in the pellet (56-84%), only few rosettes were detected at the interface (1-5%). In the B-cell rich fraction there was a significantly higher response to insoluble PHA than in the pellet fraction, whereas the pellet had a better response to soluble PHA than the interface fraction.




Fig. 4 Response of T and B lymphocytes to soluble and sepharose PHA in normals and patients with chronic lymphocytic leukemia

In patients with CLL we found the known low percentage of rosette forming lymphocytes (5-18%). After Ficoll-centrifugation no rosette forming lymphocytes were seen at the interface: all rosettes were in the pellet. In contrast to normals the B-cell rich fraction showed a minimal response to soluble as well as to insoluble PHA. In the pellet with soluble PHA as mitogen the stimulation index was within the normal range.

### Discussion

Mitogens affecting B- or T-lymphocytes to different degrees have been employed for investigating the functional capacity of these cell populations. In the mouse a variety of nonspecific mitogens were tested: PHA and concanavalin A stimulate T-cells; pokeweed mitogen (PWM) and bacterial lipopolysaccharides (LPS) B-cells [4, 6]. If PHA is linked to sepharose beads it is also capable of activating B-cells [7]. In the human PHA acts similarly to the mouse primarily as a T-cell mitogen. PWM stimulates T- and B lymphocytes. LPS is probably not a very suitable mitogen for human lymphocytes. Mitogens acting mainly on human B lymphocytes are therefore of considerable interest.

Our experiments show that insoluble PHA almost exclusively in

duced a blastogenic response of the B-cell rich fraction. The suspension with most of the rosette forming cells, on the other hand, gave almost no response to the insoluble mitogen. These results are therefore in agreement with experiments in mice, suggesting a predominant effect of insoluble PHA on B lymphocytes. In CLL a marked blastogenic response to soluble PHA was observed in our T-cell rich suspensions. The blast cell transformation of this fraction was comparable to the normal controls, confirming the results of WYBRAN *et al* [22]. On the other hand in the B-cell rich fraction obtained by gradient centrifugation of CLL-lymphocytes, the response to soluble PHA was minimal. A concomitant loss of rosette forming cells and reactivity to soluble PHA was observed. The B-cell nature of lymphocytes in CLL is well-established [8, 10, 16, 17, 20]. There is some evidence of a functionally defective cell population in CLL. Lymphocytes from patients with CLL show a low content of lysosomal enzymes [2], the production of interferon is reduced [14], the receptors for PHA are diminished [13], leukemic B lymphocytes recirculate poorly in comparison to normal B-cells [5]. The fact that leukemic lymphocytes were almost insensitive to insoluble PHA – a mitogen primarily affecting human B lymphocytes – further supports the hypothesis of functionally defective lymphocytes in this disease.

*Acknowledgment* We are indebted to Miss F. OBERWASSERLECHNER for skilful technical assistance.

### References

1. BLANCO C., PATRICK, R., and HUSSEINZWEIG, V. A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. *J exp Med* 132: 702 (1970).
2. RAUTVIOJA, G., KÖNIG, F., CONNEN, H., and ARBELY, H. G. Lysosomale Enzyme in Lymphozyten I. Lymphoretikuläre Erkrankungen. Vergleich des Enzymgehaltes (saure Phosphatase,  $\beta$ -Glucuronidase) unstimulierter Blutlymphozyten mit der Blastentransformation nach Phytohemagglutininstimulierung *in vitro*. *Acta haematol. Basel* 44: 205 (1970).
3. DICKLER, H. B., and KUNZEL, H. G. Interaction of aggregated gamma globulin with B lymphocytes. *J exp Med* 136: 191 (1972).
4. DUNGLAS, S. H. Electron receptors and functional aspects of human lymphocyte response to mitogens. *Transplant. Rev* 11: 11 (1972).
5. FLAD, H. D., HUBER, C., BREMER, A., MENY, H. D., and HUBER, H. Impaired recirculation of B lymphocytes in chronic lymphocytic leukemia. *Europ J Immunol* 3: 685 (1973).
6. GRANT, M. J., and JANOSY, G. Elicitation of selective T and B-lymphocyte responses by cell surface binding ligands. *Transplant. Rev* 11: 87 (1972).



- 7 GRAVES, M. I. and BAUMINGER, S. Activation of T and B lymphocytes by in soluble phyto mitogens. *Nature Lond* 235 67 (1972)
- 8 GREY, H. M., RABILLINO L., and PIROFSKY, H. Immunoglobulins on the surface of lymphocytes IV Distribution in hypogammaglobulinemia, cellular immune deficiency and chronic lymphatic leukemia *J clin Invest* 50 2368 (1971)
- 9 HUBER, H.; PASTNER D. und GABL, I. Laboratoriumsdiagnose hämatologischer und immunologischer Erkrankungen p. 296 (Springer, Berlin 1972)
- 10 HUBER, H., MICHELMAYER G., ASAMER H., HUBER C. und BRAUNSTETTER, H. Die Differenzierung menschlicher Blutlymphozyten mit immunologischen und autoradiographischen Methoden I Ergebnisse bei Normalpersonen und bei Patienten mit chronischer Lymphadenose *Klin Wochr* 50 504 (1972)
- 11 HUNTER, W. M. and GREENWOOD I. C. Preparation of iodine 131 labelled human growth hormone of high specific activity *Nature, Lond* 191 495 (1962)
- 12 JANOSY, G. and GRAVES M. F. Lymphocyte activation I Response of T and B lymphocytes to phyto mitogens *Clin exp Immunol* 9 483 (1971)
- 13 KORNFIELD S. Decreased phytohemagglutinin receptor sites in chronic lymphocytic leukemia *Biochim biophys Acta* 192 542 (1969)
- 14 LEE, S. H. S., OZERI, R. L., and ROOYEN C. F. van Interferon production by human leucocytes *in vitro* Reduced levels in lymphatic leukemia *Proc Soc exp Biol Med* 122 32 (1966)
- 15 MICHELMAYER G. and HUBER, H. Receptor sites for complement on certain human peripheral blood lymphocytes *J Immunol* 105 670 (1970)
- 16 PAPADIMITRIU, M., HOLDOROW, F. J., KRITH, E. J., and CURRY, H. C. I. Subpopulations of human peripheral blood lymphocytes distinguished by combined rosette formation and membrane immunofluorescence *Lancet ii* 64 (1972)
- 17 PINCUS, H., BLANCO C., and NUSSENZWEIG, V. Increased proportion of complement receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia *Blood* 40 303 (1972)
- 18 RABILLINO F., COTOW, S., GREY, H. M., and UNANUE, E. R. Immunoglobulins on the surface of lymphocytes I Distribution and quantitation *J exp Med* 133 156 (1971)
- 19 ROSS G. D., RABILLINO, E. M., POLLEY, M. J., and GREY, H. M. Combined studies of complement receptor and surface immunoglobulin bearing cells and sheep erythrocyte rosette forming cells in normal and leukemia human lymphocytes *J clin. Invest.* 52 377 (1973)
- 20 WILSON, J. D. and NOSSEL, G. J. V. Identification of human T and B lymphocytes in normal peripheral blood and in chronic lymphocytic leukemia *Lancet ii* 789 (1971)
- 21 WYBRAN, J., CARR, M. C., and FUDENBERG H. H. The human rosette-forming cell as a marker of a population of thymus derived cells *J clin. Invest* 51 2537 (1972)
- 22 WYBRAN J., CHANTLER, S., and FUDENBERG H. H. Isolation of normal T cells in chronic lymphatic leukemia *Lancet i* 126 (1973)

## Lymphocytes Devoid of T and B Cell Markers in Chronic Lymphatic Leukemia

INDIRA NATH, JILL CURTIS, A. MANGALIK and G. P. TALWAR

Departments of Biochemistry and Medicine, All India Institute of Medical Sciences, New Delhi

**Abstract** Peripheral lymphocytes of 16 patients with chronic lymphatic leukemia were studied for B and T cell markers with peroxidase labelled anti immunoglobulin antisera and complement and spontaneous rosetting techniques. Increased numbers of B cells and normal numbers of T cells were noted. A significant observation was the presence of a large proportion of circulating lymphocytes without the conventional markers for T and B cells. This finding is correlated with clinical features.

Considerable evidence has accumulated to support the idea that bone marrow-derived, bursa-dependent B lymphocytes are increased in the peripheral blood of most patients with chronic lymphatic leukemia (CLL) [1, 12, 14, 17]. The status of T lymphocytes however, has been the cause of much controversy [7, 10, 15, 17]. Few reports are available in which both T and B lymphocytes have been examined simultaneously in the same patients [15-17]. Analysis of individual cases in these reports suggests that all the lymphocytes circulating in CLL patients cannot be characterized fully. The present work carried out on Indian patients indicates that a significant number of peripheral lymphocytes, at any given time, are devoid of T and B cell markers.

### Material and Methods

Sixteen normal controls and 16 patients with CLL were studied. Fifteen of the patients were untreated and one was undergoing therapy. Eleven of them had been diagnosed on routine haematological studies (asymptomatic) and the other 5 patients



Table 1 Total lymphocyte counts and percentages of E-rosettes, EAC-rosettes and immunoglobulin-bearing lymphocytes in peripheral blood of CLL patients

Patient	Total lymphocytes $\times 10^3/\mu\text{l}$	E-rosettes % <sup>a</sup>		EAC-rosettes % $\pm$ SE	Ig-bearing lymphocytes % $\pm$ SE	Unidentified lymphocytes %
		2 h	24 h			
SSC <sup>1</sup>						
a <sup>2</sup>	105.6	-	-	-	13.0 $\pm$ 2.5	-
b	207.0	2.0	-	13.0 $\pm$ 3.3	14.0 $\pm$ 2.4	84.0
PNM <sup>3</sup>	21.5	0.6	-	27.2 $\pm$ 2.0	32.0 $\pm$ 2.1	67.4
SPJ <sup>4</sup>						
a <sup>2</sup>	114.0	4.0	-	41.0 $\pm$ 4.9	37.0 $\pm$ 2.4	55.0
b	163.0	1.0	-	40.5 $\pm$ 3.5	47.0 $\pm$ 2.5	52.0
BD <sup>2</sup>	24.4	2.4	-	36.4 $\pm$ 2.2	45.2 $\pm$ 2.2	52.4
NL <sup>2</sup>	324.9	2.0	2.7	27.1 $\pm$ 1.6	-	70.1
DFM	213.8	0.4	-	45.0 $\pm$ 2.5	43.6 $\pm$ 2.2	54.6
INK						
a <sup>2</sup>	18.0	2.5	-	-	27.0 $\pm$ 2.8	70.5
b	36.6	0.2	-	35.6 $\pm$ 2.1	30.3 $\pm$ 2.7	64.2
DNDK	15.8	3.2	-	43.0 $\pm$ 2.8	44.0 $\pm$ 2.2	52.8
BR	53.6	0.6	-	30.4 $\pm$ 2.1	31.0 $\pm$ 2.1	68.7
KHL	235.2	0.1	-	-	54.0 $\pm$ 2.2	45.9
PVA	62.5	1.2	-	54.3 $\pm$ 2.5	53.7 $\pm$ 2.9	44.6
SH	17.6	1.8	2.0	72.6 $\pm$ 2.5	69.0 $\pm$ 2.6	25.4
HRC	36.8	1.0	2.5	40.0 $\pm$ 2.0	40.5 $\pm$ 2.2	47.5
RGO	14.8	4.3	5.7	-	35.8 $\pm$ 2.0	58.4
III	38.4	2.8	2.6	46.3 $\pm$ 2.9	52.0 $\pm$ 2.3	45.2
UDG	13.6	6.4	13.7	61.0 $\pm$ 2.4	-	32.4
Normals	2.3 $\pm$ 0.2 n=23	47.4 $\pm$ 1.5 n=12	77.3 $\pm$ 1.2 n=12	13.4 $\pm$ 0.8 n=13	13.1 $\pm$ 0.6 n=16	9.8

<sup>1</sup> SE's attached to such small percentages are inaccurate<sup>2</sup> Patients in symptomatic group<sup>3</sup> Time interval between tests = 3 weeks<sup>4</sup> Time interval between tests = 2 months

cases there was a good correlation of the percentage of lymphocytes identified as B cells by the 2 techniques (table 1) [11]. Peroxidase-labelled immunoglobulins de errunants appeared as brown specks or dots on the membrane of B lymphocytes. They were distributed randomly on the

Table II Total lymphocyte counts and percentages of E rosettes, EAC rosettes and immunoglobulin-bearing lymphocytes in peripheral blood of 3 patients followed up after 3-12 months

Patient	Interval since test in table I months	Total lymphocytes $\times 10^3/\mu\text{l}$	E rosettes %		EAC rosettes % $\pm$ SE	Ig bearing lymphocytes % $\pm$ SE	Unidentifed lymphocytes %
			2 h	24 h			
INA	3	27.46	10	87	62.5 $\pm$ 2.4	-	24.8
INA	10	29.60	49	66	79.6 $\pm$ 2.3	77.3 $\pm$ 2.4	13.8
PNA <sup>1</sup>	5	27.74	20	30	74.0 $\pm$ 3.1	63.2 $\pm$ 2.4	23.0
PNA <sup>1</sup>	12	15.25	33	117	62.6 $\pm$ 2.8	55.5 $\pm$ 3.5	25.7
DPN	11	161.68	36	56	80.6 $\pm$ 1.8	76.5 $\pm$ 3.0	13.8

<sup>1</sup> Patient in symptomatic group

membrane. Polar localization was seen in only 1% of the cells, even when the incubations were carried out at room temperature.

The total lymphocyte counts in the CLL patients varied from  $14$  to  $325 \times 10^3/\mu\text{l}$  (table I). B lymphocytes were significantly increased in 15 of the 16 patients (table I). The normal range of B lymphocytes was 9-18% or  $0.086-1.01 \times 10^3/\mu\text{l}$  in absolute terms. In 15 of the CLL patients studied, the percentage of B cells was increased to 27-72.6% with absolute numbers of  $5-127 \times 10^3/\mu\text{l}$  (table I). SSC was an exception with 14% B lymphocytes as checked on 2 separate occasions. The percentage of cells bearing IgM and IgA markers was in the range of 3-6 and 1-3% respectively.

T lymphocytes were identified by their ability to form spontaneous rosettes with sheep erythrocytes (E rosettes) after 2 and 24 h of incubation at  $4^\circ\text{C}$ . In control subjects an average of 47.4% or peripheral lymphocytes formed spontaneous rosettes at 2 h, and by 24 h this percentage increased to 77.3% (table I). In CLL patients, the percentage of 2 hour T cells was markedly low (table I). A mild increase in percentage was noted after 24 h of incubation at  $4^\circ\text{C}$ . However, the absolute T cell numbers in the circulation of these patients were within the normal range.

There was no relationship between the total lymphocyte counts and the percentage of circulating B and T cells. It is significant that in 14 of the 16 patients 40% or more of circulating lymphocytes could not be identified by the methods employed (tables I). By morphological criteria on Giemsa stained smears these cells were not different from those identified as B and T lymphocytes. It is noted that in 4 patients in the sympto-

### Unidentifiable lymphocytes in CLL

matic group the circulating B cells were 40% and below, whereas the non-identifiable cells were 50% and more. Only 2 (INK and BR) of the 11 asymptomatic patients had very high levels of non identifiable cells (64-70% table I).

Follow-up studies on 3 patients 3-12 months after the first tests showed that in all 3 cases lymphocytes bearing B cell markers had markedly increased while T cell numbers remained in the normal range. The percentage of unidentifiable cells was reduced to less than 30% (table II).

### Discussion

This study was designed to investigate the nature of the lymphocytes circulating in patients with chronic lymphatic leukemia. The enzyme marker peroxidase was used in the demonstration of Ig bearing B cells. With a view to studying the total population of B lymphocytes in circulation, cells bearing both surface Ig and complement receptors were measured. These studies in both the normal subjects and patients indicate a good correlation between the 2 methods. The range of B cells in the controls (9-18%) also corresponds well with earlier reports [8, 12, 14].

The present work indicates that B cells are increased severalfold in patients with CLL. The percentage of B cells in this group of patients studied does not fall in the extremely high or low ranges reported by some workers [12, 13]. Our data is similar to that of Proctus *et al* [14] who reported a B cell increase to  $50 \pm 25\%$ . It is evident, however, that in terms of absolute numbers our patients have very high numbers of circulating B cells.

The percentage of circulating T lymphocytes forming spontaneous rosettes is markedly low (1-4%) in all the patients of CLL. However, in view of the large error inherent in reading a small proportion of positive cells all patients appear to have near normal absolute numbers of circulating T cells. Therefore the marked reduction in the percentage of T lymphocytes noted in CLL appears to be due to the dilution effect of high numbers of other cells. This is in accordance with the data of Wybran *et al* [17] who demonstrated normal transformation with phytohemagglutinin when the dilution effect of the B cells was removed.

The striking feature in some of our patients is the presence of 40% or more cells which are not identifiable as either B or T cells. Incubation of lymphocytes with sheep erythrocytes for 24 h at 4°C significantly in-

increases the E rosettes in the normal and thus reduces the unidentifiable cells to a minimum. However in the CLL patients even though there is an increase in E rosettes at 24 h this does not contribute significantly to the percentage of identifiable cells. The population of cells without surface markers therefore remains high. Similar results have also been reported by McLAUGHLIN *et al* [9]. The identity of this population of cells in CLL is not clear. The possibility exists that these may be abnormal T cells without receptors for sheep erythrocytes. However, in view of the fact that B cells are markedly increased and T cells are in normal numbers it seems likely that these cells belong to the B cell category where immunoglobulin and complement receptors are not fully expressed. This view is supported by the fact that in 3 follow up studies the percentage of B lymphocytes increased markedly with a decrease in unidentifiable cells while T cells remained in normal numbers.

CLL may represent a spectrum of disease which corresponds to the degree of abnormality in the B cells. The formation of surface Ig may be a property acquired during cell maturation. One of our patients (SSC) who had low levels of B cells was severely ill and died within 6 weeks of the second evaluation. It may also be emphasized that higher percentages of B cells were noted in the asymptomatic group. Lower numbers of unidentifiable cells were also a feature of the asymptomatic patients. The number of lymphocytes attaining the Ig markers may reflect a better clinical state of the patient. From our preliminary data it appears that the identification of both B and T cells has a prognostic value in CLL. Numbers of circulating lymphocytes without surface markers may form an important criterion for assessing the clinical form of the disease.

### References

- 1 ANDERSON A C and FLECH J. Immunoglobulins on the surface of normal B lymphocytes. *New Engl J Med* 286: 272-276 (1972).
- 2 ANDERSON S and TERNBERG T. The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunological reagents. *Biochemistry J* 53: 11 (1971).
- 3 ANDERSON S and TERNBERG T. Peroxidase labelled anti-body and Fab fragments with enhanced rates of cell penetration. *Biochemistry J* 117: 1179 (1971).
- 4 PILLER C, PATTERSON R and NATHU CUNTA-MANOHAR V. A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. *J clin Med* 11: 702-710 (1970).

# Unidentifiable Lymphocytes in CLL

- 5 DODDS, D. R., SORFEMAN, S. A., WERTHOFF, M. M., and CARTWRIGHT, G. E. Factors influencing the duration of survival of patient with chronic lymphocytic leukemia. *Amer J Med* 40: 943-954 (1966)
- 6 BORTIN, A. Separation of leucocytes from blood and bone marrow. *Scand J clin Lab Invest* 21 suppl 97 (1963)
- 7 CATOVSKY, D. and HOLT, P. Letter to editor T or B lymphocytes in chronic lymphocytic leukemia. *Lancet* ii: 976-977 (1971)
- 8 FARKAS, S. S. and NATVIG, J. B. Clones and subclones of surface bound immunoglobulins on peripheral blood lymphocytes in man. In *Progr Immunol* (Academic Press, New York 1971)
- 9 McLAREN, H., WENTZEL, G., PITCHER, C., and HOSKE, J. R. Non-immunoglobulin bearing B lymphocytes in chronic lymphatic leukaemia. *Brit J Haemat* 25: 7 (1973)
- 10 MORRIS, G. L. and MINOWADA, J. Letter to editor T or B lymphocytes in chronic lymphatic leukemia. *Lancet* i: 38 (1972)
- 11 NATVIG, J., CURTIS, J., BIRUTAM, L. W., and TALWAR, G. P. The depletion of a subpopulation of T lymphocytes in lepromatous leprosy. *Clin. exp Immunol* 17 (in press)
- 12 PRATT, B., FURBER, M., FORGE, L., and AMAR, L. Immunoglobulins in surface membranes. In *Progr Immunol* (Academic Press, New York 1971)
- 13 PISTONE, W. F., SCHEP, P. H., VALLEY, W. C., and OUCHAL, W. H. Lymphocyte surface immunoglobulin. Distribution and frequency in lymphoproliferative disorders. *New Engl J Med* 289: 116-120 (1973)
- 14 PIVETS, S., BISCO, C., and HESTERWITZ, G. Increased proportion of complement receptor lymphocytes in the peripheral blood of patients with chronic lymphatic leukemia. *Blood* 40: 303-310 (1972)
- 15 RICH, A. D. and SCHUTZ, F. Letter to editor Surface immunoglobulin on lymphocytes in leukemia. *New Engl J Med* 287: 999-999 (1972)
- 16 WILSON, J. D. and HADLER, A. D. F. Surface immunoglobulin on lymphocytes in CLL and lymphosarcoma. *Brit J Haemat* 24: 563 (1973)
- 17 WILSON, J., CHANTLER, S., and FURCHT, H. H. Isolation of normal T cells in chronic lymphatic leukaemia. *Lancet* i: 126-129 (1973)

Request reports from Dr Indira NATH, Department of Biochemistry All India Institute of Medical Sciences, Ansari Nagar New Delhi 110015 (India)



## Dissociation between Factor VIII (Activity and Antigen) and Ristocetin-Induced Platelet Aggregation in von Willebrand's Disease

T. Barnui and L. Dini

Division of Haematology (Head: Prof. L. Dini), Regional Civil Hospital, Venezia

**Abstract.** Previously we showed that von Willebrand patients could be separated into 2 groups on the basis of ristocetin-induced platelet aggregation and factor VIII (antigen and activity). Ristocetin induced platelet aggregation and factor VIII exhibited a positive correlation. This paper deals with 5 out of 31 examined von Willebrand patients in which ristocetin induced platelet aggregation was not in correlation either with factor VIII activity or antigen. The importance of these findings is discussed.

**Key Words:**  
Coagulation disorders  
Factor VIII antigen  
Platelet aggregation  
Ristocetin  
Von Willebrand's disease

Recently it has been shown that ristocetin-induced platelet aggregation is impaired in several cases of von Willebrand's disease and that the abnormality may be corrected by addition of normal or haemophilic plasma [1, 5, 8].

Weiss *et al* [9] found a positive correlation between factor VIII activity, factor VIII antigen and the magnitude of platelet-induced aggregation by ristocetin in von Willebrand patients. They suggested that factor VIII refers to a molecule on which 3 activities are located: the antihæmophilic factor/procoagulant activity (AHF), the antigen (AGN) identified by rabbit anti-VIII antiserum and the factor necessary for ristocetin induced platelet aggregation (von Willebrand factor, vWF).

AHF, AGN and vWF have been found proportionally decreased in all von Willebrand patients examined by Weiss *et al* [9].

We report here some von Willebrand patients exhibiting a dissociation of the properties of the factor VIII molecule.

## Barnet/Dent

*Material and Methods*

31 patients with von Willebrand's disease were examined. Criteria for diagnosis were as follows: prolonged bleeding time assessed using Ivy's method, decreased factor VIII activity measured on freshly drawn plasma by a one-stage activated partial thromboplastin time method, using haemophilic plasma as substrate, decreased platelet adhesiveness, performed according to SALZMAN [7], history of haemorrhage and demonstration of family autosomal dominant disease. Most of the patients have been the subjects of previous studies [2].

Plasma factor VIII antigen was determined by Laurell's technique using Behringwerke antiserum, as previously described [3].

Platelet rich plasma (PRP) was prepared by centrifuging citrated blood (1 part citrate to 9 parts blood) for 15 min at 600 rpm. Platelet poor plasma (PPP) was obtained by centrifuging PRP at 5 000 rpm for 30 min. After an initial platelet count, PRP was diluted with PPP to give a platelet concentration of 300 000/mm<sup>3</sup>. 1 ml of PRP with known platelet number was distributed into silicone-coated glass test tubes.

Platelet aggregation was measured turbidometrically in Mustard's aggregometer attached to a Bauvch Lomb recorder. Before carrying out the determinations, zero transmission was set by adjusting the recorder tracer with PRP. PPP was used to fix 100%. Platelet aggregation was expressed as the percent change in optical density of PRP after addition of ristocetin.

Ristocetin sulphate was supplied by Lundbeck Copenhagen, and dissolved in normal saline to produce a final concentration in PRP of 1.0 mg/ml. Platelet count was performed according to PATTISON and DENT [6].

*Results*

Factor VIII antigen was normal in 10 patients (our normal range being from 50 to 160%). Five patients showed normal ristocetin induced platelet aggregation and 1 just at the lower limit of normal (our normality being greater than 50%).

Figure 1 gives the relationship between ristocetin induced platelet aggregation and factor VIII antigen. The greater part of patients presented a positive correlation between ristocetin aggregation and factor VIII antigen while 5 patients presented a low degree of ristocetin aggregation despite of normal amount of factor VIII antigen.

Mean and standard deviation of coagulation values are given in table I. Groups A and B refer to the patients exhibiting a positive correlation between ristocetin aggregation and factor VIII antigen. Group C includes the patients with poor ristocetin platelet aggregation and normal factor VIII antigen. The results of statistical analysis are presented in table II.

Table I. Coagulation values in the 31 von Willebrand patients

Group	Bleeding time min (normal 3-8) mean $\pm$ SD	Platelet adhesiveness, % (normal 25-50) mean $\pm$ SD	Factor VIII activity, % (normal 60-140) mean $\pm$ SD	Factor VIII antigen, % (normal 50-140) mean $\pm$ SD	Ristocetin aggregation, % (normal 50-70) mean $\pm$ SD
Group A, n=21	10.42 $\pm$ 6.39	9.57 $\pm$ 11.45	15.71 $\pm$ 9.03	11.52 $\pm$ 9.17	9.00 $\pm$ 10.41
Group B, n=5	24.20 $\pm$ 14.70	3.70 $\pm$ 6.49	49.00 $\pm$ 22.47	89.40 $\pm$ 17.51	72.00 $\pm$ 5.70
Group C, n=5	20.00 $\pm$ 13.50	8.00 $\pm$ 9.03	35.60 $\pm$ 4.39	95.60 $\pm$ 23.34	7.00

The patients were separated into 3 groups (A, B, C) according to the relationship between ristocetin-induced platelet aggregation and factor VIII antigen

Table II. Relations between ristocetin induced platelet aggregation and factor VIII (activity and antigen), platelet adhesiveness, and bleeding time (*r* and *p* from linear regression analysis)

	Number of pairs	<i>r</i>	<i>p</i>
Ristocetin aggregation and factor VIII activity	31	0.71	< 0.001
Ristocetin aggregation and factor VIII antigen	31	0.53	< 0.01
Ristocetin aggregation and platelet adhesiveness	31	-0.18	n.s.
Ristocetin aggregation and bleeding time	31	0.33	n.s.

n.s. = Not significant

## Discussion

In a previous paper [1] we showed that von Willebrand patients could be subdivided into 2 groups on the basis of ristocetin aggregation. The values of ristocetin aggregation were in correlation both with factor VIII antigen and activity, so that one may conclude that ristocetin aggregation might be a measure of entire factor VIII molecule. But, in a wider group of patients, we recognized 5 out of 31 cases, in which ristocetin aggregation was not in correlation either with factor VIII antigen or activity. The 5 patients exhibited values of ristocetin aggregation varying between 5 and 10%, while the factor VIII protein ranged between 50 and 130%. Four of them showed reduced factor VIII activity but normal amount of factor VIII antigen. The other patient had normal factor VIII activity

# Platelet Aggregation in v Willebrand's Disease




Fig 1 Relationship between ristocetin-induced platelet aggregation and factor VIII antigen. Dashed lines represent the lower limits of normal

and antigen. These findings are of interest as they suggest that there are some von Willebrand patients with reduced factor VIII activity but with normal amounts of factor VIII antigen. This observation has been reported also by HOLMBERG and NILSSON [3]. Moreover, one may assume that ristocetin-induced platelet aggregation depends on a factor different from factor VIII antigen and activity, probably the vWF.

Therefore, von Willebrand patients may be separated into 3 groups on the basis of ristocetin aggregation and factor VIII antigen (groups A, B, C in table 1). Group A, characterized by low degree of ristocetin aggregation and low plasma content of factor VIII antigen, includes the majority of cases, while group B, normal ristocetin aggregation and normal factor VIII antigen, and C, poor ristocetin aggregation and normal factor VIII antigen are much less frequent.

According to WEISS *et al* [8, 9] the defect in von Willebrand's disease may be due to a decreased synthesis of the entire factor VIII molecule, which results in a proportional decrease in factor VIII antigen, activity and vWF. These authors also suggest the possibility of an additional abnormality in the site of the molecule, that determines the activity of vWF. The cases here presented, belonging to group C, seem to confirm this possibility.

## References

- 1 BARBER T, BATTISTA R and DRAZ F. Relationship between ristocetin-induced platelet aggregation and factor VIII (activity and antigen) in von Willebrand's disease. *Blut* (in press 1974)

- 2 DINTI, E., BARBU, T., CHISESI, T., CAZZAVILLAN, M., BATTISTA, R., and CARTEI, G.: Von Willebrand's disease in Italy. A study of 13 families from a small area in the province of Vicenza. *Acta haemat., Basel* 52: 29 (1974)
- 3 GIROLAMI, A., BARBU, T., STIOCHI, A., and BAREGGI, G.: Factor VIII immunological assay. An evaluation of several methods using whole plasma. *Blut* (in press 1974)
- 4 HOLMBERG, L., and NILSSON, I. M.: Genetic variants of von Willebrand's disease. *Brit. med. J.* iii: 317 (1972)
- 5 HOWARD, M. A., SAWERS, R. J., and FIRKIN, B. G.: Ristocetin: a means of differentiating von Willebrand's disease into two groups. *Blood* 41: 687 (1973)
- 6 PALUZZO, E., e DINTI, E.: Su di un nuovo metodo per il conteggio diretto delle piastrine. *Haematologica* 41: 373 (1956)
- 7 SALZMAN, E. W.: Measurement of platelet adhesiveness. A simple *in vitro* technique demonstrating abnormality in von Willebrand's disease. *J. Lab. clin. Med.* 62: 724 (1963)
- 8 WEISS, J. H., ROGERS, J., and BRAND, H.: Defective ristocetin induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. *J. clin. Invest.* 52: 2697 (1973)
- 9 WEISS, H. J., HOYER, L. W., RICKLES, F. R., VARMA, A., and ROGERS, J.: Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. *J. clin. Invest.* 52: 2708 (1973)

**Un cas de myelose aiguë atypique: une leucémie ARN**

Un cas de myelose aiguë atypique  
A. SCHIFFNERG, A. WICZORKIEWICZ, A. RYTWIŃSKI et W. BARTNIAKOWA  
Instytut d'Oncologie Główny

**Abstract** In a 53 year-old female patient a tumor localized in the nasopharyngeal cavity together with hematologic features of acute promyelocytic leukemia were observed. More than 70% blast cells contained giant intracytoplasmic inclusions which have been found to be strongly pyroninophilic. The electron microscopic study revealed big agglomerations of intracytoplasmic RNA inside of pseudopodial structures of the cytoplasm. The possibility of a new nomenclature entity should be considered.

Acute myeloid leukemia  
Cellular inclusions  
Cytochemistry  
Electron-microscope  
RNA-leukemia  
Tumoral leukemia

Nous rapportons l'observation d'un cas de leucémie aiguë à début tumoral localisée dans la cavité nasopharyngée. Chez ce sujet nous avons observé dans le cytoplasme des blastes des inclusions géantes qui ont été identifiées comme étant de l'ARN ribosomal. La morphologie cellulaire ainsi que la symptomatologie clinique montrent donc des particularités intéressantes.

## Données cliniques et morphologiques

Mme G.P. âgée de 53 ans est admise à l'Institut d'Oncologie le 22 octobre 1973 pour une tumeur du sein de la région buccale gauche survenue il y a 6 mois. La température est normale le pouls 90/min rythmique. La marge inférieure du sein est palpable 2 cm au-dessous de l'aréole cristalline. Le mamelon ferme mais sculpté. Toute la région buccale gauche est gonflée accompagnée d'une adénopathie cervicale sous-angulaire non-metastatique et supra-claviculaire gauche. La main gauche est gonflée III, IV, V métacarpiens et suralavancule gauche. La main droite est normale. Sa surface cutanée présente quelques fragments rouges, nécrotiques. L'examen histologique de la biopsie et présence de cellules tumorales atypiques, nécrotiques. Les examens biologiques ne montrent aucune anomalie.

aucun des traits caractéristiques du granulome de Wegener. L'examen radiologique montre une opacification partielle de la cavité maxillaire droite sans altérations osseuses. La radiographie du thorax est normale.

*Examens complémentaires du 23 octobre 1973* Hématies, 2230000, hémoglobine, 7,9 g/100 ml. Leucocytes, 14900 dont 90% de blastes. Plus de 70% de ces blastes possèdent dans le cytoplasme des inclusions arrondies de 1,0 à 3,0  $\mu$ m de diamètre, qui se colorent par la méthode de May Grunwald-Giemsa d'une façon qui les fait ressembler à la chromatine. Les contours des noyaux sont parfois transparents, avec une superposition qui rappelle le pliage de la matière nucléaire (fig. 1a). Outre les blastes, on observe aussi 6% de lymphocytes, 2% de polynucléaires, 1% d'éosinophiles et 1% de monocytes. Les hématies montrent une anisocytose et une poikilocytose. Plaquettes, 210000, hématoците, 22%, vitesse de sédimentation, 35/h. La moelle osseuse sternale est infiltrée totalement par les blastes décrits dans le sang (fig. 1b).

*Réactions cytochimiques* Coloration à la peroxydase (méthode de Sato), positive (fig. 2a), coloration au «Sudan black B», négative, coloration au «oil red», négative, coloration au PAS, positive, diffuse, coloration par la méthode de Feulgen, négative dans les inclusions (fig. 2b), coloration à la phosphatase acide (méthode de Gomori) négative, à la coloration par la méthode de Brachet, les inclusions s'avèrent fortement pyroninophiles (fig. 2c). Au vu de ces résultats, le diagnostic d'une leucémie aigue myéloïde ou myélo-monocytaire à paramyéloblastes fut établi.

*Examen de l'ultrastructure* Le sang héparinisé fut centrifugé à 1000 t/min pendant 5 min. La couche des leucocytes fut préfixée dans une solution tampon d'aldéhyde glutarique. Les préparations furent rincées puis fixées dans une solution tampon de tétroxyde d'osmium. Après déshydratation, les petits fragments furent fixés dans de l'épon. Les coupes ultra-fines furent contrastées dans de l'acétate d'uranyle et du citrate de plomb et examinées au microscope électronique TESLA BS 513.

*Résultats* Les nucléoles, qui ont passé inaperçus au microscope optique, apparaissent très nettement. Ils ont des dimensions importantes et leurs contours sont irréguliers (fig. 3a). Les granulations primaires sont rares (fig. 3). Nous n'avons trouvé aucune fusion de ces granulations, ni formation des corps d'Auer. Le nombre de ribosomes est important, très fréquemment ils peuvent être rencontrés à l'intérieur des structures filamenteuses en anneaux, qui correspondent aux «zones en croissant» décrites par Bessis *et al* [2, 3] (fig. 3). Les mitochondries sont nombreuses et parfois géantes (fig. 3e). On peut les trouver aussi enfermées dans les «zones» (fig. 3a-d). Quelques zones contiennent des fragments du réseau endoplasmique lisse très ramifié et condensé (fig. 3e, f). On note aussi de nombreuses vacuoles et des grains de glycogène dans le cytoplasme (fig. 3).

En raison de l'apparition d'une occlusion respiratoire presque complète, nous avons irradié la tumeur par une dose totale de 480 R, répartie en 3 doses de 160 R, espacées de 3 jours. Immédiatement avant et après l'irradiation, la malade a reçu trois transfusions à 250 ml de sang frais. L'état local s'améliore, la dyspnée diminue. Cependant, en quelques jours une otite purulente apparaît au côté droit. Un nouvel examen du sang révèle une leucocytose (12900 dont 80% de paramyéloblastes, 13% de polynucléaires, 4% de monocytes, 2% de lymphocytes et 1% d'éosinophiles). Hématies, 2810000, hémoglobine, 8,8 g/100 ml, vitesse de sédimentation, 48/h.

Malgré une antibiothérapie et une corticothérapie, l'état de la malade continue à s'aggraver. Le 30 novembre 1973, les douleurs abdominales accompagnées d'anurie et un

Leucémie ARN




Fig 1 Erythros May-Gruenwald Giemsa a Sang, inclusions intracytoplasmiques et piége de la matière nucléaire dans les blastes b Moelle osseuse groupe de blastes montrant des inclusions = 900

Fig 2 Erythros sanguin a Coloration à la peroxydase par la méthode de Sato les blastes montrent une réaction positive b Coloration par la méthode de Feulgen les inclusions ne se colorent pas (flèches) c Coloration par la méthode de Brachet, les mêmes structures s'avèrent fortement pyronophiles (flèche) = 900

même à gu des poumons survenant La malade meurt le même jour après 6 semaines après son hospitalisation

Cette malade de 43 ans avait donc présenté une affection aiguë d'évolution rapidement mortelle caractérisée cliniquement par une invasion néoplasique de la cavité nasale





*Fig 3* Sang, microscopie électronique *a* Un blaste contenant un nucléole grand et irrégulier, ainsi que deux «zones en croissant» (flèches), il convient de noter le grand nombre de vacuoles, de ribosomes, de mitochondries de grande taille et les grains du glycogène  $\times 11700$ . *b* Dans la même cellule on voit enfermés dans les «zones» de très nombreux

## Leucémie ARV

pharyngienne des adénopathies superficielles et une hépatomégalie. Du point de vue hématologique le diagnostic d'une myélome primitive le 1er décembre 1973 montre un arôme

Diagnostic anatomique L'autopsie pratiquée le 1er décembre 1973 montre un arôme pulmonaire et cérébral important. Un foie hypertrophié des tumeurs ganglionnaires superficielles et médullaires un envahissement bilatéral par des masses tumorales de toute la cavité naso-pharyngienne et maxillaire ainsi qu'une otite purulente bilatérale. Histologiquement on retrouve dans les coupes de tous les organes, à l'exception du cœur, des muscles striés et du tissu sous-cutané une prolifération des cellules mononucléaires rondes, dont l'aspect est uniforme et correspond à celui des cellules qui constituent le contenu de la cavité sternale.

## Commentaires

Sur le plan clinique la localisation primaire suggère le groupe entier des maladies que les auteurs anglo-saxons appellent «lethal midline granuloma». Ce terme vaut pour toutes les lésions évolutives et destructives localisées dans la région naso-pharyngienne compris les lympho-sarcomes, les réticulo-sarcomes et le granulome de Wegener [11-16]. Ce dernier désordre peut être exclu puisque les altérations typiques c'est à dire une vasculite nécrotisante généralisée accompagnée d'une néphrite et d'une réaction allergique inflammatoire [19] ne furent pas observées. L'origine lymphatique de la tumeur doit être rejetée en vue de la réaction positive à la peroxydase.

Notre cas ressemble aux réticulo-histiocytosarcomes rapportés par TAJIMA *et al* [6] et à ceux de HILLBERG *et al* [14]. Toutefois des blastes sanguins contenant des inclusions ne furent pas décrits par ces auteurs. Il reste alors à établir s'il s'agit d'une tumeur de provenance myélomonocytaire qui finit avec une dissémination ultérieure hématogène ou bien d'une leucémie aiguë à début tumoral [7]. L'effet fatal de l'irradiation plaide, à notre avis en faveur d'une leucémie.

Sur le plan cytologique les inclusions font penser au syndrome de Chediak-Higashi Steinbrink [6-17]. Pourtant l'âge du notre malade les manifestations cliniques et les données de la microscopie rendent ce diagnostic inacceptable [14-9-20]. Les inclusions ne correspondent pas d'avantage

à des myéloblastes et ont des caractéristiques de blastes contenant une zone en croissant (fig. 1) à noter l'absence des granules myéloblastiques = 11700 / La même zone = remplie par des myéloblastes et des leucocytes = 23800 / La zone est remplie par des leucocytes et le réseau endothélial = 11700 / La zone est remplie et fortement condensée = 23800

aux bâtonnets d'Auer, qui sont des agglomérations de granules azurophiles, caractérisées par une structure organisée, lamellaire ou semi-cristalline et qui montrent une réaction positive à la phosphatase acide [5, 10, 12, 16, 18]. Les corpuscules de Döhle n'apparaissent que dans les éléments sanguins mûrs. Leur ultrastructure est caractérisée par les lamelles du réseau endoplasmique raboteux, dilatées et bordées de ribosomes [3]. Par contre, nous avons trouvé nos inclusions dans les cellules indifférenciées.

Les structures que nous venons de décrire montrent une pyroninophilie évidente. Au microscope électronique, on voit les amas de ribosomes, très fréquemment enfermés dans les « zones en croissant ». Ces zones, composées de fibrilles disposées concentriquement et formant des sphères ou des cylindres creux, ne doivent apparaître que dans les leucémies myéloblastiques et monocytaires [5, 13]. Ce sont, surtout, ces « zones », remplies par l'ARN ribosomal, qui sont responsables de l'aspect bizarre des cellules observé dans la coloration panoptique et dans celle de Brachet. Il faut accentuer le pourcentage extraordinairement élevé de cellules qui montrent cette anomalie, ainsi qu'une localisation inhabituelle de ribosomes. Ces altérations témoignent d'une atteinte grave du métabolisme nucléoprotidique chez notre sujet.

Si l'on tient compte, de plus, des manifestations cliniques atypiques, ces observations morphologiques semblent donner à ce cas un trait de nouveauté. C'est pourquoi nous considérons l'observation digne d'être rapportée dans le but d'attirer l'attention sur ce désordre qui — peut-être — constitue une entité nosologique nouvelle. Nous voudrions proposer le terme de « leucémie ARN ».

*Remerciement.* Nous remercions Mme Dr KRZYŹOWSKA GRUCA d'avoir exécuté et interprété les examens au microscope électronique.

### *Résumé*

Le cas d'une malade, âgée de 53 ans, que nous venons de rapporter est caractérisé par l'apparition d'une tumeur localisée dans la cavité naso-pharyngienne, alors qu'au point de vue hématologique il possède tous les traits typiques d'une leucémie aiguë à paramyéloblastes. Dans plus que 70% de ces blastes on trouve des inclusions intracytoplasmiques géantes, fortement pyroninophiles. La microscopie électronique y révèle des amas de ribosomes enfermés dans les structures filamenteuses en anneaux, les « zones en croissant ». Il peut s'agir d'une entité nosologique nouvelle.

## Leucémie ARN

## Bibliographie

- 1 BERNARD J, BESIN M, SEERGMANN M, CHASSAGNEUX J et CHOUR J. Le cas de malade de Chediak-Higashi. Presse méd 68: 563-574 (1940).
- 2 BESIN M et BESIN-GOMEL J. Examen des cellules leucémiques au microscope électronique par la méthode des coupes. Presse méd 63: 189-193 (1955).
- 3 BESIN M. Cytology of the blood and blood forming organs (Grune & Stratton New York 1956).
- 4 BESIN M, BERNARD J et SELIGMANN M. Etude cytologique d'un cas de malade de Chediak-Higashi. Rev franç Hémat 1: 422-425 (1961).
- 5 BESIN M et BESIN-GOMEL J. Pathologie et synchronisme de développement des organelles cellulaires au cours des leucémies à grès granulocytaires. Rev franç Hémat 9: 245-277 (1969).
- 6 CHENNAI M. Nouvelle anomalie leucocytaire de caractère constitutionnel et familial. Rev Hémat 7: 362-366 (1957).
- 7 DAWSON W and GUNZ F. Leukemia (Grune & Stratton New York 1948).
- 8 DE FARIA J L, CUTLER M, VINCIGUERRA A P and FERRIS R G. Malgrants granules of the face: contribution to its nomenclature. Arch Otolaryng 65: 255-262 (1957).
- 9 FERRIS R and DAWSON D. Electron microscopical study of bone marrow cells in a case of Chediak-Higashi syndrome. Brit J Haemat 15: 173-176 (1968).
- 10 FRIEDMAN I. Auer bodies. Proc roy Soc Med 57: 289-297 (1964).
- 11 FRIEDMAN I. Auer bodies. Proc roy Soc Med 57: 289-297 (1964).
- 12 GONZALEZ A F. Acid phosphatase activity in Auer bodies. Blood 24: 305-309 (1964).
- 13 HILTON D, SCHMALZ F and KRELL V. Ultrastructure myeloid leukemia. Blut 23: 189-206 (1971).
- 14 HILTON D, MOHRER R G and MARTINSON G. Malgrants granules. Acta haematol 47: 239-249 (1957).
- 15 KATZ S H, SCHWARTZ R A and GLENN F P. Malgrants granules. Cancer 23: 970-975 (1969).
- 16 LIPER I D. A case of acute leukemia with pseudo-Pelger cells containing Auer bodies. Acta haematol 47: 46-63 (1969).
- 17 MORGAN T J and FRIEDMAN I. Chediak-Higashi disease. Arch Path 68: 379-389 (1960).
- 18 NICHOLS T M. An electron microscope investigation of Auer bodies in myeloblastic leukemia. Canad med Ass 10: 865-867 (1970).
- 19 WILLIAMS I. Über eine genetisch bedingte Granulozytose mit besonderer Beteiligung des Arteriensystems und der Niere. Beih zur Anat 10: 36-63 (1939).
- 20 WINTZ J C. Granules organellenentwicklung in Chediak-Higashi lymphocyten. Amer J Path 69: 229-234 (1972).

Demandes de prêt à part Prof. A. SCHWARTZ, Institut d'Onco-génétique, Université de Liège (Belgique)  
 Circulation 15: 481-482 (1972)

## Haemoglobin Stanleyville II (a 78 [CF 7] Asn → Lys) Found in France

M L NORTH, PHILIPPA DENISE DARBRE, H LEHMANN and J G JUIF

Centre de Transfusion sanguine Strasbourg (Directeur Prof R WAITZ)  
MRC Abnormal Haemoglobin Research Unit, University Department of  
Biochemistry, Cambridge and Service de Pédiatrie III, CHU, Strasbourg

**Abstract** Haemoglobin Stanleyville II has been found several times in individuals from Central Africa. This paper now reports its discovery in Alsace in a family of long standing local ancestry.

**Key Words**  
Haemoglobinopathies  
Hb Stanleyville II  
Mucoviscidosis

In the Centre de Transfusion Sanguine de Strasbourg, an 8-year-old girl, who was affected with Mucoviscidosis, was found to possess an abnormal haemoglobin. This haemoglobin, representing 24% of the total, had a mobility similar to Hb S on electrophoresis at pH 9.2, but at pH 6.2 similar to that of Hb A. The mother and 5 of the 7 siblings possessed this abnormal haemoglobin. Only 2 of these 5 children had all the symptoms of Mucoviscidosis. The other 3 were less seriously affected and gave only abnormal sweat tests.

Hb Stanleyville II was first found in 2 families in the north east of the Congo, which is inhabited by a population of mixed Bantu-Nilotic origin [1]. It was then discovered in a third family of Nilotic stock from the West Nile region of Uganda [2] and in a young nun, also of Nilotic stock, from north east Zaire [3]. Finally, Hb Stanleyville II has been reported in a family of Sudanese ancestry of the Ngbandi tribe in the north of the Republic of Zaire [4]. In several instances the haemoglobin was found in association with Hb S. The family now being reported comes from Alsace and has been living there for many generations.

### *Materials and Methods*

Haemolysates were fractionated using column chromatography on DEAE Sephadex according to the method of HUISMAN and Dozy [5]. The abnormal haemo-

## NORTH DAKOTA LEHMAN JURY

Globin fraction was concentrated and purified by repeated electrophoresis on filter paper in Tris EDTA borate buffer at pH 8.9 [6]. Globin was prepared by precipitation (1.5% v/v of concentrated HCl in acetone) at 0°C [7] and washed 3 times in acetone at 0°C.

Tryptic digestion was carried out at a concentration of 30 mg polypeptide/0.2 ml TPCK treated trypanol ammonium bicarbonate buffer (pH 8.5) at 37°C for 2 h. (Trypsin treated with L-(1-antylamido-2-phenyl) ethyl chloromethyl ketone (TPCK) to inhibit *n*-chymotryptic activity was obtained from Worthington Biochemical Corp., Freehold N.J., USA.) The soluble tryptic peptides were fingerprinted using high voltage electrophoresis at pH 6.4 followed by ascending chromatography at right angles [9]. The fingerprints were stained with ninhydrin (0.2% in acetone) and with reagents specific for methionine, histidine, arginine, tyrosine and tryptophan [9].

To facilitate isolation of the abnormal peptides the  $\alpha$  and  $\beta$  polypeptide chains were separated on a column of Whatman CM 23 using a gradient of phosphate buffer in 8M urea at pH 6.7 (0.1M) to 0.10M to 0.2M [10]. The abnormal  $\alpha$ -chains were eluted at a higher sodium ion concentration than normal  $\alpha$ -chains. The eluate containing the abnormal  $\alpha$ -chains was desalted by dialysis against at least 5 changes of 3 litres of 0.5% formic acid at 6°C and lyophilised. The abnormal tryptic peptides were isolated by preparative fingerprinting of the abnormal  $\alpha$ -chain globin [11] and, where necessary purified by further electrophoresis at either pH 3.5 in a Muhl tank or pH 9.0 on a flat bed electrophoresis plate. The purified abnormal peptides were eluted with constant boiling HCl, hydrolysed in sealed capillary tubes at 110°C for 18-24 h, dried over  $\text{CaOH}_2$  in vacuo and subsequently analysed on a Lomat Amino Acid Analyser [12].

## Results

Figure 1 shows a fingerprint of the soluble tryptic peptides obtained from the abnormal haemoglobin. It differed from that of Hb A by the absence of the electrically neutral peptide  $\alpha\text{TpI}$  (62-90) and the positively charged peptide  $\alpha\text{TpI}111-1\text{V}$  (61-90) (1 and 5 in fig 1) both of which contain methionine and histidine and by the presence of 3 new peptides (2, 3 and 4 in fig 1). One of these new peptides gave a positive reaction for histidine (2 in fig 1) and the other 2 for methionine (3 and 4 in fig 1). The area 2 (fig 1) was separated into 2 peptides by electrophoresis at pH 3.5 (see Materials and Methods).  $\alpha\text{TpI}11$  and a new peptide which gave an amino acid composition identical with residues 61-90 of the  $\alpha$ -chain (table I). This new peptide was thus called  $\alpha\text{TpI}1\text{V}$ . The area 3 (fig 1) was shown by electrophoresis at pH 9.0 to consist of 2 peptides,  $\alpha\text{TpI}1\text{V}$  and a new peptide possessing the amino acid residues 62-90 of the  $\alpha$ -chain except that one aspartic residue

## Hb STANLEYVILLE II




Fig 1 Fingerprint of Hb Stanleyville II 1 = Peptide  $\alpha$ TpIX missing 2 = new  $\alpha$ TpIXb (histidine-positive) +  $\alpha$ TpIII, 3 = new  $\alpha$ TpIXa (methionine histidine positive) +  $\alpha$ TpIV, 4 = new  $\alpha$ TpVIII IX $\gamma$  (methionine histidine positive) +  $\beta$ TpI, 5 = peptide  $\alpha$ TpVIII IX missing The peptides were subsequently further separated (see text)

Table 1 The amino acid composition (molar ratios) of  $\alpha$ TpIX $\gamma$  and  $\alpha$ TpIXb from Hb Stanleyville II

Amino acid	Hb Stanleyville II		Hb A $\alpha$ TpIX
	$\alpha$ TpIXa	$\alpha$ TpIXb	
ASP	3.8	1.2	6
THR	1.0	-	1
SER	-	1.9	2
PRO	0.7	-	1
ALA	4.2	3.0	7
VAL	3.0	-	3
MET	0.8	-	1
LEU	1.0	3.0	4
HIS	1.1	1.9	3
LYS	1.0	1.1	1
Yield, nmol/residue	6.6	8.9	

was missing and had been replaced by one lysine residue (table 1). This new peptide was called  $\alpha$ TpIXa. It was assumed, because of the specificity of trypsin, that lysine was in the C-terminal position of this peptide, where an asparagine is present in the  $\alpha$ -chain of Hb A.

It was concluded that the mutation was asparagine 78 (EF7)  $\rightarrow$  lysine and that the variant was Hb Stanleyville II.

## References

- 1 DIERCKE P, VANDEPITTE J, ACER J A M and LEHMANN H Stanley II 1 and II Two new variants of adult haemoglobin. *Brit med. J* II 287 284 (1959)
- 2 HALL CROGGS M, MARSDEN E D, RAPER A M, LEHMANN H and BEALE H Homozygous sickle cell anaemia arising from two different haemoglobins. 5. Interaction of haemoglobins S and Stanley II. *Brit med. J* I 87-89 (1964)
- 3 VAN RAN G, BEALE D and LEHMANN H Haemoglobin Stanleyville II (G78 Asparagine → Iysine). *Brit med. J* iv 97 93 (1968)
- 4 VAN RAN G, WILTSHIRE D, RENOMTE MONJOIE A M, VANDVOORT T H and LEHMANN H Interaction entre les hémoglobines Stanley II et S dans une famille du Zaïre. Étude de l'hybride Stanley II'S ( $\alpha_278$  Lys,  $\beta_26$  Val). *Biochimie* 55 1107-1119 (1973)
- 5 HILTMAN T H J and DURY A M Studies on the heterogeneity of hemoglobin. IX. The use of Tris (hydroxymethyl) amino methane HCl buffers in the anion-exchange chromatography of hemoglobins. *J. Chromat.* 19 160-169 (1965)
- 6 CRADOCK-WATSON J F, FENSON J C B and LEHMANN H Tris buffer for the demonstration of Hb A<sub>2</sub> by paper electrophoresis. *J. clin. Path.* 12 377-373 (1959)
- 7 ARONOW M L and MURPHY A F Protein coagulation and its reversal. The preparation of insoluble globin, soluble globin and heme. *J. gen. Physiol.* 13 469-483 (1950)
- 8 SICK K, BEALE D, IRVING D, LEHMANN H, GORDALL P T, and MacDONALD S Hb G Copenhagen and Hb J Cambridge. Two new  $\beta$ -chain variants of Hb A. *Biochim. biophys. Acta* 140 231-242 (1967)
- 9 SMITH I in *Smith Chromatography and electrophoretic techniques*. 3rd ed. vol. I pp. 119-127 (Hermann London 1969)
- 10 CHENG J H, SALTONSTALL M A and WEATHERALL D J Abnormal human haemoglobins. Separation and characterization of the  $\alpha$  and  $\beta$  chains by chromatography and the determination of two new variants, Hb Chesapeake and Hb Hwang. *J. molec. med.* II 1 19-91 104 (1966)
- 11 BEALE H A partial amino acid sequence for sheep haemoglobin A. *Biochem. J.* 101 154-160 (1967)
- 12 SPACKMAN D H, STEIN W H and HUNTER S Automatic recording apparatus for use in the chromatography of amino acids. *Analyt. Chem.* 30 1190-1196 (1958)

Request reprints from Prof H LEHMANN, MRC Abnormal Haemoglobin Unit, University Department of Biochemistry, Addenbrookes Hospital, Hills Road, Cambridge CB2 9QR (Eng. and



## A Case of Homozygous Haemoglobin Lepore<sub>Boston</sub> in Iran

S RAHIBAR, M AZIZI and G NOWZARI

Department of Applied Biology, University of Tehran and  
Bahrami Children's Hospital Tehran

**Abstract** Homozygous haemoglobin Lepore<sub>Boston</sub> disease is described in an Iranian 16-year old boy presenting the clinical manifestations of  $\beta$  thalassaemia major. The parents were related (cousins) and both carriers of Lepore trait. It seems that the symptoms are milder in this case than what reported before.

**Key Words**  
Hb Lepore  
Haemoglobinopathies  
Thalassaemia

Lepore haemoglobins are the result of unequal crossing-over between structural genes coding for  $\delta$ - and  $\beta$ -polypeptide chains of human haemoglobin during meiosis. The abnormal polypeptide chain  $\delta\beta$  produced after this crossing-over, has part of the  $\delta$  chain at its N-terminus and the remaining is similar to the  $\beta$ -chain [1]. The point of the fusion of two polypeptide chains, and the proportion of the  $\delta$ - and  $\beta$ -chains varies in different types of Lepore haemoglobins. In haemoglobin Lepore<sub>Boston</sub>, the point of the fusion of two polypeptide chains is somewhere between residue 87 of the  $\delta$ -chain and 116 of the  $\beta$ -chain [7].

Haemoglobin Lepore<sub>Boston</sub> has been reported before in heterozygous, homozygous and double heterozygous states in association with  $\alpha$ -thalassaemia [3, 9-11]. In this article, we describe a case of homozygous haemoglobin Lepore<sub>Boston</sub> in an Iranian family presenting the clinical manifestations of  $\beta$ -thalassaemia major. The disease looks to be milder in this case than the cases reported by FESSAS *et al* [3].

### Case History

The proband was a 16 year old boy admitted to the children's hospital with preliminary diagnosis of Cooley's anaemia. He has been splenectomised 8 years

ago and has the characteristic mongoloid faces, hepatomegalia and growth retardation. RBC  $3.4 \times 10^6/\text{mm}^3$ , WBC  $12,400/\text{mm}^3$ , haematocrit 32%, haemoglobin 10.2 g/100 ml, reticulocytes 9%, MCV  $87 \text{ nm}^3$ , MCH 30, MCHC 34. Red cell morphology hypochromia ++, anisocytosis ++, poikilocytosis ++, microcytosis +++.

The parents of the proband were cousins. The father, aged 57, presented a mild anaemia. Hb 11.8 g/100 ml, RBC  $4.2 \times 10^6/\text{mm}^3$ , haematocrit 34%, reticulocytes 3%. Red cells were hypochromic, anisocytosis, poikilocytosis and target cells were present. Mother, aged 43, was anaemic. RBC  $3.7 \times 10^6/\text{mm}^3$ , Hb 11.4 g/100 ml, haematocrit 32%, reticulocytes 3%. Red cells presented hypochromia, anisocytosis, poikilocytosis, microcytosis and target cells. The proband has two married sisters, not available for study and there is the history of a died child at 11 from unknown reason.

Haemolysates were prepared by washing the red cells 3 times with 0.9% saline and lysed by the addition of 1 vol of distilled water and 0.5 vol of carbon tetrachloride to the packed red cells followed by centrifugation. Fetal haemoglobin was estimated by 1 min alkali-denaturation of SPECTER *et al* [14], to be 73.5% of total haemoglobin. Heat denaturation was negative according to GIBBS *et al* [9].

Electrophoresis of the haemolysates at alkaline pH on cellulose acetate [4], and in starch gel pH 8.6 revealed the presence of fetal haemoglobin (HbF) and another slow moving band in the same position of HbS, with complete absence of HbA and HbA<sub>2</sub>. Examination of the parents haemolysates showed the same slow moving haemoglobin band in addition to HbA. There was no fetal haemoglobin found in the parents haemolysates, but HbA<sub>2</sub> was present. The proportion of the abnormal haemoglobin fraction was 2% of total haemoglobins as estimated by elution of haemoglobin bands after electrophoresis on cellulose acetate [9].

Separation of  $\alpha$  and  $\beta$  polypeptide chains of haemoglobins by electrophoresis of the haemolysates on cellulose acetate according to UEDA and SCHIMMEL [15] using buffers containing 6M urea and 0.05M 2-mercaptoethanol as well as treatment of haemolysates with *p*-hydroxymercuribenzoate (PMB) followed by starch gel electrophoresis pH 8.6 [13] revealed that the abnormality existed in the  $\beta$ -chain (non- $\alpha$ -chain). With such a low proportion of the abnormal fraction without being unstable and the entirely absence of HbA and HbA<sub>2</sub>, and large amount of fetal haemoglobin in the proband homozygous haemoglobin Lepore was suspected.

The abnormal haemoglobin was purified by column chromatography of the haemolysates on DEAE-cellulose (Whatman DE 52), using Tris HCl buffer pH 8 0.05M [6], and the protein was concentrated in vacuo. Globin was prepared by treatment of purified haemoglobin with 2% HCl in acetone at -20°C, the precipitates were washed with cold acetone and freeze dried.

Peptide chains of the globin were prepared by CMC column chromatography of the globin in phosphate buffers at pH 6.8 containing 8M urea and 0.05 2-mercaptoethanol according to CHEN *et al* [2]. The chains were acetylated and tryptic digestion and fingerprinting of 5-aminoacetylated chains were carried out [2]. Figure 1 shows the fingerprints of the 5-aminoacetylated non- $\alpha$ -chain of the abnormal haemoglobin. It can be seen that the peptide (T<sub>6</sub>) is missing from its usual place (1) and has shifted towards the cathode (2).




Fig 1 Fingerprints of the S aminoethylated non  $\alpha$  chain of Hb Lepore 1 = Peptide  $\beta$  Tp3 is missing from its usual place 2 = new peptide with the same amino acid composition of  $\delta$ -Tp3

Peptides T3 and T5 were eluted from four preparative fingerprints of the non  $\alpha$  chain of the abnormal haemoglobin with 6N HCl and hydrolysed at 110°C for 20 h in micropipettes. The amino acid composition of each peptide was determined on an automatic amino acid analyser (Hitachi KLA 5). The results indicate the same amino acid composition found in the respective tryptic peptides of the  $\delta$  chain namely  $\delta$  Tp3 and  $\delta$  Tp5. An alanine was found in  $\delta$  Tp3 instead of the glutamic acid in the  $\beta$  Tp3 and a serine residue was found in  $\delta$  Tp5 instead of threonine in the peptide  $\beta$  Tp5. This serine at residue 50 = a good index of the presence of haemoglobin Lepore<sub>Boston</sub>.

### Discussion

The clinical manifestations in the propositus, and the presence of the large amount of fetal haemoglobin in the haemolysates, mimics  $\beta$ -thalassaemia major which is frequently found among Iranians [12]. The demonstration of an abnormal haemoglobin with Lepore characteristics in the haemolysates of the propositus and his parents, the complete absence of HbA and HbA<sub>2</sub>, in the propositus and the investigation of the abnormal haemoglobin, made the diagnosis of homozygous haemoglobin Lepore<sub>Boston</sub>. Homozygous haemoglobin Lepore has been reported before by FESSAS *et al* [3], NEEB *et al* [9], and QUATTRIN *et al* [10]. In

our patient, the disease looks to be milder than the cases reported by FESSAS *et al* [3], having haemoglobin levels between 5.6 to 9.1 g/100 ml and RBC 2-3 millions/mm<sup>3</sup>.

*Acknowledgement* This work is supported by Research Grants from The University of Tehran and the Ministry of Science and Higher Education of Iran.

### References

- 1 BARTON C. The fusion of the peptide chains in hemoglobin Lepore and its interpretation as a genetic deletion. *Proc. nat. Acad. Sci., Wash.* 49: 1880 (1962)
- 2 CLEGG, J. B., SAUGHTON, M. A., and WEATHERALL, D. J. Abnormal human haemoglobins. Separation and characterisation of the  $\alpha$  and  $\beta$ -chains by chromatography and the determination of two new variants, Hb Chesapeake and Hb J Bangkok. *J molec. Biol.* 19: 91 (1966)
- 3 FESSAS P., STOMATOYANNIDIS, G., and KARAKIS A. Hemoglobin 'pylos'. Study of hemoglobinopathy resembling thalassemia in heterozygous, homozygous and double heterozygous. *Blood* 19: 1 (1962)
- 4 GRAMM, J. L. and GRUNBAUM B. W. A rapid method for microelectrophoresis and quantitation of hemoglobins on cellulose acetate. *Amer. J. clin. Path.* 34: 567 (1963)
- 5 GRIMES A. J., MURPHY A., and DACH, J. V. Congenital Heinz body anemia, further evidence of the cause of the Heinz body production in red cells. *Brit. J. Haemat.* 10: 241 (1964)
- 6 HUTSMAN T. H. J. and DUFFY A. M. J. Studies on the heterogeneity of hemoglobin 1X. The use of Tris(hydroxymethyl)aminomethane-HCl buffers in the anion-exchange chromatography of hemoglobins. *J. Chromat.* 19: 160 (1965)
- 7 LABIE D., SCHEIDTGEN W. A., and HUTSMAN T. H. J. The amino acid sequence of the chains of hemoglobin Lepore<sup>Laos</sup>. *Lepore<sup>Laos</sup> agglutination*. *Biochim. biophys. Acta* 127: 429 (1965)
- 8 MATTESON ROBERT A. J. Rapid electrophoresis and quantitation of hemoglobins on cellulose acetate. *J. clin. Path.* 19: 700 (1966)
- 9 NIEB H., BRUNER J. E., STONE, J. H. P., KAARSTADT J. A., and MILLER, C. J. Homozygous Lepore haemoglobin disease appearing as thalassemia major in two Papuan siblings. *Trop. geogr. Med.* 13: 207 (1961)
- 10 QUARANTE N., BIANCHI P., CERRI R., DI ROSA, L., DI NI, L., and VENTURATO I. Study on nine families with haemoglobin Lepore in Campania. Hb Lepore trait heterozygosity for Hb Lepore and beta thalassemia, homozygosity for Hb Lepore. *Acta haemat.* 47: 256 (1967)
- 11 RAHMAT S., GORDAN-MURHAM, N., and SARTOU, H. Hemoglobin Lepore<sup>Laos</sup> in two Iranian families. *Blood* 41: 700 (1973)
- 12 RAHMAT S. Hemoglobinopathies in Iran. 14th Int. Congr. of Haematology, Sao Paulo 1972.

- 13 ROSEMEYER M A and HUTCHINS, E R On the mechanism of the dissociation of hemoglobins *J molec Biol* 25 253 (1967)
- 14 SINGER, K, CHERNOFF, A I, and SINGER, L. Studies on abnormal hemoglobins *Blood* 6 413 (1961)
- 15 UEDA, S and SCHNEIDER R G Rapid differentiation of polypeptide chains of hemoglobins by cellulose acetate electrophoresis of hemolysates *Blood* 34 230 (1969)

## Some Aspects of Erythropoietic Cell Proliferation in Erythroleukaemia

P. S. MITROU, M. FISCHER and K. HICHTER<sup>1</sup>

Abteilung für Hamatologie (Leiter: Prof. Dr. H. MARTIN)  
Zentrum der Inneren Medizin und Abteilung III, Senckenbergisches Zentrum  
der Pathologie (Leiter: Prof. Dr. K. HICHTER)  
der Johann Wolfgang-Goethe-Universität, Frankfurt/M.

**Abstract** Cytophotometric autoradiographic investigations on erythropoiesis in erythroleukaemia indicate: (1) the decreased labelling index of erythroblasts is explained by an increased percentage of these cells in G<sub>0</sub>, (2) 'megakoblastoid' basophilic erythroblasts show a more pronounced decrease of their fraction in DNA synthesis than morphologically normal cells, (3) 'megakoblastoid' early polychromatic normoblasts represent a non-proliferating cell population, and (4) the detected disturbance of cell proliferation – even though temporary – can be reversed.

**Key Words**  
Autoradiography  
Cytophotometry  
DNA synthesis  
Erythroleukaemia  
Ineffective erythropoiesis  
'Megakoblastoid' erythroblasts

Erythroleukaemia or DiGuglielmo syndrome is defined as an acute or chronic myeloproliferative disorder in which erythrocytes and their precursors are predominantly involved [3, 7]. Hyperplastic erythropoiesis is characterized by 'megakoblastoid' changes, nuclear abnormalities, giant erythroblasts and a strongly positive PAS reaction. Recent investigations give evidence that the erythropoiesis is highly ineffective [8]. Our work with the combined cytophotometric-autoradiographic method should help to answer the following questions: (1) Are the proliferating erythroblasts arrested in a defined phase of cell cycle? (2) Have 'megakoblastoid' erythroblasts other proliferative characteristics than the morphologically normal cells?

<sup>1</sup> We wish to thank H. M. BROUWER for excellent technical assistance.

## Methods

Single cell suspensions of bone marrow were incubated for 1 h at room temperature with tritiated thymidine. The concentration of  $^3\text{H}$  thymidine was  $2\ \mu\text{Ci/ml}$ , the specific activity  $5\ \text{Ci/mmol}$ . Cell smears were fixed with absolute methanol ( $2 \times 10\ \text{min}$ ) and stained by the May Grünwald Giemsa method. Basophilic, early polychromatic and oxyphilic erythroblasts were photographed and the cell areas marked with an 'Objektmarker' (Leitz, Germany) on a second slide.

Erythroblasts were classified according to KILLMANN [10]. The May Grünwald Giemsa stain was then leached out with 5% trichloroacetic acid (30 sec) and absolute methanol (10 min) and the smears were restained by the Feulgen method using a 9 min hydrolysis in 1 N HCl at  $60^\circ\text{C}$ . The DNA content was measured with a cytophotometer UMSP I (Zeiss, Germany) at 560 nm. The mean DNA value of at least 40 lymphocytes represented the diploid value.

Autoradiographs were prepared by the dipping method at  $18^\circ\text{C}$ , using the emulsion K5 (Ilford, England). Unstained smears were exposed at  $2-4^\circ\text{C}$  for 7 days, smears stained by the Feulgen method for 21 days and developed 3 min with Kodak D19 at  $18^\circ\text{C}$ . Unlabelled cells with a diploid DNA content were in the presynthetic phase ( $G_1$ ), all labelled cells were in the S phase. Unlabelled cells with a tetraploid content of DNA could be found in  $G_2$  or premitotic phase.

## Patients

The erythropoiesis of 5 patients (table I): 3 females and 2 males, was analyzed by the combined cytophotometric autoradiographic method. In an additional case (No 1) only a cytophotometric examination was possible. The erythropoiesis of patient 6 was examined 3 weeks after therapy with cytotoxic agents.

All but one had a short anamnesis with anaemia and/or haemorrhagic diathesis. Patient 2 suffered 51 months from an aplastic anaemia before erythroleukaemia appeared. Initial severe anaemia was a common symptom (table I), thrombocytopenia was present in 5 of 6 patients. In all instances erythroblasts were present in peripheral blood, their number varied between 40 and  $17,500/\text{mm}^3$ . Bone marrow examination revealed a striking erythroid hyperplasia with 'megakaryoblastoid' changes, multinucleated erythroblasts, and other nuclear abnormalities. In 3 cases (No 1, 5, 6) a typical pattern of intense erythroblastic positivity of PAS reaction was observed. The erythroblasts of the patients 1 and 5 showed excessive cytoplasmic vacuolization.

## Results

Erythroblasts were classified in 4 compartments  $E_1 + E_2$ ,  $E_3$ ,  $E_4$ , and  $E_5$ . In each compartment 'megakaryoblastoid' and morphological normal cells were pooled. Differential counts of erythropoiesis (table II) showed

Table 1 Main haematological data of the patients. The PAS reaction was evaluated according to the scoring method of QUADRINO and HAYNIE (11)

Patient No.	Age	Hb g/100 ml	WBC $\times 10^3/\mu l$	Platelets $\times 10^3/\mu l$	Erythroblast %	Erythropoiesis					
						erythro-poiesis, %	Cytoplasmic vacuoles	PAS reaction	Giant cells	Megalo-blasts <sup>a</sup>	Nuclear abnormalities
1	73	79				50	+	202	+	+	+
2	39	93	2.0	32.0	40	50	+				
3	28	73	6.0	22.0	1100	69	0	30	+	+	+
4	18	69	2.8	90.0	350	40	0	-	+	+	+
5	38	69	3.7	150.0	110	64	0	35	+	+	+
6	62	66	3.9	11.0	110	52	+	152	+	+	+
			21.0	21.0	17,800	93	0	55	+	+	+



Table II Erythroblasts in bone marrow differential count, in each case 500 erythroblasts were differentiated

Patient No	$E_1 + E_2$	$E_3$	$E_4$	$E_5$
1	1	0.7	0.7	0.4
2	1	1	1.6	1.6
3	1	0.9	1.7	1.3
4	1	0.6	1	1.1
5	1	0.4	0.4	0.7
6	1	0.6	1	1.1
Normal values (6 cases)	1	1.3	3.0	7.4


an increased percentage of immature forms  $E_1$  and  $E_2$ , a disturbed proportion of  $E_1 + E_2$ ,  $E_3$ ,  $E_4$ ,  $E_5$  of 1.071111 (mean values) was obtained

Table III contains the results of the combined cytophotometric-autoradiographic study. In 4 cases (No 2-5) a markedly increased percentage of basophilic erythroblasts ( $E_1-E_2$ ) and early polychromatic normoblasts ( $E_4$ ) in  $G_1$  with a decrease of DNA-synthesizing cells was found, quantitative differences between these 4 cases are evident. Only in early polychromatic normoblasts a decreased S  $G_2$  ratio was obtained, the percentage of cells in premitotic phase was high in comparison to that in DNA synthesis.

In 2 cases (No 2, 5) the distribution of 'megaloblastoid' and morphological normal erythroblasts in the various stages of the cell cycle were compared (table IV). It is obvious that in both cases 'megaloblastoid' basophilic erythroblasts either show a more pronounced decrease of their portion in  $E_5$  or an increase in  $G_1$  than morphological normal cells (fig. 1). This change can be recognized in both proerythroblasts, macroblasts ( $E_1$ ,  $E_2$ ) and basophilic normoblasts ( $E_3$ ) (table V). 'Megaloblastoid'  $E_4$  of patient 3 are almost solely in  $G_1$ , normal cells showed still an increased percentage in  $G_1$  (fig. 2). The early polychromatic normoblasts of patient 2 showed marked 'megaloblastoid' changes, normal cells could not be identified, these cells are a non proliferating cell population (table III). Another case (No 6) only shows a lower S  $G_2$  ratio in the compartment  $E_4$ . The erythropoiesis of this patient was examined 3 weeks after therapy with cytotoxic agents.

Finally, in case 1 only a cytophotometric investigation of erythropoiesis was obtainable. Most of the early polychromatic normoblasts had DNA





**Fig 1** Patient 3 Relative DNA content and  $^3\text{H}$  TdR labelling (shaded areas) of basophilic erythroblasts. White areas = cells not labelled with  $^3\text{H}$  TdR, a All cells b Morphologically normal cells ■ Megaloblastoid cells Ordinate = Number of cells, abscissa = DNA content (2c = diploid, 4c = tetraploid)

values near diploid quantity, while basophilic erythroblasts attained hexaploid values (fig 3). Multinucleated cells are not included in this figure.

### Discussion

In 1960 GAVOSTO *et al* [4] reported already that erythroblasts in erythroleukaemia have a lower labelling index than in healthy individuals. Investigations by *in vivo* labelling with tritiated thymidine confirmed




Fig. 2 Patient 3. Relative DNA content and  $^3\text{H}$  TdR labeling (shaded areas) of early polychromatic normoblasts. White areas = cells not labeled with  $^3\text{H}$  TdR. a All cells. b Morphologically normal cells. c Megaloblastoid cells. Ordinate = number of cells. Abscissa = DNA content (2C = diploid, 4C = tetraploid).

these results and revealed a highly ineffective erythropoiesis in erythroleukaemia [8]. Combined cytophotometric autoradiographic investigations on erythropoiesis so far resulted in contradictory findings. WICKRAMASEKERA *et al* [3] in one case of erythroleukaemia demonstrated an arrest of early polychromatic normoblasts in the premitotic phase, while in a second case OLTESSER *et al* [12] detected an increased percentage of proliferating erythroblasts in G<sub>1</sub>. Finally CROSSER *et al* [2] in a third case found an arrest of cells in the S phase.




Fig 3 Patient 1 Relative DNA content of basophilic erythroblasts (a) and early polychromatic normoblasts (b) Ordinate=Number of cells, abscissa=DNA content (2c=diploid, 4c=tetraploid)

Table IV Distribution (%) of normal and 'megaloblastoid' erythroblasts in the various stages of cell cycle In case 2 all early polychromatic normoblasts were 'megaloblastoid'

Patient No		E <sub>1</sub> -E <sub>3</sub>				E <sub>4</sub>			
		G	S	G <sub>2</sub>	U	G <sub>1</sub>	S	G <sub>2</sub>	U
2	all cells	53.0	41.5	4.0	1.5	-	-	-	-
	normal cells	48.0	46.5	4.5	1.0	-	-	-	-
	'megaloblastoid' cells	84.0	14.0	0.0	2.0	92.0	2.5	2.5	2.0
3	all cells	57.2	39.0	3.3	0.5	79.0	16.7	2.7	1.6
	normal cells	46.0	48.5	5.0	0.5	54.0	38.7	7.3	0.0
	'megaloblastoid' cells	70.6	28.0	0.7	0.7	93.1	4.2	0.0	2.7

Table V Patient 3 Distribution (%) of normal and 'megaloblastoid' proerythroblasts and macroblasts (E<sub>1</sub> + E<sub>3</sub>) and basophilic normoblasts (E<sub>2</sub>) in the various stages of interphase

	E <sub>1</sub> + E <sub>3</sub>			E <sub>2</sub>		
	G <sub>1</sub>	S	G <sub>2</sub>	G <sub>1</sub>	S	G <sub>2</sub>
All cells	51.5	44.5	4.0	64.5	33.0	2.0
Normal cells	38.5	55.0	6.5	53.0	42.0	5.0
'Megaloblastoid' cells	64.8	34.0	1.2	72.0	28.0	0

Our own results show (1) that the percentage of DNA-synthesizing basophilic erythroblasts and especially early polychromatic normoblasts is decreased while the number of cells in  $G_1$  is increased, (2) that 'megalo-blastoid' basophilic erythroblasts are more infrequent in DNA synthesis than morphologically normal cells, (3) that 'megalo-blastoid' early polychromatic normoblasts are a non proliferating cell population. With regard to the results obtained by the *in vivo* labelling of erythropoiesis in erythroleukaemia [8] the disturbance of erythropoietic cell proliferation can be described as follows. A fraction of the proliferating erythroblasts is arrested in  $G_1$ , this may occur already in the compartment  $E_1$  and  $E_2$ . In more mature compartments the percentage of cells arrested in  $G_1$  increase, these cells develop a 'megalo-blastoid' appearance. The 'megalo-blastoid' early polychromatic normoblasts can amount to 100% of the total cell population (table IV) and do not proliferate ( $G_0$  cells). They may die intramedullary or differentiate without mitosis to late polychromatic normoblasts. The disturbed cell proliferation leads to the hyperplasia and a shift to the left (table II) of erythropoiesis. The morphologically normal erythropoiesis however, has a reduced proliferative activity and is comparable with erythropoiesis in refractory anaemia with hyperplastic bone marrow (unpublished results) and with erythropoiesis in acute leukaemia [9, 12].

Our results in case 6 (table III) show that the disturbance of cell proliferation - even though temporary - can be suspended. The erythropoiesis was studied 3 weeks after therapy with cytostatic agents at this time the erythropoiesis was in a regenerating stage following cytostatically induced bone marrow aplasia.

The cytophotometric DNA measurements in case 1 show that a portion of mononucleated basophilic erythroblasts attained hexaploid values. Similar results have been obtained in investigations of blast cells in acute leukaemia [5] and are explained by a strong aneuploidy. Cytogenetic studies indicate that chromosomal abnormalities are very similar in erythroleukaemia and acute leukaemia [1, 2, 6].

### References

1. CASTROFI G, YAM L T, MILLS W J, and CHERRY W H. Chromosomal values in erythroleukaemia and chronic erythraemia. *Br J Haematol* 31: 202-213 (1976).

- CROSSEN, P E, FITZGERALD, P H, MENZIES, R C, and BREHAUT, L A Chromosomal abnormality, megaloblastosis, and arrested DNA synthesis in erythroleukaemia *J med Genet* 6 95-104 (1969)
- 3 DAMESHEK, W The DiGuglielmo syndrome revisited *Blood* 34 567-572 (1969)
- 4 GAVOSTO, F, MARAFI G, and PILERI, A Radioautographic investigations on DNA and protein metabolism in 2 cases of DiGuglielmo's disease *Blood* 16 1122-1132 (1960)
- 5 HALE, A J and COOPER, E H DNA synthesis in infectious mononucleosis and acute leukaemia *Acta haemat, Basel* 29 257-266 (1963)
- 6 HEATH C. W, BENNETT, J M, WIIANG PENG, J, BERRY, E W, and WIERNICK P H Cytogetic findings in erythroleukaemia *Blood* 33 453-467 (1969)
- 7 WILLIAMS, BEUTLER, ERLEV and RUNDLES Hematology (McGraw Hill, New York 1972)
- 8 HOELZER, D, FLIEDNER, T M, HARRISS, E H und QUEISSER, W Umsatzkinetik der Erythropoese bei «Erythroleukämie», in GROSS und VAN DE LOO Leukämie, pp 381-386 (Springer, Berlin 1972)
- 9 HUBER, CH, LEDERER, B, SCHMALZL, F, BÜTTERICH, D, HUBER H und BRAUNSTEINER, H Autoradiographische und cytophotometrische Untersuchungen zur Proliferation erythropoetischer Vorstufen im Knochenmark unreifzelliger Leukämien *Acta haemat, Basel* 44 83-97 (1970)
- 10 KILLMANN, S A Cell classification and kinetic aspects of normoblastic and megaloblastic erythropoiesis *Cell Tiss Kinet* 3 217-228 (1970)
- 11 QUAGLINO, D and HAYHOR, F G J Periodic Acid-Schiff positivity in erythroblasts with special reference to DiGuglielmo's disease *Brit J Haemat.* 6 26-33 (1960)
- 12 QUEISSER, W, GRAUBNER, A, HOELZER, D, QUEISSER, U., and HEIMPEL H Some characteristic of the proliferative activity of erythroblasts in untreated and treated acute leukaemia *Acta haemat, Basel* 49 271-280 (1973)
- 13 WICKRAMASINGHE, S N, CHALMERS, D G., and COOPER, E H A study of ineffective erythropoiesis in sideroblastic anemia and erythraemic myelosis *Cell Tiss Kinet* 1 43-50 (1968)

## Different Molecular Weight of the Plasmatic Erythropoietin Compared with the Renal and Splenic Erythropoietic Factors in the Rabbit

ELVIO GIOVANNINI and VIRGINIA BOCCIONI

Institute of General Biology, Faculty of Medicine and Surgery  
University of Perugia, Perugia

**Abstract** The authors have studied the molecular weight of the erythropoietic factors present in the blood in the kidney and in the spleen of the rabbit, by means of ultrafiltration experiments performed by using selective permeability membranes. The erythropoietic factor present in the blood circulation shows a molecular weight of between 30 000 and 30 000. The factors detectable in the microsomal fraction of normal kidney, in the mitochondrial fraction of anaemic kidney and in the mitochondrial fraction of normal spleen show molecular weights of between 40 000 and 100 000. These data confirm the hypothesis already formulated regarding the renal origin of the splenic erythropoietic factor and the different nature of the renal erythropoietic factor compared with the plasmatic erythropoietin.

### Key Words

Erythropoietin  
Plasmatic erythropoietic factor  
Renal erythropoietic factor  
Selective ultrafiltration  
Splenic erythropoietic factor

It is known that the kidney produces an erythropoietic factor that interacts with a plasmatic substratum to form erythropoietin [1, 11]. In the rabbit this factor accumulates at least partly in the spleen and is then released into the blood circulation, both in the first few hours after bleeding and in the subsequent evolution of the anaemia [6-8]. In addition, it has been shown that the erythropoietic factors present in the kidney and in the spleen of the rabbit reveal different chemico-physical characteristics from those of the plasmatic erythropoietin [2, 9].

In these studies we performed experiments using a series of selective permeability membranes capable of allowing the filtration of substances of gradually decreasing molecular weight. In this way we tried to obtain indications on the molecular weight of the various erythropoietic fac-



tors, in order to check the possible differences in weight between the renal and splenic factors on the one hand and the plasmatic factor on the other

These studies were suggested by the works of LEWIS *et al* [4, 5] who identified in the urine concentrates of anaemic patients, two erythro stimulant factors having biological activity of the erythropoietin type, one of them having a molecular weight of between 20 000 and 30 000 and the other of over 50 000. In the same material an erythropoietin generating factor (EGF) has also been revealed, having a molecular weight situated between 30 000 and 50 000, this factor is found to be capable of producing erythropoietin when incubated with serum of a normal rabbit

### *Material and Methods*

The researches were carried out by studying the variations in the peripheral reticulocytes of normal rabbits by the administration of materials obtained by means of fractionation with ultrafiltration membranes from organ extracts or plasma extracts prepared from donor rabbits (6-8 months of age 3-3.5 kg in weight) some being normal rabbits and others having been bled by up to 20 ml/kg body weight

In particular on the basis of studies recently carried out on the subcellular localisation of the renal and splenic erythropoietic factors [3] the materials chosen as presumed source of these substances were hypotonic extracts obtained from the microsomal fraction of normal kidney the mitochondrial fraction of anaemic kidney (18 h after bleeding) and the mitochondrial fraction of normal spleen. As presumed source of erythropoietin the materials used were plasma extracts from rabbits bled 24 h previously [2, 9]

The hypotonic extracts of the subcellular fractions of renal and splenic origin were prepared according to the technique described in a previous work [3]. On the other hand the plasma extracts were prepared by removing 50 ml anaemic plasma from each donor. This material after the addition of 25 ml bid stiller water was acidified at pH 5.5 by means of 1 N HCl. It was then heated in boiling water for 10 min in order to precipitate most of the proteins and was finally centrifuged. The supernatant rich in erythropoietin was brought up to pH 7 with 1 N NaOH.

The fractionation of the plasma or organ extracts was performed with an AMICON cell for ultrafiltration provided with a series of DIAFLO membranes having different cut off values of molecular weight. With this device the materials studied were subjected to successive filtrations by means of membranes of increasing capacity of retention. During filtration the cell was pressurised with nitrogen the pressures applied for the various membranes being those recommended by the makers.

Each extract of anaemic plasma brought to a volume of 100 ml by the addition of bid stiller water was subjected to 2 successive ultrafiltrations by means of PM 30 and PM 10 membranes characterised by cut-off values of molecular weight equal to 30 000 and 10 000 respectively.

Each hypotonic extract of the subcellular fractions used brought up to a volume

# Different Molecular Weight of Erythropoietic Factors

of 100 ml by the addition of bidistilled water, was subjected to 3 successive ultrafiltrations with XM 100-A, XM 40 and PM 10 membranes, having cut-off values of molecular weight equal to 100 000, 50 000 and 10 000, respectively.

Filtration through each membrane was performed twice, in order to obtain a more precise separation of the substances of molecular weight higher or lower than the cut-off values of the membrane used. In particular, the residual volume obtained after the first filtration, equal to about 5 ml, was brought up to 100 ml by the addition of bidistilled water before being subjected to a supplementary filtration.

The various operations described were performed at a room temperature of 3°C. The residual material, obtained after each filtration was brought up to a volume of 40 ml by the addition of bidistilled water. The whole was made isotonic by means of NaCl and, after the addition of antibiotic, was kept at -20°C until use. Every fraction of 20 ml each, administered 24 h apart.

The erythro-stimulant activity of each fraction was assessed by studying the reticulocyte level in the receiver animals during the first 6 days. In every case the rabbits (4-5 months, of age, 2.5 kg in weight) were subjected on alternate days to 10 successive counts of the reticulocyte level and of the number of erythrocytes, so as to select for the experiments only those animals having an erythrocyte level of between 5 200 000 and 6 500 000  $\mu$ l and a reticulocyte level of between 1.5 and 3%, and a standard error not greater than 0.1 in the 10 values. In this way it was possible to obtain highly stable and consistent experimental data.

In all, 4 series of experiments were performed corresponding to the 4 materials studied (extracts of anaemic plasma and hypotonic extracts of the microsomal fraction of normal kidney, the mitochondrial fraction of anaemic kidney, and the microsomal fraction of normal spleen).

The first series of experiments was performed with the following groups of rabbits: (1) 6 donors killed 24 h previously from which to remove the plasma for preparation of the extract; (2) 12 donors killed 14 h previously from which to remove the plasma for preparation of the extract; (3) 6 donors killed 14 h previously from which to remove the plasma for preparation of the extract; (4) 6 donors killed 14 h previously from which to remove the plasma for preparation of the extract.

Each of the other 3 series of experiments was performed with the following groups of rabbits: (1) 6 donors killed 14 h previously from which to remove the plasma for preparation of the extract; (2) 12 donors killed 14 h previously from which to remove the plasma for preparation of the extract; (3) 6 donors killed 14 h previously from which to remove the plasma for preparation of the extract; (4) 6 donors killed 14 h previously from which to remove the plasma for preparation of the extract.

## Results

The results obtained from the treatment with extracts of anaemic plasma (table 1) show that the fraction held back by the PM-10 membrane is

*Table I* Variations with time in the reticulocyte level in rabbits treated with fractions of plasma extract removed from donors bled 24 h previously, prepared by means of successive ultrafiltrations with DIAFLO membranes PM 30 (group I A) and PM 10 (group I B)

	Group I-A		Group I B	
	mean $\pm$ SE	t test	mean $\pm$ SE	t test
Initial	2.68 $\pm$ 0.1558		2.65 $\pm$ 0.1176	
2 days	2.7 $\pm$ 0.1915	0.08103	3.78 $\pm$ 0.147	6.003 <sup>1</sup>
3 days	2.7 $\pm$ 0.1807	0.08382	4.13 $\pm$ 0.1306	8.419 <sup>1</sup>
4 days	2.67 $\pm$ 0.1819	0.04175	3.65 $\pm$ 0.1432	5.397 <sup>1</sup>
6 days	2.65 $\pm$ 0.1911	0.1217	2.88 $\pm$ 0.1815	1.064

The reticulocyte level is expressed as a reticulocyte/erythrocyte percentage. Mean values  $\pm$  standard error and comparison between the averages of initial and subsequent values by means of Student's t test (degrees of freedom, 10)

<sup>1</sup> Highly significant

lacking in erythro-stimulant activity, whereas that held back by the PM-10 membrane shows such activity. In fact, the specimens treated with the plasma fractions held back by the former membrane show no significant variation in the reticulocyte pattern (group I-A), whereas in the latter case (group I-B) they show a highly significant increase in the number of circulating reticulocytes.

The experiments performed by administering the fractions obtained from the ultrafiltration of renal or splenic subcellular extracts led to substantially equal results, so that they have been assembled in a single table in order to facilitate comparative assessment (table II). It may be seen that in all the materials of renal and splenic origin used the erythropoietically active fraction is the one that passes through the XM-100-A membrane but is held back by the XM-50 membrane. In fact, the treatment with the fractions held back by the XM-100-A membrane and obtained from the microsomal extract of normal kidney (group II-A), the mitochondrial extract of anaemic kidney (group III-A) and the mitochondrial extract of normal spleen (group IV-A) does not produce any significant variation in the reticulocyte number, whereas the treatment with the fractions relative to the same subcellular extracts, which pass through the XM-100-A membrane but are held back by the XM-50 membrane (groups II-B, III-B, IV-B), produces a very marked increase in the number of circulating reticulocytes. In addition, the fractions capable of pass-

# Different Molecular Weight of Erythropoietic Factors

Table II Variations with time in the reticulocyte level in rabbits treated with fractions obtained by successive ultrafiltrations with DIAFLO membranes XM 100-A (groups A), XM 50 (groups B) and PM 10 (groups C) from hypotonic microsomal extracts of kidney removed from normal donors (groups II), mitochondrial extracts of kidney removed from donors bled 18 h previously (groups III) and mitochondrial extracts of spleen removed from normal donors (groups IV)

	Group II A		Group II B		Group II C	
	mean $\pm$ SE	t test	mean $\pm$ SE	t test	mean $\pm$ SE	t test
Initial	2.8 $\pm$ 0.1183	0.1633	2.73 $\pm$ 0.1229		2.77 $\pm$ 0.1838	
2 days	2.83 $\pm$ 0.1406	0.407	4.18 $\pm$ 0.1275	8.187 <sup>1</sup>	2.7 $\pm$ 0.1897	0.265
3 days	2.81 $\pm$ 0.1558	0.402	4.53 $\pm$ 0.1256	10.24 <sup>1</sup>	2.85 $\pm$ 0.2452	0.2624
4 days	2.9 $\pm$ 0.1592	0.4042	3.92 $\pm$ 0.1046	7.376 <sup>1</sup>	2.89 $\pm$ 0.212	0.3921
6 days	2.84 $\pm$ 0.1869	0.3617	2.97 $\pm$ 0.1308	1.337	2.95 $\pm$ 0.1928	0.6759
	Group III A		Group III B		Group III C	
	mean $\pm$ SL	t test	mean $\pm$ SL	t test	mean $\pm$ SL	t test
Initial	2.93 $\pm$ 0.0943		2.45 $\pm$ 0.1409		2.73 $\pm$ 0.1201	
2 days	3 $\pm$ 0.1183	0.4919	3.83 $\pm$ 0.2170	5.334 <sup>1</sup>	2.93 $\pm$ 0.1382	1.092
3 days	2.95 $\pm$ 0.0972	0.4128	4.15 $\pm$ 0.2277	6.35 <sup>1</sup>	2.93 $\pm$ 0.1145	1.205
4 days	3.2 $\pm$ 0.1265	1.776	3.6 $\pm$ 0.1732	5.152 <sup>1</sup>	3.02 $\pm$ 0.1137	1.753
6 days	3.22 $\pm$ 0.1275	1.897	2.9 $\pm$ 0.1653	2.072 <sup>1</sup>	2.95 $\pm$ 0.0985	1.474
	Group IV A		Group IV B		Group IV C	
	mean $\pm$ SL	t test	mean $\pm$ SL	t test	mean $\pm$ SL	t test
Initial	2.8 $\pm$ 0.1844		2.8 $\pm$ 0.1342		2.68 $\pm$ 0.1661	
2 days	2.99 $\pm$ 0.1780	0.3196	4.25 $\pm$ 0.1945	6.137 <sup>1</sup>	2.8 $\pm$ 0.1913	0.4638
3 days	2.85 $\pm$ 0.1335	0.2196	4.53 $\pm$ 0.2216	6.679 <sup>1</sup>	2.77 $\pm$ 0.1429	0.4107
4 days	2.95 $\pm$ 0.1962	0.5571	3.9 $\pm$ 0.1483	5.51 <sup>1</sup>	2.72 $\pm$ 0.1400	0.1841
6 days	2.93 $\pm$ 0.1970	0.483	2.97 $\pm$ 0.1646	0.8005	2.83 $\pm$ 0.1422	0.7445

The reticulocyte level is expressed as a reticulocyte erythrocyte percentage. Mean values  $\pm$  standard error and comparison between the averages of the initial and subsequent values by means of Student's t test (degrees of freedom, 10).

<sup>1</sup> Highly significant.

ing through the XM 50 membrane but held back by the PM-10 membrane do not reveal any significant erythro-stimulant activity (groups II-C, III C IV-C). The increase in the number of circulating reticulocytes was always accompanied by an increase in the number of erythrocytes

### Discussion

From the results obtained in the first series of experiments it may be seen that the molecular weight of the erythropoietin present in the plasma of anaemic rabbits is between 10,000 and 30,000. This observation would appear to agree with the value of 27,000 proposed by Rosse *et al* [10] and with the results of the more recent studies carried out by Lewis *et al* [5], who found, in the urine of anaemic patients, an erythropoietin having a molecular weight of between 20,000 and 30,000.

The results obtained in the other experiments show that the erythro-stimulant factors previously identified in the microsomal fraction of normal kidney, the mitochondrial fraction of anaemic kidney and the mitochondrial fraction of normal spleen [3] have a molecular weight of between 50,000 and 100,000.

First of all, the analogies existing between the erythropoietic factors present in the 2 different renal fractions studied is in complete agreement with the already advanced theory [3] of an accumulation of the renal factor considered in the mitochondrial fraction, when, as a result of anemia, its production increases considerably. Moreover, the substantial analogy in the behaviour of the renal and splenic erythro-stimulant factors, in relation to their ability to pass through the membranes, may be considered a further confirmation of the theory previously proposed regarding their identical nature [2, 7-9].

The results obtained in the present studies also confirm that these renal and splenic factors cannot be absolutely identified with plasmatic erythropoietin, as was often proved in previous studies [2, 9]. In fact, erythropoietin forms through interaction between a factor released into the blood circulation by the kidney or by the spleen and a plasmatic substratum.

It is possible that the erythro stimulant factors identified in the kidney and in the spleen [2, 3, 8, 9] may have an origin similar to that of the EGF identified by Lewis *et al* [4, 5] in the urine of anaemic patients, even if this EGF shows a lower molecular weight of between 30,000 and 50,000. It is possible that this factor, once its cycle of activity in the blood circulation has been exhausted and it has been excreted by the kidneys, may have undergone structural modifications such as to produce a reduction in its molecular weight, though without change of its biological activity.

# References

- 1 CANTIERA, J. J. and GIMBORY, A. S. Erythropoietin production by a particulate fraction of rat kidney. *Science* 152: 613-614 (1964)
- 2 GIMBORY, E. L. Litteroni ricerche sulle proprietà dei fattori eritrostimolanti presenti nel sangue, nel rene e nella milza del coniglio. *Haematologica* (in press 1974)
- 3 GIMBORY, E. and REAL, G. The localization in the various subcellular fractions of the erythropoietic factors present in the kidney and spleen of the rabbit. *Brit J Haemat* (in press, 1974)
- 4 LEWIS, J. P., MURPHY, R. R., GIMBORY, E. J., ALTON, D. A., DEAS, W. A., WITTE, I. T., WRIGHT, C. S., and SWINN, L. L. Recent advances in the study of erythropoietic factors. *7th Int Congr clin Chem*, Geneva 2-11 Jan 1969, vol 3. Hormones, lipids and miscellaneous, pp 384-397 (Harger, Basel 1970)
- 5 LEWIS, J. P., DEAS, W. A., WITTE, I. T., LEWIS, W. G., DEBONE, C. M., JR., WRIGHT, C. S., and SWINN, L. L. The isolation of erythropoietic regulatory factors by an electrofractionation technique combined with selective membrane permeability. *Proc Soc exp Biol Med* 142: 293-294 (1973)
- 6 LUTTI, E. S. e GIMBORY, E. Ricerche sperimentali sul ruolo della milza nel controllo dell'eritropoiesi III Effetti della splenectomia sulla attività eritrostimolante del plasma nelle anemie acute post-emorragiche. *Arch Sci Biol* 53: 172-176 (1969)
- 7 LUTTI, E. S. e GIMBORY, E. Rapporti tra rene e milza nel controllo della eritropoiesi. *Haematologica* 56: 343-370 (1961)
- 8 LUTTI, E. S. e GIMBORY, E. Studi e ricerche in tema di rapporti tra rene e milza nel controllo dell'eritropoiesi. *Haematologica* 59: 691-697 (1974)
- 9 LUTTI, E. S., GIMBORY, E. e MICHIELI, R. Su alcune proprietà dei fattori eritrostimolanti presenti nel plasma del rene e nella milza del coniglio. *Riv Biol* 65: 3-51 (1972)
- 10 REAL, G., REAR, R. J., and WATKINS, T. A. Some molecular characteristics of erythropoietin from different sources determined by inactivation by unit integration. *J clin Invest* 42: 124-129 (1967)
- 11 ZANONI, E. D., GIMBORY, E. J., GIMBORY, A. S., CORREIA, G. W., WINE, A. H., and KOFF, R. The renal erythropoietic factor (REIF) III Erythropoietic role in erythropoietin production. *Proc Soc exp Biol Med* 129: 494-494 (1967)

Dr. EUGENIO GIMBORY, Istituto di Patologia Generale dell'Università Via del  
Lombardo 100, 20133 Milano (Italia)

## Desaggregation of Human Red Blood Cells by Various Surface-Active Agents as Related to Changes of Cell Shape and Hemolysis

P GAEHTGENS and K U BENNER

Institute of Normal and Pathological Physiology, University of Köln Köln

**Abstract** The effect of several surface active substances (Na oleate, Na desoxycholate Triton X 100 Pluronic F 38 Pluronic F 68 Pluronic F 108) on dextran induced red cell aggregation (RCA) and red cell shape was investigated. *Sedimentation measurements and photometric determinations* of RCA indicated a disaggregating effect of oleate, Triton, F 38 and F 68. Shape changes were found in the presence of oleate and desoxycholate (crenation) and Triton (cup formation), in addition, these substances induced pronounced hemolysis. No hemolysis and no shape changes were found with any of the Pluronic polyols.

### Key Words

Aggregation of erythrocytes  
Erythrocyte disaggregation  
Erythrocyte sedimentation  
Erythrocyte shape  
Hemolysis  
Surface-active substances

It is generally accepted that increased aggregation of red blood cells (RBC) is brought about by high molecular compounds, and the hypothesis has been forwarded that this effect is due to the formation of molecular bridges between adjacent membranes of neighboring RBC [1]. It is also known that deviations from the normal biconcave RBC shape will eventually result in disaggregation, this may be due to a reduction of the area of contact available. In addition, surface tension effects may be involved since many of the compounds which lead to shape changes also show surface active properties. In the present study, the disaggregating action of various surface-active substances is investigated and related to changes of cell shape and hemolysis.

### Materials and Methods

Blood was obtained from healthy human donors by venipuncture and anticoagulated with heparin (5 IU/ml). 40 ml blood were incubated with 0.5 ml of a 2% solution of dextran (MW 510 000) (supplied by Knoll AG Ludwigshafen Germany) in saline. Equi

## GARTNER-BENNER

molar solutions ( $10^{-10}$  to  $10^{-2}$  M) of the substances to be tested were prepared in saline and 0.5 ml of these solutions were added to 4.5 ml HMD blood while the control samples received 0.5 ml saline. Thus the final concentrations of the substances tested were 2, 1, 0.5, 0.2, and 0 m%.

Since equal volumes of the solutions were added to equal volumes of blood, all comparisons were made at a constant plasma dilution by approximately 27%. Depending upon hematocrit, the following compounds were investigated: Pluronic F 38 (Pluronic Co., F 68 Pluronic Co., F 108 (supplied by C. H. Eberle, Düsseldorf, Germany), BASF Wyandotte Corporation, Wyandotte, Mich., USA), Triton X 100 (Rohm & Haas Philadelphia, USA), supplied by Decryl-Chemie, Frankfurt/Main, Germany), Na-oleate (Riedel-de Haan Seelze-Hannover, Germany), and Na-deoxycholate (E. Merck Darmstadt, Germany).

Red cell aggregation was determined indirectly by measuring sedimentation velocities in standard Westergren tubes at room temperature. The height of the cell plasma interface was read every 10 min and the maximum slope of the plot of interface versus time was determined. These data were corrected for changes of suspension viscosity of the control sample (control sample was measured in an Ostwald capillary viscometer at room temperature. The corrections were made by taking the suspension viscosity as 100%).

Additional determinations of red cell aggregation were made photometrically. A sample of blood was drawn at a rate of 24.5 ml/min through an osmometry cuvette (Atlas osmometer) which was mounted horizontally such that the light passed vertically through the layer of blood. The transmission of light was recorded continuously on a paper recorder. After stopping the flow of blood through the cuvette, the light transmission was increased due to formation of red cell aggregates. The extent of aggregation was determined by measuring the increase of light transmission observed during a period of 1 min.

Microphotographs of the dispersed cell suspensions were made by preparing wet mounts and taking pictures 1 min after the preparation using a Leitz Ortholux microscope. A magnification of  $450\times$  was used employing  $10\times$  Periplan eyepieces and  $45\times$  Leitz objectives.

Using the cyanmethemoglobin technique hemoglobin concentrations were measured in the supernatant suspension immediately after centrifugation of the samples.

## Results

The effect of the different substances tested on RBC sedimentation velocity is shown in table I. A reduction of the sedimentation velocity was observed in the presence of the first 3 substances: the sedimentation velocity was reduced in an approximately linear fashion with increasing concentration of Na-oleate. Whereas with the first 3 substances the sedimentation velocity was this was different in the case of Na-oleate which showed little effect up to approximately 1 m% but was very effective at 2 m% (p < 0.01). At 2 m% Pluronic F 108 and Triton X 100 were equally effective whereas the effect particularly of F 68 was relatively weak. In contrast to these ob-



Table 1 Maximum sedimentation velocities ( $V_{max}$ ) of human red blood cells in samples containing surface active substances, all values were corrected for changes in suspending medium viscosity ( $\eta_0$ ), mean values and standard deviations

Concentration mM/l	Pluronic F 38		Pluronic F 63		Pluronic F 108		Triton X 100		Na-desoxycholate		Na-oleate	
	$V_{max}$	$\eta_0$	$V_{max}$	$\eta_0$	$V_{max}$	$\eta_0$	$V_{max}$	$\eta_0$	$V_{max}$	$\eta_0$	$V_{max}$	$\eta_0$
0	12.08 $\pm 2.73$	1.619 $\pm 0.141$	10.89 $\pm 3.03$	1.619 $\pm 0.141$	10.17 $\pm 2.50$	1.619 $\pm 0.141$	12.08 $\pm 2.73$	1.619 $\pm 0.141$	12.08 $\pm 2.73$	1.619 $\pm 0.141$	12.08 $\pm 2.73$	1.619 $\pm 0.141$
0.2	11.14 $\pm 3.08$	1.606 $\pm 0.130$	8.88 $\pm 2.89$	1.675 $\pm 0.104$	11.59 $\pm 3.21$	1.828 $\pm 0.047$	11.59 $\pm 3.48$	1.626 $\pm 0.134$	11.44 $\pm 3.87$	1.581 $\pm 0.151$	12.08 $\pm 3.73$	1.581 $\pm 0.124$
0.5	11.18 $\pm 3.27$	1.671 $\pm 0.155$	7.53 $\pm 2.99$	1.818 $\pm 0.145$	12.13 $\pm 3.66$	2.170 $\pm 0.190$	7.75 $\pm 3.12$	1.621 $\pm 0.135$	11.33 $\pm 4.69$	1.575 $\pm 0.139$	10.92 $\pm 3.59$	1.584 $\pm 0.137$
1.0	9.35 $\pm 3.28$	1.752 $\pm 0.157$	5.07 $\pm 2.60$	2.009 $\pm 0.168$	6.13 $\pm 2.61$	2.596 $\pm 0.401$	6.62 $\pm 3.75$	1.659 $\pm 0.148$	12.81 $\pm 6.07$	1.579 $\pm 0.172$	11.36 $\pm 2.84$	1.583 $\pm 0.136$
2.0	6.99 $\pm 1.97$	1.915 $\pm 0.177$	1.05 $\pm 0.53$	2.406 $\pm 0.236$	28.59 $\pm 21.68$	4.099 $\pm 0.552$	1.92 $\pm 1.00$	1.816 $\pm 0.210$	19.17 $\pm 11.23$	1.681 $\pm 0.135$	1.01 $\pm 1.03$	1.615 $\pm 0.139$

# Desaggregation of RBC by Surface Active Agents




Fig. 1 Photometric measurements of RBC in the presence of surface active agents: a = Pluronic F 38, b = Pluronic F 68, c = Pluronic F 109, d = Na-desoxycholate, e = Triton X-109, f = Na-oleate.

observations statistically significant effects were not observed in the case of Na-desoxycholate. With F 109 a biphasic effect was obtained: a slight decrease of sedimentation velocity ( $p = 0.025$ ) at  $1 \text{ mg/l}$  and an increase of sedimentation velocity at  $2 \text{ mg/l}$  ( $p = 0.05$ ).

Table I also gives the changes of suspending medium viscosity observed. The largest effect was measured in the samples containing F 109, here, the suspending medium viscosity increased from an average of  $1.619 \pm 0.141$  in the control samples to  $4.099 \pm 0.552$  at a concentration of  $2 \text{ mg/l}$ . This increase was somewhat less in the case of F 68, where an average of  $2.506 \pm 0.236$  was found at the highest concentration, and in the case of F 38, where

Table II Hemoglobin concentrations (g%) in the suspending medium after incubation of human blood with increasing concentrations of surface-active substances, mean values and standard deviations of 6 experiments

Concentration mm/l	Triton X 100	Na-desoxycholate	Na-oleate
0	0.177 ± 0.092	0.177 ± 0.092	0.177 ± 0.092
0.2	0.299 ± 0.168	0.181 ± 0.078	0.201 ± 0.089
0.5	0.386 ± 0.104	0.207 ± 0.141	0.155 ± 0.099
1.0	0.652 ± 0.234	0.379 ± 0.233	0.198 ± 0.073
2.0	2.062 ± 0.748	1.043 ± 0.272	0.363 ± 0.097

at 2 mm/l the average viscosity was  $1.915 \pm 0.177$ . Only a minor increase was measured in the presence of Triton X 100, whereas no statistically significant effect was found with Na-oleate and Na-desoxycholate.

The results of the photometric measurements are represented in figure 1. After stopping the blood flow through the cuvette, the light transmission decreased immediately due to randomization of cell orientation under conditions of stasis. Very rapidly, however, the process of RBC aggregation resulted in an increase of light transmission. The change of photovoltage  $\Delta V$  occurring in a period of 1 min in the sample containing only 2% HMD was taken as 100%. The changes of  $\Delta V$  in the presence of the 6 surface-active substances were corrected for changes in suspending medium viscosity  $\eta_s$  by multiplying  $\Delta V$  with the ratio of  $\eta_s$  and the viscosity of the control medium  $\eta_c$ . The corrected increase of photovoltage  $\Delta V = \Delta V \cdot \eta_s/\eta_c$  in the presence of the highest concentrations of the compounds tested was as follows: Pluronic F 38: 106.2%, Pluronic F 68: 55.1%, Pluronic F 108: 402.3%, Triton X 100: 29.9%, Na-oleate: 36.1%, Na-desoxycholate: 112.7%.

Figure 2 shows photomicrographs of blood samples containing the 6 compounds tested in a concentration of 2 mm/l. No dextran was added to these samples. In the presence of Na-oleate or Na-desoxycholate, the red blood cells were crenated, whereas in the presence of Triton X 100 they had adopted a cup-like shape. In the samples containing the 3 Pluronics, no significant shape changes were observed. Intensified red cell aggregation was found in the samples containing F 108, whereas in the presence of F 68 virtually no aggregates were observed.

The results of the hemoglobin determinations in the suspending medium are shown in table II. Significant hemolysis was observed only in the samples

# Disaggregation of RBC by Surface Active Agents




Fig. 1. Photomicrographs of human RBC in the presence of 2 mM of the following substances: a—Control; b—Pluronic F 39; c—Pluronic F 68; d—Pluronic F 108; e—Sodium lauryl sulfate; f—Sodium dodecyl sulfate; g—Triton X 100.

containing Triton X 100, Na-desoxycholate, and Na-oleate. In these samples, hemoglobin levels increased with increasing concentrations of these substances. Triton X 100 was found to have the strongest hemolytic activity, followed by Na-desoxycholate and Na-oleate. At the highest concentration of these substances (2 mM/l), the hemoglobin concentrations in the suspending medium averaged  $0.062 \pm 0.048$  g % in the presence of Triton X 100,  $0.043 \pm 0.022$  g % in the presence of Na-desoxycholate, and  $0.0363 \pm 0.0097$  g % in the presence of Na-oleate. In contrast to these results, no hemolysis was observed in the samples containing any of the Pluronic compounds.

### *Discussion*

The results of the experiments indicate that in the presence of Triton X 100, Na-oleate, Pluronic F 38 and Pluronic F 68 the RBC aggregation induced by high molecular dextran is inhibited in a dose-dependent fashion. This is obvious from the sedimentation velocity data, which after correction for suspending medium viscosity reflect changes of average particle size, corrections for changes of particle and/or suspending medium density [5] have, however, not been made. The results of the photometric measurements support the conclusions drawn from the sedimentation experiments by again demonstrating a desaggregating effect of the above-mentioned compounds. In these measurements, corrections for changes of density are not necessary since the results are not influenced by sedimentation in the measuring cuvette.

The desaggregation occurring in the presence of Na-oleate and Triton X 100 can be attributed to the shape changes observed microscopically, which have also been observed by other authors [2, 3]. The decreased tendency to aggregation of RBC which do not show the normal biconcave shape can be attributed to a reduction of contact area between adjacent cells. This has already been hypothesized [6] in explaining the decrease of yield shear stress observed in hypertonic media.

Obviously, desaggregation can be the result of either crenation (Na-oleate) or cup formation (Triton X 100). Both substances also are found to produce hemolysis which in our experiments was approximately 10 times stronger in the case of the cup-producing compound in comparison to the crenating compound. Na-desoxycholate, on the other hand, showed insignificant effects on RBC aggregation, this may be compared to its lesser crenating action. In contrast, the hemolysis found in the presence of Na-

desoxycholate was significantly stronger in comparison to that of Na oleate. It appears therefore that desaggregation of human RBC is more closely related to changes of cell shape than is hemolysis.

No shape changes and also no hemolysis was found in the presence of either of the 3 Pluronic polyols. In contrast previous studies in this laboratory [4] have shown an antihemolytic action of these compounds, notably of F 68. Consequently the desaggregating effect of F 68 must be attributed to a mechanism different from that underlying the effect of the low molecular compounds used in this study. Whereas interaction with charged groups on the RBC surface or within the cell membrane might provide the basis for shape changes in the presence of anionic or cationic substances [2], additional mechanisms must be hypothesized to explain the action of the Pluronic polyols. It appears conceivable that adsorption of these compounds onto the cell membrane might interfere with the intercellular bridging effect brought about by the dextran molecules [1].

### References

- 1 CHEN S and JAY K. M. Ultrastructural basis of the mechanism of rouleaux formation. *Microvasc Res* 5: 135-166 (1973).
- 2 DEUTCHER B. Transformation and restoration of the concave shape of human erythrocytes induced by amphiphilic agents and changes of ionic environment. *Biochim Biophys Acta* 163: 494-500 (1968).
- 3 EHRLY A. M. Untersuchungen über Wirkung und Wirkungsmechanismus verschiedener oberflächenaktiver Substanzen und Pharmaka auf Erythrozytenaggregate des Blutkörperchenauflösungsgeschwindigkeit des Viskosität und den Hämatokrit menschlichen Blutes. *Ärztl Fortsch* 21: 323-334 (1967).
- 4 GAHRTENS, P. and BESSER K. U. Osmotic behaviour of human red blood cells: effect of non-ionic detergents. *Blut* 29: 123-133 (1974).
- 5 HARDWICKER J. and SYLVE J. R. The basis of the erythrocyte sedimentation rate. *Clin Sci* 11: 335-355 (1952).
- 6 MIRMIRAN H. J., MIRMIRAN, F. W., GRILLAND E. R., PILLETIER G. A. and SALZMAN F. W. Influence of plasma osmolality on the rheology of human blood. *J Appl Physiol* 21: 772-777 (1967).

## Vitamin B<sub>12</sub> and Vegetarianism in India

V S JATHAR, A B INAMDAR-DESHMUKH, D V REGE and  
R S SATOSKAR

Department of Chemistry, Department of Chemical Technology, University of  
Bombay, and Department of Pharmacology, TN Medical College, Bombay

**Abstract** Apparently healthy Indian lactovegetarians have significantly lower serum levels and urinary excretion of vitamin B<sub>12</sub> as compared to non vegetarians. The low levels of serum vitamin B<sub>12</sub> in lactovegetarians are not due to defective absorption but to low dietary intake of this vitamin. In spite of considerably low serum vitamin B<sub>12</sub> values the lactovegetarians have no apparent signs or symptoms of vitamin B<sub>12</sub> deficiency and their response to injected cyanocobalamin mixed with tracer radioactive B<sub>12</sub> as judged by urinary excretion pattern and liver uptake, was similar to that observed in non vegetarians.

### Key Words

Lactovegetarians  
Liver B<sub>12</sub> uptake  
Serum B<sub>12</sub>  
Urinary B<sub>12</sub> excretion  
Vegetarianism  
Vitamin B<sub>12</sub>

In India, a majority of the people consume a vegetarian diet from childhood with occasional supplement of milk or dairy products, because of religious convictions and high cost, intake of non-vegetarian food is relatively little. Purely on the basis of serum vitamin B<sub>12</sub> levels, large part of the Indian population could be considered deficient in this vitamin [2, 7, 15, 18]. However, the incidence of megaloblastic anaemia or neurological disease due to B<sub>12</sub> deficiency in India does not appear to be high [5]. In fact, the lactovegetarian volunteer students with low serum vitamin B<sub>12</sub> levels showed no clinical evidence of vitamin B<sub>12</sub> deficiency [15, 18]. The present study was undertaken to investigate further the signifi-

cance of serum vitamin B<sub>12</sub> levels in apparently healthy Indian subjects with various dietetic habits

### Material and Methods

The subjects included in this study consisted of medical students between the ages of 18 and 26 years. The detailed history was obtained as regards the height, weight, previous illness and dietary habits with particular reference to the type of protein in the diet. None of these had taken any vitamin supplements at least for 4 months prior to this study. The basic food in the whole group consisted of varying amounts of polished rice, wheat flour in the form of chapatti, legumes, cooked green vegetables and occasional fruits. The vegetarians who were taking milk were grouped as lactovegetarians; the remainder source of protein was of vegetable origin in addition to 300–250 ml milk/day. Subjects who were consuming non-vegetarian food like meat, fish or fowl as often as once a day were grouped as non-vegetarians, frequent meat eaters, while those who took non-vegetarian food irregularly were classified as non-vegetarian, occasional meat eaters.

Venous blood samples were collected in the morning before breakfast. Subjects were however allowed to take a cup of tea or coffee. Blood was allowed to clot at room temperature and the serum was separated by centrifugation.

Serum vitamin B<sub>12</sub> was determined by the method of Ross [17] using *Euglena gracilis* var. *faciliaris* as the test organism. All estimations were done in duplicate.

Total plasma protein was determined by specific gravity method using copper sulphate standards. Haemoglobin, packed cell volume, red cell count and neutrophil lobe count were measured and MCV, MCH and MCHC were calculated by standard methods [11].

Urinary excretion and hepatic uptake of vitamin B<sub>12</sub> following the administration of cyanocobalamin was studied using <sup>57</sup>Co-labeled cyanocobalamin obtained from Bhabha Atomic Research Centre, India. For this purpose, a tracer dose of 1 µCi of <sup>57</sup>Co-labeled cyanocobalamin mixed with 400 µg of cyanocobalamin was injected intramuscularly. Seven lactovegetarians and five non-vegetarian, frequent meat eaters volunteered for this study. The subjects were allowed to take routine diet. Injections were made in the deltoid region and the radioactivity injected was measured immediately by using scintillation probe. 24-hour urine samples were collected during a period of 3 days and radioactivity excreted in terms of percent of the dose given was calculated.

The hepatic uptake of <sup>57</sup>Co-labeled cyanocobalamin was determined by the surface-counting technique described by Glass *et al.* [10] using a windowless detector connected to rate meter. Three cutaneous projections namely anterior, anterolateral and lateral of the liver were counted for calculation of the mean and necessary corrections for background and physical decay were made. As it takes about 4–6 days to build up the peak of radioactivity over the liver, the hepatic measurements were carried out on 3rd, 5th and 7th day after the injection.

Intestinal absorption studies with radioactive vitamin B<sub>12</sub> were carried out as described by Sherman [10].



Table 1 Haematological data and mean serum vitamin B<sub>12</sub> levels in Indian subjects (Mean values with  $\pm$  SE)

Group	Number of cases	Hb g/100 ml	PCV %	RBC $\times 10^6/\mu\text{l}$	Neutrophil lobe count	MCV $\mu\text{m}^3$	MCH $\mu\text{g}$	MCHC %	Vitamin B <sub>12</sub> pg/ml
<i>Males</i>									
Lactovegetarians	78	15.5 $\pm$ 0.12	46 $\pm$ 0.49	5.21 $\pm$ 0.07	3.51 $\pm$ 0.04	88 $\pm$ 1.29	29 $\pm$ 0.42	33 $\pm$ 0.24	107.4 $\pm$ 9.37
Non vegetarian, occasional meat eaters	85	15.4 $\pm$ 0.12	46 $\pm$ 0.50	5.32 $\pm$ 0.07	3.50 $\pm$ 0.04	87 $\pm$ 1.25	29 $\pm$ 0.38	33 $\pm$ 0.22	205.0 $\pm$ 11.49
Non vegetarian, frequent meat eaters	34	15.6 $\pm$ 0.13	47 $\pm$ 0.42	5.41 $\pm$ 0.11	3.43 $\pm$ 0.03	87 $\pm$ 1.14	29 $\pm$ 0.36	33 $\pm$ 0.20	379.3 $\pm$ 28.40
<i>Females</i>									
Lactovegetarians	38	13.6 $\pm$ 0.25	40 $\pm$ 0.66	4.51 $\pm$ 0.07	3.47 $\pm$ 0.07	88 $\pm$ 1.80	30 $\pm$ 0.65	34 $\pm$ 0.32	136.4 $\pm$ 11.87
Non vegetarian, occasional meat eaters	15	13.2 $\pm$ 0.23	40 $\pm$ 0.71	4.91 $\pm$ 0.17	3.45 $\pm$ 0.05	83 $\pm$ 3.04	27 $\pm$ 1.13	33 $\pm$ 0.53	202.3 $\pm$ 20.91
Non vegetarian, frequent meat eaters	12	13.6 $\pm$ 0.15	40 $\pm$ 0.60	4.69 $\pm$ 0.11	3.53 $\pm$ 0.07	86 $\pm$ 2.00	29 $\pm$ 0.69	34 $\pm$ 0.48	390.9 $\pm$ 64.95

## Results

### *Haematological Data, Serum Vitamin B<sub>12</sub> and Diet*

Serum vitamin B<sub>12</sub> levels in 197 males and 65 females, analysed according to their diet are given in table I. The groups were similar in respect to age, height, and weight. The mean haemoglobin, packed cell volume, red blood cell count, MCV, MCH, MCHC and neutrophil lobe count values in lactovegetarians were not significantly different from those observed in frequent non vegetarians. However, the mean serum vitamin B<sub>12</sub> level among the lactovegetarians was nearly one third of the mean level observed in non vegetarians. Further, 42 lactovegetarian males and 13 lactovegetarian females had serum vitamin B<sub>12</sub> values less than 100 pg/ml and in 19 of these, the level was as low as 50 pg/ml. None of these subjects showed any clinical or haematological evidence of vitamin B<sub>12</sub> deficiency. Non vegetarian occasional meat eaters had serum vitamin B<sub>12</sub> values in between these two groups. Serum vitamin B<sub>12</sub> levels did not differ significantly between male and female subjects although the mean weight, haemoglobin, packed cell volume and red blood cell count in females were lower than those observed in male subjects. Non-vegetarian frequent meat eaters had serum vitamin B<sub>12</sub> levels comparable to those reported by Western workers [4].

The mean 24 hour urinary excretion of vitamin B<sub>12</sub> was 36.54 ng (range 9.3–80.3 ng) in 10 lactovegetarians as compared to 69.11 ng (range 18.5–147.0 ng) in 18 frequent non vegetarian subjects.

### *Urinary Excretion and Hepatic Uptake following Cyanocobalamin Injection*

The measurement of the urinary radioactivity following intramuscular injection of 500 µg of cyanocobalamin mixed with <sup>57</sup>Co-labeled cyanocobalamin revealed the excretion of the major portion of the injected dose within first 24 h. It was  $69.9 \pm \text{SE } 2.39\%$  of the dose in lactovegetarians and  $64.1 \pm \text{SE } 4.09\%$  in non vegetarian, frequent meat eaters. The statistical comparison showed no significant difference in the total 24 hour radioactivity excreted in these two groups. During subsequent 48 h total  $1.79 \pm \text{SE } 1.33\%$  of the radioactivity was excreted by the lactovegetarians and  $3.14 \pm \text{SE } 0.69\%$  by the non vegetarian frequent meat eaters.

Studies on the hepatic uptake of the radioactive cyanocobalamin showed the mean hepatic uptake of  $1.74 \pm \text{SE } 0.23\%$  of the injected dose on 3rd day,  $1.87 \pm \text{SE } 0.22\%$  on 5th day and  $1.94 \pm \text{SE } 0.28\%$  on 7th

day in lactovegetarians. Corresponding figures in non-vegetarian, frequent meat eaters were  $1.95 \pm \text{SE } 0.27\%$ ,  $1.97 \pm \text{SE } 0.09\%$ , and  $2.08 \pm \text{SE } 0.15\%$ , respectively. Statistical analysis revealed no significant difference.

#### *Intestinal Absorption of Radio-Vitamin B<sub>12</sub>*

In order to study intestinal absorption of vitamin B<sub>12</sub>, Schilling test was carried out in 10 lactovegetarians and 10 non-vegetarian frequent meat eaters of comparable age, weight, and height ranges. The mean radioactivity excretion following the flushing dose of 1,000  $\mu\text{g}$  of stable cyanocobalamin was  $23.4 \pm \text{SE } 2.66\%$  in lactovegetarians while it was  $11.6 \pm \text{SE } 1.82\%$  in non-vegetarian, frequent meat eaters. The difference is statistically significant ( $p < 0.01$ ).

#### *Discussion*

These results confirm previous findings that the healthy Indian lactovegetarians have markedly lower serum vitamin B<sub>12</sub> levels than those in non-vegetarians [15, 18]. The lactovegetarians did not present any abnormal clinical findings and their blood picture, as judged by haemoglobin, packed cell volume, neutrophil lobe count, plasma proteins and various blood indices, did not significantly differ from that observed in the non-vegetarian group. The low serum vitamin B<sub>12</sub> levels observed in lactovegetarians could be either due to deficiency of this vitamin in the diet or its defective intestinal absorption. The results of Schilling test showed normal absorption of this vitamin as compared to non-vegetarians. The low serum vitamin B<sub>12</sub> levels in lactovegetarians were, therefore, due to low dietary intake of this vitamin. Since these subjects were habitual vegetarians such levels must be present for prolonged time.

Although purely on the basis of dietary analysis, clinical syndromes due to vitamin B<sub>12</sub> deficiency are expected to be more frequent in the Indian population, the available evidence points to the contrary. Nutritional megaloblastic anaemia seen in India is mostly due to folate deficiency [3, 5, 6] and neurological complications are conspicuously rare, even though the serum vitamin B<sub>12</sub> levels in many individuals may be as low as in pernicious anaemia. Further, serum levels of vitamin B<sub>12</sub> may be even high in patients with frank protein-calorie deficiency [19] and in protein-deficient rats [12].

It has been suggested that B<sub>12</sub> deficiency may sometimes cause mental changes without accompanying haematological or neurological complications [8]. However, no specific psychiatric syndrome could be attributed to such a deficiency and the vitamin B<sub>12</sub> deficiency in these cases was diagnosed purely on serum determination and the results with B<sub>12</sub> therapy equivocal. Our previous studies on serum vitamin B<sub>12</sub> levels in general population compared with psychiatric patients showed a similar frequency distribution [11]. The Indian subjects in this study belonged to a higher socio-economic group and probably had low serum vitamin B<sub>12</sub> levels since childhood without any apparent physical, haematological, or mental manifestations, they were all medical students. Earlier, patients have been reported with low serum B<sub>12</sub> levels but without anaemia, overt megaloblastosis or stigmata of B<sub>12</sub> deficiency other than an increased lobe average of the nuclei of the neutrophils [14]. However, in our subjects the neutrophil lobe count in non vegetarians did not differ significantly from that obtained in lactovegetarians. It is difficult, therefore, to accept that all these lactovegetarians were abnormal simply because their serum vitamin B<sub>12</sub> levels were lower than those of the non vegetarians.

In a study on B<sub>12</sub>-deficient megaloblastic anaemia a large proportion of 1000 µg of injected hydroxycobalamin is retained as compared to normal subjects without anaemia [1]. Furthermore, the liver B<sub>12</sub> content in patients with B<sub>12</sub> deficiency has been shown to be markedly low [2]. If low serum vitamin B<sub>12</sub> levels in our lactovegetarian subjects are indicative of over all tissue B<sub>12</sub> deficiency then these subjects should have retained larger proportion of injected B<sub>12</sub> in comparison with non vegetarians. The studies with stable B<sub>12</sub> mixed with labeled vitamin B<sub>12</sub>, however, indicate that lactovegetarians excreted similar proportion of the injected dose as non vegetarians and the liver uptake of the two groups was also not significantly different. Thus, the low serum vitamin B<sub>12</sub> level may not necessarily indicate low tissue level and taken alone is not always diagnostic of B<sub>12</sub> deficiency [13, 16].

The results of the urinary excretion of stable vitamin B<sub>12</sub> revealed that lactovegetarians normally excreted significantly less vitamin B<sub>12</sub> than the non vegetarians and the intestinal absorption of B<sub>12</sub> in lactovegetarians was as efficient as in non vegetarians. It appears that healthy lactovegetarians show some type of adaptation to low intake of vitamin B<sub>12</sub> and the low serum vitamin B<sub>12</sub> encountered in this group is not incompatible with normal health.

## References

- 1 ADAMS, J F and KENNEDY, E H Hydroxycobalamin excretion and retention after perenteral doses in anaemic and non anaemic subjects, with reference to the treatment of vitamin B<sub>12</sub> deficiency states *J Lab clin Med* 65 450-458 (1965)
- 2 BANERJEE, D K and CHATTERJEA, J B Serum vitamin B<sub>12</sub> in vegetarians *Brit med J* 11 992-994 (1960)
- 3 BAKER, N J Tropical megaloblastic anaemia in south India *Ind J Path Bact* 1 11-18 (1958)
- 4 CHANARIAN, I in *The megaloblastic anemia Vitamin B<sub>12</sub> in serum liver and CSF*, p 197 (Blackwell, Oxford 1969)
- 5 CHATTERJEA, J B Nutritional megaloblastic anaemia in tropical zones *J ind med Ass* 48 51-59 (1967)
- 6 CHATTERJEA J B Nutritional macrocytic anaemia in India *J ind med Ass* 31 4-10 (1958)
- 7 DHOPESHWARKAR, G S, TRIVEDI, J C, KULKARNI, B S, SATOSKAR, R S, and LEWIS, R A The effect of vegetarianism and antibiotics upon proteins and vitamin B<sub>12</sub> in the blood *Brit J Nutr* 10 105-110 (1956)
- 8 EDWIN, E, HOLTEN, K, NORUM K R, SCHRUMPF, A, and SAAVO, O E Vitamin B<sub>12</sub> hypovitaminosis in mental diseases *Acta med scand* 177 689-699 (1965)
- 9 GIRDWOOD, R H The occurrence of growth factors of *Lactobacillus leichmanii*, *Streptococcus faecalis* and *Leuconostoc citrovorum* in the tissues of pernicious anaemia patients and controls *Biochem J* 52 58-63 (1952)
- 10 GLASS, G H J, BOYD L J and GELLYN G A Surface scintillation measurements in humans of the uptake of parenterally administered radioactive vitamin B<sub>12</sub> *Blood* 10 95-102 (1955)
- 11 JATHAR, V S, PATRAWALLA, S P, DOONGAJI, D R, REGE, D V, and SATOSKAR R S Serum vitamin B<sub>12</sub> levels in Indian psychiatric patients *Brit J Psychiat* 117 699-704 (1970)
- 12 JATHAR V S, MEHTA, B M, SATOSKAR, R S, and REGE, D V Effect of the protein content of the diet on the vitamin B<sub>12</sub> status in rats *Brit J Nutr* 31 219-223 (1974)
- 13 JOSKE, R A The vitamin B<sub>12</sub> content of human liver tissue obtained by aspiration biopsy *Gut* 4 231-235 (1963)
- 14 KELLY A and HERBERT, V Coated charcoal assay of erythrocyte vitamin B<sub>12</sub> levels *Blood* 29 139-147 (1967)
- 15 MEHTA B M, REGE D V, and SATOSKAR, R S Serum vitamin B<sub>12</sub> and folic acid activity in lactovegetarian and nonvegetarian healthy adult Indians *Amer J clin Nutr* 15 77-84 (1964)
- 16 MOLLIN, D L, WATERS, A H and HARRISS E Clinical aspects of the metabolic interrelationships between folic acid and vitamin B<sub>12</sub> in Vitamin B<sub>12</sub> and intrinsic factor 2nd European Symposium II 737 (Enke Stuttgart 1962)
- 17 ROSS G I M Vitamin B<sub>12</sub> assay in body fluids using *Euglena gracilis* *J clin Path* 5 250-256 (1952)

- 18 SATOSKAR R S, KULKARNI B S., and REGE D V. Serum proteins, cholesterol, vitamin B<sub>12</sub> and folic acid levels in lactovegetarians and nonvegetarians. *Ind J med Res* 49 887-896 (1961)
- 19 SATOSKAR R S, KULKARNI B S, MEHTA B M, SANZGIRI R R., and BAJAJ M S. Serum vitamin B<sub>12</sub> and folic acid (F.G.A.) levels in hypoproteinaemia and marasmus in Indian children. *Arch Dis Childh* 37 9-16 (1962)
- 20 SCHILLING R F. Intrinsic factor studies II. The effect of gastric juice on the urinary excretion of radioactivity after the oral administration of radioactive vitamin B<sub>12</sub>. *J Lab clin Med* 42 860-866 (1953)
- 21 WINTROBE M M. in *Clinical haematology* 4th ed (Kimpton London 1961)

## Lipid Peroxidation in Human Erythrocytes in Tocopherol Deficiency

G R TUDHOPE and J HOPKINS

Department of Pharmacology and Therapeutics, University of Dundee, Dundee

**Abstract** Lipid peroxidation following exposure to  $H_2O_2$  vapour was abnormally great in the erythrocytes from certain patients with low plasma tocopherol concentrations. Following treatment of such patients with tocopherol erythrocyte lipid peroxidation was markedly reduced. The *in vitro* addition of tocopherol reduced lipid peroxidation in erythrocytes from both normal subjects and tocopherol deficient patients.

### Key Words

Erythrocyte metabolism  
Lipid peroxidation  
Malonyldialdehyde  
Tocopherol

The erythrocyte membrane is rich in polyunsaturated fatty acids and these molecules are themselves highly susceptible to oxidation. During its lifespan in the circulation the erythrocyte is exposed to small amounts of hydrogen peroxide generated as a result of normal metabolic processes, or to greater amounts resulting from the interaction of certain oxidant drugs and their metabolites with oxyhaemoglobin [6-8, 14]. Intracellular  $H_2O_2$  may cause oxidation of haemoglobin resulting in Heinz body formation, and also peroxidation of membrane lipids, with the formation of breakdown products including malonyldialdehyde (MDA) [1, 27, 28, 31]. Detoxification of intracellular  $H_2O_2$  is undertaken by the enzymes glutathione peroxidase and catalase [5, 11, 21, 23]. A number of workers [12, 26, 29] have considered that tocopherol, in an antioxidant role, is probably involved in maintaining the erythrocyte membrane.

It has been shown that erythrocytes from vitamin E-deficient rats underwent abnormally great haemolysis when exposed to dialuric acid, this haemolysis, which was associated with lipid peroxidation, was reduced by the addition of vitamin E (tocopherol) [4, 30]. Similar results have been

obtained in several animal experiments in which  $H_2O_2$  was used as the source of oxidant stress [12, 13, 19, 20, 29], and also in studies with erythrocytes from patients with abetalipoproteinaemia associated with tocopherol deficiency [9].

There has however been little investigation of the effect of tocopherol deficiency on the susceptibility to lipid peroxidation of human erythrocytes. We report such a study on erythrocytes from tocopherol-deficient adults, including observations on the effects of reducing the deficiency by tocopherol supplementation both *in vitro* and *in vivo*.

### Subjects and Methods

Blood samples were obtained by venepuncture and collected in tubes containing lithium heparin. Normal subjects in this study were healthy medical and laboratory personnel. Studies were made on blood from patients who had been admitted to acute general medical wards at Maryfield Hospital, Dundee. Plasma tocopherol was measured by the method of Birai and Privat [2] and MDA by the method of Stocks and Donnan [27]. Erythrocyte suspensions were prepared by washing blood twice in physiological saline and once in glucose buffered saline. The cell suspension was then made up in glucose buffered saline so that the haemoglobin concentration was 10–14 g%. Glucose buffered saline was prepared by adding glucose in a concentration of 200 mg% to saline containing 0.01 M Sorensen phosphate buffer pH 7.0. Washed erythrocytes at a concentration of 4 g% haemoglobin were exposed to  $H_2O_2$  vapour in the outer well of Conway units. Hydrogen peroxide (1.8 ml of 8.8 M solution) was present in the inner well. Peroxidation of erythrocytes was carried out with a range of concentrations of the catalase inhibitor sodium azide added to the erythrocyte suspensions as previously described [31]. We have shown that supravital staining with crystal violet of erythrocytes previously exposed to  $H_2O_2$  vapour resulted in the appearance not only of Heinz bodies, but also of an overall blue colouration of a proportion of the erythrocytes. A close relationship was found between the percentage of blue cells and the degree of lipid peroxidation as measured by MDA formation [31]. In the present investigation the method of staining erythrocyte suspensions with crystal violet was as previously described [31]. Tocopherol when required was added to the erythrocyte suspensions in the Conway unit, as  $\alpha$ -tocopherol phosphate in saline to make a final concentration of 5 mg%.

### Results

**Plasma tocopherol levels.** In 50 normal persons the mean plasma tocopherol level ( $\pm$  SD) was  $0.81 \pm 0.18$  mg%, the mean level in 21 male subjects ( $0.87 \pm 0.17$  mg%) was not highly significantly different from that



Table 1 The effect of added tocopherol on lipid peroxidation in normal erythrocytes, over a range of concentrations of sodium azide

	Concentrations of sodium azide, mmol/l				
	0	0.5	2.5	5.0	10.0
MDA, nmol/g Hb					
In the absence of tocopherol	9	58	140	181	256
In the presence of tocopherol	17	54	98	144	189
Blue cells, %					
In the absence of tocopherol	1	2	18	27	33
In the presence of tocopherol	1	2	14	18	25

for 29 females ( $0.77 \pm 0.18$  mg%) ( $0.1 > p > 0.05$ ). A level of plasma tocopherol  $\leq 0.50$  mg% was regarded as indicating tocopherol deficiency.

*Lipid peroxidation in normal erythrocytes* Washed erythrocyte suspensions from eight normal subjects were peroxidised in the presence of a range of concentrations of sodium azide, and lipid peroxidation was assessed by MDA and blue cell measurements. At a concentration of 10 mmol/l azide, the mean MDA and blue cell formation ( $\pm$ SD) was  $191 \pm 34$  nmol/g Hb and  $31.8 \pm 5.8\%$ , respectively.

In three experiments, the addition of tocopherol phosphate to normal erythrocyte suspensions peroxidised in the presence of azide resulted in a decrease in lipid peroxidation as measured by MDA and blue cell formation. Typical results from one experiment are shown in table 1.

*Lipid peroxidation in tocopherol deficiency* Erythrocyte suspensions from 14 patients with tocopherol deficiency were peroxidised in the presence of sodium azide (10 mmol/l). The diagnoses of this group of patients were post-gastrectomy (8), chronic pancreatitis (2), coeliac disease (2), Crohn's disease (1) and steatorrhoea of unknown cause (1). The mean values for MDA ( $236 \pm 96$  nmol/g Hb) and for blue cells ( $36.7 \pm 14.7\%$ ) were not significantly different from those for the normal subjects, however, in five of the cases of tocopherol deficiency the results for MDA formation were 274–414 nmol/g Hb, that is, greater than 2 SDs above the mean of the normal group. No apparent difference was found in the degree of tocopherol deficiency or in the clinical condition between these five patients and the other patients in the tocopherol-deficient group. Further studies were carried out in these five cases.

The *in vitro* effect of tocopherol on lipid peroxidation was studied in

Table II The effect of tocopherol on MDA formation in erythrocytes from tocopherol-deficient patients

Case	Age	Sex	Diagnosis	Plasma tocopherol mg/100 ml		MDA formation, nmol/g Hb		
				before therapy	after therapy	without toco- pherol	tocopherol phosphate (5 mg/ 100 ml) added <i>in vitro</i>	following toco- pherol therapy
1	62	F	celiac disease	0.31	0.54	414	253	218
2	66	M	post- gastrectomy	0.40	-	405	336	-
3	47	M	post- gastrectomy	0.36	0.96	341	224	242
4	62	M	post- gastrectomy	0.24	0.83	286	184	193
5	56	M	chronic pancreatitis	0.33	0.92	274	239	304

Washed cells were exposed to  $H_2O_2$  vapour in the presence of sodium azide (10 mmol/l)

erythrocytes from the five tocopherol-deficient patients referred to above. In each case, the addition of tocopherol resulted in a marked reduction in MDA formation (table II), which became less than 2 SDs above the normal mean in 4 of the 5 cases.

*The effect of tocopherol therapy.* Four of the above tocopherol-deficient patients were treated with  $\alpha$ -tocopherol acetate (Roche), 100 mg intramuscularly daily for 3-5 days. MDA formation was measured before the therapy and 2 days after the last injection. Washed cells were exposed to  $H_2O_2$  vapour in Conway units in the presence of sodium azide (10 mmol/l) as described above. In 3 of the 4 cases (No 1, 3, 4), there was a marked reduction in MDA formation following tocopherol therapy (table II). In case 5, there was no immediate decrease in lipid peroxidation following treatment, however, when erythrocytes from this patient were studied again several months later, the value for MDA had fallen from 274 to 149 nmol/g Hb. The significance of this latter finding is discussed.

### Discussion

Several drugs, including antimalarials of the 8-aminoquinoline group, certain sulphonamides and nitrofurans, are known to exert an oxidant effect on the erythrocyte [8]. This oxidant stress results from the intracellular generation of hydrogen peroxide by an autoxidation of the drug with oxyhaemoglobin [6, 7, 14]. The relative importance of tocopherol and the enzymes glutathione peroxidase and catalase in erythrocyte antioxidant protection is difficult to evaluate. In this study the greatest difference in lipid peroxidation between normal subjects and tocopherol-deficient patients was found at the highest concentrations of the catalase inhibitor sodium azide. This implies that in the circulating erythrocyte, tocopherol acts as a second line of defence to the  $H_2O_2$ -detoxifying enzymes in protecting the cell from the effects of peroxidation.

Patients with alimentary tract disorders associated with impaired absorption of tocopherol may also suffer from other nutritional disorders. In this investigation the role of this vitamin in preventing lipid peroxidation was studied by the addition of tocopherol both *in vitro* and *in vivo*; tocopherol resulted in a marked decrease in lipid peroxidation as measured by MDA formation. Erythrocytes from one patient treated with tocopherol did not immediately show a decreased tendency to lipid peroxidation, although this did become apparent when further studies were made several months later. This may be the result of a variable rate of uptake of tocopherol from the plasma by the erythrocyte. As the cell suspensions in these experiments were previously washed, it is the effect of tocopherol which has been taken up by the cell that is being measured.

The importance of an adequate tocopherol status in man may be seen from the reports of haemolytic anaemia in certain premature infants with tocopherol deficiency [16-18, 22, 25, 33] and in a reduced red cell life-span in adults with tocopherol deficiency as a result of malabsorption [3, 10, 15, 24]. The possible relevance of tocopherol deficiency to the anaemia of patients with malabsorption remains to be clarified. We have recently shown [32] that erythrocytes from adult patients with tocopherol deficiency show increased susceptibility to Heinz body formation when challenged by oxidant stress. It therefore appears probable that increased susceptibility to oxidation of both haemoglobin and the membrane lipids contribute to the haematological effects of tocopherol deficiency.

*Acknowledgements* The technical assistance of Miss JOAN SMITH is gratefully acknowledged. We are indebted to Roche Products Ltd. for the supply of ampoules of

$\alpha$ -tocopherol acetate. This research programme was supported by a grant from the Scottish Hospital Endowments Research Trust

### References

- 1 BARNES A J, GUTTERIDGE, J M C., STOCKS J., and DORMANDY, T L. Haemolytic syndrome associated with a red cell lipid abnormality *Brit. Med. J.* **11** 462-463 (1973)
- 2 BURR J G and PRIVAL, F L. Serum vitamin E determined by thin layer chromatography *Proc Soc exp Biol Med* **120** 554-557 (1965)
- 3 BRIDGER H J, HARTING H C, HERST, V, FINCH H C., and SPIRO H M. Tocopherol deficiency in man *New Engl. J. Med.* **273** 1289-1297 (1965)
- 4 BENYAN J, GREEN J, EDWIN E E., and DRISCOLL, A. T. Studies on vitamin E-S lipid peroxidation in dialuric acid induced haemolysis of vitamin E-deficient erythrocytes *Biochem. J.* **77** 47-51 (1960)
- 5 COHEN G and HUCHESMAN P. Glutathione peroxidase: the primary agent for the elimination of hydrogen peroxide in erythrocytes *Biochemistry* **2** 1420-1427 (1963)
- 6 COHEN G and HUCHESMAN P. Generation of hydrogen peroxide in erythrocytes by hemolytic agents *Biochemistry* **3** 695-900 (1964)
- 7 COHEN G and HUCHESMAN P. *In vivo* generation of  $H_2O_2$  in mouse erythrocytes by hemolytic agents *J. Pharmacol. exp. Ther.* **147** 139-143 (1965)
- 8 DALLMET J and CONTU L. Drug induced hemolysis *Annu. Rev. Med.* **18** 55-70 (1969)
- 9 DODGE J T, COHEN G, KAYDEN H J., and PHILLIPS G H. Peroxidative hemolysis of red blood cells from patients with abetalipoproteinemia (acanthocytosis) *J. clin. Invest.* **46** 357-368 (1967)
- 10 HORWITT M A. Interrelations between vitamin E and polyunsaturated fatty acids in adult men *Vitamins Hormones* **20** 541-559 (1962)
- 11 JACOB H S, JACOB S H., and JANDL, J H. Oxidative hemolysis and erythrocyte metabolism in hereditary acatalasia *J. clin. Invest.* **44** 1187-1199 (1965)
- 12 JACOB H S and LEE S I. Degradation of membrane phospholipids and thiols in peroxide hemolysis studies in vitamin E deficiency *Blood* **32** 549-568 (1968)
- 13 KANN H L, MINCELL, C E., CLANCY W T., and TRAVIS, R. Effects of *in vivo* hyperoxia on erythrocytes. 6. Hemolysis occurring after exposure to oxygen under high pressure *J. Lab. clin. Med.* **70** 340-357 (1967)
- 14 KINSF M. The biochemical production of ferrihemoglobin forming derivatives from aromatic amines, and mechanisms of ferrihemoglobin formation *Pharmacol. Rev.* **18** 1091-1161 (1966)
- 15 KUMARON P S and KUMARAKRISHNAN M S. Effect of alpha-tocopherol administration on red cell survival in vitamin E-deficient human subjects *Amer. J. clin. Nutr.* **24** 388-393 (1971)
- 16 LO S S, FRANK D., and HITZCO W H. Vitamin E and haemolytic anemia in premature infants *Arch. Dis. Child.* **48** 340-345 (1973)

- 17 MAJAJ, A S, DINNING, J S, AZZAM, S A, and DARRY, W J Vitamin E responsive megaloblastic anemia in infants with protein calorie malnutrition *Amer J clin Nutr* 12 374-379 (1963)
- 18 MELHORN, D K, GROSS S, LAKE, G A, and LEU, J A The hydrogen peroxide fragility test and serum tocopherol level in anemias of various etiologies *Blood* 37 438-446 (1971)
- 19 MENGEL, C E, KANN, H F, SMITH, W W, and HORTON, B D Effects of *in vivo* hyperoxia on erythrocytes 1 Hemolysis in mice exposed to hyperbaric oxygen *Proc Soc exp Biol Med* 116 259-261 (1964)
- 20 MENGEL, C E and KANN, H F Effects of *in vivo* hyperoxia on erythrocytes 3 *In vivo* peroxidation of erythrocyte lipid *J clin Invest* 45 1150-1159 (1966)
- 21 MILLS, G C Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown *J biol Chem* 229 189-197 (1957)
- 22 OSKI, F A and BARNES L A Vitamin E deficiency a previously unrecognized cause of hemolytic anemia in the premature infant *J Pediat* 70 211-220 (1967)
- 23 PANIKER N V and IYER, G Y N Protective factors in the detoxication of hydrogen peroxide in erythrocytes *Canad J Biochem* 47 405-410 (1969)
- 24 POWELL, L W Vitamin E deficiency in human liver disease and its relation to haemolysis *Aust N Z J Med* 3 355-360 (1973)
- 25 RITCHIE, J H, FISIL, M B, McMASTERS, V and GROSSMAN, M Edema and hemolytic anemia in premature infants A vitamin E deficiency syndrome *New Engl J Med* 279 1185-1190 (1968)
- 26 SILBER R, WINTER, R, and KAYDEN, H J Tocopherol transport in the rat erythrocyte *J clin Invest* 48 2089-2095 (1969)
- 27 STOCKS J and DORMANDY, T L The autoxidation of human red cell lipids induced by hydrogen peroxide *Brit J Haemat* 20 95-111 (1971)
- 28 STOCKS, J, OFFERMAN, E L, MODELL, C H, and DORMANDY, T L The susceptibility to autoxidation of human red cell lipids in health and disease *Brit J Haemat* 23 713-724 (1972)
- 29 TAPPEL, A L Vitamin E as the biological antioxidant *Vitamins Hormones* 20 493-510 (1962)
- 30 TSEN C C and COLLIER, H B The protective action of tocopherol against hemolysis of rat erythrocytes by dialuric acid *Canad J Biochem Physiol* 38 957-964 (1960)
- 31 TUDHOPE, G R and HOPKINS J Lipid peroxidation in erythrocytes - supravital staining of peroxidised cells by crystal violet *Acta haemat* 51 29-39 (1974)
- 32 TUDHOPE, G R and HOPKINS J Plasma tocopherol levels and the susceptibility of erythrocytes to Heinz body formation *Clin Sci Mol Med* 46 635-645 (1974)
- 33 WHITAKER J A, FORT E G, VINOKE SANT, S and DINNING J S Hematologic response to vitamin E in the anemia associated with protein calorie malnutrition *Amer J clin Nutr* 20 783-789 (1967)

Dr G R TUDHOPE, Department of Therapeutics, Ninewells Hospital Dundee DD2 1UD (Scotland)

## Aplastic Anaemia after Exposure to a Weed Killer, 2-Methyl-4-Chlorphenoxyacetic Acid

H. L. A. PALVA, O. KORVISTO and I. P. PALVA

Department of Medicine, University of Oulu, Oulu, and Department of Medicine  
University of Kuopio, Kuopio

**Abstract** A 64-year-old farmer developed aplastic anaemia after exposure to 2-methyl-4-chlorphenoxyacetic acid while spraying weed killer. Muscular weakness, haemorrhagic gastritis and slight signs of liver damage occurred at the same time. All these symptoms, including blood dyscrasia, are consistent with those described as toxic effects of chlorphenoxyacetic acids in animal experiments. A causal relationship between aplastic anaemia and the 2-methyl-4-chlorphenoxyacetic acid thus seems probable. The anaemia was reversible, but the case serves as a warning that careful safety measures are required during the use of chlorphenoxyacetic acids and related compounds.

### Key Words

Aplastic anaemia  
2-methyl-4-chlorphenoxyacetic acid  
Pancytopenia  
Weed killers

Many cases of aplastic anaemia remain 'idiopathic', as no specific causal agent can be identified. Among the known agents causing aplastic anaemia, benzene is the first known. Some derivatives of benzene have this same property, hexachlorbenzene (Lindan) being perhaps the best known [1, 4, 5]. Another compound containing a halogenated benzene ring is chlorphenothane (DDT) which is also a cause of aplastic anaemia [1, 4]. These compounds are widely used as insecticides, and all the cases of aplastic anaemia attributed to them are in connection with exposure in agriculture.

Further chemicals containing a halogenated benzene ring and extensively used for spraying are the chlorphenoxyacetic acids, which are employed as weed killers. Recently, we detected a case of aplastic anaemia after exposure to 2-methyl-4-chlorphenoxyacetic acid (MCPA).

### *Case Report*

A 64 year old farmer visited his local health officer complaining of weakness. He was found to be anemic and was referred to hospital in September 1973. He had a history of coronary heart disease extending back several years and regularly took digoxin and nitroglycerin tablets. During the last 3 years he had not taken any drugs known to cause aplastic anaemia.

During the last 5 years he had sprayed chemicals to destroy weeds on his farm. In the previous June and July he had been spraying Hormotuhon A Super® (Kemira Ltd, Helsinki) a compound containing MCPA. He employed an old manual spraying device with the container on his back. The container was leaking so that his clothes were wet with spraying solution. Two weeks after the last spraying he detected spontaneous haematomata on his body and began to feel lethargic. The first visit to a doctor was however delayed by 2 months as he thought the symptoms as occasional ones.

On admission he was pale, the tourniquet test was positive but otherwise the physical findings were normal. Haemoglobin 8.4 g%, leucocytes 16 300 /ml with 48% neutrophils, platelets 127 000/ml and reticulocytes 2.4%. The bone marrow morphology was normal. His serum bilirubin, transaminases, alkaline phosphatase, glutamyl transferase and ornithine carbamyl transferase were normal but the thymol turbidity test was slightly pathological (0.175). Serum iron was 32 µmol/l, TIBC 40 µmol/l, B<sub>12</sub> 700 pmol/l and folate 10.5 nmol/l. The urine sediment was normal and tests for glucose and protein negative. On gastroscopic examination haemorrhagic gastritis was found.

During the subsequent weeks he became more anaemic and received several transfusions of packed red cells. His lowest blood values were Hb 7.3, leucocytes 2 400 with 44% of neutrophils and platelets 37 000.

He was treated with prednisolone (80 mg daily orally) with no haematological response for 10 days then methenolon (Primobolan® Leiras/Schering Turku 100 mg daily) was added and the dosage of prednisolone gradually withdrawn to 15 mg daily. Two months later his blood count was Hb 12.6, leucocytes 5 100, platelets 308 000, serum iron 6 µmol/l. Five months later he was free of symptoms and had Hb 13.5, leucocytes 7 600 with 46% of neutrophils and platelets 190 000.

### *Discussion*

A pancytopenic blood picture developed after exposure to MCPA in a man without any previous haematological history, intake of drugs, or exposure to chemicals hitherto known to cause aplastic anaemia. Exposure to the same compound or related compounds had already occurred during the previous 4 summers. There had thus been an opportunity for sensitization against the chlorophenoxyacetic acids. On the other hand, the exposures have been massive, as all the safety measures had been neglect-

ed. On the contrary, a severely leaking device had been employed for spraying. Hence, a direct toxic effect is possible.

In animal experiments using dogs, feeding large doses of 2,4-dichlorophenoxyacetic acid (2,4-D) have resulted in loss of appetite, apathy, general muscular weakness, and after convulsions death in a coma or ventricular fibrillation [3]. In some cases, irritation and bleeding of the mucous membranes has been detected. Necropsies after suicides with phenoxyacetic acids have revealed inflammation, necroses and ulcerations of the digestive tract, necroses of liver and degenerative changes in the renal tubuli [2]. Of these symptoms, haemorrhagic gastritis, a tendency for bleeding, muscular weakness and slight liver damage were present in our case. The clinical picture thus fits with that of poisoning by a phenoxyacetic acid. In our case, at least thus far, all the symptoms and damage have been reversible.

As far as any causal relationship between exposure to MCPA and aplastic anaemia is concerned, a provocation test would, of course, supply convincing proof. As this cannot be done, more indirect evidence must be considered. Some chemical compounds related in their structure to MCPA, that is compounds with a halogenated benzene ring, are known to cause aplastic anaemia [1, 4, 5]. In addition, subacute intoxication of dogs with 2,4-D has resulted in anaemia, leukopenia and thrombocytopenia [3]. The time relationship between the exposure to MCPA and the onset of the symptoms is in accordance with the possibility of a causal relationship between the chemical and anaemia. Especially should the cumulative action of smaller doses of chlorphenoxyacetic acids be kept in mind [3]. It is thus very likely, that this aplastic anaemia was indeed caused by MCPA. Although the blood dyscrasia appeared at first only in the form of anaemia, pancytopenia of all the myeloid cell lines later developed.

Our patient had neglected all the safety measures when spraying MCPA weed killer preparations, having thus laid himself open to massive exposure to the chemical. This example again points to strict safety measures in order to minimize exposure to such agents as insecticides and weed killers.

### References

1. FRIEDG I. and MARTINSON J. Case of pancytopenia after exposure to chlorophenoxy and benzene hexachloride. *Arch. Industr. Hyg.* 8: 166-169 (1953).



- GELDMACHER VON MALLINCARODT, H und LAUTENBACH, L. Zwei tödliche Vergiftungen (Suicide) mit chlorierten Phenoxyessigsäuren (2,4 D und MCPA) *Arch Toxicol* 21 261-278 (1966)
- 3 HILL, E and CARLISLE, H Toxicity of 2,4 D for experimental animals *J Indust Hyg* 29 85-95 (1947)
- 4 SANCHEZ MEDAL, L, CASTANEDO, J P, and CARNIA ROJAS, F Insecticides and aplastic anaemia *New Engl J Med* 269 1365-1367 (1963)
- 5 STIEGLITZ, R, STORBE, H und SCHÜTTMANN, W Knochenmarkschaden nach beruflicher Einwirkung des Insektizids gamma Hexachlorcyclohexan (Lindan) *Acta haemat, Basel* 38 337-350 (1967)

## New Kind of Cytoplasmic Inclusions of Plasma Cells in Acid Maltase Deficiency<sup>1</sup>

H. PRALLE, R. SCHRÖDER and H. LÖFFLER

Centre of Internal Medicine (Directors: Prof. H.-G. LASCH and Prof. G. SCHÜTZERLE), Justus Liebig University, Giessen

**Abstract** Extensive vacuolization could be demonstrated in nearly all plasma cells and in some lymphocytes of an adult with glycogenosis type II (Pompe's disease). The biochemically defined diagnosis acid maltase deficiency (AMD) could be ascertained by examination of the maltase activity of the patient's leukocytes. Electron microscopical, microspectrographic, and cytochemical investigations revealed electron dense inclusions, which show an UV absorption at 276 nm and a positive reaction after PAS staining of plastic embedded material. Since no other abnormalities of the plasma cells could be found, our results are presumably indicative for a connection of AMD and a glycoprotein storage in the plasma cells of the patient.

### Key Words

Acid maltase deficiency  
Electron microscopy  
Glycogenosis  
Leukocyte maltase  
Plasma cell inclusions  
Pompe's disease

In an adult with acid maltase deficiency (AMD) associated with advanced muscular dystrophy (glycogenosis type II, Pompe's disease) we have regularly found plasma cells with many vacuoles in bone marrow samples after panoptical staining and isolated lymphocytes containing vacuoles in the peripheral blood. To our knowledge such cytoplasmic abnormalities appearing extensively in nearly all plasma cells have not until the present time been described in connection with a metabolic disorder – particularly AMD – or in connection with any other disease. We will report our biochemical, light and electron microscopic, microspectroscopic and cytochemical examinations in this patient.

<sup>1</sup> Supported by the Deutsche Forschungsgemeinschaft.

### Material and Methods

**Material** Bone marrow biopsies from the patient of the sternum and pelvis blood smears and leukocyte concentrates were done without the addition of anti coagulant. The tests were also carried out on a healthy brother of the patient.

**Staining methods for light microscopy** May Grünwald Giemsa, methylene blue pH 9, methyl green pyronin, Adams reaction, Sudan black B, oil red O, PAS and PAS after pretreatment with lead acetate as an oxidant and after incubation with amylase and hyaluronidase [2], as well as methods for the determination of non specific esterase [15, 16], acid phosphatase [15, 16],  $\beta$  glucuronidase [10, 17] and peroxidase [13]. Methylene blue, methyl green pyronin and PAS were also carried out on 1  $\mu$ m thick plastic embedded sections after removal of the embedding material [20].

**Microspectrophotometry** Another part of the material was smeared on quartz slides and air dried. The smears were examined after mounting in glycerol with a double beam microspectrometer (US 1206 Beckman Instruments, Munich, FRG). The measuring arrangement employed allowed a point determination of a single inclusion of 2  $\mu$ m cross section against a reference beam but also the integration of more inclusions in a larger field.

**Electron microscopy** Fragments of a sternal puncture sample were fixed in 2% glutaraldehyde in 0.135M phosphate buffer pH 7.2 for 3 h and a part was post fixed in 1% osmium tetroxide in the same phosphate buffer. After washing in buffer the preparation was dehydrated through an acetone series and embedded in Araldite (Durcupan AMC, Fluka, Switzerland) in the usual way. Serial ultra thin sections were cut on an ultramicrotome (Reichert OM U<sub>2</sub>). 1  $\mu$ m thick sections were prepared for light microscopy. The ultra thin sections (silver interference colour) were picked up on a slot grid (Veco L 12) that had been covered with formvar and carbon [11]. The electron microscopic pictures were taken on a Siemens Elmiskop 101 and a Philips 201 35 mm Agfa rollfilm 220 and Kodalith LR film 2572 were used.

**Leukocyte maltase activity** 40 ml of venous blood were taken into citrate from the patient and five controls carried out in order to isolate the leukocytes. After the addition of one fifth of the volume of 5% dextran the erythrocytes were removed by a Rapaquon dextran dense medium [5]. The following steps were carried out at 0°C. The leukocytes were collected from the plasma by centrifugation and taken into 2 ml 50 mM sodium fluoride. The cells were disrupted four times by ultrasonication for 12 sec intervals at 100 W with a Branson B 12 ultrasonicator. Nuclei and remaining undisintegrated material were removed by centrifugation at 1200 g for 10 min. Protein determination was carried out by the method of Lowry *et al.* [18]. The maltase activity was determined at different pH values beginning with pH 4.0–5.5 in 70 mM acetate buffer and from pH 5.5 to 7.0 in 70 mM cacodylate buffer with 50 mM maltose as substrate and with an average addition of 0.32 mg dialyzed protein per assay volume of 0.4 ml. The incubation was carried out at 37°C for 3 h. The reaction was stopped by the addition of 0.1 ml 1 N perchloric acid at 0°C [1]. The quantity of glucose formed in this assay was determined from 0.1 ml of the resulting supernatant with the hexokinase and glucose 6-phosphate DH reaction [4].




Fig 1 Bone marrow smears, May-Grunwald-Giemsa stain. Three plasma cells with small to medium sized vacuoles (a, b, c) one with a very large vacuole indenting the nucleus and five small vacuoles (d)  $\times 1400$


## Results

### Light Microscopy

In the examined smears which had been taken at three different times from the sternum and pelvis, a pronounced vacuolization of more than 90% of the plasma cells was found the total number of plasma cells being in the normal range. The vacuoles were preponderately round and measured 0.2–4.0  $\mu\text{m}$  cross section, a few were greater reaching the size of erythrocytes. Usually the whole cytoplasm contained additionally numerous small vacuoles (fig 1). In EDTA free blood smears isolated lymphocytes – less than 5% – were noticed, that had vacuoles in the cytoplasm. In spite of different fixation methods for smear preparations no inclusions were detected. With the clinically healthy brother of the patient the described changes were not observed.

### Microspectrophotometry

This examination gave a first hint for the existence of inclusions by means of light absorption with a sharp narrow peak at 276 nm. The microspectrographic examinations showed for the isolated measurement of a single vacuole an absorption at 276 nm. Between 300 and 600 nm an



**Fig 2** *a* Acid phosphatase reaction (naphthol AS biphosphate hexazonium pararosanilin pH 5.0) The activity is confined to the border of the vacuoles and the cytoplasm *b* Methylene blue stain pH 9.0 Plastic embedded section showing large inclusions within a plasma cell *c* Blood lymphocyte with a very intense granular PAS positivity *d* Semi thin section of plastic embedded bone marrow, PAS stain Inclusions in plasma cells are positive

irregularity of the transmission curve is evident that can be explained by optical effects. The integrated measurement of many inclusions shows a similar absorption at 276 nm. An irregularity occurs at 400–450 nm, which is presumably caused by the cytoplasm and its organelles.

### *Cytochemical Examinations*

**Smears** With all reactions, which serve to identify the material in the 'vacuoles', they seemed to be optically empty. The reaction for peroxidase was negative. The demonstration of acid phosphatase activity showed a strong reaction at the rim of the vacuoles besides the usual activity in the vacuole-free cytoplasm (fig 2a). The same behaviour is found for  $\beta$ -glucuronidase, whose activity appeared weaker. Esterase activity was confined to the vacuole-free cytoplasm. An intense granular PAS reaction corresponding with a diffuse weak PAS reaction in the cytoplasm of some plasma cells between the vacuoles – most evident in those cells with less vacuoles – was demonstrable, similar to an extraordinarily intense granular reaction in some lymphocytes of the peripheral




Fig. 1. Electron microscopy of plasma cells containing inclusions. (a) Typical arrangement of endoplasmatic reticulum and multiple small vacuoles near to the border of the cell. Besides these are electron-dense inclusions with different shape and electron density and three honeycombed inclusions. (ca.  $10 \times 10^3 \times$ ) (b) Electron-dense inclusion with irregular borders and polycrystalline structure. In the lower right corner part of a honeycombed inclusion. (ca.  $40 \times 10^3 \times$ ) (c) Detail of figure (b) showing the polycrystalline structure with a periodicity of  $100 \text{ \AA}$ . (ca.  $1 \times 10^5 \times$ ) (d) Border of an inclusion with amorphous homogeneous areas with a light electron density. (ca.  $40 \times 10^3 \times$ )

fluid and ton membrane not observable in this degree normally or in leukemia-free cases (Fig. 2c). After treatment with amylase the reaction was weaker.

Section. In plasma-embedded sections the vacuoles after methanol fixation as pH 10 were mainly identical to round vacu-




Fig 4 Specific activity of leukocyte maltase at different pH values. The patient's leukocytes (○) Leukocytes of four controls (●)

bly intense and homogeneously stained inclusions, whether the embedding material was left or dissolved (fig 2b). These inclusions were PAS-positive. After pretreatment with amylase the reaction was only minimally reduced. It remained positive if the oxidation with periodic acid was replaced by leadtetraacetate (fig 2d).

### Electron Microscopy

Electron microscopy (EM) showed the plasma cell inclusions to be of variable density to electrons. The inclusions appeared round to polygonal with fine granules, sometimes, however, honeycombed and on rare occasions empty. These different varieties of inclusions were found side by side in one cell (fig 3a, b). The most electron dense, which appeared homogeneous at low magnifications, showed a polycrystalline structure with a periodicity of approximately 100 Å (fig 3c). Besides this, myelin-like areas in the inclusions were sometimes found (fig 3b). The inclu-

sions lay between the membranes of the endoplasmatic reticulum. On the border of the inclusions were occasionally found small homogeneous spots which showed in some cases a lighter centre (fig. 3d). A defining membrane of the inclusions could not be identified.

#### *Maltase Activity in Leukocytes*

The deficiency of acid maltase could be demonstrated by biochemical analysis of leukocytes. The pH dependency of maltase activity of leukocyte extractions from the patient as well as from five controls are shown in figure 4. It can be seen that the leukocyte enzyme from the patient has only low activity in acidic conditions. The displayed curve is very comparable with those mentioned of other patients with AMD in the literature [8].

#### *Discussion*

A Persian student with AMD, whose diagnosis was confirmed by means of biochemical examination of his leukocyte maltase activity, was found to have a pronounced vacuolization of the plasma cells from the bone marrow. Moreover, a heavy deposit of PAS-positive material was visible between the vacuoles of some plasma cells and particularly pronounced in the lymphocytes of the peripheral blood and bone marrow. These vacuoles, which appeared optically empty in smears, contained inclusions in semi thin sections of plastic embedded material and also in EM preparations. They were stainable by the PAS reaction and with methylene blue pH 9 and showed an absorption maximum at 276 nm with UV microspectrography. EM revealed electron dense inclusions which were in part polycrystalline and sometimes associated with myelin structures and in part varied from honeycombed to completely empty. Our results gave evidence that they consist of both protein and polysaccharide components.

Since our patient's total serum protein and serum electrophoresis along with the quantitative determination of the immunoglobulins gave values in the normal range and the immunoelectrophoresis including the application of anti  $\mu$ -chain antibodies showed no abnormal protein fraction [9], plasma cell alterations with dys- or paraproteinemia could be discounted.

In publications about AMD in children and in few communications concerning the disease in adolescents and adults an abnormality of the



plasma cells has not been previously described. Only ENGEL and DALE [7] have mentioned isolated vacuolized lymphocytes in the peripheral blood such as have also been seen in amaurotic idiocy Tay-Sachs, in Niemann-Pick disease, and in progressive muscular dystrophy type ERB (Jordan's anomaly) [3, 12, 23]. In addition, however, isolated vacuolized lymphocytes are found in various diseases. They can in any event only serve as a hint to look for a metabolic disorder.

In AMD glycogen-rich, membrane enveloped inclusions were known in the muscle fibres and in fibroblasts after tissue culture until now [6, 7, 19, 21]. In contrast, descriptions of plasma cells containing inclusions of glycoprotein have not been given previously.

Our results show a clear-cut difference of the inclusions described in this paper from other examples in particular from Russell bodies by means of EM. Indeed such a pronounced vacuolization of all plasma cells is known neither in connection with any other muscular disease or metabolic disorder nor another disease. We therefore presume that the inclusions are connected with AMD. We must leave open the question whether the special protein synthesizing and secretory mechanisms of plasma cells cause the laying down of protein polysaccharide complexes in the described form, whereas in other sites (e.g. muscle) a concentration of glycogen in secondary lysosomes is formed [7, 21].

*Acknowledgements* We are greatly indebted to Prof. Dr F. ERBSLÖH, Director of the Department of Neurology of the Justus Liebig University Giessen who referred the patient to us.

We would also like to thank Dr G. HARTWIG, Center of Anatomy and Cytobiology, for his friendly cooperation.

### References

1. ANGELINI, C. and ENGEL, A. G. Comparative study of acid maltase deficiency: biochemical differences between infantile, childhood, and adult types. *Arch. Neurol.*, Chicago 26: 344-349 (1972).
2. ARNOLD, M. *Histochemie*, pp. 123-144 (Springer, Berlin 1969).
3. BAGIR, K. v. und HORTLING, H. Ergebnisse einer Blutanalyse bei juveniler amaurotischer Idiotie. *Nord. Med.* 39: 1072-1075 (1948).
4. BERGMAYER, H. U., BERNT, E., SCHMIDT, F. and STORK, H. D. Glucosebestimmung mit Hexokinase und Glucose 6-phosphatdehydrogenase, in BERGMAYER, Methoden der enzymatischen Analyse, 2. ed. (Verlag für Chemie, Weinheim 1970).
5. BJÖRNT, A. Separation of leukocytes from blood and bone marrow. *Scand. J. clin. Lab. Invest.* 97 (suppl. p. 77) (1967).

- 5 BROWN B I and BROWN, B H The experimental production of glycogen storage in cultured human fibroblasts *Biochem. biophys. Res. Commun.* 45 1291-1298 (1972)
- 7 ENGEL, A G and DALL, A S D Autophagic glycogenosis of late onset with mitochondrial abnormalities: light and electron microscopic observations *Mayo clin Proc* 43 233-279 (1968)
- 8 ENGEL, A G and GOMEZ, M R. Acid maltase levels in muscle in heterozygous acid maltase deficiency and in nonweak and neuromuscular disease controls *J Neurol Neurosurg Psychiatr* 33 801-804 (1970)
- 9 GERMANN H J, WESTERHAUSEN, M und KUCHTSCHEW, B = Kettenkrankheit. *Dtsch med Wochr* 97 1902-1905 (1972)
- 10 HAYASHI M  $\beta$ -Glucuronidase *J Histochem Cytochem* 12 293-295 (1964)
- 11 HIRTING H C Zur Kohlebedampfung von Formvarfilmen auf elektronenmikroskopischen Objektträgern. *Mikroskopie* 20 210-211 (1965)
- 12 JORDAN G H W The familial occurrence of fat containing vacuoles in the leukocytes diagnosed in two brothers suffering from dystrophia musculorum progressiva (FRB) *Acta med scand* 145 419-423 (1953)
- 13 KAPLOW L S Simplified myeloperoxidase staining using benzidine dihydrochloride *Blood* 26 215-218 (1965)
- 14 KOSTER F J, SEIZ R G., and HELSMANN W C. The use of leukocytes as an aid in the diagnosis of glycogen storage disease type II (Pompe's disease) *Clin chim Acta* 37 319-325 (1974)
- II FIEDER L D *Der Blutmonozyt* (Springer Berlin 1967)
- 16 LÖFFLER H Unspezifische Esterase und saure Phosphatase bei Plasmozytomen *Blut* 25 340-335 (1967)
- 17 LORRAESSER P., YAM L. T., and MITTS W J Cytochemical demonstration of  $\beta$  glucuronidase activity in blood and bone marrow cells *J Histochem* 15 680-684 (1967)
- 18 LOWRY M H, ROSENBROGH N J, FARR A L., and RANDALL, R J Protein measurement with the Folin reagent *J biol Chem* 193 265-270 (1951)
- 19 DI MAURO S, WEIZMAN W, OSKE F., and BAKER L. Glycogen and hexose metabolism in fibroblast cultures from galactosemic and glycogenosis type II patients *Pediat Res* 3 368 (1969)
- 20 MAYHEW H D, HAMPTON J C., and REMARKS B. A simple method for removing the resin from epoxy embedded tissue *J biophys. biochem. Cytol* 9 902-810 (1961)
- 21 NITOWSKY H M and GREENFIELD A. Lysosomal glucosidase in type II glycogenosis, activity in leukocytes and cell cultures in relation to genotype *J Lab clin Med* 69 472-484 (1967)
- 22 PEARSE A G F The histochemical demonstration of keratin by methods involving selective oxidation *Quart J nutr Sci* 92 393-402 (1951)
- 23 PETER C M Lymphocyte degeneration in amaurotic idiocy *Dan med Bull* 4 156-157 (1957)

## Classical Factor X Deficiency

### Report of a Further Case<sup>1</sup>

A GIROLAMI, P COSER, A BRUNETTI and O PRINOTH

University of Padua Medical School, Institute of Semeiotica Medica  
(Director Prof M AUSTONI), and Blood Bank and Immunotransfusion Center,  
Bolzano City Hospital, Bolzano

**Abstract** A case of classical factor X deficiency is reported. The propositus is a 28 year old male who presented easy bruising, epistaxis, hematomas, hematuria and occasional hemarthrosis since early childhood. The severely prolonged prothrombin time was corrected by normal serum but not by adsorbed normal plasma. The abnormality was not corrected by the plasma of a patient with factor X deficiency, but by the plasma of patients with factor II or VII deficiencies. Partial thromboplastin time, prothrombin consumption and the thromboplastin generation test were abnormal. The thromboelastogram showed a prolonged 'K' and 'r' together with a normal 'ma'. Factor X was very low (<1%). Platelet tests were normal. No factor X band or precipitates were seen on electroimmunoassay and on the cross over electrophoresis. The non consanguineous parents and several other members of the family were found to be heterozygotes.

#### Key Words

Bleeding disorders  
Blood coagulation  
Electroimmunoassay  
Electrosyneresis  
Factor X deficiency

Classical congenital factor X deficiency remains a very rare coagulation disorder. To date only about 25 proven or probable cases have been reported in the literature [2-4, 6-8, 14, 19, 21, 23, 25-31]. The reasons for such rarity are unknown and seem really striking if one takes into account the fact that congenital factor VII deficiency, a condition which resembles factor X deficiency, is at least 4 times more frequent [16].

Recently several patients with a coagulation disorder due to the presence of an abnormal factor X have been described [13, 14, 15, 17]. This

<sup>1</sup> This study was supported in part by a grant from the CNR (grant CT 73 00599 04).

variant of the factor X defect has been termed factor X Friuli since the patients originally described came from an isolated valley of the north-eastern Italian region called Friuli. The main feature of factor X Friuli patients lies in the presence of an abnormal factor X, a protein which may not be activated, or only very slowly so, by tissue thromboplastins, whereas it may be normally activated by Russell's viper venom. Consequently, in these patients, factor X is found low only when assayed using tissue thromboplastins. However, even taking into account all the Friuli patients, the total number of patients with a factor X defect or abnormality does not exceed the total of 40.

Reports of new cases with classical factor X deficiency should be welcome since they could help clarify the main features of the disease. The object of the present paper is to present a new patient with this condition. The propositus is the fourth patient with this coagulation defect reported in Italy [2, 14, 27].

### *Material and Methods*

Materials and methods have been described elsewhere [11-14]. Only new data will be given herein.

Prothrombin consumption was carried out after addition of normal serum to the patient's serum in a 2:10 proportion. Factor II in the one-stage or two-stage system was assayed after the addition of an aliquot of normal serum to the factor II substrate: the patient's defibrinated plasma or the diluted thromboplastin and patient's plasma mixture. The antiserum used for immunological studies was kindly supplied by Dr D. ARONSON of the National Institutes of Health, Bethesda, Md. [1]. Electromicroassay was carried out according to the method proposed by LATWELL [24]. The antiserum used in this system was absorbed with factor X deficient plasma as previously reported [15-18]. Cross-over electrophoresis (electroimmunesis) was carried out according to a previously reported modification [15] of the method proposed by BLISSARD [5] without absorbing the antiserum.

### *Case Report*

The propositus is a 25-year-old male who was first seen by one of us (P.C.) in March 1974 when he was admitted to the Bolzano City Hospital because of a hematoma of the left thigh. Routine coagulation studies and cross-correction studies with normal serum and absorbed normal plasma raised the question of factor X deficiency.

Subsequently, further studies done in Padua confirmed the diagnosis. The parents of the propositus were not consanguineous but were born in the same valley of the Upper Adige region. Family history was negative for severe bleeding manifestations (fig. 1).

- = Propositus homozygote symptomatic  
 □ or ○ = Male or female heterozygote asymptomatic or mildly symptomatic  
 ⊠ or ⊙ = Deceased asymptomatic or not male?  
 ⊡ or ⊢ = Not studied symptomatic or normal?  
 □ or ○ = Studied normal




Fig 1 Family pedigree. Eleven persons besides both parents were found to be heterozygotes. The factor  $\lambda$  levels found in the normal relatives varied between 86 and 125%. Those found in the heterozygote relatives varied between 47 and 74% (see table IV).

The patient started to present easy bruising and hematomas after accidental falls or major traumas in early childhood. Epistaxis and hematuria appeared too at this age. At the age of 8 the patient was admitted to the Bolzano City Hospital for anemia. On that occasion there were no bleeding manifestations but the patient was transfused with 3 units of blood to correct the anemia. At the age of 12 the patient was admitted to a local hospital for a huge hematoma of the right thigh and on another occasion for severe epistaxis. In 1963 the patient had to be admitted again to a local hospital for anemia and exertion dyspnea. On that occasion he received several blood transfusions. In 1964 the patient was admitted to the University Hospital in Innsbruck where a tentative diagnosis of factor X deficiency was apparently first postulated. In 1965 the patient was admitted to a local hospital for post transfusion

Table I Coagulation study in the propositus

Test	Propositus' values	Normal values
Glass clotting time, min	16	5-9
Platelet count	370 000	150 000-350 000
Clot retraction	complete after 6 h	complete after 12 h
Bleeding time, min	4.5	2-5
Partial thromboplastin time, sec	144	35-45
Prothrombin time, sec	125	14-15
Stypven-cephalin clotting time, sec	57	12-14
Thromboplastin generation test	38 sec in 8 min	15 sec in 6 or 8 min
Prothrombin consumption, %	43	90
Fibrinogen, mg %	380	250-450
Factor II (one-stage), %	96	85-125
Factor II (two-stage), %	100	85-125
Factor VII, %	100	85-125
Factor X, % <sup>1</sup>	<1	85-125
Factor V, VIII, IX, XI, XII	normal	60-150 %
Thrombin time, sec	19	18-25
Thromboelastogram, mm		
'Y'	71	10-20
'K'	55	6-12
am	52	50-66

<sup>1</sup> Same values with tissue thromboplastin and Stypven-cephalin

hepatitis. From 1964 till 1973 the patient had to be admitted on several occasions to local hospitals for spontaneous or post-traumatic hematomas and melenas. Hemarthroses have been rare but have occasionally caused temporary limitations of mobility. However, no permanent ankylosis has occurred.

### Results

The coagulation study is summarized in table I. Our data clearly indicate that the propositus had a first- and second-stage coagulation defect. This is consistent with factor X deficiency once a factor V or factor II deficiency is ruled out.

The prothrombin time is corrected by normal serum, normal plasma, factor II- and factor-VII-deficient plasma but not by adsorbed normal plasma, factor-X-deficient plasma and the abnormal factor X (factor X 1:100) plasma (table II). Prothrombin time derivative tests such as PT test, thrombotest and normotest were severely prolonged too (table III).

*Table II Prothrombin time correction studies in the propositus Mixtures of equal parts*

	Prothrombin time, sec	
	mixture	reference plasma
Patient's plasma alone	125.0	—
Patient's plasma + normal plasma	16.1	14
Patient's plasma + normal serum	15.8	—
Patient's plasma + adsorbed normal plasma	102	—
Patient's plasma + plasma of another patient with factor X deficiency <sup>1</sup>	114.2	111
Patient's plasma + plasma of a patient with factor X Friuli coagulation disorder <sup>2</sup>	42.8	35
Patient's plasma + plasma of a patient with hypoprothrombinemia <sup>1</sup>	15.4	20.5
Patient's plasma + plasma of a patient with factor VII deficiency <sup>1</sup>	16	50.1

<sup>1</sup> Personal case, frozen plasma<sup>2</sup> Personal case (index patient with factor X Friuli disorder)*Table III Prothrombin time derivative tests in the propositus*

Test	Propositus' values	Normal control
PP test, sec <sup>1</sup>	306.0	28
Trypsin clotting time, sec	86.11	23.3
Thrombotest, sec	706	43
Normotest, sec	405	25.3

<sup>1</sup> Tissue thromboplastin is used in the system

The factor X level was less than 1% regardless of the assay system. Factor II was normal both by the one-stage and the two-stage method.

Factors V, VII, VIII, IX, XI and XII were all within normal limits. Fibrinogen and fibrinolysis were normal too. The prothrombin consumption was defective. The thromboplastin generation test was abnormal too and the substitution of the patient's serum with normal serum corrected the abnormality (fig 2). The thromboelastogram showed a clearly prolonged 'r' and 'K', whereas the 'ma' was normal. Thrombin time and platelet tests were all within normal limits. Immunologically, no factor X peak was evident in the patient plasma on electroimmunoassay and no




Fig 2 Thromboplastin generation test 1 -- Generation mixture containing patient's adsorbed plasma and patient's serum 2 -- generation mixture containing adsorbed normal plasma and patient's serum 3 -- generation mixture containing patient's adsorbed plasma and normal serum. In each case the other components of the generation mixture were an activated cephalin preparation and 0.025 M  $\text{CaCl}_2$ .

hand was seen on electrosyneresis (fig 3, 4). Both parents of our propositus together with other family members were found to have slightly reduced factor X levels (47–74%) and were considered to be heterozygotes (fig 1, table IV).

### Discussion

The main diagnostic criteria for classical factor X deficiency are prolonged prothrombin time corrected by serum, prolonged partial thromboplastin time and Stypven-cephalin clotting time and abnormal thromboplastin generation due to a seric defect. Our patient fully meets all these criteria. The lack of correction of the propositus' prothrombin time after the addition of known factor X-deficient plasma firmly established the diagnosis. The type of deficiency is the classical type in the sense that factor X was low in both coagulation assay systems (tissue thromboplastin and Russell's viper venom) and immunologically.

In the factor XI null coagulation disorder factor X is found to be low only when tissue thromboplastin instead of RVV-cephalin is used in the assay system [13, 14, 16, 17] and a normal level is obtained immunologi-






Fig 3 Latex electrophoresis 1 = Propositus plasma 2 = abnormal factor X (factor X Friuli) plasma 3 = pooled normal plasma 4 = Dade factor X deficient plasma No peak is seen in 1 and 4 The antisera used in these studies was absorbed with factor X deficient plasma

Fig 4 Cross over electrophoresis (electrosyneresis) 1 = Propositus plasma 2 = pooled normal plasma 3 = abnormal factor X (factor X Friuli) plasma 4 = Mr Stuart plasma The antisera used in these studies was not absorbed A major or factor X band is visible only in 2 and 3 Lighter or minor bands are present in all plasmas but they may be disregarded since they are due to secondary activities of the antisera used

cally The severely prolonged prothrombin time presented by our propositus is of interest The value obtained is longer than the value reported for Mr Stuart (about 85 sec) [23] Only 2 other patients with factor X deficiency had similarly prolonged prothrombin times namely a patient presented by LECHLER *et al* [25] in 1965 and a patient studied by us in 1970 [4] The bleeding manifestations presented by our propositus were severe and were those common in classical factor X deficiency The severity of the bleeding manifestations correlates well with the very low factor X level In this regard it is interesting to note that in general bleeding manifestations are more severe in the classical factor X deficiency than in the abnormal factor X (factor X Friuli) coagulation disorder [17]

As far as heredity is concerned there is no doubt that our patient was a homozygote for the defect Both parents were in fact heterozygotes Eleven relatives of the propositus besides his parents were also heterozygotes for the abnormality The hereditary data gathered from this study fully confirm the previous observations on the matter [20-29] The defect is transmitted as an autosomal incompletely recessive trait The heterozy-

Table II Factor X level and bleeding manifestations in the heterozygote family members

Position in family tree (fig. 3)	Factor X, %	Bleeding manifestations
II <sub>1</sub>	70	none
II <sub>2</sub>	59	excessive bleeding after hysterectomy, epistaxis
II <sub>3</sub>	60	none
II <sub>4</sub>	74	none
II <sub>5</sub>	72	none
II <sub>6</sub>	60	none
III <sub>1</sub>	50	none
III <sub>2</sub>	60	none
III <sub>3</sub>	60	excessive bleeding after tooth extractions
III <sub>4</sub>	58	none
III <sub>5</sub>	47	excessive bleeding after tooth extractions
III <sub>6</sub>	68	none
IV <sub>1</sub>	60	none

Table I Main genetic variants of factor X defect. Our propositus has a coagulation pattern identical to that shown by Mr. Stuart

Index patient	Factor X level (tissue thromboplastin)	Factor X level (Stypven-cephalin mixture)	Factor X antigen
Miss Prower	low	low	normal
Mr. Stuart	very low	very low	absent
Factor X Frituli	low	normal	normal

Very low =  $\leq 1\%$ , low = 2-15%, normal = 70-100%.

gote subjects show factor X levels varying usually between 40 and 70% of normal and are often asymptomatic. The abnormal factor X (factor X Frituli) coagulation disorder has the same hereditary transmission [12, 13]. The prothrombin time in the heterozygote population may be normal or slightly prolonged. In the present family the prothrombin time was 1-1.5 sec prolonged in almost all heterozygotes. Factor X levels varied between 47 and 74%. A few of the heterozygotes belonging to the present pedigree have presented mild and minor bleeding manifestations (excessive bleeding after tooth extractions and epistaxis) (table IV).

Three genetic variants of the factor X defect seem to exist today (table V). Mr. Stuart has very low factor levels regardless of the method used

and no factor X antigen, Miss Prower has low factor X level in both assay systems but normal factor X antigen [9] The index patient with the factor X Friuli abnormality has low factor X level in the tissue thromboplastin assay system whereas a normal level is obtained in the Stypven cephalin assay and immunologically. Our propositus has a defect identical to that shown by Mr Stuart namely classical factor X deficiency

### References

- 1 ARONSON D. personal commun (1971)
- 2 ASCARI R, BARBIERI U e GOBBI F. Deficit congenito del fattore Stuart. *Minerva med* 376-2873 (1964)
- 3 BACHMANN F, DUCKERT F, FLÜCKIGER P, HITZIG W H und KOLLER F. Über einen neuartigen kongenitalen Gerinnungsdefekt (Mangel an Stuart Faktor). *Thromb Diath haemorrh* 1: 87 (1957)
- 4 BACHMANN F, DUCKERT F, FLÜCKIGER P und HITZIG W H. Hamorrhagische Diathesen verursacht durch Mangel des Stuart Prower Faktors. *Schweiz med Wschr* 87: 1221 (1957)
- 5 BUSSARD A. Description d'une technique combinant simultanément l'électrophorèse et la précipitation immunologique dans un gel l'électrosynérèse. *Biochim biophys Acta* 34: 258 (1959)
- 6 BRODY J I and FINCH S G. Improvement of factor X deficiency during pregnancy. *New Engl J Med* 263: 996 (1960)
- 7 CAEN J, BEAUMONT J L et BLINARD J. Deficit en facteur Stuart. Etude biologique. *Rev franç Et clin biol* 3: 161 (1958)
- 8 CROCKETT C L, SHOTTON D, GRADDOCK C G and LEAVELL B. Hypoprothrombinemia: studies of a case of the idiopathic type and the effect of serum administration. *Blood* 4: 1298 (1949)
- 9 DENSON K W, LURIE A, DE CATALDO F and MANNUCCI P M. The factor X defect: recognition of abnormal forms of factor X. *Brit J Haemat* 18: 317 (1970)
- 10 GIROLAMI A, MOLARO G, LAZZARIN M e SCARPA R. Una nuova coagulopatia emorragica congenita probabilmente dovuta alla presenza di un fattore X abnorme. Studio preliminare. *Minerva med* 99: 4939 (1969)
- 11 GIROLAMI A, MOLARO G, LAZZARIN M, SCARPA R, and BRUNETTI A. Congenital hemorrhagic condition similar but not identical to factor X deficiency. A hemorrhagic state due to an abnormal factor X? *Scand J Haemat* 7: 91 (1970)
- 12 GIROLAMI A, MOLARO G, LAZZARIN M, SCARPA R and BRUNETTI A. A new congenital hemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli). A study of a large kindred. *Brit J Haemat* 19: 179 (1970)
- 13 GIROLAMI A, LAZZARIN M, SCARPA R and BRUNETTI A. Further studies on the abnormal factor X (factor X Friuli) coagulation disorder: a report of another family. *Blood* 37: 434 (1971)
- 14 GIROLAMI A, MOLARO G, CALLIGARIS A and DE LUCA G. Severe congenital

- factor X deficiency in a 5 month-old child *Thromb Diath. haemorrh* 24 175 (1970)
- 15 GIROLAMI A., STICCHI A., and BAREGGI G. Cross-over electrophoresis (electro-syneresis) visualization of the abnormal factor X (factor X Friuli) *J Lab clin Med* 80 740 (1972)
  - 16 GIROLAMI A., SCURZA P., BRUNETTI A., MCGAGNI, C., and SANTINI, G.. Congenital hypoproconvertinemia (factor VII deficiency) A report of two cases belonging to two different kindreds *Acta haemat* 50 229 (1973)
  - 17 GIROLAMI A., MOLARO G., and DE MARCO L.. Factor X survival and therapeutic factor X levels in the abnormal factor X (factor X Friuli) coagulation disorder *Acta haemat* 52 222 (1974)
  - 18 GIROLAMI A., BAREGGI G., and BONVATO N. Factor X Friuli: an immunological study *Blut* (in press, 1974)
  - 19 GOWDY L. M. and KRIVIT, W. Congenital coagulation deficiency of Stuart factor activity *J Lab clin Med* 51 399 (1958)
  - 20 GRAHAM J. B., BARROW, F. M., and HOUZIE, C. Stuart clotting defect II Genetic aspects of a new hemorrhagic state *J clin Invest* 35 497 (1957)
  - 21 HOLZKNECHT F. Kongenitaler Stuart Prower Faktor (Faktor X)-Mangel *Klin Wochr* 43 88 (1965)
  - 22 HENDER M. H. Isolierter kongenitaler Faktor X Mangel *Med Klin* 59 330 (1964)
  - 23 HOUZIE, C., BARROW, F. M., and GRAHAM J. B. Stuart clotting defect I Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA proconvertin, factor VII) deficiency *J clin Invest* 35 495 (1957)
  - 24 LATHILL, C. B. Quantitative estimation of protein, by electrophoresis in agarose gel containing antibodies *Analyt. Biochem* 15 45 (1966)
  - 25 LECHEUR I., WEISSER W. P., ROBERTS H. R., and PRINICK G. D. The inheritance of Stuart disease: investigation of a family with factor X deficiency *Amer J med Sci* 229 291 (1965)
  - 26 OEHME J., SCHWICK und SCHULTZ H. E. Familiärer Faktor X Mangel *Klin Wochr* 36 521 (1958)
  - 27 PASERI G. e BONICCHI I. Disturbo emorragico da deficit di fattore X. *Riv med* 82 203 (1968)
  - 28 RABINER I. and KATSCHEW N. The Stuart Prower factor: utilization of clotting factors obtained by starch block electrophoresis for genetic evaluation. *Brit J Haemat* 7 97 (1961)
  - 29 ROSS J., VAN ABDEL C., VIRELOW M. C., and JORDAN I. L. J. A new family with Stuart Prower deficiency *Thromb Diath. haemorrh* 3 92 (1959)
  - 30 SCURZA P., PATON, T. und RENTHA M. Mangel an kongenitem Faktor X (aktiver Stuart Prower) *Z Kinderheilk* 106 190 (1969)
  - 31 TILLOT T. P., DENSON A. W., and WICKART D. R. A new coagulation defect *Brit J Haemat* 2 305 (1956)

## Materials and Methods

**Clinical series** The series consisted of 78 healthy newborn infants, aged 1 h to 12 days at the time blood was taken, and all delivered at the Women's Clinic, University of Helsinki. Their gestational age varied between 33 and 43 weeks. The first Apgar score of the infants ranged from 7 to 10 and the birth weight in each case was over 2,500 g. 25 of the infants were delivered by Caesarean section because of maternal dystocia. Samples of cord blood were taken from an additional 12 full term infants.

**Determination of cell proliferation in the blood** Cell proliferation in the cord blood was determined as described elsewhere [13]. To study the capillary blood of newborn infants a micro method was used. 50  $\mu$ l of blood, obtained from the heel with a capillary pipette, was transferred into a prewarmed (37 °C) centrifuge tube that held 0.5 ml medium RPMI 1640 containing 20% calf serum (CS), 50 IU/ml heparin and 2  $\mu$ Ci/ml tritiated thymidine ( $^3$ H TdR, specific activity 6.7  $\mu$ Ci/mM), and then incubated for 30 min at 37 °C. After incubation 0.1 ml of the suspension was diluted with 0.9 ml of 2% acetic acid, and nucleated cells were counted in a haemocytometer. To separate the mononuclear cells the rest of the suspension was layered on top of 1 ml of Ficoll Isopaque mixture in a narrow centrifuge tube and spun at 400 g for 20 min [4]. The interphase cells were collected, washed with 5 ml of RPMI 1640 containing 20% CS, and then resuspended in 0.5 ml of the same medium. Cell preparations for May Grönwald Giemsa staining and for autoradiography were made with a cytocentrifuge. Autoradiographs were prepared with Kodak AR 10 stripping film exposed for 5–6 days and stained with Giemsa.

The percentages of labelled lymphoid cells (LLC), labelled myeloid cells (LMC) and labelled erythroid cells (LEC) were determined morphologically as described elsewhere [13, 21]. Differential counts of white blood cells were made from regular blood films prepared the time each sample was taken.

**Rosette formation** 2 ml of heparinized (50 IU/ml) blood, taken from a superficial cephalic vein, was diluted with 6 ml of phosphate buffered saline (PBS) and incubated in an Erlenmeyer flask with 0.2 g Carbonyl iron powder (General Atomics Corporation, New York, N.Y.) and 1  $\mu$ Ci/ml  $^3$ H TdR for 1 h at 37 °C. Every 10 min the flask was gently agitated. After incubation the iron and the cells that had phagocytosed iron were removed from the suspension with a Teflon-coated magnet and the mononuclear cells that remained were separated by the Ficoll Isopaque gradient centrifugation method [4]. The interphase cells were collected and cell preparations were made for MGG staining and for autoradiography as previously described. On the average, 95.7% of the cells were lymphocytes and 1.2% were immature myeloid cells. The percentage of cells that formed rosettes (ERFC) with sheep red cells (SRC) was determined as described elsewhere [20] except that in the present study the cells were suspended in medium containing 20% CS instead of in serum free medium.

**Separation of ERFC** To separate out the ERFC, a velocity sedimentation method was tried and found satisfactory. 4 ml of the rosette suspension ( $8 \times 10^6$  lymphocytes, 0.5% SRC) was layered on top of 1 ml CS and centrifuged for 10 min at 10 g. The supernatant on top of the serum and the pellet that was gen-

tly resuspended in 2 ml of medium containing 20% CS were analyzed for E-RFC and non E-RFC. Cytocentrifuge preparations for MGG staining and for autoradiography were made both directly from the two fractions, and after haemolysis of SRC with ammonium chloride and the subsequent concentration of lymphocytes. Rosette-containing preparations were fixed with benzidine reagent (3) for better visualization of SRC. Autoradiographs were prepared and stained as previously described.

### Results

**Labelled cells in cord blood** The percentages of labelled cells in the cord blood of the 12 healthy newborn infants are given in table 1. In all cases the preponderance of labelled cells were LEC or LMC or both but their percentages varied greatly. The percentage of LLC on the other hand was uniformly low.

**Labelled cells in the blood of healthy newborns** The percentages of LLC and LMC in the blood of healthy infants between the ages of 0 and 12 days are shown in figure 1. During the first 2 days only about 0.1% of the mononuclear cells were LIC. At 3 days the number of LLC started to rise and by 4-7 days after birth their number had increased tenfold as compared to the numbers present immediately after birth. Thereafter the percentage of LLC gradually decreased.

The numbers of LMC were variable, and the scatter of their percentages was wider than that for LIC. During the first 3 days after birth the majority of the cells labelled with  $^3\text{H}$ -TdR were immature myeloid cells. By the 12th day the number of LMC had gradually decreased from about 0.5 to 0.1%.

Labelled erythroid cells were present in most of the samples taken from infants under the age of 12 h (highest value 1.3%). In the blood of

Table 1 Labelled cells expressed as a geometric mean percentage of the mononuclear cells, in 12 samples of cord blood

Labelled cells	Geometric mean percentage	Range
Lymphoid	0.08	0.01-0.35
Myeloid	0.74	0.17-4.03
Erythroid	0.69	0.06-10.3
Total	1.50	0.29-11.8




Fig 1 Labeled lymphoid cells (a) and labeled myeloid cells (b) as percentages of mononuclear cells in the neonatal period. Moving geometric means in the order of 3 (weighed 1, 2, 1) are connected with a line.

infants older than 12 h, LEC were seen only occasionally, and then in percentages lower than 0.2%.

In conventional differential counts the percentage of lymphocytes increased from 31% at the age of 1 day to 58% at the age of 7 days. This increase was mainly the result of a decrease in the absolute number of neutrophils, while the absolute number of lymphocytes remained essentially the same throughout the follow-up period.

No correlation could be found between the number of LLC and LMC and the duration of gestation, the sex, or the birth weight.

**Characterization of proliferating lymphoblasts** After purification with iron and separation by Ficoll-Isopaque gradient centrifugation,  $74.5 \pm 11.5\%$  (SD) of the lymphocytes from 5- to 7-day-old infants formed rosettes with SRC. This percentage is somewhat lower than that for healthy adults studied in the same laboratory ( $78.5 \pm 5.3$ ) [20].

After 10 g velocity sedimentation, an average of 95% of the cells in




Fig 2 A labelled (left) and a non labelled (right) rosette forming lymphoid cell in a 6-day-old infant

the bottom fraction and 40% in the supernatant were E-RFC. In the benzidine-stained cytocentrifuge preparations from the bottom fractions, rosettes were well preserved (fig 2), and more than 90% of the labelled cells were I RFC. Most of the non-rosette-forming cells in these preparations were LMC. In the benzidine-stained preparations from the supernatant fractions, the large number of SRC obstructed visualization of rosette formation. Quantitative counts of the labelled cells were done on the haemolyzed preparations. As shown in table II, the bottom fractions were enriched with ILC as compared with the non fractionated suspensions. On the other hand, most supernatant fractions were enriched with LMC. The ratio of ILC to LMC was, on the average, 8:1 in the bottom fractions, and 1:2:1 in the supernatant fractions.

### Discussion

Isotope incorporation methods employing labelled DNA precursors have been widely used to study the proliferation of blood leucocytes. In studies on adults, conventional sedimentation procedures for concentrating leucocytes in buffy coat of venous blood are easily carried out and were used in this investigation to study cell proliferation in cord blood.



Table II Percentages of labelled cells before and after separation of E RFC with 10 g velocity sedimentation

Case	Age days	Non fractionated			Bottom fraction			Supernatant fraction		
		total	LLC	LMC	total	LLC	LMC	total	LLC	LMC
1	5	1.80	1.67	0.13	1.72	1.67	0.05	0.26	0.02	0.24
II	5	1.13	0.88	0.24	1.24	1.16	0.08	0.67	0.27	0.40
3	5	1.72	1.41	0.31	1.59	1.07	0.52	0.72	0.36	0.36
4	5	2.35	2.09	0.26	2.17	2.13	0.04	0.72	0.57	0.15
5	5	3.02	2.70	0.32	2.22	2.01	0.21	1.05	0.78	0.24
6	5	1.71	1.24	0.47	2.02	1.72	0.30	0.95	0.56	0.39
7	6	1.92	1.33	0.53	2.11	1.77	0.31	1.27	0.40	0.87
8	7	0.87	0.83	0.04	1.01	0.97	0.04	0.35	0.34	0.01
$\bar{X}$		1.82	1.52	0.29	1.76	1.56	0.19	0.75	0.41	0.33
SD		0.67	0.63	0.16	0.45	0.44	0.17	0.34	0.23	0.25

For newborn infants, however, a method calling for smaller quantities of blood is more applicable, and a technique that involved 50  $\mu$ l samples of capillary blood, from which mononuclear cells were separated by Ficoll-Isopaque gradient centrifugation, was found to be satisfactory. The results achieved with this technique were comparable to those obtained with sedimentation of venous blood [11].

DNA synthesizing cells in human blood can be grouped into three main categories: erythroid, myeloid, and lymphoid cells [10]. In healthy adults, about 0.1% of the mononuclear cells are LLC [13]. LMC are also regularly present but in about ten times lower numbers, whereas LEC are virtually never found in blood of healthy adults [21]. In cord blood and in blood of early newborns, immature erythroid cells constitute a substantial part of the circulating mononuclear cells. The absolute and percentage counts of nucleated red blood cells are highest at birth, within 18 h their numbers decrease abruptly [14, 16, 18]. Immature myeloid cells are regularly present during the first days of life [8, 14, 23]. EFRATI *et al* [8] reported that myelocytes and metamyelocytes make up 2.5% of the leucocytes in cord blood and XANTHOV [23] recorded the presence of up to 2,000 metamyelocytes/ $\mu$ l of blood in healthy infants during the first 3 days of life. Both immature erythroid and myeloid cells have virtually disappeared by the end of the first week. During the first week of life neutrophils are known to diminish in number and the absolute white blood cell counts decrease as well, the

absolute lymphocyte counts however vary little [1, 14, 23]. In the present study, LEC were numerous in cord blood, but their number decreased abruptly within the first 12 h after birth. Large numbers of LMC were present until the 4th day of life, when their numbers gradually started to decrease. Thus, the incidence and distribution of DNA synthesizing erythroid and myeloid cells during the neonatal period parallels the numerical pattern of these cells as revealed in conventional differential counts.

Lymphoblasts increase in number in viral diseases, after immunizations, and in various other clinical conditions [7, 12, 13, 22]. In sheep, lymphoblasts are present in the intestinal lymph in vastly increased numbers immediately after birth [15]. In a few studies on lymphoid cells in newborns, higher labelling indices than those normally characteristic of adult blood have been reported. WINTER *et al* [19] and FAULK *et al* [9] in their studies of cord blood, reported  $^3\text{H}$ -TdR labelling indices for lymphocytes that are about equal to the total labelling index in the present study. However, nearly all the labelled cells in cord blood in the present study were identified as either erythroid or myeloid cells. In the study of FAULK *et al* [9] most of the cells seemed to be weakly labelled, and the morphology of the 'high labelling cell' would appear to resemble more that of a cell in the myeloid than in the lymphoid series. ANDERSEN and ANDERSEN [2] reported an increase in the count of  $^3\text{H}$ -TdR labelled cells from day 3 to 6 after birth in healthy newborns which agrees with the present results. Contrary to the present findings, however, they observed an initial decrease in labelled lymphoid cells between days 1 and 3 but the possibility that early myeloid cells were included in their count was not ruled out.

In the present study a greater than tenfold increase in the percentages of LLC occurred 4-7 days after birth in healthy infants: an increase that resembles the previously reported response of the organism to various immunizations. Whether the LLC that were detected in the blood after birth belonged to the T or the B lymphocyte population was determined by making use of the capability of T lymphocytes to bind SRC on their surface [5, 6]. The proportion of T cells in the blood of the 5- to 7-day-old infants in this study did not differ significantly from that in adults.

The 10 g centrifugation method used here to segregate rosettes separates particles according to their size rather than their density. This method was used instead of the 1 g velocity sedimentation method previously employed [20] because it is less complicated and faster. I RFC

## Intracellular Potential in Normal and Leukemic Lymphocytes

MICHAŁ MALOFIEJEW, ANNA KOSTRZEWSKA and EDMUND KOWAL

Department of Physiology of Smooth Muscle, Institute of Obstetrics and Gynecology  
Department of Allergology, Institute of Internal Diseases, The Medical School, Białystok

**Abstract** Lymphocytes obtained from fresh blood of patients suffering from chronic lymphatic leukemia have a lower intracellular potential than normal lymphocytes. Compared to normal lymphocytes, the intracellular potential in leukemic lymphocytes behaves differently in environments with a changing concentration of K and Cl ions.

**Key Words**  
Electrobiology  
Intracellular lymphocyte potential  
Lymphatic leukemia

Blood cells show only the 'membrane' or 'intracellular' potential which is measured by a difference of potentials on both sides of the cell membrane. Up to the present, the behavior of the intracellular potential in normal leukocytes [1], erythrocytes [3] and lymphocytes from the culture *in vitro* [5] and those obtained from the fresh peripheral blood [4] has been investigated.

In the present investigations, we have compared electrobiological characteristics in fresh normal lymphocytes and in the lymphocytes of blood from patients with chronic lymphatic leukemia.

### Materials and Methods

In the peripheral blood of normal subjects, lymphocytes constituted 20-40% of nucleated blood cells, and in the peripheral blood obtained from patients suffering from chronic lymphatic leukemia lymphocytic cells comprised 65-95%.

We have studied lymphocytes obtained from the peripheral blood of 20 normal persons 20-60 years old (more than 200 measurements) as well as from the peripheral blood of 10 patients 30-65 years old suffering from chronic lymphatic leukemia (more than 150 measurements). The patients had not been given corticoids and cytostatics a week prior to the experiment.

Table 1 Composition of nutritive solutions, in mM

Nutritive solution	Changes of concentration	Na <sup>+</sup>	Cl	K <sup>+</sup>
Standard	—	137.2	146.17	2.68
Reduction in Cl	2 fold	137.2	73.1 <sup>1</sup>	2.68
	27 fold	137.2	5.9 <sup>1</sup>	2.68
Changes in h <sup>+</sup>	10-fold increase	115.35	147.89	26.7
	10-fold decrease	137.2	143.7	0.27

The other ion concentrations as in Tyrode's solution

<sup>1</sup> In the nutritive solutions, sodium sulfate or potassium sulfate were substituted for sodium chloride or potassium chloride


The determinations were carried out on a suspension of lymphocytes from fresh blood obtained from the cubital vein. The blood was immediately mixed with 18% sodium citrate (9:1). Glass vessels, drains and plastic vessels were coated with several layers of silcon (Siliclad, Clay Adams). The Jaco method [2] was used to separate cells, which used differences in the density of lymphocytes. The suspension contained on an average 95% lymphocytes, 4% monocytes and 1% other nucleated cells. The suspension was made up to  $10^6$  lymphocytes/mm<sup>3</sup> with plasma from the investigated persons.

Immediately before the determinations, 0.2 ml of the lymphocyte suspension was taken into the mixture of 0.4 ml Tyrode's solution and 0.4 ml 1% agarose solution. The final concentration of lymphocytes was  $2 \times 10^4$  mm<sup>3</sup>. The whole mixture was then placed into a glass container in which a constant temperature was maintained by means of an ultra thermostat. When agarose congealed, the whole suspension was covered with Tyrode's solution. The determinations were made at 23°C.

Electrophysiological determinations were made by means of a Pyrex glass microelectrode (external tip diameter less than 0.5  $\mu$ m and 20–40 M $\Omega$  resistance) filled with 3 M KCl. The microelectrodes were made on a horizontal automatic puller constructed by the Medical Electronic and Technical Laboratory of the Experimental and Clinical Medical Centre of the Polish Academy of Science. The tip potential of the electrode did not exceed 10 mV.

The electrode was placed in a microman pulser and, under microoscopic control, introduced into a lymphocyte immobilized by congealed agarose. The potentials recorded by electrode were transmitted to a direct current amplifier and displayed on the screen of an oscilloscope. They were recorded with a Record camera. The neutral Ag-AgCl electrode was placed in the lymphocyte suspension (Fig. 1). A typical 'transmembrane' or intracellular potential recorded from a single lymphocytic cell is shown in figure 2. The magnitude of the transmembrane potentials has been constant and has remained on an unchanged level until the electrode was taken back from the cell.

The determinations were carried out in agarose gels made up with Tyrode's solution, the composition of which being changed as required. A constant osmolarity of 0.9% (cent



*Fig 1* Method of electrobiological measurements 1 = Microelectrode, 2 = micro-manipulator, 3 = optical system, 4 = layer of Tyrode's solution, 5 = lymphocytes in the net of congealed agarose, 6 = zero electrode Ag-AgCl, 7 = DC amplifier, 8 = oscilloscope, 9 = film camera, 10 = container maintaining a constant temperature



*Fig 2* Typical reading of electrobiological phenomena from the inside of lymphocytes On the left calibration = 5 mV, A = impalement of the microelectrode into a cell, B = moment of the electrode removal from a lymphocyte Observation time 2 min

solutions was achieved by adding saccharose Table 1 shows the composition of the solutions The lymphocyte solution was incubated in a nutritive fluid of a determined ion concentration, constantly oxygenized for 30 min at 23°C

The statistical significance of differences between the results obtained from different groups of experiments was evaluated by means of a variable determined by the formula

$$U = \frac{\bar{X} - \bar{Y}}{\sqrt{\frac{n_1 s_1^2}{n_1} + \frac{n_2 s_2^2}{n_2}}} \sqrt{\frac{n_1 n_2}{n_1 + n_2} (n_1 + n_2 - 2)}$$




Fig. 3. Histograms of the intracellular potential of lymphocytes. *a* Lymphocytes of normal subjects. Continuous line = curve of a normal distribution of Gauss  $N(7.42; 2.54)$ . *b* Lymphocytes of patients suffering from chronic lymphatic leukemia. Continuous line = curve of a normal distribution of Gauss  $N(5.62; 2.04)$ . Left vertical axis = theoretical frequency of normal distribution  $f(x)$ . Right vertical axis = number of measurements ( $n$ ). Horizontal axis = intracellular potential (mV).

where  $\bar{X}$ ,  $\bar{Y}$  = mean values determined from samples;  $n_1$ ,  $n_2$  = number of measurements included in the samples;  $s_1$ ,  $s_2$  = standard deviations determined from the samples.

The variable  $t$  has a Student  $t$  distribution of  $(n_1 + n_2 - 2)$  degrees of freedom. A disagreement between the normal distribution and empirical one was tested by means of  $\chi^2$  test.

### Results

**Intracellular potential.** The mean value of the intracellular potential of lymphocytes from the peripheral blood is  $-7.4 \pm 0.2$  mV. The mean value of the intracellular potential of lymphocytes from the blood obtained from patients suffering from leukemia is  $-5.6 \pm 0.1$  mV. This is a statistically significant difference. The intracellular potentials of all measurements in

Table II The intracellular potentials in relation to potassium ion concentration

Extracellular concentration of potassium ions, mm/l		Normal lymphocytes mV	Leukemic lymphocytes mV
10 times higher	268	$58 \pm 0.4$	$54 \pm 0.4$
Normal	268	$74 \pm 0.2$	$56 \pm 0.1$
10 times lower	0.268	$95 \pm 0.7$	$91 \pm 0.8$

Table III Intracellular potentials of normal and leukemic lymphocytes in the environment with a changing concentration of potassium ions

Extracellular concentration of $K^+$ ions mm/l		Normal lymphocytes %	Leukemic lymphocytes, %
10 times higher		78.4	96.4
Normal		100.0	100.0
10 times lower		128.4	162.5

The value of the intracellular potential of lymphocytes in normal Tyrode's solution has been taken as 100%.

normal and leukemic lymphocytes are presented in figure 3. The use of the  $\chi^2$  test indicates that the probability of accordance of the observed distribution with the distribution of Gauss is

$$p(\chi^2 \geq 5.86) > 0.30 \text{ and } p(\chi^2 \geq 6.72) \sim 0.20$$

for normal and leukemic lymphocytes, respectively.

*Influence of concentration changes of  $K^+$ ,  $Cl^-$  and  $Na^+$  ions upon the intracellular potential of lymphocytes.* The value of the lymphocyte intracellular potential depends on the potassium ion concentration in the extracellular environment and is a linear function of a logarithm of this concentration. The intracellular potential of lymphocytes from leukemic blood, however, does not show a linear dependence on the logarithm of potassium ion concentration in the nutritive fluid. The results are summarized in table II.

Differences of the intracellular potential between normal and leukemic lymphocytes are still more evident, when we assume conventionally in both

Table III: Intracellular potentials of normal and leukemic lymphocytes in Tyrode's solution and in the solution with low concentration of Cl ions

Solution	Normal lymphocytes, mV	Leukemic lymphocytes, mV
Normal Tyrode's solution	74±0.2	56±0.1
Solution with lowered Cl concentration	54±0.2	55±0.4

groups the value of the transmembrane potential in the medium of Tyrode's solution with a normal ionic composition as 100% (table III). Compared to a linear dependence in normal lymphocytes, in leukemic lymphocytes the transmembrane potential increases rapidly when the potassium concentration is low. In the medium containing potassium ions in 10 times higher concentrations the potential practically does not change.

Table IV represents the behavior of the transmembrane potential in normal and leukemic lymphocytes depending on the chlorine ion concentration in the outer environment. A decrease from 146.17 to 5.9 mM causes a decrease in the intracellular potential to about -5.5 mV. Compared to normal lymphocytes, in leukemic lymphocytes the removal of chlorine ions from the medium does practically not change the intracellular potential. Furthermore a gradual change of the sodium ion concentration in the nutritive solution does not influence significantly the intracellular potentials of both normal and leukemic lymphocytes.

### Discussion

The investigations indicate that the inside of lymphocytes has a negative potential in relation to the external medium (-7.6 mV). Changes of the intracellular potential depend mainly on the external potassium concentration. The second ion influencing the intracellular potential is chlorine.

The intracellular potential depends upon many factors: morphological and functional states of the cell membrane, ion concentration on both of its sides as well as on biochemical processes taking place in the cell inside. Lymphocytes of leukemia blood possess quite different electrophysiological properties which might result from different mechanisms controlling or controlling ion transport through the cell membrane.



Table II The intracellular potentials in relation to potassium ion concentration

Extracellular concentration of potassium ions, mm/l		Normal lymphocytes, mV	Leukemic lymphocytes, mV
10 times higher	26.8	$5.8 \pm 0.4$	$5.4 \pm 0.4$
Normal	2.68	$7.4 \pm 0.2$	$5.6 \pm 0.1$
10 times lower	0.268	$9.5 \pm 0.7$	$9.1 \pm 0.8$

Table III Intracellular potentials of normal and leukemic lymphocytes in the environment with a changing concentration of potassium ions

Extracellular concentration of $K^+$ ions, mm/l		Normal lymphocytes, %	Leukemic lymphocytes, %
10 times higher		78.4	96.4
Normal		100.0	100.0
10 times lower		128.4	162.5

The value of the intracellular potential of lymphocytes in normal Tyrode's solution has been taken as 100%.

normal and leukemic lymphocytes are presented in figure 3. The use of the  $\chi^2$  test indicates that the probability of accordance of the observed distribution with the distribution of Gauss is

$$p(\chi^2 \geq 5.86) > 0.30 \text{ and } p(\chi^2 \geq 6.72) > 0.20$$

for normal and leukemic lymphocytes, respectively.

*Influence of concentration changes of  $K^+$ ,  $Cl^-$  and  $Na^+$  ions upon the intracellular potential of lymphocytes:* The value of the lymphocyte intracellular potential depends on the potassium ion concentration in the extracellular environment and is a linear function of a logarithm of this concentration. The intracellular potential of lymphocytes from leukemic blood, however, does not show a linear dependence on the logarithm of potassium ion concentration in the nutritive fluid. The results are summarized in table II.

Differences of the intracellular potential between normal and leukemic lymphocytes are still more evident, when we assume conventionally in both

Table IV Intracellular potentials of normal and leukemic lymphocytes in Tyrode's solution and in the solution with low concentration of Cl ions

Solution	Normal lymphocytes, mV	Leukemic lymphocytes, mV
Normal Tyrode's solution	$74 \pm 0.2$	$56 \pm 0.1$
Solution with lowered Cl concentration	$54 \pm 0.2$	$55 \pm 0.4$

groups the value of the transmembrane potential in the medium of Tyrode's solution with a normal ionic composition as 100% (table III). Compared to a linear dependence in normal lymphocytes, in leukemic lymphocytes the transmembrane potential increases rapidly when the potassium concentration is low. In the medium containing potassium ions in 10 times higher concentrations the potential practically does not change.

Table IV represents the behavior of the transmembrane potential in normal and leukemic lymphocytes depending on the chlorine ion concentration in the outer environment. A decrease from 146.17 to 5.9 mM causes a decrease in the intracellular potential to about -5.5 mV. Compared to normal lymphocytes, in leukemic lymphocytes the removal of chlorine ions from the medium does practically not change the intracellular potential. Furthermore a gradual change of the sodium ion concentration in the nutritive solution does not influence significantly the intracellular potentials of both normal and leukemic lymphocytes.

### Discussion

The investigations indicate that the inside of lymphocytes has a negative potential in relation to the external medium ( $-7.5$  mV). Changes of the intracellular potential depend mainly on the external potassium concentration. The second ion influencing the intracellular potential is chlorine.

The intracellular potential depends upon many factors: morphological and functional states of the cell membrane, ion concentration on both of its sides as well as on biochemical processes taking place in the cell inside. Lymphocytes of leukemic blood possess quite different electrophysiological properties, which might result from different mechanisms conditioning or controlling ion transport through the cell membrane.

*References*

- 1 BECKMANN, A , JENSSEN H L , KALKOFF, W und REDMAN, K : Das bioelektrische Potential der zytoplasmatischen Membran der Granulozyten *Experientia* 26 186 (1970)
- 2 JAGO, M : A simple method for the separation of living lymphocytes from normal human blood *Brit J Haemat* 2 439 (1956)
- 3 LASSEN, U V and STEN KNUDSEN, O J : Direct measurement of membrane potential and membrane resistance of human red cells *J Physiol, Lond* 195 681 (1968)
- 4 MALOFIEJEW M , KOSTRZEWSKA, A , and KOWAL, ■ : Intracellular potentials in blood lymphocytes (in press)
- 5 MICHIO TAKI : Studies on blastogenesis of human lymphocytes by phytohemagglutinin with special reference to changes of membrane potential during blastoid transformation *Mie med J* 19 245 (1970)

## Localization of Leukocyte Alkaline Phosphatase in Human Neutrophils<sup>1</sup>

ANN D GEDDES, MARY E KIRCHEN and G JUNE MARSHALL

Departments of Pathology and Medicine University of  
Southern California School of Medicine Los Angeles Calif

**Abstract** The enzymes of blood and marrow neutrophils can be used to aid in the determination of the cell's maturity. The enzyme marker which signals the production of secondary granules, leukocyte alkaline phosphatase (LAP), was found to be inactivated by aldehyde fixation, but minimal fixation of cells gave adequate morphological preservation and good enzyme activity. Notably, LAP activity was found to be present in neutrophils from the marrow myelocyte stage to the blood neutrophil stage, and high levels were found in the synthetic organelles of some circulating mature neutrophils. These observations at the electron microscopic level confirm the classical light microscopic histochemical findings.

**Key Words**  
Cytochemistry  
Electron microscopy  
Golgi activity  
Human neutrophils  
Leukocyte alkaline phosphatase

Leukocyte alkaline phosphatase (LAP) is a potential marker for defining the maturation sequence of neutrophils in human marrow and peripheral blood. At the light microscopic level using azo dye techniques [7], LAP activity is first observed at the myelocyte stage and this activity increases through the circulating mature neutrophil stage [1]. Other leukocyte enzymes, notably acid phosphatases and peroxidases, behave in the opposite manner, i.e., activity is greatest in the promyelocytes and decreases with maturation. This pattern is similar to the enzyme fluctuations seen in the rabbit heterophil series.

In the rabbit, enzyme heterogeneity has been correlated with granule

<sup>1</sup> Supported in part by grants ACS PN 21M and NIH CA 05146-13

heterogeneity [4] Acid hydrolytic enzymes have been reported to be restricted to the primary granules synthesized at the incipient promyelocyte stage whereas other enzymes, specifically LAP, are believed to be produced and packaged in the secondary granules at the myelocyte stage

On morphologic criteria alone, ACKERMAN [2] and SCOTT and HORN [10] have proposed at least two granule populations in normal human mature neutrophils The work of BAINTON *et al* [5] supported the distinctness of enzyme content in two granule types in human neutrophils at the electron microscopic level However, LAP activity was confined to the myelocyte stage only, where reaction deposits appeared in the Golgi cisternae and within a few scattered granules NAKATSUI [8] demonstrated LAP activity rimming some granules and vacuoles in unfixed neutrophils from peripheral blood In the metamyelocyte and mature circulating neutrophil, this enzyme has not previously been demonstrated in synthetic organelles or to any great extent in the granules


### *Materials and Methods*

Bone marrow was aspirated into a heparinized syringe using standard technique from the posterior iliac crest of normal volunteers and patients with nonhematologic neoplasms The latter marrows were obtained for evaluation of marrow status prior to chemotherapy The marrow was expressed onto a small watch glass and the cellular particles removed with a Pasteur pipet, smeared on polyester plastic slides (Mylar) and force air dried Peripheral blood and marrow blood buffy coats were prepared using microhematocrit tubes After centrifugation each tube was scored between the sedimented red cell and leukocyte layers The tube was then snapped and the leukocyte layer expressed with a little plasma onto a plastic slide and smeared as above Dried smears were fixed for 5 min in Coplin jars filled with various concentrations (5–0.5%) of cold glutaraldehyde (25% stock Polysciences) in 0.1 M cacodylate buffer pH 7.4 After fixation smears were washed for a minimum of 5 min in tap water or 0.1 M cacodylate buffer, allowed to dry and incubated in the reaction medium for 1 h in a 37 °C water bath The incubation medium was a modification by WETZEL *et al* [11] of the GOMORI procedure [6] for LAP The substrate used was  $\beta$  glycerophosphate grade 1 (Sigma) Controls consisted of smeared cells incubated in media without the substrate After incubation the slides were tap water rinsed flooded with 2% lead nitrate for 5 min, rinsed and briefly covered with dilute ammonium sulfide to visualize the cellular areas more easily Slides were then processed for electron microscopy by the usual method of postfixation for 1 h in 1% osmium tetroxide alcohol dehydration brief propylene oxide wash, and infiltration with a 1:1 mixture of propylene oxide and Araldite 502 resin Beem capsules were partially filled with Araldite and inverted over the cellular areas of the slide

Polymerization took approximately 45 h in a 60°C incubator. The capsules were then snapped off the plastic slides leaving the cells embedded in the resin. The top of the block containing the monolayer of cells was then trimmed and thick and thin sections were cut with a diamond knife. Micrographs were taken without poststaining on a Hitachi 7S electron microscope.

## Results

With minimal fixation of cells at a low concentration of glutaraldehyde (0.5%), LAP was observed in the granules and synthetic apparatus of the maturing marrow neutrophils and in the circulating mature neutrophils. Preservation of morphologic detail was improved by longer fixation (or increased concentrations of glutaraldehyde, 1.0-5%) but enzyme activity decreased concomitantly. At the light microscopic level, LAP activity as determined by our modified Gomori technique correlated well qualitatively and quantitatively with the LAP activity in cells reacted by Kaplow's azo dye (fig 1) and in fact proved to be more sensitive in picking up activity in the more immature granulocytes. For instance, in cell counts of a thousand cells, the percentages of cells exhibiting enzyme activity were myelocytes, 27%, metamyelocytes, 74%, band forms, 91%, and polymorphonuclear leukocytes (PMNs), 94%. With our modified Gomori method the percentages positive were 34, 81, 92, and 95%, respectively. For every individual the intensity and proportion of neutrophil staining was dependent upon a number of factors, such as the patients' inflammatory and hormonal status. However, even in patients with a severe leukemoid reaction, an occasional mature neutrophil exhibited minimal or no reactivity as shown in fig 6. Dense deposits of the reaction product were localized in the perinuclear cisternae (fig 3), the Golgi complex (fig 3, 4) and the granules (fig 2) of the marrow and peripheral neutrophils. The Golgi complex when reactive was totally involved, and exhibited no evidence of polarization, as has been suggested for the Golgi complexes of rabbit and human neutrophils [3]. Reaction deposits were also present in phagolysosomes. Figure 5 demonstrates a reactive granule emptying its contents into a phagosome forming a secondary lysosome in a marrow neutrophil from a normal subject. Extraneous background precipitate was commonly observed especially over the heterochromatin of the nucleus and frequently throughout the cytoplasm. The omission of substrate from the incubation medium resulted in no activity.



### Discussion

The inability to demonstrate LAP at the electron microscopic level has been attributed to a structural linked latency of the enzyme [5]. This latency probably determines the minimum LAP activity demonstrable by lead salt techniques but the sensitivity of the demonstration of any LAP above this minimum is dependent upon the concentration of glutaraldehyde employed in cell fixation. Glutaraldehyde, which is the fixative of choice for most electron microscopic histochemical studies [9] inhibits the reactivity of LAP. Various concentrations of other fixatives (paraformaldehyde, acetone, acetone methacrolein glyoxal) used alone in combination, and in sequence with one another have been assessed for their ability to preserve enzyme activity. Leukocytes fixed in 60% acetone exhibited the most extensive enzyme reactivity but cell preservation at the electron microscopic level was inadequate. In drastically reduced concentrations glutaraldehyde gave the best combination of enzyme reactivity and morphological preservation. Some disruption and lysis of organelles was expected due to the incubation of the minimally fixed cells for 1 h in a medium pH 9.0-9.3.

The discrete containment of enzyme reactivity by the saccules of the Golgi membrane, the perinuclear cisternae and membranes of some granules argues that the reaction deposits are true sites of enzyme activity rather than artifactual staining. The partial reactivity of perinuclear cis-

*Fig. 1* Light micrograph of Araldite™ thick section of peripheral human neutrophil reacted for LAP and counterstained with methylene blue. Arrow 1 points to a neutrophil reactive for LAP; neutrophil at arrow 2 exhibits little or no reactivity.  $\times 900$ .

*Fig. 2* Electron micrograph of a portion of a mature reactive neutrophil from blood with artifactual cytoplasmic staining. Note positive (arrows) and negative granules; the latter apparently correspond to LAP-deficient primary granules. No heavy metal poisoning in figures 2-6 and all lines are one micron.  $\times 14,000$ .

*Fig. 3* Mature blood neutrophil reactive for LAP. Note reactive Golgi complex, nuclear cisternae and granules. Mitochondrion at m.  $\times 7,000$ .

*Fig. 4* Golgi complex with well localised LAP activity in a peripheral neutrophil.  $\times 27,000$ .

*Fig. 5* Secondary lysosome in a mature neutrophil (myeloperoxidase). Note confusion with a reactive granule (arrow).  $\times 12,000$ .

*Fig. 6* Mature blood neutrophil with membrane fragmentation exhibiting no LAP reactivity.  $\times 9,000$ .



ternac may be due in some cases to the plane of cut of the section or to the fixation of cells at the beginning or end of LAP synthesis. The synthesis of only one product at a time through the cell organelles has never been conclusively demonstrated.

Our results could not definitely characterize the reactive granules as specific granules. Besides enzymology, the other criterion for distinguishing specific from azurophilic granules is their morphology which is still disputed among electron microscopists. In addition, the morphology of these granules changes with cell maturation and is susceptible to preparative artifaction. Relevant information on the heterogeneity of human PMN granules must come from further enzymatic or functional data.

In the majority of preparations reaction deposits were seen at the cell periphery in an extracellular location (fig 3). The extraneous precipitate could be due to the fact that (1) the lead solution which couples with the enzyme product to form an insoluble deposit is not added until the end of the incubation period during which diffusion of enzyme product could occur, or (2) the extractive properties of the solvents used in subsequent processing could result in diffuse precipitate.

With the variation in fixation procedure, LAP reaction was observed in the synthetic apparatus of neutrophils from the peripheral blood. This finding indicates that the circulating neutrophil is not the synthetically inactive cell as had been generally hypothesized.

### References

- 1 ACKERMAN A. Histochemical differentiation during neutrophil development and maturation. *Ann NY Acad Sci* 133: 537-565 (1964).
- 2 ACKERMAN A. The human neutrophilic myelocyte. A correlated phase and electron microscopic study. *Z Zellforsch* 121: 153-170 (1971).
- 3 BAINTON D and FARQUHAR M. Origin of granules in polymorphonuclear leukocytes: two types derived from opposite faces of the Golgi complex in developing granulocytes. *J Cell Biol* 28: 277-301 (1966).
- 4 BAINTON D and FARQUHAR M. Differences in enzyme content of azurophil and specific granules of polymorphonuclear leukocytes. II. Cytochemistry and electron microscopy of bone marrow cells. *J Cell Biol* 39: 299-317 (1968).
- 5 BAINTON D, ULLYOT J and FARQUHAR M. The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. *J exp Med* 134: 907-937 (1971).
- 6 GOMORI G. Microscopic histochemistry: principles and practice (University of Chicago Press, Chicago 1952).

- 7 KAPLOW, L. S. A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity in smears of blood and marrow. *Blood* 10: 1023-1029 (1955).
- 8 NAKATSU, T., Ultrastructural localization of alkaline phosphatase in human neutrophils. *Acta haemat* 42: 275-280 (1969).
- 9 SARATINI, D., HENSCH, K., and BURRITT, R., Cytochemistry and electron microscopy: the preservation of cellular ultrastructure and enzymatic activity by aldehyde fixation. *J Cell Biol* 17: 19-49 (1963).
- 10 SCOTT, R. and HORN, H., Ultrastructural aspects of neutrophil granulocyte development in humans. *Lab Invest* 23: 202-215 (1970).
- 11 WETZEL, H., SPIETH, S., and HORN, R., Fine structural localization of acid and alkaline phosphatases in cells of rabbit blood and bone marrow. *J Histochem. Cytochem* 15: 311-334 (1967).

## Erythrocyte Glucose-6-Phosphate Dehydrogenase in Tehran

GHODSI DANESHBOD

Department of Experimental Medicine and Pharmacology,  
Faculty of Medicine, University of Tehran, Tehran

**Abstract** Erythrocyte glucose 6-phosphate dehydrogenase (G 6-PD) of 370 randomly selected patients referred to the pediatric service of Pahlavi Medical Center, Tehran, was studied. A deficiency was found in 42.7%. Erythrocyte G 6-PD of the 38 subjects with normal level of the enzyme and 31 patients with deficiency had the electrophoretic mobility of variant II. Fast electrophoretic band (105-110% of normal) was present in 8 and slow moving band (85-93% of normal) in 7 cases.

### Key Words

Glucose 6-phosphate dehydrogenase  
G 6-PD deficiency in Tehran  
G 6-PD variants

Erythrocyte glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is a common enzymatic abnormality in Iran [8] resulting in various clinical manifestations. This might well be due to the different variants in the deficient population in this country [15]. We present here the results of the study performed on the frequency of the G-6-PD in Tehran and electrophoretic mobility of the enzyme in the deficient and non-deficient population.

### Material and Methods

Erythrocyte G 6-PD of 370 randomly selected patients referred to the pediatric service of Pahlavi Medical Center in Tehran was studied.

Enzyme quantitation was performed by the method recommended by the WHO at 25 °C [3] and by the ultraviolet spectrophotometric method using kit manufactured by Boehringer GmbH (Mannheim, FRG).

Electrophoresis was performed on cellulose acetate (Celagam Shandon) using Tris EDTA borate buffer, pH 9.8 [28] and on starch gel (starch hydrolyzed Connaught) using the electrophoretic technique recommended by the WHO [29]. Hori

zontal starch gel electrophoresis was performed using Tris as well as phosphate buffer. 1/20 dilution of the hemolysate was used for electrophoresis.

### Results

In 370 patients studied, 158 (42.7%) were G-6-PD deficient. The enzyme activity varied from 0 to 82.5% of normal in these patients. The rest of the subjects had activities of 89.55–224.8% of normal. The main clinical findings in deficient subjects are shown in table I. 33 patients (20.9%) presented hemolytic anemia following fava bean ingestion. Nonspherocytic hemolytic anemia was seen in 14 of them (8.9%). Other hematological diseases were the clinical manifestations of 12.6% of the deficient group. 57.6% of the deficient subjects were asymptomatic. The level of G-6-PD was significantly lower in hemolysis following fava bean ingestion and in nonspherocytic hemolytic anemia (table I).

Among 24 relatives of the G-6-PD deficient, 74.7% had low enzyme activity. All the patients with hemolytic anemia following fava bean ingestion were G-6-PD deficient, while none of the patients with thalassemia (24 cases) and iron deficiency anemia (32 cases) showed any deficiency.

Starch gel and cellulose acetate electrophoresis of 65 subjects with normal G-6-PD level and of 52 patients with G-6-PD deficiency were stud-

Table I Clinical manifestations in deficient subjects

	Male	Female	Total	%	Erythrocyte G-6-PD activity %	p
Hemolytic anemia						
Following fava bean ingestion	23	10	33	20.9	26.4 ± 25.8 (0-49.6)	<0.001
Nonspherocytic hemolytic anemia	9	5	14	8.9	27.4 ± 3.8 (0-19.4)	<0.001
Other hematological diseases	16	4	20	12.6	41.3 ± 28.3 (7.9-80.6)	
Asymptomatic	70	21	91	57.6	91.9 ± 24.3 (0-82.5)	0.05 p < 0.1
Total	118	40	158	100		

Table II Electrophoretic mobility in G-6-PD normal and deficient subjects

		G-6-PD variant		
		B	fast	slow
Deficient	male	18	4	4
	female	13	—	—
	total	31	4	4
Non-deficient	male	32	4	3
	female	26	—	—
	total	58	4	3

Table III Erythrocyte G-6-PD activity and electrophoretic mobility in G-6-PD deficient subjects

G-6-PD variant	Number studied	Erythrocyte G-6-PD activity, %	Electrophoretic mobility, %
B	31	22.6 ± 19.9 (0-69.7)	100
Fast	4	25.8 ± 29.9 (0-54.3)	105-110
Slow	4	20.8 ± 25.8 (0-53.1)	85-93

ied (table II) 31 patients with low G-6-PD level (18 male and 13 female) had electrophoretic mobility of variant II. A faster electrophoretic band was present in 4 patients with low G-6-PD level (all male). The 4 other deficient male subjects showed the slow moving band. 13 patients with very low level of enzyme (8 male and 5 female) did not show any electrophoretic band.

58 subjects with normal G-6-PD level had an electrophoretic pattern compatible with variant II. A fast moving electrophoretic band was found in 4 and a slow moving one in 3 of the subjects with normal enzyme activity.

Table III shows the erythrocyte G-6-PD activity and electrophoretic

mobility in deficient subjects. The faster band was 105-110% of normal, and the slow moving band was 85-93% of normal variant II.

### Discussion

G-6-PD deficiency is found in 2-35% of the world area [20] in a wide distribution [1, 2, 8, 10-14, 16, 20-23, 26]. The high incidence in the Mediterranean area is thought to be related to genetic polymorphism in which G-6-PD deficiency protects against fatal falciparum malaria [11, 23]. However, this protection was not found in some areas [9]. GdA/GdB<sup>+</sup> females are most protected [6]. Glutathione disulfide in G-6-PD deficient red blood cells inhibits protein synthesis by the intracellular parasite [19]. The percentage of G-6-PD deficiency in this study was 42.7%. The percentage was almost the same in the symptom free control group, and this is higher than that reported previously by BOWMAN and WALKER [8] in Iran. This could partly be due to the quantitative estimation of the enzyme which detects partially deficient subjects as well.

A different clinical manifestation is seen in G-6-PD deficient subjects due to the level and biochemical characteristics of the enzyme [15, 31]. Hemolysis following fava bean ingestion is common in Mediterranean type B variety [18], however not all the patients with G-6-PD deficiency have clinical favism [7]. The presence of G-6-PD deficiency is necessary for the occurrence of favism but not sufficient. A serum deficiency is suggested to be a cause of favism [20]. An autosomal gene for acid phosphatase may be another factor [7]. Fava beans are the major source of large amounts of free  $\beta$ -(3,4-dihydroxyphenyl)-L-alanine (L-dopa) and hemolysis is dependent upon the rate of production of dopa quinone production from L-dopa [5] therefore increased tyrosinase activity may be the addition factor [4]. It was very interesting to note that some of our patients had ingested fava bean previously without developing any symptoms. This sudden reaction is not unusual in favism [15]. Hemolytic crisis of favism is seen in heterozygotes as well. As only enzymopenic red cells are selectively lysed the clinical signs may be minimal [27].

More than 70 G-6-PD variants have been discovered since 1947 [30]. The 2 major molecular forms of G-6-PD within red cells are types A<sup>+</sup> and II<sup>+</sup>. The molecular difference appears to be a single amino acid

substitution, asparagin in B<sup>+</sup> for aspartic acid in A<sup>+</sup> [15]. Approximately 18% of American Negro males have A<sup>+</sup> [23, 24] and almost all Caucasians have B<sup>+</sup> [25]. In this study, most of the cases showed electrophoretic mobility of variant II.

The fast electrophoretic band (110% of normal) which was present in 3 patients with enzyme deficiency and in 2 individuals with normal level of enzyme, is compatible with variant A [17]. The enzymes of fast and slow electrophoretic mobility are the variants which might be different to what has already been known. We are studying this matter further.

*Acknowledgements* The author is grateful to Prof. N. GURTI (Head of the Department of Experimental Medicine and Pharmacology) and Dr. S. RAHIBAR (Head of the Department of Applied Molecular Biology) for their helpful advice to Miss M. FARSHIAN for her technical assistance and to Mrs. N. SAMADI for her aid in preparing the manuscript.

### References

1. ALLISON A. C. G-6-PD deficiency in red blood cells of East African. *Nature Lond* 186: 531-532 (1960).
2. AMIN ZAKI L., TAJI EL DIN S. and KUBBA K. G-6-PD deficiency among ethnic groups in Iraq. *Bull. Wld Hlth Org* 47: 1-5 (1972).
3. BEUTLER E. Red cell metabolism. A manual of biochemical methods pp 62-64 (Grune & Stratton New York 1971).
4. BEUTLER E. G-6-PD deficiency. *Brit J Haemat* 18: 117-121 (1970).
5. BEUTLER E. L. Dopa and favism. *Blood* 36: 523-525 (1970).
6. BIENZLE U., LUCAS A. O., AYENI O. and LUZZATTA L. G-6-PD and malaria: Greater resistance of females heterozygous for enzyme deficiency and of males with no deficient variant. *Lancet* i: 107-110 (1972).
7. BOTTINI E., LUCARELLI P., AGOSTINO R., PALMARINO R., BUSINCO L. and ANTOGNONI G. Favism: association with erythrocyte acid phosphatase phenotype. *Science* 171: 409-411 (1971).
8. BOWMAN J. E. and WALKER D. G. The origin of G-6-PD in Iran: Theoretical consideration. *Proc 2nd Int Congr hum Genet* vol 1 pp 583-586 (1963).
9. BUCHANAN J. G., WILSON F. S. and NIXON A. D. Survey for erythrocyte G-6-PD deficiency in Fiji. *Amer J hum Genet* 25: 30-41 (1973).
10. CAUCHI M. N. The incidence of G-6-PD deficiency and thalassemia in Malta. *Brit J Haemat* 18: 101-106 (1970).
11. COTTON D. W. K. and SUTORIUS A. H. M. Inhibition effect of some antimalarial substances on G-6-PD. *Nature Lond* 233: 197 (1971).
12. FRISCHER H., BOWMAN J. E., CARSON H. F., RIECKMANN K. H., WILLERSON D. and COLWELL E. J. Erythrocyte glutathione reductase, G-6-PD and 6-phosphogluconic dehydrogenase deficiency in populations of the U.S., South Vietnam, Iran and Ethiopia. *J Lab clin Med* 81: 603-612 (1973).

- 13 GILPI P. P., G-6-PD deficiency in Saudi Arabia. *Blood* 25: 455-493 (1965)
- 14 GILIS H. M., FLETCHER, K. A., RIDDY S., and ALLEN N., G-6-PD deficiency: sickling and malaria in African children in South Western Nigeria. *Lancet* i: 138-140 (1967)
- 15 HARRIS, J. W. and KELLERMAYER R. W., The red cell pp. 559-574 (Harvard University Press, Cambridge 1970)
- 16 HOLY J. M. and MADDEN R. M., Favism in England. *Arch. Dis. Childh* 40: 271-273 (1965)
- 17 KAJIN A., BOVEN P. et LAGNEAU, J., Phénotype de la G-6-PD déshydrogénase érythrocytaire dans la race noire. *Humangenetik* 18: 261-270 (1973)
- 18 KATTAMIS C., KARAMBULA K., METAXATOL MAVROMATI A., and MATSIANTIS, N., G-6-PD deficiency and age. *Lancet* i: 235 (1971)
- 19 KOSOWITZ N. S. and KOSOWITZ E. M., Molecular basis for selection advantage of G-6-PD deficient individuals exposed to malaria. *Lancet* ii: 1343-1344 (1970)
- 20 MCCURDY, P. R. and MAHMUD L., Red cell G-6-PD deficiency in Pakistan. *J. Lab. clin. Med.* 76: 943-949 (1970)
- 21 MCCURDY P. R., MALDONADO, N., DILLON D. E., and CONARD H. F., Variants of G-6-PD associated with G-6-PD deficiency in Puerto Ricans. *J. Lab. clin. Med.* 82: 432-437 (1973)
- 22 MCCURDY P. R., SCIENTER J. H., and HANSEN I. M., Red cell G-6-PD variant in Rumania. *Rev. europ. Etud. clin. biol.* 17: 66-69 (1972)
- 23 MILLER D. M., The hereditary hemolytic anemia: Membrane and enzyme defects. *Fed. at Clin. Nutr. Amer.* 19: 865-897 (1972)
- 24 MOUTSKY A. G. and YOSHIDA A., Variants of G-6-PD. *Ann. N. Y. Acad. Sci.* 179: 636-643 (1971)
- 25 OYEAL S. K. and OYEAL MANTU A., Electrophoretic characterization of G-6-PD in Ghana. *Lancet* ii: 44 (1972)
- 26 PANCH V. and SCHWARTZ T., Characterization of G-6-PD deficiency in Thailand. The occurrence of 6 variants among 40 G-6-PD deficient Thai. *Humangenet.* 19: 32-46 (1973)
- 27 RISSO, G., MOREIRA J., FOUANT L., and SCHUMER, G., Hemolytic crises of favism in Sicilian females heterozygous for G-6-PD deficiency. *Pediatrics* 49: 854-859 (1972)
- 28 SPARKS R. N., BALLEW M. C., and TOWNSEND H. E., Cellulose acetate electrophoresis of human glucose-6-phosphate dehydrogenase. *J. Lab. clin. Med.* 73: 531-534 (1969)
- 29 WHO scientific groups on the standardization of procedures for the study of G-6-PD. *Tech. Rep. Ser. Wld. H. & Org.* 1966: 1-93
- 30 YOSHIDA A., BRUTTER L., and MOUTSKY A. G., Human G-6-PD variants. *Bull. Wld. H. & Org.* 45: 243-253 (1971)
- 31 YOSHIDA A. and LIN M., Regulation of G-6-PD activity in red blood cells from hemolytic and non-hemolytic variant subjects. *Blood* 47: 877-891 (1976)



## Extract of *Fagara zanthoxyloides* Root in Sickle Cell Anaemia

### Toxicology and Preliminary Clinical Trials

W A ISAACS-SODEYE, E A SOFOWORA, A O WILLIAMS,  
V. O MARQUIS, A A ADEKUNLE and C O ANDERSON

Drug Research Unit, Faculty of Pharmacy, University of Ife, Ile Ife,  
Department of Haematology, University College Hospital Ibadan,  
Division of Human Biology and Behaviour, Faculty of Health Sciences,  
University of Ife, Ile-Ife, Department of Pathology, University College Hospital,  
and Department of Biochemistry, University of Ibadan Ibadan

**Abstract** Following the demonstration of the ability of aqueous extracts of *Fagara zanthoxyloides* root to reverse sickling, toxicological studies in duck and chick embryos as well as in mice have shown these extracts to be non toxic. Preliminary clinical trials demonstrated a significant diminution in the incidence of painful episodes in *Fagara* treated individuals.

**Key Words**  
*Fagara* root extract  
Sickle cell anaemia  
Sickling prevention

The detailed knowledge of sickle cell anaemia now available at the molecular level has stimulated various attempts to improve the management of this disease. The major efforts are now directed to preventing the homozygous inheritance of the disease by genetic counselling [16], prenatal detection and selective abortion [8] as well as by interfering with the process of sickling, with antisickling agents. Urea [12] and potassium cyanate [2, 4] are perhaps the best known of the antisickling agents which are being currently investigated. They respectively interfere with hydrophobic bonds which contribute to the gelation process by binding to the N-terminal residue of globin chains thus changing the oxygen affinity of the haemoglobin in the process. However, a group of steroids, in particular testosterone and progesterone, have also *in vitro* and *in vivo* efficacy as antisickling agents [1, 5-7]. Similarly, the observation that aqueous extracts of *Fagara zanthoxyloides* root preserved the red colour of blood in blood agar culture plates [3] had led to the description of an antisickling effect in that root extract [14]. Further investigation has confirmed this

effect and a pure substance with a potent antisickling activity has been characterized from the root and synthesized [15] in our laboratories.

Since antimicrobial activity against oral microorganisms was also demonstrated with this root extract [3] its potential in the prevention of sickle cell crises (often precipitated by upper respiratory infections) is clear.

This report describes the findings of toxicological examination of the aqueous extract of this chewing stick and the preliminary clinical assessment of it on sickle cell disease patients.

### Materials and Methods

#### *Preparation of the Extract*

The aqueous extract was prepared by soaking the chopped roots of the 'Orin ala' chewing sticks - authenticated as earlier specified [3-14] - in equal weight of distilled water. The preparation was left in the refrigerator at 4°C and decanted after 2 days. This produced an extract containing 1 mg of water-soluble extractive/ml. For the toxicological studies requiring concentrated extract, the powdered root was exhausted with water in a Soxhlet extractor. The water-soluble extract was then concentrated *in vacuo* to the required strengths as necessary.

#### *Embryo Toxicology Studies*

**Method 1** The primary cell cultures were prepared by adopting the method of Mirachant *et al* [11]. Duck and chick embryos (obtained from 8-day-old infection-free birds) were removed from the eggs and, after tissue disruption, were treated with 0.25% trypsin. The individual cells so produced were counted using the improved Neubauer haemocytometer. The cells were diluted with the growth medium (consisting of 0.5% lactalbumin hydrolysate and 5% cow serum in Hanks BSS) so as to contain approximately  $4.8 \times 10^4$  cells/ml. 1 ml quantities of this cell suspension were then planted in screw-capped culture tubes and incubated. After 48 h, the growth medium was decanted and replaced with 1 ml of the growth medium containing 0.0 (control) to 0.10 ml of the root extract (1 mg of extractive/ml). The cultures were reincubated and examined every 24 h for cytopathogenicity.

The degree of cytotoxicity was determined by microscopic examination of the cells and is expressed in terms of a ratio of damaged to normal cells. The lowest level of the extract causing a 50% reduction was regarded as the toxic dose (TD<sub>50</sub>).

**Method 2** Shaves of the extract (0.0-0.10 ml) were inoculated into the chorionallantoic sacs of 15-day-old duck and chick embryos. The eggs were incubated at 37°C using a Western-Curlew incubator under appropriate relative humidity setting (95%) and aeration. The eggs were candled daily to determine mortality rate. Viable eggs were allowed to hatch on the 21st day of incubation and the hatchlings were examined for physical abnormalities.

**Counting of cells and estimation of protein** Following the method of Mirachant *et al* [11] for counting an increase in the number of cells per culture within 24 or 48 h of incubation indicated growth of the culture.

The amount of protein in the culture was estimated by the method of LOWRY *et al* [10] as modified by OYAMA and EAGLE [13]. Doses of the root extract which reduced the total cell protein per culture by 50% were designated as the 50% inhibitory dose (ID 50). This was calculated as described by LITCHFIELD and WILCOXON [9].

### *Whole Animal Toxicology Studies*

The mice used in these tests are Vom s strain (originally Wistar strain)

**Acute toxicity** Mice weighing 25 g were used for acute toxicity tests via three routes of administration (oral, intraperitoneal and intravenous) of the aqueous extract (1.25 g of extractive/ml). Oral administration was via a stomach tube (a No 2 serum tube without point or bevel attached to a polythene tubing) inserted carefully through the animal's throat when required. Intraperitoneal injections were given with an 18 $\frac{3}{4}$  inch needle passing through the abdomen while held taut and avoiding the liver, kidney, spleen or bladder. Intravenous injections were given through a tail vein. The vein was dilated by placing the tail in warm water (45 °C).

**Chronic toxicity** (a) Eight mice (average weight 15 g) were fed with 1.25 g/kg body weight of the extract daily for 7 days and set aside for observation. (b) Mice weighing 15 g were used: 15 male, 15 female, 7 pregnant and 4 nursing mother mice were fed the extract at a dose of 22 mg/kg body weight twice daily for 6 weeks and 10 male, 10 female, 6 pregnant and 2 nursing mother mice had similar volume of distilled water daily, as control for the same period. General observations were made of morbidity and mortality. In addition, lungs and livers of dissected mice were examined blind microscopically at intervals and at the end of the feeding period.

### *Preliminary Clinical Trial*

A clinical trial similar to the one earlier reported for testosterone [7] was devised. 50 young individuals (2–10 years of age) who had painful episodes of sickle cell disease at least twice a month and each with a pain score [7] of not less than 25 a month were used.

5 ml of the root extract (1 mg of extractive/ml) was administered orally thrice daily for 2 months. This followed a preliminary 2 month period spent in assessing a base line clinical picture for each patient. The treatment period was followed by another 2 month period in which a similarly tasting aqueous extract of *Massularia acuminata* (Yoruba name *Pako Ijebu*, another root used like *Fagara* for cleaning the teeth locally) was substituted for the *Fagara* extract.

## *Results*

### *Embryo Toxicology Studies*

Table I shows the growth of primary cell cultures of chick and duck embryos in relation to dose level of the extract. It shows that the extract has no significant effect ( $P < 0.01$ ) on the cell cultures and the embryonated eggs of the duck and the chick. The chicks and ducklings hatching from viable eggs on day 21 of incubation were normal birds exhibiting no

Table 1 The toxic (TD 50) inhibitory (ID 50) and lethal (LD 50) doses of *Fagara* root extract tested on chick and duck embryos

	0.0-0.10 ml of extract		
	TD50	ID50	LD50
<i>Cell culture</i>			
Primary duck (whole embryo)	0.05	2.3-2.6	-
Primary chick (whole embryo)	0.09	1.8-4.1	-
<i>Embryonated eggs</i>			
Duck	-	-	0.1-0.15
Chick	-	-	0.18-2.3

teratogenized features. Toxicity, due to the aqueous extract of this *F. zanthoxylodes* root, is virtually non-existent in cell cultures of whole embryos.

### Whole Animal Toxicology Studies

#### Acute Toxicity

**Oral.** No deaths were recorded in 10 mice when fed the water-soluble extract, orally, at dose levels of up to 50 g/kg.

**Intraperitoneal.** LD<sub>50</sub> was obtained at 20 g/kg. At this dose level 60% of the mice had convulsion, only a third of these recovered from the convulsion the rest died. The convulsions were of the clonic type and generally, the mice died of respiratory arrest. Those that recovered were often depressed and hid away in a corner with a sagging head. No piosis was observed. Mortality was inspected for 72 h.

**Intravenous.** LD<sub>50</sub> was 8 g of extract/kg body weight whilst all mice died at a dose of 14 g/kg body weight. Generally, there was increased respiratory movement with this LD<sub>100</sub> dose initially, followed by a sedative or tranquillizing effect. Reduced spontaneous activity and raised hind legs were observed before the animals died in a tonic convulsive state. Urination was frequent.

#### Chronic Toxicity

Light mice, fed with 1.25 g of extract/kg body weight daily for 7 days survived even after 60 days of observation. Sets of mice fed 22 mg/kg body weight as well as those fed 1.25 g/kg body weight for 7 days showed

*Table II* The effect of treatment with *Fagara* root extract on the pain score of sickle cell anaemia patients

Patient	Pain score while patient was treated with	
	control extract	<i>Fagara</i> extract
1	26	1
2	46	0
3	50	0
4	25	0

no pathological changes attributable to the test substance even after microscopical examination of livers and lungs

#### *Preliminary Clinical Trial*

This trial was plagued with a very high default rate. Three types of data were obtained. Firstly, 4 patients who had a pain score of 25–50 per month while on the control root (*Masularia acuminata* G. Don) extract had a zero score per month on the *Fagara* extract (table II). Secondly, 4 patients who defaulted after being switched to the control extract from *Fagara* extract had a zero per month score whilst on *Fagara*. Lastly, patients treated with *Fagara* extract who after a preliminary observation period refused to be put on a cross-over trial but who on their own took *Fagara* extract reported a complete and salutary change in well being. The haematocrits of all the patients remained fairly constant or rose whilst they were on the *Fagara* extract.

#### *Discussion*

The root of *F. zanthoxyloides* is one of the agents used to clean teeth, in the Western State of Nigeria, as a preventive measure against dental caries. It is used by chewing the sticks prepared as described earlier [3] followed by brushing of the teeth with the fibrous end thus produced. In many of these local communities, the more elderly inhabitants cleaned their teeth with only this material usually with unavoidable or often deliberate swallowing of the juice produced from chewing the root. Clearly, it would be expected that some documentation of side-effects would have

been made if any significant toxicity of the root extractive existed. In fact, it is still chewed today by many members of the present generation in this locality. However, since this local use has never been subjected to a scientifically organized toxicological testing, it was thought necessary to organize the toxicity tests here described. These have been reasonably comprehensive in the species studied including as they did studies in male, female, pregnant and embryonic forms as well as testing for both acute and chronic toxicity. The results confirm the local evidence, though circumstantial, of an absence of toxicity in the accepted usage of the root extract. Tests on primate species including subtle tests on functional capacity of treated animals will be carried out but this initial analysis of the toxicity status of the root extract is reassuring.

The clinical testing is in many ways preliminary. It was possible to take advantage of the HbSS individuals from poor, socio-economic environments who in the first 5 years get crises very frequently (e.g. one in a week or fortnight). Hence, any significant changes would be highlighted within a few months. Comprehensive clinical trials are being organized in a multicentric fashion and on a national scale spreading over the wet and dry seasons. This projected trial will give an authoritative appraisal. The limited *in vivo* examination here reported suggests, however, that there are grounds for cautious optimism that this root extract might secure a place in our armamentarium for managing sickle cell disease.

*Acknowledgment* The authors wish to thank Mr K. M. JACK and Mr DOTT ADELMAN for technical assistance. We are grateful to the University of Ife for a research grant to Tropical Products Institute, London, for an extramural research grant and to the Pharmaceutical Society of Nigeria - Sickle Cell Anaemia Research Fund for financial support. This research is also financed by the OAU-STRC.

### References

- 1 ADRIENNE, R. K. and ISAACS, W. A. The effect of Megestrol acetate on sickling. *Amer. J. med. Sci.* 241: 367-370 (1971).
- 2 CHAM, A. and MANNING, J. M. Potassium cyanate as an inhibitor of the sickling of erythrocytes *in vitro*. *Proc. nat. Acad. Sci., Wash. DC* 1102-1105 (1971).
- 3 FETTER, I., FARRELL, S. O., KURT, J. O., and SOWOWOLA, I. A. Naive cures in Nigeria. II. The antithrombotic properties of the dehydrated extract of chewing sticks. *Unj. d. J. S. A.* 172-174 (1971).
- 4 CHAFFIN, P. S., MANNING, J. M., and CHAM, A. Increased survival of sickle cell erythrocytes after treatment *in vitro* with sodium cyanate. *Proc. nat. Acad. Sci., Wash. DC* 2791-2793 (1971).

- 5 ISAACS W A and HAYHOE, F G J Steroid hormones in sickle cell disease Nature, Lond 215 1139-1142 (1967)
- 6 ISAACS, W A The effect of certain lipid substances on sickling Acta haemat 45 259-265 (1971)
- 7 ISAACS, W A, EFFIONG, C E, and AYENI, O Steroid treatment in the prevention of painful episodes in sickle cell disease Lancet i 570-571 (1972)
- 8 KAN, Y W, DOZY, A M, ALTER, B P., *et al* Detection of the sickle gene in the human fetus New Engl J Med 287 3-7 (1972)
- 9 LITCHFIELD, J T and WILCOXON F A A simplified method of evaluating dose effect experiments J Pharmacol exp Ther 96 99-113 (1949)
- 10 LOWRY, O H, ROSEBROUGH, N J FARR, A L, and RANDALL, R J Protein measurement with the Folin phenol reagent J biol Chem 193 265-275 (1951)
- 11 MERCHANT, D J, KAHN, R J, and MURPHY, W H Handbook of cell and organ cultures, 2nd ed (Burgess Minneapolis 1964)
- 12 NALBANDIAN, R M, SHIELTZ G, LUSHER, J M ANDERSON, J W, and HENRY, R L Sickle cell crisis terminated by intravenous urea in sugar solutions A preliminary report Amer J med Sci 261 309-324 (1971)
- 13 OYAMA, V I and EAGLE, H Measurement of cell growth in tissue culture with a phenol reagent (Folin Ciocalteu) Proc Soc exp Biol, N Y 91 305-312 (1956)
- 14 SOFOWORA, E A and ISAACS, W A Reversal of sickling and crenation in erythrocytes by the root extract of *Fagara zanthoxylodes* Lloydia 34(4) 383-385 (1971)
- 15 SOFOWORA E A Recent developments in research into the antisickling properties of *Fagara zanthoxylodes* J Pharmacy, Nigeria 5(2) 8-14 (1973)
- 16 WESTRING, D W and GRAND S Screening for sickle haemoglobin A review Amer J med Sci 265 358-366 (1973)

## The *in vitro* Effect of Analgesics on the Electrophoretic Pattern of the Red Cell Membrane Proteins

P. N. KOISSITOPoulos, P. SKLIRIOS and C. ANASTASIOU

Professional Medical Unit, Evangelismos Hospital, Athens

**Abstract** The *in vitro* effect of acetylsalicylic acid, phenylbutazone and indomethacin on the electrophoretic pattern of the red cell membrane proteins is described by using the vertical urea starch gel electrophoresis. Normally 8 bands are visible. Acetylsalicylic acid and phenylbutazone bring about the disappearance of 3 bands and indomethacin that of 6 bands.

### Key Words

Acetylsalicylic acid  
Analgesics  
Erythrocyte membrane proteins  
Indomethacin  
Phenylbutazone

The analgesics act on the red cells and on the hematopoietic tissue generally, causing a variety of abnormalities as aplastic, hemolytic or dyserythropoietic states [5, 8, 15, 16]. The present study describes observations on the effect of acetylsalicylic acid, phenylbutazone and indomethacin on the electrophoretic pattern of the red cell membrane proteins.

### Materials and Methods

Red cells were collected from normal donors into ACD, washed 3 times in 0.9 percent NaCl and used on the day of collection.

For the *in vitro* action of the analgesics on the red cells, the method of Mager and Smith [10] has been adopted. Cells were washed once with 0.1 M, pH 7.4 phosphate buffer containing 6 mm glucose. The experimental system consisted of 5 vol of red cell suspension plus 2.5 vol of a solution of the drug. The PCV of the red cell suspension in the normal phosphate buffer was 25% and the PCV of the experimental system was 32%. Drugs were dissolved in phosphate buffer and the pH adjusted to 7.4 with either NaOH or HCl when necessary. The concentration of each drug in the solution is given in table 1. The drug red cell



Table I Concentration, chemical characteristics and solvent of acetylsalicylic acid, phenylbutazone and indomethacin

Analgesic	Concentration mM	Formula	Molecular weight	Time of incubation h	Solvent
Acetylsalicylic acid	18	$C_9H_8O_4$	180.15	2.5	water
Phenylbutazone	2.4	$C_{19}H_{20}N_2O_2$	308.37	2.5	water
Indomethacin	9.5	$C_{19}H_{16}NO_4Cl$	357.78	2.5	water

mixtures were incubated at 37 °C under continuous agitation for 2.5 h in an Eberbach shaker

For the preparation of membrane proteins, the red cells were washed 3 times in isotonic phosphate buffer (310 mOsm, pH 7.4, 0.1 EDTA). All subsequent procedures were carried out at 4 °C. The cells were hemolyzed and washed in hypotonic phosphate buffer (20 mOsm pH 7.4, 0.1 EDTA) until the ghosts became white. The membranes were sedimented after each wash by centrifugation at 30,000 g for 20 min. The hemoglobin free ghosts were finally washed once with distilled water, resuspended in water and allowed to stand overnight [17]. Solubilization of the protein was effected by the method of MADDY [9]. An equal volume of *n*-butanol (0 °C) was added to the membrane suspension, mixed well, allowed to stand for 30 min at 0 °C and then centrifuged at 30,000 g for 20 min. The aqueous phase, containing the proteins, was removed with a cold syringe and dialyzed for 12 h against distilled water. It was then lyophilized and stored under vacuum.

**Electrophoretic procedures** 20 mg of the lyophilized protein powder were dissolved in 1 ml of a solution of 6 M urea, 3 percent acetic acid and 0.16 M 2-mercaptoethanol. On standing overnight at 4 °C, a clear solution was obtained [1]. The electrophoresis was carried out at an urea starch gel of pH 3.2 [14]. The gel for this low-pH electrophoresis was prepared as follows. 10 g of hydrolyzed starch was powdered together with 180 g of urea with pestle and mortar. The gel buffer, consisting of 300 ml of sodium lactate buffer (pH 3.2, cation concentration 0.05 M) containing 2.4 ml 2-mercaptoethanol, was added to the powder and mixed before heating to 70 °C for 7 min in an Erlenmeyer flask. After degassing, the gel was poured and allowed to set overnight. The protein solution was subjected to electrophoresis for 4 h at a 80 mA constant current in a vertical system using the same sodium lactate buffer, pH 3.2, of the same cation concentration in the electrode chambers. The gel was stained with amido black 10B and destained with a 3 percent acetic acid solution [13].

## Results

The electrophoretic pattern of normal red cell membrane proteins consists of 8 bands [2]: the slow-moving group of 3 bands (group c), a




Fig 1 Electrophoretic patterns of red cell membrane proteins treated with acetylsalicylic acid (AA), phenylbutazone (PH) and indomethacin (IN) and of normal (N). Or = origin c = group of bands c b = band b a = band a Hb = Hb band.

not always well defined band, 2 bands in the middle of the electrophoretic pattern (bands b and a) an other not always well defined band and finally, the fast moving band of hemoglobin (Hb) (fig 1, N). The electrophoretic pattern of the red cell membrane proteins treated with acetylsalicylic acid consists only of bands b, a and the band of Hb (fig 1 AA). After treatment with phenylbutazone it consists only of bands b and a which are very close one to an other, and of the Hb band (fig 1, PH). After treatment with indomethacin it consists only of band a and of the band of Hb (fig 1, IN).

### Discussion

The electrophoretic study of the red cell membrane proteins [7, 11, 12] has been proved to be a useful method for the evaluation of alterations in various disease states [3, 4, 6]. The present experiments showed that acetylsalicylic acid, phenylbutazone and indomethacin, added *in vi-*

*in vitro* to erythrocyte suspensions, bring about abnormalities in the red cell membrane proteins, consisting in the disappearance of 5-6 bands out of 8 normally found. The explanation and importance of these changes are not known. Similar abnormal findings were observed on erythrocytes treated *in vitro* with oxidative agents and by substances producing PNH-like abnormality (unpublished observations).

Thus our findings seem to indicate that the above-mentioned analgesics bring about damage of the red cell membrane, apart from their known intracellular effect.

### References

- 1 AZEN, E. A., ORR, O., and SMITHIES, O. Starch gel electrophoresis of erythrocyte stroma. *J Lab clin Med* 65: 440-449 (1965).
- 2 GOMPERTS, E. D., CANTRELL, A. C., and ZAIL, S. S. Electrophoretic patterns of red cell membrane protein from various mammalian species. *Brit J Haemat* 21: 429-434 (1971).
- 3 GOMPERTS, E. D., CAYANNIS, F., METZ, J., and ZAIL, S. S. A red cell membrane protein abnormality in hereditary elliptocytosis. *Brit J Haemat* 25: 415-420 (1973).
- 4 GOMPERTS, E. D., METZ, J., and ZAIL, S. S. Red cell membrane protein in an antibody induced haemolytic anaemia. *Brit J Haemat* 25: 421-428 (1973).
- 5 HUGULF, C. M., JR., LEA, J. W., JR., and BUTTS, J. A. Adverse hemolytic reactions to drugs. *Progr Haemat*, vol. 5 pp. 105-136 (Grune & Stratton, New York 1966).
- 6 JACKSON, P. and WHITTAKER, M. Evidence for an abnormality in the erythrocyte membranes of patients having paroxysmal nocturnal hemoglobinuria and aplastic anemia. *Clin chim Acta* 41: 299-304 (1972).
- 7 LAUF, F. K. and POULIK, M. D. Solubilization and structural integrity of the human red cell membrane. *Brit J Haemat* 15: 191-202 (1968).
- 8 MACGINNON, B. H., LOUGHRIDGE, C. W., HOURRIANE, D. O., and BOYD, H. W. Autoimmune haemolytic anaemia with acute renal failure due to phenacetin and p-aminosalicylic acid. *Lancet* i: 7-10 (1960).
- 9 MADDY, A. H. The properties of the protein of the plasma membrane of ox erythrocytes. *Biochim biophys Acta* 117: 193-200 (1966).
- 10 MILLER, A. and SMITH, H. C. The intracellular and membrane effects of oxidant agents on normal red cells. *Brit J Haemat* 19: 417-428 (1970).
- 11 POULIK, M. D. Gel electrophoresis in buffers containing urea. *Meth biochem Anal* 14: 455-495 (1966).
- 12 POULIK, M. D. Electrophoretic analysis of proteins of human and non human primate stroma. *Ann N Y Acad Sci* 162: 211-216 (1969).
- 13 REGA, A. F., WEED, R. I., RIED, C. F., BERG, G. G., and ROTHSTEIN, A. Changes in the properties of human erythrocyte membrane protein after solubilization by butanol extraction. *Biochim biophys Acta* 147: 297-312 (1967).

- 14 SMITHIES O, CONNELL, G. E., and DIXON, G. H. Inheritance of haemoglobin subtypes. *Amer J Human Genet.* 14: 14-21 (1962)
- 15 WINTA, L., SMITH, J. A. W., and SWEET, H. O. Acetylsalicylic acid as a cause of pancytopenia from bone-marrow damage. *Lancet* ii: 768-770 (1966)
- 16 WILLIAMS, J. O., MINCELL, C. E., SULLIVAN, L. W., and HAO, A. S. Megaloblastic anemia associated with chronic ingestion of an analgesic. *New Engl J Med.* 240: 312-313 (1969)
- 17 ZWAAL, R. F. A. and VAN DRESEN, L. L. M. Protein patterns of red cell membranes from different mammalian species. *Biochim biophys. Acta* 163: 44-49 (1968)

*Phenylhydrazine* (fig. 1). There is no proliferation of the marginal cells on the first 3 days. The marginal zone is 1–2 cells in thickness. There is no mitotic activity. On the 5th day, the thickness increases to a 4-cell layer. An occasional mitotic figure is seen. The proliferative activity is very short-lived, the thickness decreasing to a single layer on the 7th day.

*Antiserum* (fig. 1). The marginal cells do not show any proliferation on the first 2 days as with phenylhydrazine. On the 3rd and 5th day this layer varies from 2 to 4 layers in thickness. On the 7th day there is proliferation to 4–6 layers with occasional mitotic figures.

### Discussion

From the present study it is evident that the RE cells of the marginal zone [3] around the lymphatic sheath proliferate in response to every type of hemolysis. After copper sulphate, there is a steady rise in the marginal zone thickness, reaching a peak on the 5th day. The responses with phenylhydrazine and antiserum are low. The hemolysis after copper sulphate is short-lived as compared with the other agents. Phenylhydrazine and antiserum produce a prolonged and sustained hemolysis [1]. Thus it is likely that hemolysis *per se* does not play an important role in marginal zone proliferation.

Copper sulphate produces a predominantly extravascular hemolysis, mainly due to erythrophagocytosis in the spleen [4]. Phenylhydrazine also produces a prominent splenic erythrophagocytosis [5]. As in this case, the erythrophagocytosis is sustained over a long period whereas with copper sulphate is short-lived, the marginal zone proliferation cannot be due to erythrophagocytosis as such. Moreover, the erythrophagocytosis with antiserum is much lower than with phenylhydrazine and yet both have a similar curve of marginal zone proliferation.

Studies on iron deposition in the splenic RE cells, show that 3 zones take part in the phagocytosis and breakdown of damaged red cells [6]. These are the red pulp, the marginal zone cells and the cells around the germinal centre. After phenylhydrazine the activity is mainly in the red pulp, reaching a peak on the 5th day. The marginal RE cells do not show any erythrophagocytosis. With antiserum activity is seen in all 3 zones. The activity is around the germinal centres with copper sulphate, slower activity is seen within the red pulp and the lowest in the marginal zone, the activity being mostly on the first 2 days.

As the erythrophagocytosis by the marginal cells is highest after anti-serum whereas the proliferation is most marked after copper sulphate, it can be said that the proliferation is not connected with this activity alone. Moreover, no marginal zone activity is seen after phenylhydrazine but the proliferation is similar to that after antiserum. Copper is known to cause a marked increase in the metabolism of cells [7]. It seems likely that this action produces in the RE cells an increase in mitotic activity with proliferation and blast transformation in contrast to cell death in the stable cells.

Studies on copper deposition [8] show that copper is at first released into the splenic RE cells and thence transported to the liver via the splenic and portal veins. From the 2nd day onwards there is a gradual increase of copper in the liver indicating that the RE cells of the spleen release copper from this time onwards. The peak activity is on the 5th day [8]. Thus it can be said that the proliferation of the RE cells follows the release of copper from the red cell agglutinates and metalloprotein complexes [9].

The proliferation of the RE cells becomes prominent on the 3rd day, reaching a peak activity on the 5th day with prominent mitoses. By the 7th day there is a fall in mitotic activity. At this stage, the perivascular lymphatic sheath is almost completely replaced by the RE cells of the marginal zone. It is seen that abundant plasmacytoid cells are formed with the RE cell proliferation. This reaction is seen both in immune response [2] and with red cell sequestration [3]. In the present study, it is evident that although sequestration causes a proliferation of the marginal zone cells, it is much more prominent with red cells damaged by copper.

As copper is non antigenic and is a normal constituent of all body cells, the hemolysis produced by it being a short lived extravascular type, proliferation seems to be due to a direct action of copper on the cell metabolism [7].

*Acknowledgements:* I am very grateful to the Director Principal of the Maulana Azad Medical College, Dr. S. PADMAVATI for giving me permission to publish this work.

### References

1. FRIEDMAN, R. and CROFT, H. S. Erythrophagocytosis by the reticulo-endothelial cells of the liver and the spleen (in press).

- 2 WAKSMAN B H; ARNASON, B G, and JANKOVIC, H D Role of the thymus in immune reactions in rats III Changes in the lymphoid organs of thymectomized rats *J exp Med* 116 187 (1962)
- 3 JANDL, J H, FILES, N M, BARNETT, S B, and McDONALD, R A Proliferative response of the spleen and liver in hemolysis *J exp Med* 122 299 (1965)
- 4 IYENGAR, B and GUPTA, D N Hemolysis produced by copper sulphate I Extravascular hemolysis produced by heavy metal poisoning *Ind J med Res* 61 195-198 (1973)
- 5 IYENGAR, B and GUPTA, D N Oxidant hemolysis I The role of the reticuloendothelial cells in the breakdown of red cells damaged by phenyl hydrazine *Ind J med Res* 61 557-562 (1973)
- 6 IYENGAR, B and CHANDRA K Sites of iron deposition in the spleen after acute hemolysis *Acta morph* 21 343-350 (1973)
- 7 VOGEL, F S and KEMPER, L Biochemical reactions of copper within neural mitochondria, with consideration of the role of the metal in the pathogenesis of Wilson's disease *Lab Invest* 12 171 (1963)
- 8 IYENGAR B An experimental study of the pathogenesis of copper deposition in the liver (in press)
- 9 JANDL, J H and SIMMONS, R L The agglutination and sensitisation of red cells by metallic cations Interactions between multivalent metals and the red cell membrane *Brit J Haemat* 3 19 (1957)





- 2 WAKSMAN B H ARNASON B G and JANKOVIC B D Role of the thymus in immune reactions in rats III Changes in the lymphoid organs of thymectomized rats *J exp Med* 116 187 (1962)
- 3 JANDL J H FILES N M BARNETT S B and McDONALD E A Proliferative response of the spleen and liver to hemolysis *J exp Med* 122 299 (1965)
- 4 IYENGAR B and GUPTA D N Hemolysis produced by copper sulphate I Extravascular hemolysis produced by heavy metal poisoning *Ind J med Res* 61 195-198 (1973)
- 5 IYENGAR B and GUPTA D N Oxidant hemolysis I The role of the reticuloendothelial cells in the breakdown of red cells damaged by phenyl hydrazine *Ind J med Res* 61 557-562 (1973)
- 6 IYENGAR B and CHANDRA K Sites of iron deposition in the spleen after acute hemolysis *Acta morph* 21 343-350 (1973)
- 7 VOGEL F S and KEMPER L Biochemical reactions of copper within neural mitochondria with consideration of the role of the metal in the pathogenesis of Wilson's disease *Lab Invest* 12 171 (1963)
- 8 IYENGAR B An experimental study of the pathogenesis of copper deposition in the liver (in press)
- 9 JANDL J H and SHIMONS R L The agglutination and sensitisation of red cells by metallic cations Interactions between multivalent metals and the red cell membrane *Brit J Haemat* 3 19 (1957)

## Coexistence of $\beta$ -Thalassaemia Trait and Gilbert's Syndrome in Three Families

G. CARTEI and E. DINI

Divisione di Ematologia Ospedale Civile Regionale Vicenza

**Abstract** Three young unrelated propositi had  $\beta$  thalassaemia trait ( $\beta$  th t) and chronic unconjugated hyperbilirubinaemia (UHB). Red blood cell  $^{51}\text{Cr}$  t $_{1/2}$  was slightly reduced (from 19.0 to 22.8 days); liver function and histology and iron metabolism included ferrokinetics and iron-chelation with Desferrioxamine B were normal. Bone marrow smears did not show features of dyserythropoiesis. Out of 20 relatives with normal liver function  $\beta$  th t was present in 7, UHB in 7 and  $\beta$  th t and UHB in 3 while the remaining 3 subjects were normal. UHB was chronic, benign, familial without overt signs of haemolysis and with normal liver function (and histology in 3 propositi); it was therefore of Gilbert's type. Bromsulphthalein kinetics and the reduced caloric intake test confirmed the diagnosis.

**Key Words**  
BSP kinetics  
 $^{51}\text{Cr}$  RBC survival  
Ferrokinetics  
Gilbert's syndrome  
Hyperbilirubinaemia  
Thalassaemia

Heterozygous  $\beta$  thalassaemia is frequent in Italy, particularly the trait ( $\beta$  th t). This is characterized by microcytosis, decreased red cell osmotic fragility, elevated HbA<sub>1</sub>, and absent or slight anaemia. Frank hyperbilirubinaemia is uncommon and elevation of unconjugated bilirubin between 1.0 and 3.7 mg/100 ml has been reported in 7 out of 116 cases [4]. Haemolysis seems to be unimportant since RBC  $^{51}\text{Cr}$  t $_{1/2}$  is normal or only slightly reduced [4, 7, 12]. A bone marrow source of hyperbilirubinaemia might be present, but normal morphology of red cell precursors, absent or very mild anaemia and almost normal ferrokinetics are found in most cases [4, 6, 7, 12]. Liver disease may obviously be present and cause hyperbilirubinaemia. However in young subjects with  $\beta$  th t without anaemia and liver disease the unconjugated hyperbilirubinaemia should be not automatically ascribed to the  $\beta$  th t itself. In our region the Gilbert's syndrome (i.e. familial chronic benign unconjugated hyperbilirubinaemia without overt signs of haemolysis) is not rare [3, 4]. The coexistence of  $\beta$  th t and Gilbert's syndrome may be hypothetically expected.

In this paper the previously unreported coexistence of  $\beta$ -th-t and Gilbert's syndrome documented with familial studies is described

### *Materials and Methods*

Three unrelated *propositi* aged 17, 19 and 20 years come to our observation because of chronic scleral jaundice with otherwise normal clinical examination. Family studies were made on 20 available relatives (fig 1, table I).

Haematological tests were done with current techniques unless specified and included Hb, PCV, MCH, MCV, MCHC, RBC, WBC, reticulocytes and platelet counts, RBC osmotic fragility without and with 24 h incubation at 37 °C, ATP and glucose corrected autohaemolysis, ESR, peripheral and bone marrow smear examinations, Hb electrophoresis HbF [14] and HbA<sub>2</sub> [9] determination, pyruvic kinase and G-6-PD activity in RBC, iron and total iron binding capacity [2], bilirubin [8] (serum unconjugated bilirubin, SUB) and haptoglobin (commercially available immunoplates) in the serum.

The following liver function tests were performed in all cases: total and fractionated proteins, LDH,  $\alpha$ -HBDH, GO and GP transaminases, pseudocholinesterasis, alkaline phosphatase and  $\gamma$ GT in the serum, oral cholecystogram. Liver biopsy was done during laparoscopy in the *propositi*. Prothrombin time, PTT and fibrinogen concentration were also available.

In the 3 *propositi* RBC survival (<sup>51</sup>Cr) was studied with technique C proposed by the International Committee for Standardization in Haematology [15]. The bromsulphophthalein (BSP) clearance was obtained in 10 cases (including 3 *propositi*) after the i.v. injection of 5 mg/kg of dye (Merck). The true BSP retention (%) at 45 min was calculated taking as 100% the dye concentration at zero time. Analysis of plasma dye disappearance curve by means of the technique of BARBER, RILEY *et al* [1] gave transfer rate from plasma to liver (a), from liver to bile (h) and from liver back to plasma (b). Transfer rates are expressed in mg/mg/min. Ferrokinetics [11] (2 cases), 24 h urinary iron output after the i.m. injection of 1 g Desferrioxamine II (Desferal, Ciba) [5], bone marrow and liver tissue also stained with Perl's stain were available in *propositi*.

In *propositi* and 5 of their relatives (3 of whom had raised SUB) the reduction of caloric intake to 400 a day was made for 24 h. Serum bilirubin variations were recorded before and after the test according to OWENS and SHERLOCK [10]. An increase of 100% or more in SUB suggests that hyperbilirubinaemia is due to Gilbert's syndrome.

### *Results*

In *propositi* both the features of  $\beta$ -th-t and unconjugated hyperbilirubinaemia were present (table I).  $\beta$ -th-t and raised SUB were also found in some of the relatives (table I, fig 1).

Table 1 Haematologic data and serum bilirubin in 23 subjects from 3 families

Subject	Age and Sex	Diagnosis	Hb g <sup>100</sup>	RBC = 10 <sup>6</sup> /mm <sup>3</sup>	MCV fL	MCH pg	MCHC g/dL	Ret %	RBC coombs negative	HbA <sub>1c</sub> %	HbF %	Serum bilirubin mg <sup>100</sup>	
												Total	unconjugated
A11	75 M	G	130	494	26	87	10	10	N	21	0.5	1.6	0.9
A12	61 M	N	149	480	31	100	0.5	0.5	N	2.2	1.0	0.2	0.2
A13	42 M	N	128	610	21	73	10	10	D	4.3	0.8	0.3	0.2
A14	39 M	N	133	590	23	74	10	10	D	4.7	0.6	0.3	0.2
A15	42 F	G	149	460	32	88	10	10	N	2.9	0.3	1.8	1.2
A16	50 M	N+G	144	635	22	77	1.8	1.8	D	4.1	1.0	2.6	1.7
B11	60 M	N	130	510	29	88	10	10	N	1.9	0.7	1.6	1.0
B12	57 M	G	127	420	30	90	0.5	0.5	N	2.3	0.4	1.9	1.4
B13	47 F	N	146	720	20	75	0.6	0.6	D	6.0	1.0	0.4	0.3
B14	28 M	N+G	129	645	20	64	0.8	0.8	D	5.6	1.0	1.6	1.4
B15	23 M	N+G	124	536	21	66	1.2	1.2	D	6.1	1.3	1.8	1.4
B16	21 F	N	113	570	20	65	0.5	0.5	D	5.9	0.4	0.8	0.5
B17	18 M	N+G	128	633	20	63	1.0	1.0	D	6.3	0.6	1.8	1.6
B18	17 M	N+G	137	660	21	59	0.6	0.6	D	5.7	1.2	2.0	1.7
B19	15 M	G	137	553	28	87	0.5	0.5	N	2.3	1.0	2.3	1.8
C11	51 M	N	122	624	21	68	1.0	1.0	D	5.1	0.8	0.5	0.2
C12	48 F	N	129	400	32	95	0.3	0.3	N	3.0	0.6	0.5	0.3
C13	49 M	N	131	560	23	70	0.7	0.7	D	6.1	0.8	0.6	0.3
C14	48 F	G	131	477	27	88	0.4	0.4	N	2.1	0.3	2.2	1.7
C15	45 M	N	142	480	33	88	0.7	0.7	N	2.0	0.6	2.8	2.1
C16	24 F	N	113	525	22	66	1.5	1.5	D	5.4	0.8	0.7	0.5
C17	22 F	N	154	410	37	96	0.5	0.5	N	2.1	0.8	0.6	0.4
C18	19 F	N+G	112	510	22	68	1.2	1.2	D	5.8	0.4	2.8	2.1

\* See figure 1. A116, B17 and C18 are the progen II

N = Normal; G = Gilbert's syndrome; N+G =  $\beta$ -thalassaemia trait

D = Normal; D = Decreased

In this paper the previously unreported coexistence of  $\beta$ -th-t and Gilbert's syndrome documented with familial studies is described

### *Materials and Methods*

Three unrelated propositi aged 17, 19 and 20 years come to our observation because of chronic scleral jaundice with otherwise normal clinical examination. Family studies were made on 20 available relatives (fig 1, table I)

Haematological tests were done with current techniques, unless specified and included Hb, PCV, MCH, MCV, MCHC, RBC, WBC, reticulocytes and platelet counts, RBC osmotic fragility without and with 24 h incubation at 37 °C, ATP and glucose corrected autohaemolysis, ESR, peripheral and bone marrow smear examinations, Hb electrophoresis, HbF [14] and HbA<sub>2</sub> [9] determination, pyruvic kinase and 6-PD activity in RBC, iron and total iron binding capacity [2] bilirubin [8] (serum unconjugated bilirubin, SUB) and haptoglobin (commercially available immunoplates) in the serum

The following liver function tests were performed in all cases: total and fractionated proteins, LDH,  $\alpha$  HBDH, GO and GP transaminases, pseudocholinesterasis, alkaline phosphatase and  $\gamma$ GT in the serum, oral cholecystogram. Liver biopsy was done during laparoscopy in the propositi. Prothrombin time (PTT) and fibrinogen concentration were also available

In the 3 propositi RBC survival (<sup>51</sup>Cr) was studied with technique C proposed by the International Committee for Standardization in Haematology [15]. The bromsulphophthalein (BSP) clearance was obtained in 10 cases (including 3 propositi) after the i.v. injection of 5 mg/kg of dye (Merck). The 'true' BSP retention (%) at 45 min was calculated taking as 100% the dye concentration at zero time. Analysis of plasma dye disappearance curve by means of the technique of BARBER RILEY *et al* [1] gave transfer rate from plasma to liver ('a') from liver to bile ('b') and from liver back to plasma ('c'). Transfer rates are expressed in mg/mg/min. Ferrokinetics [11] (2 cases), 24 h urinary iron output after the i.m. injection of 1 g Desferrioxamine B (Desferal, Ciba) [5], bone marrow and liver tissue also stained with Perl's stain were available in propositi

In propositi and 5 of their relatives (3 of whom had raised SUB) the reduction of caloric intake to 400 a day was made for 24 h. Serum bilirubin variations were recorded before and after the test according to OWENS and SHERLOCK [10]. An increase of 100% or more in SUB suggests that hyperbilirubinaemia is due to Gilbert's syndrome

### *Results*

In propositi both the features of  $\beta$ -th-t and unconjugated hyperbilirubinaemia were present (table I).  $\beta$ -th-t and raised SUB were also found in some of the relatives (table I, fig 1)

Table II Iron metabolism and RBC  $^{51}\text{Cr}$  t/2 in 3 cases with  $\beta$ -thalassaemia trait and Gilbert's syndrome

Tests	Normal values	Propositi's values		
		A1116	B117	C118
Serum iron, $\mu\text{g}/100\text{ ml}$	100-150	125	129	119
TIBC, $\mu\text{g}/100\text{ ml}$	250-400	400	368	352
Perla's positive material				
Bone marrow		±	±	+
Liver tissue		±	±	+
Deferal test, $\mu\text{g}$ in 24 h	1 000-1 500	1 340	1 210	1 320
$^{51}\text{Fe}$ t/2, min	60-110	92	-	60
Utilization of $^{51}\text{Fe}$ for red cell production %	75-95	95	-	98
Haemoglobin synthesis g/day l	1.3-2.5	2.9	-	1.4
$^{51}\text{Cr}$ t/2, days	25-33	22.0	22.8	19.0

Morphology of bone marrow and  $^{51}\text{Fe}$  and  $^{51}\text{Cr}$  surface counting over sacrum, liver and spleen were normal

Table III BSP metabolism in 10 subjects from the 3 families, included propositi (A1116, B117, C118)

Subjects	Diagnosis <sup>a</sup>	'True' retention at 45 min %	Transfer rates, mg/mg/min		
			a	b	c
A114	$\beta$	1.76	0.1221	0.0578	0.0070
A115	$\beta$	4.40	0.0401	0.0335	0.0091
A116	$\beta + G$	2.67	0.1046	0.0244	0.0040
B112	G	3.71	0.0420	0.0407	0.0010
B113	$\beta$	2.60	0.1420	0.0336	0.0078
B114	$\beta$	1.87	0.1444	0.0170	0.0040
B117	$\beta + G$	1.64	0.1027	0.0166	0.0027
C115	$\beta$	2.70	0.1300	0.0330	0.0040
C116	$\beta$	2.60	0.0910	0.0242	0.0116
C118	$\beta + G$	0.98	0.1091	0.0341	0.0078
Normal values in 25 healthy subjects	{ from 0.00 to 2.57		0.1194	0.0413	0.0102
			0.2049	0.1192	0.0133

<sup>a</sup>  $\beta$  =  $\beta$ -Thalassaemia trait G = Gilbert's syndrome




Fig 1 Family trees of the 3 probands

In family A, raised SUB was present in maternal grand father (II), mother (II5) and proband (III6),  $\beta$ -th-t was found in father (II4), uncle (II3) and proband

In family B, father (I2), uncle (II1) and brother (II9) had raised SUB, mother (I3) and sister (II6) had  $\beta$ -th-t. The proband (II7), and his brothers (II4, II5 and II8) had both raised SUB and  $\beta$ -th-t

In family C, uncle (II), father (I3) and sister (II6) suffered from  $\beta$ -th-t, mother (I4) and maternal uncle (I5) had raised SUB. The proband showed both pathological conditions

Bone marrow examination did not reveal dyserythropoietic abnormalities, and Perl's stain was normal (table II). All other haematological tests, including serum haptoglobin, were normal. Liver function and liver histology in proband were normal

Iron metabolism and  $^{51}\text{Cr}$  studies are shown in table II. Serum iron, TIBC and percentage saturation of transferrin ( $30 \pm 6$ , mean  $\pm 2$  SD) were in the normal range. Ferrokinetics, available in 2 cases, showed no

Table II Iron metabolism and RBC  $^{51}\text{Cr}$  12 in 3 cases with  $\beta$ -thalassaemia trait and Gilbert's syndrome

Tests	Normal values	Propoy's values		
		A1116	B117	C118
Serum iron, $\mu\text{g}/100\text{ ml}$	100-150	125	129	119
TIBC, $\mu\text{g}/100\text{ ml}$	250-400	400	368	352
Perforative material				
Bone marrow		±	±	+
Liver tissue		±	±	+
Desferal test, $\mu\text{g Fe}/24\text{ h}$	1,000-1,500	1,540	1,210	1,320
$^{51}\text{Fe}$ 12, min	60-110	92	-	60
Utilization of $^{51}\text{Fe}$ for red cell production, %	75-95	81	-	95
Haemoglobin synthesis, g/day	1.3-2.5	2.9	-	1.4
$^{51}\text{Cr}$ 12, days	25-35	22.0	22.8	19.0

Morphology of bone marrow and  $^{59}\text{Fe}$  and  $^{51}\text{Cr}$  surface counting over sacrum, liver and spleen were normal

Table III RSP metabolism in 10 subjects from the 3 families included previously (A1116 B117 C118)

Subjects	Diagnosis	'True' retention at 45 min, %	Transfer rates, mg/mg/min		
			A	B	C
A116	$\beta$	2.76	0.1228	0.0576	0.0070
A115	$\beta$	4.30	0.0901	0.0335	0.0091
A1116	$\beta + G$	2.67	0.1046	0.0284	0.0050
B12	G	3.71	0.0920	0.0407	0.0010
B13	$\beta$	2.60	0.1420	0.0536	0.0078
B116	$\beta$	1.87	0.1444	0.0570	0.0060
B117	$\beta + G$	1.84	0.1027	0.0166	0.0027
C13	$\beta$	2.70	0.1300	0.0530	0.0050
C14	G	2.60	0.0940	0.0242	0.0116
C118	$\beta + G$	0.58	0.1091	0.0343	0.0078
Normal values in 25 healthy subjects	$\left\{ \begin{array}{l} \text{Fem} \\ \text{M} \end{array} \right. \begin{array}{l} 0.00 \\ 2.00 \end{array}$		0.1196	0.0493	0.0002
			0.2045	0.1552	0.0135

$\beta = \beta$  Thalassaemia; G = Gilbert's syndrome






Fig 2 Effect of 24 h reduced caloric intake on SUB in 3 subjects with  $\beta$ -th-t and hyperbilirubinaemia (●) in 3 relatives with hyperbilirubinaemia (○) and in 2 relatives with normal bilirubinaemia (□)

abnormalities. The RBC  $^{51}\text{Cr}$   $t/2$  was only moderately reduced. Surface counting ( $^{55}\text{Fe}$ ,  $^{51}\text{Cr}$ ) was normal.

BSP kinetics in 10 subjects (table III) showed that 'a' transfer from plasma to liver, 'h' transfer from liver to bile, and 'b' transfer from liver back to plasma were within normal range in subjects with  $\beta$ -th-t and normal SUB. The transfers 'a' and 'h' were reduced below the upper limits of normal in subjects with raised SUB, regardless of the presence of  $\beta$ -th-t (AII5, AIII6, BI2, BII7, CI4 and CII8).

The reduced caloric intake tests (fig 2) indicated an increase between 90 and 133% in subjects, and 3 relatives with raised SUB only, and it gave normal results in 2 other relatives with normal SUB.

### Discussion

After having diagnosed  $\beta$ -th-t in the subjects, investigations on their unconjugated hyperbilirubinaemia were made. Extensive studies on liver function and liver biopsy gave normal results. POWELL *et al* [13] established that in subjects with normal liver function, only an RBC  $^{51}\text{Cr}$   $t/2$  reduced below 15 days can cause hyperbilirubinaemia. In our cases the  $^{51}\text{Cr}$   $t/2$  was 22.0, 22.8 and 19 days, respectively. Haemolysis as a possible cause of raised SUB was discarded. Dyserythropoietic abnormalities were searched for. Anaemia was absent, morphology of bone marrow was






Fig 2 Effect of 24 h reduced caloric intake on SUB in 3 propositi with  $\beta$ -th-t and hyperbilirubinaemia (●), in 3 relatives with hyperbilirubinaemia (○) and in 2 relatives with normal bilirubinaemia (□)

abnormalities. The RBC  $^{51}\text{Cr}$   $t/2$  was only moderately reduced. Surface counting ( $^{59}\text{Fe}$ ,  $^{51}\text{Cr}$ ) was normal.

BSP kinetics in 10 subjects (table III) showed that 'a' transfer from plasma to liver, 'h' transfer from liver to bile, and 'b' transfer from liver back to plasma were within normal range in subjects with  $\beta$ -th-t and normal SUB. The transfers 'a' and 'h' were reduced below the upper limits of normal in subjects with raised SUB, regardless of the presence of  $\beta$ -th-t (AII5, AIII6, BI2, BII7, CI4 and CII8).

The reduced caloric intake tests (fig 2) indicated an increase between 90 and 133% in propositi, and 3 relatives with raised SUB only, and it gave normal results in 2 other relatives with normal SUB.

### Discussion

After having diagnosed  $\beta$ -th-t in the propositi, investigations on their unconjugated hyperbilirubinaemia were made. Extensive studies on liver function and liver biopsy gave normal results. POWELL *et al* [13] established that in subjects with normal liver function, only an RBC  $^{51}\text{Cr}$   $t/2$  reduced below 15 days can cause hyperbilirubinaemia. In our cases the  $^{51}\text{Cr}$   $t/2$  was 22.0, 22.8 and 19 days, respectively. Haemolysis as a possible cause of raised SUB was discarded. Dyserythropoietic abnormalities were searched for. Anaemia was absent, morphology of bone marrow was

normal and ferrokinetics showed no abnormalities. Iron metabolism was also normal.

As expected in each family  $\beta$  th t was present in one of the parents and also in some of the relatives. However the parent without  $\beta$  th t and some other relatives had chronic unconjugated hyperbilirubinaemia. In all relatives liver function was normal. They had then a familial chronic benign unconjugated hyperbilirubinaemia without overt signs of haemolysis and with normal liver function. The BSP clearance revealed some reductions in a (liver uptake) and b (excretion into bile) dye transfer rates like in Gilbert's syndrome [3]. Moreover in the proposti and in 3 of their relatives with raised SUB the reduced caloric intake tests [10] indicated the presence of Gilbert's hyperbilirubinaemia. In conclusion the hyperbilirubinaemia in the 3 families must be ascribed to Gilbert's syndrome. Consequently the 3 young proposti suffering from  $\beta$  th t also had Gilbert's syndrome.

We suggest that in  $\beta$  th t raised SUB must not automatically be considered as an obvious finding. Only after having excluded liver disease, haemolysis and dyserythropoiesis should Gilbert's syndrome be searched for.

### References

- 1 BARBER RUBY G, GUTZLER A I and RICHARDS T G. The transfer of bromine phosphatide from plasma to bile in man. *Clin Sci* 30: 147 (1961).
- 2 CARAWAY W T. Micro and macro methods for the determination of serum iron and iron binding capacity. *Clin Chem* 9: 189 (1963).
- 3 CARTER G, BARBER T, MANIENI DRU A, CHIMSI T, CAZZAVILLAN M and DIETI I. Red blood cell survival, bromine phosphatide retention and hyperbilirubinaemia in Gilbert's syndrome. (*Abstr. conf. publ. a on* 1974).
- 4 CARTER G, CAZZAVILLAN M, CHIMSI T, BARBER T, MANIENI DRU A e DIETI I. L'iperbilirubinaemia nella  $\beta$  talassaemia eterozigote (tra i nella sfereocitoma ereditaria e nella sindrome di Gilbert). Studio della morfologia eritrocitaria e della clearance della BSP. *At. Giovi Sud. Med. Toxicol.* (in press, 1973).
- 5 DUBOIS G, FICHI A, INVERNIZZI A, CARTER G e CAVALIERE G. Osservazioni sulle tecniche impiegate per la determinazione del ferro sierico nel corso del test da Desferrioxamine. *Quad. Sclav. Diagn.* 2: 347 (1966).
- 6 FARIZZI F, VENTURA S, MATTEOLI G e CATTI F. Contributo alla conoscenza dell'anemia da anemia. Ricerche condotte con l'aiuto del *WBC Haema*. *Ing.* ca 21: 517 (1966).
- 7 MILLMAN R, RICHARDS I H, CATTI F and RICHARDS D. Serum iron, albumin,  $\beta$  globulin and  $\beta$  globulin synthesis in haemolytic anaemia. *N. Engl. J. Med.* 2: 1 (1961).

- 8 MALLOY, H T and EVELYN K A The determination of bilirubin with the photoelectric colorimeter *J biol Chem* 119 481 (1936)
- 9 MARENGO ROWE, A J Rapid electrophoresis and quantitation haemoglobins on cellulose acetate *J clin Path* 18 790 (1965)
- 10 OWENS, D and SHERLOCK, S Diagnosis of Gilbert's syndrome role of reduced caloric intake test *Brit med J* *in* 559 (1973)
- 11 POLLYCOVE, M and MORTIMER R The quantitative determination of iron kinetics and haemoglobin synthesis in human subjects *J clin Invest* 40 753 (1961)
- 12 PEARSON, H A, MCFARLAND, W., and KING, E R Entokinetic studies in thalassaemia trait *J Lab clin Med* 56 866 (1960)
- 13 POWELL, L W, BILLING, B H, and WILLIAMS, H S An assessment of red cell survival in idiopathic unconjugated hyperbilirubinaemia (Gilbert's syndrome) by the use of radioactive disopropylfluorophosphate and chromium *Austr Ann Med* 16 221 (1967)
- 14 SINGER, K, CHERNOFF, A J, and SINGER, L Studies on abnormal haemoglobins, their demonstration in sickle cell anaemia and other haematologic disorders by means of alkali denaturation *Blood* 6 413 (1951)
- 15 International Committee for the Standardization in Haematology Recommended methods for radioisotope red cell survival studies *Blood* 38 378 (1971)

## Mikrokaryoblastenschub bei chronischer Myelose

II HULTZ und S. ASCHER

Lehrstuhl für Innere Medizin (Hämatologie) (Korrespondenz: Prof. R. Marx) und  
II Medizinische Klinik (Leiter: Prof. F. Buchtemann) Universität München, München

**Abstract** After a 4 years course a granulocytic leukemia terminated as a microkaryoblastic leukemia. Morphology and cytochemistry of the microkaryoblasts are described.

**Key Words**  
Granulocytic leukemia  
Megakaryocytic leukemia  
Microkaryoblast  
Myeloproliferative disorders

In der Literatur wurden bisher nur wenige Fälle primärer megakaryoblastärer Myelosen mitgeteilt [7, 8, 10]. Dennoch wird eine Mitbeteiligung der megakaryoblastären Zellreihe bei myeloproliferativen Erkrankungen häufig gesehen [6]. So finden sich bei der Mehrzahl der Patienten mit chronischer Myelose im Knochenmark kleinere Megakaryozytenformen vereinzelt sogar «Mikrokaryozyten» [1, 9]. Es wurde diskutiert, dass es sich bei diesen atypischen Zellformen um einen «Rückgriff in der Phylogenese» handeln könne [18]. Die Diagnose derartiger «Mikrokaryoblasten» kann erhebliche Schwierigkeiten bereiten und nur mit Hilfe zytochemischer und elektronenmikroskopischer Methoden gelingen. Wir berichten deshalb über einen terminalen Mikrokaryoblastenschub bei chronischer Myelose.

### Methodik

Leukozyten, Thrombozyten sowie granulocytäre und thrombozytäre Vorläufer wurden aus dem peripheren Venenblut gewonnen und für die elektronenmikroskopische Untersuchung präpariert [11]. Für zytochemische Untersuchungen wurden die Ausstriche von Blut und Knochenmark durchgefärbt sowie auf alkalische Phosphatase [12, 13], Peroxydase [14] und bei NAD(P) reaktive Enzyme [14]

- 8 MALLOY H T and EVELYN K A The determination of bilirubin with the photoelectric colorimeter *J biol Chem* 119 481 (1936)
- 9 MARENGO ROWE A J Rapid electrophoresis and quantitation haemoglobins on cellulose acetate *J clin Path* 18 790 (1965)
- 10 OWENS D and SHERLOCK S Diagnosis of Gilbert's syndrome role of reduced caloric intake test *Brit med J* *iii* 559 (1973)
- 11 POLLYCOVE M and MORTIMER R The quantitative determination of iron kinetics and haemoglobin synthesis in human subjects *J clin Invest* 40 753 (1961)
- 12 PEARSON H A, McFARLAND W and KINO H K Eritrokinetic studies in thalassaemia trait *J Lab clin Med* 56 866 (1960)
- 13 POWELL L W BILLING B H and WILLIAMS H S An assessment of red cell survival in idiopathic unconjugated hyperbilirubinaemia (Gilbert's syndrome) by the use of radioactive diisopropylfluorophosphate and chromium *Austr Ann Med* 16 221 (1967)
- 14 SINGER K CIERNOFF A I and SINGER L Studies on abnormal haemoglobins their demonstration in sickle cell anaemia and other hematologic disorders by means of alkali denaturation *Blood* 6 413 (1951)
- 15 International Committee for the Standardization in Haematology Recommended methods for radioisotope red cell survival studies *Blood* 38 378 (1971)

## Mikrokaryoblastenschub bei chronischer Myelose

D. HUTH und S. ASCHER

Lehrstuhl für Innere Medizin (Hämatologie) (Korrespondenz: Prof. R. Marx) und  
II Medizinische Klinik (Leiter: Prof. F. Buchnow) Universität München, München

**Abstract** After a 4 years' course a granulocytic leukemia terminated as a 'microkaryoblastic leukemia'. Morphology and cytochemistry of the microkaryoblasts are described.

### Key Words

Granulocytic leukemia  
Megakaryocytic leukemia  
Microkaryoblast  
Myeloproliferative disorders

In der Literatur wurden bisher nur wenige Fälle primärer megakaryoblastärer Myelosen mitgeteilt [7, 8, 10]. Dennoch wird eine Mitbeteiligung der megakaryoblastären Zellreihe bei myeloproliferativen Erkrankungen häufig gesehen [6]. So finden sich bei der Mehrzahl der Patienten mit chronischer Myelose im Knochenmark kleinere Megakaryozytenformen vereinzelt sogar «Mikrokaryozyten» [1, 9]. Es wurde diskutiert, dass es sich bei diesen atypischen Zellformen um einen «Rückgriff in der Phylogenese» handeln könne [18]. Die Diagnose derartiger «Mikrokaryoblasten» kann erhebliche Schwierigkeiten bereiten und nur mit Hilfe cytochemischer und elektronenmikroskopischer Methoden gelingen. Wir berichten deshalb über einen terminalen Mikrokaryoblastenschub bei chronischer Myelose.

### Methodik

Leukozyten, Thrombozyten sowie granulocytäre und thrombocytäre Vorläufer wurden aus heparinisiertem Venenblut gewonnen und für die elektronenmikroskopische Untersuchung präpariert [11]. Folgende cytochemische Untersuchungen wurden an Ausstrichen von Blut und Knochenmark durchgeführt: saure und alkalische Phosphatase [2, 13], Peroxidase [14], Naphthol ASD-CE-naphthyl-esterase [16].



Naphthol AS-Azetatesterase mit Hemmung durch NaF [12 17] Perjodsaure-Schiff Reagens [3]

### Kasuistik

Patient Erwin K. geb. 17.10.38. 1968 Diagnose einer chronischen myeloischen Leukämie: typisches Blutbild und Sternalpunktat, niedriger Index der alkalischen Leukozytenphosphatase, Philadelphia Chromosom (Dr. U. KRUG, Institut für Hämatologie, GSF München). Behandlung mit Myleran (mit kurzen Unterbrechungen) bis 1972. 1972 starke Grössenzunahme der Milz, vergrösserte Lymphknoten, Auftreten atypischer Megakaryozyten in Knochenmark und Blut (Tab. I). Thrombozyten 100 000/mm<sup>3</sup>. Philadelphia Chromosom bei erneuter Untersuchung weiterhin nachzuweisen. Die Erkrankung sprach auf Myleran nicht mehr an. Tod durch Verbluten aus einem Duodenalgeschwür. Bei der Autopsie wurden diffuse myeloische Infiltrate aus atypischen Vorstufen der thrombo- und granulozytären Zellreihe im untersuchten Knochenmark in Milz und Leber sowie in den vergrösserten Lymphknoten nachgewiesen.

### Morphologische Befunde

**Zytologie (1.2.1972)** Die atypischen Megakaryoblasten (Mikrokaryoblasten) in Blut und Knochenmark lagen oft herdförmig zusammen. Sie waren nur wenig grösser als Lymphozyten. Ihre Kerne waren meist nie

Tabelle 1 Kernhaltige Zellen (%) in Knochenmark und Blut 1968-1972

	1968		1970		1972	
	Knochen mark	Blut (Leuko 22 000/mm <sup>3</sup> )	Knochen mark	Blut (Leuko 46 000/mm <sup>3</sup> )	Knochen mark	Blut (Leuko 100 000/mm <sup>3</sup> )
Erythroblasten	12,5	—	6,5	—	26	7,5
Myeloblasten	3	1	1	2	2	8,5
Promyelozyten	7	5	5	13	3	7,5
(Meta-) Myelozyten	37	7	40	17	4	10
Stab- Segm.	37	69	44	58	18	21
Monozyten	1	5	—	5		3
Lymphozyten						
Plasmazellen	2	13	2,5	5	9	0,5
Mikro-						
Megakaryoblasten	0,5	—	1		38	42




Abb. 1, 2 Sternalmarkausstrich Mikrokaryoblasten mit runden oder nierenförmigen, exzentrisch gelegenen Kernen und scantem Zytoplasma (Pfeile). Etwas größere atypische Megakaryoblasten mit runden Kernen, lockerem Chromatin, ausgefranstem Zytoplasma (Doppelpfeile).

renförmig und exzentrisch gelegen, ihr Chromatin dicht, sie enthielten 0-1 Nukleolen. Das Zytoplasma erschien mittelblau und enthielt keine Granula. Die Zellgrenzen waren zum Teil unscharf. Gelegentlich waren die Zellen etwas größer, ihr Zytoplasma heller (Abb. 1, 2).

**Zytochemie** (12/1972): Die Mikrokaryoblasten zeigten keine Aktivität von Peroxydase, von Naphthol ASD-Chloracetatesterase oder von alkalischer Phosphatase. Sie wiesen eine starke Aktivität saurer Phosphatase auf. In besonders in der Kernbuchtschellig fleckig lokalisiert war Naphthol ASD-Acetatesterase war deutlich positiv und durch NaF nur teilweise hemmbar. Besonders auffällig war eine diffuse Anfärbbarkeit mit der PAS-Reaktion, alle Zellen waren diffus angefarbt, einige zusätzlich ausgeprägt granular.

Hundesee (Prof. H. BURKHARDT, I. Med. Klinik, Universität München)

Naphthol AS Azetatesterase, mit Hemmung durch NaF [12, 17], Perjodsäure Schiff Reagens [3]

### Kasuistik

Patient Erwin K., geb. 17.10.38. 1968 Diagnose einer chronischen myeloischen Leukämie: typisches Blutbild und Sternalpunktat, niedriger Index der alkalischen Leukozytenphosphatase, Philadelphia Chromosom (Dr. U. Kraus, Institut für Hamatologie, GSF München). Behandlung mit Myleran (mit kurzen Unterbrechungen) bis 1972. 1972 starke Grössenzunahme der Milz, vergrösserte Lymphknoten, Auftreten atypischer Megakaryozyten in Knochenmark und Blut (Tab. I), Thrombozyten 100 000/mm<sup>3</sup>, Philadelphia Chromosom bei erneuter Untersuchung weiterhin nachzuweisen. Die Erkrankung sprach auf Myleran nicht mehr an. Tod durch Verbluten aus einem Duodenalgeschwür. Bei der Autopsie wurden diffuse myeloische Infiltrate aus atypischen Vorstufen der thrombo- und granulozytären Zellreihe im untersuchten Knochenmark, in Milz und Leber sowie in den vergrösserten Lymphknoten nachgewiesen.

### Morphologische Befunde

**Zytologie** (1.2.1972) Die atypischen Megakaryoblasten (Mikro-karyoblasten) in Blut und Knochenmark lagen oft herdförmig zusammen. Sie waren nur wenig grösser als Lymphozyten. Ihre Kerne waren meist nie-

Tabelle 1 Kernhaltige Zellen (%) in Knochenmark und Blut 1968–1972

	1968		1970		1972	
	Knochen mark	Blut (Leuko 22 000/mm <sup>3</sup> )	Knochen mark	Blut (Leuko 46 000/mm <sup>3</sup> )	Knochen mark	Blut (Leuko 100 000/mm <sup>3</sup> )
Erythroblasten	12,5	—	6,5	—	26	7,5
Myeloblasten	3	1	1	2	2	8,5
Promyelozyten	7	5	5	13	3	7,5
(Meta-) Myelozyten	37	7	40	17	4	10
Stab-, Segm.	37	69	44	58	18	21
Monozyten	1	5	—	5	—	3
Lymphozyten,						
Plasmazellen	2	13	2,5	5	9	0,5
Mikro-,						
Megakaryoblasten	0,5	—	1	—	38	42




Abb. 1-2 Sternmarksausstrich. Mikrokaryoblasten mit runden oder nierenförmigen, exzentrisch gelegenen Kernen und schmalem Zytoplasmasaum (Pfeile). Etwas größere atypische Megakaryoblasten mit runden Kernen, lockerem Chromatin, saugelförmigem Zytoplasmasaum (Doppelpfeile).

renförmig und exzentrisch gelegen, ihr Chromatin dicht, sie enthielten 0-1 Nukleolen. Das Zytoplasma erschien mittelblau und enthielt keine Granula. Die Zellgrenzen waren zum Teil unscharf. Gelegentlich waren die Zellen etwas größer, ihr Zytoplasma heller (Abb. 1, 2).

**Zytochemie** (12.1972). Die Mikrokaryoblasten zeigten keine Aktivität von Peroxidase, von Naphthol-ASD-Chlorazetatesesterase oder von alkalischer Phosphatase. Sie wiesen eine starke Aktivität saurer Phosphatase auf, die besonders in der Kernbucht schollig fleckig lokalisiert war. Naphthol-AS-Azetatesesterase war deutlich positiv und durch NaF nur teilweise hemmbar. Besonders auffällig war eine bläuliche Anfärbbarkeit mit der PAS-Reaktion; alle Zellen waren diffus angefärbt, einige zusätzlich ausgeprägt granular.

Hist. Serie (Prof. R. BURKHARDT, I. Med. Klin. Universität Mar-




Abb 3 Mikrokaryoblast (entsprechend den mit Pfeilen gekennzeichneten Zellen der Abbildungen 1 und 2) N eiförmiger Kern mit 2 Nukleolen (NL). Die Zellmembran bildet mikrovilliartige Ausstülpungen. Im Zytoplasma zahlreiche Mitochondrien, zum Teil mit Ausstülpungen der Cristae oder Myelinfiguren (M), kleine Zytosomen (Z), kurze Ergastoplasmaschläuche, zahlreiche freie Ribosomen, Zentrosom (Z) in der Zellperipherie, Vakuolen.  $\times 11\,000$

Abb 4 Weiter differenzierter Megakaryoblast, entsprechend den mit Doppelpfeilen markierten Zellen der Abbildungen 1 und 2. Im Zytoplasma zahlreiche kurze Ergastoplasmaschläuche und kleine Zytosomen, diffus verteilte Glykogenpartikel, links oben Bezirk mit kommunizierenden Vakuolen. NL = Nukleole.  $\times 11\,900$

Abb 5 Zelle ähnlich Abbildung 4, kommunizierendes Zisternensystem, das «prospektiven Thrombozytenfeldern» gleicht. N = Nukleus.  $\times 23\,000$



chen, 3 2 1972) Die histologische Untersuchung eines durch Myelotomie gewonnenen Knochenzylinders zeigte eine dichte Infiltration des Markparenchyms mit atypischen myeloischen Zellen und hochgradig atypischen Megakaryoblasten letztere zum Teil innerhalb der Sinuslumina Vermehrung von Retikulinfasern

*Elektronenmikroskopie* (1 2 1972) Die Mikrokaryoblasten sind rundlich, aber unregelmässig begrenzt (Abb 3, 4) Die Zellmembran bildet zahlreiche mikrovilliartige Fortsätze Die Kerne sind im Schnitt oval oder nierenförmig, sie enthalten 0-1-2 Nukleolen, das Chromatin ist gleichmässig verteilt ohne wesentliche Verdichtung entlang der Kernmembran, die Nukleolen zeigen zum Teil ausgeprägte Nukleolonemata, zum Teil sind sie von homogener Konsistenz Das Zytoplasma ist dicht Der Zelleib enthält sehr zahlreiche Mitochondrien, zum Teil mit Unregelmässigkeiten ihrer Cristae, zahlreiche kurze Ergastoplasmazisternen, freie Ribosomen und diffus (selten herdförmig) abgelagertes Glykogen Selten sind kleine Granula In der Zellperipherie finden sich häufig Vakuolen, die zu einem Zisternensystem konfluieren können, wie es sonst für die «prospektiven Trombozytenbezirke» reiferer Megakaryozyten typisch ist Paranuklear waren bei einigen Zellen Bündel etwa 150 Å starker Fibrillen zu beobachten

### *Diskussion*

Im vorliegenden Fall handelt es sich um eine reifzellige Myelose, die nach 4-jährigem Krankheitsverlauf das Bild einer megakaryoblastären Leukose mit Ausschwemmung kleiner, atypischer «Mikrokaryoblasten» ins periphere Blut bot Die primäre Diagnose der reifzelligen Myelose ist gesichert durch typisches Blutbild, Knochenmarkbefund, Milztumor, niedrige alkalische Leukozytenphosphatase und Nachweis des Philadelphia-Chromosoms

Die Diagnose eines «Mikrokaryoblastenschubs» einer chronischen Myelose ergab sich aus folgenden morphologischen Befunden Elektronenmikroskopisch boten die Mikrokaryoblasten das Bild einer wenig differenzierten Zelle (Kernstruktur, weitgehendes Fehlen der für Megakaryozyten kennzeichnenden Zellorganellen) Sie zeigten fließende Übergänge zu einer etwas grösseren Zelle, welche als Megakaryozytenvorstufe zu identifizieren war (einzelne kleine Granula, konfluierende Vakuolen, unregelmässige Zelloberfläche) Beide Zellarten waren kaum grösser als Lymphozyten (als welche sie auch zunächst im Blutaussstrich fehlgedeu-

tet wurden) Die zytochemischen Befunde stützen diese Annahme Die diffuse PAS-Positivität und die Naphthol AS-Azetatesterase Aktivität grenzen die Zellen von Lymphozyten ab Von Monozyten unterscheiden sie sich durch das vollständige Fehlen einer Peroxidaseaktivität (in der hier durchgeführten Methodik) und dadurch dass die Naphthol AS-Azetatesterase nicht vollständig durch NaF zu hemmen ist Gegen die Zugehörigkeit zur granulozytären Reihe sprechen das Fehlen von Peroxidase und Naphthol ASD-Chlorazetatesterase sowie die starke granulare PAS-Positivität einiger Zellen Lediglich bei verkürzter Glutaraldehydfixierung und längerer DAB Inkubation lässt sich in Thrombozytenvorstufen Peroxidaseaktivität nachweisen [4 5]

Die von uns beobachteten Mikrokaryoblasten zeigten Merkmale leukämischer Zellen hohe Kern Zytoplasma Relation und eine Diskrepanz im Differenzierungsgrad von Kern und Zytoplasma grosse Nukleolen Vermehrung und strukturelle Besonderheiten der Mitochondrien fibrillare Zytoplasmastrukturen [11] Eine Beteiligung der megakaryozytären Zellreihe am leukämischen Prozess ist daher auch nach diesen Befunden wahrscheinlich Die Berechtigung des von DAMESIEK geprägten Begriffs der «myeloproliferativen Störungen» wird an diesem Beispiel demonstriert

Bei niederen Wirbeltieren und die gerinnungsfördernden geformten Elemente des Blutes kernhaltige diploide Zellen Erst bei den Säugern kommt es zur polyploiden Entwicklung der Gerinnungszellen mit abschliessendem Zerfall des Zytoplasmas zu kernlosen «Thrombozyten» [15] Es wird daher diskutiert dass es sich bei den Mikrokaryozyten welche gelegentlich bei hämatologischen Erkrankungen des Menschen zu beobachten sind um einen «Rückgriff in der Phylogenese» handeln könnte [16]

### Zusammenfassung

Nach 4 jährigem Krankheitsverlauf endete eine chronische Myelose mit einem «Mikrokaryoblastenwucher» Morphologie und Zytochemie der Mikrokaryoblasten werden beschrieben

### Literatur

- 1 ALBRECHT M und EISEN H Morphologie der Megakaryozyten bei Büttrich-Leukämie Blut 24 1072 (1974)
- 2 BAKER T und ANDERSON H J Histochemical methods for acid phosphatase using benzene as para-substituent J Histochem Cytochem 10 741 (1961)



- 3 BARAK T and ANDERSON P J Histochemistry Theory practice and bibliography (Harper & Row New York 1965)
- 4 BRETON GORIUS J DREYFUS H SULTAN C BASCH A and D OLIVEIRA J D Identificat on of circulating micromegakaryocytes in a case of refractory an emia an electron microscopic-cytochemical study Blood 40 453 (1972)
- 5 BRETON GORIUS J DANIEL M T FLANDRIN G and DENOEL G K Fine structure and peroxidase activity of circulating micromegakaryoblasts and plate lets in a case of acute myelofibrosis Brit J Haemat 25 331 (1973)
- 6 BURKHARDT R PABST W und KLEBER A Knochenmark Histologie und Klinik der Polycythemia vera Arch Klin Med 216 64 (1969)
- 7 CHAN H W H FLEMANS R J and ZBRINDEN G Acute leukemia with megakaryocytic predominance Cancer 28 1343 (1971)
- 8 DEMMLER K BURKHARDT R und PRICHTER K Megakaryoblastische Myelose Klin Wschr 49 1168 (1970)
- 9 FRANZ M S STREYER G and ZAJICEK J Mikroplanimetrie studies on megakaryocytes in chronic granulocytic leucaemia and polycythaemia vera Acta haemat Basel 26 182 (1961)
- 10 HELMELER G Leucémie mégakaryocytaire avec thrombocytothémie Schweiz med Wschr 78 976 (1948)
- 11 HUTIN D und SCHMALZL F Licht und elektronenmikroskopische Cytochemie der unreif zelligen Leukämien Klin Wschr 50 423 (1972)
- 12 LÖFFLER H Zytochemischer Nachweis von unspezifischer Esterase in Ausstrichen Beiträge zur Technik und Ergebnisse im Blutausstrich des Menschen Klin Wschr 39 1220 (1961)
- 13 MERKER H und HERMELYER L Die alkalische Phosphatase neutrophiler Leukozyten Dtsch med Wschr 85 253 (1960)
- 14 MOLONEY W C McPIERSON K and FLIEGELMAN L Esterase activity in leukocytes demonstrated by use of naphthol AS-D chloracetate substrate J Histochem Cytochem 8 200 (1960)
- 15 ODELL T T jr and JACKSON C W Megakaryocytopoies is in STOHLMAN Symposium on hemopoietic cellular proliferation Boston Mass 1969 (Grune & Stratton New York 1970)
- 16 SCHAEFER H E und FISCHER R Der Peroxydase nachweis an Ausstrichpräparaten sowie an Gewebsschnitten nach Entkalkung und Paraffineinbettung Klin Wschr 46 1228 (1968)
- 17 SCHMALZL F and BRAUNSTEINER H On the origin of monocytes Acta haemat Basel 39 177 (1968)
- 18 UNDRITZ E und NUSSLI BOHAUMILITZKY K Über das Auftreten von diploiden Megakaryoblasten Promegakaryozyten und Megakaryozyten bei schweren Hamopathien ein Rückgriff in die Phylogenese Blut 20 242 (1970)

M. BRAUER, R. F. WEISS and E. F. LINTON (eds.) Red Cell Shape: Physiology, Pathology, Ultrastructure. Springer, Berlin 1973. VIII + 180 pp., 147 fig., DM 32.40 US\$ 12.00 ISBN 3-540-07257-2.

Es handelt sich um einen ausführlichen Bericht von einem 1972 abgehaltenen Symposium über Erythrozyten mit dem Schwerpunkt auf ihrer Struktur und Form unter normalen und pathologischen Umständen. Die ausführlichsten Beiträge mit ausgezeichneten Abbildungen findet man im Sektor der Scanning Elektronenmikroskopie. Mit dieser Technik gelingt es dreidimensional strukturelle Veränderungen der Erythrozyten zu erkennen. Aufgrund dieser neuen morphologischen Erkenntnisse wird eine Reklassifizierung der pathologischen Erythrozytenformen vorgeschlagen.

Im zweiten Teil wird auf biochemische Faktoren eingegangen, die eine Veränderung der Erythrozytenform bewirken können. Plasmafaktoren und zelluläre Faktoren (unter anderem Alterung) werden ausführlich diskutiert.

Der dritte Teil ist hauptsächlich biophysischen Messungen, der Deformierbarkeit verschiedener Zelltypen und der Zellmembran gewidmet. Der letzte Teil setzt sich vor allem mit der Ultrastruktur von Siebelszellen, Inkernkörper enthaltender Zellen sowie von Zellen, die durch Antikörper und Komplement beschädigt und auseinander

Das Buch gibt neue Einblicke in die Ultrastruktur, Physiologie und Pathologie der Erythrozyten und ist eine wertvolle Erweiterung der bisherigen Literatur in diesem Sektor.

B. STRICK, Basel

uation of labelled cells in the blood has several advantages for eventually harmful cell separations prior to or during the labelling procedure, (2) no use of an unphysiological labile elution of label from the lymphocytes, and (3) evaluation on a physiological level. On the other hand the method of autotransfusion of labelled lymphocytes as proposed originally [5-7] has the problem of utilisation of primarily not RNA bound label. The control of this source of error is the subject of this paper.

### *Patients and Methods*

**Tritiated cytidine labelling** was performed in 11 patients with leukemia (cases A-L). 2 patients with solid tumours (cases M and N) and 1 patient with mycosis fungoides (case S). Cases A and B were patients in stage IV B of E. pretreated with chemo- and radiotherapy. The pertinent data of these cases are reported in a second paper [13].

**Cell labelling and autotransfusion.** About 500 ml venous blood was drawn into a transfusion bag (Fenwal Transfer Pack TA-4 Travenol, Inc., Becton Dickinson, being prevented by 75 ml ACD, formula A or - in patient L. H. F. (preservative free heparin, Hoffmann La Roche Grenzach). After addition of tritiated cytidine (specific activity 2.1-4.0 Ci/mmole Radiochemical Centre, Amersham) in case L, 1 mCi in all other cases) the blood was incubated for 1-1.5 h. In case L most of the unbound radioactivity (about 85%) was eluted from the cells. In all cases (including case L) after incubation the supernatant was removed. The cytidine was diluted approximately 1 000 fold by addition of 100 ml of saline. After that the labelled blood was autotransfused intravenously at a pressure of 100 mm Hg.

**Timing of blood sampling.** During autotransfusion two samples were drawn from the bag in order to determine the primary labelling of the red cells. Within the 1st h after the end of autotransfusion six blood samples were drawn from a contralateral brachial vein of the patient, up to the 24th h further up to the 5th day four samples daily and later 1-2 samples daily.

**Preparation of the samples and autoradiography.** From each blood sample a WBC count was determined, normal blood smears and smears of leucocytes (after sedimentation of the red cells with EDTA gelatin solution of the leucocyte rich plasma supernatant) were performed. The cells were fixed for 30 min with three times changed 100% methanol and then exposed to autoradiography using Kodak AR 10 stripping film. Long exposure times (mean 240) days were necessary to reach sufficient high labelling of the lymphocytes (mean 9 grains/cell in about 85% of the incubated small lymphocytes). For the autoradiographs were stained with 2% Giemsa solution and then mounted.

**Evaluation.** In the blood smears the lymphocyte proportion was determined. Using this value and the WBC count the lymphocyte

# Autotransfusion of $^3\text{H}$ -Cytidine-Labelled Blood Lymphocytes in Patients with Hodgkin's Disease and Non-Hodgkin Patients

## I. Limitations of the Method<sup>1</sup>

P. SCHUCK, F. TREPEL, E. LEHMANN, BROCKHAUS and H. NIETMANN

I Medical Division, Municipal Hospital München Schwabing, and  
Division of Clinical Physiology, University of Ulm, Ulm

**Key Words:** Autoradiography    Hodgkin's disease    Lymphocyte kinetics  
RNA metabolism

**Abstract:** Autotransfusion of  $^3\text{H}$ -cytidine labelled blood lymphocytes followed by autoradiographic evaluation as studied in 11 patients with Hodgkin's disease and 3 other patients seems to be an appropriate method to estimate migration kinetics and pool sizes of lymphocytes. However, it is complicated by two major pitfalls: (1) The free (extracellular) activity of  $^3\text{H}$ -cytidine transfused along with the cell bound label is sufficient to cause DNA labelling of newly produced lymphocytes in the body. (2) The soluble intracellular pool of  $^3\text{H}$  labelled compounds causes an increase of labelling intensity of lymphocyte RNA in the first hours after cell transfusion. Methods to correct for these sources of error are described.

There is no knowledge about intravascular behaviour of blood lymphocytes and the size of extravascular lymphocyte pools in Hodgkin's disease. The method of transfusion of  $^3\text{H}$ -cytidine-labelled autologous blood lymphocytes seems to be particularly suitable to provide quantitative estimations of exchangeable pools of lymphocytes, as has been demonstrated in patients with chronic lymphocytic leukaemia [2, 3, 5, 7, 9, 15].

Compared with the frequently applied method of autotransfusion of  $^3\text{H}$ -labelled lymphocytes and subsequent measurements of blood radioactivity, the autotransfusion of lymphocytes, labelled *in vitro* with the nucleic acid precursor  $^3\text{H}$ -cytidine and subsequent autoradiographic evaluation

<sup>1</sup> Supported by the Deutsche Forschungsgemeinschaft SFB 112.

## 9th Miles International Symposium

Cell Membrane Receptors for Viruses, Antigens and Antibodies,  
Polypeptide Hormones and Small Molecules  
The Johns Hopkins Medical Institutions  
Baltimore, Md, June 4-6, 1975

This symposium will address the identification and role of cellular receptor sites to a variety of biologically active entities, including viruses, antigens and antibodies, polypeptide hormones and small molecules. The participation of these interacting systems in immunological, endocrinological and pharmacological phenomena within the cells has become a subject of increasing interest and importance in biomedical research during the past ten years.

Symposium Chairman: ROLAND F. BEERS, Jr., MD, Ph.D., Miles Laboratories, Inc.

Program Committee Members: PURNELL W. CHOPPIN, MD, The Rockefeller University, MARTIN RODBELL, Ph.D., National Institutes of Health, MARTIN C. RAFF, Ph.D., University College, London, JESSE ROTH, MD, National Institutes of Health.

For further information, contact: EDWARD G. BASSETT, Ph.D., Symposium Coordinator, Miles Laboratories, Inc., Elkhart, IN 46514 (USA).

## Autotransfusion of <sup>3</sup>H-Cytidine-Labelled Blood Lymphocytes in Patients with Hodgkin's Disease and Non-Hodgkin Patients

### I. Limitations of the Method<sup>1</sup>

P. SCHICK, F. TREPEL, E. LEHMANN BROCKHAUS and H. NIETMANN

I. Medical Division Municipal Hospital, München-Schwabing, and  
Division of Clinical Physiology, University of Ulm Ulm

**Key Words:** Autoradiography · Hodgkin's disease · Lymphocyte kinetics  
RNA metabolism

**Abstract** Autotransfusion of <sup>3</sup>H-cytidine labelled blood lymphocytes followed by autoradiographic evaluation as studied in 11 patients with Hodgkin's disease and 3 other patients seems to be an appropriate method to estimate migration kinetics and pool sizes of lymphocytes. However, it is complicated by two major pitfalls (1) The free (extracellular) activity of <sup>3</sup>H-cytidine transfused along with the cell bound label is sufficient to cause DNA labelling of newly produced lymphocytes in the body (2) The soluble intracellular pool of <sup>3</sup>H labelled compounds causes an increase of labelling intensity of lymphocyte RNA in the first hours after cell transfusion. Methods to correct for these sources of error are described.

There is no knowledge about intravascular behaviour of blood lymphocytes and the size of extravascular lymphocyte pools in Hodgkin's disease. The method of transfusion of <sup>3</sup>H-cytidine-labelled autologous blood lymphocytes seems to be particularly suitable to provide quantitative estimations of exchangeable pools of lymphocytes, as has been demonstrated in patients with chronic lymphocytic leukaemia [2, 3, 5, 7, 9, 15].

Compared with the frequently applied method of autotransfusion of <sup>51</sup>Cr-labelled lymphocytes and subsequent measurements of blood radioactivity, the autotransfusion of lymphocytes, labelled *in vitro* with the nucleic acid precursor <sup>3</sup>H-cytidine, and subsequent autoradiographic eval-

<sup>1</sup> Supported by the 'Deutsche Forschungsgemeinschaft', SFB 112.

uation of labelled cells in the blood has several advantages (1) no need for eventually harmful cell separations prior to or immediately after the labelling procedure, (2) no use of an unphysiological label, (3) controllable elution of label from the lymphocytes, and (4) evaluation on the cytological level. On the other hand the method of autotransfusion of  $^3\text{H}$ -cytidine labelled lymphocytes as proposed originally [5, 7] introduces the problem of utilisation of primarily not RNA-bound label after transfusion. The control of this source of error is the subject of this study.

### *Patients and Methods*

Tritiated cytidine labelling was performed in 11 patients with Hodgkin's disease (cases A-L), 2 patients with solid tumours (cases M and N) and 1 patient with scleroderma (case S). Cases A and B were patients in stage IV-B of Hodgkin's disease pretreated with chemo- and radiotherapy. The pertinent data of the other patients are reported in a second paper [13].

*Cell labelling and autotransfusion.* About 500 ml venous blood were collected in a transfusion bag (Fenwal Transfer Pack TA-4, Travenol, Munich) coagulation being prevented by 75 ml ACD formula A or - in patient L - by 2,500 IU heparin (preservative free heparin, Hoffmann-La Roche, Grenzach). After addition of  $^3\text{H}$ -cytidine (specific activity 21-40 Ci/mmol, Radiochemical Centre, Amersham) (2 mCi in case L, 1 mCi in all other cases) the blood was incubated for 1-3 h at 37 °C. Only in case L most of the unbound radioactivity (about 85%) was eliminated by washing the cells. In all cases (including case L) after incubation the specific activity of hot cytidine was diluted approximately 1000-fold by addition of 100 mg cold cytidine. After that the labelled blood was autotransfused intravenously within 8-11 min using a pressure of 100 mm Hg.

*Timing of blood sampling.* During autotransfusion two samples were taken from the bag in order to determine the primary labelling of the infused lymphocytes. Within the 1st h after the end of autotransfusion six blood samples were taken from a contralateral brachial vein of the patient up to the 24th h, further ten samples up to the 5th day, four samples daily and later 1-2 samples daily.

*Preparation of the samples and autoradiography.* From each blood sample the WBC count was determined, normal blood smears and smears of leukocyte concentrates (after sedimentation of the red cells with EDTA gelatine and centrifugation of the leukocyte rich plasma supernatant) were performed. The leukocyte smears were fixed for 30 min with three times changed 100% methanol and processed for autoradiography using Kodak AR 10 stripping film. Long exposure times of 81-349 (mean 240) days were necessary to reach sufficient high labelling intensities of more than 9 grains/cell in about 85% of the incubated small lymphocytes. After development the autoradiographs were stained with 2% Giemsa solution at pH 5.7.

*Evaluation.* In the blood smears the lymphocyte proportion of the leukocytes was determined. Using this value and the WBC count the lymphocyte number per

microlitre blood was calculated. In the autoradiographs of the leukocyte concentrates 4 000 small lymphocytes (nuclear diameter below  $8.5 \mu\text{m}$ ) were evaluated recording the number of silver grains over nucleus and cytoplasm of each cell. The autoradiographic background of  $^3\text{H}$  free smears was below 2 grains/cell in 90% of the lymphocytes and did not exceed 9 grains/cell in any case. Thus, in the experimental preparations, lymphocytes with more than 9 grains/cell were considered to be labelled.


### Results and Discussion

**First survey.** The behaviour of labelled lymphocytes in the blood after autotransfusion is shown in the Hodgkin patients and non-Hodgkin patients (fig. 1). In each of these patients the labelling index (LI) decreases quickly within the 1st h, and then stabilizes transiently at a very low level. After 4 h it begins to increase, reaching a first maximum after about 24 h and, interrupted by new decreases, further maxima at about 48 and 72 h. During this period the curves of labelling intensity of the lymphocytes are nearly the reverse showing maxima at times when the LI are minimal. Case L, who received an autotransfusion of washed labelled cells, shows initially a similar, but from 4 h onward a completely different labelling pattern (fig. 2). The LI of lymphocytes, after a short rise from the 4th to the 12th h, decreases by the 24th h and thereafter shows only minor oscillations. The labelling intensity increases during the first 6 h and then declines slowly until it reaches again the initial value at day 5.

Since the labelling curves after transfusion of unwashed cells were similar in both groups, Hodgkin and non-Hodgkin patients, the wavelike pattern cannot be interpreted as a Hodgkin's disease specific phenomenon. As in case L, after transfusion of washed cells, the 24-hour periodicity of the LI is lacking and the labelling intensity in the first days exceeds the starting value, it is probable that in the other cases the 'free' activity of  $^3\text{H}$ -cytidine infused along with the cell bound activity was sufficient to cause an autoradiographically detectable additional *in vivo* labelling of lymphocytes. This possibility was checked in a further experiment.

**In vivo utilization of  $^3\text{H}$ -cytidine.** After 1-3 h of incubation less than 5% of the activity is incorporated in cells [unpublished data, 15] so that in our experiments more than 0.95 mCi 'free' activity are infused into the patient. In order to test the effect of the 1,000-fold dilution of the specific activity of the free  $^3\text{H}$ -cytidine case A received two infusions of 1 mCi  $^3\text{H}$ -cytidine of 9 min duration with an interval of 4 days. The specific activity of the first infusion of  $^3\text{H}$ -cytidine was 2.5 Ci/mmol and that of the





**Fig 1** LI and labelling intensity of small lymphocytes after autotransfusion *A* LI in the non Hodgkin patients (values of cases M and N are pooled) *B* LI of the Hodgkin patients C-F (1 h incubation of lymphocytes with  $^3\text{H}$ -cytidine) and G-K (3 h incubation) *C* Labelling intensity (all values expressed in percent of the mean labelling intensity at the time of autotransfusion) in the non Hodgkin patients *D* Labelling intensity in the Hodgkin patients

second infusion – by addition of 100 mg 'cold' cytidine – only 0.0025 Ci/mm. Blood samples were taken from the patient at similar times as in the other cases after autotransfusions. Part of the cell concentrate smears was extracted with 10% perchloric acid (PCA) for 36 h at 4 °C in order to remove macromolecular RNA from the cells [1]. Extracted and non-extracted preparations were autoradiographed together and exposed for




Fig 2 Case L. LI and labelling intensity of small lymphocytes.




Fig 3 Case A. LI of small lymphocytes following a first and a second injection of  $^3\text{H}$ -cytidine of different specific activity (first 2.5 Ci/mm second 0.0925 Ci/mm). Presentation of the LI curves using different grain count thresholds.

300 days. Figure 3 shows that small lymphocytes, labelled with more than 9 grains are found in the blood from the 4th h onward and increase to a maximum of  $10.4\%$  24 h after the first injection of  $^3\text{H}$ -cytidine. Some of these small lymphocytes were labelled with up to 55 grains. After the second injection the LI increased again until the 24th h and reached, corrected for the rest labelling remaining from the first injection,  $9.3\%$ . The highest labelling intensity in some cells was 42 grains. After RNA extraction similar labelling curves with only slightly lower values resulted: maximal LI  $8.9\%$  or  $8\%$ , respectively, and maximal labelling intensity 40 or 30




Fig 4 Case III LI of small lymphocytes following an injection of  $^3\text{H}$  cytidine (left, specific activity, 0.0025 Ci/mM) and after autotransfusion of blood labelled with  $^3\text{H}$  cytidine *in vitro* (right)

grains, respectively. These findings show (1) that the *in vivo* injection of 1 mCi of  $^3\text{H}$ -cytidine in man causes the labelling of a considerable proportion of small lymphocytes when long autoradiographic exposure times necessary for the autotransfusion studies are used, (2) that drastic dilution of the specific activity of  $^3\text{H}$ -cytidine by the factor of 1,000 does not prevent such *in vivo* labelling of lymphocytes, and (3) that most small lymphocytes labelled *in vivo* by  $^3\text{H}$ -cytidine are not labelled in their RNA (in contrast to *in vitro* labelling with  $^3\text{H}$ -cytidine) but rather in other macromolecules, not extracted by PCA under these conditions, presumably in DNA. This would mean that all labelled small lymphocytes in the PCA preparations are newly produced descendants from proliferating lymphoid cells which have actively incorporated  $^3\text{H}$ -cytidine in their DNA. The last interpretation is supported by observations in Hodgkin patients given a pulse injection of  $^3\text{H}$ -thymidine [12] and showing a similar appearance and percentage of labelled small lymphocytes as after  $^3\text{H}$ -cytidine injection described here.

An additional experiment should test whether all 'free' activity in the preincubated autotransfused blood can be utilized *in vivo* like free  $^3\text{H}$ -cytidine. For this purpose case B received firstly an infusion of 1 mCi  $^3\text{H}$ -cytidine with the low specific activity of 0.0025 Ci/mM and secondly, 6 days later, a usual autotransfusion of  $^3\text{H}$  cytidine-labelled unwashed cells. The maximal LI of small lymphocytes of 3.3% in the circulating blood






Fig 4 Case II LI of small lymphocytes following an injection of  $^3\text{H}$  cytidine (left specific activity 00025 Ci/mm) and after autotransfusion of blood labelled with  $^3\text{H}$  cyt d ne *in vitro* (right)

grains respectively. These findings show (1) that the injection of 1 mCi of  $^3\text{H}$  cytidine in man causes the labelling of a considerable portion of small lymphocytes when long autoradiographic exposure is necessary for the autotransfusion studies are used, (2) that drastic dilution of the specific activity of  $^3\text{H}$ -cytidine by the factor of 1,000 does not prevent such *in vivo* labelling of lymphocytes and (3) that most small lymphocytes labelled *in vivo* by  $^3\text{H}$ -cytidine are not labelled in their chromomolecules (contrast to *in vitro* labelling with  $^3\text{H}$ -cytidine) but rather in chromomolecules not extracted by PCA under these conditions in DNA. This would mean that all labelled small lymphocytes in preparations are newly produced descendants from proliferating cells which have actively incorporated  $^3\text{H}$  cytidine in their DNA. This interpretation is supported by observations in Hodgkin lymphoma after pulse injection of  $^3\text{H}$  thymidine [12] and showing a similar percentage of labelled small lymphocytes as after autotransfusion described here.



Table I Patient B<sup>1</sup> Distribution of label during and after autotransfusion of <sup>3</sup>H-cytidine-labelled blood lymphocytes (ly)

Threshold of labelling intensity (grains)	LI of small ly in auto-transfused blood, %	Number of labelled small ly in autotransfused blood	LI in circulating blood, % <sup>2</sup>	Number of labelled small ly in circulating blood <sup>2</sup>	Recovery of labelled small ly in circulating blood % <sup>2</sup>
≥ 10	54.0	$2.5 \times 10^8$	2.36	$8.54 \times 10^7$	34.2
≥ 20	24.4	$1.13 \times 10^8$	0.76	$2.75 \times 10^7$	24.4
≥ 30	10.0	$0.46 \times 10^8$	0.16	$0.58 \times 10^7$	12.6
≥ 40	4.0	$0.19 \times 10^8$	0.09	$0.33 \times 10^7$	17.2

<sup>1</sup> Number of small lymphocytes/ $\mu$ l blood = 880, blood volume (estimated according to NADLER *et al.*, 10) = 4.13 l, number of circulating small lymphocytes =  $3.62 \times 10^8$ , number of autotransfused small lymphocytes =  $4.63 \times 10^8$

<sup>2</sup> Average of seven blood samples taken at different times between the 24th and 48th h after autotransfusion

*Analytical procedure for separation of autotransfused lymphocytes from labelled newly produced lymphocytes* In case II it is evident that a proportion of the autotransfused cells has a higher labelling intensity than the *in vivo* labelled newly produced small lymphocytes and that the limit is a grain count of about 30 (fig 4, table I). Since most newly produced lymphocytes are labelled with 10–20 grains, the true LI is most markedly falsified using a grain count threshold of 10 grains. The error is less with a threshold of 20 grains and is practically excluded with a threshold of 30 grains.

Under these conditions the 'recovery' (% recovered labelled cells after autotransfusion of labelled cells) in the circulating blood decreases step by step if the calculation of the recovery is based on increasing grain count thresholds (table I). The lowest recovery in patient II is to be expected at a labelling threshold of  $\geq 30$  grains. As this is the case, the described procedure to look for the grain count threshold that reduces the recovery to the lowest value seems to be suitable to eliminate the admixture of labelled newly produced small lymphocytes in all other patients too (fig 5). The labelling curves, corrected on the basis of higher grain count thresholds are shown in figure 6. They now differ essentially from figure 1, but no longer from the labelling pattern in case L who had received washed cells (fig 2).





Table I Patient B<sup>1</sup> Distribution of label during and after autotransfusion of <sup>3</sup>H-cytidine-labelled blood lymphocytes (ly)

Threshold of labelling intensity (grains)	LI of small ly in auto-transfused blood, %	Number of labelled small ly in autotrans-fused blood	LI in circulating blood, % <sup>2</sup>	Number of labelled small ly in circulating blood <sup>2</sup>	Recovery of labelled small ly in circulating blood % <sup>2</sup>
≥ 10	54.0	$2.5 \times 10^8$	2.36	$8.54 \times 10^7$	34.2
≥ 20	24.4	$1.13 \times 10^8$	0.76	$2.75 \times 10^7$	24.4
≥ 30	10.0	$0.46 \times 10^8$	0.16	$0.58 \times 10^7$	12.6
≥ 40	4.0	$0.19 \times 10^8$	0.09	$0.33 \times 10^7$	17.2

<sup>1</sup> Number of small lymphocytes/ $\mu$ l blood = 880, blood volume [estimated according to NADLER *et al.*, 10] = 4.13 l, number of circulating small lymphocytes =  $3.62 \times 10^9$ , number of autotransfused small lymphocytes =  $4.63 \times 10^8$

<sup>2</sup> Average of seven blood samples taken at different times between the 24th and 48th h after autotransfusion

*Analytical procedure for separation of autotransfused lymphocytes from labelled newly produced lymphocytes* In case II it is evident that a proportion of the autotransfused cells has a higher labelling intensity than the *in vivo* labelled newly produced small lymphocytes and that the limit is a grain count of about 30 (fig 4, table I). Since most newly produced lymphocytes are labelled with 10–20 grains, the true LI is most markedly falsified using a grain count threshold of 10 grains. The error is less with a threshold of 20 grains and is practically excluded with a threshold of 30 grains.

Under these conditions the 'recovery' (% recovered labelled cells after autotransfusion of labelled cells) in the circulating blood decreases step by step if the calculation of the recovery is based on increasing grain count thresholds (table I). The lowest recovery in patient II is to be expected at a labelling threshold of  $\geq 30$  grains. As this is the case, the described procedure to look for the grain count threshold that reduces the recovery to the lowest value seems to be suitable to eliminate the admixture of labelled newly produced small lymphocytes in all other patients too (fig 5). The labelling curves, corrected on the basis of higher grain count thresholds are shown in figure 6. They now differ essentially from figure 1, but no longer from the labelling pattern in case L who had received washed cells (fig 2).




Fig. 6. Labeling intensity of heavily labelled small lymphocytes in Hodgkin and non-Hodgkin patients (for details, see Figure 1).

*Changes of the labeling intensity of the in vivo labelled cells in vivo*  
 optimal periods for calculation of the recovery. After 1 h incubation of 500 ml blood with 1 mCi  $^3\text{H}$ -cytidine the leucocytes contain only 1 or 5% of the activity [unpublished data, 15] and about 90% of this intracellular activity belongs to the soluble pool [4, 14]. Since the soluble pool is removed from the cells by methanol fixation [6] the autoradiographic labelling reflects the activity bound in macromolecules of the cell. The labelling intensity of newly synthesized RNA, however, depends on the concentration of  $^3\text{H}$ -cytidine in the soluble pool. This pool exchanges only slowly with the extracellular fluid [5, 11] so that 2 h after the end of  $^3\text{H}$ -cytidine exposure of the lymphocytes their soluble pool retains about 1% of its original maximal activity [14]. Therefore it can be expected that the lymphocytes labelled in vivo do not reach their maximal RNA labelling not during the 1 or 3 h of incubation but only some hours later, as in our experiment some hours after autotransfusion. The increase of labelling intensity observed in most patients in the first hours after cell transfusion (fig. 1, 2,

Table 11 Patient L: Distribution of label during and after autotransfusion of  $^3\text{H}$ -cytine-labelled blood lymphocytes (ly)

Threshold of labelling intensity (grains)	LI of small ly in auto-transfused blood, %	Number of labelled small ly in autotransfused blood	LI in circulating blood, % <sup>a</sup>			Number of labelled small ly in circulating blood <sup>a</sup>			Recovery of labelled small ly in circulating blood, % <sup>a</sup>		
			5-30 min		20-48 h	5-7 days		20-48 h	5-30 min		5-7 days
			min	h	h	days	days	h	min	h	days
≥ 10	95.2	$9.19 \times 10^7$	0.54	0.38	0.23	0.23		$6.91 \times 10^6$	$4.86 \times 10^6$	$2.94 \times 10^6$	5.30 3.20
≥ 30	80.1	$7.73 \times 10^7$	0.44	0.33	0.19	0.19		$5.63 \times 10^6$	$4.22 \times 10^6$	$2.43 \times 10^6$	5.46 3.15
≥ 50	55.5	$5.36 \times 10^7$	0.31	0.28	0.14	0.14		$3.97 \times 10^6$	$3.58 \times 10^6$	$1.80 \times 10^6$	7.40 6.69 3.35
≥ 70	35.6	$3.44 \times 10^7$	0.21	0.23	0.09	0.09		$2.69 \times 10^6$	$2.94 \times 10^6$	$1.10 \times 10^6$	7.81 8.56 3.20
≥ 90	22.2	$2.14 \times 10^7$	0.13	0.17	0.05	0.05		$1.66 \times 10^6$	$2.18 \times 10^6$	$0.67 \times 10^6$	7.90 10.20 3.13

<sup>a</sup> Number of small lymphocytes/ $\mu\text{l}$  blood = 270, blood volume (estimated according to NADLER *et al.*, 10) =  $4.72 \text{ l}$ , number of circulating small lymphocytes  $1.28 \times 10^8$ , number of autotransfused small lymphocytes =  $9.65 \times 10^7$ .

<sup>b</sup> Intervals after autotransfusion. The decreasing concentration of labelled lymphocytes in the blood with time after autotransfusion will be discussed later [3].

6) can be explained by this phenomenon. It is likely that the prolonged increase of labelling intensity causes a shift of *in vitro* labelled cells from lower into higher grain count classes so that the distribution of the grain counts of the labelled cells *in vivo* differs from that evaluated in the autotransfused blood. Therefore the recovery is overestimated unless all infused small lymphocytes have been categorized as labelled. This overestimation should be low for instance in case L, where 95% of the transfused lymphocytes were labelled. If all labelled cells are considered, however, the labelling threshold is increased, the recovery values also increase as expected (table II). Also in the other patients, after elimination of lightly labelled cells representing mostly labelled, newly produced not transfused cells, the recovery values increase with increasing grain count thresholds (fig. 5). About 5 days after autotransfusion the labelling intensity reaches again the starting values in the autotransfused blood and in the first samples in the circulating blood (fig. 5, 6). Now the recovery values are no longer dependent upon the labelling threshold applied. Hence it is assumed that the course of the labelling intensity curve indicates the optimal times for calculation of the true recovery from the LI of the more heavily labelled lymphocytes.

### Conclusions

The LI of lymphocytes found in the circulating blood within the first 3 or 4 h after autotransfusion of  $^{3}\text{H}$ -cytidine labelled blood can provide information on circulation kinetics of the cells if most autotransfused cells are labelled. The further course of the LI curve is falsified by the appearance in the circulating blood of lightly labelled newly formed lymphocytes so that in this phase the behaviour of the labelled originally transfused lymphocytes can only be observed selecting the more heavily labelled cells. Since however, the labelling intensity of the *in vitro* labelled cells increases for some time following autotransfusion an overestimation of the recovery of transfused cells can only be avoided if the calculations are based on the LI of heavily labelled cells after the labelling intensity has returned to the initial values.

Only taking into account these limitations the method of analysing the recovery of autotransfused  $^{3}\text{H}$ -cytidine labelled lymphocytes is suitable to estimate kinetic parameters of the traffic of lymphocytes in patients with Hodgkin's disease and other non-leukemic patients [13].

*Acknowledgement* We wish to thank Miss M. MATZNER and Mr. M. EDER for diligent help in evaluation of the autoradiographs.

### References

1. BASERGA, R. and KISILEWSKI, W. E. Effects of histological and histochemical procedures on the intensity of the label in radioautographs of cells labeled with tritiated compounds. *Lab Invest* 12: 648 (1963).
2. BINET, J. L., VILLENEUVE, B.; BÉCART, R., LOGEAT, Y., LAUDAT, P. et MATHEY, J. Temps de passage dans le canal thoracique des lymphocytes du sang de la leucémie lymphoïde chronique. *Nouv. Revue fr. Hémat.* 7: 621-624 (1967).
3. BREMER, K., FLIEDNER, T. M., and SCHICK, P. Kinetic differences of autotransfused  $^3\text{H}$ -cytidine labeled blood lymphocytes in leukemic and non leukemic lymphoma patients. *Eur. J. Cancer* 9: 113-124 (1973).
4. BREMER, K., SCHIRMEL, W., and HARRISS, E. B. Comparative studies on the *in vitro* uptake of  $^3\text{H}$ -cytidine and  $^3\text{H}$  uridine by normal and leukaemic lymphocytes. *Scand. J. Haematol.* 11: 122-130 (1973).
5. CUTTNER, J.; CROWTHER, E. P.; KESSE, M., and FLIEDNER, T. M. Behaviour of autotransfused *in vitro*  $^3\text{H}$ -cytidine ( $^3\text{H}$  CDR) labeled lymphocytes in chronic lymphocytic leukemia (CLL). *J. clin. Invest.* 43: 1236 (1964).
6. FEENEDEGEN, L. E. Tritium labeled molecules in biology and medicine (Academic Press, New York 1967).
7. FLIEDNER, T. M. Experimental studies on PHA stimulated lymphocytes and autotransfusion of  $^3\text{H}$ -cytidine labelled lymphocytes in chronic lymphocytic leukaemia, in YOFTEY The lymphocyte in immunology and haemopoiesis, pp. 198-206 (Arnold, London 1967).
8. LUCAS, Z. J. Pyrimidine nucleotide synthesis: regulatory control during transformation of lymphocytes *in vitro*. *Science, N.Y.* 156: 1237-1239 (1967).
9. MANASTER, J., GRUHLINO, J., and STRACKMANS, P. Kinetics of lymphocytes in chronic lymphocytic leukemia. I. Equilibrium between blood and a 'readily accessible pool'. *Blood* 41: 425-438 (1973).
10. NADLER, S. B., HIDALGO, J. U., and BLOCH, T. Prediction of blood volume in normal human adults. *Surgery, St. Louis* 51: 224-232 (1962).
11. RUBIN, A. D., JOHNSON, L. I., and BROWN, S. M. Lymphocyte proliferation and lymphoproliferative disorders. *Progr. exp. Tumor Res.*, vol. 13, pp. 135-180 (1970).
12. SCHICK, P., TREPEL, F., THIEM, H., BENEDEK, S., TRUMPP, P., KABOTH, W., BEGEMANN, H., and FLIEDNER, T. M. Kinetics of lymphocytes in Hodgkin's disease. *Blut* 27: 223-235 (1973).
13. SCHICK, P., TREPEL, F., EDER, M., MATZNER, M., BENEDEK, S., THIEM, H., KABOTH, W., BEGEMANN, H., and FLIEDNER, T. M. Autotransfusion of  $^3\text{H}$ -cytidine-labelled blood lymphocytes in patients with Hodgkin's disease and non Hodgkin patients. II. Exchangeable lymphocyte pools. *Acta haemat.* 53: 206-218 (1975).
14. SCHIRMEL, W., BREMER, K., and SCHICK, P. Studies on the intracellular nucleic

## Autotransfusion of Lymphocytes in Hodgkin's Disease

- acid metabolism of circulating leukemia cells. Autotransfusion studies in patients with chronic lymphocytic leukemia. *Int. Soc. Hemat., Milano 1971*, abstracts, p. 147.
15. STERNBERG, P. A., CHANANA, A. D., CROOK, E. P., GRIFFITHS, M. L., and SCHIFFER, L. M. Studies on lymphocytes. IX. The survival of autotransfused labeled lymphocytes in chronic lymphocytic leukemia. *Eur. J. Cancer* 4: 241-245 (1969).

*Acknowledgement* We wish to thank Miss M. MATZNER and Mr. M. EDER for diligent help in evaluation of the autoradiographs

### References

- 1 BASERGA, R. and KISIELESKI, W. E. Effects of histological and histochemical procedures on the intensity of the label in radioautographs of cells labeled with tritiated compounds *Lab Invest* 12 648 (1963)
- 2 BENET, J. L., VILLENEUVE, B., BÉCART, R.; LOGEAYS, Y., LAUDAT, P. et MATHIEY, J. Temps de passage dans le canal thoracique des lymphocytes du sang de la leucémie lymphoïde chronique *Nouv Revue fr Hémat* 7 621-624 (1967)
- 3 BREMER, K.; FLIEDNER, T. M., and SCHICK, P. Kinetic differences of autotransfused  $^3\text{H}$ -cytidine labeled blood lymphocytes in leukemic and non leukemic lymphoma patients *Eur J Cancer* 9 213-224 (1973)
- 4 BREMER, K., SCHIREML, W., and HARRISS, E. H. Comparative studies on the *in vitro* uptake of  $^3\text{H}$  cytidine and  $^3\text{H}$  uridine by normal and leukaemic lymphocytes *Scand J Haematol* 11 122-130 (1973)
- 5 CUTTNER, J.; CROWKITE, E. P.; KESSE, M., and FLIEDNER, T. M. Behaviour of autotransfused *in vitro*  $^3\text{H}$  cytidine ( $^3\text{H}$  CDR) labeled lymphocytes in chronic lymphocytic leukemia (CLL) *J clin Invest* 43 1236 (1964)
- 6 FEINENDEGEN, L. E. Tritium labeled molecules in biology and medicine (Academic Press, New York 1967)
- 7 FLIEDNER, T. M. Experimental studies on PHA stimulated lymphocytes and autotransfusion of  $^3\text{H}$ -cytidine labelled lymphocytes in chronic lymphocytic leukemia, in YOFFEY The lymphocyte in immunology and haemopoiesis, pp 199-206 (Arnold, London 1967)
- 8 LUCAS, Z. J. Pyrimidine nucleotide synthesis: regulatory control during transformation of lymphocytes *in vitro* *Science*, NY 156 1237-1239 (1967)
- 9 MANASTER, J., FRÜHLING, J., and STRICKMANS, P. Kinetics of lymphocytes in chronic lymphocytic leukemia. I. Equilibrium between blood and a 'readily accessible pool' *Blood* 41 425-438 (1973)
- 10 NADLER, S. B., HIDALGO, J. U., and BLOCH, T. Prediction of blood volume in normal human adults *Surgery, St Louis* 51 224-232 (1962)
- 11 RUBIN, A. D., JOHNSON, L. L., and BROWN, S. M. Lymphocyte proliferation and lymphoproliferative disorders *Progr exp Tumor Res*, vol 13, pp 135-180 (1970)
- 12 SCHICK, P., TREFFL, F., THIEM, H., BENEDEK, S., TRUMPF, P., KABOTH, W., BEGEMANN, H., and FLIEDNER, T. M. Kinetics of lymphocytes in Hodgkin's disease *Blut* 27 223-235 (1973)
- 13 SCHICK, P., TREFFL, F., EDER, M., MATZNER, M., BENEDEK, S., THIEM, H., KABOTH, W., BEGEMANN, H., and FLIEDNER, T. M. Autotransfusion of  $^3\text{H}$  cytidine labelled blood lymphocytes in patients with Hodgkin's disease and non Hodgkin patients II Exchangeable lymphocyte pools *Acta haemat* 53 206-218 (1975)
- 14 SCHIREML, W., BREMER, K., and SCHICK, P. Studies on the intracellular nucleic

acid metabolism of circulating leukemic cells. Autotransfusion studies in patients with chronic lymphocytic leukemia. *Int. Soc. Hemat., Milano 1971*, abstracts, p. 147

- 15 STRICKMANS, P. A., CHANANA, A. D., CROXITE, E. P., GREENBERG, M. L., and SCHIFFER, L. M. Studies on lymphocytes. IX. The survival of autotransfused labeled lymphocytes in chronic lymphocytic leukemia. *Eur. J. Cancer* 4: 241-246 (1968)



*Acknowledgement* We wish to thank Miss M MATZNER and Mr M EDER for diligent help in evaluation of the autoradiographs

### References

- 1 BASERGA, R and KISTELESKI, W E Effects of histological and histochemical procedures on the intensity of the label in radioautographs of cells labeled with tritiated compounds *Lab Invest* 12 648 (1963)
- 2 BINET, J L, VILLENEUVE, B; BÉCART, R, LOGEAI, Y; LAUDAT, P, et MATHEY, J Temps de passage dans le canal thoracique des lymphocytes du sang de la leucémie lymphoïde chronique *Nouv Revue fr Hémat* 7 621-624 (1967)
- 3 BREMER, K, FLIEDNER, T M, and SCHICK, P Kinetic differences of autotransfused  $^3\text{H}$ -cytidine labeled blood lymphocytes in leukemic and non leukemic lymphoma patients *Eur J Cancer* 9 113-124 (1973)
- 4 BREMER, K, SCHIREML, W, and HARRISS, F B Comparative studies on the *in vitro* uptake of  $^3\text{H}$ -cytidine and  $^3\text{H}$  uridine by normal and leukaemic lymphocytes *Scand J Haematol* 11 122-130 (1973)
- 5 CUTTNER, J, CROKITE, L P; KESSE, M, and FLIEDNER, T M Behaviour of autotransfused *in vitro*  $^3\text{H}$ -cytidine ( $^3\text{H}$  CDR) labeled lymphocytes in chronic lymphocytic leukemia (CLL) *J clin Invest* 43 1236 (1964)
- 6 FEINENDEGEN, L E Tritium labeled molecules in biology and medicine (Academic Press, New York 1967)
- 7 FLIEDNER, T M Experimental studies on PHA stimulated lymphocytes and autotransfusion of  $^3\text{H}$ -cytidine labelled lymphocytes in chronic lymphocytic leukemia, in YOFFEY The lymphocyte in immunology and haemopoiesis, pp 198-206 (Arnold, London 1967)
- 8 LUCAS, Z J Pyrimidine nucleotide synthesis: regulatory control during transformation of lymphocytes *in vitro* *Science*, NY 156 1237-1239 (1967)
- 9 MANASTER, J, FRÜHLING, J., and STRACKMANS, P Kinetics of lymphocytes in chronic lymphocytic leukemia I Equilibrium between blood and a 'readily accessible pool' *Blood* 41 425-436 (1973)
- 10 NADLER, E B, HIDALGO, J U., and BLOCH, T Prediction of blood volume in normal human adults *Surgery, St Louis* 51 224-232 (1962)
- 11 RUBIN, A D, JOHNSON, L I, and BROWN, S M Lymphocyte proliferation and lymphoproliferative disorders *Progr exp Tumor Res*, vol 13, pp 135-180 (1970)
- 12 SCHICK, P, TREFFEL, F, THIEM, H, BENEDEK, S, TRUMPF, P, KABOTH, W, BEGEMANN, H., and FLIEDNER, T M Kinetics of lymphocytes in Hodgkin's disease *Blut* 27 223-235 (1973)
- 13 SCHICK, P, TREFFEL, F, EDER, M, MATZNER, M, BENEDEK, S, THIEM, H, KABOTH, W, BEGEMANN, H., and FLIEDNER, T M Autotransfusion of  $^3\text{H}$ -cytidine-labelled blood lymphocytes in patients with Hodgkin's disease and non Hodgkin patients II Exchangeable lymphocyte pools *Acta haemat* 53 206-218 (1975)
- 14 SCHIREML, W, BREMER, K., and SCHICK, P Studies on the intracellular nucleic

- acid metabolism of circulating leukemic cells. Autotransfusion studies in patients with chronic lymphocytic leukemia. Int. Soc. Hemat., Milano 1971, abstracts, p 147
- 15 STRICKMAN, P. A., QUANA, A. D., CROWTHER, E. P., GREENBERG, M. L., and SCHIFFRIN, L. M. Studies on lymphocytes IX The survival of autotransfused labeled lymphocytes in chronic lymphocytic leukemia. Eur J Cancer 4 241-246 (1968)

## Autotransfusion of $^3\text{H}$ -Cytidine-Labelled Blood Lymphocytes in Patients with Hodgkin's Disease and Non-Hodgkin Patients

### II Exchangeable Lymphocyte Pools<sup>1</sup>

P. SCHUCK, F. TREFEL, M. EDER, M. MATZNER, S. BENEDER,  
H. THIEML, W. KABOTH, H. BEGEMANN and T. M. FLIEDNER

I Medical Division, Municipal Hospital, München-Schwabing, and  
Division of Clinical Physiology, University of Ulm Ulm

**Key Words:** Autoradiography · Hodgkin's disease · Lymphocyte kinetics · Recirculation of lymphocytes

**Abstract** The dilution in the circulating blood of lymphocytes labelled *in vitro* with  $^3\text{H}$ -cytidine was examined after autotransfusion in 9 patients with Hodgkin's disease (HD) stage II A-IV B, 5 of whom were untreated, in 2 untreated patients with carcinoma, and in 1 treated patient with scleroderma. The blood transit time of exchangeable lymphocytes was  $37 \pm 18$  min in the patients with HD and  $26 \pm 6$  min in the other patients. The proportion of exchangeable (recirculating) small blood lymphocytes was 39-84% in HD and 81-91% in the carcinoma patients. The relation between the size of the circulating pool of small blood lymphocytes and the total exchangeable (recirculating) lymphocyte pool was 1.20 to 1.30 in HD and 1.29 to 1.34 in the other patients. The absolute size of the recirculating pool of lymphocytes was  $46-90 \times 10^6$  cells in HD and  $100-150 \times 10^6$  cells in the carcinoma patients.

In Hodgkin's disease blood lymphocytopenia is characterized by a more or less pronounced decrease of the long-lived small lymphocyte population, whereas the short-lived lymphocytes are quantitatively normal or even increased [19, 21]. Since long-lived blood lymphocytes are known to be part of the recirculating pool of lymphocytes [4, 5, 7, 8, 11, 17, 18], it could be supposed that this pool and other related exchangeable lymphocyte pools are diminished in correlation with the long-lived blood lymphocytes in Hodgkin's disease. The present study attempts to

<sup>1</sup> Supported by the 'Deutsche Forschungsgemeinschaft', SFB 112

clarify this point using autotransfusions of blood lymphocytes labelled *in vitro* with  $^{14}\text{C}$ -cytidine

# Patients and Methods

In all, 9 patients with Hodgkin's disease (cases C-L), 2 patients with carcinoma (cases M and N) and 1 patient with scleroderma (case S) were examined. The relevant clinical data are summarized in table I. The method of labelling and autotransfusion of lymphocytes and of the evaluation of radioautographic data is described in the preceding report [20].

# Results

After incubation *in vitro* of 500 ml blood with  $2 \mu\text{Ci}$   $^{14}\text{C}$ -cytidine for 1-3 h 64-95% of the lymphocytes were labelled with more than 9 grains (table II). The number of the autotransfused labelled ( $\geq 10$  grains) small lymphocytes (%) varied from 0.92 to  $7.37 \times 10^6$  (table III).

In all patients the concentration of labelled small lymphocytes in the circulating blood after autotransfusion decreases rapidly. The initial slope of the labelling index (LI) corresponds to a simple exponential function, characterized by a half time ( $t_{1/2}$ ) of 13-45 min in the patients with Hodgkin's disease and 14-22 min in the other patients. By extrapolation of the slope of the disappearance curve towards the ordinate the LI for the time zero ( $t=0$ ) corresponding to the end of autotransfusion can be estimated to be  $0.46-3.54$  (table III). The LI of 0.27-0.95 and 1.03% directly measured at time zero in cases L, M and N agree with the estimated values of 0.46, 0.95 and 1.17% respectively. After the rapid decline in the first 10-45 min the LI remained constant until the 3-4 h. During this plateau phase the level of the LI in the single cases was rather different, varying from 0.19 to 1.03%.

Behind the 4 h after the LI decreased [20]. Expressing as a half time the LI of the 100 grains labelled ( $\geq 10$  grains) population, for methodological reasons, cannot be used for evaluation of lymphocyte traffic, because results from highly labelled small lymphocytes come in the blood [20]. For quantitative reasons only the LI of more heavily labelled ( $\geq 30$  grains) small lymphocytes are suitable [20]. The LI of the more heavily labelled cells in the autotransfused blood are presented in table II.

## Autotransfusion of $^3\text{H}$ -Cytidine-Labelled Blood Lymphocytes in Patients with Hodgkin's Disease and Non-Hodgkin Patients

### II Exchangeable Lymphocyte Pools<sup>1</sup>

P. SCHUCK, F. TREPPEL, M. EDER, M. MATZNER, S. BENDEK,  
H. THIENL, W. KABOTH, H. BEGEMANN and T. M. FLIEDNER

I Medical Division Municipal Hospital, München-Schwabing and  
Division of Clinical Physiology, University of Ulm Ulm

**Key Words:** Autoradiography · Hodgkin's disease · Lymphocyte kinetics · Recirculation of lymphocytes

**Abstract** The dilution in the circulating blood of lymphocytes labelled *in vitro* with  $^3\text{H}$ -cytidine was examined after autotransfusion in 9 patients with Hodgkin's disease (HD) stage II A-IV B 5 of whom were untreated, in 2 untreated patients with carcinoma, and in 1 treated patient with scleroderma. The blood transit time of exchangeable lymphocytes was  $37 \pm 18$  min in the patients with HD and  $26 \pm 6$  min in the other patients. The proportion of exchangeable (recirculating) small blood lymphocytes was 39-84% in HD and 81-91% in the carcinoma patients. The relation between the size of the circulating pool of small blood lymphocytes and the total exchangeable (recirculating) lymphocyte pool was 1.20 to 1.30 in HD and 1.29 to 1.34 in the other patients. The absolute size of the recirculating pool of lymphocytes was  $46-90 \times 10^9$  cells in HD and  $100-150 \times 10^9$  cells in the carcinoma patients.

In Hodgkin's disease blood lymphocytopenia is characterized by a more or less pronounced decrease of the long-lived small lymphocyte population, whereas the short-lived lymphocytes are quantitatively normal or even increased [19, 21]. Since long-lived blood lymphocytes are known to be part of the recirculating pool of lymphocytes [4, 5, 7, 8, 11, 17, 18], it could be supposed that this pool and other related exchangeable lymphocyte pools are diminished in correlation with the long lived blood lymphocytes in Hodgkin's disease. The present study attempts to

<sup>1</sup> Supported by the 'Deutsche Forschungsgemeinschaft' SFB 112

clarify this point using autotransfusions of blood lymphocytes labelled *in vitro* with  $^3\text{H}$ -cytidine

### *Patients and Methods*

In all, 9 patients with Hodgkin's disease (cases C-L) 2 patients with carcinoma (cases M and N) and 1 patient with scleroderma (case S) were examined. The pertinent clinical data are summarized in table I. The method of labelling and autotransfusion of lymphocytes and of the evaluation of radioautographic data is described in the preceding report [20].

### *Results*

After incubation *in vitro* of 500 ml blood with  $2 \mu\text{Ci/ml}$   $^3\text{H}$ -cytidine for 1-3 h 64-95% of the lymphocytes were labelled with more than 9 grains (table II). The number of the autotransfused labelled ( $\geq 10$  grains) small lymphocytes ( $N_s$ ) varied from 0.92 to  $7.37 \times 10^6$  (table III).

In all patients the concentration of labelled small lymphocytes in the circulating blood after autotransfusion decreases rapidly. The initial decline of the labelling index (LI) corresponds to a simple exponential function characterized by a half time (fig. 1). The half times of disappearance of labelled lymphocytes were 13-45 min in the patients with Hodgkin's disease and 14-22 min in the other patients. By extrapolation of the slope of the disappearance curve towards the ordinate the LI for the time zero (corresponding to the end of autotransfusion) can be estimated to be 0.86-3.75% (table III). The LI of 0.87, 0.95 and 1.03%, directly measured at time zero in cases L, M and N, agree with the estimated values of 0.86, 0.95 and 1.17%, respectively. After the rapid decline in the first 30-45 min the LI remained constant until the 3rd h. During this plateau phase the level of the LI in the single cases was rather different, varying from 0.09 to 1.07%.

Beyond the 4th hour the LI increased [20]. Beginning with that time the LI of the total labelled ( $\geq 10$  grains) population, for methodological reasons, cannot be used for evaluation of lymphocyte traffic, because newly formed lightly labelled small lymphocytes arrive in the blood [20]. For quantitative investigation only the LI of more heavily labelled ( $\geq 30$  grains) small lymphocytes are suitable [20]. The LI of the more heavily labelled cells in the autotransfused blood are presented in table II, the

Table 1 Clinical data of patients

Patients	Age, years	Sex	Duration of symptoms	Clinical stage	Histologic classification <sup>1</sup>	Spleno- megaly	Response to <sup>2</sup>		Lymphocyte count/ $\mu$ l	Pretreatment, free interval until this study
							PPD	DNCB		
Hodgkin's disease										
C	64	m	3 months	III A	MC	+	+	-	1 660	-
D	27	f	3 weeks	II A	MC	+	-	+	1,070	-
E	26	m	3 months	II A	MC	-	-	nd	2 060	-
F	67	f	3 months	III B	MC	-	+	+	1,240	-
G	76	f	4 years	III B	LD	+	-	-	1,200	chemotherapy, 2 months
H	33	f	7 years	IV B	LD	+	-	nd	930	chemotherapy, 2 days
J	70	m	3 years	III A	LP	-	+	+	2,200	local irradiation, 2 years
K	20	m	1 month	III A	MC	-	-	-	1,460	-
L	49	m	8 months	IV B	MC	+	+	-	670	local irradiation, 6 months
Carcinoma										
M	66	m	6 months			+	-	nd	700	-
N	65	m	1 year			+	+	nd	1,800	-
Scleroderma										
O	72	f	5 years			-	-	-	1,390	chemotherapy, 1 year

<sup>1</sup> MC = Mixed cellularity, LD = lymphocyte depletion, LP = lymphocyte predominance<sup>2</sup> PPD = Skin test with purified tuberculo-protein, DNCB = skin test with dinitrochlorobenzol, PHA = *in vitro* response of blood lymphocytes to phytohemagglutinin (incorporation of <sup>3</sup>H thymidine) - = Negative to + + + = normal range nd = Not done

## Lymphocyte Circulation in Hodgkin's Disease

Table II  $^3\text{H}$ -Cytidine labelling of small lymphocytes (SL) *in vitro*

Patients	<i>In vitro</i> incubation period with $^3\text{H}$ -cytidine, h	LI of SL after incubation, % <sup>1</sup>	
		$\geq 10$ grains	$\geq 30$ grains
		78.3	59.3
		92.4	57.0
	1	84.8	48.8
C	1	64.0	17.6
D	1	89.2	59.0
E	1	88.4	50.0
F	3	95.3	86.3
G	3	89.6	49.0
H	3	95.2	
I	3	94.0	80.1
J	2	94.4	80.2
K	3	88.1	46.5
L	3		
M	1		
N			
S			

<sup>1</sup> In cases C, J and N a grain count threshold of  $\leq 20$  was used, in case L no higher threshold was necessary [20].

corresponding absolute number of autotransfused labelled cells ( $N_{III}$ ) and the LI in the circulating blood from the 5th to the 7th day after autotransfusion are given in table IV

## Discussion

If the circulating pool (CP) of small lymphocytes were a closed compartment it would be possible to calculate the LI expected in the circulating blood after autotransfusion of a definite number of labelled small lymphocytes ( $N_0$ ) into a known pool of circulating lymphocytes (number of small lymphocytes  $\mu\text{l}$  blood  $\times$  blood volume in  $\mu\text{l}$ ). The expected LI would vary from 7.19 to 14.42% (table III). Since, however, the initially observed exponential disappearance of labelled lymphocytes begins not only after but already during the autotransfusion, the expected LI derived from the above simple calculation must be overestimated. Assuming that all autotransfused labelled small lymphocytes are randomly eliminated from the circulation with a definite half time (fig. 1), the theoretically ex-



Table III Ratio of intravascular pool (IP) to circulating pool (CP) of small lymphocytes (SL)

Patients	Small lymphocytes/ $\mu$ l <sup>1</sup>	Blood volume, l	Circulating pool of SL (CP)	Labelled SL auto-transfused (N <sub>II</sub> )	LI expected in CP (L <sub>II</sub> ), %
C	1,190	5.45 <sup>2</sup>	$6.48 \times 10^9$	$4.89 \times 10^9$	7.55
D	620	3.65 <sup>2</sup>	$2.26 \times 10^9$	$3.26 \times 10^9$	14.42
E	1,320	4.92 <sup>2</sup>	$6.47 \times 10^9$	$5.13 \times 10^9$	7.93
F	760	2.90 <sup>2</sup>	$2.20 \times 10^9$	$2.69 \times 10^9$	12.23
G	640	3.16 <sup>2</sup>	$2.03 \times 10^9$	$2.84 \times 10^9$	13.99
H	420	3.60 <sup>2</sup>	$1.51 \times 10^9$	$1.75 \times 10^9$	11.59
J	1,590	4.25 <sup>2</sup>	$6.74 \times 10^9$	$7.33 \times 10^9$	10.88
K	1,130	4.40 <sup>2</sup>	$4.97 \times 10^9$	$4.62 \times 10^9$	9.30
L	270	4.72 <sup>2</sup>	$1.28 \times 10^9$	$0.92 \times 10^9$	7.19
M	480	4.93 <sup>2</sup>	$2.35 \times 10^9$	$2.49 \times 10^9$	10.60
N	1,520	3.60 <sup>2</sup>	$5.47 \times 10^9$	$7.37 \times 10^9$	13.47
E	720	4.40 <sup>2</sup>	$3.18 \times 10^9$	$3.16 \times 10^9$	9.94

<sup>1</sup> Note that small lymphocytes are only a fraction of all blood lymphocytes reported in table I

Table IV Estimation of the recirculating small lymphocyte (SL) pool (RP)

Patients	Heavily labelled SL autotransfused (N <sub>III</sub> )	LI expected in CP (L <sub>III</sub> ), %	Heavily labelled long lived SL autotransfused (N <sub>IV</sub> )	LI expected in CP (L <sub>IV</sub> ), %
C	$3.71 \times 10^9$	5.73	$2.30 \times 10^9$	3.55
D	$2.01 \times 10^9$	8.89	$1.65 \times 10^9$	7.30
E	$2.95 \times 10^9$	4.56	$2.44 \times 10^9$	3.77
F	$0.74 \times 10^9$	3.36	$0.53 \times 10^9$	2.41
G	$1.88 \times 10^9$	9.26	$1.30 \times 10^9$	6.40
H	$0.99 \times 10^9$	6.56	$0.38 \times 10^9$	2.52
J	$6.64 \times 10^9$	9.85	$4.67 \times 10^9$	6.93
K	$2.53 \times 10^9$	5.09	$2.12 \times 10^9$	4.27
L	$0.92 \times 10^9$ <sup>c</sup>	7.19	$0.57 \times 10^9$ <sup>a</sup>	4.45
M	$2.12 \times 10^9$	9.02	$1.93 \times 10^9$	8.21
N	$6.26 \times 10^9$	11.44	$5.05 \times 10^9$	9.23
S	$1.67 \times 10^9$	5.25	$1.24 \times 10^9$	3.90

<sup>a</sup> Mean of 3.5 values

<sup>b</sup> For calculation of maximal and minimal values, see text

## Lymphocyte Circulation in Hodgkin's Disease

Table III (continued)

Expected number of circulating autotransfused labelled SL ( $N_{11}$ ) <sup>1</sup>	LI expected in CP (LI <sub>in</sub> ) <sup>2</sup>	Calculated LI for zero time, %	Ratio of LI <sub>1</sub> to calculated LI	LI <sub>1</sub> to calculated LI
$4.44 \times 10^6$	7.01	1.72	4.39	4.07
$2.52 \times 10^6$	11.15	1.84	7.84	6.04
$4.26 \times 10^6$	6.58	2.36	3.36	2.79
$2.19 \times 10^6$	9.95	3.75	3.26	2.65
$2.55 \times 10^6$	12.56	1.14	12.27	11.02
$1.12 \times 10^6$	10.73	1.52	7.63	7.06
$6.64 \times 10^6$	9.85	1.80	3.10	5.47
$3.72 \times 10^6$	7.48	3.00	8.36	2.49
$0.80 \times 10^6$	6.25	0.86	11.16	7.27
$2.03 \times 10^6$	8.64	0.95	11.51	9.09
$6.32 \times 10^6$	11.55	1.17	5.85	5.09
$2.75 \times 10^6$	8.65	1.70		

<sup>1</sup> Measured by <sup>125</sup>I albumin method<sup>2</sup> Estimated from body weight, height and sex (16).

Table II (continued)

Observed LI in CP 5-7 days after autotransfusion, % <sup>2</sup>	Ratio of LI <sub>1</sub> to observed LI	LI <sub>1</sub> to observed LI	Size of RPs	
			maximal values	minimal values
0.142	15.0	9.29	$97.2 \times 10^6$	$37.35 \times 10^6$
0.191	46.44	39.22	$104.18 \times 10^6$	$70.71 \times 10^6$
0.194	23.27	19.21	$140.46 \times 10^6$	$102.84 \times 10^6$
0.190	11.2	8.03	$24.64 \times 10^6$	$12.63 \times 10^6$
0.160	51.44	35.46	$104.42 \times 10^6$	$49.78 \times 10^6$
0.116	46.55	21.72	$85.12 \times 10^6$	$11.04 \times 10^6$
0.512	18.42	13.03	$124.82 \times 10^6$	$61.76 \times 10^6$
0.193	14.42	12.1	$71.67 \times 10^6$	$40.46 \times 10^6$
0.240	31.26	19.35	$40.01 \times 10^6$	$15.29 \times 10^6$
0.165	44.67	49.76	$129.47 \times 10^6$	$105.99 \times 10^6$
0.414	27.57	22.24	$140.81 \times 10^6$	$95.04 \times 10^6$
0.246	18.36	13.64	$49.38 \times 10^6$	$32.31 \times 10^6$

Cells in count threshold  $\approx 10$  grains (see Table III)

pected number of labelled small lymphocytes in the CP ( $N_{11}$ ) at the end of autotransfusion can be calculated as follows

$$N_{11} = \frac{N_1}{t \times \lambda} (1 - e^{-\lambda t})$$

where  $N_1$  = number of autotransfused labelled small lymphocytes,  $t$  = duration of autotransfusion, and  $\lambda = \ln 2/T_{1/2}$ .

According to this calculation 77.2–92.8% of the infused labelled cells should be in the CP at time zero (end of autotransfusion). That would correspond to LI ( $LI_{11} = N_{11} \times 100/CP$ ) of 6.25–12.56% (table III). As this calculation is based on the assumption that all infused labelled small lymphocytes are disappearing with the measured half times, the calculated values are minimum estimates of the expected LI. This is about the sixfold value of the LI (0.86–3.75%) observed in the circulating blood at time zero (table III). Thus, most labelled infused lymphocytes leave the CP during autotransfusion in a time shorter than the half-times of disappearance observed after autotransfusion.

One can argue that this is not a physiological phenomenon. Killed lymphocytes are quickly eliminated from the circulation [6, 12]. Since, however, after the trypan blue dye exclusion test more than 98% of the infused cells can be regarded as alive, cell death is an unlikely explanation. A rapid loss of labelling, that could simulate a rapid loss of labelled cells from the circulation, can also be excluded, for the labelling intensity of the lymphocytes does not decrease but rather increases after autotransfusion [21]. We prefer two other explanations of the rapid disappearance of labelled cells during autotransfusion: the intravascular trapping of labelled lymphocytes and/or the rapid mixture of the infused cells with an intravascular pool (IP) of lymphocytes which is larger than the CP. Trapping of lymphocytes in non-lymphoid tissue after autotransfusion of  $^{51}Cr$ -labelled cells in normal persons and in patients with chronic lymphocytic leukaemia does not seem to take place on a large scale [12, 15, 23]. On the other hand, lymphocyte trapping in the patients under study cannot be excluded with certainty.


On the premise that labelled small lymphocytes disperse homogeneously in the IP like granulocytes [1] the ratio of the expected LI ( $LI_1$  or  $LI_{11}$ , respectively) to the measured LI at time zero yields a maximum or minimum value respectively defining how much larger the IP should be than the CP (table III). In the Hodgkin patients the minimum values were 2.5–11.0, and the maximum values 3.1–12.3. Comparing with maximum

values of about 3 in haematologically normal person [2], the corresponding values in the four Hodgkin patients without splenomegaly (cases E, F, J, K) were similar (average  $3.9 \pm 1.4$ ), in the other five Hodgkin patients with splenomegaly, however, considerably higher (average  $8.1 \pm 2.8$ ).

While the rapid disappearance of labelled lymphocytes from the CP during autotransfusion could reflect the dilution in the larger IP, the random loss from the CP of labelled lymphocytes with half times of 15-45 min is interpreted to mean the efflux of small lymphocytes from the IP into an extravascular compartment. Similar half times of 15-30 min were observed after autotransfusion of normal blood lymphocytes labelled with  $^{51}\text{Cr}$  [12] or normal thoracic duct lymphocytes labelled with  $^{125}\text{I}$ -uridine [17]. Estimations of the blood transit time of lymphocytes ( $T_{1/2}/\ln 2$ ) using another approach (exchange rate of radiologically damaged lymphocytes) amounted to maximally 60 min in man [6] and 20-40 min in calves [5]. The transit times calculated in our patients are on an average  $37.5 \pm 1.8$  min in cases C-L and  $26 \pm 6$  min in cases M-N and O. Since these values agree with the blood transit times mentioned above, it is concluded that the random loss of labelled small lymphocytes after autotransfusion reflects the emigration of recirculating cells from the intravascular pool into the extravascular part of the recirculating pool.

After the rapid exponential decrease in the 1st h after autotransfusion the 11 becomes constant for at least 1 or 2 h (fig. 1). Since an influx of labelled small lymphocytes which could counterbalance a continued efflux is unlikely in this early phase it is concluded that the transient plateau of the 11 is caused by the presence of labelled non-recirculating small lymphocytes in the CP. Accordingly the maximal proportion of non-recirculating small lymphocytes (equal to the 11 of the plateau phase divided by the 11 of time zero) could be estimated to be 16-61.4% in the patients with Hodgkin's disease and 9.2-19.4% in the patients with carcinoma.

In rats non-recirculating lymphocytes are regarded as predominantly short-lived [14-25]. In uraemic patients the proportion of non-recirculating lymphocytes of the thoracic duct lymph containing many short-lived cells was estimated to be about 17% [17]. On the basis of data from  $^{125}\text{I}$ -thymidine labelling *in vivo* it was deduced that the proportion of short-lived small blood lymphocytes was about 10% in haematologically normal tumor patients [unpublished data] and 13.5-55% in patients with active Hodgkin's disease [22]. This is compatible with the hypothesis, that the non-recirculating small lymphocytes in our patients are predominantly short-lived. The mean life span of short-lived small blood lymphocytes



*Fig 1* Semilogarithmic plot of the LI of small lymphocytes during the initial 4 h after autotransfusion C-L = Patients with Hodgkin's disease M, N, S = non Hodgkin patients. The half times of disappearance of labelled lymphocytes are indicated separately for each patient

was reported to be 4-7 days in rats and hematologically normal man [4, unpublished data] and 2.5-5.5 days in patients with Hodgkin's disease [21]. Therefore it can be expected that most of the autotransfused short-lived lymphocytes are eliminated by the 5th day after autotransfusion. For this reason and on methodological grounds [20] the LI of heavily labelled cells between days 5 and 7 are suitable for the estimation of the size of the recirculating pool of long-lived lymphocytes (RP), if the pro-

portion of long lived non recirculating lymphocytes is negligibly small. Taken this condition for granted the ratio of the LI expected in a closed CP to the observed LI yields the factor by which the RP is larger than the CP. Maximum values of the expected LI ( $LI_{III}$ ) are deduced from the total number of autotransfused heavily labelled small lymphocytes ( $N_{III}$ ) in the following way  $LI_{III} = N_{III} \times 100 / CP$ . Minimum values ( $LI_{IX}$ ) are expected if instead of  $N_{III}$  a number of autotransfused heavily labelled small lymphocytes reduced by the proportion of short lived lymphocytes ( $N_{IX}$ ) is used  $LI_{IX} = N_{IX} \times 100 / CP$ . The maximal factor by which RP is larger than CP is on an average  $29.8 \pm 17.5$  in the patients with Hodgkin's disease and  $33.5 \pm 18.9$  in the other patients whereas the minimal values amount to  $19.6 \pm 10.9$  and  $28.6 \pm 11.9$  (table IV).

Similar values between 10 and 30 were estimated in patients without haematological disease and in normal animals [6, 13, 17, 18, 22]. Accordingly the proportion of the RP represented by the CP with about 4% seems to be normal in Hodgkin's disease. The absolute size of the RP, however, is apparently reduced (table IV). The maximum values ( $CP \times LI_{III} / LI_{normal}$ ) vary between 25 and  $150 \times 10^6$  (average  $103 \pm 39.5 \times 10^6$ ) the minimal values ( $CP_{normal} \times LI_{IX} / LI_{normal}$ ) range from 11 to  $103 \times 10^6$  (average  $45.8 \pm 30.6 \times 10^6$ ). Compared to the size of the RP of the two carcinoma patients with  $100-150 \times 10^6$  at the lower range of normal [24] the values indicate an average reduction of the RP to 75 and 64% respectively in the patients with Hodgkin's disease. In lymphopenic patients with chronic uraemia undergoing prolonged drainage of thoracic duct lymph the recirculating pool of small lymphocytes can be estimated to be  $100-200 \times 10^6$  cells [17, 18] which would also correspond to the double value of that observed in patients with Hodgkin's disease.

If the IP is a homogeneous compartment transit times of recirculating cells through CP and IP must be identical. Thus the ratios of the minimal and maximal RP to the maximal and minimal IP multiplied by the transit time through the CP should yield minimum and maximum estimates of the mean transit times through the RP. These average recirculation times would be 2 and 3.4 h in the patients with Hodgkin's disease and 1.3 or 1.8 h in the other patients. These very short mean transit times, however,

\* Although the proportion of short lived cells was estimated on the basis of all labelled ( $\geq 10$  grains) lymphocytes, it seems also to be valid for the heavily labelled cells, because the mean grain count did not change during the initial rapid decrease of LI after autotransfusion [10].

are compatible neither with the LI curves (fig 1) nor with data reported in the literature suggesting minimal transit times through the RP of 1–5 h [3, 7, 11, 17] and mean transit times of 6 or 27 h [7, 9].

Overestimation of the IP due to initial trapping of labelled lymphocytes must be considered as the most likely explanation of this discrepancy. An initial trapping of transfused isogeneic thoracic duct lymphocytes lasting for less than 1 h has been described in rats, e.g. in the lung [10]. The main consequence of a short term initial trapping of labelled autotransfused lymphocytes in the present study would be an overestimation of the IP. The estimates of the blood transit time of exchangeable lymphocytes or the proportion of exchangeable and non exchangeable lymphocytes such as of the pool size of exchangeable lymphocytes (RP) should be correct. The evaluation of these parameters depends on the fact that there is no permanent sequestration of damaged labelled cells. This possibility is considered very unlikely, because autologous fresh anticoagulated whole blood without washing or centrifugation was transfused and because there was no difference of the recovery pattern of labelled lymphocytes after autotransfusion of blood cells incubated for 1 or 3 h.

*Acknowledgment* We wish to thank Dr K. BREMER (Department of Medicine University of Essen) who advised on the autotransfusion method, Dr H. CZERNIHL (Nuclear Medical Division Municipal Hospital Schwabing) for measuring the blood volumes and Dr A. H. STERNBACH (Division of Clinical Physiology University of Ulm). The help in evaluation of the autoradiographs by Misses U. DLASKA, I. DÖHRMANN, E. LEHMANN, BROCKHAUS, I. OLSEN and K. SCHMIDT-RAUERT is gratefully appreciated.

### References

1. ATHENS J. W., HAAB O. P., RAAB E. O., MAUER A. M., ASHENBRUCKER H., CARTWRIGHT G. E. and WINTROBE, M. M. Leukokinetic studies. IV. The total blood circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. *J. clin. Invest.* 40: 989–995 (1961).
2. BREMER K., FLIEDNER T. M. and SCHICK P. Kinetic differences of autotransfused  $^3\text{H}$ -cytidine labeled blood lymphocytes in leukemic and non leukemic lymphoma patients. *Eur. J. Cancer* 9: 113–124 (1973).
3. BREMER K., SCHICK P., WACK O., THIEM, H., BRASS B. und HEIMFEL, H. Rezirkulation von Lymphocyten bei Patienten mit malignen lymphatischen Systemerkrankungen. *Blut* 24: 215–225 (1972).
4. CATTREY H. W., RIEKE W. O. and EVERETT N. H. Radioautographic studies of small lymphocytes in the thoracic duct of the rat. *Acta haemat.* 28: 145–154 (1962).

- 5 CROCKHIT, F. P., JANSEN, C. R., COTTER, H. R., and SIRE, C. R. Lymphocyte production measured by extracorporeal irradiation, cannulation and labeling techniques. *Ann NY Acad Sci* 113 566-577 (1964)
- 6 FELD, E. O., SHARPE, H. B. A., DAWSON, K. B., ANDERSEN, V., KILIMANN, S. A., and WEIER, E. Turnover rate of normal blood lymphocytes and exchangeable pool size in man calculated from analysis of chromosomal aberrations sustained during extracorporeal irradiation of the blood. *Blood* 39 39-46 (1972)
- 7 FORD, W. L. The kinetics of lymphocyte recirculation within the rat spleen. *Cell Tiss Kinet* 2 171-191 (1969)
- 8 FORD, W. L. and GOWANS, J. L. The traffic of lymphocytes. *Semin. Hemat* 6 67-83 (1969)
- 9 FORD, W. L. and SUMMONDS, S. J. The tempo of recirculation of lymphocytes from blood to lymph in the rat. *Cell Tiss Kinet* 5 175-189 (1972)
- 10 GRIMSCHEIMER, I. and MCGREGOR, D. H. Migration of lymphocytes and thymocytes in the rat. II. Circulation of lymphocytes and thymocytes from blood to lymph. *Lab Invest* 18 397-406 (1968)
- 11 GOWANS, J. L. and KNOTT, E. J. The route of recirculation of lymphocytes in the rat. *Proc R Soc* 259 237-242 (1964)
- 12 HERSTY, P. The separation and <sup>51</sup>chromium labeling of human lymphocytes with *in vivo* studies of survival and migration. *Blood* 38 360-371 (1971)
- 13 MCGREGOR, D. H. Studies by thoracic duct drainage of the functions and potentialities of the lymphocyte. *Fed Proc* 25 1713 (1966)
- 14 MCGREGOR, D. H., KNOTT, E. J., and MACKANESS, G. B. The mediator of cellular immunity. I. The life-span and circulation dynamics of the immunologically committed lymphocyte. *J exp Med* 133 389-399 (1971)
- 15 MERRITT, J. A., COOK, J. V., and DISBORNE, J. I. Blood and organ studies of circulating lymphocytes in humans with normal leukocyte counts. *Am J med Sci* 258 237-244 (1969)
- 16 NADLER, S. B., HEMALON, J. U., and BUNCH, T. Prediction of blood volume in normal human adults. *Surgery St Louis* 53 224-232 (1942)
- 17 RIVILLARD, J. P., BROCHIER, J., DERIC, A., BERNHARDT, J. P., BRYON, P. A., ARCHIMBULT, J. E., FRIIS, D. et TRACIER, J. Drainage du canal thoracique avant transplantation chez des malades atteints d'insuffisance rénale chronique. *Nouv Revue fr Hémat* 8 585-602 (1968)
- 18 SALLIS, H. F., SMITH, G. H., FISH, J. C., and REMMERS, A. R., jr. Observations concerning human lymphocyte homeostasis during prolonged thoracic duct lymph diversion. *Tex Rep Biol Med* 24 573-583 (1967)
- 19 SCHUCK, P. Lymphocytenkinetik bei lymphatischen Systemerkrankungen (chronische lymphatische Leukämie, Lymphogranulomatose). *Verh dt Ges inn Med* 79 184-188 (1973)
- 20 SCHUCK, P., TREBEL, E., LEHMANN-BROCKMANN, E., and NITZWANG, H. Autransfusion of <sup>51</sup>Cr-cytal ne labeled blood lymphocytes in patients with Hodgkin's disease and non-Hodgkin patients. I. Limitations of the method. *Acta haemat* 53 193-208 (1974)
- 21 SCHUCK, P., TREBEL, E., THOM, H., RUSCHKE, S., TREMPER, H., KADOTH, W., Bz



- GEMANN H and FLIEDNER T M Kinetics of lymphocytes in Hodgkin's disease Blut 27 223 235 (1973)
- 22 SCHNAPPAUF H und SCHNAPPAUF H Drainage des Ductus thoracicus und Grösse der «leicht mobilisierbaren» Lymphozyten bei Kalbern Schafen und Hunden Blut 16 209 220 (1968)
- 23 SPIVAK J L and PERRY S Lymphocyte kinetics in chronic lymphocytic leukaemia Br J Haemat 19 511 522 (1970)
- 24 TREFFT F Kinetik der Lymphocyten Verh dt Ges inn Med 79 105 111 (1973)
- 25 TYLER R W and GARRETT N H Radioautographic study of cellular migration using parabiotic rats Blood 39 249 266 (1972)

## Cellular and Subcellular Localization of Heme and Hemopexin in the Rabbit

H. HENG LIM, MIRIAM TAVASSOLI and URSULA MÜLLER-EBERHARD

Departments of Biochemistry and Hematology, Scripps Clinic and Research Foundation and the Department of Pediatrics, University of California at San Diego, La Jolla, Calif.

**Key Words:** Albumin, Autoradiography, Heme metabolism, Hemopexin, Liver ultrastructure

**Abstract.** The cellular distribution of intravenously administered  $^3\text{H}$ -heme,  $^{125}\text{I}$ -hemopexin and  $^{125}\text{I}$ -albumin was studied in rabbits. Radioautography of the tissue slides of several organs was examined by light and electron microscopy. All experiments were terminated 60 min after injection of the isotope labeled materials.  $^3\text{H}$ -heme and native monomeric  $^{125}\text{I}$ -hemopexin (heme saturated) were found to be associated with the endoplasmic reticulum and microbodies of the hepatocytes. Aggregated hemopexin was also taken up by macrophages of lung alveoli, splenic pulp, interstitial cells of the kidney and Kupffer cells.  $^{125}\text{I}$ -albumin (heme saturated) could not be located in liver, spleen, bone marrow, lung or kidney tissues.

Hemopexin, a serum  $\gamma$ -glycoprotein, serves as a carrier of heme in the blood [12]. It binds heme with a much greater avidity than albumin [16]. Heme is transported to the liver, where it is degraded mainly to bilirubin [14]. Previous work from our laboratory [8] has shown that the heme-hemopexin complex is removed exclusively by hepatocytes and not by the reticuloendothelial elements of the liver (Kupffer cells). In the present report, we have extended our investigations to the subcellular localization of  $^3\text{H}$ -heme and  $^{125}\text{I}$ -hemopexin. We have furthermore shown that aggregated hemopexin is taken up by the reticuloendothelial system throughout the body. In addition, we have shown that  $^{125}\text{I}$ -albumin is not removed by the hepatocytes during the process of plasma heme clearance.

### Materials and Methods

**Animals** New Zealand white rabbits, 0.8–1.1 kg, were purchased from Rancho de Conejo, Calif. Several days prior to the experiment, Lugol's solution was added to the drinking water.

**$^3\text{H}$  heme preparation** Heme was labeled *in vitro* with  $^3\text{H}$  aminolevulinic acid as previously described [11], the specific activity was  $4 \times 10^6$  dpm/mg. Heme solutions were freshly prepared and 1 ml serum was admixed. Approximately 65  $\mu\text{g}$   $^3\text{H}$  heme were injected.

**Purification and isotope-labeling of proteins** Rabbit hemopexin was purified from rabbits induced with lead acetate according to a previously described method [3]. Rabbit albumin was purified from plasma of healthy adult rabbits by preparative zone electrophoresis employing Pevikon as supportive medium [7]. Both proteins were tested for purity by immunoelectrophoresis and polyacrylamide gel electrophoresis [3].

Purified rabbit hemopexin and albumin were labeled with  $^{125}\text{I}$  according to MCCONAHEY and DIXON [6]. The specific activity of the proteins was  $7 \times 10^6$  dpm/mg protein. Rabbit serum, 0.2 ml, was added to each aliquot of isotope labeled protein and the mixture was centrifuged at 105,000 g for 2 h. This step was omitted when partly aggregated protein was used [9]. The amount of  $^{125}\text{I}$  hemopexin injected was  $3.8 \times 10^6$  dpm, that of albumin was  $1.7 \times 10^6$  dpm. More than 97% of the isotope was protein bound when tested either by precipitation with 95% ethanol or with monospecific antibodies.

**Experimental procedure** Six rabbits were used. In two of them hemolysis was produced by administration of phenylhydrazine s.c. dissolved in phosphate buffered saline, pH 7.4 and administered (10 mg/kg body weight) every other day times five. Their hematocrit was 42 and 45% before treatment and 27 and 30% preceding the experiment, at which time intense reticulocytosis was present. Two animals were injected with either  $^{125}\text{I}$  hemopexin or  $^3\text{H}$  heme mixed with 1 ml serum. Two animals served as controls, i.e. they were not treated with phenylhydrazine, but were given either isotope labeled heme or heme-saturated hemopexin. Two additional animals, also untreated, received either  $^{125}\text{I}$  methemalbumin or partly aggregated  $^{125}\text{I}$  heme-hemopexin as previously described [9].  $^{125}\text{I}$  hemopexin was incubated with 0.4 mg hematin, an amount enough to saturate all circulating hemopexin, and  $^{125}\text{I}$  albumin with 4 mg hematin for 30 min at room temperature before injection.

1 h after injection of  $^3\text{H}$  heme or iodinated protein, the rabbits were sacrificed under anesthesia with sodium pentobarbital (Valley Veterinary Supply, North Hollywood, Calif.) 40 mg/kg body weight. Immediately following exsanguination through the abdominal aorta, liver, lung, kidney, spleen and bone marrow were removed. Small sections were taken for microscopic studies and autoradiography.

**Microscopic and autoradiographic studies** For light microscopy, the tissues were fixed in 10% phosphate buffered formaline and embedded in paraffin. Sections were obtained at 5  $\mu\text{m}$  and processed for radioautography using NTB II (Kodak nuclear emulsion) [15]. The exposure time varied from 2 to 8 weeks. Sections were then lightly stained with hematoxylin and examined for localization of silver grains in the tissues. Several slides were studied for each exposure period.

For electron microscopy small pieces of tissue were fixed in 3% phosphate-buffered glutaraldehyde (pH 7.4) at 4°C. The tissue was then rinsed in buffer, post fixed in 1% cold  $\text{OsO}_4$  similarly buffered. After dehydration in graded alcohol it was embedded in epoxy resin. Ultrathin sections in the range of silver were obtained with a Dupont diamond knife and placed on a Formvar-coated grid and processed for radioautography [15] using Ilford 3 emulsion (Fover, England) after an exposure time varying from 2 to 8 weeks. After each exposure period several grids were stained with uranyl acetate and lead citrate and studied in a Hitachi HU 11 A electron microscope for subcellular localization of radioactivity [15].

### Results and Discussion

In a previous report, we had demonstrated that intravenously administered  $^{51}\text{Cr}$  heme and  $^{125}\text{I}$  hemopexin are removed by hepatocytes [8]. The evidence was obtained by examining radioautographic tissue slides of several organs with the light microscope. A tracer amount of  $^{51}\text{Cr}$  heme was given as hematin, cyanmethemoglobin, methemalbumin or heme hemopexin. Whatever pigment was injected, the heme was associated with liver parenchymal but not with Kupffer cells within 15–120 min of injection. In the same study, tracer amounts of  $^{125}\text{I}$  rabbit hemopexin were demonstrated to gain access to the hepatocyte. The results of the present study confirm this conclusion.

In contrast,  $^{125}\text{I}$  albumin administered as methemalbumin, was not found in any organ studied. This supports our recent suggestion that all hepatic  $^{125}\text{I}$  albumin could be attributed to the plasma content of this organ [4] and is in agreement with results described by BISSILL *et al* [1]. Even when a large quantity of hematin was given (12.5 mg/kg heme) the amount of  $^{125}\text{I}$  albumin found in the liver did not increase [4].

By contrast in the experiment in which partly aggregated hemopexin was given silver grains were discernible both in hepatocytes and Kupffer cells (fig. 1). Silver grains were also seen in the interstitial tissue of the lung and the kidney and in the cordal compartment of the splenic red pulp. This distribution pattern suggests that the aggregated hemopexin was removed by the reticuloendothelial system. In this context, it is of interest to note that intravenously administered hemoglobin [13] and hapto-globin hemoglobin were found in cells of the reticuloendothelial system [17]. Uptake of aggregated protein molecules may have been the cause of engulfment of these pigments. BISSILL *et al* [1] located both entities only in hepatocytes.






Fig. 2 Subcellular localization of  $^{125}\text{I}$  hemopexin injected as heme hemopexin in a normal rabbit hepatocyte. The radioactivity is associated with rough and smooth endoplasmic reticulum and with microbodies (arrow). Similar distribution was found in phenylhydrazine treated animals.  $\times 10,000$ .

Fig. 1 Cellular distribution of aggregated  $^{125}\text{I}$  hemopexin. Note that silver grains in the liver (A) are not confined only to hepatocytes but are also found in Kupfer cells. The radioactivity is seen in the interstitial spaces of lung (C, arrows) and kidney (B). In the spleen (D), the radioactivity is associated with the cordal compartment of the red pulp (arrows).







Fig. 2 Subcellular localization of  $^{125}\text{I}$  hemopexin injected as heme-hemopexin in a normal rabbit hepatocyte. The radioactivity is associated with rough and smooth endoplasmic reticulum and with microbodies (arrow). A similar distribution was found in phenylhydrazine-treated animals.  $\times 10,000$ .

Fig. 1 Cellular distribution of aggregated  $^{125}\text{I}$  hemopexin. Note that silver grains in the liver (A) are not confined only to hepatocytes but are also found in Kupffer cells. The radioactivity is seen in the interstitial tissues of lung (C, arrows) and kidney (B). In the spleen (D) the radioactivity is associated with the cordal compartment of the red pulp (arrows).








Fig. 2. A normal endoplasmic reticulum in phenylhydrazine treated animals. Similar distribution was found in the liver (A) are not confined only to hepatocytes but are also found in Kupffer cells. The radioactivity is seen in the interstitial spaces of lung (C arrow) and kidney (B). In the spleen (D) the radioactivity is associated with the central compartment of the red pulp (arrows). (1000x)

Fig. 1. Cellular distribution of aggregated hemepexin. Note that silver grains in the liver (A) are not confined only to hepatocytes but are also found in Kupffer cells. The radioactivity is seen in the interstitial spaces of lung (C arrow) and kidney (B). In the spleen (D) the radioactivity is associated with the central compartment of the red pulp (arrows).

The finding that tracer doses of heme are taken up exclusively by liver parenchymal cells was confirmed in radioautographic studies by HERSHKO *et al* [2] who employed  $^{59}\text{Fe}$  heme. Their experiments also suggested heme to be entering the hepatocytes as the heme-hemopexin complex. We have now verified these results by electron microscopy employing radioautography and  $^3\text{H}$  heme as well as  $^{125}\text{I}$  hemopexin. We found the radioactivity after administration of both  $^3\text{H}$  heme [10] or  $^{125}\text{I}$ -hemopexin (fig 2) in the hepatocytes to be confined to the endoplasmic reticulum. This was true both in normal and phenylhydrazine-treated animals. A few silver grains were associated with microbodies. No radioactivity was noted overlying plasma membrane, nucleus, glycogen granules or mitochondria. This subcellular distribution of heme-hemopexin is in accordance with results obtained on the distribution of  $^3\text{H}$  heme in microsomal, mitochondrial and cytosol fractions. Within 45 min the major amount of  $^3\text{H}$  was found in the microsomal fraction [4].

In view of the presented electron microscopic evidence and considering the much higher  $K_d$  of hemopexin than albumin for heme, we conclude that small amounts of heme are preferentially taken up by the hepatocyte as heme-hemopexin. Minute amounts of plasma heme have been considered to be naturally occurring repressors of microsomal cytochromes [5]. This amount of heme is probably transported in the serum by hemopexin.

*Acknowledgements:* Supported by research grants HF 04660 from the National Heart Institute, grant HD 04445 from the Institute of Child Health and Human Development and grant AM HL 16737 from the Institute of Arthritis and Metabolic Diseases and by Career Development Award AM 70551 to M. TAVASSOLI from the National Institute of Arthritis and Metabolic Diseases and Career Development Award AM 16923 to U. MULLER ERNHARD from the National Institute of Arthritis and Metabolic Diseases.

### References

1. BISSELL, M. M., HAMMAKER, L. and SCHMID, R. Hemoglobin and erythrocyte catabolism in rat liver: the separate roles of parenchymal and sinusoidal cells. *Blood* 40: 812-822 (1972).
2. HERSHKO, C., COOK, J. D. and FINCH, C. A. Storage iron kinetics. II. The uptake of hemoglobin iron by hepatic parenchymal cells. *J. Lab. clin. Med.* 80: 624-634 (1972).
3. HRAAL, Z. and MULLER ERNHARD, U. Partial characterization of the heme binding serum glycoproteins of rabbit and human hemopexin. *Biochemistry* 10: 1746-1750 (1971).

- 4 LHM H H Hepatic uptake of heme and hemopexin but not albumin *Biochim biophys Acta* 343 546-550 (1974)
- 5 MARVER H S, SCHWED R., and SCHUTZEL H Heme and methemoglobin naturally occurring repressors of microsomal cytochrome *Biochem biophys Res Commun* 33 969-974 (1968)
- 6 MCCOMBLY P J and DIXON F J A method of trace iodination of proteins for immunologic studies *Int Arch Allergy* 29 185-189 (1966)
- 7 MULLER FRIEDHARD H J A new supporting medium for preparative electrophoresis *Scand J clin Lab Invest* 12 33-37 (1960)
- 8 MULLER FRIEDHARD U, BONMAN C., and LHM H H Tissue localization of the heme hemopexin complex in the rabbit and the rat as studied by light microscopy with the use of radioisotopes *J Lab clin Med* 76 426-431 (1970)
- 9 MULLER FRIEDHARD U and ENGELSH F C Purification and partial characterization of human hemopexin *J Lab clin Med* 70 619-626 (1967)
- 10 MULLER FRIEDHARD U and JOHNSON F E Bilirubin production from erythroid sources. *Canad med Ass J* (in press)
- 11 MULLER FRIEDHARD U, LHM H H, HANSTEIN A., *et al* Studies on the disposal of intravascular heme in the rabbit *J Lab clin Med* 73 210-218 (1969)
- 12 MULLER FRIEDHARD U and LHM H H Hemopexin the heme binding serum  $\beta$  glycoprotein in *Structure and function of plasma proteins* (Allison, 1974)
- 13 OKUYAMA S and ITO Y Reticuloendothelial uptake of hemoglobin assessed with radiocollid an experimental approach to intravascular hemolytic sequelae *J reticuloendoth Soc* 16 68-78 (1973)
- 14 ROBINSON S H Formation of bilirubin from erythroid and nonerythroid sources *Semin Hemat* 9 43-53 (1972)
- 15 ROBERTS A W Techniques of autoradiography (Elsevier Amsterdam 1969)
- 16 STREY V L and MULLER FRIEDHARD U Binding of porphyrins to rabbit hemopexin and albumin *J Biol Chem* 248 3796-3800 (1973)
- 17 WADA T, OHTSU H, WATANABE K., *et al* Autoradiographic study on the site of uptake of the haptoglobin hemoglobin complex *J reticuloendoth Soc* 8 185-193 (1970)

## Erythrocytic Committed Hematopoietic Stem Cells in the Peripheral Blood of Mice

KENNETH F. MCCARTHY and THOMAS J. MACVITTIE

Armed Forces Radiobiology Research Institute Bethesda, Bethesda Md

**Key Words:** CFU Erythrocytic commitment Hematopoietic stem cells

**Abstract:** Hematopoietic stem cells (CFU) found in the peripheral blood of mice might be functionally, a heterogeneous cellular population. A comparison of our data with that of others leads to the conclusion that peripheral blood CFU belong to two or more marrow CFU subpopulations, one of which consists of erythrocytic committed CFU.

An approach to the problem of characterizing circulating hematopoietic stem cells (CFU) as being either multipotent [1] or unipotent [4, 5] is suggested by the recent finding that the hematopoietic organs of anemic  $Sl/Sl^1$  mice are deficient in erythrocytic committed CFU [9]. Apparently, the  $Sl/Sl^1$  defect either disrupts the flow of multipotent CFU to the erythrocytic cell line or fails to support erythrocytic committed CFU proliferation. It is believed that the granulocytic cell line continues to function normally in the presence of the defect [6, 9] and, although there is evidence that megakaryocyte maturation is altered [3], this apparently does not occur at the stem cell level [9]. Therefore, a study of CFU migration in  $Sl/Sl^1$  mice might afford one the opportunity of examining the contribution of a single committed stem cell compartment to the overall circulating CFU population. In this communication data are presented characterizing erythrocytic committed CFU in the peripheral blood of mice and their mobilization into the circulation during periods of hematopoietic stress.

### Methods

Mutant  $Sl/Sl^1$  mice and their normal congenic littermates (+/+) were obtained from the mating of WC/Re +/Sl females with C57BL/6J  $Sl^1/+$  males [1].

the Jackson Laboratory Bar Harbor Me. Recipient B6WCl<sub>1</sub> (12-17 months old) used for the *in vivo* CFU assay were obtained by mating WCRc males with C57BL/1 females at the AFRR1.

Blood was collected from the jugular vein of Sl<sup>h</sup>Sl<sup>h</sup> and +/+ mice (10-18 weeks old) using 0.004 percent EDTA as an anticoagulant. Aliquots of pooled whole blood from two Sl<sup>h</sup>Sl<sup>h</sup> or two +/+ mice were injected intravenously into each of 7-10 recipient mice which had previously received 950 rad of <sup>60</sup>Co whole body radiation. The mice were then housed 3 per cage and were allowed acidified water and food *ad libitum*. Nine days later, the mice were sacrificed, their spleens removed and fixed in Bouin's solution [8]. Gross nodule counts were made and, in some experiments, the spleens were sectioned (5  $\mu$ m), HE stained and the number of colonies determined microscopically.

*Bordetella pertussis* organisms in saline were purchased from Eli Lilly Indianapolis.

### Results and Discussion

As seen in table 1, whole blood from +/+ mice injected into irradiated recipient mice generated twice as many macroscopic splenic colonies as an equivalent volume of blood taken from Sl<sup>h</sup>Sl<sup>h</sup> donors. In an attempt to identify the missing circulating CFU in Sl<sup>h</sup>Sl<sup>h</sup> mice, 5-6 spleens from the recipient mice were sectioned, stained and examined microscopically. It was found that 1 ml of +/+ blood generated approximately 99 microscopic colonies, 45 of which were erythrocytic, 20 granulocytic, 20 megakaryocytic and 14 mixed. Alternatively, blood from Sl<sup>h</sup>Sl<sup>h</sup> donors generated only 78 microscopic colonies, 36 of which were erythrocytic, 24 granulocytic, 11 megakaryocytic and 10 mixed. Thus it would appear that the 'missing' peripheral blood CFU capable of generating macroscopic colonies are predominantly erythrocytic committed CFU, a finding which in some respects is consistent with the work of BIKSSTEN [2] who reported that blood from Sl<sup>h</sup>Sl<sup>h</sup> mice is only half as effective in curing the anemia of mutant W/W<sup>u</sup> mice as is blood from +/+ mice.

It is noteworthy that peripheral blood CFU from both +/+ and Sl<sup>h</sup>Sl<sup>h</sup> mice generated colonies whose hematopoietic type distribution was more characteristic of CFU from marrow than CFU of splenic origin [9]. Thus the Sl<sup>h</sup>Sl<sup>h</sup> defect does not appear to alter the previously

\* On a per ml basis, multiple sections gave the following results: +/+ (Sl<sup>h</sup>Sl<sup>h</sup>) control - 45 (70%) erythrocytic, 12 (12%) granulocytic, 11 (6%) mixed and 2 (2%) megakaryocytic; 60h - 100 (70%) erythrocytic, 54 (44%) granulocytic, 66 (5%) mixed and 4 (16%) megakaryocytic.

Table 1 Blood cellularity and CFU number of +/+ and SI/SI<sup>1</sup> mice following a single injection of *B. pertussis* vaccine

Interval	Blood cellularity × 10 <sup>6</sup> /ml	CFU/10 <sup>6</sup> cells	CFU ml of blood
<i>+/+ mice</i>			
Control	59 ± 19 <sup>1</sup>	90 ± 12	50 ± 12
28 h	2.2 ± 0.6	128 ± 22	28 ± 4
76 h	10.4 ± 1.4	31.3 ± 4.4*	325 ± 51**
158 h	70 <sup>2</sup>	182	131
<i>SI/SI<sup>1</sup> mice</i>			
Control	74 ± 18	36 ± 11	26 ± 10
28 h	—	—	—
76 h	62 ± 11	109 ± 19***	62 ± 5****
158 h	—	—	—

<sup>1</sup> Mean ± SEM of 2-4 determinations performed on 2 animals

<sup>2</sup> One determination on 2 animals

Significantly different from control at \*  $p < 0.005$ , \*\*  $p < 0.010$ , \*\*\*  $p < 0.025$ , \*\*\*\*  $p < 0.050$

suggested marrow origin of peripheral blood CFU [4], only the concentration of CFU committed to specific lines of hematopoietic cellular differentiation

CFU migration was further investigated by challenging both SI/SI<sup>1</sup> mice and their normal congenic littermates with a single injection (i.p.) of  $20 \times 10^6$  heat killed *B. pertussis* organisms. In normal mice, this treatment effects a rapid fall of marrow erythroid precursors and a sharp increase in the number of circulating CFU [7]. In the present study, a 6.5-fold increase in blood CFU concentration in +/+ mice was observed, while in SI/SI<sup>1</sup> mice there was only a 2.4-fold increase (table 1). The observed increase in +/+ mice was distributed among the various colony types. This was not the case for SI/SI<sup>1</sup> mice. Specifically, in the periphery of +/+ mice, CFU generating erythrocytic colonies increased 4.2-fold, granulocytic 2.5 fold, megakaryocytic 2.1-fold and mixed 3.5-fold. The corresponding values for SI/SI<sup>1</sup> blood were as follows: erythrocytic 3.4-fold, granulocytic 2.0 fold, megakaryocytic 13.0-fold and mixed 4.0 fold. Thus *B. pertussis* vaccine treatment did not effect an increase in the number of circulating erythrocytic committed CFU in SI/SI<sup>1</sup> mice, only in +/+ mice.

In summary, it appears that in  $Sl^{+}Sl^{+}$  mice, CFU capable of generating granulocytic and megakaryocytic colonies are released into the circulation independently of erythrocytic committed CFU, possibly indicating that peripheral blood CFU are, functionally, a heterogeneous cellular population. Furthermore, in view of the work of GIMLI *et al* [4] suggesting that peripheral blood CFU represents a subpopulation of the heterogeneous marrow CFU population, and the work of WOLF [9] demonstrating that  $Sl/Sl^{+}$  marrow is deficient in erythrocytic committed CFU, it might also be concluded that peripheral blood CFU belong to two or more marrow CFU subpopulations, one of which consists of erythrocytic committed CFU.

*Acknowledgements* We are grateful to Mr GEORGE LEE and Mr PETER KITCHEN for their technical assistance.

### References

- 1 BENNETT M and CUDKOWICZ G. Hemopoietic progenitor cells of the mouse incapable of self replication. *Proc Soc Exp Biol Med* 129: 99-104 (1969).
- 2 BIRNBAUM S I. Hemopoietic tissue transplantation via blood transfusion. *Exp Hematol* 1: 19 (1973).
- 3 EAST S, PHILLIPS F., and STORIMAN E., jr. Abnormalities of megakaryocytes in  $Sl^{+}Sl^{+}$  mice. *Blood* 42: 865-871 (1973).
- 4 GIMLI J, TIEHL E., and AVITAL S. Some properties of the circulating hemopoietic stem cells. *Blood* 43: 573-580 (1974).
- 5 HARRISON M S. Properties of haemopoietic stem cells in phenylhydrazine treated mice. *Cell Tissue Kinet* 6: 199-208 (1973).
- 6 KROEMER W J, HIRAKAWA H, FRIED W, ROBINSON W., and THOMASON F., jr. Studies of marrow granuloid stem cells (GSC) and colony stimulating factor (CSF) in  $Sl^{+}Sl^{+}$  mice. 3rd A Meet Int Soc Exp Experimental Hematology p 9 (1974).
- 7 MOWATTE J C, MUMF B S, HEMARD D, ANGELOTTI E., and STORIMAN E., jr. Hemopoietic stem cell proliferation and migration following *Bordetella pertussis* vaccine. *Cell Tissue Kinet* 5: 121-129 (1972).
- 8 THIEL J F and McCLELLAND E A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res* 34: 213-222 (1961).
- 9 WOLF N S. Directly the hematopoietic environment. *Cell Tissue Kinet* 7: 87-99 (1974).



## Massive Splenomegaly, Pancytopenia and Haemolytic Anaemia in Sarcoidosis

U THADANI, C P. ABER and J J TAYLOR

Departments of Medicine and Haematology, Kingston General Hospital,  
Kingston upon Hull

**Key Words** Haemolytic anaemia Hypersplenism Pancytopenia Sarcoidosis  
Spleen sarcoidosis

**Abstract** A 53-year-old dock labourer, presented with massive splenomegaly and subsequently developed pancytopenia. Complete haematological remission was observed following splenectomy. Histological examination of the liver and spleen revealed sarcoid granulomata. A year after splenectomy, he died in an acute haemolytic crisis a very rare complication of sarcoidosis. Evidence of generalized sarcoidosis was found at autopsy. The literature on haematological complications in sarcoidosis is reviewed.

Splenomegaly is a relatively uncommon feature of sarcoidosis. In a series of 275 patients with sarcoidosis SCADDING [35] recorded a palpable spleen in 31 instances. In only 5 of these patients was the enlargement considerable and none had any symptoms attributable to this finding. However, associated anaemia, leucopenia, thrombocytopenia, singly or in various combinations, have been described [4, 9, 10, 12, 14, 16, 18-21, 23, 24, 28, 31-34, 37, 43]. Haemolytic anaemia is a very rare complication of sarcoidosis and to date we have been able to trace only 13 well-documented examples [2, 6-8, 13, 17, 22, 25, 26, 38, 41, 42-44].

We wish to report a patient with sarcoidosis who presented with massive splenomegaly and developed features of hypersplenism. Following splenectomy he died as a result of an acute haemolytic crisis.

### *Case Report*

A 53 year old dock labourer was admitted to hospital on 28.7.1969 with a 3 year history of recurrent abdominal distension and recent weight loss 2 weeks

1. The first part of the document is a list of names and addresses, which are arranged in a columnar fashion. The names are written in a cursive script, and the addresses are written in a more formal, printed style. The list appears to be a directory or a roster of some kind.

2. The second part of the document is a series of short, handwritten notes or entries. These are arranged in a columnar fashion, with each entry starting with a number. The notes are written in a cursive script, and they appear to be a continuation of the information provided in the first part of the document.

3. The third part of the document is a series of short, handwritten notes or entries. These are arranged in a columnar fashion, with each entry starting with a number. The notes are written in a cursive script, and they appear to be a continuation of the information provided in the first part of the document.

4. The fourth part of the document is a series of short, handwritten notes or entries. These are arranged in a columnar fashion, with each entry starting with a number. The notes are written in a cursive script, and they appear to be a continuation of the information provided in the first part of the document.

5. The fifth part of the document is a series of short, handwritten notes or entries. These are arranged in a columnar fashion, with each entry starting with a number. The notes are written in a cursive script, and they appear to be a continuation of the information provided in the first part of the document.

6. The sixth part of the document is a series of short, handwritten notes or entries. These are arranged in a columnar fashion, with each entry starting with a number. The notes are written in a cursive script, and they appear to be a continuation of the information provided in the first part of the document.

7. The seventh part of the document is a series of short, handwritten notes or entries. These are arranged in a columnar fashion, with each entry starting with a number. The notes are written in a cursive script, and they appear to be a continuation of the information provided in the first part of the document.

8. The eighth part of the document is a series of short, handwritten notes or entries. These are arranged in a columnar fashion, with each entry starting with a number. The notes are written in a cursive script, and they appear to be a continuation of the information provided in the first part of the document.

9. The ninth part of the document is a series of short, handwritten notes or entries. These are arranged in a columnar fashion, with each entry starting with a number. The notes are written in a cursive script, and they appear to be a continuation of the information provided in the first part of the document.

10. The tenth part of the document is a series of short, handwritten notes or entries. These are arranged in a columnar fashion, with each entry starting with a number. The notes are written in a cursive script, and they appear to be a continuation of the information provided in the first part of the document.




Fig 1. Photomicrograph of liver showing non-caseating epithelioid cell granuloma of sarcoidosis, containing multinucleated giant cells. H&E  $\times 360$

bin, 7.6 g/100 ml, white cell count, 26,000  $\mu$ l, and reticulocyte count 12%. The serum bilirubin was 5.2 mg/100 ml. The direct antiglobulin test was strongly positive. The serum proteins and electrophoretic pattern were still within normal limits and fluorescent antibody tests for antinuclear factor were negative. The bone marrow examination revealed erythromyeloid hyperplasia. A diagnosis of acute haemolytic anaemia of warm antibody type was made, but before treatment could be started he died.

At autopsy (J J T) the tissues were jaundiced. The liver now appeared macroscopically normal but histologically there were many lymphoid and reticulum cells in the portal tracts. The mediastinal and abdominal lymph nodes were visibly enlarged and histologically there was replacement of germinal follicles by lymphoid cells with some larger cells of reticulum cell type. The bone marrow, kidneys and liver contained multiple nodules which closely resembled the original liver biopsy in his-

tological appearance. The lungs showed areas of organized and acute pneumonic changes. Guinea pig inoculation of the bone marrow taken at autopsy failed to show any abnormality.

### Discussion

The diagnosis of sarcoidosis in this patient was made on the basis of typical histological findings, multiple organ involvement, and exclusion of other categories of granulomatous disease [36]. A negative Ascoli test does not necessarily preclude this diagnosis [27, 40]. Massive splenomegaly as the presenting feature of sarcoidosis, although described previously [3, 5, 15, 18-29, 45] is unusual and poses diagnostic problems. Enlargement of this organ, irrespective of the primary aetiology may be associated with the syndrome of hypersplenism [39] with the development of either a pancytopenia or anaemia, leucopenia and thrombocytopenia in various combinations. Great diagnostic problems were encountered in our patient who initially presented with massive splenomegaly and subsequently developed pancytopenia. Diagnosis of sarcoidosis was made only after histological examination of the liver and splenic tissue obtained at laparotomy. Hypersplenism in sarcoidosis leading to pan- or selective cytopenia is a rare but well-documented complication [4, 9, 10, 12, 14, 16, 18-21, 23, 24, 28, 31-34, 37, 43]. However, it is still not known why only a minority of patients with sarcoidosis who have enlarged spleens develop either a total or selective cytopenia. In the present case and in all the reported examples of cytopenic syndromes in sarcoidosis the spleen has been infiltrated with sarcoid granulomata.

It is well recognized that splenectomy can lead to amelioration of the haematological complications in sarcoidosis [1, 4, 5, 15, 21, 28, 30, 33, 37]. Our patient was unusual in that he remained clinically well for 1 year following splenectomy and then died in an acute haemolytic crisis. However in 1946 Lissac *et al* [22] also reported a 23 year-old girl in whom splenectomy performed for the cytopenic syndrome affecting the white and red cell series with a normal platelet count was followed by complete haematological remission. 6 months later she developed a haemolytic crisis which responded to ACTH therapy. A year later she developed a fatal septicemia.

Severe haemolytic anaemia in sarcoidosis is rare and to date only 13 patients have been reported. The salient features of these together with the present case have been summarized in table I. It is apparent that haemo-

Table I Haemolysis

Reference	Age	Sex	Race	Lowest haemoglobin	Peak reticulo- cyte count, %	White cell count/ $\mu$ l	Platelet count/ $\mu$ l
CRANE and ZETLIN [7]	45	F	Negro	41%.	44	15,600	150,000
STATS <i>et al.</i> [41]	8	F	Negro	43%.	15	6,600	270,000
McCORT <i>et al.</i> [25]	58	M	white	55%.	NR	9,900	NR
BRUSCHI and HOWE [2]	45	F	Negro	52 g%.	22	1,900	274,000
SCHU- BOTHIE [38]	16	M	white	NR	incr.	NR	NR
DAVIS <i>et al.</i> [8]	34	M	Negro	61 g%.	12	6,800	204,000
LEBACQ <i>et al.</i> [22]	23	F	white	32%.	23.6	10,700	NR
MICHON <i>et al.</i> [26]	52	M	white	7.7 g%.	NR	4,800	NR
JOHANS- SON [17]	33	F	white	24%.	24%.	30,000	409,000

## In sarcoidosis

Ant body coombs test	Diagnosis confirmed by	Involvement of spleen with sarcoid granulomata	Management	Outcome
NR	lymph node bone marrow	-	splenectomy	fatal haemolytic crisis 5 days after splenectomy
NR	axillary lymph node	unknown	non-specific	NR
NR	med axillary lymph node	-	splenectomy	recurrence of haemolytic anaemia 8 months after splenectomy final outcome not known
not demonstrated	liver spleen lymph node	+	splenectomy	recurrence of haemolytic anaemia 8 months after splenectomy 5 years later patient well without treatment
direct Coombs +	sarcoid changes in the lung	unknown	corticosteroids	remission following corticosteroid therapy no long-term follow up
Coombs test -	cervical mass lymph node	+	corticosteroids and splenectomy	haemolytic crisis 35 months after splenectomy remission following corticosteroid therapy 10 months follow-up
direct Coombs +	spleen	+	corticosteroids	haemolytic anaemia occurred for the first time 8 months after splenectomy for a cytopenic syndrome initial response to corticosteroid therapy but patient died from bone marrow
direct and indirect Coombs +	lymph node	unknown	corticosteroids and ACTH	remission following corticosteroid therapy 6 months follow-up
direct Coombs +	lungs heart and	-	corticosteroids and splenectomy	no response to corticosteroids pericarditis and pulmonary embolism after splenectomy died from cerebral aneurysm 3 months after splenectomy

Table I

Reference	Age	Sex	Race	Lowest haemoglobin	Peak reticulo-cytic count, %	White cell count/ $\mu$ l	Platelet count/ $\mu$ l
GARCIA <i>et al</i> [13]	31	M	white	76%.	23	4,100	normal
WEST [42]	32	F	white	60 g%.	29.8	12,100	414 000
COX and DONALD [6]	29	M	white	NR	8	11,250	normal
WYSS and MAIER [44]	35	M	white	48%.	55	4,500	180 000
Present case	53	M	white	52%.	12	26 000	254 000

NR = Not recorded

molysis recurred in 3 [2, 8, 25], did not remit in 3 [6, 7, 17] and developed for the first time in 2 [22 and the present case] of the 11 patients who underwent splenectomy. Furthermore, only 7 of the 11 spleens examined contained sarcoid granulomata (table I), but in this context, it may be relevant that FARRER-BROWN *et al* [11] have recently stressed that meticulous care is required to detect deposits of Hodgkin's disease in excised spleens and no doubt a similar technique is required in order to reveal splenic granulomata in sarcoidosis. Nevertheless, the above observations suggest that splenic involvement is not the prime factor in the genesis of haemolytic anaemia in sarcoidosis. In some patients an autoimmune reaction must receive consideration. It is also reasonable to suppose that reticulo-endothelial tissue elsewhere in the body may have an aetiol-

(continued)

Antibodies Coomb's test	Diagnosis confirmed by	Involvement of spleen with sarcoid granulomata	Management	Outcome
NR	lymph nodes, hypercalcaemia	+	splenectomy and cortico- steroids	remission following splenectomy and corticosteroid therapy, no long term follow-up
Coomb's -	mediastinal mass	+	splenectomy	remission following splenectomy, follow-up for 1.5 months
Coomb's +	supraclavicular lymph node	-	splenectomy and cortico- steroids	no remission after splenectomy and corticosteroid therapy, ultimate outcome not recorded
Coomb's -	lymph nodes, lungs	+	splenectomy	remission following splenectomy, no long-term follow-up
direct Coomb's +	spleen, liver, lungs, kidneys	+	none	haemolytic anaemia occurred for the first time 1 year after splenectomy for pancytopenia, patient died in acute haemolytic crisis

logical role in both the causation and maintenance of the haemolytic process.

The best treatment of haemolytic anaemia in sarcoidosis remains uncertain. Splenectomy has been effective in only a minority of the patients [12-14] whereas a more aggressive approach has been advocated by

described by Cox and Donald [6] and Jonasson [17]. The case described by Craxi and Zileri [7] died in an acute haemolytic crisis 5 days after splenectomy and the patient reported by Jonasson [17] who had failed to respond to splenectomy and corticosteroids died from a cerebral insult. Our patient who had undergone splenectomy for a pancytopenia died a



year later in an acute haemolytic crisis before therapy with corticosteroids or immunosuppressive drugs could be instituted

*Acknowledgements* We are grateful to Dr A J REYES of the Cardiovascular Unit, University of Leeds, and Dr H LEDERER of the Doncaster Royal Infirmary, for the translation of the articles

### References

- 1 BERTINO, J and MYERSON, R M The role of splenectomy in sarcoidosis Arch intern Med 106 213-217 (1960)
- 2 BRUSCHI M and HOWE, J S Classification of haematologic variations and abnormalities associated with Boeck's sarcoid Review of the literature, report of case of thrombocytopenic purpura associated with sarcoidosis, with recovery following splenectomy Blood 5 478-490 (1950)
- 3 BURT, R W and KUIL, E T Giant splenomegaly in sarcoidosis demonstrated by radionuclide scintiphotography J amer med Ass 215 2110-2111 (1971)
- 4 CATTELL, R B and WILSON, R O Sarcoidosis of spleen Report of two cases. Lahey clin Bull 7 66-71 (1951)
- 5 COWDELL, R H Sarcoidosis with special reference to diagnosis and prognosis Quart J Med 23 29-55 (1954)
- 6 COX, W L and DONALD, J M Acquired hemolytic anemia and Boeck's sarcoidosis Review of the literature Amer Surg 30 199-202 (1964)
- 7 CRANE A R and ZETLIN, A M Haemolytic anaemia, hyperglobulinemia and Boeck's sarcoid Ann intern Med 23 892-899 (1945)
- 8 DAVIS A E, BELBER, J P, and MOVITT, E R The association of haemolytic anaemia with sarcoidosis Blood 9 379-383 (1954)
- 9 DICKERMAN, J D, HOLBROOK, P R, and ZINHAM W H Etiology and therapy of thrombocytopenia associated with sarcoidosis J Pediat 81 758-764 (1972)
- 10 EDWARDS, M H, WAGNER J A, and KRAUSE, L A M Sarcoidosis with thrombocytopenia Report of a case Ann intern Med 37 803-812 (1952)
- 11 FARRER BROWN, G, BENNET, M H, HARRISON, C V, MILLETT, Y, and JELLIFFE, A M The diagnosis of Hodgkin's disease in surgically excised spleens J clin Path 25 294-300 (1972)
- 12 FERGUSON H H and PARIS J Sarcoidosis study of 29 cases, with a review of splenic, hepatic, mucous membrane, retinal and joint manifestations. Arch intern Med 101 1065-1084 (1959)
- 13 GARCIA E L, GARRIDO T A, LORENZO, E M y GUEDES, J R Sarcoidosis con anemia hemolitica sintomática Rev clin esp 72 183-186 (1959)
- 14 HICKLING, R A Tuberculous splenomegaly with miliary tuberculosis of the lungs Quart J Med 7 263-269 (1938)
- 15 JACKSON A S Splenectomy in sarcoidosis Amer J Surg 94 802-805 (1957)
- 16 JERSID M The syndrome of Heerfordt (uveo-parotid fever) a manifestation of Boeck's sarcoid Acta med scand 97 322-328 (1938)

- 17 JONSSON W. R. Sarcoidosis (morbus Schaumann) och hemolytisk anemi. Nord Med 60: 1746-1749 (1959)
- 18 KAY S. Sarcoidosis of spleen. Report of 4 cases with a 23-year follow up in one case. Amer J Path 26: 427-443 (1950)
- 19 KNAUTH H. C., jr. Sarcoidosis of the spleen. New Engl J Med 257: 128-131 (1957)
- 20 KRAUSE, E. J. Sarcoidosis (Brock-Benier-Schaumann disease) as cause of Pott's syndrome. J Lab clin Med 28: 140-146 (1942)
- 21 KUNKEL, P. and YASSER, R. Thrombocytopenic purpura associated with sarcoid granulomas of the spleen. Arch Path 50: 779-786 (1950)
- 22 LABARO F., TISSAINT A., MAMILLAT, F. et PEUTGENS E. Sarcoidose de Benier-Schaumann avec anémie hémolytique par auto-immunisation. Bu'll Soc méd H p., Paris 72: 614-620 (1956)
- 23 LEMSCOTT, W. T. and FRIEDMAN D. G. Study of sarcoidosis based on combined investigation of 160 cases including 30 autopsies from John Haynes Hospital and Massachusetts General Hospital. Medicine Balt J: 1-132 (1952)
- 24 MATCHEK, R. I., BIRNBAUM P., MORRISON C. E., and SCOTT, J. H. Manifestation of sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Amer J Med 35: 67-89 (1963)
- 25 MCCOMB J. T., WOOD R. H., HAMPTON J. B., and FRIEDMAN D. I. Sarcoidosis. Clinical and roentgenologic study of 28 proved cases. Arch Intern Med 80: 293-321 (1947)
- 26 MICHON P., DORVILLE R., KINE C., LARCAN A. et HENRIET C. Anémie hémolytique avec auto-anticorps et maladie de Benier-Brock-Schaumann. Bull Soc méd H p., Paris 73: 903-909 (1957)
- 27 MICHAN, J. H. and MITCHELL, D. S. The Krum test in sarcoidosis. Postgrad med J 45: 444-449 (1970)
- 28 MIELCKEN W. Splenektomie bei einem Fall von Lymphogranulomatosis benigna (Schaumann). Acta med scand 137: 20-26 (1950)
- 29 MINO, R. A., FRIEDER R. W., MURPHY A. J., jr., and HUNTER J. W. Severe systemic sarcoidosis with anæmia and splenomegaly. Del med J 29: 65-73 (1948)
- 30 NICHOLAND M., YEASAYER R. S., LARSON P., and REHR, R. Pregnancy complicated by idiopathic thrombocytopenic purpura. Sarcoid disease of spleen, spleenectomy and subsequent normal delivery. case report. Mon Med 29: 166-170 (1946)
- 31 OLIVA OTTELO, G., TASSO-AQUINO M. T. y CASANOVA, F. Sarcoidosis generalizada. presentación de un caso que evoluciona con purpura trombocitopénica. Rev. clín. exp. 105: 140-145 (1967)
- 32 PARINSONIEMER R. E. and MEINERTZ, H. C. Splenomegaly with hyperproteinemia due to sarcoidosis. New Engl J Med 243: 810-812 (1950)
- 33 RIVINGTON, C. A., GRIFFITHS T. J., and ROTHMAN, A. Purpura haemorrhagica associated with sarcoidosis. Arch intern Med 81: 322-330 (1942)
- 34 RIVER, J. H. and PROCTOR M. Sarcoidosis: one case report and literature review of autopsy cases. Amer Rev Tuberc. 47: 146-163 (1941)
- 35 SARCOSIDIOS J. G. Sarcoidosis, p. 251 (Fyfe & Spence, second, London 1967)
- 36 SARCOSIDIOS J. G. The definition of sarcoidosis. Postgrad med J 45: 465-467 (1970)

- 37 SCHRIJVER H and SCHILLINGS P H M Thrombocytopoemic purpura with sarcoidosis cured after splenectomy *Acta med scand* 144 213-216 (1952)
- 38 SCHUBOTHS H Antikörperbedingte hämolytische Anämien *Verh dtsch Ges inn Med* 58 679-694 (1952)
- 39 SCOTT R B Spleen and splenectomy *Brit med J* i 1063-1070 (1949)
- 40 SILTZBACH L E Proc 4th int Conf Sarcoidosis Paris 1967 p 201
- 41 STALS D ROSENTHAL N., and WASSERMAN L R Hemolytic anaemia associated with malignant diseases *Amer J clin Path* 17 585-613 (1947)
- 42 WEST W O Acquired haemolytic anaemia secondary to Boeck's sarcoid Report of a case and review of the literature *New Engl J Med* 261 688-690 (1959)
- 43 WRIGHT C S DOAN C A BOURONCLE, B A., and FOLLINGER R M Direct splenic arterial and venous studies in hypersplenic syndromes before and after epinephrine *Blood* 6 195-212 (1951)
- 44 WISS S and MAIER C Hämolytische Anämie bei Sarkoidose der Milz *Acta haemat Basel* 37 126-136 (1967)
- 45 YOUNG H H and MOONEY R A H Giant splenomegaly in sarcoidosis *Brit J Surg* 55 554-557 (1968)

## Acute Myelo-Monocytic Leukaemia: A Terminal Complication of Paroxysmal Nocturnal Haemoglobinuria

III ZITTOUN, A. BERNADOU, J. M. JAMES, J. SORIA and J. BOUSSER

Service d'Hématologie Hôtel Dieu, Paris

**Key Words:** Myelo-monocytic leukaemia PNH Paraleukaemia

**Abstract** The authors report a case of acute myelo-monocytic leukaemia occurring in a patient, 3 years after the beginning of a typical paroxysmal nocturnal haemoglobinuria (PNH). An intermediate phase characterized by worsening of the anaemia was observed, with disappearance of the *in vitro* haemolysis tests. The kinetic studies showed a replacement of the early peripheral haemolysis by a bone marrow insufficiency with intra medullary cell death. A review of the five previous reported cases of this association show that PNH is generally a typical one so that acute leukaemia must be considered as an unfrequent but possible complication of any PNH.

It is well known that paroxysmal nocturnal haemoglobinuria (PNH) may be associated to aplastic anaemia [16], refractory anaemia [1, 24], or myeloproliferative diseases such as myelofibrosis [11]. The PNH syndrome, present since the beginning of these diseases, or occurring during their course is either conspicuous with clinical manifestations or limited to positive *in vitro* lysis test. Aplastic or refractory anaemia may evolve also in acute leukaemia [7, 15, 17]. Consequently, DAMESIEK [5] hypothesized in 1967 a link between PNH and acute leukaemia, both conditions resulting from abnormal clones developing in these diseases, whether idiopathic or secondary to toxic or radiations. This was confirmed soon after by five reported cases of acute leukaemia in patients suffering from PNH [3, 12-14, 23]. In the following case, when acute leukaemia was observed the early peripheral haemolysis was replaced by an intra medullary cell death.

### Case Report

**1st phase PNH** Mr S.D., a 21 year-old man, is referred in 1968 in the haematological department for bicytopenia noticed during the treatment of a sorethroat. He noted for 1 year a gradual onset of pallor and weakness. His past history was unremarkable, as so as the family history. However, in 1966, while in the army, he attended from a ship to an atomic bomb explosion, and he was told about a 'negligible' contamination of the drinkable water.

Physical examination showed nothing but skin and mucous pallor, with slight conjunctival icterus. There was no enlargement of liver, spleen, or lymph nodes. Nocturnal urins were darker than during the day, with frank haemoglobinuria.

The haematological data resulted in diagnosis of PNH. RBC  $2.6 \times 10^{12}/\text{mm}^3$ , Hb 7.6 g%, PCV 25%, MCV 98  $\mu\text{m}^3$ , MCHC 31%, reticulocytes 8.1%, WBC  $4.4 \times 10^3$  (PMN 24, lympho 16, mono 0.3). Platelets  $74 \times 10^3$ . On blood smears, many polymorphonuclears with Pelger's abnormality and giant platelets were observed. Bone marrow aspirate was hypercellular, with gross erythroid hyperplasia, some inter nuclear bridges between erythroblasts and a slight histio-monocytic infiltration (proerythroblasts 3%, erythroblasts basophilic 10%, polychromatophilic 20%, acidophilic 13%, myeloblasts 2%, promyelocytes 2.5%, myelocytes 2%, metamyelocytes 6%, poly neutro 13%, eosino 1%, monocytes 4.5%, round cells 19%). Serum iron 170  $\mu\text{g}/\text{g}$ , TIBC 305  $\mu\text{g}/\text{g}$ , serum total bilirubin 1.9 mg%, Coombs test negative. Haemosiderinuria ++ after Perl's staining, with 24 hour urinary iron excretion between 3 and 6 mg. The Ham-Dacie test was positive, as so as *in vitro* lysis tests with thrombin or sucrose. The red cell acetyl-cholinesterase was slightly lowered (0.44 U, normal 0.5-1). The leucocyte alkaline phosphatase was absent. Iron kinetics showed with  $^{59}\text{Fe}$  the typical pattern of PNH: plasma clearance was rapid with important fixation in sacrum, the red cell incorporation began early, at the third day, and increased to 50% with the characteristic curve break indicating an early peripheral haemolysis.

During 2 years, the course of the disease was characterized by haemoglobinuric crisis occurring at various moments and requiring transfusions of washed red cells, approximately each 2 weeks, then each month. No improvement was observed after corticoids, androgens or anti vitamin K.

**2nd phase PNH + excessive myeloblastosis** At the end of 1970, the patient suffered from herpes zoster and corticotherapy was stopped. Then the frequency of haemolytic crisis increased. The anaemia was more severe and the transfusions more difficult since the appearance of anti K, E and platelet antibodies. Hepatosplenomegaly developed.

At this time progressive modifications of the haematological data were observed: the reticulocyte count decreased to 138 then  $51 \times 10^3/\text{mm}^3$ , the WBC to 2.8 then  $1.3 \times 10^3/\text{mm}^3$  with marked neutropenia, and the platelets to  $46 \times 10^3/\text{mm}^3$ . There were rare immature circulating cells. Haemoglobinuria and haemosiderinuria were less pronounced, and the *in vitro* lysis tests were less positive (4% then <1% lysis with Ham test, and 20% then <2% with sucrose). The red cell acetyl cholinesterase increased to 0.72 U. The marrow aspirate was still hypercellular but with less erythroblasts (29%) and with an excess of myeloblasts (11.5 then 15.5%) and of mono-

cytes (7%). The myeloblasts, with frequent monocytoid features, had the cytochemical features of the granulocyte series (peroxidase +, Sudan black II +) and rare but unmistakable Auer bodies were observed. The study of the karyotype revealed no chromosomal abnormality. The search for some erythrocytic abnormalities was negative: there was no positive PAS staining of erythroblasts, nor hypernucleoblastosis. The activities of G-6-PD, 6-PGD, hexokinase and pyruvate kinase were normal. Only a moderate increase of HbF to 3% was observed.

Many differences appeared at a second ferrokinetic study: the erythrocytic incorporation of  $^{51}\text{Fe}$  was strongly reduced (maximum 10%) this bone marrow deficiency preventing the identification of a persistent early peripheral haemolysis. Inefficient erythropoiesis was also evidenced with a marked contrast between a still satisfactory bone fixation and a slow and incomplete release of  $^{51}\text{Fe}$ . This disorder was confirmed by autoradiography study carried out after *in vitro* labelling of bone marrow erythroblasts with  $^{3}\text{H}$  thymidine: the construction of a model according to the method developed by HAZAN *et al.* [18] was compatible with a significant intra medullary haemolysis.

At the end of this period, the anaemia worsened. An attempt of chemotherapy with 6-mercaptopurine and cytosine-arabine resulted in severe bone marrow failure, complicated with *Klebsiella septicemia*, followed by a return to the previous haematological status with excessive myeloblastosis.

**3rd phase: acute myelo-monocytic leukaemia.** This condition appeared in November 1971, characterized by hyperleucocytosis (WBC  $13.4 \times 10^9/\text{mm}^3$ , then  $8.6 \times 10^9$  2 months later) with blood myeloblastosis. The marrow was markedly hypercellular and contained 55.5% leucoblasts of the myelo-monocytic type. There were still many erythroblasts (30.5%) with arrest of their maturation at a very early stage. Numerous megakaryocytes were also observed, contrasting with a peripheral thrombopenia ( $11 \times 10^9/\text{mm}^3$ ). The myelo-monocytic type of this acute leukaemia was confirmed by the high levels of lysozyme in serum ( $42.5 \mu\text{g/ml}$ ) and urine ( $47 \text{ mg/l}$ ). At this stage the clinical and biological signs of PNH had completely disappeared with negative *in vitro* lysis tests.

The course of the disease was very short: a marked enlargement of liver (20 cm high) spleen (7 cm beyond the costal margin) and lymph nodes was observed. The patient suffered from bruise, buccal and anal ulcerations. He died on February 1972 from septicemia with pulmonary manifestations, renal failure and leuka. The autopsy showed, aside the lesions related to septicemia and diffuse haemorrhagic syndrome: a leukaemic infiltration of bone marrow, liver, spleen, as well as cutaneous, muscular and gastric areas — the last infiltration presenting as a necrosis and haemorrhagic pseudo-tumour (Prof. J. Durouan).

## Discussion

With our patient, there are now six reported cases of PNH terminating in acute leukaemia (table I). Although these observations support DAMON and KATZ's [6] opinion that any PNH is a potentially pre-leukaemic condition,

Table 1 Association PNH acute leukaemia

Reference	Age years	Sex	Delay, months		PNH		Type of acute leukaemia	Disap- pearance PNH when leukaemia occurs
			first sign diagnosis PNH	diagnosis PNH acute leukaemia	acute leukaemia- death	intermediate pre-leukaemic phase		
NALTMANN <i>et al</i> [14]	58	M	24	30	6	24	+	myeloblast + myelo- fibrosis
HOLDEN and LIGITMAN [12]	37	F	14	72	few	12	+	corticoids + iron
JENKINS and HARTMANN [13]	31	F	36	8	7	3	+	corticoids + iron
CARUEL <i>et al</i> [3]	32	M	1	4	complete remission	1	0	corticoids myelobl ?
TSIVREVIS <i>et al</i> [25]	50	M	36	36	4	0	+	vitamins erythro- myelobl
Present case	21	M	12	47	3	9	+	corticoids, erythro L folic acid androgens + corti- coids erythro- myelo- monocytic

it is probably a rare occurrence that has not been mentioned in important series and reviews until 1967 [4]. The clinical and biological features of PNH are characteristic in 5 out of 6 cases with paroxysmal haemoglobinuria haemosiderinuria positive *in vitro* lysis tests with acid sucrose or thrombine decrease of erythrocytic acetyl-cholinesterase [13] and of leucocytic alkaline phosphatase [14-25]. Usual complications may be observed such as allo-immunisation [3, 13] and thrombo-embolism. In only one single observation reported by CARMIEL *et al* [3] PNH was restricted to *in vitro* lysis test without haemoglobinuria during a pre leukaemic syndrome with circulating myeloblasts since the beginning the acute leukaemia supervening rapidly. The possibility of such positive tests and/or decrease of erythrocytic acetyl cholinesterase activity during common leukaemia or myeloproliferative diseases have already been emphasized [9].

In the five other cases acute leukaemia occurred after a prolonged course of typical PNH (from 4 to 7 years) and was characterized by worsening of anaemia with decrease of reticulocytes hepatosplenomegaly and lymph node enlargement [12, 13, 25]. The decrease of neutrophils and platelet led to infections and haemorrhagic complications and patients died within 3 to 7 months after unsuccessful chemotherapy. Autopsy conducted in the case of KAUTSMAN *et al* [14] and in our case showed the usual features of acute leukaemia with massive visceral infiltration. Before acute leukaemia became evident an intermediate phase was observed lasting from 1 to 24 months and characterized by progressive bone marrow failure [3, 12-14] and hepatosplenic enlargement [13]. The haematological examinations showed some abnormalities of pre leukaemic signification: hypochromasia [3, 25], acquired Pelger's abnormality [13], monocytosis [13], circulating immature cells such as erythroblasts, myelocytes [14, 25] and even some myeloblasts [3, 12, 13]. Bone marrow aspirates were difficult to get [12] because of myelofibrosis [14] and showed a relative excess of myeloblasts [12, 13]. Chromosomal abnormalities could have a prognostic value in view of their significance in the pre leukaemic conditions [20] and of their possible existence in PNH [26]. In fact only two cases have been studied and aneuploidy was found by CARMIEL *et al* [3] but there was no chromosomal abnormality in our case. At last the existence of possible leukaemogenic etiological factors may be interesting but such factors were not reported, except in our patient who undergone perhaps a continuous and increasing exposure.

The acute leukaemia reported after PNH included frequently erythroblastic proliferation with myeloblastosis [3, 12, 25] and in our case



as well as in HOLDEN's one [12], was of the myelo-monocytic type. It is interesting to point out that the acute malignancy evolving after acquired erythrocytic diseases such as refractory anaemia [2, 15, 27] or polycythaemia vera [23] are frequently of the erythroleukaemic type, the possible association of a monocytic proliferation [8] deserves the name of erythromonocytic leukaemia. Myelo-monocytic leukaemia, which involves the myeloid stem cell with abnormalities of all three myeloid lines [22], is the condition which exhibits the more frequent and multiple erythrocytic defects [28].

A decrease or disappearance of clinical and biological symptoms of PNH when acute leukaemia occurred has been noticed in three other cases [3, 12, 13]. The kinetic study carried out in our patient showed, however, that it is not a simple regression of a qualitative defect indicating the disappearance of the abnormal clone. Our study shows, indeed, that a severe bone marrow insufficiency makes it difficult to find again an early peripheral haemolysis, taking into account the very low erythrocytic incorporation of  $^{51}\text{Cr}$ . Moreover, inefficient erythropoiesis appeared, and the kinetic model constructed after  $^3\text{H}$  thymidine autoradiography suggests an haemolysis at a more primitive, intra-medullary stage. In fact numerous proerythroblasts and basophilic erythroblasts persisted in the bone marrow, with 'maturation arrest'. It can be assumed, therefore, that the characteristic abnormality of PNH which causes *in vivo* haemolysis, far from disappearing, involves during leukaemic transformation the most primitive stages of erythrocytic lines, thus inducing intra medullary cell death. This is however only an hypothesis: the cause of *in vivo* haemolysis in PNH remains unclear, and an intra medullary lysis associated with quantitative deficiency is usually found in malignant conditions, especially in acute leukaemia [19], or at a late phase of polycythaemia vera [21].

*Acknowledgment* We are grateful to Prof. Y. NAJEAN and Dr. C. DRESCH who performed the iron kinetic studies and autoradiography with  $^3\text{H}$  thymidine.

### References

- 1 BART J H. Paroxysmal nocturnal hemoglobinuria. Report of a case with refractory megaloblastic hypoplastic bone marrow, bizarre erythrocyte morphology and a positive Coombs test. *Arch Intern Med* 120: 487-493 (1967).
- 2 BLAIR T, HAYRD E D., and PEASE E L. Atypical leukemia. *J amer med Ass* 193: 139 (1966).

## PvII and Leukaemia

- 3 CARMEL, R., COLEMAN, C. A., JR., YATTEAL, R. E., and COSTANTINI, J. J.: Association of paroxysmal nocturnal hemoglobinuria with erythroleukemia. *New Engl. J. Med.* 29: 1329-1331 (1970).
- 4 DACEY, J. V.: The haemolysis, anaemias, congenital and acquired. IV. Paroxysmal nocturnal haemoglobinuria, 2nd ed., pp. 1125-1160 (Grune & Stratton, New York 1967).
- 5 DAMELIEUX, W.: Réflexions: What do aplastic anaemia, paroxysmal nocturnal hemoglobinuria (PNH) and 'hypoplastic' leukaemia have in common. *Blood* 30: 251-252 (1967).
- 6 DAMELIEUX, W.: Foreword and a proposal for considering PNH as a 'candidate' myelodysplastic disorder. *Blood* 33: 263-264 (1967).
- 7 DREYFUS, B., ROCHOUX, H., and SUTTER, C.: Anémies réfractaires enzymopathiques acquises des cellules ou des hématopoïétiques. *Souv. Rev. franç. Hémat.* 9: 65 (1967).
- 8 FINE, L., and SCHWARTZ, C.: Syndrome of erythremia di Guglielmo after splenic injury with anti-immune antibodies and terminating in acute monocytic leukemia. *Blood* 25: 845 (1965).
- 9 EVANS, D.: Paroxysmal nocturnal haemoglobinuria and leukaemia. *Brit. med. J.* 4: 300 (1967).
- 10 FLEISCHMANN, T., and BOHRER, F.: Aneuploidy in paroxysmal nocturnal hemoglobinuria. *Acta haemat.* 44: 231-253 (1970).
- 11 HANSEN, A. F., and KJELLMAN, S. A.: Paroxysmal nocturnal hemoglobinuria in myeloblasts. *Blood* 35: 428 (1970).
- 12 HODGSON, D., and LICHTMAN, H.: Paroxysmal nocturnal hemoglobinuria with acute leukemia. *Blood* 33: 293-294 (1969).
- 13 JENSEN, D. F., and HARTMAN, R. C.: Paroxysmal nocturnal hemoglobinuria terminating in acute myeloblastic leukemia. *Blood* 33: 274-282 (1969).
- 14 KAJTANOVIC, R. W., SCHWARTZ, G. P., and McFARLAND, W.: Paroxysmal nocturnal hemoglobinuria terminating in acute granulocytic leukemia. *Blood* 33: 287-291 (1969).
- 15 KATZ, J. P., LEE, G. R., WEISSER, M. M., and CARPENTIER, D. E.: Idiopathic refractory sideroblastic anemia. Clinical and laboratory investigation of 17 patients and review of the literature. *Medicine* 50: 179 (1971).
- 16 LEVINE, S. M., and DACEY, J. V.: The aplastic anaemia-paroxysmal nocturnal hemoglobinuria syndrome. *Brit. J. Haemat.* 33: 236 (1967).
- 17 MARTEL, G., DAMELIEUX, W., and BASSI-PAGET, M.: Sur les transformations des érythrocytes médulloires en leucocytes aigus. *Souv. Rev. franç. Hémat.* 1: 221-232 (1961).
- 18 NATHAN, Y., DREYFUS, C., and DREYFUS, C.: Modèle de l'érythrocytose obtenue à partir de l'urée ou de H<sub>2</sub>O<sub>2</sub> chimique par la modification de la régulation par le système de la chaîne de la chaîne de la chaîne. *Souv. Rev. franç. Hémat.* 11: 575 (1971).
- 19 NATHAN, Y., DREYFUS, C., and DREYFUS, J.: Résultats de l'expérimentation de l'érythrocytose dans le cas d'anémie due à une hémopathie maligne à ce stade avancé. *Souv. Rev. franç. Hémat.* 9: 131 (1967).
- 20 NATHAN, Y., and C. M.: Marrow chromosomal studies in 'pre-leukemia'. *Leukemia* 1: 100-101 (1971).

- 21 POLLACOVÉ M, WINCHELL, H S, and LAWRENCE, J H Classification and evolution of patterns of erythropoiesis in polycythemia vera as studied by iron kinetics *Blood* 28 807 (1966)
- 22 SAARNI M I and LENMAN J W Myelomonocytic leukemia Disorderly proliferation of all marrow cells *Cancer* 27 1221 (1971)
- 23 SCOTT R B, ELLISON R R., and LEVY, A H A clinical study of twenty cases of erythroleukemia (di Guglielmo's syndrome) *Amer J Med* 37 162 (1964)
- 24 SULTAN, C., COSSON A, PRIOLET, G et DREYFUS B Anémie sidéroblastique compliquant l'aplasie médullaire *Nouv Presse méd* 1 443-445 (1972)
- 25 TSEVENIS H, POUCCOURAS P, SEMOS A, CONTOPOULOU I PAPAZACHARIAS, A et DARIOOTS A Evolution d'une hémoglobininurie nocturne paroxysmique, maladie de Marchiafava Micheli en leucose aigue *Nouv Rev franç Hémat* 10 274-277 (1970)
- 26 TSUCHIMOTO, T, ISHII Y, UCHENO H, and INOUE, S Paroxysmal nocturnal hemoglobinuria with chromosome abnormalities Possible preleukaemia. *Lancet* i 617-618 (1970)
- 27 VILTER R W, WILL, J J., and JARROLD, T Refractory anemia with hyperplastic bone marrow *Semin Hemat* 4 175 (1967)
- 28 ZITTOUN, R, BERNADOU, A, LECLERC, M, POUILLART, P, SORIA, J, COSSON, G, VAGNER, D, BILSKI PASQUIER, G et BOUSSER J Recherche de différentes anomalies érythrocytaires dans les leucémies *Rev europ ét clin biol* 15 215-219 (1970)

## Anti-Heparin Activity of a Macroglobulin from a Patient with Breast Adenocarcinoma

F. POGGIANI, L. CORRANDESCO, and C. PRAGA

Medical Clinic I (Head: Prof. F. E. POLI) University of Milan, Milan

**Key Words:** Anti-heparin • Bleeding disorders • Macroglobulin • Paraproteinemia • Platelet aggregation

**Abstract.** We describe a case of IgM paraproteinemia, whose macroglobulin reacted anomalously with heparin. Anti-heparin activity of the paraprotein was suggested by linessibility of the patient's plasma to heparin in heparin-thrombin clotting time. Moreover, the presence of heparin in the medium markedly reduced the inhibitory effect of the paraprotein on platelet aggregation by ADP.

Dysproteinemic syndromes are frequently associated with coagulation anomalies, which may result in a bleeding tendency [5, 6, 8, 10] or, sometimes, in thrombosis [1, 11].

Recently we observed a case of IgM paraproteinemia, in which two opposite anomalies were present: the patient had a bleeding tendency and, at the same time, an linessibility to heparin due to an anomalous interaction between the paraprotein and heparin.

### Case Report

A. M., a housewife aged 57, was admitted to our haematological division in November 1971 because of symptomsology characterized by deep aches, thoracic pain, parasthesia, articular burnings and headache. Blood analysis showed slight anaemia (Hb 10 g/l) and a clearly altered electrophoretic pattern. Electrophoresis on cellulose acetate detected the presence of a large peak in the  $\gamma_2$  region (total protein 11.2 g/l) of a monotypic nature, which by immunoelectrophoresis was shown to be formed by an IgM k type. After ultra-centrifugation several different components with high sedimentation constants were noted; the most common component

having a sedimentation constant of 28.2 S. Bence Jones protein was not found in the urine. Abnormal data for haemostasis are reported in the results.

Since a bleeding tendency was present several plasmaphereses were performed. The electrophoretic pattern and the haemostasis indexes clearly improved. The patient was discharged in good general condition. About 1 year later, during a periodical examination, a large, hard, irregular nodule adherent to the superficial and deep layers was detected in the right breast. The axillary lymph glands were not palpable. Liver and spleen were normal. Several plasmaphereses were performed to prepare the patient for surgery. A right mastectomy was carried out with emptying of the corresponding axillary nodes. From histological examination of the mammary nodule a diagnosis of breast adenocarcinoma was made. The post-operative period was good and the patient was discharged a month after the operation in tolerable general condition.

### *Materials and Methods*

*Heparin* (Liquemin, Roche) was diluted in saline. A stock solution (10 IU/ml) was kept at  $-20^{\circ}\text{C}$  in small aliquots until use. Serial dilutions (from 0.25 to 10 IU/ml) were prepared just before the test.

*Thrombin* (Topostasine, Roche) was diluted in saline. A stock solution (30 NIH units/ml) was kept at  $-20^{\circ}\text{C}$  in small aliquots until use. These were thawed just before the test, diluted in saline to 10 NIH units/ml and kept on ice during the test.

*Adenosine 5-diphosphate* (ADP, Biochemia) dissolved in buffered saline pH 7.4 was used at final concentrations of  $8 \times 10^{-4}$  or  $8 \times 10^{-5}$  M.

*Thromboxan* (TBX, Orto) was used as stock solution.

*Preparation of platelet rich (PRP), platelet poor plasma (PPP) and serum.* Blood samples from the patient and normal subjects were added to citrate (one part of 3.8% trisodium citrate to 9 parts of blood) or heparin (0.2 ml heparin 100 IU/ml to 9.8 ml blood) and centrifuged at 400 g for 10 min to obtain the PRP and at 2,000 g for 20 min to obtain the PPP. All equipment for handling blood and plasma was plastic or siliconized. Serum from the patient's blood was obtained after 4 h incubation at  $37^{\circ}\text{C}$  in glass tubes and centrifugation at 2,000 g for 20 min.

*Gel filtered platelets (GFP)* were obtained by the method of TANGEN *et al* [12].

*Coagulation studies.* The following standard assays were used in the coagulation studies: standardized bleeding time [MIELKE], clotting time [LEE WHITE], platelet count [CRISLY LORRY], prothrombin time [QUICK], thrombin time [BRIGGS], partial thromboplastin time [MACFARLANE], plasma recalcification time [HOWELL], thromboelastogram [HARTERT], clot retraction [FONVIO], coagulation factor VIII [BRIGGS], serum fibrin(ogen) derivative products (FDP) [MERKSLEY]. Fibrinogen was determined by a method of heat precipitation [RECALCATI].

*Heparin-thrombin clotting time* was performed at  $37^{\circ}\text{C}$  by addition of 0.05 ml of various concentrations of heparin and 0.1 ml thrombin (10 NIH units/ml) to 0.25 ml PPP, according to the method of HARADA and ZUCKER [3].

*Platelet aggregometry.* The changes in optical density of both PRP and GFP induced by ADP and TBX were measured in an FCL 169 platelet aggregation meter.

## Anti Heparin Activity of Macroglobulin

Table 1 Routine coagulation studies and effect of plasmaphereses on coagulation tests

	Before plasmaphereses	After plasmaphereses	Normal
Bleeding time, min	8	3	<4
Platelets $\times 10^3/\mu$ l	150	200	250-350
Prothrombin time, sec	14.5	12.5	12-14
Thrombin time, sec	24	17	17-24
Partial thromboplastin time, sec	40	42	35-40
Howell time, sec	60	140	85-140
Plasma clot retraction	280	---	----
Fibrinogen, mg/100 ml	-	340	200-400
Factor VIII %	310	90	95
Thromboelastogram	90		7-10
r	26	-	6-8
k	31	-	50-65
ma	30	absent	absent
Serum FDP	absent	absent	absent

<sup>a</sup> 301 litres of plasma removed over a 7-day period

(Trans Electromedex Ltd) connected to a pen recorder (Servogor I near logarithmic integrating recorder) to permit the automatic registration of variations in the transmitted light. The sensitivity was adjusted so that PPP or buffer (in the case of GIP) was set close to 100% and PRP or GIP was set to 0%. Reagents were added to the cuvette of the aggregometer as follows: 0.8 ml PRP or GIP, 0.2 ml saline or PPP and 0.2 ml ADP or TRX.

## Results

**Coagulation and fibrinolysis studies.** The results are reported in table 1. Prolonged bleeding and Howell times, a deficient plasma clot retraction and an altered thromboelastogram were observed before plasmaphereses. Anti-heparin activity of macromolecule. After addition of heparin to the patient's plasma or serum a dense precipitate appeared. The heparin in thrombin clotting time was not prolonged by increasing concentrations of heparin added to the patient's citrated PPP until a concentration of 10 IU/ml (fig. 1). Anti-heparin activity also was present in the patient's serum.

having a sedimentation constant of 28.2 S Bence Jones protein was not found in the urine Abnormal data for haemostasis are reported in the results

Since a bleeding tendency was present, several plasmaphereses were performed The electrophoretic pattern and the haemostasis indexes clearly improved The patient was discharged in good general condition About 1 year later, during a periodical examination a large, hard, irregular nodule adherent to the superficial and deep layers was detected in the right breast The axillary lymph glands were not palpable Liver and spleen were normal Several plasmaphereses were performed to prepare the patient for surgery A right mastectomy was carried out with emptying of the corresponding axillary nodes From histological examination of the mammary nodule a diagnose of breast adenocarcinoma was made The post-operative period was good and the patient was discharged a month after the operation in tolerable general condition

### *Materials and Methods*

*Heparin* (Liquemin Roche) was diluted in saline a stock solution (10 IU/ml) was kept at  $-20^{\circ}\text{C}$  in small aliquots until use, serial dilutions (from 0.25 to 10 IU/ml) were prepared just before the test

*Thrombin* (Topostasine, Roche) was diluted in saline, a stock solution (30 NIH units/ml) was kept at  $-20^{\circ}\text{C}$  in small aliquots until use, these were thawed just before the test, diluted in saline to 10 NIH units/ml and kept on ice during the test

*Adenosine 5-diphosphate* (ADP, Biochemia) dissolved in buffered saline pH 7.4 was used at final concentrations of  $8 \times 10^{-4}$  or  $8 \times 10^{-2}$  M

*Thrombofax* (TBX, Orto) was used as stock solution

*Preparation of platelet rich (PRP) platelet poor plasma (PPP) and serum* Blood samples from the patient and normal subjects were added to citrate (one part of 3.8% trisodium citrate to 9 parts of blood) or heparin (0.2 ml heparin 100 IU/ml to 9.8 ml blood) and centrifuged at 400 g for 10 min to obtain the PRP and at 2,000 g for 20 min to obtain the PPP All equipment for handling blood and plasma was plastic or siliconized Serum from the patient's blood was obtained after 4 h incubation at  $37^{\circ}\text{C}$  in glass tubes and centrifugation at 2,000 g for 20 min

*Gel filtered platelets (GFP)* were obtained by the method of TANGRY *et al* [12]

*Coagulation studies* The following standard assays were used in the coagulation studies: standardized bleeding time [MIELKE], clotting time [LEX WHITE], platelet count [FELISLY LEDIN], prothrombin time [QUICK], thrombin time [BRIGGS], partial thromboplastin time [MACFARLANE], plasma recalcification time [HOWELL], thromboelastogram [HARTERT], clot retraction [FONIO], coagulation factor VIII [BRIGGS], serum fibrin(ogen) derivative products (FDP) [MERKSEY] Fibrinogen was determined by a method of heat precipitation [RICALCATI]

*Heparin thrombin clotting time* was performed at  $37^{\circ}\text{C}$  by addition of 0.05 ml of various concentrations of heparin and 0.1 ml thrombin (10 NIH units/ml) to 0.25 ml PPP, according to the method of HARADA and ZUCKER [3]

*Platelet aggregometry* The changes in optical density of both PRP and GFP induced by ADP and TBX were measured in an EEL 169 platelet aggregation meter




Fig 3 Thrombin time (TT) of normal and the patient's PPP after intravenous injection of heparin (50 mg)

Table II Platelet aggregation by ADP ( $5 \times 10^{-7}$  M) and TBA of normal and the patient's PRP

	Platelet aggregation %	
	patient	normal
ADP	40	90
TBA	41	90

Table III Effect of addition of the patient's citrated PPP (C-PPP), the patient's heparinized PPP (H-PPP) and normal citrated PPP on the aggregation both of normal and the patient's gel filtered platelets (GFP)

	Platelet aggregation by ADP ( $5 \times 10^{-7}$ M) %		
	patient's C-PPP	patient's H-PPP	normal C-PPP
Patient's GFP	0	30	40
Normal GFP	20	80	90

whereas 90% was observed with normal PRP (table II). Moreover, the addition of the patient's citrated PPP to gel filtered platelets both from the patient and from a normal subject provoked a marked inhibition of platelet aggregation by ADP ( $5 \times 10^{-7}$  M). On the other hand, the addition of the patient's heparinized PPP to the platelets had only a slight inhibitory effect on platelet aggregation by ADP (table III).






Fig 1 Heparin thrombin clotting time (HTT) of normal and the patient's PPP




Fig 2 Heparin thrombin clotting time (HTT) of mixtures of normal and the patient's plasma

When increasing concentrations of the patient's plasma were added to normal plasma the heparin thrombin clotting time of the mixture was decreased (fig 2). Even very low concentrations of the patient's PPP (5%) reduced the clotting time to a measurable value.

The effect of heparin *in vivo* was studied by injecting a standard dose (50 mg) intravenously into the patient and into a normal subject of the same age and sex. Thrombin time was determined at various times after injection (fig 3). Although the thrombin time of the normal PPP was greater than 1 min within 5 min after heparin injection the thrombin time of the patient's PPP remained about 13 sec.

**Platelet aggregation in the presence of the paraprotein.** When ADP ( $8 \times 10^{-7}$  M) or TBA were tested for platelet aggregation against the patient's PRP only 50% aggregation was registered in the aggregometer.

- 2 DE GATTANO, G., VANDENBROUCKE, A. et VERMYLEN J.: Etude de l'aggrégation plaquettaire pour le Thromboplastine. *Experientia* 28 1127-1128 (1972)
- 3 HARADA, K. and ZUCKER, M. B.: Simultaneous development of platelet factor 4 activity and release of 14C-acetone. *Thromb. Diath. haemorrh.* 25 41-45 (1971)
- 4 GLUTCK, H. I., MACKENZIE, M. R., and GLUTCK, C. J.: Crystalline IgG protein in multiple myeloma: Identification effects on coagulation and on lipoprotein metabolism. *J. Lab. clin. Med.* 77 731-744 (1972)
- 5 LACKNER, H.: Hemostatic abnormalities associated with dysproteinemias. *Semin. Hemat.* 10 125-133 (1973)
- 6 LACKNER, H., HUNT, V., ZUCKER, M. B., and PEARSON J.: Abnormal fibrin ultrastructure, polymerization and clot retraction in multiple myeloma. *Brit. J. Haemat.* 13 625-636 (1970)
- 7 MILLER, D.: Heparin precipitability of the macroglobulin in a patient with Waldenström's macroglobulinemia. *Blood* 16 1313-1317 (1960)
- 8 NURDIN, J. E. and NURDIN, I. M.: Coagulation studies in different types of myeloma. *Acta med. scand.* 179 suppl. 445, pp. 194-197 (1966)
- 9 PEARSON, H. A., MACKENZIE, M. R., and FREDERICK, H. H.: Hemostatic defects in dysproteinemias. *Blood* 35 695-707 (1970)
- 10 PRIGÉ, C., JEAN, G. et CHATELAIN, M.: Anomalie de la formation du caillot dans un cas de IgG myélome: Influence de la paraprotéine isolée sur la coagulation et étude ultrastructurale du caillot. *Nouv. Rev. franç. Hémat.* 7 343-346 (1967)
- 11 TAJERMAN, A.: Thromboembolic complications in myelomatosis. *Br. L. med. J.* iii 707 (1970)
- 12 TANGEN, H., RICHMAN, H. J., and MARLEY, P.: Gel filtration: A new technique for separation of blood platelets from plasma. *Thromb. Diath. haemorrh.* 25 265-274 (1971)

### Discussion

The blood of the patient contained a paraprotein which reacted anomalously with heparin, forming a precipitate visible to the naked eye. The protein was shown by immunological analysis to be an IgM,  $\lambda$  type, present in the plasma as a complex. Studies on the physical and chemical structure of the complex are in progress. The paraprotein was responsible for the haemostatic changes (bleeding time and clot retraction), which improved after repeated plasmaphereses.

Furthermore, from studies with gel filtered platelets, it was shown that the paraprotein interfered with platelet aggregation induced by ADP and Thromboxan [2], probably masking the specific receptors for aggregating agents. The presence of heparin in the reaction mixture markedly reduced the inhibitory effect of the paraprotein. Anti-heparin activity of the paraprotein was suggested by insensibility of the patient's plasma to heparin in heparin-thrombin clotting time. It was confirmed by demonstrating that the patient's plasma shortened the heparin-thrombin clotting time of normal plasma, even at very low concentrations. Moreover, the intravenous injection of a high dose of heparin did not prolong the thrombin time.

In 1960, MILLER [7] described an IgM macroglobulin which was able to precipitate heparin *in vitro*. GLUECK *et al* [4] reported a patient who was a carrier of a paraprotein IgG,  $\lambda$  type, and who had three thrombotic events that disappeared after administration of extremely high doses of heparin. It is probable that in the case described by GLUECK *et al* the anomalous globulin exerted a 'procoagulant' action. We cannot exclude an analogous action for the paraprotein of our patient. It may be significant that in our patient the clinical symptoms of bleeding were not remarkable, although several abnormalities of coagulation and platelet function were present.

The nature of the interaction between heparin and paraprotein is not clear. Immunological binding between the complex and heparin is a possible explanation, but non specific affinity cannot be excluded. Studies on the chemical structure and the nature of the interaction between heparin and macroglobulin are in progress.

### References

- 1 CATOVSKY, D., IKOKU, N. B., PITNEY, W. R., and GALTON, D. A. ■ Thrombotic complications in myelomatosis. *Brit. med. J.* III 433-439 (1970).

## Hairy Cell Leukemia ('Leukemic Reticuloendotheliosis'), Reticulosarcoma, and Monocytic Leukemia

Cytochemical and Ultrastructural Investigations

I. SCHMALZ, II. HUBIN, H. ASAMER and H. BRAUNSTEINER

Department of Internal Medicine (Head: Prof. H. Braunsteiner), University of Innsbruck,  
Innsbruck, and Division of Hematology, I. Department of Medicine  
(Acting Head: Prof. R. Marx), University of Munich, Munich

**Key Words:** Cytochemistry · Electron microscopy · Hairy cell leukemia · Monocytic leukemia · Reticulosarcoma · Reticulosis

**Abstract.** Cytochemical and electron-microscopic studies have been carried out on leukemia, monocytes and 'hairy cells' (HC), reticulosarcoma (RS) cells and cells of cases of reticulosis and 'reticulosarcoma cell leukemia'. Additional investigations included quantitative determinations of the urinary hyaline excretion, skin and bone studies, testing of the phagocytosis of ferritin by HC, and labeling of the Fc receptors on HC at the ultrastructural level. Clear evidence against any cytological relationship among leukemia, HC and monocytes have been provided. Further results argued also against the frequently stressed relationship among leukemia, monocytes and RS cells. Cases of RS cell leukemia and 'reticulosis' had to be reclassified as lymphosarcoma cell leukemia, acute lymphatic and myeloblastic leukemias. Besides distinct ultrastructural differences among HC, RS cells, and lymphocytes, mainly gradual differences have been noted using cytochemical methods and by evaluating the phagocytosis of ferritin particles. A further common trait of HC, RS cells, and B lymphocytes seems to be the presence of surface Fc receptors. A more precise classification in each of the diagnosed 'reticulosarcoma' and 'reticulosarcoma cell leukemia' is required, and the use of the term 'hairy cell' leukemia is suggested instead of the misleading term 'leukemia reticuloendotheliosa'.

The origin of the blood monocytes from the reticuloendothelial system (RES) was first proposed by SCHUMER and subsequently was widely accepted [for literature see 33-64]. Accordingly, monocytic leukemia continued until quite recently to be defined as the merely leukemia manifestation of a general edematous process of the RES, as opposed to the localized tumorous reticulosarcoma. Development of leukemia following a primary 'reticulosis'

MATHIÉ, G. SCHWARZENBERG L. and POURLIART, P. Nomenclature, Methodology, and Results of Clinical Trials in Acute Leukemias; in RENTCHINICK P (ed) Recent Results in Cancer Research, Vol 43 Springer Berlin 1973 \ + 168 pp fig 79, tab 64 DM 58,-/US \$ 23.80

Diese Publikation basiert auf den Mitteilungen die an einem internationalen Workshop am CNRS in Paris im Juni 1972 präsentiert wurden. Bei der akuten Lymphoblastenleukämie (ALL) liegt das Schwergewicht eindeutig auf der Unterteilung in 4 zytologische Typen welche sich mit konventioneller Färbung unterscheiden lassen. Dass diese neue Klassierung grosse diagnostische, therapeutische und prognostische Bedeutung hat wird vor allem am Patientengut aus Villejuif dokumentiert. Zytochemie und Elektronenmikroskopie leukämischer Zellen werden anhand der Daten aus verschiedenen Zentren neu auf ihre Aussagekraft geprüft. Vor allem bei der Zytochemie ist auffallend wie gross die Divergenzen der Meinungen sind. Dies kommt einerseits zustande durch methodische Unterschiede und anderseits durch die subjektive Interpretation von Positivität bzw. Negativität. Die Akten über den Wert der Zytochemie in der Diagnostik der akuten Leukämien konnten also auch bei diesem Workshop durchaus nicht geschlossen werden. Die therapeutischen Trials bei ALL an verschiedenen Zentren zeigen erfreulich gute Resultate, und neue Wege scheinen sich anzubahnen um die Prognose noch weiter verbessern zu können. Bei der akuten myeloischen Leukämie (AML) sieht es trotz höherer Remissionsraten noch düster aus. Vor allem wird man pessimistisch gestimmt durch die kooperative Studie der europäischen Gruppe (EORTC). Im ganzen ist das Buch für Hämatologen und Onkologen sehr stimulierend und gibt einen guten Überblick über den heutigen Stand in der Diagnostik und Therapie der akuten Leukämien.

B. SPECK Basel





Fig. 1. a Typical hairy cell, monocyte. b Typical hairy cells: the nuclei are fused (monocyte area  $\times 140$  mm). c d The cytoplasmic projections ( $\times 170$ ) vary in size and frequency as well as in the superficial extension. The nuclei are fused (monocyte area  $\times 110$  mm). e Reticulation: area IRS of the bone PBS cell: nucleus of the element of a plasma cell: note the texture of the nucleus (the  $\times 170$  mm). f Atypical hairy cell: cytoplasmic projections in IRS cells of a hairy node: present. Morphology:  $\times 140$  mm. g  $\times 120$  mm. h  $\times 140$  mm.







sarcoma' or 'histioblastic lymphoma' and occurrence of tumors in monocytic leukemia were felt to corroborate SCHILLING's opinion. Confusion arose as BOURONCLL *et al.* [7] termed 'leukemic reticuloendotheliosis' an obviously new recognized nosological entity, referring to EWALD [13], who in 1923 - using this term - described what he thought to be a leukemic manifestation of a malignant process involving primitive cells of the RES.

However, recent investigations led to a thorough characterization of the normal blood monocytes so far as their myelogenous origin [16, 17, 33, 53, 57], their kinetics [18, 39], their ultrastructure [6, 19, 26, 44, 65] and cytochemistry [33, 44, 55, 67], their functional capacities [16, 55], and their immunological membrane properties [25] are concerned. These peculiar features unequivocally distinguish monocytes from other hematopoietic or blood cells. Furthermore, monocytic leukemia has been studied with the same techniques, and their close relationship to normal monocytes and their physiological precursors has been proved [4, 15, 25, 27, 33, 52, 56].

We studied the cytochemistry, ultrastructure, and functional capacities of the leukemic cells in patients with 'hairy cell' and monocytic leukemia as well as with 'reticulosarcoma' and 'reticulosarcoma cell leukemia' (RC-leukemia). The results and conclusions drawn from these comparative studies are presented.

### *Material and Methods*

Blood and bone marrow smears were studied in the following cases:

17 patients with monocytic leukemia. The diagnosis of monocytic leukemia was made following to previously outlined criteria [52, 56]. According to these, 2 cases were defined as 'immature' monocytic leukemia. 15 patients exhibited the criteria of 'mature' monocytic leukemia (fig. 1a).

One patient, whose histological examination of the bone marrow biopsy prompted the diagnosis of 'reticulosis' (presence of considerable argyrophilic reticulin fibers). However, according to the cytochemical and ultrastructural criteria, this case was classified as atypical 'monomyelocytic' leukemia [58] (case 3).

10 patients suffering from 'hairy cell' leukemia (HC-leukemia) (fig. 1b-d).

4 patients with the first diagnosis of 'reticulosarcoma' who subsequently developed frank leukemia (RC-leukemia, fig. 1e). Smears and imprints of 'reticulosarcoma' cells were studied as follows. Imprints of 4 lymph nodes in which the histological diagnosis of 'reticulosarcoma' had been made. Smears of pleural effusion of a patient cited in the aforementioned group in which conspicuous 'reticulosarcoma' (RS) cells were present in the pleural fluid (case 9, fig. 1f). Smears from bone marrow aspiration of a patient (case 10) suffering from a 'reticulosarcoma of the bone' with infiltration of the bone marrow, but without neoplastic cells in the peripheral blood.

Cytochemical stainings were performed in all smears and imprints listed above. The



Table I

Case No	Cytological type of leukemia or tumor	Number of cases	POX	SuB	Chloroacetylase	AcP-L + tartrate	AcP-L + tartrate
1	monocytic I mature	15	(+) - +	+ - +	(+) - +	++ - +++	  (+)
2	immature	2	(+) - +	+ - +	(+) - +	+ - +++	 (+)
3	monomyelocytic I	1	+ - +++	+ - +++	(+) - ++	+ - +++	 (+)
4	lymphosarcoma cell I	2	-	-	-	+	nd
5	undifferentiated I	1	-	-	-	(+) - +	 nd
6	myeloblastic I	1	(+) - +	+ - +	- - +	(+) - +	 nd
7	'hairy cell' I	10	- - -	- - (+)	- - -	+ - +++	+ - ++
8	'reticulosarcoma' lymph node imprints	4	- - -	- - (+)	- - -	- - +	- - +
9	smears from pleural effusion	1	- - -	- - (+)	- - -	- - +	- - (+)
10	bone marrow aspirate	1	- - (+)	- - (+)	- - -	(+) - ++	- - +

- = Negative (+) = uncertain positive staining, + = weak positive staining, ++ = moderate positive staining, +++ = strong positive staining nd = Not done




Fig. 3. a) Leukemic monocyte. Nucleus (N), sheets of rough endoplasmic reticulum (RER), Golgi apparatus (G), mitochondria (M), small granules (GR). A thymocyte is phagocytosed by the cell (TH). b) Leukemic monocyte. Densest of lead indicating the activity of acid phosphatase are located in the Golgi apparatus (G) and in some granules (GR). (The thin section was not stained with lead but made of uranyl acetate.) c) Leukemic monocyte. A site of perinuclear associated to perinuclear space (ER), rough endoplasmic reticulum (RER), and some granules (GR).

Activities of acid phosphatase can be demonstrated in nearly all leukemic monocytes. It is localized in the perinuclear space, in the cisternae of the rough plasma and of the Golgi field and in some granules (Fig. 3b). Activity of POX is less conspicuous. In reticulosarcoma monocytes, perinuclear space, rough plasma, and some granules may show the enzyme activity (Fig. 3c). In mature cells, only a few granules may be stained.

HC are moderately large and are characterized by conspicuous small, firm, eosinophilic promastigotes (Fig. 4a). The nuclei are spherical, rounded, or kidney-shaped with heterochromatin distribution. The heterochromatin

staining of the HC cytoplasm with SuB is not due to peroxidatic activity as it is in the azurophilic granules of the neutrophils and monocytes [51] but probably indicates presence of lipidic inclusions. PAS staining also is inconsistent and does not show the typical granular pattern present in chronic and acute lymphatic leukemia.

The cytochemical pattern of RS cells obtained from lymph nodes includes absent or weak staining for AcP, r-N-AS-E (fig. 2c) and moderate or weak staining for  $\alpha$ -N-E. AcP was inhibited by L+-tartrate. Cytoplasmic vacuoles present in some of these cells show a weak peripheral staining with SuB probably indicating storage of lipids. The pyroninophilia of the cytoplasm is usually prominent (fig. 1g). PAS staining yielded different results varying from virtually absent to strong positive granular staining. Actually the same cytochemical pattern is observed in the cells of pleural effusions and – with the exception of strong granular PAS positivity and a marked activity of AcP – in the cells infiltrating the bone marrow in the case of RS of the bone.

*Electron microscopy:* Mature leukemic monocytes are rather large cells with frequent finger-like cytoplasmic protrusions which, however, differ in shape and number from the 'villi' of the HC (fig. 3a). The monocyte nuclei are large, irregular, frequently lobulated. Nuclear pockets are rather frequent. The chromatin is evenly distributed and is condensed in a small rim along the nuclear membrane. Mitochondria may be numerous and large. Profiles of ergastoplasm are well developed, usually short. The Golgi apparatus is large, and conspicuous vesicles and vacuoles are present. Besides some large granules, 0.5–0.8  $\mu$ m in diameter, most cytoplasmic granules are distinctly smaller, 0.1–0.2  $\mu$ m in diameter, electron dense, occasionally comma shaped. Bundles of fibrils occur as well as phagocytosis of degenerated thrombocytes and erythrocytes [15, 27].

The immature leukemic monocytes differ in so far as their nuclei are less polymorphous – usually rounded or kidney-shaped – and occasionally deep clefts are observed. The ribosomes usually are numerous and arranged to polysomes, ergastoplasm and Golgi apparatus are not as conspicuous as in the mature monocytes, and granules are less frequent [27, 52].

Atypical 'monomyelocytic' leukemia is characterized by large cells with a few cytoplasmic protrusions. The nuclei are large and resemble those of the monocytes. The cytoplasm appears rather dense. It contains long profiles of ergastoplasm and a well developed Golgi apparatus. Mitochondria are large and show a dense matrix with electron dense granules. The cytoplasmic granules are of different types, small as those in the monocytes or resembling neutrophilic granules. Rare Auer bodies could also be detected [27, 58].

is irregularly arranged along the nuclear envelope, but clumps are also distributed throughout the nuclei, corresponding to the reticular appearance of the heterochromatin following May-Grünwald-Giemsa stain and in the phase contrast microscope. Mitochondria are frequent and occasionally rather large. Some electron-dense, osmophilic lysosomes arise from the Golgi apparatus (fig. 4c). They show positive staining for AcP (fig. 4f). Some short profiles of ergastoplasm are present in these cells. Free ribosomes are moderately frequent, occasionally they are arranged to polysomes [14, 32, 49, (6)]. Uropods with prominent pinocytotic activity are rather frequent; if they occur, the villi are mainly localized on them. Lamellar inclusion bodies [32] were developed only incompletely (fig. 4d). We had observed a case of chronic lymphocytic leukemia with similar structures. Activity of POX never was observed in HC at the ultrastructural level.


Membrane-bound immunoglobulins were investigated in 2 patients by electron microscopy. In 5-30% of HC either IgG, IgA or IgM were detected. In most cases the POX labelled immunoglobulins were constricted to areas of microvilli formation (fig. 4a), they often were deposited in a system of small tubules and vesicles near the cell surface (fig. 4b).

RS cells are moderately large. They show few and small cytoplasmic projections when studied in lymph node sections. Nuclei are large and contain an evenly distributed chromatin and few nucleoli. Ribosomes are usually numerous and mostly arranged to polysomes, whereas the rough endoplasmatic reticulum is poorly developed and also the Golgi apparatus is not prominent and only a few lysosomal structures are present. Mitochondria are usually moderate in size and number. A few vesicles are present. Occasionally the cells may appear more mature showing distinct vacuolar structures and less ribosomes [43].

**Skin window investigations: Monocytic leukemia.** As already shown in previous publications, conspicuous migration of leukemic cells into the exudate occurred (fig. 4a). Consequently, these cells transformed into macrophages showing the same qualitative changes of the cytochemical pattern as in normal monocytes [44].

In the "monocytic" leukemia the leukemic cells neither migrated specifically into the exudates nor did the few leukemic cells present amidst the other accumulated nucleated cells transform into macrophages [45].

**HC-leukemia.** 1 of the 2 patients studied by skin window technique contained about 70000 HC/mm<sup>3</sup> in the peripheral blood. In this case a few small clusters of HC were present in the exudates suggesting some migration and perhaps chemotaxis. However, the number of HC in the exudates never



**Fig. 4** *a* Hairy cell. Prominent nucleolus (NL). Bundles of fibrils along the nuclear periphery (F). Short strands of ergastoplasm (ER). Prominent Golgi zone (G) and many small vacuoles and vesicles at the periphery of the cell. Membrane-bound immunoglobulins labelled by peroxidase are concentrated mostly to the area of microvilli (arrows)  $\times 8,600$ . *b* Peroxidase-labelled immunoglobulins located in small tubules and vesicles  $\times 22,700$ . *c* Small granules sometimes enclosed by a double membrane and larger deposits of an electron-dense material (arrow). Small vesicles and tubules  $\times 33,200$ . *d* Lamellar inclusions (arrows)  $\times 28,300$ . *e* Uptake of ferritin by a hairy cell. Ferritin in small vesicles (arrow) and deposited together with an electron-dense material (double arrow)  $\times 37,500$ . *f* Activity of acid phosphatase located in the perinuclear space in terms of ergastoplasm and in small granules  $\times 19,000$ .

the same percentage of lymphocytes and HC take up ferritin which is found to be localized in vesicles and vacuoles. By contrast, in HC after 30 min of incubation the ferritin is additionally localized in secondary lysosomes.

**LYS determination in urine.** In mature monocytic leukemia, the urinary excretion of LYS ranged between 90 and 700  $\mu\text{g}/\text{ml}$  if leukemia was actually present. In remissions the excretion was markedly reduced [4]. In the case of 'monomyelocytic' leukemia, urinary LYS levels were normal or weakly increased. LYS excretion was normal or reduced in the patients with HC-leukemia independently of the degree of leukemia.

**NBT test.** No reduction of NBT and no phagocytosis of latex particles occurred in the HC.

### Discussion

**Relationship of leukemia HC to monocytes and monocytic leukemia.** Only few authors considered a close relationship among the HC and the monocytes [40, 41, 44] and quoted the observed differences in the histochemical patterns as merely gradual differences [40, 44]. However, recent histochemical investigations which are confirmed and extended by our present results reveal true qualitative differences (table I) — at least as far as the most characteristic enzymes in these cells are concerned.  $\alpha\text{-NAP-E}$ ,  $\text{NA}$  and LYS as the enzymes peculiar for monocytes, and  $\text{L + tartrate resistant isoenzyme 5}$  of the leukocytic  $\text{AcPs}$  as the enzyme peculiar for HC [31, 49].

All investigators agree on the differences existing among monocytes and HC at the ultrastructural level [9, 14, 32, 43, 46]. As far as the function is concerned, no converse exists on the phagocytic ability of HC. Relevant uptake of latex particles did not occur in our hands, and herein we are in accordance with the findings reported by SCHIRMER and DOWNNEY [11] and YAM *et al.* [19]. REIS *et al.* [47] and HALL *et al.* [22] could not detect phagocytosis of bacteria by the HC. LEANDERS *et al.* [14] noted an uptake of latex, and DANIEL and LEANDERS [11] were able to confirm these findings with the electron microscope. KATSUMATA *et al.* [32] observed an *in vitro* phagocytosis of erythrocytes with a hairy cell which, however, had no typical vacuole on its surface. In order to prove the phagocytic or pinocytotic activity, we studied the uptake of ferritin particles with the electron microscope. HC showed a weak intracellular accumulation of ferritin, which was in the same range as that of lymphocytes and was markedly less than that seen in monocytes. However, in contrast to lymphocytes and monocytes, in the HC ferritin and ferritin also in secondary lysosomes. Normal and leukemia monocytes take



prominent phagocytic activity both in the cytologically mature and immature types. *In vivo* phagocytized materials include erythrocytes and thrombocytes [27]. *in vitro* uptake of latex particles occurred as well as uptake of cell debris in skin window exudates. Transformation of HC into macrophages did not occur in skin window exudates in contrast to the early observable transformation of leukemic monocytes into large and highly phagocytic macrophages [55]. Both normal and leukemic monocytes have been shown to exhibit subclass specific IgG receptors on their surface [25-56] but constant demonstration of these receptors in all HC failed in the HCl [23]. In accordance with the absence of cellular LYS in the HC the urinary excretion of the enzyme was reduced or normal in patients with HC leukemia where is high excretion of LYS seems to be typical for mature monocytic leukemia [4-56].

**RS and RS cell leukemia** Prior to discussion of the cytological relationship occurring among monocytic or HC leukemias and the RS cells the materials studied for the latter group should be briefly reviewed. Diagnosis of RS was made from lymph node sections. Imprints from these lymph nodes and from the pleural effusions of one patient showed closely resembling cells. The cytochemically demonstrable hydrolytic enzymatic equipment of these cells was uniformly poor. The very weak AcP and rNASE activities were probably related to the ultrastructurally poorly developed GERL of these cells which also generally showed poor cytologic maturation. The faint staining of small cytoplasmic vacuoles with SuB suggests the storage of lipids. It is worth to mentioning that pyroninophilia was constantly very marked in the RS cells whereas PAS positivity was found to be variable although usually rather weak [64]. Aspirated cells infiltrating the bone marrow in a case previously identified as RS of the bone consisted of a nearly identical cell population which differed only in the more intense activity of AcP and in the still more prominent pyroninophilia and PAS positivity. Further approaches to the cytological characterization of these cells had not been made.

Among 295 cases of acute leukemia we never had observed cases which reasonably could be termed as RS cell leukemia. In 4 patients primary localized tumors were originally identified as RS. However the subsequently arising leukemias have been classified as lymphosarcoma cell leukemias as undifferentiated or as acute myeloblastic leukemias and because no reason existed to assume two independent malignancies we concluded that a primary tumorous manifestation of the leukemic process had occurred. A further case originally diagnosed as reticulosis following the examination of a bone marrow biopsy clearly belonged to the myelogenous leukemia presenting both monocytic and promyelocytic features in the same leukemic cells.

This case has been separately published together with three cytologically similar cases [55].

**HC leukemia and RS.** As far as the cytochemical pattern is concerned differences among RS cells and HC are merely quantitative – for instance as the activities of AcP and  $\alpha$ -N E are concerned. Because of the weak activity of AcP the L + -tartrate resistance is difficult to evaluate in RS cells, however, distinct reduction of AcP activity occurred in most cases, whereas in HC the overwhelming activity of AcP is tartrate-resistant. Identical results have been reported also by KATAYAMA *et al* [31].

The electron microscopic examination of the HC gives the impression of a rather differentiated cell. RC cells are distinctly less differentiated, do not show villiform cytoplasmic projections, and usually contain less mitochondria.

As previously reported the immunocytological demonstration of IgG determinants in our hands revealed the presence – in decreasing order – of IgG, IgM and IgA on the surface of HC [4]. These data are in good accordance with the findings of other authors [10–22] and suggest – although not conclusively – the B-cell nature of these cells [9, 10, 12–22]. A further important finding which strongly supports this view has been reported by RUMIS *et al* [40] who were able to demonstrate IgG synthesis by *in vitro* cultured HC; however, these data have not been confirmed since that report. Recent studies suggest that at least a considerable part of the RS or histiocytic lymphomas also share typical B-cell features in that they are able to produce immunoglobulins [64] and that they bear immunoglobulin determinants and receptors of aggregated  $\gamma$ -globulin on their surface [2, 23–24, 34]. Monoclonal gammopathies have been detected in 5 out of 140 patients who had RS and were studied by serum electrophoresis: peaks of IgG or IgM have been shown in 1 and in 4 patients respectively [42]. A relationship of HC leukemia to the RS – as originally defined – cannot reasonably be affirmed. As we have outlined previously in this paper the phagocytability of the HC is obviously poor and immaturity as the cause of poor phagocytosis is ruled out by the rather mature appearance of these cells under the electron microscope. In HC leukemia no involvement occurs of the cell types typically belonging to the RS. The cells in ELWIS's [13] case are clearly different from HC.

**Monocytic leukemia and RS or 'RS cell' leukemia.** In introducing this paper we have already outlined that the theory of the reticuloendothelial origin of monocytic and monocythemic leukemia conceivably plays a role in the cytological characterization of the monocytic leukemia as a giant reticuloendothelial

tionship or cytological identity of 'histiocytic' or 'histioblastic' lymphomas or 'RS' to monocytic or monoblastic leukemia are discussed still in recent papers [6, 9, 37, 59]. Reticulin fibers as identifying features of tumors consisting of 'reticular' or 'reticuloendothelial' cell types seem to have little real value in that they can be observed in unequivocally myelogenous malignancies (see cases 3 and 6) as well as in HC-leukemia [14, 35].

Some authors have stressed the similarity of the cytochemical esterase pattern of RS, HC, and monocytes [37, 59]. However, as shown in table I, clear-cut qualitative differences can be shown among monocytes and the other cell types. Frequently, pitfalls in characterizing hemopoietic cells are due to the exclusive use of  $\alpha$ -N-A as substrate for the demonstration of esterase activity, they can be overcome by using the N-AS E reaction, especially when in connection with the inhibition by N1F (table I). This staining procedure allows substantially better characterization of normal and leukemic monocytes, and misinterpretations due to insufficient techniques are avoided [54-56]. HUBER and FUDENBERG [25] reported on the presence of subclass specific IgG or Fc receptors on the surface of monocytes and macrophages. This technique has been successfully applied to characterize leukemic monocytes too [25, 56]. Some criticism has been made of the specificity of this method because presence of EA (i.e. IgG) receptors was also detected on B cells [38]. Receptors of the Fc fragment of aggregated Ig have been demonstrated on B cells as well [24]. However, by careful performance of these technique, blocking of the Fc receptors for EA complexes can be produced by preincubating the monocytes with IgG or subclasses of IgG, whereas no blocking occurred with the same concentrations of IgG in the demonstration of Fc receptors on B cells [23, 25] thus suggesting a qualitative difference among the receptors on these cells and monocytes. Following the conception of the 'mononuclear phagocytic system' (MPS) which recently has been put forward by VAN FURTH and THOMPSON [20] one could assume that 'RSs' could be derived from immature monocytes or monoblasts. However, the differences occurring among monocytes and RS cells argue also against this possibility.

### *Conclusions*

Clear evidence against any cytological relationship among monocytic and HC-leukemia is given by cytochemical, ultrastructural, biochemical, immunologic, and functional criteria. In contrast to previous reports, which

have stressed the similarities of RS cells and leukemic monocytes, striking differences could be demonstrated at the cytochemical, ultrastructural, and immunologic levels which argue against a close relationship among these cells. Besides distinct ultrastructural differences, further gradual and some qualitative cytochemical differences were detected among leukemic HC and RS cells. However, remote relationship of HC and at least some of the RS cells can be assumed as far as the possible B-cell nature of these cells is concerned. The observed cases of 'RS cell leukemia' and 'reticulosis' actually had to be classified either as acute lymphatic or myelomonocytic leukemias. The terms 'reticulosarcoma' or 'reticulum' or 'reticulosarcoma cell leukemia' should be avoided and a more precise characterization should be afforded. The descriptive term 'hairy cell leukemia' should be preferred to the biologically inconsistent and historically erroneous term 'leukemic reticuloendotheliosis'. No actual biological relationship seems to exist among these malignancies and RES as it was originally described.

### References

- 1 ACHTMAN, G. A. Histochemical demonstration of an arylamidase activity in the leukocytes of blood and bone marrow. *J. Histochem. Cytochem.* **8**: 316 (1960).
- 2 ASANU, H. Zur immunzytologischen Charakterisierung unreifer lymphatischer Lymphozyten. *Wien Klin. Wochschr.* **84**: 401 (1972).
- 3 ASANU, H., SCHMALZ, I., and BRAUNSTEINER, H. Immunocytochemical demonstration of lysozyme (muramidase) in human leukaemia cells. *Br. J. Haemat.* **20**: 571 (1971).
- 4 ASANU, H., SCHMALZ, I., and BRAUNSTEINER, H. Immunocytochemical and biochemical demonstration of lysozyme in leukemia cells. In OGDEN, CANNING and BRITTON, *Lysozyme (Academic Press, New York, 1974)*.
- 5 BARR, T. and ANDERSON, I. J. Histochemical methods for acid phosphatase using hexazotized pararosanilin as coupler. *J. Histochem. Cytochem.* **10**: 341 (1962).
- 6 BIRN, M. Living blood cells and their ultrastructure (Springer, Berlin, 1973).
- 7 BURROWS, R. A., WATMAN, B. K., and DIXON, C. A. Leukemia reticuloendotheliosis. *Br. J. Haemat.* **11**: 401 (1966).
- 8 BRAUNSTEINER, H., SCHMALZ, I., and ASANU, H. Zytologische Untersuchungen bei hairy cell Leukämie. *Acta med. Austriaca* **7**: 35 (1974).
- 9 CANNING, D., PETER, J. E., GALLON, D. A. G., SEGER, A. S.-D., and HARRIS, C. V. Leukemia reticuloendotheliosis ('hairy' cell leukemia): A distinct clonal B-lymphocytosis. *Br. J. Haemat.* **25**: 9 (1974).
- 10 CANNING, D., PETER, J. E., GALLON, D. A., ASANU, H., and GALLON, D. A. G. The B-lymphocyte nature of the hairy cell leukemia reticuloendotheliosis. *Br. J. Haemat.* **26**: 21 (1974).
- 11 DIXON, M. T. and FLEISCHMAN, G. Fine structure of abnormal cells in hairy cell leukemia (reticuloendotheliosis): A special reference to their morphologic features. *Lab. Invest.* **3**: 1 (1974).

- 12 DÜLLMANN, J., WILHECKEL, U., DRESCHER, S. und HAUSMANN, K. Die Haarzellen-hämoblastose (hairy cell leukemia) Dt med Wschr 99 859 (1974)
- 13 EWALD, O. Die leukämische Retikuloendotheliose Dt Arch klin Med 142 22 (1923)
- 14 FLANDRIN, G., DANIEL, M. T., FOUCARDE, M. et CHELLOUL, N. Leucémie à 'tricho leukocyte' (hairy cell leukemia), étude clinique et cytologique de 55 observations Nouv Revue fr Hémat 13 609 (1973)
- 15 FREEMAN, A. J. and JOURNEY, L. J. Ultrastructural studies of monocytic leukemia Br J Haemat 20 225 (1971)
- 16 FURTH, R. VAN (ed.) Mononuclear phagocytes (Blackwell Oxford 1970)
- 17 FURTH, R. VAN and COHN, Z. A. The origin and kinetics of mononuclear phagocytes J exp Med 128 415 (1968)
- 18 FURTH, R. VAN and DIRSSELHOR-DEY DULK, M. The kinetics of promonocytes and monocytes in the bone marrow J exp Med 132 813 (1970)
- 19 FURTH, R. VAN, HIRSCH, J. G., and FEDORAK, M. E. Morphology and peroxidase cytochemistry of mouse promonocytes, monocytes, and macrophages J exp Med 132 794 (1970)
- 20 FURTH, R. VAN and THOMPSON, J. Review of the origin and kinetics of the promonocytes, monocytes, and macrophages and a brief discussion of the mononuclear phagocytic system Annls Inst Pasteur, Paris 120 337 (1971)
- 21 GIFFORD, R. H. and MALAWISTA, S. A simple rapid micromethod for detecting chronic granulomatous diseases of childhood J clin Invest 50 2204 (1971)
- 22 HAAK, H. L., MAN, J. C. H. DE, HJMAAS, W., KNAPP, W., and SPRICK, B. Further evidence for the lymphocytic nature of leukemic reticuloendotheliosis (hairy cell leukemia) Br J Haemat 27 31 (1974)
- 23 HUBER, CH., MICHELMAYR, G. und HUBER, H. Immunologische Marker in der Differentialdiagnose lymphatischer Erkrankungen Dt med Wschr 99 2262 (1974)
- 24 HUBER, CH., DWORZAK, E., FINK, U., MICHELMAYR, G., BRAUNSTEINER, H., and HUBER, H. Receptor sites for aggregated gammaglobulin (AGG) on lymphocytes in lymphoproliferative disorders Br J Haemat 27 643 (1974)
- 25 HUBER, H. and ELDENBERG, H. H. Receptor sites of human monocytes for IgG Int Archs Allergy appl Immun 34 18 (1968)
- 26 HUHN, D. and STICH, W. Fine structure of blood and bone marrow. An introduction to electron microscopic hematology (Lehmanns, München 1969)
- 27 HUHN, D., SCHWALZ, F. und DEMMLER, K. Monozytenleukämie Licht und elektronenmikroskopische Morphologie und Zytochemie Dt med Wschr 96 1594 (1971)
- 28 HUIJN, D., RÖDT, H. und THIERFELDER, S. Immunhistochemische Untersuchungen an T Lymphozyten der Maus Blut 28 415 (1974)
- 29 KAPLOW, L. S. A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity of blood and bone marrow Blood 10 1023 (1955)
- 30 KAPLOW, L. S. Simplified myeloperoxidase stain using benzidine dihydrochloride Blood 26 215 (1965)
- 31 KATAYAMA, I., LI, C. Y., and YAM, L. T. Histochemical study of acid phosphatase isoenzyme in leukemic reticuloendotheliosis. Cancer, N Y 29 157 (1972)
- 32 KATAYAMA, J., LI, C. Y., and YAM, L. T. Ultrastructural characterization of the hairy cells of leukemic reticuloendotheliosis Am J Path 67 361 (1972)

- 33 LIEBER, L. D. *Der B-Lymphozyt* (Springer, Berlin 1967).
- 34 LIEBER, L. D. Zytochemischer Nachweis der unipolaren Esterase in Ausstrichen. *Klin. Wochschr.* 39: 1229 (1961).
- 35 LIEBER, L. D. und HILZ, K. Zur Tumorbildung bei Leukose. III. 27. III (1973).
- 36 MÄHR, G., REINER, R. und SCHMALZ, F. Zur Spezifität des Glykogennachweises in Leukozyten, Leber und quergestreiftem Muskel. Glykogenhydrolyse durch alpha-1,6-Amyloglukosidase. *Klin. Wochschr.* 51: 570 (1973).
- 37 MATHÉ, G., GIRARD-MARCHANT, R., TEXIER, J. L., SCHILMBERGER, J. R., RICHARD, L., and PAINBRAND, M. The two varieties of lymphoid tissue reticulosarcoma, histiocytic and histioblastic types. *Br. J. Cancer* 24: 687 (1970).
- 38 MATHÉ, G. and BUCHMANN, D. T and B lymphocytic nature of leukemias and lymphosarcomas: a new but still uncertain parameter for their classification. *Berlin. Monatsschr.* 20: 81 (1974).
- 39 MILBURN, G. and HOFFMANN, G. Monocyte kinetics studies in normal and disease states. *Br. J. Haemat.* 24: 273 (1973).
- 40 MITTS, W. J., MITSCHKE, I. B., WITTIG, B., and DAMASCH, W. Neoplasia, lymphoid reticulum cells in the peripheral blood: a histochemical study. *Blut* 17: 209 (1961).
- 41 MORRIS, W. E., McPHERSON, K., and FINEGEMAN, L. Esterase activity in leukocytes demonstrated by the use of naphthol-AS-D-chloroacetate substrate. *J. Histochem. Cytochem.* 8: 200 (1960).
- 42 MURPHY, D. J., MURPHY, P. J., SULLIVAN, C. C., and ALLEN, P. Monoclonal macropoietinemia in adult giant lymphoma. *Ann. intern. Med.* 72: 43 (1970).
- 43 MURTY, Y. and LENNERT, K. *Histoenzymochemie, atlas of lymph node cytology and pathology* (Springer, Berlin 1969).
- 44 NICHOLS, R. A., BAIRNS, D. E., and FARRAR, M. G. Differentiation of monocytes. Origin, nature and fate of their azurophilic granules. *J. Cell Biol.* 50: 449 (1971).
- 45 OBERMAN, I. E. and LAWSON, D. P. Serum and urinary histone (muramidase) in mononuclear and mononuclear leukemia. *J. clin. Med.* 124: 921 (1964).
- 46 PRATT, A. G. I. *Histochemistry: Theoretical and applied* (Churchill, London 1964).
- 47 REINER, J. W. and CHASSIN, J. H. A method of studying leukocyte function in situ. *Ann. N. Y. Acad. Sci.* 73: 8 (1969).
- 48 REYNOLDS, I. S. The use of lead citrate at high pH as an electronopaque stain in electron microscopy. *J. Cell Biol.* 17: 208 (1973).
- 49 RICH, A. H., DAVIS, S. D., CHEN, L. S., GLASS, H. R., and DAMASCH, W. Chronic reticulosarcoma leukemia. *Am. J. Med.* 47: 182 (1969).
- 50 SCHMIDT, H. E. und FRIEDRICH, R. Der Peroxydase-Nachweis an Ausstrichen, Präparaten sowie an Gewebsschnitten nach Fixierung und Paraffineinbettung. *Klin. Wochschr.* 45: 1224 (1963).
- 51 SCHMIDT, H. E. und FRIEDRICH, R. Peroxydaseaktivität als Ursache zahlreicher Sudanphosphor- und als allgemeine Färbemerkmal beim histochemischen Lymphknoten-Ausstrich. *Histochem. J.* 22: 319 (1972).
- 52 SCHMALZ, F. Unreife Myelomonoklonale BL. 22: 147 (1971).
- 53 SCHMALZ, F. and FRIEDRICH, R. On the origin of monocytes. *Acta haemat.* 30: 177 (1964).

- 54 SCHMALZL, F. und BRAUNSTEINER, H. Cytochemische Darstellung von Esteraseaktivitäten in Blut und Knochenmarkszellen *Klin Wschr* 46 642 (1968)
- 55 SCHMALZL, F. and BRAUNSTEINER, H. Monocytes and macrophages - cytochemical investigations *Ser Haemat III/2* 93 (1970)
- 56 SCHMALZL, F. and BRAUNSTEINER, H. The application of cytochemical methods to the study of acute leukemia *Acta haemat* 45 209 (1971)
- 57 SCHMALZL, F., HUBER, CH., and BRAUNSTEINER, H. Demonstration of proliferating monocytic precursors by the combination of cytochemical and autoradiographic methods *Klin Wschr* 47 887 (1969)
- 58 SCHMALZL, F., HUIHN, D., ASAMER, H., ABBREIDERIS, K., and BRAUNSTEINER, H. Atypical - monomyelocytic - myelogenous leukemia. Cytochemical, electromicroscopic, and biochemical investigations *Acta haemat* 48 72 (1972)
- 59 SCHNITZER, B. and KASS, L. Leukemic phase of reticulum cell sarcoma (histiocytic lymphoma). A clinicopathological and ultrastructural study *Cancer, N Y* 31 547 (1973)
- 60 SCHNITZER, B. and KASS, L. Hairy cell leukemia. A clinicopathological and ultrastructural study *Am J clin Path* 61 176 (1974)
- 61 SCHIRK, R. and DONNELLY, J. W. 'Hairy' cells in blood in lymphoreticular neoplastic disease and 'flagellated' cells of normal lymph nodes *Blood* 27 199 (1966)
- 62 SHEEHAN, H. L. and STOREY, G. W. An improved method of staining leukocyte granules with Sudanblack B *J Path Bact* 59 336 (1947)
- 63 STEIDLE, CH. und HUIHN, D. Elektronenmikroskopische Untersuchungen zur Phagozytose von Blutlymphozyten *Res exp Med* 163 155 (1974)
- 64 STEIN, H., LENNERT, K., and PARAWISCH, M. R. Malignant lymphoma of B cell type *Lancet* ii 855 (1972)
- 65 SUTTON, J. S. Ultrastructural aspects of *in vitro* development of monocytes into macrophages, epitheloid cells, and multinucleated giant cells *Natn. Cancer Inst Monogr* 26 71 (1967)
- 66 WINTROBE, M. M. Clinical hematology, 6th ed (Lea & Febiger, Philadelphia 1968)
- 67 WULF, H. R. Morphological and histochemical features of leukocytes in experimental inflammation and in disease (Munksgaard, Copenhagen 1967)
- 68 YAM, L. T., CASTOLDI, G. E., GERBEY, M. B., and FRANKEL, H. E. Functional cytogenetic and cytochemical study of the leukemic reticulum cells *Blood* 32 90 (1969)
- 69 YAM, L. T., LI, C. Y., and LAM, K. W. Tartrate resistant acid phosphatase in the reticulum cells of leukemic reticuloendotheliosis *New Engl J Med* 284 357 (1971)

## The Cytochemical $\beta$ -Glucuronidase Reaction in the Differential Diagnosis of Acute Leukaemias<sup>1</sup>

C. WASASTJERN, E. VUORINEN, M. LEHTINEN, L. IKKALA and  
I. HUCHTALA

Second Department of Pathology, University of Helsinki, Helsinki

**Key Words:** Acute leukaemia •  $\beta$ -Glucuronidase • Cytochemistry • Lymphoblastic leukaemia

**Abstract.** The value of the cytochemical  $\beta$ -glucuronidase ( $\beta$ -gluc) reaction in the differential diagnosis of acute leukaemia was assessed in a series of 160 adult patients. A purely granular type of reaction was observed in 7 out of 8 cases of lymphoblastic leukaemia and in 2 of 11 cases of acute leukaemia of uncertain type. Such an exclusively granular reaction was never seen in other types of acute leukaemia. In most cases of myeloblastic, promyelocytic, myelomonocytic and monocytic leukaemia a positive staining reaction was noted which was either diffuse or a combination of diffuse and finely granular. The cells of one patient with lymphoblastic leukaemia were negative for  $\beta$ -gluc. A coarsely granular PAS reaction was noted in 9 cases of lymphoblastic leukaemia including the one with negative  $\beta$ -gluc. Our results show that the  $\beta$ -gluc reaction is of definite value in the diagnosis of lymphoblastic leukaemia and that it is probably more sensitive than the PAS reaction. In monomyelocytic or myelomonocytic leukaemia, the pattern and intensity of the reaction did not differ appreciably from those seen in myeloblastic leukaemia.

The diffuse reaction to the toluidine blue (TB) fast blue B (Sudan) is given by the promyelocytic (or monocytic) cells and as substrate for peroxidase [6-11].

It is still difficult in some cases of acute leukaemia to distinguish between the reaction for myeloperoxidase (peroxidase) and the reaction for  $\beta$ -glucuronidase (peroxidase) by the use of Sudan black B as a substrate. The reaction for  $\beta$ -glucuronidase (peroxidase) is given by the cells [11]. A strong peroxidase reaction is characteristic of mature and immature granulocytes and is considered to be negative for  $\beta$ -glucuronidase.

<sup>1</sup> This study was

supported by the Finnish Cancer Society.



dan and for the perox and chloroacetate esterase reactions, but because some myeloblasts are also negative for these reactions, the value of a negative reaction is equivocal. Hence, a reliable positive staining method for lymphoblasts would be of decisive value. In many laboratories, the periodic acid-Schiff (PAS) reaction is used for this purpose. A coarse granular staining with the PAS reaction is considered characteristic for cells of lymphocytic origin whereas myeloblasts are either completely negative or weakly positive [3, 10], with staining in the latter case being faintly diffuse or discretely granular. The PAS reaction is clearly a valuable tool in the differentiation of acute leukaemias but, because blast cells are negative in some cases of lymphoblastic leukaemia, and because the distinction between the small granules in myeloblasts and the large granules in lymphoblasts can be subtle, doubtful cases still remain. Furthermore, some authors, e.g., LEDER [5] and SCHMALZL and BRAUNSTEINER [11], have found large PAS positive granules in leukaemic cells not belonging to the lymphocytic series.

In their extensive studies of  $\beta$ -glucuronidase ( $\beta$ -gluc) activity in leukocytes, LORNBACHER [7] and LORNBACHER *et al* [8, 9] found that most normal myeloblasts were negative. Other cells of the granulocytic series were positive, with myelocytes staining more intensely than mature cells. A strong reaction was also observed in monocytes. In the granulocytic series, as well as in monocytes, the staining pattern was either diffuse, or diffuse and granular, but never exclusively granular. An intense staining reaction was noted in the leukaemic cells of patients with myelomonocytic leukaemia [7]. Most normal lymphocytes were found to contain  $\beta$  gluc-positive granules, distributed either as a few coarse clumps or as many small granules, but a diffuse reaction was never seen. In most cases of chronic lymphocytic leukaemia, the percentage of negative lymphocytes was higher than in normal blood [9]. In cases of acute lymphoblastic leukaemia LORNBACHER [7] found a granular staining product in at least 10–20% of the blast cells.

In the present investigation the  $\beta$ -gluc reaction was studied in blood and bone marrow smears from adult patients with acute leukaemia to obtain answers to the following questions. Are  $\beta$  gluc-positive lymphoblasts always present in acute lymphoblastic leukaemia? Is the staining pattern of such lymphoblasts different from that of other immature leukaemic cells? Is the  $\beta$ -gluc reaction of value in the diagnosis of lymphoblastic leukaemia? Is the  $\beta$  gluc reaction useful in the diagnosis of monocytic and myelomonocytic leukaemia?

### Patients and Methods

The series comprised 100 consecutive cases of adults suffering from acute leukaemia and treated in various hospitals belonging to the Finnish Leukaemia Group project [1]. Blood and bone marrow smears stained with May-Grunwald-Giemsa (MGGs) were independently evaluated by three haematologists. In addition the following special stains were used in most cases: peroxidase by the method of Karmali [4] with safranin counterstained from the solution and MGGs used as counterstain; Sudan [5] (part No. 45) acetic esterise test [6] and PAS as modified by M. Manus method [12]. The  $\beta$ -glucuronidase ( $\beta$ -gluc) reaction as described by Lemmich *et al.* [8], was studied in all 100 cases. Because this reaction was the subject of our study it was not used as a diagnostic criterion.

The diagnoses were made as follows:

*Acute myeloblastic leukaemia (AML)* includes cases in which morphological changes were apparent in erythroblasts and megakaryocytes, definite myeloid pregranulatum present in some or all cells or Sudan or peroxidase test.

*Pro-myeloblastic leukaemia (PML)* promyelocytes, heavily granulated, were the predominant cell type.

*Monoblastic leukaemia (MblL)* large numbers of immature monocytes or monocytes in the blood or in the blood and bone marrow with at least 50% of the marrow immature cells heavily est. peroxidase (+ on a scale of 0-4).

*Myelomonoblastic leukaemia (MML)* immature monocytes or monocytes in the blood or marrow or in both with 50-90% of the immature cells heavily peroxidase test. In most of these cases, pathological changes were noted in erythroblasts or megakaryocytes, or in both.

*Acute lymphoblastic leukaemia (ALL)* lymphomonocytes of the three haematopoietic cell lineages present and haemopoiesis.

*Acute leukaemia of undetermined type (LAL)* cells negative for Sudan and peroxidase test among the investigations or when morphological features in these cases could not be determined on morphological grounds.

In bone marrow smears stained for $\beta$ -gluc activity the peroxidase stain was bright red. As observed by Lemmich <i>et al.</i> [8] the staining pattern was granular diffuse or granular and diffuse. The strength of reaction was determined on a scale of 1-4. Threshold (+) reactions were	1-4
---	-----

### Results

Most patients (three fourths (table 1)). The last cells (4%) were normal and with a diffuse pattern.	42 out of 100 suffered from AML. In about half cases showed a positive $\beta$ -gluc reaction. It was weak but some extremely strong. In 13 cases. In a positive cases the peroxidase reaction was granular or granular and diffuse and a granular staining were common.
--	--

Table I The  $\beta$ -glucuronidase reaction in acute leukaemia

Diagnosis	Number of cases	$\beta$ -Glucuronidase staining				
		negative	positive, diffuse	positive, diffuse and granular	positive, granular	strongly positive (4-5+)
AML	62	15	32	15	0	13
PML	4	1	1	2	0	1
Mon L	10	1	6	3	0	3
MML	5	0	3	2	0	2
ALL	8	1	0	0	7	6
UAL	11	6	0	3	2	1
All cases	100	24	42	23	9	26


Table II Comparison of the  $\beta$ -gluc and PAS reaction in ALL and UAL

		$\beta$ -gluc	PAS
ALL, 8 cases	granular	7	{ coarsely granular 4 negative 3
	negative	1	coarsely granular 1
UAL, 11 cases	granular	2	negative 2
	diffuse and granular	3	{ negative 1 not done 2
			{ finely granular 4 negative 2
	negative	6	

ent (fig 1) An exclusively granular reaction was not encountered in any case of AML. In 15 cases moreover the blast cells were completely negative.

In 3 out of the 4 cases of PML the leukaemic cells were  $\beta$ -gluc-positive with staining either diffuse, or diffuse and granular.

The leukaemic cells were  $\beta$ -gluc-positive in almost all cases of Mon L and MML. They were completely negative in only one case of Mon L. The positive staining pattern, either diffuse, or diffuse and granular, was considered strong in 5 cases (3 of Mon L and 2 of MML). A purely granular reaction was not seen in these two groups.




*Fig. 1. AML bone marrow: a) M10; b) p. gl.*

The morphological diagnosis was ALL in 8 cases. The blast cells of 1 of these patients were completely glucose negative whereas positive cells were noted in the other 7. The staining pattern was granular in all 7 cases and considered strong in 6 (fig. 2). Large red clumps or coarse granules predominated in 5 of the positive cases and groups of small red granules in the remaining 2. No diffuse staining reaction was seen in this group.

The morphological type of acute leukaemia remained uncertain (LAM) in 11 cases. No glucose reaction was noted in 6 of them. A granularly positive reaction was recorded in 2 cases and a combined diffuse and granular staining in 3.

A comparison of the results obtained with the glucose and the PAS reactions in ALL and LAM is reported in table II. A coarsely granular (lymphocytic) PAS staining was seen in 5 cases of ALL, one of them glucose negative and in no case of LAM. The glucose positive cells were considered to be more numerous than the PAS-positive cells in 4 cases of ALL.



*Fig 2* All *a* Blood MGG *b* Blood  $\beta$  gluc *c* Bone marrow  $\beta$  gluc (all pictures from the same case)  $\times 700$

### Discussion

The evaluation of a cytochemical procedure for the identification of immature cells requires that a reliable diagnosis be made by other means. To be as certain as possible about the diagnoses in the present study, we grouped together all doubtful cases as uncertain (UAL). Assuming that the diagnosis was correct in the remaining 89 cases, we can certainly, in agreement with LÖNNBÄCK [7] and LÖNNBÄCK *et al.* [8, 9] conclude that an exclusively granular staining product in the  $\alpha$ , gluc reaction is specific for cells of the lymphocytic series. By this method 7 out of the 8 morphologically identified cases could be diagnosed as lymphoblastic leukaemia. Moreover, on the basis of the PAS reaction a correct diagnosis was possible in 5 of these cases. The  $\alpha$ , gluc reaction thus seems to be the more sensitive of the two reactions. However, because the blast cells were PAS-positive in the one  $\alpha$ , gluc negative case, the use of both methods is recommended.

In the 11 cases of UAL, 2 had granularly  $\beta$ -gluc positive blast cells, and we may now retrospectively assume that they were in fact lymphoblastic leukaemias. The PAS reaction was negative in both cases. The finely granular PAS staining product seen in 4 other cases in the UAL group was not specific for any cell type [3, 6, 11]. In 3 cases of UAL the blast cells showed a combined diffuse and granular  $\beta$ -gluc reaction and hence they were probably cases of myeloblastic leukaemia.

The staining pattern of glucose-positive cells was similar in ALL, MLL and AML either diffuse or a combination of diffuse and granular. A strong (4-5+) reaction of this type was seen in 33% of the cases of MLL, 10% of the cases of MLL and in 22% of the cases of ALL. Hence, difference in staining among these groups was not significant. Therefore, the glucose reaction could not be used in the differential diagnosis of leukemias.

### Reference

- |               |   |
|---------------|---|
| 1. Fenchone   | Chemical structure of fenchone is shown   |
| 2. Menthol    | Chemical structure of menthol is shown    |
| 3. Camphor    | Chemical structure of camphor is shown    |
| 4. Thymol     | Chemical structure of thymol is shown     |
| 5. Eucalyptol | Chemical structure of eucalyptol is shown |

- 4 KAPLOW L S Simplified myeloperoxidase stain using benzidine dihydrochloride *Blood* 26 215-219 (1965)
- 5 LEDER L D *Der Blutmonocyt* (Springer Berlin 1967)
- 6 LEDER L D Histochemie und Cytochemie der Leukosen in GROSS und VAN DE LOO Leukämie (Springer Berlin 1972)
- 7 LORBACHER P Zur diagnostischen Anwendung des cytochemischen  $\beta$  Glucuronidase Nachweises in GROSS und VAN DE LOO Leukämie (Springer Berlin 1972)
- 8 LORBACHER P YAM L T and MITLS W J Cytochemical demonstration of  $\beta$  glucuronidase activity in blood and bone marrow cells *J Histochem Cytochem* 15 680-687 (1967)
- 9 LORBACHER P YAM L und QUAYNOR E Cytochemischer Nachweis von  $\beta$  Glucuronidase in normalen und leukämischen Blutlymphocyten *Klin Wschr* 46 1046-1051 (1968)
- 10 PLÜSS H und HITZIG W H Cytochemische Untersuchungen bei akuten Leukämien des Kindesalters *Schweiz med Wschr* 96 1212-1214 (1966)
- 11 SCHWALZL F and BRAUNSTEINER H The application of cytochemical methods to the study of acute leukaemia *Acta haemat* 45 209-217 (1971)
- 12 WASASTJERNA C, PASTERNAK A and KORVUNEN O A study of blood and bone marrow in patients with chronic renal failure before and after transplantation *Ann clin Res* 3 212-219 (1971)

## Functional Heterogeneity of the Transport Iron Compartment

### I. *In vivo* Radioiron Clearance from High and Low Saturated Transferrin

Dietrich Hahn, Bruno Bavier and Andreas M. Ganzoni

Departments of Internal Medicine, Universities of Basel and Zurich,  
German Red Cross Blood Bank, and Division of Transfusion Medicine, University  
of Ulm, Ulm

**Key Words:** Iron metabolism · Serum iron · Transferrin

**Abstract.** Two transferrin solutions of 4 and 80%  $^{59}\text{Fe}$  saturation respectively were administered to humans 30 min apart. The radioiron clearance from the high saturated preparation was significantly accelerated. Comparable results were obtained in rats when normal rat serum was used instead of purified transferrin.

The two iron atoms bound by each transferrin molecule possess equal affinities to the two metal binding sites. This is indicated by equilibrium dialysis studies [1] and by the statistical distribution of iron when mixed with excess transferrin [2]. The extremely high affinity constant between the carrier and its metal at pH 7.5 excludes a dissociation controlled iron cell transfer mechanism [6]. It is generally assumed that the transferrin molecule is taken up by specific membrane receptor sites, thereby undergoing conformational changes which facilitate the iron release, thereafter the carrier protein is shunted back into the surrounding medium [4, 12].

Current models of internal iron exchange are based on the existence of a homogeneous plasma iron pool [7]. But recently, *in vitro* experiments Hutterich and Hutterich [10] produced evidence for functional differences between transferrin molecules carrying one or two iron atoms [9], a finding not confirmed *in vivo* so far [14]. Further testing of this phenomenon forms the basis of this communication.

### Material and Methods

**Experiment 1.** 100  $\mu\text{Ci}$  of iron transferrin solution (80% purified human transferrin (Gibco) was dissolved in saline in a volume of 0.5 l (mg 10 ml). The concentration of



capacity was calculated to be  $1.28 \mu\text{g/mg}$  protein on the basis of a molecular weight of 80 000. All work was done under atmospheric conditions.  $^{55}\text{FeCl}_3$  (SA 10-17 mCi/mg, Reaktor AG Würenlingen, Switzerland) was obtained in  $0.1 \text{ N HCl}$ . The desired amount of radioiron was added stepwise to the transferrin solution in amounts of approximately 0.05 ml. The pH of the mixture was kept between 6.0 and 8.0 by small additions of  $0.1 \text{ N HCl}$  and  $0.1 \text{ N NaOH}$ . Each addition was followed by vigorous shaking; at the end the solution was exposed to open air for 30 min providing the bicarbonate necessary for stable iron binding by transferrin [3]. The total volume of acid and alkaline added did not exceed 3% per volume even when the transferrin was fully saturated with iron. If transferrin was loaded with  $^{55}\text{FeCl}_3$ , an identical procedure was followed. All solutions had a pH of 7.4 adjusted as above. In some experiments  $10^{-3} \text{ M}$  Na citrate dissolved in saline was added to the transferrin solutions to give a final citrate concentration of  $10^{-2}$ - $10^{-3} \text{ M}$ . All solutions studied *in vitro* or administered to rats were provided with 200 U penicillin G Na/ml. In human experiments the preparations injected contained 200 000 U of penicillin G Na.

**Iron binding to transferrin.** In order to check for undesired binding of radioiron to contaminants of the transferrin preparation the following experiments were carried out: (1) Electrophoresis on cellulose acetate, pH 7.4, demonstrated all radioactivity in the  $\beta_1$  position of control plasma. (2) Since the transferrin preparation is contaminated with EDTA (0.003% per weight, thus giving a molar ratio of EDTA to transferrin of 1:127, communicated by Behringwerke), electrophoresis on thin layer chromatography (Cellulose Merck) plates was performed. 0.01% solutions of transferrin in saline giving a pH of 7.4 were mixed with different amounts of radioiron and subsequently run at 500 V and 10 mA for 60 min at different pH values in a phosphate-pyridine and ammonium acetate buffer system respectively. After staining the distribution of radioactivity was registered (Thin Layer Scanner II B, Berthold model LB 2723, Autochron Recorder, Berthold rate meter integrator, Berthold model LB 241K).  $^{55}\text{Fe}$ -EDTA control solutions were run in parallel on the same plates. At 5 and 90%  $^{55}\text{Fe}$ -transferrin saturations and pH values of 7.4 and 6.4, all radioactivity was located within the transferrin band. If the saturation level was raised to 130% or the pH lowered to 4.75, some radioactivity migrated towards the cathode but none was concentrated at the EDTA site.

**Studies in humans.** Eleven volunteers were fully informed about the experimental purpose of the planned studies. In all cases they explicitly agreed to participate in the present investigation. Within 1 h they had two subsequent  $^{55}\text{Fe}$  clearance studies. First, approximately 5 ml of a transferrin solution of 4%  $^{55}\text{Fe}$  saturation (3 mg transferrin/10 ml saline) were injected, corresponding approximately to  $1 \mu\text{Ci}$  radioiron. Over the next 30 min at least eight 5 ml blood samples were drawn immediately followed by the injection of an identical transferrin preparation but saturated to 80% with  $^{55}\text{Fe}$ . Blood was again collected over the next 30 min. In five control studies  $^{55}\text{FeCl}_3$  was added to the 4% radioiron saturated transferrin to raise the saturation level to 80%. The plasma radioiron clearance curves were established as described by FINCH *et al.* [7].

**Studies in rats.** Instead of purified transferrin, pooled serum of sideropenic rats (transferrin saturation below 10%) was employed. Iron deficiency was produced by

repeated blood removal through heart puncture. Equal amounts of  $^{59}\text{FeCl}_3$  (approximately  $5 \mu\text{Ci}$  each) were added to different serum volumes to give the iron saturation to 15 and 85%, respectively. Immediately prior to injection through a jugular vein catheter the volumes were equalized by addition of original unlabeled serum [11]. Over 10 min 10-002 ml blood samples were collected from the catheter and immediately pipetted into 2 ml saline. The cells were washed twice and the radioactivity of the supernatant was measured. The study was terminated by drawing blood from the heart for serum iron assay. All animal work was done under ether anaesthesia. In four separate experiments using four serum pools a total of 19 and 23 rats injected with one of the two preparations were studied in parallel.

*General methods.* Haematocrits were determined by the micro-method. Serum iron was assayed according to Moricau and Carter [14]. Radioactivity was measured in a Nuclear Chicago Gamma Well Type Scintillation Counter (model 2433). Iron free glassware was used throughout. All chemicals were of reagent grade. Statistical comparisons between group data were carried out by Student's *t* test.

## Results

*Studies in humans.* Each individual experienced an accelerated radioiron clearance from the high saturated transferrin as compared to the low saturated preparation. This difference was not explained by the slight drop in serum iron concentration. In control subjects the clearance rates become identical in both studies (table I).

*Studies in rats.* A significant difference in plasma radioiron clearance rate between the two groups investigated was observed ( $p < 0.05$ ). Thus in the low and high iron saturation studies the average  $t_{1/2}$  were 83 and 65 min, respectively, while the mean serum iron levels and haematocrits were almost identical (table II).

## Discussion

This study was designed to test in vivo the in vitro observation of a preferential incorporation of iron by transferrin from transferrin molecules carrying two iron atoms rather than one [4, 10]. First a group of subjects had two subsequent ferrokinetic studies: the first using a commercial transferrin preparation of 40% radioiron saturation for the first study and 85% saturation for the second. As iron attachment to transferrin binding sites occurs at random [2], in the former preparation molecules carrying one iron atom or non-bound fully loaded molecules which on the other

Table 1 Individual subjects after having had two subsequent ferrokinetics within 1 h

No	Sex	Age	Clinical diagnosis	Hae- mato- crit %	Study A <sup>1</sup>		Study B	
					serum iron $\mu\text{g}/$ 100 ml	t $\frac{1}{2}$ , min	serum iron $\mu\text{g}/$ 100 ml	t $\frac{1}{2}$ , min
<i>Experimental group</i>								
1	M	58	Christian Weber's disease	35	43	49	37	38
2	M	52	aortic valvular disease	44	70	79	72	49
3	M	68	arteriosclerosis	42	100	135	95	49
4	M	54	diabetes mellitus	40	77	122	63	75
5	M	59	aortic valvular disease	42	75	98	58	69
6	M	57	peptic ulcer	39	87	66	77	46
Mean $\pm$ 1 SD					75 $\pm$ 19	92 $\pm$ 33	67 $\pm$ 20	54 $\pm$ 15
<i>Control group</i>								
1	M	50	mitral valvular disease	34	24	36	25	33
2	M	60	arteriosclerosis	41	30	33	27	33
3	F	71	arteriosclerosis	51	56	36	57	36
4	M	58	thrombosis	43	50	44	47	50
5	M	60	atrophic gastritis	46	73	62	69	62
Mean $\pm$ 1 SD					47 $\pm$ 20	42 $\pm$ 12	45 $\pm$ 19	43 $\pm$ 13

<sup>1</sup> The difference between study A and B consisted in differences of the radioiron transferrin saturation levels, being 4 and 80%, respectively. In control subjects (study A) the transferrin saturation was raised to 80% by the addition of cold iron.

<sup>2</sup> No correction was made for the radioactivity still present from study A.

hand, predominated in the latter. Indeed, in each individual investigated, radioiron clearance from the saturated transferrin preparation was accelerated unequivocally as compared to the low iron probe. Moreover, in a control group the clearance rates became equal after cold iron had been added to the low radioiron preparation. Second, groups of rats were injected with one of two homologous serum preparations identical in <sup>59</sup>Fe, <sup>55</sup>Fe and transferrin concentration containing either a small proportion of fully loaded <sup>59</sup>Fe transferrin in presence of a large excess of apotransfer-

Table II. Rats were injected with adrenergic rat serum brought to transferrin saturation levels of 15 and 85%, respectively, each experiment was carried out simultaneously in the high and low iron saturation recipients and was based on four different serum pools

Experiment	15% saturation			85% saturation		
	Hematocrit, %	serum iron $\mu$ g/100 ml	t <sup>1/2</sup> , min	Hematocrit, %	serum iron $\mu$ g/100 ml	t <sup>1/2</sup> , min
1	47	140	82	45	136	99
	46	146	95	47	140	81
	46	152	73	46	81	66
	47	118	95	46	134	124
				42	141	97
				47	147	104
2	42	190	132	47	132	64
	44	194	84	47	225	47
	44	214	136	47	310	49
	47	225	109	47	142	31
	47	241	116	43	217	31
	47	202	82	45	231	44
3	45	144	112	46	147	36
	47	137	87	44	143	40
	41	140	19	44	129	31
	46	143	44	47	121	42
	44	172	41	46	161	37
				45	132	49
4	52	192	47	50	176	45
	49	194	46	48	136	23
	45	193	16	48	142	47
	47	124	111	49	184	31
				47	229	147
Mean	45.7 $\pm$ 4.1	177 $\pm$ 47	81 $\pm$ 16*	47 $\pm$ 2	171 $\pm$ 92	61 $\pm$ 22*

\*  $p < 0.05$

low or predominate is the transferrin type. The plasma clearance experiments conducted with these preparations confirmed the data provided in human studies.

These findings are difficult to explain other than by an accelerated rate of uptake of iron by transferrin saturated transferrin receptors as compared to the partially saturated species. Variability in the response is

ceptor sites of the transferrin molecule according to its state of iron saturation could explain this finding [8, 13]. The association rate between reticulocytes and transferrin molecules complexed with one or two iron atoms has been found identical, however [5]. Therefore, the efficiency of the iron to cell transfer may be critically influenced by the degree of iron load of the carrier protein. Reflux of transferrin still carrying its original iron from reticulocytes has in fact been demonstrated [16].

The question may arise if impurities of the commercial protein preparation, EDTA in particular, have contributed to the results obtained. Taking into account a ratio of iron binding sites between EDTA and transferrin below 1/250, and the greatly differing affinity constants [2] this possibility appeared unlikely. Also, significant iron binding to EDTA was excluded by thin layer chromatography. Further, using a similar approach as described herein, FLETCHER [9] was unable to detect unequal clearance rates from 3 and 60% saturated transferrin respectively. But, theoretically, at 60% saturation the proportion of fully saturated transferrin molecules was relatively small.

*Acknowledgements* This investigation was supported by grants from the Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung (3 89 69 3 393 70 and 3 7710 72) and the Hartmann Müller Stiftung der Universität Zürich.

### References

- 1 AASA R, MALMSTRÖM B G, SALTMAN P and VANGGARD T. Specific binding of iron (III) and copper (II) to transferrin and conalbumin. *Biochim biophys Acta* 75: 203-222 (1963).
- 2 AISEN P, LEIRMAN A and REICH H A. Studies on the binding of iron to transferrin and conalbumin. *J. biol. Chem.* 241: 1666-1671 (1966).
- 3 AISEN P, AASA R, MALMSTRÖM B G and VANGGARD T. Bicarbonate and the binding of iron to transferrin. *J. biol. Chem.* 242: 2484-2490 (1967).
- 4 BAKER E and MORGAN E H. The kinetics of the interaction between rabbit transferrin and reticulocytes. *Biochemistry* 8: 1133-1141 (1969).
- 5 BAKER E and MORGAN E H. The role of iron in the reaction between rabbit transferrin and reticulocytes. *Biochemistry* 8: 2954-2958 (1969).
- 6 DAVIS H, SALTMAN P, and BENSON S. The stability constants of the iron transferrin complex. *Biochem biophys Res Commun* 9: 56-60 (1968).
- 7 FINCH C A, DEUBELBEISS K, COOK J D, ESCHBACH J W, HAXEIR L, A, FUNK B D, MARSALEA G, HILMAN R S, SLETCHER M, ADAMSON J W, GANZONI A and GIBBYTT F R. Ferrokinetics in man. *Medicine* 49: 17-53 (1970).



ceptor sites of the transferrin molecule according to its state of iron saturation could explain this finding [8, 13]. The association rate between reticulocytes and transferrin molecules complexed with one or two iron atoms has been found identical, however [5]. Therefore, the efficiency of the iron to cell transfer may be critically influenced by the degree of iron load of the carrier protein. Reflux of transferrin still carrying its original iron from reticulocytes has in fact been demonstrated [16].

The question may arise if impurities of the commercial protein preparation, EDTA in particular, have contributed to the results obtained. Taking into account a ratio of iron binding sites between EDTA and transferrin below 1:250, and the greatly differing affinity constants [2] this possibility appeared unlikely. Also, significant iron binding to EDTA was excluded by thin layer chromatography. Further, using a similar approach as described herein FLETCHER [9] was unable to detect unequal clearance rates from 3 and 60% saturated transferrin, respectively. But theoretically, at 60% saturation the proportion of fully saturated transferrin molecules was relatively small.

*Acknowledgements* This investigation was supported by grants from the Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung (3 89 69, 3 393 70 and 3 7710 72) and the Hartmann Müller Stiftung der Universität Zürich.

### References

1. AASA R, MALMSTRÖM B G, SALTMAN P and VÄNNGÅRD T. Specific binding of iron (III) and copper (II) to transferrin and conalbumin. *Biochim biophys Acta* 75: 203-222 (1963).
2. AISEN P, LEHRMAN A and REICH H A. Studies on the binding of iron to transferrin and conalbumin. *J biol Chem* 241: 1666-1671 (1966).
3. AISEN P, AASA R, MALMSTRÖM B G and VÄNNGÅRD T. Bicarbonate and the binding of iron to transferrin. *J biol Chem* 242: 2484-2490 (1967).
4. BAKER L and MORGAN E H. The kinetics of the interaction between rabbit transferrin and reticulocytes. *Biochemistry* 8: 1133-1141 (1969).
5. BAKER E and MORGAN E H. The role of iron in the reaction between rabbit transferrin and reticulocytes. *Biochemistry* 8: 2954-2958 (1969).
6. DAVIS B, SALTMAN P and BENSON S. The stability constants of the iron transferrin complex. *Biochem biophys Res Commun* 8: 56-60 (1968).
7. FINCH C A, DEUBELBEISS K, COOK J D, ESCHBACH J W, HARKER L A, FUNK D D, MARSAGLIA G, HILLMAN R S, SLITCHER S, ADAMSON J W, GANZONI A and GIBLET F R. Ferrokinesics in man. *Medicine* 49: 17-53 (1970).

embryonic tissues and to elucidate the structural features of its accumulation at the cellular level.

### Material and Methods

#### *Animals*

Female C<sub>57</sub>Bl/6J inbred mice aged from 4 to 6 weeks obtained from the Weizmann Institute of Science, Rehovot, Israel, were hormonally primed [6] and mated with 3- to 6-month-old males of the same strain. The morning after mating was designated as day 0 of gestation [1]. The gestation period of this strain of mice is 20–21 days.

Anemic mice: a second group of mice was bled repeatedly till the average level hemoglobin fell to 70% of that of the control group.

Both groups were given intraperitoneally 17 mg of <sup>125</sup>I-insulin (42 mCi/ml, obtained from the Radiochemical Centre, Amersham, England) on day 10 of gestation. The animals were killed between the 12 h and 14 h gestational day. The bone marrow, liver, spleen and peripheral blood of the pregnant animals and the embryonic liver, spleen and peripheral blood were examined. Embryonic liver and spleen were removed under a dissecting stereomicroscope on sequential days of fetal development beginning on gestational day 12. Embryonic blood was collected in Petri dishes containing 1:1 Tyrode's solution and fetal bovine serum (Microbiological Associates, Bethesda, Md.) by heart puncture.

#### *Electron microscopy*

Tissues for electron microscopy examination were immediately transferred to cold 1 percent phosphate buffered glutaraldehyde solution (pH 7.2) postfixed in 1 percent osmium tetroxide dehydrated in ethanol and embedded in 1 percent Epon 812. Thin (400 nm) sections were cut on an LKB Ultratome III, stained with uranyl acetate and lead citrate and examined with a Philips 300 electron microscope. Specimens for demonstration of insulin structure were obtained by placing a drop of diluted insulin (1.5%) in distilled water) onto a formvar coated grid.

#### *Insulin in fetal placenta from pregnant mice*

*Liver and spleen.* Portions of liver and whole spleens were weighed and transferred to tubes containing 1 ml Tyrode's solution and homogenized. 0.25 ml of the homogenate was transferred into glass vials (Packard Inst. Co., Downers Grove, Ill.) 1.4 ml 6.4% TM 170 (Packard Inst. Co.) and supernatant (1:1) and 0.5 ml 20 percent perchloric acid were added into the vials. They were incubated for 10 min at room temperature and for an additional 15–15 min at 47°C. After addition of the acid, 0.5 ml 0.5% HCl and 0.5 ml 10% HCl (Packard Inst. Co.) the vials were kept overnight in the dark at 4°C. The activity of the deionized water was measured using a Log 3000™ automatic spectrometer (Packard Inst. Co., model 550). The results are expressed in a net percentage for each organ of a single animal. Comparable experiments were carried out using identical amounts of tissue.

*Fetal mouse.* Fetal mouse bone marrow pooled from 9 animals was resuspended in 1 ml 1:1 Tyrode's solution and fetal bovine serum. The cells were counted the day



## Transfer of Iron-Dextran Across the Placenta

M DIALDETTI, I NOTTI, P FISHMAN and H BESSLER

Department of Medicine B and Hematology Clinic, Hasharon Hospital, Petah Tikva  
and Tel Aviv University Medical School Tel Aviv

**Key Words** Anemia Imferon® Iron in pregnancy Iron-dextran Placental passage of iron

**Abstract** In pregnant mice  $^{59}\text{Fe}$  labeled iron-dextran (Imferon®) is transferred across the placenta. It was detected in the bone marrow, liver, spleen and peripheral blood of the pregnant animal as well as in the embryonic liver erythroid precursors and peripheral blood. Uptake by liver and peripheral blood cells of pregnant anemic mice and by liver erythroid precursors of anemic embryos was significantly higher than in normal control animals. Electron microscopic examination revealed that the iron deposits in the embryonic liver erythroid precursors had the same structure as the injected Imferon.


Iron dextran (Imferon®, Fisons Ltd, England) is widely acknowledged to be an effective drug in the treatment of iron-deficiency anemia [6]. While the beneficial results of the drug in anemia of pregnancy are frequently reported, studies on its placental transfer are scarce. COX *et al* [3] studied the serum iron level and iron-binding capacity in progeny of mothers given iron-dextran infusions and demonstrated that there is no passage of iron-dextran across the placenta once the maternal serum iron level has returned to normal. When the serum iron level is at its peak after infusion of the total dose, a small amount of iron is believed to cross the placenta possibly as unchanged iron-dextran, but the iron stores of the progeny do not contain excessive amounts of iron. On the other hand, COTES *et al* [2] showed that 25–45% of  $^{59}\text{Fe}$  labelled iron-dextran administered to pregnant monkeys was recovered in the fetuses.

The aim of the present study is to examine the transfer of Imferon through the placenta to follow its mode of deposition in maternal and

Table 1. Levels of  $^{211}\text{Po}$  inferred by stages of pregnant women, based on different days of gestation

Tissue	1 <sup>st</sup> day		11 <sup>th</sup> day		14 <sup>th</sup> day		16 <sup>th</sup> day	
	A	C	A	C	A	C	A	C
Livers cpm/g	77,417	51,419	130,214	100,277	121,499	92,940	117,670	110,977
Spleens cpm/g	37,678	39,473	61,412	51,571	44,745	47,771	40,214	61,046
Blow marrow								
cpm 1.7 × 10 <sup>6</sup> cells	307	164	117	131	223	176	225	205
Peritoneal blood								
cpm 0.1 ml packed cells	1,177	1,116	4,707	2,970	6,827	3,074	4,070	4,113

A = Aortic pressure C = central venous pressure



1. The use of an outboard motor is prohibited on the 1st of July and on every following day of the day between 10:00 a.m. and 6:00 p.m. on the 1st of July. The use of outboard motors is prohibited on the 2nd of July.

pension centrifuged and after discarding the supernatant the cells were again suspended in 0.25 ml of the same mixture and transferred into vials for counting.

*Peripheral blood* Heparinized blood was obtained by heart puncture. The cells were washed three times with 0.9 percent saline solution. Packed cells (0.1 ml) were transferred into vials and their activities counted as previously described.

#### *<sup>55</sup>Fe Imferon Uptake in Embryos*

*Livers* Whole embryonic livers extracted on gestational days 12-15 were cut into small pieces, placed in 1:1 Tyrode's solution and fetal bovine serum and disaggregated by squeezing through a fine tipped Pasteur pipette. Activity of the cells was then counted as previously described.

*Peripheral blood* Peripheral blood from embryos of gestational days 12-15 was pooled, the cells counted, sedimented and 0.1 ml of packed cells transferred into vials for radioactive counting.

### *Results*

*Mothers* Uptake of <sup>55</sup>Fe-Imferon in tissues of anemic mice is recorded in table I. In both the anemic and control animals, activities are significantly increased on day 13 of gestation, i.e. 3 days after injection of Imferon, as compared with uptake on day 12 ( $p < 0.005$ ). In the anemic mice there was a twofold increase in uptake by the spleen between days 12 and 13, in the control animals, spleen uptake increased with gestation time. While uptake in the bone marrow of both anemic and control mice was more or less steady, the peripheral blood cells showed a marked increase in the uptake during gestation, which was much more pronounced in the anemic animals ( $p < 0.005$ ).

*Embryos* As the gestation period progressed, in both anemic and control embryos there was a marked increase in the Imferon uptake by the liver, which was even more pronounced in the anemic fetuses ( $p < 0.01$ ), uptake by the peripheral blood was approximately constant.

*Electron microscopy* Deposits of iron were easily detected in the liver red cell precursors of both anemic and control mice, but in much greater amounts in the embryos of anemic mothers. They were found in precursors of different gestational stages, but appeared to be most abundant in liver red cell precursors of the 13th day. The iron deposits were visible mainly in the poly- and orthochromatic erythroblasts, located in large clusters surrounded by membrane (fig. 1). Their structure suggested the presence of ferritin granules, but we were not able to show the typical configuration of the ferritin molecule. On the other hand, the structures appeared compatible with those of the Imferon molecule (fig. 1, insert).

Table 1 Uptake of  $^{51}\text{Cr}$ -labeled iron by tissues of pregnant anemia mice on different days of gestation

Tissue	13th day		13 1/2 day		14 1/2 day		15 1/2 day	
	A	C	A	C	A	C	A	C
Liver, cm/g	77.4 <sup>a</sup>	51.619	130.234	100.245	121.429	92.940	117.670	110.927
Spleen, cm/g	35.7	18.423	63.432	51.571	55.775	57.731	50.244	61.056
Bone marrow cm, $3.7 \times 10^6$ cells	3	168	317	131	223	176	223	205
Peripheral blood cm 0.1 ml packed cc	1.7	1.116	4.707	2.960	6.827	3.046	6.070	4.313

A = Anemia, mice  
C = mice




Fig. 1. Photomicrographs of liver from anemia mice. A = 13-day, B = 13 1/2-day.

maximal deposition in the liver of a 13-day anemia mouse is comparable to the amount of iron deposited in the spleen of a nonpregnant anemia mouse (Fig. 1).




Fig 2 Iron deposit in the nucleus of a polychromatophilic erythroblast  $\times 73,000$

Fig 3 Unstained thin section of a 13-day embryonic liver showing large amounts of iron deposits in an orthochromatic erythroblast  $\times 20,000$

Table II Uptake of  $^{59}\text{Fe}$ -labeled Iron by tissues of embryos from anemic mice at different gestational ages

Tissues	12th day		13 1/2 day		14th day		15 1/2 day	
	A	C	A	C	A	C	A	C
Livers, cpm $3.8 \times 10^7$ cells	916	578	1122	509	1,211	893	1,311	876
Peripheral blood cpm $2.5 \times 10^7$ cells	-	1,536	2,972	1,875	2,310	2,042	1,456	2,808

A = embryos from anemic mothers; C = control embryos.

On rare occasions iron deposits were found even in the nucleus (fig. 2). The iron deposits were promptly detected in unstained thin sections due to their electron density (fig. 3). They were not found in the parenchymal liver cells, nor in the mesenchymal cells of the embryonic spleen.

### Discussion

The detection of radioactivity in the erythroid precursors of embryonic livers and peripheral blood confirms the transplacental transfer of the drug. The increased incorporation of radioactive  $^{59}\text{Fe}$  in embryonic livers with advancing gestation may be explained by the increase in more mature erythroid precursors during embryonic development. While in the embryonic livers of the 13th day 20% of the erythroid precursors are proerythroblasts, by day 14 the proportion of these cells decreases to 5%, during the same period the proportion of more mature erythroblasts such as polychrome and orthochromatic erythroblasts capable of synthesizing hemoglobin increases rapidly [7]. It was shown that the late erythroblasts and particularly the polychromatophilic erythroblasts are the most active in hemoglobin synthesis [8, 10] and in iron incorporation [4, 9].

The more pronounced uptake of radioactive  $^{59}\text{Fe}$  in the livers of embryos of anemic mothers is rather surprising since the anemia was mild, and it is supposed that the iron content in the embryo was not reduced.

The steady increase of  $^{59}\text{Fe}$  in the peripheral embryos, however, during the progress of gestation may be explained by the presence of ma-

ture yolk sac cells in the peripheral blood which are not able to synthesize new hemoglobin

The electron-microscopic findings suggest that the iron deposits in the erythroid precursors of the embryonic livers are most probably Imferon. The similar structure of the Imferon molecule *in vivo* and *in vitro* (fig. 1) would support this indication. This observation is compatible with the findings of Muir reported by Cox [3] who demonstrated that infused human and rhesus trophoblasts contain particles similar in size and structure to pure iron-dextran which do not have the ultrastructure of ferritin or hemosiderin. However, the author could not find such particles in specimens obtained after iron dextran infusion.

The uptake of Imferon in the maternal tissues is as expected (except for the peak of radioactivity) found in the livers of both control and anemic animals at day 13 of gestation, i.e. 3 days after Imferon administration. It is possible that by this stage of gestation, the liver, which is one of the important organs for iron storage, is already iron-saturated and cannot store more.

*Acknowledgment.* Our thanks are given to Mrs. SONIA SELICSON ZINCER and Mrs. RIVKA REZNICK from the Department of Biostatistics, LUPAT HOLMI for their help in preparing the statistical data. This study was supported by a grant from Fisons Ltd. England and partially by a grant obtained from the Chief Scientist Bureau, Ministry of Health of which M. D. is an established investigator.

### References

- 1 COLE, R. J. and PAUL, J. The effects of erythropoietin on haem synthesis in mouse yolk sac and cultured foetal liver cells. *J. Embryol. exp. Morph.* 15: 245-260 (1966).
- 2 COTTS, P. M., MOSS, G. F., MUIR, A. R., and SCHIELER, P. J. Distribution of iron in maternal and foetal tissues from pregnant Rhesus monkeys treated with a single intravenous infusion of  $^{59}\text{Fe}$  iron dextran. *Br. J. Pharmac. Chemother.* 26: 633-648 (1966).
- 3 COX, J. S. G., MILLS, P., and MOSS, G. I. Transplacental passage of iron-dextran. *Lancet* i: 821 (1966).
- 4 DIALDETTI, M., CHILI, H., MARKS, P. A., and RIKKEND, R. A. Erythroid cell development in fetal mice: stabilization of the hemoglobin synthetic capacity. *J. molec. Biol.* 50: 345-358 (1970).
- 5 GRASSO, J. A., WOODHARD, J. W., and SWIFT, H. Cytochemical studies of nucleic acids and proteins in erythrocytic development. *Proc. nat. Acad. Sci. USA* 50: 134-140 (1963).

- 6 *Inferon* in Clinical Use, 2nd ed (Tavox, 1964)
- 7 MILES P. A. and REYNOLDS R. A. Protein synthesis: its control in erythropoiesis. *Science* 171: 955-961 (1972)
- 8 SCHMIDT J. I., WOODRUFF H. G., and RUSSELL, I. S. An fetal ironemia of dystrophic mice with features of spermatoma. *Nature Lond.* 208: 1126-1127 (1965)
- 9 SEITZ H. D., LARSEN L. G., OLIVER R., and FARRIS E. Studies on the  $^{59}\text{Fe}$  uptake by normoblasts and failure of  $\lambda$  irradiation to affect uptake. *Br. J. Haemat.* 3: 365-374 (1957)
- 10 THOMAS, R. Studies on the formation of cellular substances during blood cell proliferation (Lecture in London 1947)



## *In vitro* and *in vivo* Influence of Penicillin G on Platelet Aggregation<sup>1</sup>

L. HOUBOUYAN, J. F. STOLTZ and A. GOGUEL<sup>2</sup>

Service Central d'Hématologie Hôpital A. Paré Boulogne Billancourt III  
Groupe de Recherches Hémothéologiques Centre Régional de Transfusion Sanguine  
et d'Hématologie Vandœuvre lès Nancy

**Key Words** Platelet aggregation Platelet electrophoretic mobility Platelet function Penicillin G Screen filtration pressure test

**Abstract** The influence of penicillin G on the *in vitro* and *in vivo* ADP induced platelet aggregation and on the platelet electrophoretic mobility has been studied. The *in vitro* investigations in presence of penicillin concentrations varying between 1 000 and 10 000 IU/ml of plasma and doses of adenosine diphosphate (ADP) between 0.3 and 25  $\mu$ M/ml have shown that the photometric aggregation as well as the screen filtration pressure are both decreased according to the doses of antibiotic and ADP. The electrophoretic mobility is also impaired. The *in vivo* study of 8 patients submitted to massive penicillin therapy for bacterial endocarditis seems to be in agreement with the *in vitro* results and has shown a prolonged bleeding time an hypodhesiveness an impaired photometric aggregation with an early disaggregation and a decrease of the screen filtration pressure and platelet electrophoretic mobility.

At the present time, many drugs are known to affect blood platelet functions, and, particularly their aggregability. However, very few reports have dealt with the possible interference of antibiotics with haemostasis [4, 6-8].

Our study reports *in vitro* and *in vivo* investigations about the influence of penicillin G on some platelet functions. Such a work has been motivated by the observation of a patient who being submitted to massive penicillin therapy for bacterial endocarditis, had haemorrhage dur-

<sup>1</sup> This work was supported by Grant No. 74-34-202-00-480-75-01 of the DIRM (Biological Section).

<sup>2</sup> We thank Mrs J. DEXTER for her technical assistance.



lic screens formed by multiple 20- $\mu\text{m}^2$  micropores. This technique was applied to the PRP to which addition of ADP induces an increase in the SFP [12] due to the formation of platelet aggregates. The results were expressed in mm Hg. The measurements were made at different times after the addition of ADP. The conditions of experiments and the proportions were the same as those used with the photometric study.

The platelet electrophoretic mobility (EM) was determined in liquid phase in an apparatus with a rectangular chamber [11]. All the measures were performed in autologous plasma.


*Reagents* ADP (Sigma Laboratories) used at final plasmatic concentrations of 0.3 to 25  $\mu\text{M}/\text{ml}$ , collagen (Strigo Laboratories) diluted in Tris buffer (ionic strength 0.15 M, pH 7.4) and used at 50  $\mu\text{g}/\text{ml}$  as a final concentration, penicillin G. For the *in vitro* studies sodium salt of benzylpenicillinate was used. It was dissolved in distilled water, then diluted with Michreli's buffer (ionic strength 0.15 M, pH 7.35) and finally PRP samples were incubated with various dilutions of penicillin (1 vol of antibiotic and 9 vol of PRP) at 37°C for 10 min before the addition of ADP. Final plasmatic concentrations of penicillin were 1 000, 2 000, 5 000, 10 000 IU/ml. Control samples consisted in the same PRP incubated with buffer in the same proportion, instead of penicillin.

The patients were treated either with sodium or potassium salt of benzylpenicillinate.

## Results

*In vitro studies* The influence of penicillin on platelet aggregation with ADP and electrophoretic mobility is illustrated in figure 1 and table I. As is obvious from table I, the relative EM of platelet suspensions in contact with penicillin is progressively decreased, according to the dose of antibiotic. On the other hand, the SFP is significantly decreased. This decrease becomes much more perceptible as the concentrations of penicillin arise. We may notice also, that, for the lowest dose of antibiotic (2,000 IU) there is still a difference in the results of SFP, as regards the concentrations of ADP added, but, for high doses of penicillin (10,000 IU), the SFP becomes nearly equal to that of PRP alone, i.e. nearly without any aggregates in the suspension.

Furthermore, a closely parallel inhibitory effect of penicillin on platelet behaviour is found out by the photometric study of ADP induced aggregation. Figure 1 presents an example of aggregation curves recorded with the same PRP incubated with different concentrations of penicillin in the presence of ADP at 1.25  $\mu\text{M}/\text{ml}$ , and points out the inhibitory effect in relation to the dose of this antibiotic. In fact, this aggregation is all the more disturbed as the penicillin concentration is higher and the



lic screens formed by multiple 20- $\mu\text{m}^2$  micropores. This technique was applied to the PRP to which addition of ADP induces an increase in the SFP [12] due to the formation of platelet aggregates. The results were expressed in mm Hg. The measurements were made at different times after the addition of ADP. The conditions of experiments and the proportions were the same as those used with the photometric study.

The platelet electrophoretic mobility (EM) was determined in liquid phase in an apparatus with a rectangular chamber [11]. All the measures were performed in autologous plasma.

*Reagents* ADP (Sigma Laboratories) used at final plasmatic concentrations of 0.3 to 25  $\mu\text{M}/\text{ml}$ , collagen (Strigo Laboratories) diluted in Tris buffer (ionic strength 0.15 M pH 7.4) and used at 50  $\mu\text{g}/\text{ml}$  as a final concentration. penicillin G. For the *in vitro* studies sodium salt of benzylpenicillinate was used. It was dissolved in distilled water, then diluted with Michaelis buffer (ionic strength 0.15 M pH 7.35) and finally PRP samples were incubated with various dilutions of penicillin (1 vol of antibiotic and 9 vol of PRP) at 37°C for 10 min before the addition of ADP. Final plasmatic concentrations of penicillin were 1 000 2 000 5 000 10 000 IU/ml. Control samples consisted in the same PRP incubated with buffer in the same proportion instead of penicillin.

The patients were treated either with sodium or potassium salt of benzylpenicillinate.

## Results

*In vitro studies* The influence of penicillin on platelet aggregation with ADP and electrophoretic mobility is illustrated in figure 1 and table I. As is obvious from table I, the relative EM of platelet suspensions in contact with penicillin is progressively decreased, according to the dose of antibiotic. On the other hand, the SFP is significantly decreased. This decrease becomes much more perceptible as the concentrations of penicillin arise. We may notice also, that for the lowest dose of antibiotic (2,000 IU) there is still a difference in the results of SFP, as regards the concentrations of ADP added, but, for high doses of penicillin (10,000 IU), the SFP becomes nearly equal to that of PRP alone, i.e. nearly without any aggregates in the suspension.

Furthermore, a closely parallel inhibitory effect of penicillin on platelet behaviour is found out by the photometric study of ADP induced aggregation. Figure 1 presents an example of aggregation curves recorded with the same PRP incubated with different concentrations of penicillin in the presence of ADP at 1.25  $\mu\text{M}/\text{ml}$ , and points out the inhibitory effect in relation to the dose of this antibiotic. In fact this aggregation is all the more disturbed as the penicillin concentration is higher and the

Table 1 *In vitro* influence of penicillin G on EM and SFP of platelets (SFP of PRP only  $7 \pm 3$  mmHg)

Final concentrations of Penicillin G IU ml in PRP	EM, means of 8 measures	SFP, mmHg in presence of ADP, means of 4 measures					
		ADP, 0.625 $\mu$ M ml			ADP, 0.875 $\mu$ M ml		
		1 min	3 min	5 min	1 min	3 min	5 min
2,000	$0.96 \pm 0.05$	18	14	12	36	33	21
5,000	$0.91 \pm 0.06$	8	7	9	7	12	10
10,000	$0.86 \pm 0.06$	7	12	10	12	7	6
■ (buffer instead of penicillin G)	$1.01 \pm 0.04$	44	25	18	50	44	27




Fig 1 Example of ADP induced platelet aggregation in a normal PRP. The PRP was incubated for 10 min at  $37^{\circ}\text{C}$  before addition of ADP ( $1.25 \mu\text{M}$  ml) with penicillin, 10,000 IU/ml (curve A) penicillin 5,000 IU/ml (curve B) penicillin 2,000 IU/ml (curve C) penicillin, 1,000 IU/ml (curve D) and Michaelis buffer (curve E).

inductive dose lower. Thus, for 10,000 IU, aggregation remains irreversible only for very important inductive doses (superior to  $5 \mu\text{M}$ /ml) whereas controls disaggregate only for doses always below or equal to  $0.625 \mu\text{M}$ /ml. We observed then that the dose of 5,000 IU leads to a lesser inhibitory effect (and disaggregation appears at lower doses of

ADP), whereas concentrations of 2,000 and 1,000 IU/ml are less effective

As for the collagen-induced aggregation, we found that low concentrations had no significant effect. On the contrary, in presence of 5,000 and 10,000 IU either no aggregation occurred, even after 6 min recording or, when it occurred, the latency time was very prolonged and velocity very low. But, the rate of complete aggregation was finally normal.

*In vivo studies.* Our study concerning patients submitted to massive penicillin G therapy corroborates the *in vitro* results. Bleeding time was prolonged in all of these patients (about 15 min and in 3 of them, it was longer than 20 min) with normal platelet count. Platelet retention to glass beads was very low (2–12%). In the same way, ADP-induced platelet aggregation was markedly disturbed (table II). Disaggregation occurred very early, even for high inductive doses, it generally appeared already at 5  $\mu$ M and irreversible aggregation was enhanced only by important doses (12.5–25  $\mu$ M/ml).

Results from the *in vitro* collagen induced aggregation were less constant. We found a slight decrease in the aggregation rate (15–40% diminution). In 4 of the patients, PRP velocity was significantly decreased (6–14%, control range 25–35%). When platelet function tests were repeated during the course of penicillin treatment, nearly the same results were obtained.

On the other hand, we did not find any alteration of the platelet function tests in a patient perfused with usual concentrations of penicillin G ( $10 \times 10^6$  IU daily).

Intensive penicillin therapy did not affect the plasmatic coagulation tests which always remained within a normal range. Prothrombin consumption time was not significantly altered.

Platelet factor 3 availability was found normal in the 3 patients' plasmas studied.

### Discussion

The present study shows that high concentrations of penicillin G prolong the bleeding time and impair platelet adhesiveness to glass and platelet aggregation. Our *in vitro* findings are in agreement with those of CAZENAVE *et al* [3] who reported that penicillin G, when used at 1,000–8,000 IU/ml inhibited the ADP-, collagen- and thrombin induced platelet aggregation and the release reaction. Similar observations were

Table II ADP induced platelet aggregation and EM in patients submitted to penicillin therapy

Cases	ADP induced aggregation, ADP in $\mu\text{M}$ ml							Electrophoretic Mobility
	15	12.5	5	2.5	1.25	0.625	0.312	
Patient 1, 250 000 P/mm <sup>3</sup>								
velocity, %	40	35	40	31 (57)	28 (55)	(53)	(40)	0.79 (1.00)
aggregation max., %	62	58	50	39 (71)	36 (70)	(64)	(48)	
disaggregation, %		46	52	78	78			
Patient 2, 250 000 P/mm <sup>3</sup>								
velocity, %		28 (35)		6 (35)		(21)		
aggregation max., %		42 (84)		18 (76)		(40)		
disaggregation, %		77		92		(86)		
Patient 3, 300 000 P/mm <sup>3</sup>								
velocity, %		28	24	24 (60)	17 (54)	13 (51)	(35)	
aggregation max., %		66	55	53 (77)	39 (71)	27 (52)	(43)	0.89 (1.01)
disaggregation, %					75	77	(84)	
Patient 4, 200 000 P/mm <sup>3</sup>								
velocity, %	35	27	23 (44)	21 (44)	(44)	(29)	(7)	0.96 (10 days
aggregation max., %	51	55	44 (80)	35 (78)	(73)	(60)	(37)	after end of
disaggregation, %		55	63	95			(65)	treatment)
Patient 5, 300 000 P/mm <sup>3</sup>								
velocity, %	20	22 (53)	16 (46)	15 (40)	(36)	(25)		
aggregation max., %	51	49 (80)	42 (75)	32 (75)	(56)	(40)		0.87 (1.03)
disaggregation, %			75	79		(85)		
Patient 6, 300 000 P/mm <sup>3</sup>								
velocity, %	33	33 (48)	31	31 (47)	25 (38)	(30)	(19)	
aggregation max., %	59	51 (84)	50	42 (77)	34 (74)	(57)	(36)	0.93 (0.99)
disaggregation, %	33	58	64	82	81		(77)	
Patient 7, 300 000 P/mm <sup>3</sup>								
velocity, %	33	30 (58)	28 (59)	24 (50)	24 (48)	(43)	(33)	
aggregation max., %	85	83 (85)	53 (90)	39 (89)	27 (86)	(64-84)	(40)	0.82 (1.02)
disaggregation, %	65	67	68	80	94		(70)	
Patient 8, 350 000 P/mm <sup>3</sup>								
velocity, %		55 (68)	50 (68)	40 (66)	29 (65)	(47)		
aggregation max., %		63 (80)	63 (83)	55 (73)	38 (70)	(44)		0.95 (0.99)
disaggregation, %			50	63	75	(91)		

Figures in parentheses are normal PRP values measured on the same day P = Platelet.






Fig 2 Bleeding times and photometric ADP ( $1.25 \mu\text{M/ml}$ ) induced platelet aggregation curves in a patient's PRP at different times during penicillin treatment (curve A), 3 days after treatment (curve B), 6 days after treatment (curve C), before treatment (curve D)

reported *in vivo* by Mc CLURE *et al* [9] with carbenicillin, (disodium salt of  $\alpha$ -carboxypenicillin) when used at a high dosage

On the other hand, in contrast with the *in vitro* studies of FLEMING [5], we could not find any *in vivo* plasmatic coagulation change. However, it is possible that the purity of the antibiotic may be an important factor to explain this discrepancy.

The platelet function changes seem to occur very quickly after the onset of treatment as we found alterations as soon as the 3rd day. Then, the modifications were present during all the treatment period with a progressive recovery of normal aggregation after the end of the treatment (fig 2). In all cases, 10 or 15 days after penicillin therapy had been stopped, bleeding time and platelet aggregation were strictly normal (whereas platelet adhesiveness was still slightly impaired). This fact might correspond to a complete renewal of the circulating platelet pool from the bone marrow.

From our *in vitro* and *in vivo* studies, it appears that penicillin may act only at high concentrations, as usual treatment with  $10 \times 10^6$  IU daily, did not influence platelet function.

Our *in vitro* results, obtained after an incubation of only 10 min, confirm a direct inhibitory action of penicillin. However, there is a discrepancy between the *in vivo* and *in vitro* effects, according to the dose. As concerns clinical use, serum concentrations achieved were below 300 IU/ml, on the other hand, the *in vitro* ADP-induced aggregation in presence of 1,000 IU was less impaired than the *in vivo* aggregation for the same inductive dose. There might be several hypothesis for this fact: first, it may be suggested that, although penicillin is not very much degraded *in vivo*, some derivatives might have a stronger action than the antibiotic itself, requiring lower doses; second, under continuous perfusions, patients' platelets are suffusing in penicillin for long periods of time, and it may be assumed that this long contact time permits some interferences between certain particular structures of platelets and the antibiotic. The possible interferences with some membrane phospholipids might also be considered [10].

Besides this, the decrease of EM *in vitro*, after a short incubation time, emphasizes the fact that penicillin could have a direct effect on platelet membrane. The decrease observed might suggest that this antibiotic has an action upon some biochemical sites on the platelet surface (ionized groups or formation of an eventual positive complex between penicillin, plasma proteins and some membrane components). Although the mechanism by which penicillin interacts with platelet functions is not known at the present time, some suggestions can be made on the basis of this experiment and of observations with other cells [7].

### References

- 1 BORN G V R and CROSS J. The aggregation of blood platelets. *J Physiol., Lond.* 163: 178 (1963).
- 2 CAEN J, LARRIEU M J et SAMAMA M. L'hémostase méthodes d'exploration et diagnostic pratique (Expansion scientifique française, Paris 1968).
- 3 CATENAVE J P, PACHEM M A, GUCCIONE M A, and MUSTARD J F.. Effects of penicillin G on platelet aggregation, release and adherence to collagen. *Proc Soc exp Biol Med.* 142: 159-166 (1973).
- 4 DELAVAU P et DIDON D. Art biotiques et coagulation sanguine *in vitro*. *Cr Soc Biol* 164: 2456-2459 (1970).
- 5 FLEMING A and ELLIS F W.. Influence of penicillin on the coagulation of blood. *Br med J* 2: 242-243 (1947).
- 6 LACOMBE M J, VARET B, GODEAU P, HERRIMAN G et CENAC A. Action de fortes doses de pénicilline G sur les plaquettes. Etude au cours de la maladie d'Osier. *Nouv Presse méd J* 1435-1437 (1974).

- 7 LEVINE, B B Immunochemical mechanisms of drug allergy *A Rev Med* 17 23 (1966)
- 8 LURIE, A, OGILVIE, M, TOWNSEND R, GOLD G, MEYERS A M, and GOLD BERG, B Carbenicillin induced coagulopathy *Lancet* i 1114-1115 (1970)
- 9 Mc CLURE, P D, CASSERLY, J G, MONSIEU C, and CROZIER, E Carbenicillin induced bleeding disorder *Lancet* ii 1307-1308 (1970)
- 10 PADFIELD J M and KELLAWAY, J W Rheological studies on mixed phospholipid sols and their interaction with penicillins I Continuous shear viscometry *Chem Phys Lipids* 10 356-368 (1973)
- 11 STOLTZ, J F, STOLTZ, M, PETERS A, COLLIN F et LARCAN, A Methode de mesure de la mobilité électrophorétique de particules colloïdales en suspension Théorie et comparaison entre différentes cellules *J chimie phys* 66 922-928 (1969)
- 12 STOLTZ, J F, ALEXANDRE, P NICOLAS A et STREIFF, F Application du test de pression de filtration à l'étude de l'agrégation des plaquettes par l'ADP *Blut* 27 92-98 (1973)

## An *in vitro* Method to Study the Participation of Various Components in Autoimmune Hemolytic Anemia

THOMAS MULJEARN, HENRY ROTHSCILD and JAMES FREEMAN

Department of Medicine L. S. U. Medical Center New Orleans La., and  
Department of Pathology Earl A. Long Memorial Hospital Baton Rouge La.

**Key Words** Autoimmune hemolytic anemias Osmotic fragility test Poliovirus III

**Abstract** A method is described which allows for the *in vitro* evaluation of various etiological components in autoimmune hemolytic anemia. As an example of the applicability of the technique erythrocytes and serum from a patient with an autoimmune hemolytic anemia suspected to be due to poliovirus III were tested with poliovirus III and complement. Incubation of the patient's cells with complement, poliovirus and autologous serum was required for optimal *in vitro* fragility. The method is proposed as a practical and convenient *in vitro* technique for evaluating the participation of individual components in the pathogenesis of autoimmune hemolytic anemia.

Cytomegalovirus, Epstein Barr, influenza A, influenza C, herpes simplex and zoster, hepatitis B, coxsackie A and measles viruses have been implicated as etiological agents in autoimmune hemolytic anemia, but the precise role of viruses in the erythrolysis has not been clearly established [7]. The implication of various etiological agents in autoimmune hemolytic anemia has been limited by the lack of an *in vitro* correlate of *in vivo* hemolysis. To this end we have adapted the erythrocyte fragility test, which has been shown to be a reliable *in vitro* model of *in vivo* erythrolysis [1], to investigate the possible participation of a viral agent and other components of erythrolysis in the pathogenesis of an autoimmune hemolytic anemia.

The recovery of poliovirus III on two separate occasions during two hospitalizations from the stools of an unvaccinated 9 month-old male with a recurrent and fatal nonspherocytic "warm type" autoimmune hemolytic anemia suggested the possible etiological participation of the vi-

rus in the hemolytic process. The patient's hemoglobin was consistently less than 10 g/100 ml with persistent reticulocytosis and the direct antiglobulin test was positive. However, there was no rise in serum antibodies to poliovirus type I, II, or III, the virus could not be recovered from the blood or bone marrow, and the IgG autoantibody did not demonstrate anti-poliovirus specificity. No other etiological agents or immunodeficiency state were demonstrable.

Since poliovirus has not been implicated in the pathogenesis of autoimmune hemolytic anemia, this case seemed suitable for the *in vitro* evaluation of the possible independent and collective roles of the virus, serum constituents, and erythrocytes in the production of erythrolysis. The demonstration of virus-mediated red cell instability *in vitro* may suggest a possible viral etiology in the patient's hemolytic illness.

### Materials and Methods

Prior to therapy the patient's blood was collected by venesection under sterile conditions and defibrinated with glass beads. The serum was separated by centrifugation and frozen in sterile containers at  $-20^{\circ}\text{C}$ . Blood from a clinically healthy, compatible 12 month-old control subject was collected and fractionated similarly. The red blood cells (RBC) from the patient and control, collected 1 h prior to the incubation procedure, were washed three times with normal saline. Fox strain poliovirus type III ( $10^{6.5}$  TCID<sub>50</sub>/0.1 ml LLCMK2 cells) was obtained from the American Type Culture Collection. The virus preparation was found to have an osmolality of 280 mOsm/l and a sodium concentration of approximately 150 mEq/l. Incubation mixtures consisting of 0.2 ml of patient or control serum, 0.2 ml of patient or control RBC, 0.2 ml of guinea pig complement (Hyland), and 0.05 ml of virus were prepared in duplicate. Final volume was made up to 0.7 ml with 0.9 percent saline. The mixtures were incubated for 20 h at  $37^{\circ}\text{C}$ .

The osmotic fragility of the incubated cells was measured with the Erythrocyte Fragility Kit (Becton Dickinson). After thorough shaking, 20- $\mu\text{l}$  aliquots of the incubation mixtures were delivered into a series of 10 reservoirs of ascending sodium chloride concentration (0.00%, 0.30%, 0.35%, 0.40%, 0.45%, 0.50%, 0.55%, 0.60%, 0.65%, 0.85%). After incubation at room temperature for 20 min, the contents of the reservoirs were centrifuged at 365 g for 5 min. The absorbance (A) of the supernatant fluid in each of the 10 cuvettes was measured at 540 nm in a Coleman Jr spectrophotometer. The percentage of hemolysis was determined by the following formula:

$$\text{Percent hemolysis} = \frac{A_x - A_{0.55\%}}{A_{0.85\%} - A_{0.55\%}},$$

where  $A_x$  is the absorbance of the tube with solution of sodium chloride




Fig 1 Results of osmotic fragility tests performed on incubation mixtures prepared as indicated and incubated at 37°C for 20 h. Each point represents the mean value of duplicate determinations. Plus (+) indicates presence of the component, zero (0) indicates absence of the component in the mixture. See *Material and Methods* for concentrations of components.

Curve	RBC		Serum		Poliovirus	Complement
	patient	control	patient	control		
A	+	0	+	0	+	+
B	0	+	+	0	+	+
C	+	0	+	0	0	+
D	+	0	+	0	+	0
E	+	0	0	+	+	+
F	0	+	0	+	+	+

### Results

As shown in figure 1, when the patient's RBC and autologous serum were incubated with complement and poliovirus III, there was a marked shift to the left of the osmotic fragility curve (curve A). When homologous, compatible erythrocytes were substituted for autologous RBC in the test system (curves B and F), there was no significant shift in fragility from the control cells regardless of the serum used. As can be seen from curves C and D, virus and complement were required for maximum fragility. When homologous serum was substituted in the test system (curve E), the osmotic fragility curve was shifted to the left, but not to the extent seen with autologous serum.

rus in the hemolytic process. The patient's hemoglobin was consistently less than 10 g/100 ml with persistent reticulocytosis and the direct antiglobulin test was positive. However, there was no rise in serum antibodies to poliovirus type I, II, or III, the virus could not be recovered from the blood or bone marrow, and the IgG autoantibody did not demonstrate anti-poliovirus specificity. No other etiological agents or immunodeficiency state were demonstrable.

Since poliovirus has not been implicated in the pathogenesis of autoimmune hemolytic anemia, this case seemed suitable for the *in vitro* evaluation of the possible independent and collective roles of the virus, serum constituents, and erythrocytes in the production of erythrolysis. The demonstration of virus-mediated red cell instability *in vitro* may suggest a possible viral etiology in the patient's hemolytic illness.

### Materials and Methods

Prior to therapy the patient's blood was collected by venesection under sterile conditions and defibrinated with glass beads. The serum was separated by centrifugation and frozen in sterile containers at  $-20^{\circ}\text{C}$ . Blood from a clinically healthy, compatible 12 month old control subject was collected and fractionated similarly. The red blood cells (RBC) from the patient and control, collected 1 h prior to the incubation procedure, were washed three times with normal saline. Fox strain poliovirus type III ( $10^{7.3}$  TCID<sub>50</sub>/0.1 ml LLCMK2 cells) was obtained from the American Type Culture Collection. The virus preparation was found to have an osmolality of 280 mOsm/l and a sodium concentration of approximately 150 mEq/l. Incubation mixtures consisting of 0.2 ml of patient or control serum, 0.2 ml of patient or control RBC, 0.2 ml of guinea pig complement (Hyland) and 0.05 ml of virus were prepared in duplicate. Final volume was made up to 0.7 ml with 0.9 percent saline. The mixtures were incubated for 20 h at  $37^{\circ}\text{C}$ .

The osmotic fragility of the incubated cells was measured with the Erythrocyte Fragility Kit (Becton Dickinson). After thorough shaking, 20- $\mu\text{l}$  aliquots of the incubation mixtures were delivered into a series of 10 reservoirs of ascending sodium chloride concentration (0.00%, 0.30%, 0.35%, 0.40%, 0.45%, 0.50%, 0.55%, 0.60%, 0.65%, 0.85%). After incubation at room temperature for 20 min, the contents of the reservoirs were centrifuged at 365 g for 5 min. The absorbance (A) of the supernatant fluid in each of the 10 cuvettes was measured at 540 nm in a Coleman Jr spectrophotometer. The percentage of hemolysis was determined by the following formula:

$$\text{Percent hemolysis} = \frac{A_{0.45\%} - A_{0.85\%}}{A_{0.45\%} - A_{0.85\%}}$$

where  $A_{0.45\%}$  is the absorbance of the tube with solution of sodium chloride




Fig 1 Results of osmotic fragility tests performed on incubation mixtures prepared as indicated and incubated at 37°C for 30 min. Each point represents the mean value of duplicate determinations. Plus (+) indicates presence of the component, zero (0) indicates absence of the component in the mixture. See *Material and Methods* for concentrations of components.

Curve	RBC		Serum		Poliovirus	Complement
	patient	control	patient	control		
A	+	0	+	0	+	+
B	0	+	+	0	+	+
C	+	0	+	0	0	+
D	+	0	+	0	+	0
E	+	0	0	+	+	+
F	0	+	0	+	+	+

### Results

As shown in figure 1, when the patient's RBC and autologous serum were incubated with complement and poliovirus III, there was a marked shift to the left of the osmotic fragility curve (curve A). When homologous, compatible erythrocytes were substituted for autologous RBC in the test system (curves B and F) there was no significant shift in fragility from the control cells regardless of the serum used. As can be seen from curves C and D, virus and complement were required for maximum fragility. When homologous serum was substituted in the test system (curve E), the osmotic fragility curve was shifted to the left, but not to the extent seen with autologous serum.



### Discussion

The occurrence of a persistent hemolytic state in a patient from whose stools poliovirus III was repeatedly recovered raised the question of the role of this virus in the pathogenesis of the hemolysis. Suggested mechanisms by which viruses may produce autoimmune hemolytic anemia are by (a) alteration of erythrocyte surface antigens leading to auto-sensitization [2], (b) eliciting antibody which has cross-specificity with red cell surface antigens [2], (c) acting as an adjuvant [4], (d) autosensitization in the setting of a disturbed immune system [10], or (e) direct effect of viruses on erythrocytes [8, 9].

The implication of viral responsibility in the pathogenesis of autoimmune hemolytic anemia has been chiefly by clinical association [6, 10]. However, in none of these studies has the virus or the other components of the hemolytic system been tested to prove their independent or collective roles in the production of erytholysis.

The action of autoantibody on the cell membrane in the production of spherocytosis has been described by NEGRINI [5] and DAMESIEK and SCHWARTZ [3], who produced spherocytosis with autoimmune and hetero-immune red cell antibodies. Since the patient's cells incubated with autologous serum were less stable than when incubated with homologous serum, it appears that hemolysis in this patient required the presence of an antibody. Since exhaustive viral studies failed to demonstrate a rise in serum antibodies to poliovirus III, an antibody may have been present which was directed against the red cell-virus union rather than the virus alone, or a faulty antibody directed against the virus may have been present. An immunopathy, although not detected, may be an alternative explanation for the lack of antibody response [10].

The patient's cells incubated without the virus demonstrated an increased fragility compared to control cells. This perhaps suggests an intrinsically defective erythrocyte and could be explained by virus modification of the red cell stroma *in vivo* or defective erythrocyte morphogenesis mediated by the virus. The patient's cells were markedly less stable in the presence of virus than in a virus free system, indicating a direct action of the virus on the red cell membrane may cause accelerated *in vivo* hemolysis. It is possible that the medium in which the virus was suspended may have contributed to the observed osmotic instability. However, such is unlikely since the virus was highly concentrated and the medium was osmotically physiologic.

The patient's cells were more fragile in the presence of exogenous complement than when incubated in the complement free system. The exogenously supplied complement in our system was not independently cytotoxic [7] since the control system does not demonstrate osmotic instability (curve F). Therefore, complement contributed to the instability of the patient's erythrocytes, although it is not clear whether viral action, antibody action or both are complement-dependent.

Maximal hemolysis *in vitro* occurred when the patient's cells were incubated with autologous serum, complement, and poliovirus. Thus, it would appear that in the case studied, an intrinsic red cell defect manifest in the presence of virus, autoantibody and complement is operative in the production of maximal *in vitro* erythrolysis. *In vivo* hemolysis may be an additive phenomenon wherein minimal hemolytic activity occurs when only defective red cells are present and maximal hemolysis may occur when all the components of erythrolysis (autoantibody, complement, virus) are operative.

**Acknowledgement** The critical review and helpful suggestions of Dr. ■ JOHN RUDOLPH are gratefully acknowledged. Drs. LARRY HERBERT and SHEILA MOORE (Department of Pediatrics, Earl A. Long Memorial Hospital, Baton Rouge, La.) provided the clinical material.

### References

1. BAEKER VAN AARDENNE, W. I. T., VERLOOF, M. C., and VAN BORTZELAAR, G. C. ■ Osmotic and mechanical fragility of erythrocytes. Proc. 6th Congr. Eur. Soc. of Hematology (Karger, Basel, 1957).
2. DACEY, J. V. The hemolytic anemias (Grune & Stratton, New York, 1962).
3. DAMESHEK, W. and SCHWARTZ, S. O. Presence of hemolysins in acute hemolytic anemia. New Engl. J. Med. 218: 75-80 (1939).
4. MORTON, J. I. and SIEGEL, B. H. Development of Coombs positive hemolytic anemia in NZB mice injected with Freund's complete adjuvant. Immunology 18: 379-386 (1970).
5. NEGAND, A. C. Erythrocyte osmotic resistance in autoimmune hemolytic anemia, with special reference to relations between spherocytosis and osmotic fragility. Observations before and after therapy. Arch. Magagnoli Pat. Clin. 16: 533-575 (1960).
6. PIORSKY, B. Autoimmunization and the autoimmune hemolytic anemias (Williams & Wilkins, Baltimore, 1969).
7. ROSS, W. F. Correlation of *in vivo* and *in vitro* measurements of hemolysis in hemolytic anemia due to immune reactions. Prog. Hemat. 8: 51-75 (1973).

- 8 STEWART, W. B., PETENYL, C. W., and ROSE, H. M. The survival time of canine erythrocytes modified by influenza virus. *Blood* 10: 228-234 (1954)
- 9 WOLLMAN, R. L.; PANG, E. J., EVANS, A. E., and KIRSTEN, W. H.. Virus induced hemolytic anemia in mice. *Cancer Res* 30: 1003-1010 (1970)
- 10 ZUHLER, W. W., MASTRANGELO, R., STULBERG, C. S., POULIK, M. D., PAGE, E. H., and THOMPSON, R. I. Autoimmune hemolytic anemia. Natural history and viral immunological interactions in childhood. *Am J Med* 49: 80-93 (1970)

## Further Investigations of the $\gamma$ -Chain in a Ghanaian Adult, Homozygous for Hereditary Persistence of Fetal Haemoglobin

Isolation of  $\gamma$  CB-3 Peptides and  $G_\gamma/A_\gamma$  Ratio Determination in Human Hb F

H KAMUZORA, H RINGELHANN, F I D KONOTEY-AHULU,  
H LEHMANN and P A LORKIN

Medical Research Council Abnormal Haemoglobin Unit,  
University Department of Clinical Biochemistry, Cambridge, and  
Ghana Medical School, Departments of Chemical Pathology and Medicine, Accra

**Key Words**  $\gamma$ -chains of Hb F Dansyl Edman technique: Fetal haemoglobin  
Haemoglobinopathies Hereditary persistence of Hb F

**Abstract** The  $\gamma$ -chain in a Ghanaian homozygous for hereditary persistence of fetal haemoglobin was considered to be of the  $G_\gamma$  type on the basis of the amino acid analysis of  $\gamma$ Trp XIV ( $\gamma$ 133-144) of the Hb F of this subject [1]. Recently the sequence of residues  $\gamma$ 134-137 of the  $\gamma$ -chain of this subject was determined and found to contain some alanine at position  $\gamma$ 136. It is therefore of the  $G_\gamma + A_\gamma$  type. A rapid technique for the isolation of  $\gamma$ CB-3 ( $\gamma$ 134-146) peptides in human fetal haemoglobin for  $G_\gamma/A_\gamma$  ratio determination is described.

The two types of  $\gamma$ -chain which occur in normal fetal haemoglobin differ at position 136, being glycine in  $G_\gamma$ -chains and alanine in  $A_\gamma$ -chains [2]. These  $\gamma$ -chains are products of non allelic genes which appear to be expressed independently. However, recent studies have shown that several factors such as age and pathological conditions may influence the  $G_\gamma/A_\gamma$  ratio. The ratio of  $\gamma$ -chains with glycine at position 136 ( $G_\gamma$ ) to those with alanine at that position ( $A_\gamma$ ) in patients homozygous for hereditary persistence of fetal haemoglobin (HPFH) is usually 1:1, but may vary from 0:1 to 1:0. This is due to the suppression of the  $A_\gamma$ -chain gene, to no residue of glycine at  $\gamma$ 136, i.e. complete suppression of the  $G_\gamma$ -chain gene, and instead, a whole residue of alanine at  $\gamma$ 136. Patients of African and Indian origin homozygous for

HPFH have been found to synthesize mainly the  $\alpha\gamma$ -chain type [3, 4]; whereas those of Caucasian origin have been shown to synthesize mainly the  $\Lambda\gamma$  type [5]. In our previous publication [1], a patient from Ghana, homozygous for HPFH was reported to synthesize  $\alpha\gamma$ -chains only, on the basis of the amino acid analysis of  $\gamma$  Tp XIV (residues 133-144), of the Hb F on this subject. On reading our article, Prof. W. A. SCHROEDER of the California Institute of Technology, Pasadena, wrote: '... when we have had analyses with Gly = 0.91 and Ala = 2.17 such as you show for  $\gamma$  Tp XIV, it has been shown by PTH degradation of  $\gamma$  CB-3 that the departure of these values from 1.00 and 2.00 was indeed real, both PTH (3-phenyl-2-thiohydantoin)-glycine and PTH-alanine were detectable in position 136.' To test this suggestion, the  $\gamma$  CB-3 fragment was isolated using a technique which had just been developed. Dansyl-Edman degradation of the  $\gamma$  CB-3 fragment revealed DNS-glycine with detectable DNS-alanine at position  $\gamma$  136. The present paper corrects our previous report on the type of the  $\gamma$ -chain in this subject, to read as  $\alpha\gamma + \Lambda\gamma$  rather than  $\alpha\gamma$  only. The present report will also include a description of a rapid technique for the isolation of  $\gamma$  CB-3 peptides for  $\alpha\gamma/\Lambda\gamma$  ratio determination in human fetal haemoglobins.

### *Materials and Methods*

Blood samples were obtained from infants heterozygous for Hb F Texas I [6], Hb F Fort Royal [7], Hb F Poole [8] and adult homozygous for HPFH [1], homozygous Hb S with raised Hb F, and a patient with raised Hb F due to leukaemia. The Hb F fractions were either separated from haemolysates by DEAE Sephadex chromatography [9] prior to removing the haem [10] or the total haemolysate was used for the determination of glycine/alanine ratio at position  $\gamma$  136. Each sample was divided into two portions, in the first, chain separation was carried out [11], and the  $\gamma$ -chain digested with trypsin and fingerprints prepared [12]. The  $\gamma$  Tp XIV (133-144) peptide was separated from  $\gamma$  Tp II (9-17) by paper electrophoresis at pH 3.5 as previously described [1]. Globin from the other portion (10 mg) was treated with cyanogen bromide [13] in 70% formic acid and lyophilized. It was then re-dissolved in pH 6.4 buffer (pyridine/acetic acid/water 100/4/900 by volume) and applied on Whatman No. 3 papers. Electrophoresis was carried out for both preparations in the same pH-6.4 buffer for 1 h in a Michl type tank at a gradient of 55 v/cm, followed by ascending chromatography (isoamyl alcohol/pyridine/water 6/6/7 by volume) for 30 h. Peptides on the fingerprints obtained were identified by staining with 0.02% ninhydrin in acetone. The same procedure was carried out on globins from whole haemolysates, except that the starting materials were calculated to contain 10 mg Hb F. In two of the samples, the  $\gamma$  CB-3 peptides were eluted with 0.5 M

Table 1

	Hb F Port Royal		Hb F Texas I		Hb SS h gh Hb F		H gh F/leukaemia	
	$\gamma$ CB-3	$\gamma$ TP XIV	$\gamma$ CB-3	$\gamma$ TP XIV	$\gamma$ CB-3	$\gamma$ TP XIV	$\gamma$ CB-3	$\gamma$ TP XIV
Threonine	0.91	0.96	0.96	1.01	0.90	0.96	0.92	0.95
Serine	2.53	3.02	2.54	2.90	3.07	3.01	2.50	2.49
Glycine	1.09	1.10	0.09	0.12	0.59	0.56	0.74	0.77
Alanine	2.17	1.98	3.19	3.11	2.52	2.51	2.58	2.56
Valine	2.31	2.21	1.98	2.20	2.17	2.20	2.19	2.20
Methionine	-	0.33	-	0.47	-	0.45	-	0.31
Leucine	1.00	1.00	1.00	0.98	1.00	1.00	1.00	1.00
Tyrosine	0.32	-	0.82	-	0.76	-	0.21	-
Histidine	0.76	-	1.00	-	0.84	-	0.84	-
Arginine	0.92	1.05	0.99	0.96	1.11	0.94	0.73	0.98
Total, nmol/residue	25.44	18.88	10.72	15.10	10.32	14.71	31.99	12.61

NH<sub>4</sub>OH lyophilised and the sequence of the first 4 residues determined using the dansyl Edman degradation technique [14]. The dansyl derivatives were chromatographed in polyamide layer plates using the solvents described by Woods and Wano [15].

### Results

The pattern of the cyanogen bromide peptides of Hb F in a fingerprint m shown in figure 1.  $\gamma$  CB 3 ( $\gamma$ 134-146) and  $\alpha$  CB 2 ( $\alpha$ 33-76) separate quite neatly from the rest.  $\alpha$  CB 1 ( $\alpha$ 1-32),  $\alpha$  CB-3 ( $\alpha$ 77-141) and  $\gamma$  CB 1 ( $\gamma$ 1-55) do not separate under these conditions. When globin from total haemolysate was used the separation of  $\gamma$  CB 3 and  $\alpha$  CB 2 was not affected because  $\beta$  CB 1 ( $\beta$ 1-55) and  $\beta$  CB 2 ( $\beta$ 56-146) remained at the point of origin. The same applied to  $\delta$  CB 1 ( $\delta$ 1-55) and  $\delta$  CB-2 ( $\delta$ 56-126).  $\delta$  CB 3 ( $\delta$ 127-146) is a small peptide, slightly bigger than  $\gamma$  CB 3 and more positively charged than  $\gamma$  CB 3. It would therefore be expected to move fastest towards the negative electrode but this peptide was not detected presumably due to very low concentrations of Hb A<sub>2</sub> in human haemolysates. The amino acid compositions of  $\gamma$  CB 3 peptides were compared with the amino acid compositions of purified  $\gamma$  TP XIV and the glycine:alanine ratios were found to be almost identical. On dansyl Edman degradation of the  $\gamma$  CB 3 peptide from Hb F Texas I only

HPFH have been found to synthesize mainly the  $\epsilon$ -chain type [3, 4], whereas those of Caucasian origin have been shown to synthesize mainly the  $\Delta\gamma$  type [5]. In our previous publication [1], a patient from Ghana, homozygous for HPFH was reported to synthesize  $\Delta\gamma$ -chains only, on the basis of the amino acid analysis of  $\gamma$ Tp XIV (residues 133-144), of the Hb F on this subject. On reading our article, Prof W A SCHROEDER of the California Institute of Technology, Pasadena, wrote 'when we have had analyses with Gly = 0.91 and Ala = 2.17 such as you show for  $\gamma$ Tp XIV, it has been shown by PTH degradation of  $\gamma$  CB-3 that the departure of these values from 1.00 and 2.00 was indeed real, both PTH (3-phenyl-2-thiohydantoin) glycine and PTH-alanine were detectable in position 136'. To test this suggestion, the  $\gamma$  CB-3 fragment was isolated using a technique which had just been developed. Dansyl Edman degradation of the  $\gamma$  CB-3 fragment revealed DNS-glycine with detectable DNS-alanine at position  $\gamma$ 136. The present paper corrects our previous report on the type of the  $\gamma$ -chain in this subject, to read as  $\Delta\gamma + \Delta\gamma$  rather than  $\Delta\gamma$  only. The present report will also include a description of a rapid technique for the isolation of  $\gamma$  CB-3 peptides for  $\Delta\gamma/\Delta\gamma$  ratio determination in human fetal haemoglobins.

### Materials and Methods

Blood samples were obtained from infants heterozygous for Hb F Texas I [6] Hb F Port Royal [7] Hb F Poole [8] and adult homozygous for HPFH [1] homozygous Hb S with raised Hb F, and a patient with raised Hb F due to leukaemia. The Hb F fractions were either separated from haemolysates by DEAE Sephadex chromatography [9] prior to removing the haem [10] or the total haemolysate was used for the determination of glycine/alanine ratio at position  $\gamma$ 136. Each sample was divided into two portions: in the first chain separation was carried out [11] and the  $\gamma$ -chain digested with trypsin and fingerprints prepared [12]. The  $\gamma$ Tp XIV (133-144) peptide was separated from  $\gamma$ Tp II (9-17) by paper electrophoresis in pH 3.5 as previously described [1]. Globin from the other portion (10 mg) was treated with cyanogen bromide [13] in 70% formic acid and lyophilised. It was then redissolved in pH 6.4 buffer (pyridine/acetic acid/water 100:4:900 by volume) and applied on Whatman No. 3 papers. Electrophoresis was carried out for both preparations in the same pH-6.4 buffer for 1 h in a Michl type tank in a gradient of 55 v/cm followed by ascending chromatography (isoamyl alcohol/pyridine/water 6:6:7 by volume) for 30 h. Peptides on the fingerprints obtained were identified by staining with 0.02% ninhydrin in acetone. The same procedure was carried out on globins from whole haemolysates except that the starting materials were calculated to contain 10 mg Hb F. In two of the samples the  $\gamma$ CB-3 peptides were eluted with 0.5 M

Table I

	Hb F Port Royal		Hb F Texas I		Hb SS high Hb F		High F/leukaemia	
	$\gamma$ CB-3	$\gamma$ TP XIV	$\gamma$ CB-3	$\gamma$ TP XIV	$\gamma$ CB-3	$\gamma$ TP XIV	$\gamma$ CB-3	$\gamma$ TP XIV
Threonine	0.91	0.96	0.96	1.01	0.90	0.96	0.92	0.95
Serine	2.53	3.02	2.54	2.90	3.07	3.01	2.50	2.49
Glycine	1.09	1.10	0.09	0.12	0.59	0.56	0.74	0.77
Alanine	2.17	1.98	3.19	3.11	2.52	2.51	2.58	2.56
Valine	2.31	2.21	1.98	2.20	2.17	2.20	2.19	2.20
Methionine	-	0.33	-	0.47	-	0.45	-	0.31
Leucine	1.00	1.00	1.00	0.98	1.00	1.00	1.00	1.00
Tyrosine	0.32	-	0.82	-	0.76	-	0.21	-
Histidine	0.76	-	1.00	-	0.84	-	0.84	-
Arginine	0.92	1.05	0.99	0.96	1.11	0.94	0.73	0.98
Total, nmol residue	25.44	14.84	10.72	15.10	10.32	14.71	31.99	12.61

NH<sub>4</sub>OH lyophilised and the sequence of the first 4 residues determined using the dansyl Edman degradation technique [14]. The dansyl derivatives were chromatographed in polyamide layer plates using the solvents described by Woods and Wang [15].

### Results

The pattern of the cyanogen bromide peptides of Hb F in a fingerprint is shown in figure 1.  $\gamma$  CB-3 ( $\gamma$ 134-146) and  $\alpha$  CB-2 ( $\alpha$ 33-76) separate quite neatly from the rest.  $\alpha$  CB-1 ( $\alpha$ 1-32),  $\alpha$  CB-3 ( $\alpha$ 77-141) and  $\gamma$  CB-1 ( $\gamma$ 1-55) do not separate under these conditions. When globin from total haemolysate was used the separation of  $\gamma$  CB-3 and  $\alpha$  CB-2 was not affected because  $\beta$  CB-1 ( $\beta$ 1-55) and  $\beta$  CB-2 ( $\beta$ 56-146) remained at the point of origin. The same applied to  $\delta$  CB-1 ( $\delta$ 1-55) and  $\delta$  CB-2 ( $\delta$ 56-126).  $\delta$  CB-3 ( $\delta$ 127-146) is a small peptide, slightly bigger than  $\gamma$  CB-3 and more positively charged than  $\gamma$  CB-3. It would therefore be expected to move fastest towards the negative electrode, but this peptide was not detected, presumably due to very low concentrations of Hb A<sub>2</sub> in human haemolysates. The amino acid compositions of  $\gamma$  CB-3 peptides were compared with the amino acid compositions of purified  $\gamma$  TP XIV and the glycine/alanine ratios were found to be almost identical. On dansyl Edman degradation of the  $\gamma$  CB-3 peptide from Hb F Texas I only






Fig 1 Fingerprint of the soluble cyanogen bromide peptides of Hb F

DNS alanine was found at position 136 with no detectable glycine. The  $\gamma$  CB-3 fragment from the HPFH homozygote gave mainly DNS-glycine for position 136 but with a definite trace amount of DNS-alanine. No DNS-alanine was detected at positions  $\gamma$ 134,  $\gamma$ 135 and  $\gamma$ 137. As stated already, the nature of the  $\gamma$ -chain in this HPFH case should therefore have been described as  $\alpha_1 + \alpha_2$  rather than  $\alpha_1$  only.

### Discussion

Human haemoglobins have a methionine residue at positions  $\alpha$ 32 and 76,  $\beta$ 55,  $\delta$ 55 and 126, and  $\gamma$ 55 and 133. Cyanogen bromide breaks the  $\alpha$ -,  $\beta$ -,  $\delta$ - and  $\gamma$ -chains at these positions to smaller peptides. Of these fragments  $\gamma$  CB-3 (134-146) is of particular significance because the duplication of the  $\gamma$ -chain is located at position 136 which can be either glycine or alanine [2], and all known  $\gamma$ -chain mutations involve one of these chains but not both simultaneously.

The fragments that are obtained on treatment of Hb F with cyanogen bromide are  $\alpha$  CB-1 (32 residues),  $\alpha$  CB-2 (44 residues),  $\alpha$  CB-3 (65 residues),  $\gamma$  CB-1 (55 residues),  $\gamma$  CB-2 (78 residues) and  $\gamma$  CB-3 (13 residues). Except for  $\alpha$  CB-2 and  $\gamma$  CB-1 these peptides can be separated by passage through two 1  $\times$  160 cm columns of Bio-gel P-100 in series which

are developed with 50% acetic acid. The  $\gamma$  CB 3 peptide obtained by this method has to be purified further in columns of Dowex 1 [2]. The peptides are detected by UV spectrophotometry, and since  $\gamma$  CB 3 peptide has only one tyrosine at position 145, large quantities of starting material are required for easy detection. The other approach involves chain separation of Hb F and tryptic hydrolysis of the  $\gamma$ -chains. Peptide chromatograms are prepared and the  $\gamma$ TP XIV peptide is isolated and analysed [1, 16]. The  $\gamma$ TP XIV has to be separated from  $\gamma$ TP II by paper electrophoresis in a pH 3.5 buffer (pyridine acetic acid water 5.50:9.45 by volume) a process which results in loss of material up to 50%. Using these methods only few specimens can be handled at a time and relatively large quantities of starting materials are needed. The technique described in the present paper provides an efficient, quick and economic way of achieving the same end.

In the  $\gamma$  CB 3 peptide, the values of glycine and alanine are 1.00 and 2.00 for the  $\alpha$  $\gamma$ -chain when the  $\beta$  $\gamma$ -gene is completely suppressed and 0.00 and 3.00 for the  $\beta$  $\gamma$  when the  $\alpha$  $\gamma$ -gene is completely suppressed. Variations from these values even at the level of 0.1 residue may indicate that neither gene is completely nonfunctional. It had been our custom to ignore such small variations in molar ratios. The present study, however, shows their significance.

### References

- 1 KAMILZORA, H., RINGELHANN, B., KONOTEV, A., HILL, F. I. H., LITTMANN, H., and LOWRIE, P. A. The  $\gamma$ -chain in a Ghanaian adult homozygous for hereditary persistence of fetal haemoglobin. *Acta haemat.* 51: 179-184 (1974).
- 2 SCHROEDER, W. A., HUTTMAN, T. H. J., SHELTON, J. B., KLEIDHALER, E. F., DOZY, A. M., and ROBBINSON, H. Evidence for multiple structural genes for  $\gamma$ -chain of human fetal haemoglobin. *Proc. nat. Acad. Sci., Wash.* 60: 537-544 (1963).
- 3 SULKAMARAN, H. K., HUTTMAN, T. H. J., SCHROEDER, W. A., McCLEDDY, P. R., FREE, HALLER, J. T., BOUTER, N., SHELTON, J. R., SHELTON, J. B., and APILL, G. A homozygote for the Hb  $\alpha$  $\gamma$  type of foetal haemoglobin in India. A study of two Indian and four Negro families. *Brit. J. Haemat.* 23: 403-417 (1972).
- 4 SCHROEDER, W. A., HUTTMAN, T. H. J., and SULKAMARAN, P. K. A second type of hereditary persistence of fetal haemoglobin in India. *Brit. J. Haemat.* 25: 131-135 (1973).
- 5 HUTTMAN, T. H. J., SCHROEDER, W. A., STAMATOYANNOPOLLOU, G., BOUTER, N., SHELTON, J. H., SHELTON, J. B., and APILL, G. Nature of fetal haemoglobin in the Greek type of hereditary persistence of fetal haemoglobin with and without concurrent  $\alpha$ -thalassaemia. *J. clin. Invest.* 69: 1036-1040 (1970).

- 6 JENKINS, G C., BEALE, D., BLACK, A J., HUNTSMAN, R G., and LEHMANN H  
Haemoglobin F Texas I ( $\alpha_{127} \text{Glu} \rightarrow \text{Lys}$ ) a variant of haemoglobin F Brit J Haemat  
13 252-255 (1967)
- 7 BRIMHALL, H., VEDVICK, T S., JONES, R T., AHERN, E., PALOMINO, E., and AHERN, V.  
Haemoglobin F Port Royal ( $\alpha_1 \text{G}_{125} \text{Glu} \rightarrow \text{Ala}$ ) Brit J Haemat 27 313-318 (1974).
- 8 LEE POTTER, J P., DEACON SMITH, R A., SIMPKISS, M J., KAMUZORA, H., and LEH  
MANN, H A new cause of haemolytic anaemia in the new born A description of an  
unstable foetal haemoglobin F Poole et  $\alpha_1 \text{G}_{130} \text{Tryptophan} \rightarrow \text{Glycine}$  J clin Path  
In press
- 9 HUSMAN, T H J and DOZY, A M Studies on the heterogeneity of haemoglobin 1X  
The use of Tris (hydroxymethyl) amino methane - HCl buffer in the anion exchange  
chromatography of haemoglobins J Chromatography 19 160-169 (1965)
- 10 ROSSI FANELLI, A R., ANTONINI E., and CAPUTO, A : Studies on the structure of  
haemoglobin I Physicochemical properties of human globin Biochim biophys Acta  
30 603-615 (1958)
- 11 CLEGG, J B., NAUGHTON, M A., and WEATHERALL, D J . Abnormal human haemo-  
globins Separation and characterisation of the  $\alpha$  and  $\beta$ -chains by chromatography and  
the determination of two new variants Hb Chesapeake and Hb J (Bangkok) J  
molec. Biol 19 91-108 (1966)
- 12 SICK, K., BEALE, D., IRVINE, D., LEHMANN, H., GOODALL, P T., and MACDOWDALL,  
S Haemoglobin G Copenhagen and Haemoglobin J Cambridge Two new  $\beta$ -chain  
variants of Haemoglobin A Biochim biophys Acta 140 231-242 (1967)
- 13 GROSS, E. and WITKOP, B Non enzymatic cleavage of peptide bonds the methionine  
residues in bovine pancreatic ribonuclease J biol Chem 237 1856-1860 (1962)
- 14 GRAY, W R Sequence analysis with dansyl chloride, in HIRS and TIMASHEFF Methods  
in Enzymology, vol 25, pp 333-344 (Academic Press New York 1972)
- 15 WOODS, K R. and WANG, K T Separation of dansyl-amino acids by polyamide  
layer chromatography Biochim biophys Acta 133 369-370 (1967)
- 16 CALCHI, M N., CLEGG, J B., and WEATHERALL, D J Haemoglobin F (Malta) a  
new foetal haemoglobin variant with a high incidence in Maltese infants Nature,  
Lond 233 311-313 (1969)

ferrin molecules has been found non-existent or minimal [18, 21]. AISEN and LEIBMAN [2] demonstrated radioiron transfer between electrophoretically separable transferrins in the presence of citrate. Stimulation for the present study came from FLETCHER and HUEHNS's [8] experiments demonstrating different rates of iron delivery to reticulocytes from the two transferrin iron binding sites *in vitro*.

### *Material and Methods*

**Preparation of transferrin solutions** The procedures followed have already been described in detail [12]. In some experiments to the saline transferrin solutions  $10^{-3}$  M Na citrate dissolved in saline was added to give final citrate concentrations of  $10^{-3}$ – $10^{-4}$  M.

**Preparation of rabbit reticulocytes** 3 kg rabbits of different origin were bled three times from the ear vein up to 1% of body weight at 2-day intervals. 2 days following the last bleeding blood was drawn by cardiac puncture and immediately cooled to 0°C. At that time the haematocrits were 25–35%, and the reticulocyte counts ranged between 10 and 25%. The cells were washed twice with cold saline and the packed cells, referred to as packed reticulocytes, used for incubation studies. The haematocrit of the packed cells was 65–80%.

**Conditioning of transferrin solutions** 80–90% iron saturated transferrin solutions in saline (0.5 mg transferrin/10 ml pH 7.4) were exposed to packed reticulocytes in volume ratios of 1.25–1.4 in different experiments. After 20 min of incubation at 37°C the supernatant was recovered by sharp centrifugation at 0°C. The concentration change of transferrin due to the saline content of the packed reticulocytes was corrected on the basis of volumes and haematocrits. Changes in  $^{59}\text{Fe}$  transferrin saturation were monitored by radioactivity measurements of the solution prior to and after incubation. Generally within 20 min 50% of the radioiron initially present had been taken up by cells. The method just described is similar to the procedure originally introduced by FLETCHER and HUEHNS [8]. Preparations conditioned in this way are referred to as preincubated solutions.

***In vitro* studies** Four different transferrin solutions identical in protein concentration and  $^{59}\text{Fe}$  saturation were simultaneously investigated in respect to their capacity to deliver iron to reticulocytes (a) preincubated (b) freshly prepared (c) preincubated containing  $10^{-3}$  M citric acid, and (d) freshly prepared containing citrate ( $10^{-3}$ – $10^{-4}$  M). The solutions were kept at 37°C throughout the experiment in a shaking bath, the pH being continuously checked. At 1 to 2 hour-intervals, 0.2 ml portions were removed and incubated with 0.1 ml of packed reticulocytes for 20 min at 37°C. Radioiron removal from the transferrin solution was measured after rapid cooling to 0°C followed by centrifugation.

**Studies in rats** Female Wistar rats, weighing 250–300 g, were made slightly anaemic by cardiac puncture 2 days prior to the experiment. The amount of blood removed was 1% of body weight. Two types of transferrin solutions employed for




Fig 1 Relative iron uptake by reticulocytes from preincubated transferrin containing citrate and freshly prepared transferrin as compared to the preincubated citrate free preparation (5 experiments). The solutions were incubated at 37 °C for 7 h and samples removed at the time points indicated for a 20-min exposure to packed reticulocytes. The radioiron incorporation for the citrate free preincubate was 30–50% in different experiments. The amount of citrate added in the freshly prepared solutions (open symbols, 13 experiments) varied between  $10^{-3}$  and  $10^{-2}$  M; the results were pooled because no concentration-dependent effect was evident.

citrate free solutions was reduced by 50%. Addition of citrate to freshly prepared solutions failed to modify iron uptake. In preliminary experiments it could be shown that the concentration of citrate influenced the rate of iron transfer from preincubated transferrin solutions to reticulocytes whereas no such influence could be detected in freshly prepared solutions.

**Studies in rats** The radioiron plasma disappearance was significantly more rapid if the  $^{59}\text{Fe}$  had been added after *in vitro* reticulocyte exposure. The average  $t_{1/2}$  for the two groups were 49.0 and 84.4 min, respectively ( $p < 0.05$ ). No differences in mean serum iron levels and haematocrits were observed (table I).

### Discussion

FLETCHER and HUEHNS [8] reported that a radioiron transferrin solution which had been preincubated with immature red cells delivered significantly less radioactivity to reticulocytes than a fresh preparation equal in radioiron and transferrin concentration. This difference persisted if both solutions were fully saturated with cold iron prior to the final reticulocyte exposure. Preferential iron uptake from one of the two binding sites by erythroid cells was concluded. This would imply dissimilar behaviour of binding sites, a concept compatible with the partly non repeating amino acid sequence of the molecule [15, 22] made most likely by paramagnetic resonance spectroscopy of the chromium and the iron transferrin complex [1, 3, 19], and by the binding characteristics of lanthanide ions to transferrin [16].

The above *in vitro* observation has been confirmed by CIERNELCH and BROWN [5], and once more in the studies reported herein. However, if citrate was added to the preincubated transferrin in physiological concentration the availability of iron for reticulocytes gradually increased. Whereas, during a 7 hour period the fresh solution exceeded the preincubate in iron donating capacity by a constant factor of 1.65, this difference was halved after 5 h in presence of citrate in the preincubated solution. No effect of citrate on the fresh solutions was evident. As mentioned earlier citrate mediated iron exchange between different transferrin species has already been demonstrated [2]. The present finding indicates that citrate also promotes an interbinding site iron exchange. Using a different *in vitro* system, intraplasmatic iron redistribution among transferrin molecules curtailed by removal of low molecular compounds through dialysis but restored by citrate has recently been confirmed in this laboratory [10].

The significance of chelating agents in general and of citrate in particular in iron metabolism has been stressed by SALTMAN [20]. Citrate removes iron from transferrin in greater amounts than expected from the stability constant [6] and the transfer of ferrous iron from citrate to apotransferrin in an isomolar solution is a slow process terminated after 20 h only [4]. The rate limiting step appears to be the formation of the ternary complex citrate ferrous iron transferrin which is broken down very rapidly. The transitional character of such a compound is supported by the minimal changes of spectral absorbance induced by  $10^{-4} M$  citrate added to a  $10^{-4} M$  solution of iron-saturated transferrin [2]. Chelating agents other

than citrate might contribute to intraplasmatic iron exchange. Such a role may be visualized for some amino acids and sugars keeping iron soluble in the alkaline duodenum [4], and for several phosphate compounds apparently involved in iron transfer between transferrin and ferritin [17].

Interbinding site iron transfer still appeared to be rather slow *in vivo* as evident from persistent differences in plasma clearance rates of  $^{59}\text{Fe}$  bound to different transferrin preparations. Briefly, slightly anemic rats obtained one of two transferrin solutions which were first saturated with  $^{59}\text{Fe}$  or  $^{55}\text{Fe}$ , and after reticulocyte exposure, resaturated with the opposite iron isotope. As expected, the  $^{59}\text{Fe}$  added after *in vitro* incubation disappeared more rapidly from circulation being preferentially attached to the reticulocyte-oriented binding sites. Rapid iron redistribution among binding sites probably would have caused a progressive similarity in clearance rates. Nevertheless, these results confirm the functional non equivalence of the two transferrin iron binding sites in an *in vivo* system. Exactly the opposite phenomenon was encountered in polycythemic rats injected with similar transferrin preparations [11]. Radioiron was cleared more rapidly from the compound initially labeled, and preferentially accumulated in the liver. Thus, through minimizing iron flow to the erythropoietic tissue a liver-oriented transferrin binding site became apparent.

The present investigations are open to a number of possible criticisms. It must be conceded, for instance, that the biological significance of inter-binding site iron exchange is by no means clarified. If it proceeds at the rate observed in our rather simple *in vitro* system, it would be difficult to recognize an important physiological process. Furthermore, a system including human transferrin, rabbit reticulocytes, and rats may introduce variables little related to physiology. This object creates little concern in view of the rates of reticulocyte iron uptakes and plasma iron clearances as measured in these studies, being entirely in the order of magnitude found in a homogenous animal system [9]. Finally, one might concede limited significance to data based on the use of purified transferrin possibly denatured to some extent or deprived from hypothetical molecules essential for physiological function.

The above reservations in mind we conclude that *in vivo* evidence for a functionally heterogeneous transport iron pool was obtained. The iron distribution between transferrin binding sites and, independently, the saturation degree of the individual carrier proteins, are intimately linked to erythropoietic activity. In addition iron exchange between binding sites possibly imparts an internal dynamic to the transport iron compartment.

It is attractive to envisage a decisive function of this complex system for iron distribution following specific tissue demands. The hypothesis has been advanced that iron absorption from the gastrointestinal tract and iron mobilization from storage sites is governed by the number of unoccupied haemoglobin-oriented transferrin binding sites [8]. Our findings are compatible with this idea. From a practical point of view, reevaluation of ferrokinetic data seems compelling; specifically, the slow components of plasma radioiron disappearance may not only be caused by reflux phenomena [7] but also mirror iron fractions leaving the plasma compartment at a slow rate.

*Acknowledgements* This investigation was supported by grants from the Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung (3.89.69, 3.393.70 and 3.7710.72) and the Hartmann-Müller-Stiftung der Universität Zürich.

### References

1. AASE, R. Reinterpretation of the electron paramagnetic resonance spectra of transferrin. *Biochem. Biophys. Res. Commun.* **49**, 806-812 (1972).
2. AMEN, E. and LERMAN, A. Citrate-mediated exchange of  $\text{Fe}^{3+}$  among transferrin molecules. *Biochem. Biophys. Res. Commun.* **33**, 220-226 (1968).
3. AMEN, P., AASE, R., and REDFERN, A. G. The chromium, manganese and cobalt complexes of transferrin. *J. Mol. Chem.* **244**, 4623-4633 (1969).
4. DAVIS, G. W., BILLYUS, G., and SALTMAN, P. The kinetics and mechanism of iron (III) exchange between chelates and transferrin. I. The complexes of citrate and nicotinic acid. *J. Mol. Chem.* **242**, 2810-2815 (1967).
5. CHERNICOFF, M. and BROWN, F. B. *In vitro* testing of the Fletcher-Hoehrs hypothesis of functional differences of iron stores bound by transferrin. *Nature Lond.* **246**, 356 (1970).
6. DAVIS, B., SALTMAN, P., and BILLYUS, S. The stability constants of the iron-transferrin complex. *Biochem. Biophys. Res. Commun.* **8**, 56-60 (1968).
7. DEAN, R. J., MONTI, A., and GLYNN, M. F. Studies with doubly labeled iron. IV. Evidence for a second iron binding system in plasma. *J. Lab. Clin. Med.* **61**, 280-291 (1963).
8. FLETCHER, J. and HUTTON, F. R. Significance of the binding of iron by transferrin. *Nature Lond.* **215**, 943-946 (1967).
9. GAXTON, A. M. Iron uptake and heme synthesis in rat reticulocytes. Quantitative considerations. *Helv. med. Acta* **34**, 416-427 (1971).
10. GAXTON, A. M., BASTIERA, R., and HARRIS, D. Transferrin intracellular iron exchange. *Experimenta* **30**, 32 (1974).
11. HARRIS, D. Functional behaviour of transferrin. *Eur. J. Biochem.* **34**, 311-316 (1973).



- 12 HAIN D, BAVIERA B., and GANZONI A M Functional heterogeneity of the transport iron compartment I *Acta haemat* (1975)
- 13 HOSAIN, F and FINCH C. A Ferrokinetics a study of transport iron in plasma *J Lab clin Med* 64 905-912 (1964)
- 14 JACOBS A and MILES P M Intraluminal transport of iron from stomach to small intestinal mucosa *Brit med J* II 778-781 (1969)
- 15 JEFFSON J O and SJOQUIST, J Structural studies on genetic variants of human transferrin *Prot. biol Fluids* 14 87-91 (1966)
- 16 LUK, C. K. Study of the nature of the metal binding sites and estimate of the distance between the metal binding sites in transferrin using trivalent lanthanide ions as fluorescent probes *Biochemistry* 10 2838-2843 (1971)
- 17 MILLER, J P G and PERKINS E J Model experiments for the study of iron transfer from transferrin to ferritin *Eur J Biochem* 10 146-151 (1969)
- 18 MORGAN, E. H., MARSAOLLA, G., GIBLETT, F. R., and FINCH C. A A method of investigation internal iron exchange utilizing two types of transferrin *J Lab clin Med* 69 370-381 (1967)
- 19 PRICE, E. M and GIBSON, J F Electron paramagnetic resonance evidence for a distinction between the two iron binding sites in transferrin and conalbumin *J biol Chem* 247 8031-8035 (1972)
- 20 SALTMAN P The role of chelation in iron metabolism *J chem Educ* 42 682-687 (1965)
- 21 TURNBULL, A and GIBLETT, E. R The binding and transport of iron by transferrin variants *J Lab clin Med* 57 450-459 (1961)
- 22 WANG, A. C. and SUTTON, H E Human transferrin C and II chemical difference in a peptide *Science* 149 435-437 (1965)

## Binding of Folic Acid to Serum Proteins

### V. Tritiated Folic Acid in the Liver

T. MARKKANEN, R.-L. PAJULA, S. VIRTANEN, P. HIMANEN and  
M. JÄRVINEN

Departments of Medical Microbiology and Medicine, University of Turku, Turku

**Key Words:** Carrier proteins · Folic acid metabolism · Gel chromatography · Liver cell metabolism

**Abstract** Sephadex G-200 chromatographies of the liver cell sap of rabbits, 1, 3 and 6 days after an injection of <sup>3</sup>H folic acid activity (FAA) into the circulation were used in an attempt to study the binding of this labelled FAA to liver proteins. The labelled FAA was quickly accumulated in the liver, and in the cell sap it was grouped chromatographically to two maxima, which corresponded to the two maxima of microbiological FAA (*L. casei*). The maxima were eluted in the chromatography together with cell sap proteins. The possible coupling of FAA to proteins in the liver is discussed.

*In vitro*, about half of the serum folic acid activity (FAA) is eluted together with proteins from the DEAE Sephadex A-50 column [5]. This half forms 3 FAA maxima in the protein area [6]. More detailed chromatographic study has shown that these maxima are projected to the  $\alpha_2$ -macroglobulin, transferrin and albumin areas [7, 8] quantitatively in this order. In healthy test subjects the maxima are similar, though the FAA of the transferrin area lies at a slightly higher level in women than in men and the distribution in women varies slightly according to the different phases of the menstrual cycle [14]. When pregnancy develops, the FAA distribution undergoes a distinct change [9] and the use of oral contraceptives has much the same effect [14]. Diphenylhydantoin increases the binding of FAA to the transferrin zone [10]. Certain diseases such as hyperthyroidism, myeloma, pernicious anaemia and liver diseases clearly affect the FAA distribution [11].

The FAA levels of the liver are high and the liver is, as far as is known, the metabolic centre of folic acid. In the present study an effort

- 12 HAIN, D., BAVIERA, B., and GANZONI, A. M. Functional heterogeneity of the transport iron compartment I *Acta haemat* (1975)
- 13 HOSAIN, F. and FINCH, C. A. Ferrokinetics: a study of transport iron in plasma *J Lab clin Med* 64 905-912 (1964)
- 14 JACOBS, A. and MILES, P. M. Intraluminal transport of iron from stomach to small intestinal mucosa *Brit med J* II 778-781 (1969)
- 15 JEFFSON, J. D. and SJOQUIST, J. Structural studies on genetic variants of human transferrin *Prot Biol Fluids* 14 87-91 (1966)
- 16 LUK, C. K. Study of the nature of the metal binding sites and estimate of the distance between the metal binding sites in transferrin using trivalent lanthanide ions as fluorescent probes *Biochemistry* 10 2838-2843 (1971)
- 17 MILLER, J. P. G. and PERKINS, D. J. Model experiments for the study of iron transfer from transferrin to ferritin *Eur J Biochem* 10 146-151 (1969)
- 18 MORDAN, E. H., MARSAGLIA, G., GIBLETT, E. R., and FINCH, C. A. A method of investigation internal iron exchange utilizing two types of transferrin *J Lab clin Med* 69 370-381 (1967)
- 19 PRICE, E. M. and GIBSON, J. F. Electron paramagnetic resonance evidence for a distinction between the two iron binding sites in transferrin and conalbumin *J Biol Chem* 247 8031-8035 (1972)
- 20 SALTMAN, P. The role of chelation in iron metabolism *J chem Educ* 42 682-687 (1965)
- 21 TURNBULL, A. and GIBLETT, E. H. The binding and transport of iron by transferrin variants *J Lab clin Med* 57 450-459 (1961)
- 22 WANG, A. C. and SUTTON, H. E. Human transferrin C and D: chemical difference in a peptide *Science* 149 435-437 (1965)

## Binding of Folic Acid to Serum Proteins

### V. Tritiated Folic Acid in the Liver

T. MARKKANEN, H.-L. PAJULA, S. VIRTANEN, P. HIMANEN and  
M. JÄRVINEN

Departments of Medical Microbiology and Medicine, University of Turku Turku

**Key Words** Carrier proteins Folic acid metabolism Gel chromatography  
Liver cell metabolism

**Abstract** Sephadex G 200 chromatographies of the liver cell sap of rabbits, 1, 3 and 6 days after an injection of  $^3\text{H}$  folic acid activity (FAA) into the circulation, were used in an attempt to study the binding of this labelled FAA to liver proteins. The labelled FAA was quickly accumulated in the liver and in the cell sap it was grouped chromatographically to two maxima which corresponded to the two maxima of microbiological FAA (*L. casei*). The maxima were eluted in the chromatography together with cell sap proteins. The possible coupling of FAA to proteins in the liver is discussed.

*In vitro*, about half of the serum folic acid activity (FAA) is eluted together with proteins from the DEAE Sephadex A-50 column [5]. This half forms 3 FAA maxima in the protein area [6]. More detailed chromatographic study has shown that these maxima are projected to the  $\alpha_2$ -macroglobulin, transferrin and albumin areas [7, 8], quantitatively in this order. In healthy test subjects the maxima are similar, though the FAA of the transferrin area lies at a slightly higher level in women than in men and the distribution in women varies slightly according to the different phases of the menstrual cycle [14]. When pregnancy develops the FAA distribution undergoes a distinct change [9] and the use of oral contraceptives has much the same effect [14]. Diphenylhydantoin increases the binding of FAA to the transferrin zone [10]. Certain diseases, such as hyperthyroidism, myeloma, pernicious anaemia and liver diseases clearly affect the FAA distribution [11].

The FAA levels of the liver are high, and the liver is, as far as is known, the metabolic centre of folic acid. In the present study an effort

was made to observe the metabolism of tritium labelled folic acid in the liver, giving special attention to the way in which FAA seemed to be coupled to liver proteins in the course of this process

### *Material and Methods*

Folic acid dissolved in physiological saline solution was injected intravenously into the rabbits ear (folic acid  $359\text{ }^3\text{H(n)}$  potassium salt Rad ochemical Centre Amersham specific activity  $31\text{ Ci/mmol}$ ) The rabbit which was followed up for 24 h was given  $70\text{ }\mu\text{Ci}$  the one followed up for 3 days  $100\text{ }\mu\text{Ci}$  and the animals followed up for 6 days  $45\text{ }\mu\text{Ci}$  After the injection the test animals stayed in their cages on the normal dietary regime for the relevant 1, 3 and 6 days respectively

The livers of the rabbits were removed carefully rinsed with saline solution and cooled in an ice bath Approximately 10 g of the liver was sectioned and homogenized in 100 ml physiological saline in a Potter Elvehjem homogenizer (with a teflon piston) The suspension obtained was further treated in an ice bath with an ultrasound equipment (MSE ultrasonator 15 A) for 3 min and finally centrifuged for 30 min at 14 000 rpm

The supernatant (40 ml) of the liver suspension was then fractionated immediately in column chromatography (Sephadex G 200 Pharmacia Uppsala) using techniques described earlier [6] In each chromatography 180 samples (10 ml) were collected and the  $^3\text{H}$  activity as well as the microbiological FAA of every sample were measured The rate of elution was 45–60 ml/h


The proteins of both the supernatant of the liver suspension and its chromatography fractions were determined with the biuret method and the folic acid with the *L. casei* method (after the addition of ascorbic acid) as reported earlier [6]

Samples (0.2 ml) of the supernatant of the liver suspension and its chromatography fractions were taken into scintillation flasks for the determination of  $^3\text{H}$  activity The  $^3\text{H}$  activity of the serum of the test animal was determined in the same way After this scintillation fluid (10 ml Merck) was added and the  $^3\text{H}$  activity was measured for 10 min per sample with a Packard Tri Carb fluid scintillation counter (Model 3375)

The results are presented in fig 1 and table 1

### *Results*

Figure 1B shows that the  $^3\text{H}$  FAA injected into the test animal's vein is seen in the chromatogram of liver cell sap concentrated primarily into two maxima coinciding with the site of the microbiological FAA analysed simultaneously with *L. casei* (fig 1A) A small proportion of the latter, of course, is  $^3\text{H}$  FAA injected into the vein



**Fig 1** *A* Typical chromatography curve of the cell sap of rabbit liver 24 h after intravenous injection of  $^3\text{H}$  FAA. The continuous line indicates protein areas I-IV and is identical to that in *B*. Vertical shading indicates the microbiological FAA (1 case). Note the two distinct maxima in the protein area. *B* The continuous line synchronously with the former indicates protein areas I-IV. Vertical shading indicates  $^3\text{H}$  FAA. Note the two distinct maxima coinciding with those of the microbiological FAA in the protein area.

Both the radioactive and microbiological FAA are eluted from the column in Sephadex G-200 chromatography simultaneously with proteins. When this gel is used, the proteins form 4 groups (protein areas I-IV, fig 1A, B). These protein groups are not sharply differentiated. After the elution of proteins, chromatography was still prolonged up to

Table I

Liver cell sap	Animal		
	1	3	6
Proteins, mg/ml	17.9	14.2	14.5
Recovery of injected $^3\text{H}$ FAA, %	31	56	32
Activity of $^3\text{H}$ FAA in protein areas %	81	78	76
$^3\text{H}$ FAA/mg proteins, cpm/mg	450	1 019	408
$^3\text{H}$ FAA in protein areas I-III, %	40	40	27
$^3\text{H}$ FAA in protein area IV, %	60	40	73
IV/I-III	1.49	1.04	2.78
<i>Serum</i>			
$^3\text{H}$ FAA, cpm/ml	594	0	223

$^3\text{H}$  FAA was injected into the veins of three rabbits. A Sephadex G 200 chromatography of the liver cell sap was carried out for one animal after 24 h (1) for the second after 3 days (3) and for the third after 6 days (6). Recovery indicates the amount of the injected  $^3\text{H}$  FAA in % recorded in the animal's liver after these periods. cpm = Counts per minute. Protein areas I-IV are shown in fig. 1A and 1B. The serum  $^3\text{H}$  FAA of each animal recorded at the same time as the liver sample was studied is shown at the bottom of the table.

the 180th fraction, but neither radioactive nor microbiological (*L. casei*) activity was any longer eluted from the column (fig. 1A, B). The results after 1, 3 and 6 follow-up days are qualitatively similar, in other words the FAA maxima coincide with those of the protein chromatogram.

Table I reveals, however, that when more than 3 days have passed since the injection of  $^3\text{H}$ -FAA, changes begin to occur in the  $^3\text{H}$  FAA distributions of liver cell sap: activity diminishes in protein areas I-III and increases in protein area IV. At the same time,  $^3\text{H}$  activity in clearly measurable quantities again begins to appear in the serum of the test animals. This activity at the 3-day follow up was 0 cpm/ml (table I). With prolongation of the follow-up period, a slight tendency towards a diminishing percentage of the  $^3\text{H}$  FAA eluted with proteins into the liver cell sap is observed.

### Discussion

A considerable amount of the tritium labelled FAA injected into test animals' circulation seems to accumulate in the liver. There, in the liver cell sap, it is grouped into two maxima. These maxima are eluted to-

gether with proteins which, in turn are distributed into 4 protein areas in Sephadex G 200 chromatography. The microbiological FAA (*L. casei*) is also eluted with the said proteins, and the maxima coincide with the two  $^3\text{H}$  FAA maxima mentioned. The first of the two radioactive maxima to be eluted diminishes relatively with time, while the second grows. At the same time  $^3\text{H}$  FAA appears in the serum.

Relatively little is as yet known of the binding relations of folic acid to serum proteins. However, it is known that at least half of the total serum FAA is eluted in chromatography with the proteins, and in the electrophoretic study of the various protein fractions FAA moves in the manner peculiar to each protein [12] while the unbound FAA follows a separate course (unpublished observation). Transferrin,  $\alpha_2$ -macroglobulin and albumin have been suggested as the FAA carrier proteins [12]. At least for transferrin, findings similar to ours have been reported by certain other authors [15], but a differing view has also been published [3]. In different animal species the binding proportions seem to be different [4, 13].

It is highly presumable that the coupling of FAA to proteins takes place in the liver, side by side with FAA metabolism in general. The present study demonstrated in fact, that liver cell sap chromatography has two separate FAA maxima and that these maxima are eluted together with apparently, fairly large molecular proteins. The question arises whether the labelled FAA is really attached to these proteins or whether the FAA for some other reason is eluted together with the proteins. One and perhaps the most important, reason is that the molecular weight of the possibly polymerized FAA would be equal to those of the eluted proteins. However, the FAA eluted in the first protein maximum can hardly be of a molecular weight as high as the usually very large molecular protein that is eluted in this maximum.

The FAA metabolism in the liver has been studied also from aspects other than binding to proteins. It has been noted that some 85% of the FAA in the liver are in the form of reduced pteroyl polyglutamates (more than 3 glutamate moieties/molecule), 12–15% in the form of reduced pteroyl glutamate, ca 1% in the form of pteroyl-diglutamate and only traces in the form of reduced pteroyl monoglutamate [1]. The same authors found that endogenous and injected  $^3\text{H}$  FAA is concentrated in liver mitochondria and the cell-sap fraction (21 and 71%, respectively) [2]. They also pointed out that the binding of FAA to liver proteins is not known [2].



We began an electrophoretic analysis of the fractions obtained by chromatography but found that the protein concentrations were too small to obtain a good immunoelectrophoresis. When we tried a simultaneous autoradiography and immunoelectrophoresis, it was found that the  $^3\text{H}$  FAA radiation was not strong enough to show on even a sensitive film. Hence the direct and conclusive evidence of the binding of  $^3\text{H}$  FAA to the liver cell sap proteins could not be verified by the present methods. Only the elution simultaneously with proteins justifies the assumption that FAA probably is bound to proteins in the liver and only then passes into circulation where it occurs at least partly bound to proteins.

A great deal of additional study, preceded by advances in chromatographic techniques, is required before the present laborious problem can really be tackled in greater detail.

### References

- 1 CORROCHIER, R., BRUYAN, H. L., and HOFFBRAND, A. V., Composition of pteroylglutamates (conjugated folates) in guinea pig liver and their formation from folic acid. *Clin. Sci.* 43: 799 (1972).
- 2 CORROCHIER, R., and HOFFBRAND, A. V., Subcellular localization of folate and effect of methotrexate on the incorporation of radioactive folic acid into guinea pig liver folate. *Clin. Sci.* 43: 815 (1972).
- 3 JACOB, E., and HERBERT, V., Evidence against transferrin as a binder of either vitamin  $\text{B}_{12}$  or folic acid. *Blood* 43: 767 (1974).
- 4 MANTZOS, J. D., ALEVIPOU-TERZAKI, V., and GYFTAKI, E., Folate binding in animal plasma. *Acta haemat.* 51: 204 (1974).
- 5 MARKKANEN, T., Pteroylglutamic acid (PGA) activity of serum in gel filtration. *Life Sci.* 7: 887 (1968).
- 6 MARKKANEN, T., and PELTOLA, O., Carrier proteins of folic acid activity in human serum. *Acta haemat.* 45: 106 (1971).
- 7 MARKKANEN, T., PAJULA, R. L., VIRTANEN, S., and HIMANEN, P., New carrier protein(s) of folic acid in human serum. *Acta haemat.* 45: 145 (1972).
- 8 MARKKANEN, T., VIRTANEN, S., HIMANEN, P., and PAJULA, R. L., Transferrin, the third carrier protein of folic acid activity in human serum. *Acta haemat.* 48: 213 (1972).
- 9 MARKKANEN, T., HIMANEN, P., PAJULA, R. L., RUTONEN, S., and CAYRÉN, B., Binding of folic acid to serum proteins. I. The effect of pregnancy. *Acta haemat.* 50: 111 (1973).
- 10 MARKKANEN, T., HIMANEN, P., PAJULA, R. L., and MORNIS, G., Binding of folic acid to serum proteins. II. The effect of diphenylhydantoin treatment and of various diseases. *Acta haemat.* 50: 264 (1973).

- 11 MARKKANEN T, HONANEN P., and PAJULA R.-L. Binding of folic acid to serum proteins. III. The effect of pernicious anaemia. *Acta haemat.* 51: 193 (1974)
- 12 MARKKANEN T, PAJULA, R. L., HONANEN P. and VIRTANEN S. Serum folic acid activity (*L. casei*) in Sephadex gel chromatography. *J. clin. Path.* 25: 456 (1973)
- 13 MARKKANEN, T., PAJULA, R. L., HONANEN P., and VIRTANEN S. Binding of folic acid to serum proteins. IV. In some animal species. *Int. Z. VitamForsch.* 44 (to be published, 1974)
- 14 MARKKANEN T, VIRTANEN S, PAJULA, R. L., and HONANEN P. Hormonal dependence of folic acid protein binding in human serum. *Int. Z. VitamForsch.* 44 (to be published, 1974)
- 15 WAXMAN S. and SCHREIBER C. Characteristics of folic acid binding protein in folic acid-deficient serum. *Blood* 42: 791 (1973)

We began an electrophoretic analysis of the fractions obtained by chromatography but found that the protein concentrations were too small to obtain a good immunoelectrophoresis. When we tried a simultaneous autoradiography and immunoelectrophoresis, it was found that the  $^3\text{H}$ -FAA radiation was not strong enough to show on even a sensitive film. Hence the direct and conclusive evidence of the binding of  $^3\text{H}$ -FAA to the liver cell sap proteins could not be verified by the present methods. Only the elution simultaneously with proteins justifies the assumption that FAA probably is bound to proteins in the liver and only then passes into circulation, where it occurs at least partly bound to proteins.

A great deal of additional study, preceded by advances in chromatographic techniques, is required before the present laborious problem can really be tackled in greater detail.

### References

- 1 CORROCHIER R, BHUYAN B K, and HOFFBRAND A V. Composition of pteroylglutamates (conjugated folates) in guinea pig liver and their formation from folic acid. *Clin Sci* 43: 799 (1972).
- 2 CORROCHIER R and HOFFBRAND A V. Subcellular localization of folate and effect of methotrexate on the incorporation of radioactive folic acid into guinea pig liver folate. *Clin Sci* 43: 815 (1972).
- 3 JACOB L and HERBERT V. Evidence against transferrin as a binder of either vitamin  $\text{B}_{12}$  or folic acid. *Blood* 43: 767 (1974).
- 4 MANTZOS J D, ALEVIZOU TERZAKI V, and GYFTAKI T. Folate binding in animal plasma. *Acta haemat* 51: 204 (1974).
- 5 MARKEKANEN T. Pteroylglutamic acid (PGA) activity of serum in gel filtration. *Life Sci* 7: 897 (1969).
- 6 MARKEKANEN T and PILLTOLA O. Carrier proteins of folic acid activity in human serum. *Acta haemat* 45: 106 (1971).
- 7 MARKEKANEN T, PAJULA R I, VIRTANEN S, and HIMANEN P. New carrier protein(s) of folic acid in human serum. *Acta haemat* 48: 145 (1972).
- 8 MARKEKANEN T, VIRTANEN S, HIMANEN P, and PAJULA R L. Transferrin the third carrier protein of folic acid activity in human serum. *Acta haemat* 48: 213 (1972).
- 9 MARKEKANEN T, HIMANEN P, PAJULA R L, RUPONEN S, and CASTRÉN O. Binding of folic acid to serum proteins. I. The effect of pregnancy. *Acta haemat* 50: 85 (1973).
- 10 MARKEKANEN T, HIMANEN P, PAJULA R L, and MÖLNÉR G. Binding of folic acid to serum proteins. II. The effect of diphenylhydantoin treatment and of various diseases. *Acta haemat* 50: 284 (1973).

- 11 MAREKANTY, T., HIMANEN, P., and PAJULA, R. L., Binding of folic acid to serum proteins. III The effect of pernicious anaemia. *Acta haemat.* 51 193 (1974)
- 12 MAREKANTY, T., PAJULA, R. L., HIMANEN, P., and VIRTANEN, S., Serum folic acid activity (*L. casei*) in Sephadex gel chromatography *J. clin. Path.* 26 496 (1973)
- 13 MAREKANTY, T., PAJULA, R. L., HIMANEN, P., and VIRTANEN, S., Binding of folic acid to serum proteins. IV In some animal species *Int. Z. VitamForsch.* 44 (to be published, 1974)
- 14 MAREKANTY, T., VIRTANEN, S., PAJULA, R. L., and HIMANEN, P., Hormonal dependence of folic acid protein binding in human serum. *Int. Z. VitamForsch.* 44 (to be published, 1974)
- 15 WAXMAN, S. and SCHREIBER, C., Characteristics of folic acid binding proteins in folate-deficient serum *Blood* 42 291 (1973)

## Quantitative Determination of Immunoglobulins in Chronic Renal Failure

N KALLIAMANIS, K MELISSINOS, I ECONOMIDOU and K VLASSOPOULOS

II Medical Clinic (Director Prof G MERKAS) Athens University, Athens

**Key Words** Blood urea · Immunoglobulins · Proteinuria · Renal failure · Uremia

**Abstract** Immunoglobulins IgG, IgM and IgA in the serum of 61 patients suffering from chronic renal failure of various etiology and not being under hemodialysis treatment were measured. Cases of nephropathy, due to collagen or blood disease or uremia with heavy proteinuria were excluded. No statistically significant difference was found between patients and controls in respect to the serum level of the 3 immunoglobulins studied. No correlation was found between the level of serum immunoglobulins and the blood urea or the amount of protein daily excreted in the urine.

Uremic patients show an abnormal immune response [2, 4, 6, 7, 9, 11, 13, 14]. The alterations in the globulin fraction by changes in the immunoglobulins may be a contributory factor. On the other hand, the use of immunosuppressive drugs for treatment of the renal disease or for protection from rejection episodes after renal allografting needs a good estimation of the immunological state of the patients. Proteinuria is a characteristic feature of renal insufficiency, and it has been established that proteinuria itself can result in a catabolic hypogammaglobulinemia with a reduction in the IgG fraction [1]. The present study concerns itself with the quantitative determination of the 3 major serum immunoglobulins (IgG, IgM and IgA) and with their correlation to blood urea or the daily amount of protein excreted in the urine.

### *Material and Methods*

89 adults of both sexes, aged between 20 and 70 years, were studied. They were divided into two groups.

Table 1 Blood serum immunoglobulin levels (mg/100 ml) in 61 uremic patients and 28 normal controls. Mean  $\pm$  SD (range)

Immunoglobulins	Uremic patients	Normal controls	Significance <sup>1</sup>
IgA	264 $\pm$ 142 (90-900)	297 $\pm$ 93 (85-440)	n.s.
IgG	1,127 $\pm$ 516 (290-2,900)	1,312 $\pm$ 596 (500-2,000)	n.s.
IgM	89 $\pm$ 45 (27-270)	100 $\pm$ 37 (34-170)	n.s.

<sup>1</sup> Student's *t* test. n.s. = not significant.

**Group I** 61 uremic patients suffering from chronic renal failure of various etiology with blood urea values between 34 and 450 mg% and protein excreted between 11 and 9.25 g/24 h. In most cases chronic glomerulonephritis, chronic pyelonephritis and polycystic disease has been diagnosed while in a few cases it was not possible to identify the exact etiology of the disease. Patients with chronic renal failure due to collagen or blood diseases, as well as those with heavy proteinuria have been excluded. No patient had undergone peritoneal dialysis or hemodialysis.

**Group II** 28 normal adults were used as controls. IgG, IgA and IgM were quantitated by a single radial immunodiffusion method [10], with the use of commercially available antibody-agar plates (Immuno-plates, Hyland Laboratories, Los Angeles, Calif.).

Blood urea was determined by the method of LAYNE *et al.* [9] and urine protein by the method of GROSSMAN [1].

### Results

The results are shown in table 1 and in figures 1-3.

### Discussion

SCHEFFER *et al.* [12] in a study of 45 patients with chronic renal failure, found that in the majority of cases the concentration of immunoglobulins was abnormal, i.e. there was a decrease of IgG in renal insufficiency of short duration and of IgM in chronic cases. LO GUZZO *et al.* [1] found the following quantitative differences of serum immunoglobulins in 25 cases: 6 patients had decreased IgG while 2 had an increase, 8 patients had increased IgA and 4 had decreased values. 6 patients had decreased IgM and 3 had an




Fig. 1. Relation of serum IgA to blood urea.  $r = -0.218$ ;  $p =$  not significant;  $n = 61$ .




Fig. 2. Relation of serum IgG to blood urea  $r = -0.419$ ,  $p =$  not significant,  $n = 61$




Fig. 1. Relation of serum IgM to blood urea  $r = -0.23$   $p =$  not significant,  $n = 61$

increase, 2 patients registered low levels of all three immunoglobulins, whereas 6 patients had normal levels of all three. According to Honns [5] the uremic environment of chronic renal failure is considered to effect a toxic inhibition of globulin synthesis affecting primary IgM, then IgA and finally IgG.

Our findings did not prove any statistically significant difference of immunoglobulins between uremic patients and normal controls. No correlation could be found between the levels of IgG, IgA, IgM and the severity of uremia, as judged by blood urea. In patients with chronic renal disease in a nephrotic stage there may be a significant urinary loss of IgG and to a lesser degree of IgM. Our study concerned with uremic patients without excessive urine protein loss (proteinuria up to 5.25 g/24 h), and it did not prove any correlation to the amount of serum immunoglobulins.

### References

- 1 ANDERSON, S. B. Metabolism of gamma globulin in secondary hypergammaglobulinemia. *Amer J Med* 35: 708 (1963).
- 2 DAWSON, G. J., COHEN, S. P., and MURPHY, J. E. Prolonged survival of dialyzed hemophiliacs in uremia, *papers Ann N.Y. Acad. Sci.* 64: 67 (1967).



- 3 GOODWIN J F An evaluation of technics for the separation and estimation of plasma fibrinogen *Clin Chem* 11 63 (1965)
- 4 GOWLAND, R and SMIDDY, F G The effect of acute experimental uremia on the immunological responses of the rabbit to bovine serum albumin *Br J Urol* 34 274 (1962)
- 5 HORRIS, J H Immune globulins in some diseases *Br J Hosp Med* 3 669 (1970)
- 6 HUMF, D M, MERRILL, J P, MILLER, B F, and THORN, G W Experiences with renal homotransplantation in the human report of nine cases *J clin Invest* 34 327 (1955)
- 7 KIRKPATRICK, C H, WILSON, W E C, and TALMACE, D W Immunologic studies in human organ transplantation I Observation and characterization of suppressed cutaneous reactivity in uraemia *J exp Med* 119 727 (1964)
- 8 LEVINE, J M, LEON, B, and STEIGMANN, F A rapid method for the determination of urea in blood and urine *Clin Chem* 7 488 (1961)
- 9 LO GRIPPO, G A, RUFF, C E, HAYASHI, J, and LESHER, D Immunologic status of uremic patients *Henry Ford Hosp med J* 19 83 (1970)
- 10 MANCINI, G, CARONARA, A O, and HERMANS, S F Immunochemical quantitation of antigens by single radial immunodiffusion *Immunochemistry* 2 235 (1965)
- 11 ROWLANDS, D T, WILSON, W E C, and KIRKPATRICK, C H Immunologic studies in human organ transplantation II The histology of passively transferred delayed hypersensitivity *J Allergy* 35 242 (1964)
- 12 SCHIEURLEN P G, BAAKE M, FREY, M, MOERS P und SICHERTH, G Über Immuninsuffizienz bei chronischen urämischen Nierenerkrankungen *Dt med Wschr* 1 17 (1969)
- 13 SMIDDY, F G, BURWELL, R G, and PARSONS, F M Influence of uraemia on the survival of skin homografts *Nature Lond* 190 732 (1961)
- 14 SOUHAMY B L Antibody production in uremic mice *Clin Sci* 40 11 (1971)

## Changes of Trace Minerals (Serum Iron, Zinc, Copper and Magnesium) in Thalassemia

AYHAN ARCAVOY and AYHAN O. CAVDAR

Hematology Division, Department of Pediatrics,  
Medical School of Ankara University, Ankara

**Key Words:** Thalassemia · Trace minerals · Zinc in serum

**Abstract** We have determined serum Zn, Fe, Cu and Mg in 42 patients aging from 3 months to 22 years with homozygous  $\beta$ -thalassemia and thalassemia intermedia and in 16 control subjects of the same ages. Serum zinc was significantly decreased. Serum copper and iron were increased, but magnesium was found to be at normal levels.

The thalassemia syndromes are characterized by an inherited defect in the synthesis of one or more of the peptide chains of hemoglobin [1]. Biochemical changes, especially of the essential trace minerals such as zinc, copper, and magnesium have not been fully investigated in homozygous thalassemia [1, 2]. Clinicians have noticed growth retardation in patients with homozygous thalassemia. Zinc is an essential element, and its deficiency retards growth and maturation in plants, animals and man. A hypogonadal type of dwarfism prevalent in Iran, Egypt and Turkey is found to be related to zinc [3-5]. Therefore, we wanted to study changes of the essential trace minerals zinc, copper, iron and magnesium in thalassemia.

### Materials and Methods

A total of 42 cases (19 with homozygous  $\beta$ -thalassemia and 3 with thalassemia intermedia) aged between 3 months and 22 years (17 girls and 25 boys) were studied. 16 subjects of the same ages were used as controls. All of the 42 patients were hospitalized and studied clinically, hematologically and genetically.

Routine hematologic tests were performed with standard methods. Furthermore, the following studies were carried out: hemoglobin A<sub>2</sub> was measured by starch block electrophoresis.

Table I Trace mineral concentrations in thalassemia (biochemical methods)

Minerals in serum	Thalassemia			Controls			p
	n	$\bar{x}$	$\pm s_x$	n	$\bar{x}$	$\pm s_x$	
Fe, $\mu\text{g}^{\circ}$	19	186.10	9.1	10	99.75	7.2	<0.05
Zn, $\mu\text{g}^{\circ}$	16	86.96	4.2	10	176.8	12.6	<0.05
Cu, $\mu\text{g}^{\circ}$	19	168.57	3.7	14	128.1	11.4	<0.05
Mg, $\text{mg}^{\circ}$	14	1.69	0.05	10	2.11	0.43	<0.05

Table II Trace mineral concentrations in thalassemia (atomic absorption spectrophotometry)

Minerals in serum	Thalassemia			Controls			p
	n	$\bar{x}$	$\pm s_x$	n	$\bar{x}$	$\pm s_x$	
Fe, $\mu\text{g}^{\circ}$	18	197.06	17.4	22	99.32	5.5	<0.01
Zn, $\mu\text{g}^{\circ}$	21	94.70	5.3	22	111.95	5.0	<0.05
Cu, $\mu\text{g}^{\circ}$	20	247.80	21.0	22	136.73	4.1	<0.01
Mg, $\text{mg}^{\circ}$	12	2.34	0.16	22	2.33	0.09	<0.05

phoresis [6] and fetal hemoglobin by alkali denaturation by the method of SINGER *et al.* [7]. In a first group of 20 patients, the levels of iron, zinc, copper and magnesium in serum, were determined according to previously described biochemical methods [5], in the other 22 patients by Perkin Elmer atomic absorption spectrophotometer Model 103 [8, 9].

### Results

Table I shows the results obtained in the first group. An increase in serum iron and copper was observed, but serum zinc showed a statistically significant ( $p < 0.05$ ) decrease as compared to the controls. Serum magnesium was found to be normal. Table II shows the results of these determinations in the second group. There were significant increases in serum iron and copper but a significant decrease in serum zinc as compared to the controls. Serum magnesium was again found to be normal.

### Discussion

As reported by many authors, serum iron is increased in thalassemia because of inability to use adequate quantities of iron in the production

of hemoglobin, frequent blood transfusions and increased intestinal absorption [1, 11, 12]. In our cases, serum iron was found high and the unsaturated iron binding capacity was decreased.

Zinc is considered to be an essential trace mineral for growth of plants, animals and man. This element has been observed to be an integral part of several metalloenzymes including carbonic anhydrase, alkaline phosphatase, pancreatic carboxypeptidase and lactic dehydrogenase. It is also required for synthesis of nucleic acids and protein metabolism [13-16].

Zinc deficiency was once thought impossible in man owing to the widespread presence of the element in food and water. This concept is now changed. Zinc deficiency has been found in malnourished populations as well as associated with various diseases. Human zinc deficiency associated with nutritional dwarfism has been reported for the first time in Iran and Egypt [3, 4].

The principal manifestations of zinc deficiency in man are growth retardation, hypogonadism, decrease in the production of endogenous ACTH, increase to insulin sensitivity disturbance in protein synthesis, and delay in healing of wounds, etc. [14]. It has been shown that these clinical manifestations improve after zinc treatment [17].

Several factors may be responsible for zinc deficiency in man, but we consider the following three to be the most important ones.

1. *Unavailability of zinc* Inability of the organism to use the zinc consumed by the diet. Phytates, found in large quantities in certain foods, namely cereals, bind zinc and form unabsorbable complexes. In addition, calcium, cadmium, phosphate, and chelating agents also affect the zinc availability [15, 17].

2. *Loss of zinc* The zinc concentration in red blood cells is approximately 12 times that found in plasma, and therefore chronic blood loss causes zinc deficiency. According to some reports, whitening and ankytosis are responsible for zinc deficiency in the Delta region in Egypt. The zinc content of sweat was found to be  $115 \mu\text{g} \pm 30\%$ . Thus, hot climate may cause a loss of zinc up to 2-3 mg/day. Consequently, loss of zinc with sweat may be another important factor [17].

3. *Malnutrition factors* There have been sporadic reports of low circulating zinc levels in clinical disorders such as liver disease, pernicious anemia, thalassemia, malignant diseases, acute and chronic infections, and myocardial infarction [17].

In the light of these informations, the question arises why the plasma zinc level decreases in thalassemia. In the  $\beta\beta$  thalassemia patients from Iran investigated by PRASAD *et al* [18], a decrease in plasma zinc levels in ad-

dition to growth retardation was found. The results in our patients are similar. With one exception, the patients showed growth retardation as well.

As we mentioned above, nutritional factors may be responsible for zinc deficiency in man. Most of our cases were from good socioeconomic level and their diets contained adequate amounts of animal proteins. None had schistosomiasis and hookworm infections which may cause blood loss. Therefore, zinc deficiency in our cases cannot be explained on the basis of blood loss and malnutrition.

VALLEL *et al* [19] investigated zinc metabolism in liver dysfunctions and reported zinc deficiency in liver cirrhosis. There was no clinical and laboratory evidence of cirrhosis in our patients.

Although the explanation of zinc deficiency in thalassemia cannot definitely be made, the symptoms of the deficiency, such as severe growth retardation, bone changes, and retardation in sexual maturation were obvious in our cases. Growth retardation was present in all but one. Hypogonadism and sexual retardation were very prominent, especially in two cases of the first group where the serum zinc level was also very low.

Our study has demonstrated increased iron and copper levels in the patient's serum. ERLANDSON *et al* [20, 21] also found increased serum iron and copper and decreased serum magnesium in thalassemia patients. Iron absorption needs copper containing enzymes and cofactors. In addition, copper affects release of iron from body stores and utilization of iron in hemoglobin synthesis. In the study of PRASAD *et al* [18] serum copper levels were increased in thalassemia. Hypercupremia occurs in pregnancy, prematurity, acute and chronic infections, iron deficiency anemia, hyperthyroidism and hemochromatosis [22]. Hemochromatosis is a principal complication of thalassemia. Frequent blood transfusions, increased iron absorption and hemolysis facilitate marked accumulation and excess deposition of iron in tissues causing visceral hemochromatosis.

Serum magnesium levels were normal in our patients. According to some investigators, serum magnesium is normal [18] but other studies showed abnormally low concentrations in the majority of thalassemia patients older than 15 years [20, 21].

### References

1. WEATHERALL, D. J. and CLEGG, J. B. The thalassemia syndromes. 2nd ed., p. 43 (Blackwell, London 1972).
2. INGRAM, V. M. The hemoglobins in genetic and evolution (Columbia University Press, New York 1973).

- 3 PRASAD, A. S., HALESTAD, J. A., and NADIM, N. Syndrome of iron deficiency anemia, hepatosplenomegaly, hypogonadism, dwarfism and geophagia. *Am J Med Sci* 432 (1971).
- 4 PRASAD, A. S., SCHLEED, A. R., MILES, A., Jr., FARID, Z., and SANDSTAD, H. H. Zinc and iron deficiency in male subjects with dwarfism and hypogonadism but without ankylostomiasis, schistosomiasis or severe anemia. *Am J Clin Nutr* 12 437 (1971).
- 5 CAYDAR, A. O. and ARCAKCI, A. Hematologic and biochemical studies of Turkish children with pica: A presumptive explanation for the syndrome of geophagia, iron deficiency anemia, hepatosplenomegaly and hypogonadism. *Clin Pediat* 11 215 (1972).
- 6 KENNEL, H. G. and VALENCY, G. New hemoglobin in normal adult's blood. *Science*, N.Y. 1935 249.
- 7 SINGER, K., CHURCH, A. I., and SWEET, J. Studies on abnormal hemoglobin. I. Alkali denaturation. *Blood* 6 913 (1951).
- 8 PERKIN ELMER. Clinical methods for atomic absorption spectroscopy, determination of copper in serum, determination of zinc in serum (Perkin Elmer, Norwalk 1971).
- 9 SPRUELL, S. and STANN, V. Determination of iron, copper and zinc in blood serum by an atomic absorption method requiring only dilution. *Atom Absorp Newsl* 4 228 (1974).
- 10 HANSEN, J. L. and EHRH, F. F. The measurement of serum magnesium by atomic absorption spectrophotometry. *Am J med Technol* 33 198 (1977).
- 11 LEHMANN, H. and HUNSMAN, R. G. Man's hemoglobin (North-Holland, Amsterdam 1967).
- 12 ARCAKCI, A. ve CAYDAR, A. O. Thalassemia sendromları hemozigot beta thalassemida klinik, hematolojik ve genetik tetkikler. *Ankara Univ Tıp Fak Mec* 23 suppl 35 (1970).
- 13 CHICK, D. B. and GRAYSTONE, J. I. Changes in enzymes and metals (Zn, Mn and Mg) in liver rats during endocrine imbalance and caloric restriction. *Pediat Res J* 433 (1977).
- 14 HOLT, A. B., MILLER, I. D., and CHICK, D. B. Comparisons between calcium, protein, zinc and manganese in rat liver: a relation between zinc and calcium. *Pediat Res J* 4 197 (1970).
- 15 PRASAD, A. S. Zinc metabolism (Thomas, Springfield 1967).
- 16 BERLBERG, D. and BERLAND, W. L. Mineral metabolism in pediatrics, p. 85 (Blackwell Oxford 1969).
- 17 HALESTAD, J. et al. Zinc deficiency in man: The Shorr experiment. *Am J Med Sci* 277 (1972).
- 18 PRASAD, A. S. et al. Biochemical studies in thalassemia. *Ann intern Med* 62 87 (1964).
- 19 VALLI, B. E. et al. Zinc metabolism in hepatic dysfunction. I. Serum zinc concentrations in *Lathyrus cirrhosis* and their validation by sequential analysis. *New Engl J Med* 281 673 (1969).
- 20 BRANSON, M. E., GORDON, J., and SMITH, C. H. Ill effects caused in homozygous thalassemia. *J Pediat Med* 637 (1969).

therefore be established conclusively but the overall ratio of  $\epsilon_1$  to  $\lambda_1$  chains was determined by analysing the CB-3 peptide [13] and was found to be 2.1:1 for position 136. As the  $\lambda_1$ -chains amounted therefore to 29% of all the  $\epsilon_1$ -chains and the mutant  $\gamma$ -chain (see above) to 25% it is most unlikely that the latter would be an  $\lambda_1$ -chain leaving only 4% for the normal  $\lambda_1$ -chain. It is much more likely that the mutant amounts to 36% of the  $\epsilon_1$ -chain. The distribution would then be 71%  $\epsilon_1\gamma$  of which about one-third would be the mutant  $\epsilon_1\gamma_1$ , and 29%  $\lambda_1$ .

### References

- 1 LEHMANN H and HUNTSMAN H G. *Mutant haemoglobins. Including the haemoglobinopathies and their investigation*. 2nd ed. (North Holland, Amsterdam, 1974).
- 2 ROSSI FANELLI A R, ANTONINI E and CAPUTO A. Studies on the structure of haemoglobin I. Physicochemical properties of human globin. *Biochim biophys. Acta* 30: 608-615 (1959).
- 3 HUISMAN T H J and DOZY A M. Studies on the heterogeneity of haemoglobin IX. The use of Tris (hydroxymethyl) amino methane HCl buffer in the anion exchange chromatography of haemoglobins. *J Chromat* 19: 160-169 (1965).
- 4 SICK K, BEALE D, IRVINE D, LEHMANN H, GOODALL P T and MACDOUGALL S. Haemoglobin G Copenhagen and haemoglobin J Cambridge. Two new  $\beta$ -chain variants of haemoglobin A. *Biochim biophys. Acta* 140: 231-242 (1967).
- 5 LIE INJO I, UAN ENG KAMUZORA H and LEHMANN H. Haemoglobin J Malay.  $\alpha_1\beta_1$  1 (NA1) glycine-cysteine 136 glycine. *J med Genet* 11: 25-30 (1974).
- 6 BACCIONI C and INGRAM V T. Abnormal human haemoglobins V. Chemical investigation of haemoglobins A G C X from one individual. *Biochim biophys. Acta* 47: 409-421 (1960).
- 7 FRENCH E A and LEHMANN H. Is haemoglobin Q Philadelphia linked to  $\beta$  thalassaemia? *Acta haemat* 46: 149-156 (1971).
- 8 MCCURDY P, KAMUZORA H, and LEHMANN H. Globin synthesis in patients doubly heterozygous for haemoglobin S or C and haemoglobin Q Philadelphia. (in press 1975).
- 9 WEATHERALL D J and CLEGG J B. *The thalassaemia syndromes*. 2nd ed. p. 260 (Blackwell, Oxford 1972).
- 10 SCHROEDER W A, HUSMAN T H J, HYMAN C, SHELTON J R and APPELL G. An individual with Miyada like haemoglobin indistinguishable from haemoglobin A<sub>2</sub>. *Biochem Genet* 10: 135-142 (1973).
- 11 DUMA H, FIREMOV G, SADIKARIO A, TROPOUSOVA B, MLADENOVSKI B, VLASKI M and ANDRIEVA M. Study of nine families with haemoglobin Lepore. *Br J Haemat* 15: 161-172 (1968).

- 12 SCHROEDER, W. A., HUISMAN, T. H. J., SHELTON, J. R., SHELTON, J. B., KLEIHAUER, I. I., DORY, A. M., and ROBERSON, B. Evidence for multiple structural genes for the  $\gamma$ -chain of human foetal haemoglobin. *Proc. natn Acad. Sci. USA* 60: 537-544 (1968).
- 13 KAMUYAMA, H., RINGELHANN, B., KINOTTE-ARTEL, I. I. D., LEHMANN, H., and LORRIN, P. A. Further investigations of the  $\gamma$ -chain in a Ghanaian adult homozygous for hereditary persistence of foetal haemoglobin. *Acta haemat.* (in press 1975).



## Chronic Eosinophilic Leukemia Complicated by Epidural Myeloblastoma

ALEXANDER DVLANSKY, MICHAEL L. ALMAN, WINSTON HO,  
HELENA KAPLAN, PASKAL TIBERIN and BRACHIA RACHMILEWITZ

Departments of Medicine B Neurosurgery and Hematology, The Soroka Medical Center, University Center for Health Sciences, The Ben Gurion University of the Negev, Beer Sheva and the Department of Experimental Medicine and Cancer Research, Hebrew University, Hadassah Medical School Jerusalem

**Key Words** Eosinophilic leukemia Myeloblastoma Transcobalamins Vitamin B<sub>12</sub>

**Abstract** Epidural myeloblastoma which compressed the spinal cord was the first evidence for chronic granulocytic leukemia, eosinophilic type, Ph chromosome negative. This manifestation was preceded by 3 years follow up of a patient with persistent eosinophilia of 60% mature eosinophils. The only clues for the diagnosis of leukemia were splenomegaly and high serum vitamin B<sub>12</sub>, most of which was bound to transcobalamin I. The latter finding presents a useful diagnostic criterium in myeloproliferative disorders.

Eosinophilic leukemia [1] is a variant of chronic granulocytic leukemia, Philadelphia (Ph) chromosome positive [2-4], or negative [5-7]. Mature cell eosinophilic leukemia with an acute or chronic course and leukemia beginning with increased blast cells in the peripheral blood and/or bone marrow were described [8, 9]. Eosinophilic granulocytes can form green tumors (chloroma) and non-green tumors (myeloblastoma) [10, 11].

In the case to be described the diagnosis of chronic eosinophilic leukemia was made on the basis of the highly increased serum vitamin B<sub>12</sub> concentration and the corresponding elevation of transcobalamin (TC) I, findings similar to those present in chronic myeloid leukemia [12]. The development of myeloblastoma and subsequently acute granulocytic leukemia confirmed this diagnosis.

Table I

Date	Serum B <sub>12</sub> pg/ml		UBHC	TC I	TC II	TBC TC I	TBC TC II	WBC $\mu$ l
	total	bound	pg/ml	%	%	pg/ml	pg/ml	
27.7.73	8,000	8,000	4,000	99	1	7,200	800	11,000
4.2.74	6,800	6,800	3,500	91	9	6,120	680	7,000
16.6.74	4,000	4,000	2,400	80	20	3,200	800	12,900
22.7.74	1,000	3,200	845	73	27	1,500	1,400	4,900
21.8.74	3,200	875	1,000	56	44	912	1,023	2,000
Normal values	400-800	450-750	800-1,100	16-28	70-80	200-300	400-700	4,000-10,000

UBHC = Unsaturated B<sub>12</sub> binding capacity, TC I = transcobalamin I, TC II = transcobalamin II, TBC = total binding capacity, WBC = white blood cells

### Case Report

II A, a 42-year-old male was first hospitalized in July, 1973. Two years previously he underwent thoracotomy because of a pleural effusion with empyema. Eosinophilia and splenomegaly were noticed. On admission there was no history of fever, night sweats or pruritus. Physical examination revealed good nutritional state. The blood pressure was 130/80 mm, regular pulse 80/min. No lymph nodes were palpable. The abdomen was soft and the liver not palpable. A firm spleen was palpable 3 cm below the left costal margin. No abnormal neurological findings. Sedimentation rate (Westergren) 5-15 mm. Hemoglobin 14.1 g%. White cell count 14,000/ $\mu$ l with 87% of mature eosinophils, 14% neutrophils, 2% band forms, 1% basophils, 14% lymphocytes, 2% monocytes, 1% myelocytes. Total eosinophil count 7,400/ $\mu$ l. Platelets 110,000/ $\mu$ l (113). Blood glucose, urea, electrolytes and liver function tests within normal limits. Repeated stool examinations for parasites negative.

The chest X-ray did not reveal any masses in the lungs or mediastinum. A liver scan showed a normal liver without filling defects and an enlarged spleen. A liver biopsy at this stage revealed normal liver tissue. Stereotaxic aspiration revealed cellular marrow with myeloid-erythroid ratio 4:1. The granulocyte series included 87% eosinophils in different stages of maturation (promyelocytes, myelocytes, metamyelocytes, band forms and mature polymorphonuclears). No other abnormalities were found. Leukocyte alkaline phosphatase 184 (normal 15-30). Ph chromosomes were negative (14). Excessively high levels of serum vitamin B<sub>12</sub> were found (16). Vitamin B<sub>12</sub> binding capacity was very high and most of the vitamin was bound to TC I (table I). The patient was observed for a period of 1 year during which time his general condition was unchanged.

He was hospitalized again 1 year later in June 1974 with redular pain and hyperreflexia along the intercostal nerves #17. A rapid progression of the neuro-



The epider-  
mology

b



Fig 3. Imprint of the tumor showing 3 blasts. May-Grunwald-Giemsa  $\times 1,000$ .

logical signs occurred with the development of spinal paraparesis and urinary incontinence. On myelography complete obstruction was found at the level of L7. Laminectomy was performed and an epidural vascular, greyish yellow tumor was removed. Sections and imprints revealed a tumor consisting of mature eosinophils, eosinophils, myelocytes and blast cells, a picture compatible with myeloblastoma (Fig 3). No neurological improvement was obtained after removal of the tumor and the spinal column was irradiated with a total dose of 2,400 rad. This therapy did not improve the neurological signs. Pancytopenia was found subsequently. Bone marrow aspiration at this stage showed hypercellular marrow with myeloid erythroid ratio of 20:1 due to granulocyte hyperplasia. Almost all the cells were blasts and promyelocytes. No sideroblasts were found.

The general condition of the patient deteriorated rapidly with clinical signs of leukemia with blood counts suggestive of  $L_2$  crisis. The peripheral blood count at this time showed pancytopenia with myeloblasts. The last phase of the disease characterized by myeloblast crisis and septicemia was reflected in the changes observed in the serum  $B_{12}$  levels and the  $B_{12}$  binding proteins. The most important change was the decrease in the TCB and increase in the TCB associated with reduction in the bound serum  $B_{12}$ . The latter findings were observed in hepaticular damage [16].

#### DISCUSSION

The observations made in this case of the serum  $B_{12}$  concentration and TCB are similar to those in the absence of any other clinical




Fig. 1 The epidural tumor macroscopically

Fig. 2 Histology of the tumor H&E 400



Fig 3. Imprint of the tumor showing 3 blasts. May-Grunwald Giemsa  $\times 1000$ .

Actual signs occurred with the development of spastic paraparesis and urinary incontinence. On myelography complete obstruction was found at the level of D9. Laminectomy was performed and an epidural vascular greyish yellow tumor was removed. Sections and imprints revealed a tumor consisting of mature eosinophils, eosinophilic myelocytes and blast cells, a picture compatible with myeloblasticosis (Fig 3). No neurological improvement was obtained after removal of the tumor and the spinal column was irradiated with a total dose of 2400 rad. This therapy did not improve the neurological signs. Pancytopenia was found subsequently. Bone marrow aspiration at this stage showed hypercellular marrow with myeloid myeloid ratio of 20:1 due to granulocytic hyperplasia. Almost all the cells were blasts and promyelocytes. No Auer bodies were found.

The general condition of the patient deteriorated rapidly with clinical signs of septicemia with blood cultures positive for *E. coli*. The peripheral blood count at this time showed pancytopenia with myeloblasts. The last phase of the disease characterized by myeloblastic crisis and septicemia was reflected in the changes observed in the serum  $B_{12}$  levels and the  $B_{12}$  binding proteins. The most important change was the decrease in the TC I and increase in the TC II associated with reduction in the bound serum  $B_{12}$ . The latter findings were observed in hepatocellular carcinoma [16].

#### Comments

The observations demonstrate the significance of the serum  $B_{12}$  concentration and TC I determination in the absence of any other diagnos-

tic criteria of myeloid leukemia. The possibility that marked eosinophilia associated with different conditions other than leukemia was excluded when sera of patients with eosinophilia of different causes (parasites, allergy, etc.) were found to have no abnormal vitamin B<sub>12</sub> parameters. The latter findings were corroborated also in reported cases of marked eosinophilia associated with tumor [17]. Leukemic eosinophilia with high serum B<sub>12</sub> values were reported in a few cases [6].

Our findings clearly demonstrate that the eosinophilic granulocytes have the capacity to produce excessive amounts of TCI, similar to neutrophilic granulocytes [12]. The lack of parallelism between the peripheral white cell count and the levels of TCI and B<sub>12</sub>, as observed in other cases of CMIL is demonstrated in this case as well. It is therefore apparent that the TCI producing cells are present in the organs where the myeloid cells proliferate, namely the bone marrow and the spleen. The determination of serum B<sub>12</sub> binders is important in the differentiation between high serum B<sub>12</sub> due to hepatic injury and to myeloid proliferation.

Myeloblastoma [18] as a complication of eosinophilic leukemia was described and 6 cases of myeloblastoma occurred in a series of 65 cases of eosinophilic leukemia [10]. In some of these cases the diagnosis of leukemia was made only on the basis of the complication of myeloblastoma. Some of these cases are reported as chronic eosinophilia preceding myeloblastoma [11].

### References

- 1 ACKERMAN A. Eosinophilic leukemia. A morphologic and histochemical study. *Blood* 24: 372-398 (1964).
- 2 GRUNWALD H, KLOSSOGLOU K, A MITUS W J and DAMENHEK W. Philadelphia chromosome in eosinophilic leukemia. *Am J Med* 39: 1003-1010 (1965).
- 3 KAUFER G L and ENGLE R L. Eosinophilic leukemia with Ph positive cells. *Lancet* ii: 1340 (1964).
- 4 ELVES U W and ISRAELIS M C G. Cytogenetic studies in the unusual forms of chronic myeloid leukemia. *Acta haemat* 39: 129-141 (1967).
- 5 HOSSEFIELD D K and SANDBERG A A. The Philadelphia Chromosome. *Klin Wschr* 48: 1431-1441 (1970).
- 6 FLEDELIS, H. Extreme persistent eosinophilia with high serum B<sub>12</sub> values. *Acta med scand* 187: 235-240 (1970).
- 7 GOTT K, SWISHER E N and ROSENBERG C A. Cytogenetic studies in eosinophilic leukemia. *Ann intern Med* 62: 80-86 (1965).





S SUMIDA *Transfusion of Blood Preserved by Freezing* Thieme Stuttgart 1974  
92 pp., 117 fig. 15 cpl. 11 tab. DM 59.-

Der mit vielen zum Teil farbigen Fotografien und Zeichnungen versehene Band gibt eine gute Übersicht über den heutigen Stand der Kenntnisse über die Herstellung Lagerung und Transfusion von gefrorenen Erythrozyten und Thrombozyten. Ein länger Abschnitt ist dem eigentlichen Gefrier- und Auftauvorgang von Erythrozytensuspensionen in physiologischer Kochsalzlosung und in Glycerin gewidmet. Die Technik der Blutkonservierung ist sehr ausführlich mit detaillierten Vorschriften behandelt und mit vielen zum Teil allerdings wenig instruktiven und unnötigen Bildern erläutert. Die Aufzählung und Beschreibung der nötigen Analysen der Blutkonserven insbesondere der Transfusionsfähigkeit der Erythrozyten nach der Auftauung sowie der prätransfusionellen Serologie zeigt, dass hier ein wesentlich grosserer Aufwand getrieben werden muss als bei den nach herkömmlicher Art gelagerten Transfusionseinheiten. Ein Kapitel enthält die Erörterung der Vorteile bei Verwendung von gefrorenem Blut gegenüber der Verwendung von konventionell gelagertem Blut. Der grösste Teil dieser Vorteile lässt sich allerdings in einem gut organisierten Spendezentrum auch ohne die sehr teure Zellgefrierung erreichen. Es ist deshalb wohl etwas übertrieben, wenn auf dem Klappentext des Buches vermerkt wird: « It is therefore only a matter of time before frozen blood will become an integral part of every bloodbank ». Das Schlusskapitel befasst sich mit dem Gefrieren von Blutplättchen insbesondere auch mit Funktionsprüfungen eingefrorener und wieder aufgetauter Thrombozyten einschliesslich der klinischen Wirksamkeit solcher Präparate. Der Band kann allen empfohlen werden, die sich mit der Kriobiologie der Blutzellen befassen, speziell Medizinern und Biochemikern, die sich in Blutspendezentren mit Problemen der Herstellung Lagerung und Administration von gefrorenen Zellen konfrontiert sehen.

R. FREUCHAULT Bern

S. SHERRY and A. SCRIBNER (eds.) *Platelets and Thrombosis* Urban & Schwarzenberg München 1974. 332 pp. 120 fig.

This book represents the printed version of a symposium held in Philadelphia. The problem of thrombosis and the role of platelets are becoming more and more important. Many of the twenty articles are completed by an abundant list of references. In this field investigations are progressing rapidly and the various aspects have been taken into consideration.

An interesting attempt has been made by P. N. WALSH to integrate the blood coagulation and haemostatic processes. In special contributions the storage in platelets and the release reactions have been carefully reviewed. The inhibition of platelet function, particularly of their aggregation, has been examined and the role of the cyclic AMP and prostaglandins is discussed. It still remains to be established if the experimental data are relevant as regards the *in vivo* role of platelets. Anyhow, the accumulated data will greatly influence the future progress of our knowledge concerning the platelet physiology. Other chapters are more directly

concerned with practical problems such as inhibition of platelet aggregation after renal transplantation or with subjects not primarily related to platelets such as defibrination with Arvin.

Platelets and thrombosis, edited by S. SIEBRY and A. SCHIAPPEL, presents an up-to-date view of the recent development in this field and a very valuable source of information. J. DICKERT, Basel.

LEWIS B. (Ed.) (ed.) Progress in Hematology, vol. VIII Grune & Stratton, New York 1973 322 pp. U.S.\$ 22.50.

This volume of the series contains chapters on ion and water movements in red blood cells (F. P. OGBURN and J. C. PARKER), clinical usefulness of specific anti globulin reagents in autoimmune hemolytic anemia (H. CHAPMAN), acquired disorders of hemoglobin (T. B. BARNES and H. M. RANNEY), dyserythropoiesis and dyserythropoietic anemias (S. M. LEWIS and R. L. VERMILION), hereditary disorders of the red cell in animals (S. M. HANSMAN, A. EDWARDS, P. H. PRITCHARD), immunologic properties on anti hemophilic factor (L. W. HOSICK), regulation of myelopoiesis as approached within *in vivo* and *in vitro* techniques (F. STEINLEMAN, Jr., B. J. QUANSTRUP, W. A. TILLEY) and human marrow transplantation, current status (C. D. PIERCE, R. A. CHITT, F. D. TIMMEL, *et al.*) correlations of *in vivo* and *in vitro* measurements of hemolysis in hemolytic anemia due to immune reactions (W. J. ROSS). G. ROUSSEAU, New York, N. Y.

## Competition

The *Dr. Heinrich Karger Memorial Foundation* invites the submission of original research papers to compete for the 1976 and 1977 award on the following subjects:

1976 *Methods for the Early Diagnosis of Genetic Disorders*

1977 *Molecular Biology of Metabolic Diseases*

Submission date: Manuscripts marked "Competition" must reach the publishers S. Karger AG, Arnold Bocklin Strasse 25, CH-4011 Basel (Switzerland) not later than February 28 of either year.

The manuscripts shall not exceed 20 typewritten pages, including illustrations, tables and bibliography. They must be typewritten on one side only, double spaced, and are to be submitted in quadruplicate and in accordance with the instructions contained in "Rules for the Preparation of Manuscripts". This leaflet can be obtained free of charge from the publishers if the request is marked "Competition".

Language: English, German or French.

Publication: The winning papers will be published in English in one of the Karger journals.

The award for the prize will be Sfr. 7000.- The Council of the Foundation will judge the papers and confer the prize.

## Index rerum ad Vol. 53

Bearbeitet von G. BREHM, Basel

(B) = Book Reviews - Buchbesprechungen    **LISTS NEWCASTLE**

- Acetylcholine acetylcholinesterase  
 Acid malate deficiency: new kind of  
 cytoplasmic inclusions of plasma cells  
 in acid malate deficiency 109  
 Acute leukaemia: phagocytosis activity in  
 cells of leukaemia blasts 17  
 Acute leukaemias: cytochemical  $\beta$ -glucuron-  
 idase reaction in the differential diagnosis  
 of acute leukaemias 277  
 Acromioclavicular: methodology and re-  
 sults of clinical trials in acute leuka-  
 emias (Recent results in cancer research  
 Vol. 41), 246 (B)  
 Adenocarcinoma of the breast: anti-  
 heparin activity of a macrophage from a  
 patient with breast adenocarcinoma 243  
 Aggregation of erythrocytes: disaggrega-  
 tion of human red blood cells by various  
 surface active agents as related to  
 changes of cell shape and haemolysis 8  
 Aggregation of platelets: *in vitro* and *in vivo*  
 influence of penicillin G on platelet  
 aggregation 300  
 AIIIG A vs Factor VIII  
 Albumin (1) albumin, vs. Home  
 Atrial natriuretic factor: isolation of leu-  
 kocyte atrial natriuretic phosphatase in human  
 neutrophils 149  
 Anaemia: a trial of apheresis to a weed  
 killer: 2-methyl-2-butanethiolacetate  
 acid 105  
 Anaemia, haemolytic, autoimmune: an *in*  
 vitro method to study the participation  
 of various components in autoimmune  
 haemolytic anaemia 302  
 Anaemia, haemolytic: passive hemagglu-  
 tination and passive hemolysis 280  
 Anaemia, haemolytic: anaemia, vs. Iron  
 deficiency  
 Anaemia, sickle cell: anaemia: extract of  
*Escherichia coli* exerts effect on sickle cell  
 anaemia (Toxicology and preliminary  
 clinical trials), 144  
 Analgesics: *in vitro* effect on the electro-  
 phoretic pattern of the red cell mem-  
 brane proteins 164  
 Anemia, hemolytic, autoimmune: an *in*  
 vitro method to study the participation  
 of various components in autoimmune  
 hemolytic anemia 300  
 Anticancer: vs. Penicillin G: Rn acetin  
 Anticancer: an erythrocyte antibody, vs.  
 Reticulo-endothelial cells  
 Antigen of factor VIII vs. Factor VIII  
 Antithrombin: high titer A vs. Factor VIII  
 Anti-heparin activity of a macrophage from  
 a patient with breast adenocarcinoma  
 243  
 Aplan: a anaemia after exposure to a weed  
 killer: 2-methyl-2-butanethiolacetate  
 acid 105  
 ARN leucemia vs. Methylene blue  
 Autoimmune haemolytic anaemia: an *in*  
 vitro method to study the participation  
 of various components in autoimmune  
 haemolytic anaemia 302  
 Autoradiography: vs. Erythrocyte haemolysis  
 Home Hemolytic disease: neonatal  
 leukocytes  
 Auto-adsorption of HLA distributed  
 blood hemocytes in patients with  
 Hemolytic disease and neonatal  
 polycythemia: Let's review the methods  
 183  
 (II) Exchangeable hemolytic  
 protein 306  
 Bessie vs. Bessie

- Beta glucuronidase, cytochemical  $\beta$ -glucuronidase reaction in the differential diagnosis of acute leukaemias, 277
- Beta thalassaemia trait and GILBERT's syndrome in three families, coexistence, 175
- , v Haemoglobin I Sardinia
- Bilirubin, v Hyperbilirubinaemia
- Blast transformation of lymphocytes, v Macrophages PHA, insoluble
- Blasts, leukaemic, phagocytic activity *in vitro*, 17
- Blood coagulation, v Factor VIII, Factor X deficiency, Macroglobulin
- Blood cultures, v HOROKIN'S disease, Neonatal leukocytes
- Blood transfusion, v Transfusion (B)
- Blood urea, v Immunoglobulins
- Blutplättchen, v Platelet aggregation
- B-lymphocytes, insoluble PHA - v B-cell mitogen in man? 30
- B lymphocytes, markers, lymphocytes devoid of T and B cell markers in chronic lymphatic leukaemia, 37
- BORCK-BRESSNER-SCHALMANN'S disease, v Sarcoidosis
- Bone marrow, v B lymphocytes
- Book reviews, 191 (B) 256 (B) 362 (B)
- Bromsulphophtalein (=BSP) kinetics v Beta thalassaemia
- BSP, v Bromsulphophtalein kinetics
- Buchbesprechungen, 191 (B) 256 (B) 362 (B)
- Bursa FABBICCI, v B lymphocytes
- Carcinoma, v Adenocarcinoma
- Cell cultures v HOROKIN'S disease, Neonatal leukocytes
- Cell membrane receptors, v Miles International Symposium
- Cellular inclusions (leukaemic cells), v Myelose aiguë
- CFU, v Haematopoietic stem cells
- Chain in a *Ghanaian* adult homozygous for hereditary persistence of fetal haemoglobin further investigations (Isolation of CB3 peptides and  $\epsilon/\alpha$  ratio determination in human Hb F) 315
- Chlorophenoxyacetic acid, v MCPA
- Chromatography, gel chromatography (Sephadex<sup>®</sup>), v Folic acid
- Clinical factor X deficiency (Report of a further case), 118
- Clinical trials (leukaemic) results, v Acute leukaemias (B)
- Coagulation of blood, v Factor VIII, Factor X deficiency, Macroglobulin
- Competition, DR HEINZ KARCER Memorial Foundation, prizes 1976 and 1977, 364
- Copper, v Thalassaemia
- Cord blood, proliferation of blood leukocytes in the neonatal period, 129
- Corda umbilicalis v Cord blood
- <sup>51</sup>Cr erythrocyte survival, v Beta thalassaemia
- Cross-over electrophoresis (=electrosyneresis) v Factor X deficiency
- Culture des cellules, v HOROKIN'S disease, Neonatal leukocytes
- Cu, v Thalassaemia
- CuSO<sub>4</sub>, v Reticulo-endothelial cells
- Cyanocobalamin, v Eosinophilic leukaemia, Vitamin B<sub>12</sub>
- Cytidine(<sup>3</sup>H-cytidine) v HOROKIN'S disease
- Cytochemistry, v Alkaline phosphatase  $\beta$  Glucuronidase, Hairy cell leukaemia Hairy cell leukaemia, Mikrokaryoblastenschub Myelose aiguë, Plasma cells
- Cytophotometry, v Erythroleukaemia
- Cytoplasmic inclusions of plasma cells, new kind, in acid maltase deficiency 109
- DANIEL EDMAN technique, v  $\gamma$ -Chain
- Desaggregation of human red blood cells by various surface active agents as related to changes of cell shape and haemolysis, 82
- Desoxyribonucleic acid, v DNA
- Dextran induced red cell aggregation, v Desaggregation of human red blood cells
- Diagnosis (differential diagnosis of acute leukaemias) v  $\beta$ -Glucuronidase
- Differential diagnosis (acute leukaemias), v  $\beta$ -Glucuronidase



- Beta glucuronidase, cytochemical  $\beta$ -glucuronidase reaction in the differential diagnosis of acute leukaemias, 277
- Beta thalassaemia trait and GILBERT's syndrome in three families, coexistence, 175
- , v. Haemoglobin F Sardinia
- Bilirubin, v. Hyperbilirubinaemia
- Blast transformation of lymphocytes, v. Macrophages, PHA, insoluble
- Blasts, leukaemic, phagocytic activity *in vitro*, 17
- Blood coagulation, v. Factor VIII, Factor X deficiency, Macroglobulin
- Blood cultures, v. HOPKIN'S disease, Neonatal leukocytes
- Blood transfusion, v. Transfusion (B)
- Blood urea, v. Immunoglobulins
- Blutplättchen, v. Platelet aggregation
- B lymphocytes, insoluble PHA - a B-cell mitogen in man? 30
- B lymphocytes, markers, lymphocytes devoid of T and B cell markers in chronic lymphatic leukaemia, 37
- BOECK-JANSSEN-SCHAUMANN disease, v. Sarcoidosis
- Bone marrow, v. B lymphocytes
- Book reviews 191 (B), 236 (B), 362 (B)
- Bromsulphophthalein (=BSP) kinetics, v. Beta thalassaemia
- BSP, v. Bromsulphophthalein kinetics
- Buchbesprechungen, 191 (B) 246 (B), 362 (B)
- Bursa FABRICII, v. B-lymphocytes
- Carcinoma, v. Adenocarcinoma
- Cell cultures v. HOPKIN'S disease, Neonatal leukocytes
- Cell membrane receptors v. Miles International Symposium
- Cellular inclusions (leukaemic cells) v. Myelose aiguë
- CFU, v. Haematopoietic stem cells
- $\gamma$  Chain in a Ghanaian adult homozygous for hereditary persistence of fetal haemoglobin: further investigations (Isolation of  $\gamma$ CB3 peptides and  $\delta/\alpha$  ratio determination in human Hb F), 315
- Chlorophenoxyacetic acid, v. MCPA
- Chromatography, gel chromatography (Sephadex<sup>®</sup>), v. Folic acid
- Classical factor X deficiency (Report of a further case), 118
- Clinical trials (leukaemia) results, v. Acute leukaemias (B)
- Coagulation of blood, v. Factor VIII, Factor X deficiency, Macroglobulin
- Competition, Dr. HEINZ KARGER Memorial Foundation prizes 1976 and 1977, 364
- Copper, v. Thalassaemia
- Cord blood, proliferation of blood leukocytes in the neonatal period, 129
- Corda umbilicilis v. Cord blood
- <sup>51</sup>Cr erythrocyte survival, v. Beta thalassaemia
- Cross over electrophoresis (=electrosynthesis), v. Factor X deficiency
- Culture des cellules, v. HOPKIN'S disease, Neonatal leukocytes
- Cu, v. Thalassaemia
- CuSO<sub>4</sub>, v. Reticulo-endothelial cells
- Cyanocobalamin, v. Leuconophilic leukaemia, Vitamin B<sub>12</sub>
- Cytidine(2H-cytidine), v. HOPKIN'S disease
- Cytochemistry, v. Alkaline phosphatase  $\beta$  Glucuronidase, Haarzell Leukämie, Hairy cell leukaemia, Mikrokaryoblastenschub, Myelose aiguë, Plasma cells
- Cytrophotometry, v. Erythroleukaemia
- Cytoplasmic inclusions of plasma cells: new kind in acid maltase deficiency, 109
- DANIEL-EDMAN technique, v.  $\gamma$ -Chain
- Desaggregation of human red blood cells by various surface active agents as related to changes of cell shape and haemolysis, 82
- Desoxyribonucleic acid, v. DNA
- Dextran induced red cell aggregation, v. Desaggregation of human red blood cells
- Diagnosis (differential diagnosis of acute leukaemias) v.  $\beta$ -Glucuronidase
- Differential diagnosis (acute leukaemias) v.  $\beta$ -Glucuronidase

- Dicentric chromosome v Erythrocytæmia
- DNA (= Deoxyribonucleic acid) synthesis v Erythrocytæmia Neonatal leukocytes
- Iron v Iron
- Electrophysiological determinations, v Intracellular potential (lymphocytes)
- Electromyography v Factor X deficiency
- Electron microscope v Alkaline phosphatase Hairy cell leukaemia Heme Iron-dextran Microkaryoplastenchub, Myeloneuroblastoma cells Red cell shape (B)
- Electrophoresis v Electrophoresis
- Electrophoresis, mobility of platelets v Platelet aggregation
- Electrophoresis, pattern of the red cell membrane proteins *in vitro* effect of anaemia, 165
- Electrophoresis (= cross-over electrophoresis) v Factor X deficiency
- Embryonic leukaemia chromosomal complemented by extrachromosomal 166
- Epithelial myeloblastoma v Myeloblastoma nodular
- Erythrocyte megakaryoblast v Erythrocytæmia
- Erythrocyte glucose-6-phosphate dehydrogenase in Tet 152
- Erythrocyte membrane proteins, electrophoretic pattern, *in vitro* effect of anaemia, 165
- Erythrocyte disaggregation, disaggregation of human red blood cells by various surface active agents as related to changes of cell shape and haemolysis 82
- Erythrocyte human (metab. Lunt) find protein in human erythrocytes in erythrocytæmia 91
- Erythrocyte, osmotic fragility test v Erythrocytæmia, osmotic fragility test
- Erythrocyte, Red cell shape (Physiology) Factor X v structure, 101 (B)
- Erythrocyte shape v Erythrocyte deformability
- Erythrocytes, v Haemolysis
- Erythrocytic committed hematopoietic stem cells in the peripheral blood of mice 226
- Erythrocytæmia some aspects of erythropoiesis, cell proliferation in erythrocytæmia 65
- Erythropoiesis some aspects of erythropoiesis, cell proliferation in erythrocytæmia 65
- Erythropoietin plasmids, different molecular weight of the plasmids, erythropoietin compared with the renal and vitelline erythropoietic factors in the rabbit 75
- Factor VIII (= A11G A = Anti haemophilic globulin A) dissociation between factor VIII (activity and antigen) and ristocetin induced platelet aggregation in von Willebrand's disease 41
- Factor X (= Stuart Prower factor) deficiency classical factor X deficiency (Report of a further case) 119
- Fagaria anthracoides root extract in sickle cell anaemia (Toxology and preliminary clinical trials) 194
- Famlet v Beta thalassaemia Factor X deficiency Haemoglobin I Sardinia Haemoglobin Stanley's 11
- Fc v Thalassaemia
- <sup>51</sup>Fe labelled iron-dextran (Iron-51) v Iron-dextran
- <sup>51</sup>Fe v Transport iron compartment
- Fibrin fukur v Ultrastructure
- Fer v Iron
- Ferments, v Alkaline phosphatase Alkaline phosphatase Glucose-6-phosphate dehydrogenase  $\beta$ -Glucuronidase Ferron diphosphate phagocytosis v Leukaemia Ha v
- Ferrokinetic v Beta thalassaemia
- Fetal haemoglobin hereditary persistence further investigation of the nature of the haemoglobin gene expression in hereditary persistence of fetal haemoglobin (showing of CB $\gamma$  protein and  $\delta$  gene) as a determinant in human Hb F 115



- Filtration, screen filtration pressure test, v Platelet aggregation
- Fine structure, v Ultrastructure
- Fingerprints, v Gamma-chain Haemoglobin F Sardinia, Haemoglobin Lepore, Haemoglobin Stanleyville II
- Foie v Liver
- Folic acid binding to serum proteins (v Tritiated folic acid in the liver) 329
- Fragility, osmotic, of erythrocytes, v Autoimmune haemolytic anaemia
- France Haemoglobin Stanleyville II (a 78 [EF 7] Asn  $\rightarrow$  Lys) found in France, 56
- Freezing of blood, Transfusion of blood preserved by freezing, 362 (B)
- Gamma-chain in a *Ghanaian* adult, homozygous for hereditary persistence of fetal haemoglobin, further investigations (Isolation of  $\gamma$ CB 3 peptides and  $^1\gamma$   $^2\gamma$  ratio determination in human Hb F), 315
- Gel chromatography (Sephadex<sup>®</sup>) v Folic acid
- Ghanaians* further investigations of the  $\gamma$ -chain in a *Ghanaian* adult, homozygous for hereditary persistence of fetal haemoglobin (Isolation of  $\gamma$ CB 3 peptides and  $^1\gamma$   $^2\gamma$  ratio determination in human Hb F), 315
- GILBERT's syndrome, coexistence of  $\beta$ -thalassaemia trait and GILBERT's syndrome in three families, 175
- Globulins, v Immunoglobulins
- Glucose-6-phosphate dehydrogenase (=G-6-PD) (deficiency and variants), erythrocyte glucose-6-phosphate dehydrogenase in *Tehran*, 152
- $\beta$ -Glucuronidase, cytochemical glucuronidase reaction in the differential diagnosis of acute leukaemias 277
- Glycogenosis type II (POWELL's disease) v Acid maltase deficiency
- G-6-PD, v Glucose-6-phosphate dehydrogenase
- Granulocytic leukaemia, v Mikrokaryoblastenschub
- Grossesse, v Pregnancy
- Haarzell Leukämie, I
- , v Hairy cell leukaemia
- Hematology, progress (Vol. VIII), 363 (B)
- Haematopoietic stem cells (CFU), erythrocytic committed haematopoietic stem cells in the peripheral blood of mice, 226
- Haeme and haemopexin, cellular and subcellular localization in the rabbit, 219
- Haemoglobin As, v Haemoglobin I Sardinia
- Haemoglobin, fetal, hereditary persistence, further investigations of the  $\gamma$ -chain in a *Ghanaian* adult, homozygous for hereditary persistence of fetal haemoglobin (Isolation of  $\gamma$ CB 3 peptides and  $^1\gamma$   $^2\gamma$  ratio determination in human Hb F) 315
- Haemoglobin F Sardinia  $\gamma^{75}$  (I 18) isoleucine Threonine a new Hb variant found in a family with Hb G Philadelphia,  $\beta$ -chain deficiency and a Lepore-like Haemoglobin indistinguishable from Hb As, 347
- Haemoglobin G Philadelphia, v Haemoglobin F Sardinia
- Haemoglobin Lepore <sup>newton</sup>, homozygous, in Iran, a case, 60
- Haemoglobin Lepore, v Haemoglobin I Sardinia
- Haemoglobin Stanleyville II (a 78 [EF7] Asn  $\rightarrow$  Lys) found in France, 56
- Haemoglobin variant new, v Haemoglobin F Sardinia
- Haemoglobinopathies, v Haemoglobin, fetal, hereditary persistence, Haemoglobin F Sardinia, Haemoglobin Lepore, Haemoglobin Stanleyville II
- Haemoglobinuria, paroxysmal, nocturnal acute myelo-monocytic leukaemia a terminal complication of paroxysmal nocturnal haemoglobinuria, 241
- Haemolysis, disaggregation of human red blood cells by various surface-active agents as related to changes of cell shape and haemolysis, 82
- , influence on the marginal zone reticulo-endothelial cells of the spleen, 170

- Haemolytic anaemia, autoimmune, an *in vitro* method to study the participation of various components in autoimmune haemolytic anaemia, 309
- Haemolytic anaemia, massive splenomegaly and pancytopenia in sarcoidosis, 230
- Haemopexin and haeme, cellular and sub-cellular localization in the rabbit, 219
- Haem, v Hem
- Hairy cell leukaemia (leukaemic reticulo-endotheliosis), reticulocarcinoma, and monocytic leukaemia (Cytochemical and ultrastructural investigations), 257
- , v Haasch-Leukämie
- Hb A<sub>2</sub>, v Haemoglobin A<sub>2</sub>
- Hb F, v Haemoglobin, fetal
- Hb F Sardania, v Haemoglobin F Sardania
- Hb G Philadelphia, v Haemoglobin G Philadelphia
- Hb Stanleyville II, v Haemoglobin Stanleyville II
- Histiocytosis, v Histiocytosis
- Hitzelberger, Dr., Memorial Foundation, competition, prizes 1976 and 1977, 364
- Hematology, progress (Vol. VIII), 363 (B)
- Hematopoietic stem cells (CTU), erythrocytic committed hematopoietic stem cells in the peripheral blood of mice, 226
- Heme and hemopexin, cellular and sub-cellular localization in the rabbit, 219
- Hemolytic anemia, autoimmune, an *in vitro* method to study the participation of various components in autoimmune hemolytic anemia, 309
- Hemopexin and heme, cellular and sub-cellular localization in the rabbit, 219
- Hepar, v Hepatocytes
- Hepatic anti-hepatitis activity of a macroglobulin from a patient with breast adenocarcinoma, 247
- Hepatocytes (ultrastructural), v Heme
- Hirsch (C. Methyl- $\beta$ -D-glucopyranosyl- $\alpha$ -D-glucopyranoside), v Aplasia anaemia
- Hirsutism, v Polycystic ovaries
- Factor X deficiency, Fetal haemoglobin, hereditary persistence, Haemoglobin Stanleyville II, Thalassaemia
- <sup>3</sup>H folic acid, v Folic acid
- <sup>3</sup>H-haeme, v Haeme
- Histochemistry, v Cytochemistry
- H<sub>2</sub>O<sub>2</sub> vapour, v Lipid peroxidation
- Hogben's disease, auto-transfusion of <sup>3</sup>H-cytidine labelled blood lymphocytes in patients with Hogben's disease and non Hogben patients (I. Limitations of the method), 193
- , (II - Exchangeable lymphocyte pools), 206
- , quantitative studies of macrophages in blood cultures in Hogben's disease, 25
- Hormic, v Human, Man
- Homozygous haemoglobin Lepore syndrome, a case, 60
- <sup>3</sup>H thymidine, v Erythrocytosis, Neonatal leukocytes
- Human erythrocytes, disaggregation of human red blood cells by various surface-active agents as related to changes of cell shape and haemolysis, 82
- Human erythrocytes (metabolism), lipid peroxidation in human erythrocytes in tocopherol deficiency, 98
- Human fetal haemoglobin, v Haemoglobin, fetal, hereditary persistence
- Human neutrophils, localization of alkaline phosphatase, 145
- Human, v Man
- Hyperbilirubinaemia, v Gilbert's syndrome
- Hypersplenism, v Massive splenomegaly
- <sup>125</sup>Iodine, v Heme
- IgA, IgG, IgM, v Immunoglobulins
- IgM paraproteinemia, v Haemoglobin
- <sup>125</sup>I-hemopexin, v Hemopexin
- Iron, v Iron deficiency
- Immune response, v Neonatal leukocytes
- Immunoglobulin, quantitative determination in chronic renal failure, 334

- Immunology of lymphocytes, v Lymphocytes devoid
- Inclusions in leukaemic cells, v Myelose aiguë
- India vitamin B<sub>12</sub> and vegetarianism in India, 90
- Indomethacin, v Analgesics
- Ineffective erythropoiesis, v Erythro-leukaemia
- International Symposium, 9th Miles International Symposium (Cell membrane receptors) (Baltimore, Md., June 4-6, 1975), 192
- Intracellular potential in normal and leukaemic lymphocytes, 138
- Iran a case of homozygous haemoglobin Lepore *positus* in Iran, 60
- , v Tehran
- Iron-deficiency anaemia, v Iron-dextran
- Iron-dextran (Imferon®), transfer across the placenta, 292
- Iron metabolism, functional heterogeneity of the transport iron compartment (I *In vitro* radio-iron clearance from high and low saturated transferrin), 285
- — —, (II *In vitro* differences between transferrin iron binding sites and *in vitro* interbinding iron exchange), 321
- Iron in pregnancy, v Iron-dextran
- Iron, serum iron, v Thalassaemia
- Isotope, radioactive, v Beta thalassaemia, Erythro-leukaemia, Folic acid, Heme, HODOKIN's disease, Iron-dextran, Transport iron compartment
- Kaninchen, v Rabbit
- KARGER, DR. HEINZ KARGER Memorial Foundation, competition, prizes 1976 and 1977, 364
- Kidney, v Renal failure
- Kürsch, v Clinical
- Lactovegetarians, v Vegetarianism
- Lapin, v Rabbit
- Leber, v Liver
- Leucémie ARN, un cas de myélose aiguë atypique une leucémie ARN, 49
- Leukaemia, eosinophilic, chronic, complicated by epidural myeloblastoma, 356
- Leukaemia, erythro-leukaemia, v Erythro-leukaemia
- Leukaemia, granulocytic, v Mikrokaryoblastenschub
- Leukaemia, hairy cell leukaemia (Leukaemia reticuloendotheliosis), reticulosarcoma, and monocytic leukaemia (Cytochemical and ultrastructural investigations), 257
- , v Haartzell Leukämie
- Leukaemia, lymphatic, chronic, lymphocytes devoid of T and B cell markers in chronic lymphatic leukaemia, 37
- — —, v PHA, insoluble
- Leukaemia, lymphoblastic, v  $\beta$ -Glucuronidase
- Leukaemia, lymphocytic, v Leukaemic lymphocytes
- Leukaemia, megakaryocytic, v Mikrokaryoblastenschub
- Leukaemia, monocytic, hairy cell leukaemia (Leukaemia reticuloendotheliosis), reticulosarcoma, and monocytic leukaemia (Cytochemical and ultrastructural investigations), 257
- — —, v Haartzell Leukämie
- — —, v Leukaemia, myelo-monocytic
- Leukaemia, myeloid, acute, un cas de myélose aiguë atypique une leucémie ARN, 49
- Leukaemia, myelo-monocytic, acute a terminal complication of paroxysmal nocturnal haemoglobinuria, 241
- Leukaemias, acute, cytochemical  $\beta$ -glucuronidase reaction in the differential diagnosis of acute leukaemias, 277
- — —, phagocytic activity, *in vitro*, of leukaemic blasts, 17
- Leukaemias, acute, Nomenclature, methodology and results of clinical trials in acute leukaemias (Recent results in cancer research, Vol. 43), 256 (II)
- Leukaemic blasts, phagocytic activity, *in vitro*, 17

- Leukaemic lymphocytes, intracellular potential in normal and leukaemic lymphocytes, 111
- Leukaemic reticulo-endotheliosis, hairy cell leukaemia (leukaemic reticulo-endotheliosis), reticulosarcoma, and monocytic leukaemia (Cytochemical and ultrastructural investigations), 257
- -, v Haarzell-Leukämie
- Leukämie, Haarzell Leukämie, 1
- -, v Leukemia, hairy cell leukemia
- Leukemia, hairy cell leukemia (leukaemic reticuloendotheliosis), reticulosarcoma, and monocytic leukemia (Cytochemical and ultrastructural investigations), 257
- -, v Leukämie, Haarzell Leukämie
- Leukemias acute, nomenclature, methodology and results of clinical trials in acute leukemias (Recent results in cancer research, Vol 43), 256 (B)
- Leukocyte alkaline phosphatase in human neutrophils, localization, 145
- Leukocyte maltase, v Acid maltase deficiency
- Lymphocytes, neonatal, proliferation of blood leukocytes in the neonatal period, 129
- Lyf, 191 (B), 256 (B), 362 (B)
- Lien, v Spleen, Splenomegaly
- Lipid peroxidation in human erythrocytes in folic acid deficiency, 95
- Liver, treated folic acid in the liver (Biochemistry of folic acid to serum proteins), 13
- Liver (ultrastructure), v Heme
- Liver vitamin B<sub>12</sub> uptake, v Vegetarianism
- Liver neoplasia, 191 (B), 246 (B), 362 (B)
- Lymphatic leukaemia, intracellular potential in normal and leukaemic lymphocytes, 111
- Lymphatic leukaemia, chronic, lymphocytes devoid of T and B cell markers, in chronic lymphatic leukaemia, 37
- Lymphoblastic leukaemia, v  $\beta$ -Glucuronidase
- Lymphoblasts, v Neonatal leukocytes
- Lymphocyte circulation, v Lymphocytes, blood lymphocytes
- Lymphocyte kinetics, v Lymphocytes, blood lymphocytes
- Lymphocyte stimulation (transformation), v Macrophages, PHA, insoluble
- Lymphocytes, B-lymphocytes, insoluble PHA - a B-cell mitogen in man, 30
- Lymphocytes, blood lymphocytes, <sup>3</sup>H-cytidyl-labelled autotransfusion in patients with Hodgkin's disease and non-Hodgkin patients (I. Limitations of the method), 193
- -, (II. Exchangeable lymphocyte pools), 206
- Lymphocytes, intracellular potential in normal and leukaemia lymphocytes, 111
- Lymphocytes devoid of T and B cell markers in chronic lymphatic leukaemia, 37
- Lymphocytes, neonatal, v Neonatal leukocytes
- Lymphocytic leukaemia, chronic, v PHA, insoluble
- Lymphogranulomatous maligna, v Hodgkin's disease
- Lymphoid reticular cells, neoplasia, in the blood, v Haarzell-Leukämie, hairy cell leukaemia
- Macroglobulin anti-heparin activity of a macroglobulin from a patient with breast adenocarcinoma, 247
- Macrophages, quantitative studies of macrophages in blood cultures in Hodgkin's disease, 25
- Magnesium, v Thalassemia
- Makroglukoprotein, v Lipid peroxidation
- Maltase, v Acid maltase deficiency
- Malignant carcinoma, v Adenocarcinoma
- Malignant soluble PHA - a B-cell mitogen in man, 30
- -, v Human
- Malignant splenomegaly, paraneoplasia and haemolytic anaemia in pernicious anaemia, 239
- Melan, v Melanoderma, Melan

- MCPA (= 2 Methyl-4-chlorophenoxyacetic acid), v Aplastic anaemia
- Mediterranean anaemia, v Thalassaemia
- Megakaryocytic leukaemia, v Mikrokaryoblastenschub
- 'Megaloblastoid' erythroblasts, v Erythro-leukaemia
- Membrane, cell membrane receptors, v Miles International Symposium
- Membrane potential, v Intracellular potential
- Mensch, v Human, Man
- Methodology (leukaemia) v Acute leukaemias (B)
- 2 Methyl-4-chlorophenoxyacetic acid, v Aplastic anaemia
- Mg, v Thalassaemia
- Mice, erythrocytic committed hematopoietic stem cells in the peripheral blood of mice, 226
- , v Iron-dextran
- Microcytoblast, v Mikrokaryoblastenschub
- Microscope électronique, v Electron microscope
- Microspectrophotometry, v Plasma cells (Acid maltase deficiency)
- Mikrokaryoblastenschub bei chronischer Myelose, 183
- Miles International Symposium, 9th (Cell membrane receptors) (Baltimore, June 4-6, 1975), 192
- Milz, v Spleen, Splenomegaly
- Mitogen, insoluble PHA - a B-cell mitogen in man? 30
- Monocytic leukaemia, hairy cell leukaemia ('leukaemic reticuloendotheliosis'), reticulosarcoma, and monocytic leukaemia (Cytochemical and ultrastructural investigations), 257
- -, v Hsazell Leukämie
- -, v Myelo-monocytic leukaemia
- Mouse, v Iron-dextran, Mice
- Mucoviscidosis, v Haemoglobin Stanley ville II
- Mus musculus, v Iron-dextran, Mice
- Muscular dystrophy, advanced, v Acid maltase deficiency
- Myeloblastoma, epidural, chronic eosinophilic leukaemia complicated by epidural myeloblastoma, 356
- Myeloid leukaemia, acute, un cas de myélose aiguë atypique une leucémie ARN, 49
- Myelo-monocytic leukaemia, acute = terminal complication of paroxysmal nocturnal haemoglobinuria, 241
- Myeloproliferative disorders, v Mikrokaryoblastenschub
- Myélose aiguë atypique une leucémie ARN, un cas, 49
- Myelose chronische, mit terminalem Mikrokaryoblastenschub, 183
- Nabelschnurblut, v Cord blood
- Neonatal leukocytes, proliferation of blood leukocytes in the neonatal period, 129
- Neonatal lymphocytes, v Neonatal leukocytes
- Nephropathies v Immunoglobulins
- Neugeborene, v Neonatal leukocytes
- Newborns, v Neonatal leukocytes
- Niere, v Renal failure
- Nocturnal haemoglobinuria, paroxysmal, v Paroxysmal nocturnal haemoglobinuria
- Nomenclature (leukaemia), v Acute leukaemias (B)
- Nouveau nés v Neonatal leukocytes
- Oberflächenaktive Substanzen v Surface-active agents
- Oligoéléments, v Thalassaemia
- Osmotic fragility of erythrocytes, v Auto-immune haemolytic anaemia
- Pancytopenia, massive splenomegaly, pancytopenia and haemolytic anaemia in sarcoidosis, 230
- Pancytopenia, v Aplastic anaemia
- PAPPENHEIM Preis 1975, 128
- Paramyeloblastic leukaemia, v Myélose aiguë

- Paraproteinaemia** (IgM paraproteinaemia), v Macroglobulin
- Paroxysmal nocturnal haemoglobinuria**, acute myelo-monocytic leukaemia a terminal complication of paroxysmal nocturnal haemoglobinuria, 241
- Pathology**, v Red cell shape (B)
- Peracetic acid**, *in vitro* and *in vivo* influence of peracetic acid on platelet aggregation, 300
- Peripheral blood of mice**, erythrocytic committed hematopoietic stem cells in the peripheral blood of mice, 226
- PHA** (= Phytohaemagglutinin), insoluble - a B-cell mitogen in man? 30
- Phagocytic activity *in vitro*** of leukaemic blasts, 17
- Phenylbutazone**, v Analgesics
- Phenyldiazine**, v Reticulo-endothelial cells
- Phosphatase**, v Alkaline phosphatase
- Phytohaemagglutinin**, v PHA, Macroplages
- Physiotype**, v Red cell shape (B)
- Placenta**, transfer of iron-dextran across the placenta, 292
- Plaques sanguinis**, v Platelet aggregation
- Plasma cells**, new kind of cytoplasmic inclusions of plasma cells in acid malate deficiency, 109
- Plasma erythropoietin**, d "correct molecular weight of the plasma's erythropoietin compared with the renal and splenic erythropoietic factors in the rabbit, 75
- Platelet aggregation**, d association between factor VIII (activity and antigen) and ristocetin-induced platelet aggregation in von Willebrand's disease, 44
- d *in vivo* and *in vitro* influence of peracetic acid, 300
- v Macroglobulin
- Platelets and thrombosis**, 342 (B)
- Peliosis III**, v Autoimmune haemolytic anaemia
- Peliosis disease** (Glycogenosis type III), v Acid malate deficiency
- Potential, intracellular**, in normal and leukaemic leukocytes, 138
- Prachylaemia**, v Myelo-monocytic leukaemia
- Pregnancy** (iron in pregnancy), v Iron-dextran
- Preis**, Pappenheimer Preis 1975, 128
- Preserved blood by freezing**, Transfusion of blood preserved by freezing, 362 (B)
- Prices**, Dr Heinz Karger Memorial Foundation, competition, prizes 1976 and 1977, 364
- v Preis
- Progress in haematology** (Vol. VIII) 363 (B)
- Proliferation of blood leukocytes** in the neonatal period, 129
- Proteins**, serum proteins, binding of folic acid (V Tetrahydrofolic acid in the liver), 329
- v Erythrocyte membrane proteins
- Protein** v Stuart Protein
- Rabbit**, cellular and subcellular localization of heme and hemopexin in the rabbit, 219
- d "correct molecular weight of the plasma's erythropoietin compared with the renal and splenic erythropoietic factors in the rabbit, 75
- Radiochrome**, v Beta-thalassemia
- Radiolabel**, v Heme
- Radiation**, v Iron-dextran, Transportation compartment
- Raster Elektronenmikroskopie**, v Red cell shape (B)
- Rate**, v Spleen, Splenomegaly
- Receptors**, cell membrane receptors, v Miles International Symposium
- Regulation of lymphocytes**, v Hirschman's disease (autoimmunity)
- Red cell shape** (Pharmacological pathway, ultrastructure), 191 (B)
- Red cells**, disaggregation of human red blood cells on various surface-active agents in relation to changes of cell shape and haemolysis, 82
- Red cells**, v Erythrocytes

- MCPA (= 2 Methyl-4-chlorophenoxyacetic acid), v. Aplastic anaemia
- Mediterranean anaemia, v. Thalassaemia
- Megakaryocytic leukaemia, v. Mikrokaryoblastenschub
- 'Megaloblastoid' erythroblasts, v. Erythro-leukaemia
- Membrane, cell membrane receptors, v. Miles International Symposium
- Membrane potential, v. Intracellular potential
- Mensch, v. Human, Man
- Methodology (leukaemia), v. Acute leukaemias (B)
- 2 Methyl-4-chlorophenoxyacetic acid, v. Aplastic anaemia
- Mg, v. Thalassaemia
- Mice, erythrocytic committed hematopoietic stem cells in the peripheral blood of mice, 226
- , v. Iron-dextran
- Microcytoblast, v. Mikrokaryoblastenschub
- Microscope électronique, v. Electron microscope
- Microspectrophotometry, v. Plasma cells (Acid maltase deficiency)
- Mikrokaryoblastenschub bei chronischer Myelose, 183
- Miles International Symposium, 9th (Cell membrane receptors) (Baltimore, June 4-6, 1975), 192
- Milz, v. Spleen, Splenomegaly
- Mitogen, insoluble PHA - a B-cell mitogen in man? 30
- Monocytic leukaemia, hairy cell leukaemia ('leukaemia reticuloendotheliosa'), reticulosarcoma, and monocytic leukaemia (Cytochemical and ultrastructural investigations), 257
- , v. Haarzell Leukämie
- , v. Myelo-monocytic leukaemia
- Mouse, v. Iron-dextran, Mice
- Mucoviscidosis, v. Haemoglobin Stanley ville II
- Mus musculus, v. Iron-dextran, Mice
- Muscular dystrophy, advanced, v. Acid maltase deficiency
- Myeloblastoma, epidural, chronic eosinophilic leukaemia complicated by epidural myeloblastoma, 356
- Myeloid leukaemia, acute, un cas de myélose aiguë atypique une leucémie ARN, 49
- Myelo-monocytic leukaemia, acute a terminal complication of paroxysmal nocturnal haemoglobinuria, 241
- Myeloproliferative disorders, v. Mikrokaryoblastenschub
- Myélose aiguë atypique une leucémie ARN, un cas, 49
- Myelose, chronische, mit terminalem Mikrokaryoblastenschub, 183
- Nabelschnurblut, v. Cord blood
- Neonatal leukocytes, proliferation of blood leukocytes in the neonatal period, 129
- Neonatal lymphocytes, v. Neonatal leukocytes
- Nephropathies, v. Immunoglobulins
- Neugeborene, v. Neonatal leukocytes
- Newborns, v. Neonatal leukocytes
- Niere, v. Renal failure
- Nocturnal haemoglobinuria, paroxysmal, v. Paroxysmal nocturnal haemoglobinuria
- Nomenclature (leukaemia), v. Acute leukaemias (B)
- Nouveau-né, v. Neonatal leukocytes
- Oberflächenaktive Substanzen, v. Surface-active agents
- Oligoéléments, v. Thalassaemia
- Osmotic fragility of erythrocytes, v. Auto-immune haemolytic anaemia
- Pancytopenia, massive splenomegaly, pancytopenia and haemolytic anaemia in sarcoidosis, 230
- Pancytopenia, v. Aplastic anaemia
- PAPPENHEIM Preis 1975, 128
- Paramyeloblastic leukaemia, v. Myelose aiguë

- Paraproteinaemia (Ig<sup>G</sup> paraproteinaemia),  
v Macroglobulin
- Paroxysmal nocturnal haemoglobinuria,  
acute myelo-monocytic leukaemia a  
terminal complication of paroxysmal  
nocturnal haemoglobinuria, 241
- Pathology v Red cell shape (B)
- Peracetic acid, *in vitro* and *in vivo* influence of  
peracetic acid on platelet aggregation, 300
- Peripheral blood of mice, erythrocytic com-  
mitted hematopoietic stem cells in the  
peripheral blood of mice, 226
- PIIA (= Phytohaemagglutinin), insoluble -  
a B-cell mitogen in man? 30
- Phagocytic activity *in vitro* of leukaemic  
platelets, 17
- Phenylbutazone, v Analgesics
- Phospholipase, v Reticulo-endothelial  
cells
- Phosphatase, v Alkaline phosphatase
- Phytohaemagglutinin, v PIIA, Macro-  
phages
- Physiology, v Red cell shape (B)
- Placental transfer of iron-dextran across  
the placenta, 292
- Platelets sanguine, v Platelet aggregation
- Plasma cells, new kind of cytoplasmic  
inclusions of plasma cells in acid maltase  
deficiency, 101
- Plasma erythropoietin, different molec-  
ular weight of the plasma erythro-  
poietin compared with the renal and  
splenic erythropoietin factors in the rab-  
bit, 75
- Platelet aggregation, discussion between  
factor VII (activity and antigen) and  
factor-induced platelet aggregation  
in von Willebrand's disease, 44  
*in vivo* and *in vitro* influence of  
peracetic acid, 300  
- v Macroglobulin
- Platelets and thrombosis, 362 (B)
- Platelet III, v Autoimmune haemolytic  
anemia
- Platelet disease (Glanzmann's type III), v  
Acid maltase deficiency
- Potential, intracellular, in normal and  
leukaemic leukocytes, 138
- Pracileukaemia, v Myelo-monocytic leu-  
kaemia
- Pregnancy (iron in pregnancy), v Iron-  
dextran
- Preis, PAPPENHEIM-Preis 1975, 128
- Preserved blood by freezing, Transfusion  
of blood preserved by freezing, 362 (B)
- Prizes, Dr. Heinz Karger Memorial  
Foundation, competition, prizes 1976  
and 1977, 364  
- v Preis
- Progress in haematology (Vol. VIII), 363 (B)
- Proliferation of blood leukocytes in the  
neonatal period, 129
- Proteins, serum proteins, binding of folic  
acid (V - Translated folic acid in the liver),  
329  
- v Erythrocyte membrane proteins
- Prower, v Erlang Prower
- Rabbit, cellular and subcellular locali-  
zation of heme and hemopexin in the  
rabbit, 219  
- different molecular weight of the plasma-  
tic erythropoietin compared with the  
renal and splenic erythropoietic factors  
in the rabbit, 75
- Radio-chrome, v Beta thalassaemia
- Radio-iodine, v Heme
- Radio-iron, v Iron-dextran, Transport iron  
compartment
- Raster Elektronenmikroskop, v Red cell  
shape (B)
- Rate, v Spleen, Splenomegaly
- Receptors, cell membrane receptors, v  
Miles International Symposium
- Recirculation of lymphocytes, v HOOKER'S  
disease (auto-transfusion)
- Red cell shape (Physiology, pathology,  
ultrastructure), 391 (B)
- Red cells, desaggregation of human red  
blood cells by various surface-active  
agents as related to changes of cell shape  
and haemolysis, 82
- Red cells, v Erythrocyte(s)



- Rein, v Renal failure
- Renal erythropoietic factor, v Plasmatic erythropoietin
- Renal failure, chronic, quantitative determination of immunoglobulins, 336
- RES, v Reticulo-endothelial cells
- Reticulo-endothelial cells, influence of haemolysis on the marginal zone reticulo-endothelial cells of the spleen, 170
- Reticulo-endotheliosis, leukaemic, hairy cell leukaemia ('reticulo-endotheliosis'), reticulosarcoma, and monocytic leukaemia (Cytochemical and ultrastructural investigations), 257
- - -, Haarzell Leukämie
- Reticulosarcoma, hairy cell leukaemia (leukaemic reticuloendotheliosis'), reticulosarcoma, and monocytic leukaemia (Cytochemical and ultrastructural investigations), 257
- , v Haarzell Leukämie
- Ribonucleic acid (= RNA) leukaemia, v Myelose aiguë
- Ribonucleic acid metabolism, v HODOKRY'S disease
- Ristocetin, dissociation between factor VIII (activity and antigen) and ristocetin-induced platelet aggregation in von WILLEBRAND'S disease, 44
- RNA (= Ribonucleic acid) metabolism, v HODOKRY'S disease
- RNA leukaemia, v Myelose aiguë
- Rosette formation, v Lymphocytes devoid of Neonatal leukocytes
- Sarcoidosis, massive splenomegaly, pancytopenia and haemolytic anaemia in sarcoidosis, 230
- Scanning electron microscope, v Red cell shape (B)
- SCHALMANN, v BOECK-
- Schwangerschaft, v Pregnancy
- Screen filtration pressure test, v Platelet aggregation
- Selective ultrafiltration, v Plasmatic erythropoietin
- Sephadex® (gel chromatography), v Folic acid
- Serum iron, v Thalassemia, Transport iron compartment
- Serum proteins, binding of folic acid (V Trilited folic acid in the liver), 329
- Serum vitamin B<sub>12</sub>, v Vegetarianism
- Sickle cell anaemia, extract of *Fagara zanthoxylodes* root in sickle cell anaemia (Toxicology and preliminary clinical trials) 158
- Sickling prevention, v Sickle cell anaemia
- Sours, v Iron-dextran, Mice
- Spleen, influence of haemolysis on the marginal zone reticulo-endothelial cells of the spleen, 170
- Spleen sarcoidosis, v Sarcoidosis
- Splen, v Spleen
- Splenic erythropoietic factor, v Plasmatic erythropoietin
- Splenomegaly, massive, pancytopenia and haemolytic anaemia in sarcoidosis, 230
- Spurenelemente, v Thalassemia
- Statistische Auswertung v Factor VIII, Glucose-6-phosphate dehydrogenase, Hematopoietic stem cells, Immunoglobulins, Intracellular potential, Lipid peroxidation, Lymphocytes devoid Macrophages, Vegetarianism
- STUART POWELL factor, v Factor X deficiency
- Submicroscopical structure, v Ultrastructure
- Surface active agents, disaggregation of human red blood cells by various surface-active agents as related to changes of cell shape and haemolysis, 82
- Symposium, 9th Miles International Symposium (Cell membrane receptors) (Baltimore, Md., June 4-6, 1975), 192
- Tehran erythrocyte glucose-6-phosphate dehydrogenase in Tehran, 152
- , v Iran
- Tenside, v Surface-active agents
- Thalassemia, changes of trace minerals

(iron, iron, zinc, copper and magnesium) in thalassaemia, 341

Thalassaemia, v Haemoglobin Lepore  
 $\beta$ -Thalassaemia trait and G6PD's syndrome in three families, coexistence, 175

$\beta$ -Thalassaemia, v Haemoglobin F Sardina  
 Therapy, v Sickle cell anaemia

Thrombocytes, v Platelet aggregation

Thrombin and platelets, 362 (B)

Thymidine (74) (thymidine), v Erythro-leukaemia, hematal leukocytes

T-lymphocytes, v T-lymphocytes

T-lymphocytes, markers, lymphocytes devoid of T and B cell markers in chronic lymphatic leukaemia, 37  
 v Hematal leukocytes

Tocopherol deficiency, lipid peroxidation in human erythrocytes in tocopherol deficiency 98

Trace elements, change of trace minerals (iron, iron, zinc, copper and magnesium) in thalassaemia, 341

Transferrin (1, v Eosinophilic leukaemia

Transfer of iron-dextran across the placenta, 212

Transferrin functional heterogeneity of the transferrin iron compartment (I: *In vivo* radio-iron clearance from high and low saturated transferrin), 335

(II: *In vivo* differences between transferrin iron binding sites, and *in vitro* interbinding site iron exchange), 321

Transfusion of blood preserved by freezing, 32 (B)

Transferrin, v Auto-transferrin

Transport iron compartment, functional heterogeneity (I: *In vivo* radio-iron clearance from high and low saturated transferrin), 335

Transport iron compartment, functional heterogeneity (II: *In vivo* differences between transferrin iron binding sites, and *in vitro* interbinding site iron exchange), 321

Trinitated folic acid, v Folic acid

Tumoral leukaemia, v Myelose aiguë

Tumoren, v Adenocarcinoma, Myeloblastoma

Ultrafiltration, selective, v Plasmatic erythropoietin

Ultrastructure, v Alkaline phosphatase, Hairy cell leukaemia, Hairy cell leukaemia, Heme, Iron-dextran, Mikrokaryoblastenschub, Myelose aiguë, Plasma cells, Red cell shape (B)

Uraemia, quantitative determination of immunoglobulins in chronic renal failure, 336

Urea of the blood, v Immunoglobulins

Urmay excretion of vitamin B<sub>12</sub>, v Vegetarianism

Vari, 128, 192, 364

Vegetarianism and vitamin B<sub>12</sub> in India, 90

Vitamin B<sub>12</sub> and vegetarianism in India, 90

Vitamin B<sub>12</sub>, v Eosinophilic leukaemia

Vitamin E, v Tocopherol deficiency

VON WILLEBRAND'S disease, dissociation between factor VIII (activity and antigen) and ristocetin-induced platelet aggregation in VON WILLEBRAND'S disease, 44

Wood killer (2-Methyl-4-chlorophenoxy-acetic acid), v Aplastic anaemia

Willebrand, v VON WILLEBRAND

Zell, v Cell

Zinc, v Thalassaemia

Zn, v Thalassaemia

Zyto, v Cyto

# Index autorum ad Vol. 53

(B) = Book Reviews - Buchbesprechungen - Livres nouveaux

- Aber, C. P., v Thadani, U  
Adekunle, A. A., v Isaacs Sodeye, W. A  
Alkan, M. L., v Dvilansky, A  
Anastasiou, C., v Kotsifopoulos, P. N  
Anderson, C. O., v Isaacs Sodeye, W. A  
Arcasoy, A. and Cavdar, A. O. 341  
Asamer, H., v Schmalzl, F  
Ascher, S., v Huhn, D  
Azizi, M., v Rahbar, S
- Barbui, T. and Dini, E. 44  
Bartnikowa, W., v Schneiberg, K.  
Baviera, B., v Hahn, D  
Begemann, H., v Schick, P  
Benedek, S., v Schick, P  
Benner, K. U., v Gaehdgens, P  
Bernadou, A., v Zittoun, R  
Bessis, M., Weed, R. I., and Leblond, P. I  
191 (B)  
Bessler, H., v Djaldetti, M  
Bocchini, V., v Giovannini, E  
Boussier, J., v Zittoun, R  
Braunsteiner, H., v Michlmayr, G  
Braunsteiner, H., v Schmalzl, F  
Brown, E. B. 363 (B)  
Brunetti, A., v Girolami, A
- Cartei, G. and Dini, E. 175  
Cavdar, A. O., v Arcasoy, A  
Charlesworth, D., v Grifoni, V  
Cofrancesco, E., v Fogliani, E.  
Coser, P., v Girolami, A  
Curtis, J., v Nath, I
- Daneshbod, G. 152  
Darbre, Ph. D., v North, M. L.  
Dini, E., v Barbui, T  
Dini, E., v Cartei, G  
Djaldetti, M., Nott, I. Fishman, P., and  
Bessler, H. 292  
Donner, L., v Neuwirtová, R
- Dorazilová, V., v Neuwirtová, R  
Dvilansky, A., Alkan, M. L., Ho, W.,  
Kaplan, H., Tiberin, P., and Rachmile  
witz, B. 356
- Economidou, I., v Kaliskmanis, N  
Eder, M., v Schick, P
- Fischer, M., v Mitrou, P. S  
Fishman, P., v Djaldetti, M  
Fliedner, T. M., v Schick, P  
Freeman, J., v Mulhearn, T
- Gaehdgens, P. and Benner, K. U. 82  
Ganzoni, A. M., v Hahn, D  
Geddes, A. D., Kirchen, M. F., and Mar  
shall, G. J. 145  
Giovannini, E. and Bocchini, V. 75  
Girolami, A., Coser, P., Brunetti, A., and  
Prinot, O. 118  
Goguel, A., v Houbouyan, L.  
Grifoni, V., Kamuzora, H., Lehmann, H.,  
and Charlesworth, D. 347
- Hahn, D., Baviera, B., and Ganzoni, A. M.  
285  
Hahn, D. and Ganzoni, A. M. 321  
Heng Liem, H., Tavassoli, M., and Müller  
Eberhard, U. 219  
Hennekeuser, H. H., v Möbius, W.  
Himanen, P., v Markkanen, T.  
Ho, W., v Dvilansky, A.  
Hopkins, J., v Tudhope, G. R.  
Houbouyan, L., Stoltz, J. F., and Goguel  
A. 300  
Housková, J., v Neuwirtová, R.  
Huber, H., v Michlmayr, G.  
Hübner, K., v Mitrou, P. S.  
Huhn, D. and Ascher, S. 183  
Huhn, D., v Schmalzl, F.  
Huhtala, E., v Watstjerna, C.

- Jakša, F., v. Wasserstrom, C.  
 Janszky Deutch, H. A. B., v. Jaskar, S.  
 Janszky-Sodory, H. A., Soloway, E. A.  
 Williams, A. O.; Marston, V. O., Ad-  
 kin, A. A., and Anderson, C. O. 175  
 Jerges, B. 170  
  
 Jones, J. M., v. Zimov, R.  
 Jorinen, M., v. Markkanen, T.  
 Jaskar, S., Janszky Deutch, H. A. B.  
 Rege, D. v., and Sankkar, R. S. 93  
 Juel, J. G., v. North, M. L.  
  
 Kahane, W., v. Schuck, P.  
 Kalakman, N., McCann, A., Econo-  
 mical, I., and Vlasovskoy, A. 335  
 Karmozin, H., v. Grison, J.  
 Karmozin, H., Ringbom, B., Komoy  
 Akiba, F. I. D., Lehmann, H., and  
 Lerner, P. A. 315  
 Kaplan, H., v. Driksky, A.  
 Kirchen, M. F., v. Geller, A. D.  
 Korman, O., v. Palva, H. L. A.  
 Korman-Akiba, F. I. D., v. Karmozin, H.  
 Kormoska, A., v. Makolejew, M.  
 Kormoska, P. A., Skirou, P., and  
 Anastasiu, C. 163  
 Korm, E., v. Makolejew, M.  
  
 Laia, M. 129  
 Laskin, P. F., v. Brune, M.  
 Lehmann-Brosch, E., v. Schuck, P.  
 Lehmann, H., v. Geller, A.  
 Lehmann, H., v. Karmozin, H.  
 Lehmann, H., v. North, M. L.  
 Lehmann, M., v. Wasserstrom, C.  
 Lerner, P. A., v. North, M.  
 Lerner, H., v. Palva, H.  
 Lerner, P. A., v. Karmozin, H.  
  
 MacVine, T. J., v. McCarthy, K. F.  
 McVine, M., Karmozin, A., and  
 Korm, E. 113  
 Mangil, A., v. North, M.  
 Markkanen, T., Palva, H. L., Vlasov,  
 S., Homan, P., and Homan, M. 329  
 Mar, A., v. D., v. Karmoska, R. A.  
 Marshall, G. J., v. Geller, A. D.  
 Maske, G., Schwarzenberg, L., and Poul-  
 lert, P. 256 (B)  
 Matzer, M., v. Schuck, P.  
 McCarthy, K. F., and MacVine, T. J. 226  
 McCann, K., v. Kalakman, N.  
 Michtay, G., Huber, C., Braunmeyer,  
 H., and Huber, H. 30  
 Merou, P. S., Fischer, M., and Huber, K.  
 65  
 Meyer, W., Henneleiser, H. H., Wester-  
 karmen, M., Seng, Voss, C., and Leich,  
 R. 1  
 \*Mithern, T., Rothschild, H., and Free-  
 run, J. 309  
 Moller Eberhard, U., v. Hong Liem, H.  
  
 Nash, I., Curran, J., Mangil, A., and Tai-  
 war, G. P. 37  
 Navone, R., Palestro, G., and Resegotti, L.  
 25  
 Neumitov, R., Setford, O., Houskov, J.,  
 Poch, T., Doranik, V., and Donner,  
 L. 17  
 Neumann, H., v. Schuck, P.  
 North, M. L., Darby, Ph. D., Lehmann,  
 H., and Juel, J. G. 56  
 North, L., v. Djaldin, M.  
 Nowari, G., v. Rahbar, S.  
  
 Palva, H. L., v. Markkanen, T.  
 Palestro, G., v. Navone, R.  
 Palva, H. L. A., Korman, O., and Palva,  
 J. P. 105  
 Palva, J. P., v. Palva, H. L. A.  
 Poch, T., v. Neumitov, R.  
 Poglar, E., Coltrance, E., and Pross, C.  
 247  
 Poullet, P., v. Maske, G.  
 Pross, C., v. Poglar, E.  
 Pross, H., Schroeder, R., and Lerner, H.  
 109  
 Priodit, O., v. Grolman, A.  
  
 Radford, H. B., v. Driksky, A.  
 Rahbar, S., Anil, M., and Nowari, G. 60  
 Page, D. v., v. Jaskar, S.

- Resegotti, L., v Navone, R  
 Ringelmann, B., v Kamuzora, H  
 Rothschild, H., v Mulhearn, T  
 Rytwiński, K., v Schneiberg, K  
  
 Satokkar, R S., v Jathar, V S  
 Schick, P., Trepel, F., Eder, M., Matzner,  
 M., Benedek, S., Theml, H.; Kaboth,  
 W., Begemann, H., and Thiedner, T M  
 206  
 Schick, P., Trepel, F., Lehmann Brock-  
 haus, E., and Nietmann, H 193  
 Schmalzl, F., Huhn, D., Asamer, H., and  
 Braunsteiner, H 257  
 Schneiberg, K., Wiczorkiewicz, A., Ryt-  
 wiński, K. et Bartnikowa, W 49  
 Schröder, R., v Pralle, H  
 Schwarzenberg, L., v Mathé, G  
 Scriabine, A., v Sherry, S  
 Setková, O., v Neuwirtová, R  
 Sherry, S. and Scriabine, A 362 (B)  
 Skliros, P., v Kotsifopoulos, P N  
 Sofowara, E. A., v Isaacs Sodeye, W A  
 Soria, J., v Zittoun, R  
 Stangoross, C., v Möbius, W  
  
 Stoltz, J F., v Houbouyan, L  
 Sumida, S 362 (B)  
  
 Talwar, G P., v Nath, I  
 Tavassoli, M., v Heng Liem, H  
 Taylor, J J., v Thadani, U  
 Thadani, U., Aber, C P., and Taylor, J J  
 230  
 Theml, H., v Schick, P  
 Tiberin, P., v Dvilansky, A  
 Trepel, F., v Schick, P  
 Tudhope, G R. and Hopkins, J 98  
  
 Virtanen, S., v Markkanen, T  
 Vlassopoulos, K., v Kaliakmanis, N  
 Vuorinen, E., v Wasastjerna, C.  
  
 Wasastjerna, C., Vuorinen, E., Lehtinen,  
 M., Ikkala, E., and Huhtala, E. 277  
 Weed, R I., v Bessis, M  
 Westerhausen, M., v Möbius, W  
 Wiczorkiewicz, A., v Schneiberg, K  
 Williams, A O., v Isaacs-Sodeye, W A  
  
 Zittoun, R., Bernadou, A., James, J M.,  
 Soria, J., and Bousser, J 241

